Rank,NCT Number,Title,Acronym,Status,Study Results,Conditions,Interventions,Outcome Measures,Sponsor/Collaborators,Gender,Age,Phases,Enrollment,Funded Bys,Study Type,Study Designs,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents,URL
1,NCT02187198,Buprenorphine Treatment for Opioid Dependence,,Recruiting,No Results Available,Opioid Dependence,Drug: Buprenorphine,Change in Timeline Follow-Back (TLFB) assessment,Yale University|United States Department of Defense,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,20,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IP0040,2015-03-01,2018-03-01,2018-03-01,2014-07-10,null,2017-10-25,"VA Connecticut Healthcare System - West Haven Campus, West Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT02187198
2,NCT01738503,Multiple Dose Pharmacokinetics Depot Buprenorphine in Opioid-Dependent Subjects,,Completed,Has Results,Opioid Related Disorder,Drug: RBP-6000|Drug: Subutex,"Participants With Treatment-Emergent Adverse Events (TEAEs)|Buprenorphine PK: % Fluctuation|Buprenorphine PK: Area Under Plasma Concentration Time Curves (AUC)|Buprenorphine PK: Average Plasma Concentration (Cavg)|Buprenorphine PK: Maximum Observed Plasma Concentration (Cmax)|Buprenorphine PK: Minimum Observed Plasma Concentration (Cmin)|Buprenorphine PK: Swing of Plasma Concentrations|Buprenorphine PK: Time to Maximum Buprenorphine Plasma Concentration (Tmax)|Buprenorphine PK: Accumulation Index in Terms of Area Under the Curve (Rac(AUC))|Buprenorphine PK: Accumulation Index in Terms of Maximum Observed Plasma Drug Concentration (Rac(Cmax))|Buprenorphine PK: Apparent Clearance at Steady-State (CLss/F) Following Injections 4 and 6|Buprenorphine PK: Area Under Plasma Concentration Time Curve From Time Zero Of Injection 4 (AUC0-∞)|Buprenorphine PK: Terminal Phase Half Life (t1/2) Calculated For Injection 4|Norbuprenorphine PK: % Fluctuation|Norbuprenorphine PK: Area Under Plasma Concentration Time Curves (AUC)|Norbuprenorphine PK: Average Plasma Concentration (Cavg)|Norbuprenorphine PK: Maximum Observed Plasma Concentration (Cmax)|Norbuprenorphine PK: Minimum Observed Plasma Concentration (Cmin)|Norbuprenorphine PK: Swing of Plasma Concentrations|Norbuprenorphine PK: Time to Maximum Buprenorphine Plasma Concentration (Tmax)|Norbuprenorphine PK: Accumulation Index in Terms of Area Under the Curve (Rac(AUC))|Norbuprenorphine PK: Accumulation Index in Terms of Maximum Observed Plasma Drug Concentration (Rac(Cmax))|Norbuprenorphine PK: Area Under Plasma Concentration Time Curve From Time Zero Of Injection 4 and 6 (AUC0-∞)|Norbuprenorphine PK: Terminal Phase Half Life (t1/2) Calculated For Injection 4|Change From Baseline in the Clinical Opiate Withdrawal Scale (COWS) Prior to Injections 1, 2, 3, 4 and 6|Change From Baseline in the Subjective Opiate Withdrawal Scale (SOWS) Prior to Injections 1, 2, 3, 4 and 6|Change From Baseline in the Clinical Opioid Craving Visual Analog Scale (VAS) Total Score Prior to Injections 1, 2, 3, 4 and 6|Change From Baseline in the Clinical Global Impression Severity (CGI-S) Scale on Days 1, 7, 29, 57, 85 and 141|Change From Baseline in the Clinical Global Impression Improvement (CGI-I) Scale on Days 7, 29, 57, 85 and 141|Columbia Suicide Severity Rating Scale (C-SSRS): Severity|Percentage of Urine Drug Screen Samples Negative for Opioids",Indivior Inc.,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,124,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RB-US-12-0005,2012-10-01,2014-05-01,2014-05-01,2012-11-30,2018-01-23,2018-02-23,"Vince and Associates Clinical Research, Overland Park, Kansas, United States",,https://ClinicalTrials.gov/show/NCT01738503
3,NCT02737696,Computer-based Prescription Opioid Abuse Prevention for Adolescents,,"Active, not recruiting",No Results Available,Opioid Related Disorders,Behavioral: Web-based prescription opioid prevention for adolescents|Behavioral: JustThinkTwice.gov website (DEA),Negative attitudes and perceived risk associated with their misuse|Intentions to use prescription opioids|Rates of prescription opioid use.|Knowledge about key issues relevant to prescription opioid abuse among youth|Skill acquisition relevant to preventing misuse of prescription opioids (decision making/refusal skills),Dartmouth-Hitchcock Medical Center,All,12 Years to 17 Years   (Child),Not Applicable,431,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,28283,2017-05-15,2018-03-18,2018-09-01,2016-04-14,null,2018-07-17,"Center for Technology and Behavioral Health, Lebanon, New Hampshire, United States",,https://ClinicalTrials.gov/show/NCT02737696
4,NCT00637000,Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone,,Completed,Has Results,Opioid-related Disorders,Drug: Buprenorphine soluble film|Drug: Buprenorphine/naloxone film strip|Drug: Placebo,"Severity of Withdrawal Symptoms Measured Using the Clinical Opiate Withdrawal Scale (COWS) at Baseline and the Peak COWS up to 23.5 Hours After the First Administration|Severity of Withdrawal Symptoms Measured Using the Clinical Opiate Withdrawal Scale (COWS) at the End of Induction and the Peak COWS Post Induction|Pupil Diameter Measurements at Baseline and the Maximum Pupil Diameter up to 23.5 Hours After the First Administration|Pupil Diameter Measurements at Baseline and the Minimum Pupil Diameter up to 23.5 Hours After the First Administration|Pupil Diameter Measurements At End of Induction (End of Day 2) and the Minimum Pupil Diameter During the Post Induction Period (Days 3-5)|Visual Analog Scale (VAS) Score at Baseline and the Peak (Maximum Increase) VAS up to 23.5 Hours After First Administration for the Question: ""How High Are You?""|Visual Analog Scale (VAS) Score at Baseline and the Peak (Maximum Increase) VAS up to 23.5 Hours After First Administration for the Question: ""Do You Feel Any Drug Effect?""|Visual Analog Scale (VAS) Score at Baseline and the Peak (Maximum Increase) VAS up to 23.5 Hours After First Administration for the Question: ""Does the Drug Have Any Good Effects?""|Visual Analog Scale (VAS) Score at Baseline and the Peak (Maximum Increase) VAS up to 23.5 Hours After First Administration for the Question: ""Does the Drug Have Any Bad Effects?""|CVisual Analog Scale (VAS) Score at Baseline and the Peak (Maximum Increase) VAS up to 23.5 Hours After First Administration for the Question: ""Do You Like the Drug?""|Visual Analog Scale (VAS) Score at Baseline and the Peak (Maximum Increase) VAS up to 23.5 Hours After First Administration for the Question: ""Does the Drug Make You Sick?""|Visual Analog Scale (VAS) Scores at End of Induction Period and the Post-induction Period (Maximum Increase) for the Question: ""How High Are You?""|Visual Analog Scale (VAS) Scores at End of Induction Period and the Post-induction Period (Maximum Increase) for the Question: ""Do You Feel Any Drug Effect?""|Visual Analog Scale (VAS) Scores at End of Induction Period and the Post-induction Period (Maximum Increase) for the Question: ""Do You Feel Any Good Effects?""|Visual Analog Scale (VAS) Scores at End of Induction Period and the Post-induction Period (Maximum Increase) for the Question: ""Does the Drug Have Any Bad Effects?""|Visual Analog Scale (VAS) Scores at End of Induction Period and the Post-induction Period (Maximum Increase) for the Question: ""Do You Like the Drug?""|Visual Analog Scale (VAS) Scores at End of Induction Period and the Post-induction Period (Maximum Increase) for the Question: ""Does the Drug Make You Sick?""|Summary of Participants With Treatment-Emergent Adverse Events (TEAEs)",Indivior Inc.,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,38,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RB-US-07-0002,2008-03-01,2008-09-01,2008-09-01,2008-03-17,2014-05-09,2017-06-05,"Johns Hopkins University School of Medicine, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00637000
5,NCT03610672,Mobile Intervention for Young Opioid Users,,Recruiting,No Results Available,Opioid-Related Disorders,Behavioral: OD prevention/response training|Behavioral: OD prevention/response training + PI mobile application,Change in opioid use|Change in self-reported injection status via Timeline Followback|Change in HIV/HCV risk behavior|OD|Peer IDU norms,"National Development and Research Institutes, Inc.",All,18 Years to 29 Years   (Adult),Not Applicable,64,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R34DA043957,2017-09-15,2019-11-28,2020-02-28,2018-08-01,null,2018-08-02,"National Development and Research Institutes, Inc., New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03610672
6,NCT02718352,A Naturalistic Study of Adolescents and Young Adults in Treatment for Opioid Dependence,,Completed,No Results Available,Opioid Dependence,Other: Naturalistic Prospective Cohort,Opioid Use Patterns|Cigarette Use Patterns,Yale University,All,"16 Years to 25 Years   (Child, Adult)",,8,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,16010 17074,2016-03-01,2018-02-01,2018-03-01,2016-03-24,null,2018-06-27,"APT Foundation, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT02718352
7,NCT03306368,Youth Opioid Recovery Support: A Developmentally-specific Intervention for Home Delivery of Extended Release Naltrexone,YORS,Recruiting,No Results Available,Opioid-Related Disorders,Behavioral: Youth Opioid Recovery Support,Number of weeks retained in treatment|Number of weeks negative for opioid use|Number of patients who linked to after care|Number of XR-NTX doses received|Number of weeks negative for substances other than opiates,Potomac Health Foundations,Female,18 Years to 26 Years   (Adult),Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB00144092,2018-02-01,2019-08-01,2019-12-01,2017-10-11,null,2018-04-06,"Mountain Manor Treatment Center, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT03306368
8,NCT00218101,Buprenorphine as a Treatment for Individuals Dependent on Analgesic Opioids,,Completed,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine,Substance use|medication compliance|treatment retention|Behavioral and psychological measures (measured during the dose reduction phase),National Institute on Drug Abuse (NIDA)|University of Texas,All,25 Years to 55 Years   (Adult),Phase 2,10,NIH|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NIDA-09262-11|P50-09262-11|DPMC,2004-05-01,null,2005-03-01,2005-09-22,null,2017-01-12,"University of Texas Health Science Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00218101
9,NCT00134875,Assessing Abuse Potential of Parenteral Buprenorphine/Naloxone in Non-Dependent Opioid Abusers,,Terminated,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine/naloxone,Opioid agonist effects|Physiologic measures,National Institute of Allergy and Infectious Diseases (NIAID)|National Institute on Drug Abuse (NIDA),All,18 Years to 55 Years   (Adult),Not Applicable,9,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",NIDA-08045-3|R01-08045-3|DPMC,2000-12-01,2002-12-01,2017-12-01,2005-08-25,null,2017-01-12,"Johns Hopkins University (BPRU) Bayview Campus, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00134875
10,NCT02437344,Glutamatergic Modulation to Facilitate Naltrexone Initiation in Opioid Dependence,,Completed,Has Results,Opioid Dependence,Drug: CI-581aa|Drug: Naltrexone titration and XR-NTX initiation,Successful Naltrexone Initiation|Withdrawal: Subjective Opioid Withdrawal Scale Scores at Baseline and Administered Subsequently,New York State Psychiatric Institute|National Institute on Drug Abuse (NIDA),All,21 Years to 60 Years   (Adult),Phase 2,16,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,#7057,2015-01-01,2016-12-01,2016-12-01,2015-05-07,2017-09-06,2017-09-06,"New York State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02437344
11,NCT01024335,Dronabinol Naltrexone Treatment for Opioid Dependence,Domino,Completed,Has Results,Opioid Dependence,Drug: injectable naltrexone and dronabinol|Drug: Naltrexone and placebo,Opiate Withdrawal Measured by the Subjective Opiate Withdrawal Scale (SOWS) .|Retention,New York State Psychiatric Institute|National Institute on Drug Abuse (NIDA),All,18 Years to 60 Years   (Adult),Phase 2|Phase 3,60,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",#5962 DA027124|R01DA027124|DPMC,2010-01-01,2012-12-01,2012-12-01,2009-12-02,2014-09-05,2018-06-18,"New York State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01024335
12,NCT02548728,Oxytocin Treatment of Opioid Dependence,,Enrolling by invitation,No Results Available,Opioid Dependence|Opioid Withdrawal,Drug: Intranasal Oxytocin Spray|Drug: Placebo,Area Under the Curve (AUC) in Clinical Opiate Withdrawal Scale (COWS) Total Score on Days 1 to 5 Inclusive|AUC in Subjective Opiate Withdrawal Scale (SOWS) Total Score on Days 1 to 5 Inclusive|AUC in Visual Analog Scale (VAS) Score for Craving on Days 1 to 5 Inclusive,"University of North Carolina, Chapel Hill|National Institute on Alcohol Abuse and Alcoholism (NIAAA)",All,21 Years to 45 Years   (Adult),Phase 1|Phase 2,25,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",14-3041|5R21AA021927-02,2016-02-01,2018-12-01,2018-12-01,2015-09-14,null,2018-06-25,"University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT02548728
13,NCT01556425,The Separate and Combined Effects of Vivitrol and Opiate Abstinence Reinforcement in the Treatment of Opioid Dependence,,Completed,Has Results,Opioid Dependence,Drug: Vivitrol|Behavioral: Employment-based opiate abstinence reinforcement|Other: Usual Care Control,Percent of Weekly Urine Samples Negative for Opiates|Percent of Weekly Urine Samples Negative for Cocaine,Johns Hopkins University|National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,84,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NA_00052254|2R01DA019497-06,2012-05-01,2016-12-12,2017-08-06,2012-03-16,2018-02-13,2018-03-12,"Johns Hopkins Bayview Center for Learning and Health, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01556425
14,NCT00000195,Neurobiology of Opioid Dependence: 4 - 4,,Withdrawn,No Results Available,Opioid-Related Disorders,Drug: Naltrexone,"Behavioral, physiological, neuroendocrine response to yohimine",Yale University|National Institute on Drug Abuse (NIDA),All,"Child, Adult, Older Adult",Phase 2,0,Other|NIH,Interventional,Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,NIDA-00191-4|K20DA000191|K20-00191-4,1993-01-01,1998-01-01,1998-01-01,1999-09-21,null,2016-05-06,"VA Connecticut Healthcare System, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00000195
15,NCT00000194,Neurobiology of Opioid Dependence: 3 - 3,,Withdrawn,No Results Available,Opioid-Related Disorders,Drug: Cycloserine,"Behavioral, subjective, measures of naloxone-preci|Phsyiological, neuroendocrine measures of naloxone",Yale University|National Institute on Drug Abuse (NIDA),Male,"Child, Adult, Older Adult",Phase 2,0,Other|NIH,Interventional,Masking: Double|Primary Purpose: Treatment,NIDA-00191-3|K20DA000191|K20-00191-3,1993-01-01,1998-01-01,1998-01-01,1999-09-21,null,2016-05-06,"VA Connecticut Healthcare System, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00000194
16,NCT00000193,Neurobiology of Opioid Dependence: 2 - 2,,Withdrawn,No Results Available,Opioid-Related Disorders,Drug: Gamma hydroxybutyric,"Behavioral, subjective, measures of naloxone-preci|Phsyiological, neuroendocrine measures of naloxone",Yale University|National Institute on Drug Abuse (NIDA),Male,"Child, Adult, Older Adult",Phase 2,0,Other|NIH,Interventional,Masking: Double|Primary Purpose: Treatment,NIDA-00191-2|K20DA000191|K20-00191-2,1993-01-01,1998-01-01,1998-01-01,1999-09-21,null,2015-08-07,"VA Connecticut Healthcare System, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00000193
17,NCT00000192,Neurobiology of Opioid Dependence: 1 - 1,,Withdrawn,No Results Available,Opioid-Related Disorders,Drug: Lamotrigine,"Behavioral, subjective, measures of naloxone-precipitated opiate withdrawal|Phsyiological, neuroendocrine measures of naloxone-precipitated opiate withdrawal",Yale University|National Institute on Drug Abuse (NIDA),All,"Child, Adult, Older Adult",Phase 2,0,Other|NIH,Interventional,Masking: Double|Primary Purpose: Treatment,NIDA-00191-1|K20DA000191|K20-00191-1,1993-01-01,1998-01-01,1998-01-01,1999-09-21,null,2015-08-07,"VA Connecticut Healthcare System, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00000192
18,NCT00772785,Study of Probuphine in Patients With Opioid Dependence,PRO-809,Terminated,No Results Available,Opioid Dependency,Drug: Probuphine (buprenorphine implant),Number of adverse events|Plasma buprenorphine concentration,Braeburn Pharmaceuticals,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,16,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PRO-809,2008-09-01,2009-02-01,2009-02-01,2008-10-15,null,2017-06-14,"Scientific Clinical Research, Inc., North Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT00772785
19,NCT00768482,A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence,PRO-810,Terminated,No Results Available,Opioid Dependence,Drug: Probuphine (buprenorphine implant)|Drug: Sublingual Buprenorphine,Plasma BPN AUC(0-24)during 24 hours at steady state.|Plasma BPN and NorBPN Cmax|Time to maximum plasma BPN and NorBPN concentration (tmax)|Plasma BPN and NorBPN AUC(0-24) during 24 hours at steady state|Change in plasma BPN concentration|Number of subjects with adverse events as a measure of safety and tolerability,Braeburn Pharmaceuticals,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,9,Industry,Interventional,Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PRO-810,2008-09-01,2008-12-01,2008-12-01,2008-10-08,null,2017-06-14,"Segal Institute For Clinical Research, Fort Lauderdale, Florida, United States",,https://ClinicalTrials.gov/show/NCT00768482
20,NCT00000243,Effects of Buprenorphine/Naloxone in Treating Opioid Dependent Individuals Who Are Maintained on Methadone,,Terminated,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine,Physiological effects|Analog rating scale for drug effects,National Institute on Drug Abuse (NIDA),All,18 Years to 55 Years   (Adult),Not Applicable,16,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,NIDA-08045-1|R01-08045-1|DPMC,2002-09-01,null,2004-01-01,1999-09-21,null,2017-01-12,"Johns Hopkins University (BPRU) Bayview Campus, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00000243
21,NCT01759446,Abuse Potential of Intranasal VYCAVERT Tablets (Hydrocodone Bitartrate/Acetaminophen) in Recreational Opioid Users,,Completed,No Results Available,Opioid-Related Disorders,Drug: Hydrocodone/Acetaminophen,The primary endpoint analysis will evaluate pharmacodynamics parameters,Acura Pharmaceuticals Inc.,All,18 Years to 55 Years   (Adult),Phase 2,40,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",AP-ADF-301,2013-02-01,2013-04-01,2013-04-01,2013-01-03,null,2013-04-09,"Lifetree Clinical Research, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT01759446
22,NCT03034278,Self-reported Usage Patterns of Opioid Analgesic Medications After Surgery,,Recruiting,No Results Available,Opioid Use,Other: Not applicable - no intervention,Ratio of patient-reported intake of oral opioids to prescribed amount of oral opioid medications|Storage of opioid medication in surgical patients after hospital discharge,"University of Colorado, Denver|National Institute on Drug Abuse (NIDA)",All,"18 Years to 89 Years   (Adult, Older Adult)",,853,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,14-1938|1K23DA040923-01A1,2017-02-03,2021-07-31,2021-07-31,2017-01-27,null,2018-07-16,"University of Colorado Hospital, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT03034278
23,NCT00158236,Abuse Potential of Buprenorphine and Naloxone in Non-Dependent Opioid Users,,Completed,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine|Drug: Buprenorphine and Naloxone|Drug: Hydromorphone,"Opioid agonist effects (measured by Visual Analog Scale and Adjective Rating Scale during the medication challenge sessions)|Physiological effects (measured by pulse oximeter, blood pressure, heart rate, and pupillary camera during the medication challenge sessions)",National Institute on Drug Abuse (NIDA),All,18 Years to 55 Years   (Adult),Not Applicable,7,NIH,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,NIDA-08045-5|R01-08045-5|DPMC,1997-01-01,null,1998-03-01,2005-09-12,null,2017-01-12,"Johns Hopkins University (BPRU) Bayview Campus, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00158236
24,NCT00134914,Effects of Buprenorphine/Naloxone Administered in Different Ways For Treating Opioid Dependence,,Completed,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine,Opioid agonist rating|opiate withdrawal|physiologic measures,National Institute on Drug Abuse (NIDA),All,18 Years to 55 Years   (Adult),Not Applicable,10,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",NIDA-08045-4|R01-08045-4|DPMC,1996-08-01,1998-04-01,1998-05-01,2005-08-25,null,2017-01-12,"Johns Hopkins University (BPRU) Bayview Campus, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00134914
25,NCT02017041,Using mHealth to Aid Opioid Medication Adherence Pilot Study,,Completed,No Results Available,Opioid Dependence,Device: Medsignals|Device: smartphone app,questionnaire assessing usability of the system.,Care Team Solutions,All,"21 Years and older   (Adult, Older Adult)",,9,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,HHSN271201300015C-1|HHSN271201300015C,2014-01-01,2014-06-01,2014-06-01,2013-12-20,null,2015-02-03,"Care Team Solutions, Lexington, Kentucky, United States",,https://ClinicalTrials.gov/show/NCT02017041
26,NCT00000196,Neurobiology of Opioid Dependence: 5 - 5,,Withdrawn,No Results Available,Opioid-Related Disorders,Drug: Naltrexone,"Behavioral, physiological, neuroendocrine response to yohimbine",Yale University|National Institute on Drug Abuse (NIDA),All,"Child, Adult, Older Adult",Phase 2,0,Other|NIH,Interventional,Masking: Double|Primary Purpose: Treatment,NIDA-00191-5|K20DA000191|K20-00191-5,1993-01-01,1998-01-01,1998-01-01,1999-09-21,null,2015-06-03,"VA Connecticut Healthcare System, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00000196
27,NCT00000204,Buprenorphine Maintenance for Opioid Addicts - 3,,Completed,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine,Drug use|Retention|Withdrawal symptoms,Yale University|National Institute on Drug Abuse (NIDA),All,"Child, Adult, Older Adult",Phase 2,0,Other|NIH,Interventional,Primary Purpose: Treatment,NIDA-05626-3|R01DA005626|R01-05626-3,1988-08-01,2006-05-01,2006-05-01,1999-09-21,null,2013-07-25,"VA Connecticut Healthcare System, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00000204
28,NCT00000203,Buprenorphine Maintenance for Opioid Addicts - 2,,Completed,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine,Drug use|Withdrawal symptoms|Psychological symptoms,Yale University|National Institute on Drug Abuse (NIDA),All,"Child, Adult, Older Adult",Phase 2,0,Other|NIH,Interventional,Primary Purpose: Treatment,NIDA-05626-2|R01DA005626|R01-05626-2,1988-08-01,2006-05-01,2006-05-01,1999-09-21,null,2013-07-25,"VA Connecticut Healthcare System, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00000203
29,NCT00000202,Buprenorphine Maintenance for Opioid Addicts - 1,,Completed,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine,,Yale University|National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,0,Other|NIH,Interventional,Primary Purpose: Treatment,NIDA-05626-1|R01DA005626|R01-05626-1,1988-08-01,2006-05-01,2006-05-01,1999-09-21,null,2013-07-25,"VA Connecticut Healthcare System, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00000202
30,NCT03098407,Opioid Dependence Treatment Therapies in Pregnancy,,Recruiting,No Results Available,Opioid-Related Disorders|Pregnancy,Drug: Buprenorphine|Drug: Methadone,"Number of participants who are recruited, enrolled, retained, and who complete the study.",University of Pittsburgh|National Institute on Drug Abuse (NIDA),Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,50,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,PRO16020403|1K23DA038789-01A1,2017-04-20,2019-06-01,2019-06-01,2017-03-31,null,2018-08-03,"Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03098407
31,NCT02431793,EHR‐Based Medication Complete Communication Strategy to Promote Safe Opioid Use,EMC2,"Active, not recruiting",No Results Available,"Opioid Use, Unspecified",Behavioral: EMC2 Strategy|Behavioral: SMS Texting Reminders,Safe medication dosing (prescription understanding)|Medication Knowledge|Medication Use,Northwestern University|Agency for Healthcare Research and Quality (AHRQ),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,652,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,1R18HS023459-01,2015-07-01,2017-08-01,2018-09-01,2015-05-01,null,2018-04-02,"Northwestern University, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT02431793
32,NCT00000238,Temporal Discounting Delayed Outcomes on Opioid-Dependent Outpatients - 20,,Completed,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine,Drug use|Money choice|Heroin craving,National Institute on Drug Abuse (NIDA)|University of Vermont,All,18 Years to 47 Years   (Adult),Phase 2,0,NIH|Other,Interventional,Primary Purpose: Treatment,NIDA-06969-20|R01-06969-20,1997-08-01,null,null,1999-09-21,null,2008-11-20,"Treatment Research Center, Burlington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT00000238
33,NCT02854800,Smoking Cessation & Opioid Dependence Treatment Integration,,Unknown status,No Results Available,Smoking Cessation|Opioid Related Disorders,Drug: varenicline,"Cigarette smoking quit rates|Relapse rates for all drugs (cigarettes, opioid, other illicit substances)|Days until successful cigarette quit day|Drug withdrawal ratings|Genetic markers in nicotinic and opiate-receptor regions|Medication side effect ratings",West Virginia University|Pfizer|National Institute on Drug Abuse (NIDA),All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,80,Other|Industry|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,WestVirginiaU|NOT-DA-16-013,2016-07-01,2017-04-01,2017-04-01,2016-08-03,null,2016-08-03,"West Virginia University Chestnut Ridge Center, Morgantown, West Virginia, United States",,https://ClinicalTrials.gov/show/NCT02854800
34,NCT01967641,Prescription Opioid Abuse Among Pain Patients: Predictors of Relapse,PAIN,Completed,Has Results,Opioid Dependence,Drug: buprenorphine/naloxone combination,Number of Participants Retained in Study|Number of Participants Abstinent From Opioids|Pain Measurement,New York State Psychiatric Institute,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,51,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,#6269R|DA020448-05,2005-11-01,2011-06-01,2011-06-01,2013-10-23,2018-06-15,2018-06-15,"SURC, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01967641
35,NCT00723177,"Phase IIa Study of AV411, a Glial Activation Inhibitor, for Opioid Withdrawal",AV411,Completed,Has Results,Opioid-Related Disorders,Drug: AV411|Drug: Placebo (PCB),Subjective Opioid Withdrawal Scale Score (SOWS)|The Effects of AV411 on the Analgesic Effects of Oxycodone.,New York State Psychiatric Institute|National Institute on Drug Abuse (NIDA),All,21 Years to 45 Years   (Adult),Phase 2,30,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science",#5725|P50DA009236,2008-10-01,2010-04-01,2012-06-01,2008-07-28,2016-12-05,2016-12-05,"New York State Psychiatric Institute/Columbia University, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00723177
36,NCT02299024,Prescribing Opioid Pain Relievers in the Emergency Department: Understanding and Optimizing the Encounter,,Completed,No Results Available,"Opioid Use, Unspecified",Behavioral: Additional Opioid Information,Knowledge of medication name|Knowledge and counseling recall outcomes|Actual Use outcomes|Response to the intervention,Northwestern University|Emergency Medicine Foundation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,278,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,SP0017808,2012-10-01,2013-05-01,2013-05-01,2014-11-24,null,2014-11-24,"Northwestern University, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT02299024
37,NCT01536925,Studies of Opioid Seeking Behavior: Yohimbine and Hydrocortisone Effects,YHO,Completed,No Results Available,Heroin Dependence|Opioid-Related Disorders,,,Wayne State University|National Institute on Drug Abuse (NIDA),All,18 Years to 55 Years   (Adult),,21,Other|NIH,Observational,Observational Model: Case-Only|Time Perspective: Prospective,YHO-1|R01DA015462-06A1,2011-12-01,2017-04-01,2017-04-01,2012-02-22,null,2018-04-05,"Wayne State University, Detroit, Michigan, United States",,https://ClinicalTrials.gov/show/NCT01536925
38,NCT03394261,Pilot Test of Patient Decision Aid for Opioid Use Disorder,PtDA-MAT,Not yet recruiting,No Results Available,Opioid Use Disorder,Behavioral: Patient Decision Aid,Treatment Retention|Drug screening results|Treatment Adherence,"University of California, Los Angeles",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OPIOD1,2018-05-15,2018-08-31,2018-08-31,2018-01-09,null,2018-05-14,"Tarzana Treatment Centers, Inc., Tarzana, California, United States",,https://ClinicalTrials.gov/show/NCT03394261
39,NCT01517165,Pioglitazone to Treat Opioid Withdrawal Symptoms,,Terminated,No Results Available,Opioid-Related Disorders,Drug: Pioglitazone|Drug: Placebo,"Treatment response, defined as opioid abstinence without severe withdrawal symptoms during the last week of the taper (week 6) and duration in treatment (retention)|Overall proportions of opioid-negative urines, proportions of participants needing adjunct medications status at follow-up",National Institute on Drug Abuse (NIDA)|National Institutes of Health Clinical Center (CC),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,24,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment,999912469|12-DA-N469,2012-01-04,2015-02-02,2015-02-02,2012-01-25,null,2018-07-04,"National Institute on Drug Abuse, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01517165
40,NCT00134888,Blockade Efficacy of Buprenorphine/Naloxone For Opioid Dependence,,Completed,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine/naloxone,Physiological effects|drug effects (measured at Week 11),National Institute on Drug Abuse (NIDA),All,18 Years to 55 Years   (Adult),Not Applicable,8,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,NIDA-08045-2|R01-08045-2|DPMC,2000-12-01,null,2002-11-01,2005-08-25,null,2017-01-12,"Johns Hopkins University (BPRU) Bayview Campus, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00134888
41,NCT02038790,Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population,,Completed,Has Results,Opioid Dependence,Drug: Suboxone Sublingual Film|Drug: Zubsolv sublingual tablets,"Overall Intervention Preference As Assessed by Participants|Participant Preference With Regard to Overall Taste of Interventions|Participant Assessments With Regard to Ease of Dissolution of Interventions|Percentage of Participant Favorable and Unfavorable Response to the Question: How Easy or Difficult Was it to Open the Package?|Percentage of Participant Favorable and Unfavorable Response to the Question: How Easy or Difficult Were the Package Instructions to Follow?|Percentage of Participant Favorable and Unfavorable Response to the Question: How Comfortable Did It Feel In Your Mouth?|Percentage of Participant Favorable and Unfavorable Response to the Question: How Easily Did the Medication Dissolve in Your Mouth?|Percentage of Participant Response to the Question: Did You Experience Any Uncomfortable Effects of Burning or Stinging?|Percentage of Participant Response to the Question: Did You Experience Any Uncomfortable Effects of Skin Irritation or Blisters?|Percentage of Participant Response to the Request: Please Rate the Medication You Received Today in Terms of the Drug's Ability to Product a 'High'|Percentage of Participant Response to the Request: When Thinking About the Medication You Used Today, Indicate on the Line Below Your Ability to Abuse This Medication|Percentage of Participant Response to the Question: If You Did Want to Abuse This Medication, Would You Prefer to......|Percentage of Participant Response to the Question: Compared to the Medication That You Are Currently Using for Treatment of Opioid Dependence, The Study Medication You Just Used Was.....|Dissolution Time of Intervention as Recorded by a Trained Observer|Change From Baseline in Subject Opiate Withdrawal Scale (SOWS)",Indivior Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 4,33,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RBP-OSZ1|13-131220-108,2013-11-01,2013-11-01,2013-11-01,2014-01-17,2017-03-21,2017-03-21,"Hill Top Research, St Petersburg, Florida, United States",,https://ClinicalTrials.gov/show/NCT02038790
42,NCT00727675,Chronic Pain and Opioid Dependence Assessment and Treatment,CPODAT,Completed,No Results Available,Chronic Pain|Opioid Dependency,Behavioral: Integrated Cognitive Behavioral Therapy,Reduced illicit opioid use and pain,Yale University|National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,15,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1K23DA024050-01A1,2008-08-01,2014-07-01,2015-07-01,2008-08-04,null,2016-06-29,"Yale University School of Medicine, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00727675
43,NCT01436474,Pilot Study of Varenicline to Treat Opioid Dependence,,Completed,No Results Available,Chronic Pain|Opioid Dependence,Drug: Varenicline|Drug: Placebo,assessment of opioid withdrawal symptoms|Assessment of cravings at one month following opioid tapering,Mayo Clinic,All,"21 Years and older   (Adult, Older Adult)",Phase 1,21,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,11-002062,2011-06-01,2012-09-01,2012-12-01,2011-09-19,null,2013-01-23,"Mayo Clinic in Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT01436474
44,NCT02559973,"Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder",,Completed,No Results Available,Opioid Use Disorder,Drug: RBP-6000|Drug: SUBOXONE Sublingual Film,Area Under the Concentration-Time Curve from Study Day 1 to Day 29 (AUC0-28days) of Buprenorphine|Maximum Observed Plasma Concentration (Cmax) of Buprenorphine|Area Under the Concentration-Time Curve from Study Day 1 to Day 29 (AUC0-28days) of Norbuprenorphine|Maximum Observed Plasma Concentration (Cmax) of Norbuprenorphine|Participants with Treatment-Emergent Adverse Events,Indivior Inc.,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,47,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RB-US-13-0006,2015-09-01,2016-02-01,2016-03-01,2015-09-25,null,2017-01-31,"Vince & Associates Clinical Research, Overland Park, Kansas, United States",,https://ClinicalTrials.gov/show/NCT02559973
45,NCT03570320,Does Altering Narcotic Prescription Methods Affect Opioid Distribution Following Select Upper Extremity Surgeries?,,Not yet recruiting,No Results Available,Opioid Use,Other: Modification of opioid prescription method,Number of pills dispensed from a pharmacy to patients,John Yanik|University of Iowa,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,201804820,2018-08-01,2019-12-31,2020-02-28,2018-06-26,null,2018-06-27,"University of Iowa, Iowa City, Iowa, United States",,https://ClinicalTrials.gov/show/NCT03570320
46,NCT01751789,Linking Opioid Dependent Patients From Inpatient Detoxification to Primary Care,,Recruiting,No Results Available,Illicit Opioid Drug Use,Behavioral: Linkage|Other: Treatment as Usual,Illicit opioid use|Health Service Utilization,Butler Hospital,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,370,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DA034261,2012-10-01,2017-12-01,2018-08-01,2012-12-18,null,2018-01-19,"SSTAR, Fall River, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01751789
47,NCT01082679,Treatment for Opioid Dependent Offenders,,Unknown status,No Results Available,Opioid Dependence,Drug: Methadone|Drug: buprenorphine (Suboxone),Effectiveness,"University of Wisconsin, Madison|University of Wisconsin, Milwaukee",All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,16,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RTB-20080242,2009-06-01,2011-02-01,2011-02-01,2010-03-08,null,2010-03-08,"University of Wisconsin - Madison, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT01082679
48,NCT03287180,Adolescent Community Reinforcement Approach in Combination With Buprenorphine/Naloxone for Severe Opioid Use,A-CRA/MAT,Not yet recruiting,No Results Available,"Opioid-Related Disorders|Behavior, Addictive",Behavioral: Adolescent Community Reinforcement Approach (A-CRA)|Other: Combination of Buprenorphine/naloxone 4/1,Proportion of opiates-negative urine drug screens over the total number of urine drug screens at each stage|Percent of days of opioid use within the past 90 days as indicated by self-report on the GAIN-Q3-Standard|Completion of the final phase of treatment defined as final study session (yes/no)|Number of clinic visits by patient and any expected joint family member sessions,Emory University,All,18 Years to 25 Years   (Adult),Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB00093907,2018-09-07,2019-04-01,2019-04-01,2017-09-19,null,2017-09-19,"Executive Park, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT03287180
49,NCT03396276,Houston Emergency Opioid Engagement System,HEROES,Recruiting,No Results Available,Opioid Dependence,Drug: Suboxone|Behavioral: Brief counseling in the ED|Behavioral: Referral to outpatient treatment|Behavioral: Follow-up coaching,Patient enrollment in outpatient treatment|Patient retention in outpatient treatment,"The University of Texas Health Science Center, Houston",All,"18 Years and older   (Adult, Older Adult)",Phase 4,50,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HSC-SBMI-17-1021,2018-04-01,2019-03-31,2019-03-31,2018-01-10,null,2018-05-08,"The University of Texas Health Science Center at Houston, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03396276
50,NCT00608504,Effects of Environmental Factors on Opiate Drug Choice in Opioid Dependent Individuals.,DSC,Completed,No Results Available,Heroin Dependence|Opioid-Related Disorders,,,Wayne State University|National Institute on Drug Abuse (NIDA),All,18 Years to 55 Years   (Adult),,16,Other|NIH,Observational,Observational Model: Case-Only|Time Perspective: Prospective,NIDA-15462-3|R01DA015462-03|DPMCDA,2007-07-01,2009-04-01,2009-04-01,2008-02-06,null,2012-06-05,"Wayne State University, Detroit, Michigan, United States",,https://ClinicalTrials.gov/show/NCT00608504
51,NCT03190954,Brain Dopaminergic Signaling in Opioid Use Disorders,,Recruiting,No Results Available,Normal Physiology|Opioid-Related Disorders,Other: Placebo|Drug: Methylphenidate,To assess whether the balance between D1R and D2R in striatum is disrupted in participants with an opioid use disorder (OUD) who are being treated with an opioid medication (MAT+) and does who are not (MAT-).|To assess the impact of disruptions on striatal D1R to D2R availability on: DA release; Function of brain reward and control networks; Behavior.|To assess if DA increases as achieved with oral MP influence the brain functional measures.,National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institutes of Health Clinical Center (CC),All,"18 Years to 65 Years   (Adult, Older Adult)",Early Phase 1,240,NIH,Interventional,Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,170114|17-AA-0114,2017-08-17,2024-12-31,2024-12-31,2017-06-19,null,2018-08-08,"National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT03190954
52,NCT03183882,Peer Comparison Feedback on Opioid Prescribing,,Completed,No Results Available,Opioid Use,Behavioral: Personal Feedback|Behavioral: Peer Normative Comparison Feedback,Normative beliefs|Number of opioid prescriptions per month,University of Pittsburgh,All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,49,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research",PRO17040547,2017-08-07,2017-09-28,2017-09-28,2017-06-12,null,2017-12-02,"University of Pittsburgh Medical Center Emergency Department, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03183882
53,NCT03575273,The Impact of Methadone Maintenance Therapy on Food Reward Processing in Opioid Dependence,,Recruiting,No Results Available,Opioid Dependence|Obesity,Behavioral: Sniffin' Sticks Odor Identification and Hedonic Scale|Behavioral: Sucrose Taste Preference Assessment|Behavioral: Food Preferences Task|Behavioral: Progressive Ratio (PR) Task|Procedure: Clinical Electrophysiology|Dietary Supplement: Standardized Meal and Hunger and Satiety Ratings,Event-related potentials measured via BrainVision actiCHamp system|Chemosensory Processing|Food Preferences Task|Progressive Ratio Task,Johns Hopkins University|Mid-Atlantic Nutrition Obesity Research Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,18 Years to 60 Years   (Adult),Not Applicable,45,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,IRB00092798|P30DK072488,2018-02-12,2018-12-01,2018-12-01,2018-07-02,null,2018-07-02,"Broadway Center for Addictions, Baltimore, Maryland, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT03575273
54,NCT00460239,Buprenorphine's Dose Response Curve,,Completed,Has Results,Opioid-related Disorders,Drug: Buprenorphine|Drug: Morphine|Drug: Placebo,Peak Change From Baseline in Drug Effect Assessed by Visual Analog Scale (VAS)|Psychomotor/Cognitive Performance Effects Assessed by Digit Symbol Substitution Test (DSST)|Psychomotor/Cognitive Performance Effects Assessed by Trails B|Physiologic Effects as Assessed by Blood Pressure|Physiologic Effects as Assessed by Heart Rate|Physiologic Effects as Assessed by Body Temperature|Physiologic Effects as Assessed by Oxygen Saturation|Physiologic Effects as Assessed by Pupil Diameter,Johns Hopkins University|National Institute on Drug Abuse (NIDA),All,21 Years to 55 Years   (Adult),Phase 2,12,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",NIDA-08045-8|5R01DA008045-08|R01DA008045|DPMCDA,2007-01-01,2009-07-01,2009-07-01,2007-04-13,2017-03-03,2017-03-03,"Johns Hopkins University (BPRU) Bayview Campus, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00460239
55,NCT01562353,Determining Genetic Biomarkers Predictive of the Development of Prescription Opioid Addiction,,Unknown status,No Results Available,Usage of Prescription Opioids,,mRNA Levels|FTQ|TEQ|LSQ|POCS|POAQ|mARCI|MINI,Analgesic Solutions,All,"18 Years and older   (Adult, Older Adult)",,30,Industry,Observational,Observational Model: Case Control|Time Perspective: Retrospective,CPH.CSA.0005,2012-04-01,2013-12-01,2013-12-01,2012-03-23,null,2013-09-16,"Analgesic Solutions, Natick, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01562353
56,NCT00742170,Transdermal Electroacupuncture for Opioid Detoxification,,Completed,Has Results,Opioid Dependency,Device: Electroacupuncture,Percent of Participants Using Drugs|Opioid Craving (Self-report),Mclean Hospital|Harvard Medical School,All,18 Years to 59 Years   (Adult),Phase 1|Phase 2,48,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,2007-P000711,2007-08-01,2009-10-01,2010-01-01,2008-08-27,2014-10-21,2014-10-21,"McLean Hospital, Belmont, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00742170
57,NCT01841931,Buprenorphine Treatment: A Safe Alternative for Opioid Dependent Pain Patients,,Terminated,Has Results,Opioid Use Disorder,Drug: Buprenorphine/Naloxone,Opiate Withdrawal|Pain Severity|Psychiatric Distress|Quality of Life|Positive Affect,Maimonides Medical Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,4,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11/09/VA05,2013-02-01,2013-07-01,2013-08-01,2013-04-29,2018-04-23,2018-04-23,"Maimonides Medical Center, Brooklyn, New York, United States",,https://ClinicalTrials.gov/show/NCT01841931
58,NCT02110264,Injectable Pharmacotherapy for Opioid Use Disorders (IPOD),IPOD,"Active, not recruiting",No Results Available,Opioid Use Disorders,Drug: XR-NTX|Behavioral: XR-NTX+PN|Behavioral: ETAU,Opioid use|Opioid Use Disorder,"University of California, Los Angeles|Alkermes, Inc.",All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 3,151,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DA034743,2015-06-01,2018-08-01,2019-02-01,2014-04-10,null,2018-06-05,"University of New Mexico Center on Alcoholism, Substance Abuse and Addictions, Albuquerque, New Mexico, United States",,https://ClinicalTrials.gov/show/NCT02110264
59,NCT01909076,Transforming Opioid Prescribing in Primary Care,TOPCARE,Completed,No Results Available,Chronic Pain|Opioid-Related Disorders,Behavioral: Electronic decision support tools|Behavioral: Enhanced patient education materials|Behavioral: Nurse care management|Behavioral: Electronic Patient Registry|Behavioral: Academic detailing,"PCP adherence to chronic opioid therapy guidelines|Patient opioid misuse, as measured by number of early refills|Patient opioid and illicit substance misuse and/or abuse, as measured by urine toxicology results",Boston Medical Center|National Institute on Drug Abuse (NIDA),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,53,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,R01DA034252-01,2014-01-01,2016-03-01,2016-03-01,2013-07-26,null,2016-03-03,"Boston Medical Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01909076
60,NCT03022890,Study of Yoga vs. Health Education for Chronic Pain in Persons Receiving Opioid Agonist Therapy,,Recruiting,No Results Available,"Opioid-Related Disorders|Pain, Chronic",Behavioral: hatha yoga|Behavioral: health education,Client Satisfaction Questionnaire|Credibility Expectancy Questionnaire (CEQ)|Participant adherence|Participant homework adherence|Instructor manual fidelity checklist|Systematic Assessment of Treatment-Emergent Events - General Inquiry,Butler Hospital|National Center for Complementary and Integrative Health (NCCIH),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R34AT009432,2017-04-01,2018-09-01,2019-07-01,2017-01-18,null,2018-06-14,"Stanley Street Treatment and Resources, Fall River, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03022890
61,NCT00684554,Buprenorphine Maintenance Treatment of Opioid Dependence in Primary Care: A Randomized Clinical Trial,,Completed,Has Results,Opioid-Related Disorders|Heroin Dependence,Drug: Buprenorphine,The Primary Outcome Will Include a Comparison of the Proportion of Patients Successfully Inducted One Week After the Initial Primary Care Visit.|Prolonged Withdrawal,New York State Psychiatric Institute|National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,20,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,#5600|K23DA020000,2007-12-01,2008-08-01,2010-04-01,2008-05-26,2016-01-11,2018-05-15,"Columbia University/New York State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00684554
62,NCT01377610,Improved Strategies for Outpatient Opioid Detoxification,,Completed,No Results Available,Opioid Dependence,Drug: oral naltrexone|Drug: Buprenorphine|Drug: Vivitrol,Percentage of patients in each group successfully inducted onto Vivitrol,New York State Psychiatric Institute|National Institute on Drug Abuse (NIDA),All,18 Years to 60 Years   (Adult),Phase 1,150,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,#6374/7250R|2R01DA010746-09A1,2011-06-01,2017-12-01,2017-12-01,2011-06-21,null,2018-05-21,"Substance Treatment and Research Service (STARS), Columbia University, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01377610
63,NCT03616379,Stress Response in Opioid Use Disorder,,Not yet recruiting,No Results Available,Opioid-use Disorder,Behavioral: Psychoeducational Control|Behavioral: Affect Regulation|Behavioral: Affect Labelling,Change in Negative Affect|Distress Tolerance|Change in Cortisol Response|Change in Skin Conductance Level|Change in Opioid Craving,Mclean Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Other,2018P001419,2018-11-01,2020-06-01,2020-08-01,2018-08-06,null,2018-08-06,"McLean Hospital, Belmont, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03616379
64,NCT01740414,Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers,,Completed,Has Results,Opioid Abuse|Opioid Dependence,Drug: MN-166 (50 mg) First|Drug: Placebo First,Drug Self-administration Breakpoint|Positive Subjective Effects to Oxycodone,New York State Psychiatric Institute|National Institute on Drug Abuse (NIDA)|MediciNova,All,21 Years to 55 Years   (Adult),Phase 2,28,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",#6021|P50DA009236,2012-11-01,2015-12-01,2017-05-01,2012-12-04,2017-08-17,2017-08-17,"New York State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01740414
65,NCT02044094,Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder,,Completed,Has Results,Opioid Use Disorder,Drug: Buprenorphine|Drug: buprenorphine and naloxone|Drug: hydromorphone|Drug: placebo,"Opioid Blockade Following Administration of Hydromorphone Challenge As Measured Using the Subjective Opioid Effects Rating for the Question ""Do You Like the Drug?"" Visual Analog Scale (VAS) at Weeks 1-4 Analyzed by Mixed Model for Repeated Measures|Reinforcing Effects (Breakpoint) by Study Week Analyzed by Mixed Model for Repeated Measures|Reinforcing Effects Of the Daily Randomized Hydromorphone Challenge as Measured by the Mean Hydromorphone Break Point Value at Weeks 1-12|Participants With Treatment-Emergent Adverse Events (TEAE)|Plasma Concentrations of Buprenorphine Summarized by Study Week|Predicted mu Opioid Receptor Occupancy (μORO) by Mean Buprenorphine Concentrations and Study Week|Change From Placebo in Reinforcing Effects (Breakpoint) by Study Week and Simulated mu Opioid Receptor Occupancy (μORO)|Visual Analog Scale (VAS) Score for ""Do You Like the Drug?"" by Study Week Analyzed by Mixed Model for Repeated Measures|Change From Placebo in VAS Score for ""Do You Like the Drug?"" by Study Week and Simulated mu Opioid Receptor Occupancy (μORO)|VAS Score for ""How High Are You Right Now?"" by Study Week Analyzed by Mixed Model for Repeated Measures|Change From Placebo in VAS Score for ""How High Are You Right Now?"" by Study Week and Simulated mu Opioid Receptor Occupancy (μORO)|VAS Score for ""Do You Feel Any Drug Effect?"" by Study Week Analyzed by Mixed Model for Repeated Measures|Change From Placebo in VAS Score for ""Do You Feel Any Drug Effect?"" by Study Week and Simulated mu Opioid Receptor Occupancy (μORO)|VAS Score for ""Does the Drug Have Any Good Effects?"" by Study Week Analyzed by Mixed Model for Repeated Measures|Change From Placebo in VAS Score for ""Does the Drug Have Any Good Effects?"" by Study Week and Simulated mu Opioid Receptor Occupancy (μORO)|VAS Score for ""Does the Drug Have Any Bad Effects?"" by Study Week Analyzed by Mixed Model for Repeated Measures|Change From Placebo in VAS Score for ""Does the Drug Have Any Bad Effects?"" by Study Week and Simulated mu Opioid Receptor Occupancy (μORO)|VAS Score for ""Do You Feel Sedated?"" by Study Week Analyzed by Mixed Model for Repeated Measures|Change From Placebo in VAS Score for ""Do You Feel Sedated?"" by Study Week and Simulated mu Opioid Receptor Occupancy (μORO)",Indivior Inc.,All,18 Years to 55 Years   (Adult),Phase 2,39,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RB-US-13-0002,2013-11-01,2014-07-01,2014-07-01,2014-01-23,2018-04-24,2018-04-24,"Vince & Associates Clinical Research, Overland Park, Kansas, United States",,https://ClinicalTrials.gov/show/NCT02044094
66,NCT03168425,Opioid Prescribing After Cesarean Delivery,,Completed,No Results Available,Surgery|Opioid Use,Other: Tailored prescription|Other: Control,Unused opioids|Pain: Frequency that participants reported uncontrolled pain,Vanderbilt University Medical Center,Female,18 Years to 50 Years   (Adult),Not Applicable,190,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OSMUNDSS04192017181235,2017-06-14,2017-09-30,2017-10-31,2017-05-30,null,2018-05-08,"Sarah Osmundson, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT03168425
67,NCT03151655,Changing Opioid Users' Negative Attitudes Toward Medication Assisted Treatment,,Not yet recruiting,No Results Available,Opioid Use Disorder,Behavioral: MATTeRS Video|Behavioral: Didactic Video,Initiation of Medication Assisted Treatment,Butler Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,1610-001,2019-01-01,2022-01-01,2022-01-01,2017-05-12,null,2018-04-12,"Butler Hospital, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT03151655
68,NCT02586896,Comparing Interventions for Opioid Dependent Patients Presenting in Medical Emergency Departments,,Recruiting,No Results Available,Opioid Dependence,"Behavioral: Strengths-based Case Management (SBCM)|Behavioral: Screening, Assessment, and Referral (SAR)",Initiation of and engagement in treatment for opioid dependence|Opioid and other substance use|Initiation and engagement in participants with higher levels of environmental instability at baseline|Quality of life,New York University School of Medicine|Wright State University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,300,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,15-00862,2016-03-01,2020-09-01,2020-09-01,2015-10-27,null,2017-10-19,"Bellevue Hospital Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02586896
69,NCT01122030,Study to Evaluate the Safety and Efficacy of Naldemedine (S-297995) for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain,,Completed,Has Results,Opioid Induced Bowel Dysfunction,Drug: Naldemedine|Drug: Placebo,Number of Participants With Adverse Events|Change From Baseline to 24 Hours Post-dose in Number of Spontaneous Bowel Movements (SBMs) Per Day|Change From Baseline to 48 Hours Post-dose in the Number of SBMs Per Day|Change From Baseline to 24 Hours Post-dose in Number of Bowel Movements (BM) Per Day|Change From Baseline to 48 Hours Post-dose in Number of Bowel Movements Per Day|Change From Baseline to 24 Hours Post-dose in Number of Complete Spontaneous Bowel Movements (CSBMs) Per Day|Change From Baseline to 48 Hours Post-dose in Number of Complete Spontaneous Bowel Movements (CSBMs) Per Day|Time to First Spontaneous Bowel Movement|Time to First Bowel Movement|Time to First Complete Spontaneous Bowel Movement|Change From Baseline in Straining During Bowel Movements|Change From Baseline to 24 Hours Post-dose in Number of Complete Bowel Movements Per Day|Change From Baseline to 48 Hours Post-dose in Number of Complete Bowel Movements Per Day|Change From Baseline in Abdominal Bloating|Change From Baseline in Abdominal Discomfort|Change From Baseline in BM Consistency|Change From Baseline in Number of False Start Bowel Movements Per Day|Change From Baseline in the Number of Bowel Movements With No Straining Per Day|Change From Baseline in Number of Rescue Medications Used Per Day|Percentage of Participants With Clinical Opiate Withdrawal Scale (COWS) Score > 8 at Any Time During the Study|Percentage of Participants With Webster Opiate Withdrawal Scale (WOWS) Score > 8 at Any Time During the Study|Maximum Observed Plasma Concentration (Cmax) of Naldemedine and Metabolite Nor-S-297995|Time to Maximum Observed Plasma Concentration of Naldemedine and Metabolite Nor-S-297995|Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Measurable Concentration of Naldemedine and Metabolite Nor-S-297995|Area Under the Plasma Concentration-time Curve From Time Zero to Infinity for Naldemedine and Metabolite Nor-S-297995|Apparent Elimination Half-life of Naldemedine and Metabolite Nor-S-297995,Shionogi|Shionogi Inc.,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,72,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",1007V9214,2010-05-19,2011-02-23,2011-03-22,2010-05-12,2017-05-30,2017-05-30,"Shionogi Research Site, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT01122030
70,NCT01999946,Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry,XOR,Recruiting,No Results Available,Heroin Dependence|Opioid-Related Disorders,Drug: Extended-Release Naltrexone,Time-to-Relapse: XRNTX vs. ETAU following release from jail|Time-to-relapse: XR-NTX vs. Methadone (MTP) cohort following release from jail|Community treatment retention/initiation post-release|Any drug or alcohol misuse|Injection drug use and HIV sexual risk factors|Accidental drug overdose and mortality|Re-incarceration and exploratory cost-effectiveness,"New York University School of Medicine|National Institute on Drug Abuse (NIDA)|Friends Research Institute, Inc.|University of California, Los Angeles",All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 4,255,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12-03724|1U01DA033336-01A1,2014-06-27,2021-01-01,2021-01-01,2013-12-03,null,2018-04-20,"Bellevue Hospital Center, New York, New York, United States|NYC Department of Corrections: Rikers Island Jail Facilities, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01999946
71,NCT01333540,"A Study to Assess the Safety, Tolerability and Clinical Activity of TD−1211 in Patients With Opioid-Induced Constipation",,Completed,No Results Available,Opioid-induced Constipation (OIC),Drug: TD-1211|Drug: Placebo,Frequency and Severity of Treatment Emergent Adverse Events in Subjects with Opioid-Induced Constipation Treated with TD-1211|Evaluation of clinical activity measured as frequency of bowel-movements at different dose levels,"Theravance Biopharma R & D, Inc.|Theravance Biopharma Antibiotics, Inc.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,69,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",74,2011-05-01,2012-05-01,2012-06-01,2011-04-12,null,2014-09-10,"Clinical Research Unit, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT01333540
72,NCT03143543,Phase I Functional Magnetic Resonance Imaging (fMRI) Pharmacodynamic Studies of Compounds for Opioid Use Disorder and Cocaine Use Disorder,,Recruiting,No Results Available,Cocaine-Related Disorders|Opioid-Related Disorders,Drug: Group A Lorcaserin (10mg)|Drug: Group A2 Lorcaserin (20 mg)|Other: Group B Parallel Placebo|Other: Group B2 Parallel Placebo,Target engagement by lorcaserin,Virginia Commonwealth University|National Institute on Drug Abuse (NIDA),All,18 Years to 55 Years   (Adult),Phase 1,60,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HM20003329|5U54DA038999-04,2015-07-01,2019-07-31,2020-07-31,2017-05-08,null,2017-10-02,"Virginia Commonwealth University, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT03143543
73,NCT02990377,Reducing Non-Medical Opioid Use: An Automatically Adaptive mHealth Intervention,,Not yet recruiting,No Results Available,Non-Medical Opioid Use,Behavioral: RL-supported IVR intervention,Level of Non-Medical Opioid Use|Emergency Department (ED) Utilization|Driving after consuming opioids|Overdose Risk Behaviors,University of Michigan|National Institute on Drug Abuse (NIDA),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,600,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,R01DA039159,2018-08-01,2020-07-01,2021-06-01,2016-12-13,null,2018-06-11,"University of Michigan Medical Center, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT02990377
74,NCT02712034,Impact on Opioid Use of Bundling Medication-assisted Treatment With mHealth,Bundling,Recruiting,No Results Available,Opioid Use Disorder,Behavioral: MAT + A-CHESS|Other: MAT,Opioid use,"University of Wisconsin, Madison|Stanley Street Treatment and Resources (SSTAR)|Gosnold on Cape Cod|ARC Community Services, Inc.|National Institute on Drug Abuse (NIDA)",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,440,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",2015-1418|1R01DA040449-01,2016-04-01,2020-04-01,2020-08-01,2016-03-17,null,2017-10-16,"Access Community Health Centers, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02712034
75,NCT03559179,Clinical Decision Support for Opioid Use Disorders in Medical Settings: Usability Testing in an EMR,COMPUTE,Enrolling by invitation,No Results Available,Opioid-use Disorder,Other: Opioid Wizard,Survey providers to gather feedback on the CDS tool and assess attitudes towards OUD.|Calculate post-intervention rates of screening for OUD in high-risk patients|Compare pre- and post-intervention rates of OUD diagnosis in high-risk patients.|Compare pre- and post-intervention rates of medication-assisted therapy (MAT) use.|Compare post-intervention referral patterns between intervention and control groups,HealthPartners Institute|National Institute on Drug Abuse (NIDA)|Minneapolis Medical Research Foundation,All,"Child, Adult, Older Adult",Not Applicable,43,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,0076-ot|3UG1DA040316-03S1,2018-04-30,2018-12-31,2019-01-31,2018-06-18,null,2018-06-18,"HealthPartners, Bloomington, Minnesota, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT03559179/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT03559179
76,NCT02294253,Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone,,Completed,No Results Available,Opioid Dependence,Drug: Buprenorphine/naloxone,Successful Induction onto XR-NTX|Opioid Abstinence,New York State Psychiatric Institute|National Institute on Drug Abuse (NIDA),All,18 Years to 60 Years   (Adult),Phase 2|Phase 3,30,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,6999,2014-09-01,2017-12-01,2017-12-01,2014-11-19,null,2018-06-14,"STARS, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02294253
77,NCT01401985,A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC),,Completed,No Results Available,Opioid Induced Constipation,Drug: TD-1211,Safety and tolerability of TD-1211|Complete spontaneous bowel movements (CSBM); Spontaneous bowel movements (SBM),"Theravance Biopharma R & D, Inc.|Theravance Biopharma Antibiotics, Inc.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,95,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,TD-1211-0076,2011-10-01,2012-05-01,2012-08-01,2011-07-26,null,2014-09-10,"Pasadena, California, United States",,https://ClinicalTrials.gov/show/NCT01401985
78,NCT02861976,Screening in Trauma for Opioid Misuse Prevention,STOMP,Recruiting,No Results Available,Opioid Use Disorder,Other: Opioid risk screen development & implementation,Opioid use disorder (CIDI-SAM) or opioid misuse (COMM) Opioid Use Disorder in 6 Months Post Traumatic Injury,"University of Wisconsin, Madison",All,"18 Years to 65 Years   (Adult, Older Adult)",,295,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2016-0430|3152,2016-09-01,2019-06-01,2019-07-01,2016-08-10,null,2017-05-05,"University of Wisconsin - Madison, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02861976
79,NCT01136356,A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals,,Completed,Has Results,Opioid Abuse|Opioid Dependence,Drug: buprenorphine|Drug: morphine,Mean Peak Opioid Withdrawal Assessed by the Clinical Opiate Withdrawal Scale (COWS)|Mean Daily Peak Pain Ratings Assessed by the Visual Analog Scale (VAS)|Mean Peak Sleep Assessed by Pittsburgh Sleep Quality Index (PSQI),Johns Hopkins University|National Institute on Drug Abuse (NIDA),All,18 Years to 60 Years   (Adult),Phase 1|Phase 2,12,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",NIDA-08045-9|R01DA008045|DPMC,2010-07-01,2012-03-01,2012-03-01,2010-06-03,2017-03-03,2017-03-03,"Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01136356
80,NCT02120612,Increasing Patient Knowledge of the Signs of Opioid Overdose and Naloxone in a Suburban Treatment Program,,Recruiting,No Results Available,Opioid Dependence|Opioid Use Disorder,Other: Naloxone Education Intervention,Opiate Overdose Knowledge Scale (OOKS)|History Survey|Guilt and Shame Proneness Scale (GASP),Edward Hospital|Edward-Elmhurst Health System,All,"18 Years and older   (Adult, Older Adult)",,150,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,LOH32414,2014-04-01,2018-10-01,2018-10-01,2014-04-23,null,2018-02-05,"Linden Oaks, Naperville, Illinois, United States",,https://ClinicalTrials.gov/show/NCT02120612
81,NCT03169816,Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder,,Recruiting,No Results Available,Opioid-use Disorder,Drug: Lorcaserin|Drug: Placebo,Proportion of patients successfully retained to receive 2nd naltrexone injection,New York State Psychiatric Institute,All,18 Years to 60 Years   (Adult),Phase 2|Phase 3,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",7501,2017-05-25,2019-10-30,2019-12-30,2017-05-30,null,2018-05-16,"Substance Treatment and Research Service (STARS), Columbia University, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03169816
82,NCT02765867,"Single-dose, Study of RBP-6000 in Opioid Dependent Individuals",,Completed,No Results Available,Opioid Use Disorder,Drug: RBP-6000,To assess the incidence of treatment emergent adverse events (safety and tolerability) of a single SC injection of RBP-6000 in subjects with opioid dependence.|Maximum plasma concentration (Cmax) for buprenorphine and norbuprenorphine|Time to occurrence of Cmax (Tmax) for buprenorphine and norbuprenorphine|Area under the plasma concentration versus time curve (AUC) for buprenorphine and norbuprenorphine,Indivior Inc.,All,18 Years to 60 Years   (Adult),Phase 1,18,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RB-US-10-0011,2010-11-01,2011-05-01,2011-05-01,2016-05-09,null,2016-05-09,"Scientific Clinical Research, Ft. Lauderdale, Florida, United States",,https://ClinicalTrials.gov/show/NCT02765867
83,NCT00158184,Prescription Opioid Effects in Abusers Versus Non-Abusers,,Completed,Has Results,Opioid-Related Disorders|Substance-Related Disorders,Drug: oxycodone 15 mg|Drug: oxycodone 30 mg|Drug: Placebo 0 mg,Breakpoint|Drug Liking,New York State Psychiatric Institute|National Institute on Drug Abuse (NIDA),All,21 Years to 45 Years   (Adult),Phase 2,27,Other|NIH,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science",#4691|R01DA016759-01,2004-06-01,2009-06-01,2009-06-01,2005-09-12,2017-07-07,2017-07-07,"New York State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00158184
84,NCT01713803,Evaluation of BEMA® Buprenorphine NX for Buprenorphine Induction of Opioid Dependent Subjects,,Withdrawn,No Results Available,Opioid Dependence,Drug: Buprenorphine and naloxone,The mean change in clinical opioid withdrawal scale (COWS) total score from Baseline to 6 hours following the initial dose|The percentage of subjects with a negative result on the urine drug screen at Day 7|The percentage of subjects with a clinical opioid withdrawal scale (COWS) total score ≤4 at 6 hours after the initial study drug dose,BioDelivery Sciences International,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,0,Industry,Interventional,,BNX-350,null,2017-05-01,2017-05-01,2012-10-25,null,2017-05-04,"Birmingham, Alabama, United States",,https://ClinicalTrials.gov/show/NCT01713803
85,NCT00218361,Effects of Post-Session Supplemental Hydromorphone on Drug Seeking Behavior in Opioid Dependent Individuals,,Completed,No Results Available,Heroin Dependence|Opioid-Related Disorders,Drug: Hydromorphone,,Wayne State University|National Institute on Drug Abuse (NIDA),All,18 Years to 55 Years   (Adult),,16,Other|NIH,Observational,Observational Model: Case-Only|Time Perspective: Prospective,NIDA-15462-2|R01DA015462|R01-15462-2|DPMC,2005-08-01,null,null,2005-09-22,null,2012-06-05,"Wayne State University, Detroit, Michigan, United States",,https://ClinicalTrials.gov/show/NCT00218361
86,NCT01459926,"A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation",,Completed,No Results Available,Opioid Induced Constipation,Drug: TD-1211|Drug: Placebo,Change from baseline in the weekly average CSBMs over Weeks 2 to 5 of treatment|Change from baseline in the weekly SBM frequency in the last week of treatment,"Theravance Biopharma R & D, Inc.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,217,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",84,2011-11-01,2012-05-01,2012-06-01,2011-10-26,null,2015-07-02,"G and L Research, LLC, Foley, Alabama, United States",,https://ClinicalTrials.gov/show/NCT01459926
87,NCT00719095,Effective Treatment for Prescription Opioid Abuse,,Completed,No Results Available,Prescription Opioid Dependence,Drug: buprenorphine taper followed by naltrexone maintenance|Behavioral: Behavioral therapy,percentage of subjects abstinent from all opioids through the final day of detoxification|percentage of subjects retained in treatment through the final day of detoxification,University of Vermont Medical Center|National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,105,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",R01DA019989,2006-04-01,2010-03-01,2010-03-01,2008-07-21,null,2013-04-15,"Substance Abuse Treatment Center, University of Vermont, Burlington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT00719095
88,NCT00125515,Memantine and Naltrexone Treatment for Opioid Dependence,NAMHS-1,Completed,Has Results,Opioid Dependence,Drug: Memantine|Drug: Naltrexone,Retention in Treatment,New York State Psychiatric Institute|National Institute on Drug Abuse (NIDA),All,18 Years to 60 Years   (Adult),Phase 2,81,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",#4847/R01-15822|K23DA000429,2005-06-01,2008-08-01,2008-08-01,2005-08-01,2013-01-24,2018-06-18,"New York State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00125515
89,NCT03032822,Opioid Consumption in Cystectomy Patients,,Recruiting,No Results Available,Cystostomy; Complications|Opioid Use,,opioid consumption over time,Ohio State University,All,"18 Years and older   (Adult, Older Adult)",,80,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2017H0430,2018-01-17,2019-12-31,2019-12-31,2017-01-26,null,2018-04-09,"The Ohio State University Wexner Medical Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03032822
90,NCT00218127,Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens,,Completed,No Results Available,Heroin Dependence|Opioid-Related Disorders,Drug: Levoacetyl Methadol,drug use,National Institute on Drug Abuse (NIDA),All,25 Years to 55 Years   (Adult),Phase 2,142,NIH,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NIDA-13664-1|R01-13664-1|DPMC,2001-11-01,2005-07-01,2005-07-01,2005-09-22,null,2017-01-12,"Department of Psychatiry, Mental Services, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00218127
91,NCT00756990,Depot Naltrexone Treatment of Opioid Dependent Parolees,,Completed,No Results Available,Opioid Dependence,Drug: Depot Naltrexone,UDS results|Treatment completion,University of Pennsylvania|National Institute on Drug Abuse (NIDA),All,18 Years to 55 Years   (Adult),Not Applicable,61,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,708310|R01DA024553,2005-11-01,2009-03-01,2011-08-01,2008-09-22,null,2015-10-02,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00756990
92,NCT01052662,Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults,,Completed,Has Results,Opioid Dependence,Drug: Memantine|Drug: Placebo,Change of Opioid Use From Week 1 to 13|Number of Participants Who Were Estimated to Have Survived as Assessed by Survival Curve of Relapse Rate After Achieving Complete Abstinence on Week 8|Treatment Retention,"University of Massachusetts, Worcester|National Institute on Drug Abuse (NIDA)",All,18 Years to 25 Years   (Adult),Phase 2|Phase 3,87,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",H-13261|1R01DA027138-01,2009-10-01,2013-06-01,2013-10-01,2010-01-20,2015-03-06,2015-04-01,"University of Massachusetts Medical School, Worcester, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01052662
93,NCT01371903,The Effects of Patient Features on Opioid Induced End-Tidal CO2,Capno,Completed,No Results Available,Opioid Use During Medical Care,,end tidal carbon dioxide,Albany Medical College,All,"18 Years and older   (Adult, Older Adult)",,278,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2792,2010-08-01,2012-11-01,2012-11-01,2011-06-13,null,2014-03-24,"Albany Medical Center Emergency Department, Albany, New York, United States",,https://ClinicalTrials.gov/show/NCT01371903
94,NCT03566459,MAT for Opioid Use Disorders,,Recruiting,No Results Available,Opioid Use Disorder,Other: CBOC offering MAT for opioid use disorder,Population potentially able to benefit from telemedicine MAT|AUDIT-C|Cost of Telemedicine MAT|Cost of Training and Implementation|Veterans' subjective experience of telemedicine MAT|Providers' experience of implementing MAT|Negative toxicology tests|Number of CBOCs participating in telemedicine MAT|Brief Addiction Monitor-Revised (BAM-R)|Number of providers participating in telemedicine MAT,VA Office of Research and Development,All,"Child, Adult, Older Adult",,10,U.S. Fed,Observational,Observational Model: Case-Only|Time Perspective: Prospective,PIX 18-001|PII 18-178,2018-04-01,2019-03-31,2019-03-31,2018-06-25,null,2018-06-25,"VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven, Connecticut, United States|Charlie Norwood VA Medical Center, Augusta, GA, Augusta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT03566459
95,NCT01030406,Study of the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users,,Completed,No Results Available,Opioid Abuse,Drug: Drug A|Drug: Drug B|Drug: Drug C|Drug: Drug D|Drug: Placebo,Drug Liking/Disliking analyzed over 0-3 hours|Take Drug Again Assessment (TDAA)|Global Assessment of Overall Drug Liking|Pupillometry,Acura Pharmaceuticals Inc.|King Pharmaceuticals is now a wholly owned subsidiary of Pfizer,All,18 Years to 55 Years   (Adult),Phase 2,47,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",AP-ADF-114,2010-01-01,2010-02-01,2010-02-01,2009-12-11,null,2010-03-10,"Lifetree Clinical Research, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT01030406
96,NCT00142727,Opioid Agonist and Antagonist Effects on Opioid Dependence,,Terminated,No Results Available,Opioid-Related Disorders,Drug: Methadone|Drug: Full opioid agonist|Drug: Partial opioid agonist|Drug: Opioid antagonist,Opiate withdrawal|Opiate agonist symptoms|Physiologic measures,National Institute on Drug Abuse (NIDA)|Johns Hopkins University,All,18 Years to 55 Years   (Adult),Phase 2,16,NIH|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,NIDA-08045-6|R01-08045-6|DPMC,2004-01-01,null,2006-02-01,2005-09-02,null,2017-01-12,"Johns Hopkins University (BPRU) Bayview Campus, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00142727
97,NCT03294174,Opioid Induced Loss of Local Anesthetic Potency in Patients Undergoing Total Knee Arthroplasty,,Recruiting,No Results Available,"Opioid Tolerance, Opioid Naive, Opioid Exposure",Drug: Ropivacaine injection,Sensory and motor function loss after nerve block procedures|pain|sodium channel subunit changes in synovial tissues,University of Pittsburgh,All,"18 Years to 80 Years   (Adult, Older Adult)",,90,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,PRO15020146,2017-12-01,2019-05-01,2019-05-01,2017-09-26,null,2017-10-27,"University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03294174
98,NCT00142896,Tramadol to Reduce Opioid Withdrawal Symptoms,,Completed,No Results Available,Opioid-Related Disorders,Drug: Tramadol|Drug: Naloxone|Drug: Morphine,"Opioid withdrawal symptoms (measured by Visual Analog Scale during the experimental sessions)|Opioid agonist effects (measured by Visual Analog Scale during the experimental sessions)|Physiological effects (measured by pulse oximeter, blood pressure, heart rate, and pupillary camera during the experimental sessions)",National Institute on Drug Abuse (NIDA),All,21 Years to 55 Years   (Adult),Phase 2,16,NIH,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,NIDA-18125-1|R01-18125-1|DPMC,2005-02-01,2005-12-01,2005-12-01,2005-09-02,null,2017-01-12,"Johns Hopkins University (BPRU) Bayview Campus, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00142896
99,NCT00699010,Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse,,Completed,No Results Available,Opioid Abuse,Drug: Niacin|Drug: Oxycodone HCL plus Niacin|Drug: Placebo|Drug: Oxycodone HCl,"Evaluation of the Drug Rating Questionnaire-Subject (DRQS), and the Addiction Research Center Inventory (ARCI)|Evaluation of the DRQS, the ARCI, the Street Value Assessment Questionnaire (SVAQ), and the Treatment Enjoyment Assessment Questionnaire (TEAQ)",Acura Pharmaceuticals Inc.,All,18 Years to 55 Years   (Adult),Phase 2,30,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",AP-ADF-111,2008-03-01,2008-08-01,2008-08-01,2008-06-17,null,2008-10-23,"Johns Hopkins Medical Center, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00699010
100,NCT02669901,Naloxone Auto-injector as a Universal Precaution for Patients With Opioid Substance Use Disorder,,Recruiting,No Results Available,Opiate Antagonist Overdose|Opioid-Related Disorders,Behavioral: Naloxone Auto-Injector,number of fatal over dose deaths by use of naloxone auto-injector co-prescribing from the University of New Mexico Addiction and Substance Abuse Program (UNM ASAP)|number of near fatal overdoses prevented by use of naloxone auto-injector co-prescribing from the University of New Mexico Addiction and Substance Abuse Program (UNM ASAP),University of New Mexico|Kaleo Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,400,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,15-616,2016-04-01,2018-04-01,2018-04-01,2016-02-01,null,2016-10-26,"UNM Hospitals - Alcohol and Substance Abuse Program, Albuquerque, New Mexico, United States",,https://ClinicalTrials.gov/show/NCT02669901
101,NCT00301210,Assessment of Tramadol as a Treatment for Opioid Addiction,,Completed,No Results Available,Opioid-Related Disorders,Drug: Tramadol,Self-reported effects|physiologic measures|observer ratings of effects|cognitive/performance measures,Johns Hopkins University|National Institute on Drug Abuse (NIDA),All,21 Years to 55 Years   (Adult),Phase 1|Phase 2,9,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",NIDA-18125-2|R01DA018125-02|DPMC,2006-01-01,2007-10-01,2007-11-01,2006-03-10,null,2015-04-17,"Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00301210
102,NCT03586466,Improving Office Based Treatment of Opioid Use Disorder With Technology,,Recruiting,No Results Available,Opioid-use Disorder,Device: BupreCare|Drug: Buprenorphine/naloxone|Other: MEMS,Compliance|Urine Drug Screens|Relapse,"MedicaSafe, Inc.|Artemis Institute for Clinical Research|Total Health Care",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,80,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00023570,2018-06-25,2019-07-01,2019-07-01,2018-07-13,null,2018-07-13,"Artemis Institute for Clinical Research, San Diego, California, United States|Total Health Care, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT03586466
103,NCT01380093,Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users,,Completed,Has Results,"Nondependent Opioid Abuse, Episodic","Drug: Placebo|Drug: MS Contin (morphine sulfate, controlled release)|Drug: EMBEDA (morphine sulfate / naltrexone hydrochloride)",Drug Liking: Area Under Effect Curve (AUE) From 0-2 Hours|Drug Liking: Peak Effect (Emax)|High: Area Under Effect Curve (AUE) From 0-2 Hours|High: Peak Effect (Emax)|Drug Liking: Area Under Effect Curve (AUE) From 0-1 Hour|Drug Liking: Area Under Effect Curve (AUE) From 0-4 Hours|Drug Liking: Area Under Effect Curve (AUE) From 0-8 Hours|Drug Liking: Area Under Effect Curve (AUE) From 0-12 Hours|Drug Liking: Area Under Effect Curve (AUE) From 0-24 Hours|Drug Liking: Time to Maximum (Peak) Effect (TEmax)|High: Area Under Effect Curve (AUE) From 0-1 Hour|High: Area Under Effect Curve (AUE) From 0-4 Hours|High: Area Under Effect Curve (AUE) From 0-8 Hours|High: Area Under Effect Curve (AUE) From 0-12 Hours|High: Area Under Effect Curve (AUE) From 0-24 Hours|High: Time to Maximum (Peak) Effect (TEmax)|Good Effects: Area Under Effect Curve (AUE) From 0-1 Hour|Good Effects: Area Under Effect Curve (AUE) From 0-2 Hours|Good Effects: Area Under Effect Curve (AUE) From 0-4 Hours|Good Effects: Area Under Effect Curve (AUE) From 0-8 Hours|Good Effects: Area Under Effect Curve (AUE) From 0-12 Hours|Good Effects: Area Under Effect Curve (AUE) From 0-24 Hours|Good Effects: Peak Effect (Emax)|Good Effects: Time to Maximum (Peak) Effect (TEmax)|Any Effects: Area Under Effect Curve (AUE) From 0-1 Hour|Any Effects: Area Under Effect Curve (AUE) From 0-2 Hours|Any Effects: Area Under Effect Curve (AUE) From 0-4 Hours|Any Effects: Area Under Effect Curve (AUE) From 0-8 Hours|Any Effects: Area Under Effect Curve (AUE) From 0-12 Hours|Any Effects: Area Under Effect Curve (AUE) From 0-24 Hours|Any Effects: Peak Effect (Emax)|Any Effects: Time to Maximum (Peak) Effect (TEmax)|Bad Effects: Area Under Effect Curve (AUE) From 0-1 Hour|Bad Effects: Area Under Effect Curve (AUE) From 0-2 Hours|Bad Effects: Area Under Effect Curve (AUE) From 0-4 Hours|Bad Effects: Area Under Effect Curve (AUE) From 0-8 Hours|Bad Effects: Area Under Effect Curve (AUE) From 0-12 Hours|Bad Effects: Area Under Effect Curve (AUE) From 0-24 Hours|Bad Effects: Peak Effect (Emax)|Bad Effects: Time to Maximum (Peak) Effect (TEmax)|Nausea: Area Under Effect Curve (AUE) From 0-1 Hour|Nausea: Area Under Effect Curve (AUE) From 0-2 Hours|Nausea: Area Under Effect Curve (AUE) From 0-4 Hours|Nausea: Area Under Effect Curve (AUE) From 0-8 Hours|Nausea: Area Under Effect Curve (AUE) From 0-12 Hours|Nausea: Area Under Effect Curve (AUE) From 0-24 Hours|Nausea: Peak Effect (Emax)|Nausea: Time to Maximum (Peak) Effect (TEmax)|Feel Sick: Area Under Effect Curve (AUE) From 0-1 Hour|Feel Sick: Area Under Effect Curve (AUE) From 0-2 Hours|Feel Sick: Area Under Effect Curve (AUE) From 0-4 Hours|Feel Sick: Area Under Effect Curve (AUE) From 0-8 Hours|Feel Sick: Area Under Effect Curve (AUE) From 0-12 Hours|Feel Sick: Area Under Effect Curve (AUE) From 0-24 Hours|Feel Sick: Peak Effect (Emax)|Feel Sick: Time to Maximum (Peak) Effect (TEmax)|Sleepy: Area Under Effect Curve (AUE) From 0-1 Hour|Sleepy: Area Under Effect Curve (AUE) From 0-2 Hours|Sleepy: Area Under Effect Curve (AUE) From 0-4 Hours|Sleepy: Area Under Effect Curve (AUE) From 0-8 Hours|Sleepy: Area Under Effect Curve (AUE) From 0-12 Hours|Sleepy: Area Under Effect Curve (AUE) From 0-24 Hours|Sleepy: Peak Effect (Emax)|Sleepy: Time to Maximum (Peak) Effect (TEmax)|Dizzy: Area Under Effect Curve (AUE) From 0-1 Hour|Dizzy: Area Under Effect Curve (AUE) From 0-2 Hours|Dizzy: Area Under Effect Curve (AUE) From 0-4 Hours|Dizzy: Area Under Effect Curve (AUE) From 0-8 Hours|Dizzy: Area Under Effect Curve (AUE) From 0-12 Hours|Dizzy: Area Under Effect Curve (AUE) From 0-24 Hours|Dizzy: Peak Effect (Emax)|Dizzy: Time to Maximum (Peak) Effect (TEmax)|Overall Drug Liking Effect at 24 Hours|Take Drug Again Effect at 24 Hours|Pupillometry: Area Under Effect Curve (AUE) From 0-1 Hour|Pupillometry: Area Under Effect Curve (AUE) From 0-2 Hours|Pupillometry: Area Under Effect Curve (AUE) From 0-4 Hours|Pupillometry: Area Under Effect Curve (AUE) From 0-8 Hours|Pupillometry: Area Under Effect Curve (AUE) From 0-12 Hours|Pupillometry: Area Under Effect Curve (AUE) From 0-24 Hours|Pupillometry: Peak Effect (Emax)|Pupillometry: Time to Maximum (Peak) Effect (TEmax)|Time to Reach Maximum Observed Plasma Concentration (Tmax) of Morphine|Maximum Observed Plasma Concentration (Cmax) of Morphine|Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-1)] of Morphine|Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-2)] of Morphine|Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-4)] of Morphine|Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-8)] of Morphine|Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-12)] of Morphine|Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-24)] of Morphine|Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Morphine|Time to Reach Maximum Observed Plasma Concentration (Tmax) of Naltrexone|Maximum Observed Plasma Concentration (Cmax) of Naltrexone|Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-1)] of Naltrexone|Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-2)] of Naltrexone|Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-4)] of Naltrexone|Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-8)] of Naltrexone|Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-12)] of Naltrexone|Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-24)] of Naltrexone|Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Naltrexone|Time to Reach Maximum Observed Plasma Concentration (Tmax) of Naltrexone Metabolite (6-beta-naltrexol)|Maximum Observed Plasma Concentration (Cmax) of Naltrexone Metabolite (6-beta-naltrexol)|Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-1)] of Naltrexone Metabolite (6-beta-naltrexol)|Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-2)] of Naltrexone Metabolite (6-beta-naltrexol)|Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-4)] of Naltrexone Metabolite (6-beta-naltrexol)|Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-8)] of Naltrexone Metabolite (6-beta-naltrexol)|Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-12)] of Naltrexone Metabolite (6-beta-naltrexol)|Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-24)] of Naltrexone Metabolite (6-beta-naltrexol)|Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Naltrexone Metabolite (6-beta-naltrexol),Pfizer,All,18 Years to 55 Years   (Adult),Phase 1,80,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",ALO-01-10-4005|B4541003,2011-02-01,2011-05-01,2011-05-01,2011-06-27,2012-05-31,2012-05-31,"Lifetree Clinical Research, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT01380093
104,NCT03149718,Community Pharmacists and Opioid Misuse,,Recruiting,No Results Available,Opioid Misuse,Behavioral: Brief Intervention Medication Therapy Management|Behavioral: Standard Medication Counseling (SMC),Intervention feasibility|Intervention acceptability|Opioid Misuse|Patient Self-Management,University of Utah|National Institute on Drug Abuse (NIDA),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,46,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,PRO17010410|R21DA043735,2017-09-15,2019-05-01,2019-05-01,2017-05-11,null,2018-07-17,"Falk Pharmacy, Pittsburgh, Pennsylvania, United States|Medicine Shoppe, Somerset, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03149718
105,NCT03143855,Drug Interaction and Subjective Effects of Compounds for Opioid Use Disorder,,Recruiting,No Results Available,Opioid Abuse|Opioid Dependence|Opioid-Related Disorders|Opioid Use,Drug: Lorcaserin|Drug: Placebo,Change in subjective response to oxycodone measured with 100 milimeter visual analog scale,Virginia Commonwealth University|National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,18,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HM20008062|U54DA038999,2017-01-30,2018-07-30,2018-07-30,2017-05-08,null,2018-02-12,"Virginia Commonwealth University, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT03143855
106,NCT01186770,"A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation in Subjects With Chronic, Non-Malignant Pain",,Completed,No Results Available,Opioid-Induced Constipation,Drug: Methylnaltrexone bromide|Drug: Oral Placebo,Proportion of subjects with rescue-free laxation,"Valeant Pharmaceuticals International, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,700,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MNTX 3201,2010-09-01,2012-05-01,2013-05-01,2010-08-23,null,2013-11-08,"PRA International, Raleigh, North Carolina, United States|PRA, Intl., Raleigh, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01186770
107,NCT01527994,Aprepitant Effects in Intravenous Heroin Dependence,,Completed,No Results Available,Opioid Dependence,Drug: Aprepitant|Drug: Placebo pill,Opioid Withdrawal|Opioid Intoxication|Neuro-economic Choice Procedure,New York University|National Institute on Drug Abuse (NIDA),All,18 Years to 55 Years   (Adult),Phase 1,64,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",09-0457|5R01DA027151-02,2012-01-01,2014-06-01,2015-02-01,2012-02-07,null,2015-04-14,"Bellevue Hospital Center & the NYU School of Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01527994
108,NCT00000326,Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment 1 - 1,,Withdrawn,No Results Available,Heroin Dependence|Opioid-Related Disorders,Drug: Heroin Dependence,Drug use|Retention|Subjective dose estimate|Observed withdrawal rating|Opioid agonist rating|Opioid antagonist rating|Pupil diameter|Compliance|Analog rating scale for drug effects|Drug effect characteristics|Dose order estimate-nurse|Dose order estimate-client,"University of Colorado, Denver|National Institute on Drug Abuse (NIDA)",All,18 Years to 64 Years   (Adult),Phase 2,0,Other|NIH,Interventional,Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,NIDA-11160-1|1R01DA011160|R01-11160-1,1997-04-01,1997-08-01,1997-08-01,1999-09-21,null,2017-05-04,"University of Colorado Health Sciences Center, Denver, Colorado, United States",,https://ClinicalTrials.gov/show/NCT00000326
109,NCT00000328,Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment III) - 3,,Withdrawn,No Results Available,Heroin Dependence|Opioid-Related Disorders,Drug: Opioid-Related Disorders,Drug use|Retention|Opioid agonist rating|Opioid antagonist rating|Compliance|Medication identification|Addiction Severity Index (ASI) Composite Score Rating,"University of Colorado, Denver|National Institute on Drug Abuse (NIDA)",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,0,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,NIDA-11160-3|1R01DA011160|R01-11160-3,1997-07-01,1997-08-01,1997-08-01,1999-09-21,null,2017-05-04,"University of Colorado Health Sciences Center, Denver, Colorado, United States",,https://ClinicalTrials.gov/show/NCT00000328
110,NCT00000331,Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-3 - 6,,Withdrawn,No Results Available,Heroin Dependence|Opioid-Related Disorders,Drug: Test Drug|Drug: Placebo Drug,Observed withdrawal rating|Pupil diameter|Drug effect characteristics,"University of Colorado, Denver|National Institute on Drug Abuse (NIDA)",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,0,Other|NIH,Interventional,Masking: Double|Primary Purpose: Treatment,NIDA-11160-6|R01DA011160|R01-11160-6,2002-12-01,2002-12-01,2002-12-01,1999-09-21,null,2017-05-04,"University of Colorado Health Sciences Center, Denver, Colorado, United States",,https://ClinicalTrials.gov/show/NCT00000331
111,NCT00000330,Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5,,Withdrawn,No Results Available,Heroin Dependence|Opioid-Related Disorders,Drug: Opioid-Related Disorders,Subjective dose estimate|Observed withdrawal rating|Opioid antagonist rating|Pupil diameter|Analog rating scale for drug effects|Drug effect characteristics|Drug/Money Preferences,"University of Colorado, Denver|National Institute on Drug Abuse (NIDA)",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,0,Other|NIH,Interventional,Masking: Double|Primary Purpose: Treatment,NIDA-11160-5|R01DA011160|R01-11160-5,1999-10-01,1999-11-01,1999-11-01,1999-09-21,null,2017-05-04,"University of Colorado Health Sciences Center, Denver, Colorado, United States",,https://ClinicalTrials.gov/show/NCT00000330
112,NCT00000329,Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-1 - 4,,Withdrawn,No Results Available,Heroin Dependence|Opioid-Related Disorders,Drug: Opioid-Related Disorders,Subjective dose estimate|Observed withdrawal rating|Opioid agonist rating|Opioid antagonist rating|Pupil diameter|Analog rating scale for drug effects|Drug effect characteristics|Drug/Money Preferences,"University of Colorado, Denver|National Institute on Drug Abuse (NIDA)",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,0,Other|NIH,Interventional,Masking: Double|Primary Purpose: Treatment,NIDA-11160-4|R01DA011160|R01-11160-4,1999-04-01,1999-08-01,1999-08-01,1999-09-21,null,2017-05-04,"University of Colorado Health Sciences Center, Denver, Colorado, United States",,https://ClinicalTrials.gov/show/NCT00000329
113,NCT00000327,Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment I(2) - 2,,Withdrawn,No Results Available,Heroin Dependence|Opioid-Related Disorders,Drug: Heroin Dependence,Drug use|Retention|Compliance|Dosing schedule preferences|Analog rating scale for dosing schedule effects,"University of Colorado, Denver|National Institute on Drug Abuse (NIDA)",All,18 Years to 62 Years   (Adult),Phase 2,0,Other|NIH,Interventional,Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,NIDA-11160-2|R01DA011160|R01-11160-2,1997-06-01,1997-08-01,1997-08-01,1999-09-21,null,2017-05-04,"University of Colorado Health Sciences Center, Denver, Colorado, United States",,https://ClinicalTrials.gov/show/NCT00000327
114,NCT03015246,Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence,BOS,Recruiting,No Results Available,Heroin Dependence|Opioid Use Disorder,Drug: Buprenorphine-Naloxone|Drug: Morphine|Drug: Yohimbine|Drug: Hydrocortisone|Drug: Matching Placebo for Yohimbine|Drug: Matching Placebo for Hydrocortisone,Opioid Use Urine Drug Testing|Opioid Symptom Questionnaire (Self-Report Measure)|Visual Analog Scales (VAS) (Self-Report Measure)|Profile of Mood States (Self-Report Measure)|Systolic blood pressure (physiological effects)|Diastolic blood pressure (physiological effects)|Heart rate (physiological effects)|Respiration Rate (physiological effects)|Oxygen saturation (physiological effects)|Pupil diameter (physiological effects),Wayne State University,All,18 Years to 55 Years   (Adult),Phase 1,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",BOS-1,2016-12-01,2020-12-01,2020-12-01,2017-01-10,null,2018-04-05,"Wayne State University, Detroit, Michigan, United States",,https://ClinicalTrials.gov/show/NCT03015246
115,NCT00640146,Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures,,Completed,No Results Available,Opioid-induced Constipation,Drug: Methylnaltrexone bromide|Drug: Placebo,The effect of the interventional treatment will be measured by bowel movements.,"Valeant Pharmaceuticals International, Inc.|Wyeth is now a wholly owned subsidiary of Pfizer",All,"18 Years and older   (Adult, Older Adult)",Phase 2,33,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MNTX2101,2007-10-01,2009-01-01,2009-01-01,2008-03-21,null,2011-07-19,"Progenics Pharmaceuticals, Inc, Tarrytown, New York, United States",,https://ClinicalTrials.gov/show/NCT00640146
116,NCT03624985,The Effect of Perioperative Intravenous Lidocaine Infusion on Opioid Consumption After Lumbar Spine Surgery,,Recruiting,No Results Available,"Pain, Postoperative|Opioid Use",Drug: Intravenous Lidocaine Infusion|Drug: Placebo Infusion,Total morphine equivalent consumed at 24 hours after surgery|Total morphine equivalent consumed at 48 hours after surgery|Pain score 4 hours post-operation|Pain score 10 hours post-operation|Pain score 24 hours post-operation|Pain score 48 hours post-operation|Quality of Recovery Score 36 hours post-operation|Quality of Recovery Score 48 hours post-operation|Length of Stay|Incidence of nausea|Time to first flatus|Time to first bowel movement,University of Vermont Medical Center,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,140,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CHRMS 18-0111,2018-06-04,2020-06-04,2020-06-09,2018-08-10,null,2018-08-10,"University of Vermont Medical Center, Burlington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT03624985
117,NCT00218309,Effects of Pre-Session Supplemental Hydromorphone on Drug Seeking Behavior in Opioid Dependent Individuals,,Completed,No Results Available,Heroin Dependence|Opioid-Related Disorders,Drug: Hydromorphone,,National Institute on Drug Abuse (NIDA)|Wayne State University,All,18 Years to 55 Years   (Adult),,16,NIH|Other,Observational,Time Perspective: Prospective,NIDA-15462-1|R01-15462-1,2003-09-01,null,2005-07-01,2005-09-22,null,2017-01-12,"Wayne State University, Detroit, Michigan, United States",,https://ClinicalTrials.gov/show/NCT00218309
118,NCT00182572,Science-Based Treatment for Opioid-Dependent Adolescents,,Unknown status,No Results Available,Opioid-Dependence Among Adolescents,Drug: buprenorphine|Drug: naltrexone|Procedure: behavior therapy|Procedure: voucher-based contingency management,opiate use|treatment retention|other drug use|HIV risk behavior|opiate agonist and withdrawal effects|psychological status|family relations|motivation to change drug use|opiate craving|criminal activity,"National Development and Research Institutes, Inc.|St. Luke's-Roosevelt Hospital Center",All,"13 Years to 18 Years   (Child, Adult)",Phase 2,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,R01DA018297,2005-07-01,null,null,2005-09-16,null,2008-08-12,"Behavioral Science Research Unit, St. Luke's Hospital, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00182572
119,NCT03233633,Marijuana in Combination With Opioids in Palliative and Hospice Patients,,Enrolling by invitation,No Results Available,Pain Management in Terminally Ill Patients Receiving Scheduled Opioid Therapy,Drug: Medical Marijuana,primary reduction of pain and reduction in overall opioid utilization|improvement in overall patient well being|weight stabilization with increased appetite|improved oxygen saturation|improvement or prevention of nausea and vomiting,The Connecticut Hospice Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 1,66,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,WIRB Protocol 20161880-1167645,2017-05-10,2018-08-01,2018-09-01,2017-07-28,null,2017-08-31,"The Connecticut Hospice Inc., Branford, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT03233633
120,NCT01004393,Methylnaltrexone for Opioid-induced Constipation in Cancer Patients,,Completed,Has Results,Neoplasms|Constipation|Opioid-Related Disorders,Drug: Methylnaltrexone bromide,"Rescue-free Laxation After Administration of Subcutaneous Methylnaltrexone|Laxation After Administration of Subcutaneous Methylnaltrexone|Time to Laxation After Administration of Subcutaneous Methylnaltrexone|Overall Pain Scores (0-10; 0=no Pain, 10=Worst Pain) After Administration of Subcutaneous Methylnaltrexone|Symptoms of Opioid Withdrawal (Modified Himmelsbach Withdrawal Scales (Ranging 7-28 in Total; 1=None - 4=Severe for 7 Items)) After Administration of Subcutaneous Methylnaltrexone|Bowel Movement Assessment (Frequency, Consistency and Difficulty) After Administration of Subcutaneous Methylnaltrexone|Constipation Assessment (Severity and Distress) After Administration of Subcutaneous Methylnaltrexone|Patient Satisfaction With the Study Medication After Administration of Subcutaneous Methylnaltrexone",University of Vermont,All,"18 Years and older   (Adult, Older Adult)",Phase 2,12,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,VCC 0911,2009-10-01,2013-12-01,2013-12-01,2009-10-29,2016-02-02,2016-02-02,"Fletcher Allen Health Care, Burlington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT01004393
121,NCT00000352,Effects of Dextromethorphan on Opioid Tolerance in Methadone Patients - 1,,Completed,No Results Available,Opioid-Related Disorders|Substance-Related Disorders,Drug: Dextromethorphan,,National Institute on Drug Abuse (NIDA)|University of Pennsylvania,All,21 Years to 55 Years   (Adult),Phase 2,0,NIH|Other,Interventional,Primary Purpose: Treatment,NIDA-3-0012-1|Y01-3-0012-1,1996-12-01,1998-02-01,1998-04-01,1999-09-21,null,2017-01-12,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00000352
122,NCT03389750,A Study to Evaluate the Abuse Potential of Oxymorphone Compared to Other Mu Opioid Agonists.,,Not yet recruiting,No Results Available,Opioid-use Disorder|Opioid Abuse,Drug: Intravenous Challege Drug,Reinforcing effects|Positive Subjective Effects,New York State Psychiatric Institute|University of Kentucky,All,21 Years to 55 Years   (Adult),Phase 2,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science",7565,2018-02-15,2020-02-01,2020-03-01,2018-01-04,null,2018-01-04,"University of Kentucky, Lexington, Kentucky, United States|New York State Psychiatric Institute in the Division on Substance Use Disorders, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03389750
123,NCT00000358,Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 7,,Completed,No Results Available,Opioid-Related Disorders|Substance-Related Disorders,Drug: Lofexidine,,National Institute on Drug Abuse (NIDA)|University of Pennsylvania,All,21 Years to 59 Years   (Adult),Phase 1,0,NIH|Other,Interventional,Primary Purpose: Treatment,NIDA-3-0012-7|Y01-3-0012-7,null,null,null,1999-09-21,null,2017-01-12,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00000358
124,NCT00000354,Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 3,,Completed,No Results Available,Opioid-Related Disorders|Substance-Related Disorders,Drug: Lofexidine,,National Institute on Drug Abuse (NIDA)|University of Pennsylvania,All,21 Years to 59 Years   (Adult),Phase 1,0,NIH|Other,Interventional,Primary Purpose: Treatment,NIDA-3-0012-3|Y01-3-0012-3,1996-07-01,1997-09-01,1997-12-01,1999-09-21,null,2017-01-12,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00000354
125,NCT03552120,Serving Women Using Opioids During Pregnancy,SWOOP,Enrolling by invitation,No Results Available,Opioid Use|Pregnancy Related,Behavioral: Mindfulness-Oriented Recovery Enhancement|Behavioral: Supportive Psychotherapy,"Current Opioid Misuse Measure|Brief Child Abuse Potential Inventory|Opioid Craving Visual Analog Scale|Depression, Anxiety and Stress Scale","University of Utah|Mind and Life Institute, Hadley, Massachusetts",Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,IRB_00099361,2018-04-23,2020-08-01,2021-01-01,2018-06-11,null,2018-06-11,"The University of Utah, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT03552120
126,NCT02791399,A Patient-Centered Intervention to Improve Opioid Safety,ISOP,Recruiting,No Results Available,Opioid Safety|Prescription Opioid Misuse|Chronic Pain,Behavioral: ISOP Intervention with the Nurse Care Manager,Current Opioid Misuse Measure|Structured Clinical Interview for DSM-5|Urine Drug Test|Chronic Pain Grade|Patient Health Questionnaire,VA Office of Research and Development,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,300,U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IIR 14-020|9024,2016-03-23,2018-10-01,2020-03-31,2016-06-06,null,2018-07-13,"VA Portland Health Care System, Portland, OR, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT02791399
127,NCT02411357,Improving Effective Contraceptive Use Among Opioid-maintained Women: Stage II,,Recruiting,No Results Available,Contraceptive Usage|Opioid Dependence,Behavioral: Treatment as usual|Behavioral: WHO contraception protocol|Behavioral: Incentives,Period prevalence use of a prescription contraceptive,University of Vermont,Female,18 Years to 44 Years   (Adult),Not Applicable,195,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,R01DA036670,2015-03-01,2019-05-01,2019-05-01,2015-04-08,null,2017-11-06,"Vermont Center on Behavior and Health, Burlington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT02411357
128,NCT01262092,Effects of Gabapentin Versus Placebo on Buprenorphine Detoxification of Opioid-dependent Individuals,Detox,Completed,Has Results,Opioid Dependence|Opioid Withdrawal|Opioid Detoxification,Drug: Buprenorphine,Illicit Opioid Use as Determine by Urine Dipsticks,University of Arkansas|National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,30,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",R01-DA010017-pilot|112714|R01DA010017,2010-10-01,2011-12-01,2012-01-01,2010-12-17,2013-06-21,2013-06-21,"University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States",,https://ClinicalTrials.gov/show/NCT01262092
129,NCT03536065,"Post-Discharge Opioid Reduction Intervention for Open, Laparoscopic, and Endoscopic Surgery",ORIOLES,Recruiting,No Results Available,Prostate Cancer|Opioid Use,Drug: Opioid Reduction Intervention|Behavioral: Current Care,Opioid Use|Opioid Prescription|Opioid Disposal|Need for Refill or Additional Opioid Medication,Johns Hopkins University,Male,"18 Years to 100 Years   (Adult, Older Adult)",Phase 4,500,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,IRB00162359,2017-08-01,2018-12-01,2019-01-01,2018-05-24,null,2018-05-24,"Johns Hopkins Hospital, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT03536065
130,NCT02998606,Movantik for Opioid-Related Esophageal Disorders,,Recruiting,No Results Available,Opioid-Induced Disorders|Esophagus Disorder,Drug: Naloxegol|Drug: Placebo Oral Capsule,Manometric improvement in IRP (Integrated Relaxation Pressure)|Overall Symptom Management|Pain Management|GERD Symptom Management|Chest Pain Management|Daily Symptom Management|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability|Quality of Life,Temple University|AstraZeneca,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,50,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",23289,2017-01-01,2019-01-01,2020-01-01,2016-12-20,null,2017-04-26,"Temple University, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02998606
131,NCT03248765,Human Brain Adaptation to Chronic Pain and Its Effects on Opioid Use,,Recruiting,No Results Available,"Pain, Chronic|Opioid Use",Other: post-surgical opioid use measured at 1 day and 1 week.,Post-surgical opioid use,Washington University School of Medicine,All,"18 Years to 65 Years   (Adult, Older Adult)",,60,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,201707017,2017-08-30,2019-09-01,2019-09-01,2017-08-14,null,2017-08-31,"Washington University in St Louis School of Medicine, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT03248765
132,NCT03205423,Medication Development for Opioid and Alcohol Abuse,,Recruiting,No Results Available,Opioid-use Disorder|Alcohol Use Disorder,Drug: Gabapentin,Positive subjective responses to placebo.|Positive subjective responses to Oxycodone (80mg) + Low Alcohol Dose.|Positive subjective responses to Oxycodone (80mg) + High Alcohol Dose.|Positive subjective responses to Oxycodone (40mg) + High Alcohol Dose.|Positive subjective responses to Oxycodone (40mg) + Low Alcohol Dose.|Positive subjective responses to Low Alcohol Dose.|Positive subjective responses to High Alcohol Dose.|Positive subjective responses to Oxycodone (80mg)|Positive subjective responses to Oxycodone (40mg),New York State Psychiatric Institute,All,21 Years to 59 Years   (Adult),Phase 2,36,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science",7476,2017-08-01,2019-08-01,2019-12-01,2017-07-02,null,2017-08-22,"New York State Psychiatric Institute in the Division on Substance Use Disorders, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03205423
133,NCT00142909,Effectiveness of Lofexidine to Prevent Stress-Related Opiate Relapse During Naltrexone Treatment - 1,,Completed,Has Results,Opioid-Related Disorders,Drug: Lofexidine|Drug: Placebo,SOWS: the Subjective Opiate Withdrawal Scale|Systolic Blood Pressure|Diastolic Blood Pressure,Yale University|National Institute on Drug Abuse (NIDA),All,"18 Years and older   (Adult, Older Adult)",Phase 2,86,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NIDA-18219-1|R01-18219-1|DPMC,2005-02-01,2009-01-01,2009-01-01,2005-09-02,2013-11-20,2015-07-30,"Yale University, Psychiatry, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00142909
134,NCT01425060,Improving Effective Contraceptive Use Among Opioid-maintained Women,,Completed,No Results Available,Contraceptive Usage|Opioid Dependence,Behavioral: Contraceptive management program|Other: Usual care,Point prevalence use of a prescription contraceptive,University of Vermont,Female,18 Years to 44 Years   (Adult),Phase 1,31,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,R34DA030534,2011-10-01,2014-06-01,2014-06-01,2011-08-29,null,2015-03-17,"University of Vermont Substance Abuse Treatment Center, Burlington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT01425060
135,NCT03377855,Addressing Origins of the Opioid Epidemic by Improving Prescribing for Opioid-Naive Patients,,Recruiting,No Results Available,Opioid Use|Opioid-Related Disorders|Opioid Abuse|Prescription Drug Abuse and Dependency,Other: Default Prescribing Change,Change in the proportion of opioid prescriptions for opioid-naïve patients that comply with CDC recommendations before and after the intervention|Change in the average days of supply of opioids for opioid naive patients,Weill Medical College of Cornell University|New York State Health Foundation|The Institute for Family Health,All,"18 Years to 89 Years   (Adult, Older Adult)",Not Applicable,400,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,1710018646|17-05047,2018-02-01,2018-11-01,2018-11-01,2017-12-19,null,2018-05-09,"The Institute for Family Health, New York, New York, United States|Weill Medical College of Cornell University, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03377855
136,NCT02359006,The Effects of Minocycline in Opioid-maintained Patients,,Completed,No Results Available,Opioid Dependence|Pain,Drug: Minocycline|Drug: Placebo,pain sensitivity (Cold pressure test out come),Yale University,All,18 Years to 55 Years   (Adult),Not Applicable,55,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",1412015119,2015-03-12,2017-03-24,2017-04-19,2015-02-09,null,2018-01-30,"VA Hospital, West Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT02359006
137,NCT01590251,Yoga for Pain and Opioid Dependence,Yoga,Completed,No Results Available,Chronic Pain|Opioid Addiction,Other: Yoga|Behavioral: Educational Counseling,Pain reduction|Reduce illicit opioid use,Yale University,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,8,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1111009292,2012-04-01,2014-11-01,2014-11-01,2012-05-02,null,2015-09-25,"MRU, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01590251
138,NCT03363243,Advancing STOP: Self-regulation Therapy for Opioid Addiction and Pain,,Recruiting,No Results Available,Opioid-use Disorder|Chronic Pain,Other: STOP Therapy Treatment group|Other: Treatment as usual (TAU) group,Changes in Daily Functioning - Pain|Changes in Substance Use,"University of Colorado, Denver",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17-1849,2018-03-01,2020-03-01,2020-03-01,2017-12-06,null,2018-03-30,"UC Denver, Denver, Colorado, United States",,https://ClinicalTrials.gov/show/NCT03363243
139,NCT02526212,Buprenorphine Group Medical Visits in Primary Care,G-BMT,Recruiting,No Results Available,Opioid-Related Disorders,Behavioral: G-BMT|Behavioral: Treatment as usual|Drug: Buprenorphine,"Efficacy - Opioid abstinence (composite measure, yes/no)|Retention in treatment (yes/no)|HIV risk behaviors (scale)|Acceptability (scale)|Feasibility (percentage of visits attended)",Montefiore Medical Center|National Institute on Drug Abuse (NIDA),All,"18 Years and older   (Adult, Older Adult)",Phase 3,80,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2014-3580|R34DA039041,2017-01-01,2018-10-01,2019-03-31,2015-08-18,null,2018-04-19,"Comprehensive Health Care Center, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT02526212
140,NCT03498261,A Prospective Randomized Double Blind Trial to Assess the Effect of a Single Preoperative Dose of Gabapentin on Postoperative Opioid Consumption in Patients Undergoing Rhinoplasty,,"Active, not recruiting",No Results Available,"Pain, Postoperative|Opioid Use",Drug: Gabapentin|Drug: Placebos,Effects of Gabapentin vs Placebo in Postoperative Opioid Consumption|Pain Assessment|IV Opioids in PACU|Time to rescue medication|Opioids within 7 days|Length of stay (minutes) in recovery from end of surgery until discharge.|Nausea|Side Effects|Respiratory Distress,Ohio State University,All,"18 Years and older   (Adult, Older Adult)",Phase 1,64,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",2017H0466,2018-01-30,2020-01-30,2020-02-07,2018-04-13,null,2018-04-17,"The Ohio State University Wexner Medical Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03498261
141,NCT02360007,Interim Buprenorphine: Leveraging Medication + Technology to Bridge Delays in Treatment Access,IBT,Completed,No Results Available,Opioid-related Disorders,Drug: Interim Buprenorphine Treatment (IBT),Illicit opioid abstinence|ASI subscale scores,University of Vermont Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,70,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CHRMS 14-063,2015-01-01,2016-06-01,2016-06-01,2015-02-10,null,2018-05-03,"Substance Abuse Treatment Center, University of Vermont, Burlington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT02360007
142,NCT02241824,Chronic Opioid Use in Low Back Pain and Lumbar Orthosis Intervention,,Unknown status,No Results Available,Chronic Lower Back Pain|Chronic Opioid Use,Device: In-elastic lumbar brace|Device: Elastic abdominal binder,Brace fitting and assessment|Pain and opioid reduction,Geoffrey C. Garth|VA Long Beach Healthcare System|Aspen Medical Products,Male,"20 Years to 72 Years   (Adult, Older Adult)",Not Applicable,36,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MIRB# 1273,2015-01-01,2016-09-01,2016-12-01,2014-09-16,null,2015-07-09,"Long Beach VA, Long Beach, California, United States",,https://ClinicalTrials.gov/show/NCT02241824
143,NCT03185117,Opioid Consumption After Hospital Discharge in Orthopedic Surgery,,Recruiting,No Results Available,Opioid Use|Arthropathy of Knee|Arthropathy of Hip,,opioid consumption over time,Ohio State University,All,"18 Years and older   (Adult, Older Adult)",,300,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2016H0219,2016-09-01,2019-09-05,2019-09-05,2017-06-14,null,2018-04-05,"The Ohio State University Wexner Medical Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03185117
144,NCT02028533,Cocaine Opioid Oxytocin Option - Limited,COOOL,Completed,No Results Available,Opioid Use Disorder|Cocaine Use Disorder,Drug: Oxytocin|Drug: Placebo,Number of patients with non-serious and serious adverse events,"University of California, San Francisco",All,"18 Years and older   (Adult, Older Adult)",Phase 1,30,Other,Interventional,"Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",13-12534,2014-07-01,2014-12-01,2014-12-01,2014-01-07,null,2015-07-22,"San Francisco General Hospital Opiate Treatment Outpatient Program, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT02028533
145,NCT02243670,Using Artificial Intelligence To Monitor Medication Adherence in Opioid Replacement Therapy,,Completed,No Results Available,Opiate Addiction|Medication Non-adherence|Addiction|Opioid Dependence,Device: AiCure monitoring and intervention,To evaluate the feasibility and acceptability to participants and study staff in using AiCure to monitor medication adherence.|To evaluate the acceptability of using AiCure to optimize care pathways.|To measure the reliability and validity of AiCure in detecting interruptions in treatment.|The degree of participant maximum craving (during the 24 hour period prior to the study visit) for opioids as measured by the Brief Substance Craving Scale (BSCS).|The change in participant's psychosocial well being over time as measured by the seven subscales of the Addiction Severity Index (ASI).,AiCure|Orexo AB|Montefiore Medical Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,9,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AIC-HHSN271201300036C-01|HHSN271201300036C,2016-08-01,2017-03-01,2017-03-01,2014-09-18,null,2017-09-12,"Montefiore Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02243670
146,NCT03588806,Use of Xtampza ER to Overcome Difficulties in Swallowing Opioid Pills,,Recruiting,No Results Available,Chronic Pain|Opioid Use|Deglutition,Drug: Xtampza ER (oxycodone),"Effect of Xtampza ER conversion on pain intensity in the last 24 hours|Effect of Xtampza ER conversion on pain intensity in the last 7 days|Pill Swallowing Difficulty Questions|Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference|Opioid Medication Satisfaction|PROMIS Depression, Anxiety, Satisfaction with Social Roles, Sleep Disturbance, and Fatigue|PROMIS Physical Function|Patient Global Impression of Change (PGIC)","Ajay Wasan, MD, Msc|University of Pittsburgh",All,"21 Years to 65 Years   (Adult, Older Adult)",Phase 4,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,PRO17040444,2018-05-01,2019-04-30,2020-04-30,2018-07-17,null,2018-07-17,"UPMC Pain Medicine at Centre Commons, Pittsburgh, Pennsylvania, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT03588806/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT03588806/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03588806
147,NCT02737826,Discontinuation From Chronic Opioid Therapy For Pain Using a Buprenorphine Taper,,Recruiting,No Results Available,Chronic Pain|Opioid Pain Medication,Drug: Buprenorphine - Phase I|Drug: Gabapentin - Phase II|Drug: Placebo - Phase II|Drug: Buprenorphine taper - Phase II,Percentage of patients who tolerate buprenorphine initiation|Opioid cessation,Medical University of South Carolina,All,18 Years to 55 Years   (Adult),Not Applicable,150,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Pro00046473,2016-05-01,2019-06-01,2020-01-01,2016-04-14,null,2018-05-17,"Medical University of South Carolina, Charleston, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT02737826
148,NCT00000206,Clinical Rescue Protocol - 2,,Completed,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine,Retention|Opiate use|Opiate craving|Adverse events,"University of California, Los Angeles|National Institute on Drug Abuse (NIDA)",All,21 Years to 50 Years   (Adult),Phase 2,0,Other|NIH,Interventional,Masking: Double|Primary Purpose: Treatment,NIDA-06082-2|R18DA006082|R18-06082-2,1991-04-01,2005-08-01,null,1999-09-21,null,2016-11-07,"Friends Research Institute, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT00000206
149,NCT00000345,Evaluation of Lofexidine for Treatment of Opiate Withdrawal - 10,,Completed,No Results Available,Opioid-Related Disorders,Drug: Lofexidine,Opiate withdrawal|Adverse effect measures|Craving of opiates|Liking of opiates|Efficacy of lofexidine|Euphoria,National Institute on Drug Abuse (NIDA),All,21 Years to 50 Years   (Adult),Phase 1,0,NIH,Interventional,Masking: None (Open Label)|Primary Purpose: Treatment,NIDA-3-0010-10|Y01-3-0010-10,1996-04-01,null,null,1999-09-21,null,2017-01-12,"Friends Research Institute, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT00000345
150,NCT00000344,Buprenorphine/Naloxone for Treatment of Opiate Dependence - 9,,Completed,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine/naloxone,,National Institute on Drug Abuse (NIDA),All,21 Years to 50 Years   (Adult),Phase 2,40,NIH,Interventional,Allocation: Randomized|Masking: Double|Primary Purpose: Treatment,NIDA-3-0010-9|Y01-3-0010-9,null,null,2000-08-01,1999-09-21,null,2017-01-12,"Friends Research Institute, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT00000344
151,NCT00000341,Evaluation of Liquid vs. Tablet Buprenorphine - 6,,Completed,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine,Subjective and observer rater physiological effects of bup,National Institute on Drug Abuse (NIDA),All,21 Years to 50 Years   (Adult),Phase 2,1,NIH,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,NIDA-3-0010-6|Y01-3-0010-6,1996-08-01,null,2000-08-01,1999-09-21,null,2017-01-12,"Friends Research Institute, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT00000341
152,NCT00000335,Activity Monitoring Assessment of Opiate Withdrawal - 4,,Completed,No Results Available,Opioid-Related Disorders,Drug: Morphine,Depression|Anxiety|Withdrawal severity|Activity|Opiate secondary withdrawal,National Institute on Drug Abuse (NIDA)|Washington D.C. Veterans Affairs Medical Center,Male,21 Years to 55 Years   (Adult),Phase 2,0,NIH|U.S. Fed,Interventional,Primary Purpose: Treatment,NIDA-3-0009-4|Y01-3-0009-4,1995-09-30,1996-03-20,1996-05-20,1999-09-21,null,2017-01-31,"Washington DC VA, Washington, District of Columbia, United States",,https://ClinicalTrials.gov/show/NCT00000335
153,NCT00000320,Buprenorphine Formulation Comparison: Sublingual Tablet vs. Solution - 1,,Completed,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine formulation: liquid vs. tablet,blood level|drug use|craving|withdrawal symptoms,National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,120,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NIDA-10068-1|R01-10068-1,1997-10-01,1999-08-01,1999-08-01,1999-09-21,null,2017-01-12,"Friends Research Institute, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT00000320
154,NCT01549652,5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence,,Unknown status,No Results Available,Opioid Withdrawal|Physical Dependence,Drug: Ondansetron,Change in baseline of Objective Opioid Withdrawal Score|Change in the Baseline of Subjective Opioid Withdrawal Score|Beck Depression Inventory|Pain Inventory|Change in Baseline of Physical Vital Signs|Serum Factors|Pain Sensitivity,Stanford University|National Institute on Drug Abuse (NIDA),All,18 Years to 60 Years   (Adult),Not Applicable,76,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",5HT3 19821|1R01DA029078,2011-04-01,2015-04-01,2016-12-01,2012-03-09,null,2016-02-10,"Stanford University, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT01549652
155,NCT02902835,BUPrenorphine Facilitated Access and Supportive Treatment --AIM 3,BUPFAST,Recruiting,No Results Available,Opioid-related Disorders,Behavioral: BUP_FAST|Behavioral: Referral to treatment,Initiation of buprenorphine treatment|Opioid use (self-reported)|Opioid use (urine drug testing)|Criminal activity,Montefiore Medical Center|National Institute on Drug Abuse (NIDA),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,72,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2016-6559|K23DA034541,2016-09-01,2018-06-30,2019-01-01,2016-09-16,null,2018-04-19,"Montefiore Medical Center, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT02902835
156,NCT00000299,Rapid Opiate Detoxification and Naltrexone Induction Using Buprenorphine - 2,,Completed,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine,Opiate craving|Opiate withdrawal symptoms,"University of California, Los Angeles|National Institute on Drug Abuse (NIDA)",All,21 Years to 50 Years   (Adult),Phase 2,12,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,NIDA-09260-2|P50DA009260|P50-09260-2,2008-10-01,2009-11-01,2009-11-01,1999-09-21,null,2016-01-29,"Friends Research Institute, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT00000299
157,NCT00684840,Effects of Stress and Other Factors on Opiate Drug Choice.,DSS,Completed,No Results Available,Heroin Dependence|Opioid-Related Disorders,,,Wayne State University|National Institute on Drug Abuse (NIDA),All,18 Years to 55 Years   (Adult),,16,Other|NIH,Observational,Observational Model: Case-Only|Time Perspective: Prospective,NIDA-15462-4|R01DA015462-04|DPMCDA,2008-03-01,2011-12-01,2011-12-01,2008-05-28,null,2012-06-05,"Wayne State University, Detroit, Michigan, United States",,https://ClinicalTrials.gov/show/NCT00684840
158,NCT02617628,Outcomes of Opioid Addicted Prisoners With Extended-Release Injectable Naltrexone,OAPXRNTX,"Active, not recruiting",No Results Available,Opiate Dependence,Drug: extended release naltrexone,Proportion without relapse month 3|weeks in treatment through month 6|Rearrests|quality of life (Euroqol),University of Pennsylvania|Patient-Centered Outcomes Research Institute,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FC14-1409-21688,2015-09-01,2018-04-01,2018-09-01,2015-12-01,null,2017-07-26,"Center on the Studies of Addiction, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02617628
159,NCT00471042,Study of Buprenorphine Maintenance Treatment for Opioid Dependence in Primary Care,,Completed,No Results Available,"Heroin Dependence|Opioid-Related Disorders|Substance Abuse, Intravenous",Drug: Buprenorphine,,New York State Psychiatric Institute|National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",,30,Other|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,#5258|NIDA-020000|K23DA020000,2006-06-01,2008-08-01,2012-08-01,2007-05-09,null,2018-05-16,"Columbia University/New York State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00471042
160,NCT02602535,Mindfulness-Oriented Recovery Enhancement For Chronic Pain and Prescription Opioid Misuse in Primary Care,,Recruiting,No Results Available,Chronic Pain|Opioid Use Disorders,Behavioral: Mindfulness-Oriented Recovery Enhancement|Behavioral: Support Group,Change in opioid misuse|Change in pain severity and interference|Change in opioid craving|Change in psychological distress|Change in opioid dose,University of Utah,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,260,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,78615,2016-01-01,2021-10-01,2021-10-01,2015-11-11,null,2018-02-08,"University of Utah Primary Care Clinics, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT02602535
161,NCT03057847,Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection,,Recruiting,No Results Available,"Hepatitis C, Chronic|Opioid-use Disorder",Drug: Sofosbuvir/Velpatasvir,Number of participants enrolled in HCV treatment|Intravenous Drug Use Recidivism|HCV reinfection|Health-related quality of life|Number of participants achieving sustained virologic response|Number of participants reporting treatment side effects|Treatment adherence assessed by medication diaries,"Elizabeth Krans, MD|University of Pittsburgh",Female,"18 Years and older   (Adult, Older Adult)",Phase 4,75,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,PRO17020116,2018-01-30,2018-12-01,2019-12-01,2017-02-20,null,2018-03-09,"Magee Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03057847
162,NCT03411265,RETAIN: Retaining Opioid Users Entering Medication Assisted Treatment and Encouraging HCV/HIV Testing,RETAIN,Enrolling by invitation,No Results Available,Opioid-Related Disorders|Opioid-use Disorder|Drug Addiction|Substance Use Disorders,"Other: self-administered, e-health application",treatment retention status after 3 months|treatment retention status after 6 months|MAT Knowledge Assessment|The Injection-Related Infection and Treatment Survey (I-RITS)|Feedback on the RETAIN e-health application,University of Cincinnati,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,2017-1074-1,2017-11-08,2018-11-01,2018-11-01,2018-01-26,null,2018-01-26,"University of Cincinnati Addiction Sciences Division, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03411265
163,NCT00591617,Optimizing Outcomes Using Suboxone for Opiate Dependence,OpBup,Completed,No Results Available,Opioid Dependency,Other: Psychosocial treatment plus Suboxone pharmacotherapy,"Comparison the effectiveness of four psychosocial treatment conditions as measured by self-reported abstinence from opioids verified by urine toxicology tests|Comparison across treatment conditions for reducing the severity of opioid-related problems|Comparison across treatment conditions for reducing the proportion of use-days of other substances of abuse (alcohol, marijuana, amphetamines, methamphetamines, benzodiazepines and barbiturates) as determined by self-report and urine test results.|Comparison across treatment conditions in reducing psychiatric and mood disturbance as measured with the BDI and SF-36.","University of California, Los Angeles",All,"15 Years and older   (Child, Adult, Older Adult)",Not Applicable,202,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,5R01DA020210,2006-09-01,2012-01-01,2012-12-01,2008-01-11,null,2013-01-29,"UCLA Integrated Substance Abuse Programs Outpatient Clinical Research Center, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT00591617
164,NCT03489161,Feasibility of the Utilization of Buprenorphine in the Emergency Room to Treat Clinical Opioid Withdrawal,,Recruiting,No Results Available,Drug Overdose|Opioid Withdrawal|Opioid-use Disorder,Drug: Buprenorphine,Recruitment rates|Acceptability of transferral to outpatient clinic (MOTIVATE)|Feasibility of 5-Trial Delay Discounting,Virginia Commonwealth University,All,"18 Years to 65 Years   (Adult, Older Adult)",Early Phase 1,100,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HM20012543,2018-08-01,2018-10-01,2018-10-01,2018-04-05,null,2018-07-31,"Virginia Commonwealth University, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT03489161
165,NCT01880086,Clomiphene Citrate for the Treatment of Low Testosterone Associated With Chronic Opioid Pain Medication Administration,,Completed,Has Results,Hypogonadism|Opioid-Related Disorders|Male Infertility,Drug: Clomiphene citrate|Drug: Placebo,Serum Total Testosterone (Change From Baseline)|Other Hormonal Profile (Change From Baseline)|Androgen Deficiency in the Aging Male (ADAM) Questionnaire|Hematocrit (%)|Estradiol|Sexual Health Inventory for Men (SHIM) Questionnaire|Men's Sexual Health Questionnaire (MSHQ) Questionnaire,Weill Medical College of Cornell University,Male,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,13,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Cornell-1301013472,2013-08-01,2016-03-01,2017-11-01,2013-06-18,2017-06-05,2018-07-17,"Weill Cornell Medical College, Department of Urology, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01880086
166,NCT02978417,Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings,DC,Enrolling by invitation,No Results Available,Opioid-Related Disorders,Drug: Naltrexone for extended-release injectable suspension|Drug: Oral naltrexone,New arrests|New incarcerations|Number of positive drug screens|Number of sanctions imposed by the court|Number of missed court appointments|Vivitrol participation|Treatment participation (non-Vivitrol)|Change in subjective functioning: medical status|Change in subjective functioning: employment/support status|Change in subjective functioning: alcohol/drug use|Change in subjective functioning: legal status|Change in subjective functioning: family/social relationships|Change in subjective functioning: psychiatric status|Treatment satisfaction|Treatment attitudes,"Duke University|Laura and John Arnold Foundation|Alkermes, Inc.|FHR (Fellowship Health Resources, Inc.)|Drug Treatment Court (Wake County, NC)",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,40,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,Pro00074507|69665,2017-09-21,2019-06-01,2019-06-01,2016-12-01,null,2017-10-02,"Fellowship Health Resources (FHR), Raleigh, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT02978417
167,NCT01874964,Trial of Methadone Maintenance Versus Methadone Detox in Jail,,Unknown status,No Results Available,Opioid-Related Disorders,Behavioral: Methadone Maintenance|Behavioral: Linkage to methadone maintenance,Time to post release treatment engagement|Reduction of HIV risk behaviors|Time to relapse|Cost effectiveness|Treatment retention|Fatal and nonfatal overdose,The Miriam Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,450,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,NIDA-R01DA027211,2010-06-01,2013-06-01,2014-05-01,2013-06-11,null,2013-06-11,"Rhode Island Department of Corrections, Cranston, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT01874964
168,NCT03306147,Negating Opioid and Pain Actively Through Intervention,NOPAIN,Recruiting,No Results Available,Pain|Chronic Pain|Opioid Use,Behavioral: Pain education with follow up encounters,Decrease in opioid prescription strength|Reduction in pain as evidenced by decrease in opioid daily dose|Improvement in quality of life score as measured by the PEG pain screening tool by units on a scale,Loma Linda University|Cardinal Health,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,300,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,5170244,2017-10-12,2018-06-30,2018-06-30,2017-10-10,null,2017-11-14,"Loma Linda University, Loma Linda, California, United States",,https://ClinicalTrials.gov/show/NCT03306147
169,NCT02660606,A Qualitative Study to Assess the Content Validity of the Prescription Opioid Misuse and Abuse Questionnaire,POMAQ,Completed,No Results Available,Opioid-Related Disorders|Opiate Addiction|Narcotic Abuse|Drug Abuse,Other: Prescription Opioid Misuse and Abuse Questionnaire (POMAQ),Content validity of POMAQ,Member Companies of the Opioid PMR Consortium|Evidera,All,"18 Years and older   (Adult, Older Adult)",,54,Industry,Observational,Observational Model: Case-Only|Time Perspective: Prospective,Observational Study 2A (Qual)|2065-2A (Qual),null,2015-11-01,null,2016-01-21,null,2016-01-21,"Evidera, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02660606
170,NCT00000207,Multicenter Clinical Trial of Buprenorphine - 3,,Completed,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine,Retention|Opiate use|Opiate craving,"University of California, Los Angeles|National Institute on Drug Abuse (NIDA)",All,21 Years to 50 Years   (Adult),Phase 3,0,Other|NIH,Interventional,Allocation: Randomized|Masking: Double|Primary Purpose: Treatment,NIDA-06082-3|R18DA006082|R18-06082-3,1992-05-01,1997-04-01,null,1999-09-21,null,2016-07-11,"Friends Research Institute, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT00000207
171,NCT03521960,Buspirone for Opioid Tapering,,Recruiting,No Results Available,"Opioid-Related Disorders|Dependency (Psychology)|Pain, Chronic|Opiate Withdrawal Syndrome",Drug: Buspirone oral capsule|Drug: Placebo oral capsule,Taper Completion|Opioid Withdrawal Symptom Severity,Johns Hopkins University,All,"18 Years and older   (Adult, Older Adult)",Phase 1,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IRB00125620,2018-05-30,2020-05-30,2020-05-30,2018-05-10,null,2018-07-13,"Johns Hopkins University, Baltimore, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT03521960/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03521960
172,NCT02804152,Program for Pain & Prescription Opioid Use in Pregnancy,,Recruiting,No Results Available,Pain|Opioid Abuse|Pregnancy,Behavioral: CBT for Chronic Pain in Pregnancy,Brief Pain Inventory (BPI)|Current Opioid Misuse Measure (COMM)|Current Opioid Dose,Medical University of South Carolina,Female,18 Years to 45 Years   (Adult),Not Applicable,200,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1K23DA039318-01,2016-04-01,2019-06-01,2019-12-01,2016-06-17,null,2018-06-19,"The Medical University of South Carolina, Charleston, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT02804152
173,NCT02696096,Neuroimaging Predictors of Relapse During Treatment for Opiate Dependence,,Recruiting,No Results Available,Opioid Addiction,Other: FMRI|Drug: Suboxone,length of time to use opioid after buprenorphine initiated|length of time to return to opioid use after buprenorphine initiated,Butler Hospital,All,21 Years to 50 Years   (Adult),Phase 3,72,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,793387,2016-08-01,2019-04-01,2020-04-01,2016-03-02,null,2018-04-12,"Butler Hospital, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT02696096
174,NCT03179566,Pain and Medication Use Following Surgery,SODAS,Completed,No Results Available,Opioid Use,Behavioral: Information Sheet|Behavioral: Deterra Drug Deactivation System,Drug disposal|Opioid disposal technique,University of Michigan|Michigan Department of Health and Human Services,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,391,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,HUM00129418|MA-2017,2017-06-06,2017-09-01,2017-09-01,2017-06-07,null,2017-09-11,"East Ann Arbor Ambulatory Surgery & Medical Procedures Center - Michigan Medicine, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT03179566
175,NCT00476242,Memantine as a Supplement to Naltrexone in Treating Heroin Dependence,NAMHS,Completed,Has Results,Opioid Dependence|Heroin Dependence,Drug: Vivitrol|Drug: memantine,"Opiate Use Measured by Urine Toxicology Results|Retention in Treatment The Primary Outcome Measure Will be the Dichotomous Measure Retention in Treatment (Whether the Patient Completes the 12 Week Trial, Yes/no).|Opiate Craving Based on Heroin Craving Scale",New York State Psychiatric Institute|National Institute on Drug Abuse (NIDA),All,18 Years to 60 Years   (Adult),Phase 2|Phase 3,82,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",#5936R R01 DA015822-01|R01DA015822,2008-06-01,2011-08-01,2011-08-01,2007-05-21,2014-07-04,2018-07-17,"STARS, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00476242
176,NCT02070003,"Perioperative Recovery of Moods, Opioids, and Pain Trial (PROMPT)",PROMPT,Enrolling by invitation,No Results Available,Opioid Cessation,Behavioral: Motivational Interviewing and Physician Guided Opioid Weaning,Trial Feasibility - The proportion of people consented who complete the study in the group to which they were randomized|Efficacy - time to opioid cessation,Stanford University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,130,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,26234,2014-04-01,2018-09-01,2018-12-01,2014-02-24,null,2018-04-26,"Stanford University School of Medicine, Palo Alto, California, United States",,https://ClinicalTrials.gov/show/NCT02070003
177,NCT01505101,Mindfulness-Oriented Recovery Enhancement for Chronic Pain Patients Receiving Opioid Therapy,,Completed,No Results Available,"Chronic Pain|Opioid Abuse, Unspecified Use",Behavioral: Mindfulness-Oriented Recovery Enhancement|Behavioral: Conventional Support Group (SG),"Pain severity, pain functional interference|Opioid craving|Opioid misuse behaviors|Well-being|Attentional bias|Psychophysiological cue-reactivity|Emotional response inhibition|Pain coping strategies|Anhedonia|Fear of pain|Mindfulness|Positive reappraisal",Florida State University|National Institute on Drug Abuse (NIDA)|Fahs Beck Fund for Research and Experimentation,All,"18 Years and older   (Adult, Older Adult)",Phase 1,115,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,DA032517-01|R03DA032517,2011-10-01,2013-07-01,2013-07-01,2012-01-06,null,2014-08-06,"FSU College of Social Work, Tallahassee, Florida, United States",,https://ClinicalTrials.gov/show/NCT01505101
178,NCT00734461,Study to Evaluate the Subjective Effects of PTI-801 in Non-Physically Dependent Subjects With a History of Drug Abuse,,Completed,No Results Available,Opioid-Related Disorders,Drug: oxycodone and naltrexone,The primary objective of this study is to evaluate the subjective effects of PTI-801 formulated with either 0.001 mg naltrexone or 0.0001 mg naltrexone compared to oxycodone alone in individuals with a history of opioid abuse.|Secondary objectives include determining the safety and physiological effects of single doses of PTI-801 compared to oxycodone following oral administration in individuals with a history of opioid abuse.,Pain Therapeutics,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,14,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",PTI-801-XM,2007-08-01,2009-03-01,2009-03-01,2008-08-14,null,2016-05-02,"Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00734461
179,NCT03129347,Pharmacokinetic Evaluation of Nalmefene Administered Intranasally to Healthy Volunteers,,Completed,No Results Available,Opioid-Related Disorders,Drug: Nalmefene,Pharmacokinetic parameters of nalmefene|Safety and tolerability,National Institute on Drug Abuse (NIDA),All,18 Years to 55 Years   (Adult),Phase 1,14,NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",Nalmefene-Ph1a-001,2017-06-01,2017-06-09,2017-07-03,2017-04-26,null,2018-03-26,"Vince and Associates Clinical Research, Overland Park, Kansas, United States",,https://ClinicalTrials.gov/show/NCT03129347
180,NCT02941809,Harnessing Placebo Effects in Methadone Treatment,,Enrolling by invitation,No Results Available,Opioid-related Disorders,Behavioral: Placebo Dose Extension,"Dose of methadone|Adapted Credibility/Expectancy Questionnaire|Urine Drug Testing|The Subjective Opiate Withdrawal Scale|Days in treatment|The Objective Opioid Withdrawal Scale|Craving Assessment|World Health Organization Quality of Life Scale - Brief (WHOQOL-BREF)|Compliance|Past Week Substance Use|Methadone Symptom Severity Checklist|Cleveland Clinic Constipation Scoring System|Past 2 Weeks Drug Use|PEG Pain Screening Tool|Behavioral Inhibition/Activation System Scales (BIS/BAS)|Pain Catastrophizing Scale (PCS)|Pittsburgh Sleep Quality Index|Monetary Choice Questionnaire (MCQ)|Barratt Impulsivity Scale, version 11 (BIS-11)|Baseline and Post-Baseline Drug Use History and Assessment|Exit Survey|Spatial Accessibility Instruments|Drug Test Results Awareness Assessment|Naloxone Perceptions and Attitudes Assessment",University of Maryland,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HP-00070829,2017-06-19,2020-07-31,2020-07-31,2016-10-21,null,2018-08-15,"Maryland Methadone Treatment Center, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02941809
181,NCT00344812,Opioid Maintenance Medications Comparison Study,,Completed,No Results Available,Opioid Dependence,Drug: LAAM. buprenorphine and methadone,Study retention|Drug use|Safety,Johns Hopkins University,All,21 Years to 55 Years   (Adult),Phase 2,220,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,BPR-95-07-24-03,1996-01-01,null,1998-06-01,2006-06-27,null,2006-06-27,"Behavioral Pharmacology Research Unit; Johns Hopkins Bayview Campus, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00344812
182,NCT02750748,"Pharmacokinetic Evaluation of Intranasal, Intramuscular, and Oral Naltrexone in Healthy Volunteers",,Completed,No Results Available,Opioid-Related Disorders,Drug: Naltrexone|Other: Intravail,Plasma Concentration (Cmax)|Plasma Concentration (Tmax)|Plasma Concentration (AUC 0-t)|Plasma Concentration (AUC 0-inf)|Adverse Events|Vital Signs|12-lead electrocardiogram|Nasal Irritation Scoring,National Institute on Drug Abuse (NIDA),All,18 Years to 55 Years   (Adult),Phase 1,14,NIH,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Naltexone-Ph1a-002,2016-07-01,2016-09-01,2016-09-01,2016-04-25,null,2017-01-12,"Vince and Associates Clinical Research, Inc., Overland Park, Kansas, United States",,https://ClinicalTrials.gov/show/NCT02750748
183,NCT02152397,Safety and Health Intervention Project,SHIP,Completed,No Results Available,Drug Overdose|Opioid Related Disorders,Behavioral: Therapist-led brief intervention (TBI),Overdose risk behavior|HIV risk behavor,University of Michigan,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,139,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,1R34DA035331-01A1,2014-10-01,2016-12-01,2016-12-01,2014-06-02,null,2017-04-17,"Community Programs, Inc., Waterford, Michigan, United States",,https://ClinicalTrials.gov/show/NCT02152397
184,NCT01860885,Critical Respiratory Events in Children Requiring Naloxone: Naloxone Use as Opioid Safety Measure,,Completed,No Results Available,Opioid Induced Respiratory Depression,,Descriptive: Medical history and Risk Factors for critical respiratory events requiring Naloxone in children,"Children's Hospital Medical Center, Cincinnati",All,"Child, Adult, Older Adult",,95,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,CIN1-2012-1219,2012-08-01,2013-05-01,2013-05-01,2013-05-23,null,2013-05-23,"Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01860885
185,NCT01894087,Safety & Prevention Outcomes Study,SPOS,Completed,Has Results,Drug Overdose|Opioid-Related Disorders,Behavioral: TBI - Cohort 1|Behavioral: TBI - Cohort 2,Overdose Risk Behavior|Overdose Knowledge|Behavioral Intentions|Substance Use - Current Opioid Misuse Measure,University of Michigan|Centers for Disease Control and Prevention,All,18 Years to 60 Years   (Adult),Not Applicable,204,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,R49CE002099,2013-04-01,2015-01-01,2015-01-01,2013-07-09,2018-01-19,2018-01-19,"University of Michigan Health System Emergency Department, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT01894087
186,NCT02922959,"A Tailored, Peer-delivered Intervention to Reduce Recurring Opioid Overdoses",TTIP-PRO,"Active, not recruiting",No Results Available,Drug Overdose|Opioid-Related Disorders|Drug Addiction|Drug Abuse|Substance Abuse,Behavioral: TTIP-PRO|Drug: naloxone nasal spray kit|Behavioral: information,Medication-Assisted Treatment Enrollment|Opioid Overdose Experience|Change in Opioid Use (Timeline Follow-back)|Change in Opioid Use (Urine drug screen),University of Cincinnati|National Institute on Drug Abuse (NIDA),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,2016-6635|R34DA040862,2017-02-07,2019-07-01,2019-07-01,2016-10-04,null,2018-08-15,"University of Cincinnati Addiction Sciences Division, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02922959
187,NCT02882048,Auricular Acupuncture to Facilitate Outpatient Opioid Weaning,,Recruiting,No Results Available,Narcotic Addiction,Procedure: NADA Protocol|Other: Medication management,"Change from baseline in clinical institute narcotic assessment scale (CINA) for withdrawal|Off-opioids rate|Change from baseline assessment of psychological distress of weaning, assessed using the Hospital Anxiety and Depression Scale (HADS)|Time to cessation of opioids",Vanderbilt University Medical Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,160725,2016-09-01,2020-09-01,2020-09-01,2016-08-29,null,2018-01-29,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT02882048
188,NCT00218374,"Dextromethorphan, Gabapentin, and Oxycodone to Treat Opioid-Induced Hyperalgesia",,Completed,No Results Available,Hyperalgesia|Opioid-Related Disorders,Drug: Gabapentin,"Pain response (measured after each pain testing session on Days 1, 4, 36, and 39)",National Institute on Drug Abuse (NIDA),All,18 Years to 55 Years   (Adult),Not Applicable,60,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",NIDA-15463-1|R01-15463-1|DPMC,2006-10-01,2007-06-01,2007-06-01,2005-09-22,null,2017-01-12,"University of California, Los Angeles, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT00218374
189,NCT01462084,Effectiveness of Adaptive Servoventilation (ASV) in Patients With Central Sleep Apnea Due to Chronic Opioid Use,,Completed,Has Results,Obstructive Sleep Apnea|Central Sleep Apnea (Diagnosis)|Chronic Opioid Use,Device: Adaptive servo-ventilation (ASV)|Device: Bi-Level PAP,Apnea Hypopnea Index (AHI)|Patient Comfort,ResMed,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,21,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MA-01-10,2011-09-01,2012-11-01,2012-12-01,2011-10-28,2017-04-17,2017-04-17,"Stanford Center for Human Sleep Research, Redwood City, California, United States",,https://ClinicalTrials.gov/show/NCT01462084
190,NCT01873989,Testosterone Replacement for Male Opioid Agonist Maintained Patients,,Completed,Has Results,Chronic Pain|Opioid Addiction|Symptomatic Hypogonadism,Drug: Testosterone replacement|Other: Waitlist control,Number of Participants Demonstrating Abstinence|Change in Pain Ratings|Change in Sexual Dysfunction From Baseline to Week 8,Yale University,Male,18 Years to 50 Years   (Adult),Phase 1|Phase 2,15,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1105008492,2012-04-01,2015-01-01,2015-01-01,2013-06-10,2017-06-12,2017-06-12,"MRU, APT Foundation, Inc, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01873989
191,NCT00000216,Buprenorphine Maintenance for Cocaine Abusing Opioid Addicts - 1,,Completed,No Results Available,Cocaine-Related Disorders|Opioid-Related Disorders|Substance-Related Disorders,Drug: Buprenorphine,Depression|Withdrawal symptoms|Opioid and cocaine use|Social and psychological functioning|AIDS risk behavior,National Institute on Drug Abuse (NIDA)|Yale University,All,"Child, Adult, Older Adult",Phase 3,0,NIH|Other,Interventional,Primary Purpose: Treatment,NIDA-06266-1|R01-06266-1,null,null,null,1999-09-21,null,2005-08-17,"APT Residential Services Division, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00000216
192,NCT01986283,Abuse Potential Study of PF-00345439,,Completed,No Results Available,Opioid Users,Drug: Capsule|Drug: PF-00345439|Drug: oxycodone,Drug Liking: Peak Effect (Emax)|High: Peak Effect (Emax)|Drug Liking: Area Under Effect Curve (AUE) From 0-2 Hours|High: Area Under Effect Curve (AUE) From 0-2 Hours|Take Drug Again Effect at 24 Hours|Overall Drug Liking|Any Drug Effects: Area Under Drug Effect Curve (AUE) From 0-1 Hour|Pupillometry: Area Under Effect Curve (AUE) From 0-1 Hour|Chewing Duration|Taste: Subjective Experience from Chewing|Any Drug Effects: Area Under Drug Effect Curve (AUE) From 0-2 Hours|Any Drug Effects: Area Under Drug Effect Curve (AUE) From 0-3 Hours|Any Drug Effects: Area Under Drug Effect Curve (AUE) From 0-12 Hours|Pupillometry: Area Under Effect Curve (AUE) From 0-2 Hours|Pupillometry: Area Under Effect Curve (AUE) From 0-3 Hours|Pupillometry: Area Under Effect Curve (AUE) From 0-12 Hours|High: Area Under Effect Curve (AUE) From 0-1 Hour|High: Area Under Effect Curve (AUE) From 0-3 Hours|High: Area Under Effect Curve (AUE) From 0-12 Hours|Good Drug Effects: Area Under Drug Effect Curve (AUE) From 0-1 Hour|Good Drug Effects: Area Under Effect Curve (AUE) From 0-2 Hours|Good Drug Effects: Area Under Effect Curve (AUE) From 0-3 Hours|Good Drug Effects: Area Under Effect Curve (AUE) From 0-12 Hours|Bad Drug Effects: Area Under Effect Curve (AUE) From 0-1 Hour|Bad Drug Effects: Area Under Effect Curve (AUE) From 0-2 Hours|Bad Drug Effects: Area Under Effect Curve (AUE) From 0-3 Hours|Bad Drug Effects: Area Under Effect Curve (AUE) From 0-12 Hours|Feeling Sick: Area Under Effect Curve (AUE) From 0-1 Hour|Feeling Sick: Area Under Effect Curve (AUE) From 0-2 Hours|Feeling Sick: Area Under Effect Curve (AUE) From 0-3 Hours|Feeling Sick: Area Under Effect Curve (AUE) From 0-12 Hours|Nausea: Area Under Effect Curve (AUE) From 0-1 Hour|Nausea: Area Under Effect Curve (AUE) From 0-2 Hours|Nausea: Area Under Effect Curve (AUE) From 0-3 Hours|Nausea: Area Under Effect Curve (AUE) From 0-12 Hours|Sleepy: Area Under Effect Curve (AUE) From 0-1 Hour|Sleepy: Area Under Effect Curve (AUE) From 0-2 Hours|Sleepy: Area Under Effect Curve (AUE) From 0-3 Hours|Sleepy: Area Under Effect Curve (AUE) From 0-12 Hour|Dizzy: Area Under Effect Curve (AUE) From 0-1 Hour|Dizzy: Area Under Effect Curve (AUE) From 0-2 Hours|Dizzy: Area Under Effect Curve (AUE) From 0-3 Hours|Dizzy: Area Under Effect Curve (AUE) From 0-12 Hours|Bad Effects: Peak Effect (Emax)|Nausea: Peak Effect (Emax)|Feel Sick: Peak Effect (Emax)|Sleepy: Peak Effect (Emax)|Dizzy: Peak Effect (Emax)|Pupillometry: Peak Effect (Emax)|Good Drug Effects: Peak Effect (Emax)|Drug Liking: Area Under Effect Curve (AUE) From 0-1 Hour|Drug Liking: Area Under Effect Curve (AUE) From 0-3 Hours|Drug Liking: Area Under Effect Curve (AUE) From 0-12 Hours|Drug Liking: Time to Maximum (Peak) Effect (TEmax)|High: Time to Maximum (Peak) Effect (TEmax)|Any Drug Effects: Time to Maximum (Peak) Effect (TEmax)|Good Drug Effects: Time to Maximum (Peak) Effect (TEmax)|Bad Drug Effects: Time to Maximum (Peak) Effect (TEmax)|Feel Sick: Time to Maximum (Peak) Effect (TEmax)|Nausea: Time to Maximum (Peak) Effect (TEmax)|Sleepy: Time to Maximum (Peak) Effect (TEmax)|Dizzy: Time to Maximum (Peak) Effect (TEmax)|Pupillometry: Time to Maximum (Peak) Effect (TEmax)|Any Drug Effects: Peak Effect (Emax)|Texture: Subjective Experience from Chewing|Maximum Observed Plasma Concentration (Cmax)|Time to Reach Maximum Observed Plasma Concentration (Tmax)|Area under the curve (AUC)|Systemic Clearance (CL)|volume of distribution (Vd)|Half-Life (t1/2),Pain Therapeutics,All,18 Years to 55 Years   (Adult),Phase 1,67,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",B4501016,2013-11-01,2014-08-01,2014-08-01,2013-11-18,null,2016-04-04,"Lifetree Clinical Research, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT01986283
193,NCT00857350,The Prevalence of HIV Drug Resistance and Transmission Risk in Opioid Agonist Treatment,,Completed,No Results Available,HIV Positive|Opioid Dependence|Opioid Agonist Treatment|HIV Infections,,HIV drug resistance|Illicit drug use|HIV transmission risk behaviors,Yale University,All,"18 Years to 90 Years   (Adult, Older Adult)",,60,Other,Observational,Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional,709003082,2008-06-01,2010-06-01,2012-09-01,2009-03-06,null,2013-07-22,"Yale University Hospital, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00857350
194,NCT00992095,Bioequivalency Study of Buprenorphine Hydrochloride 8 mg Tablet Under Fasted Conditions,,Completed,No Results Available,Opioid-Related Disorders,Drug: buprenorphine hydrochloride,bioequivalence determined by statistical comparison Cmax,Roxane Laboratories|West-Ward Pharmaceutical,All,18 Years to 45 Years   (Adult),Not Applicable,48,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BUPR-T8-PVFS-1,2006-08-01,2006-09-01,2006-09-01,2009-10-09,null,2018-01-23,"CEDRA Clinical Research, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT00992095
195,NCT01231191,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Relationship Between Intraoperative Intravenous Acetaminophen and Postoperative Opioid Avoidance for Ambulatory Surgical Procedures",Cadence,Withdrawn,No Results Available,Postoperative Pain|Intraoperative and Postoperative Opioid Requirements,Drug: Intravenous acetaminophen|Drug: Intravenous placebo,"The primary endpoint is the difference in proportions of patients from each treatment group who avoid using any opioids following anesthesia emergence until recovery room discharge.|A secondary endpoint for this investigation will be the total dose of fentanyl administered to the patient.|A secondary outcome for this investigation will be the total dose of morphine administered to the patient.|A secondary outcome for this investigation will be the total dose of ibuprophen administered to the patient.|A secondary outcome measure for this investigation will be the total dose of oxycodone administered to the patient.|A secondary outcome measure will be any surgeon-administered local anesthetics used for wound infiltration.|A secondary outcome measure for this study will be any recovery-room anti-emetics administered to the patient.|Patients will be asked at time of PACU discharge, ""Overall, how would you rate the study treatments?"" Responses will be on 0 to 3 scale where 0=poor and 3=excellent.|Patients will be asked at time of PACU discharge, ""Overall, how would you rate the level of pain relief from study medication?"" Responses will be on 0 to 3 scale where 0=poor and 3=excellent.|Adverse events","University of California, San Diego|Mallinckrodt",All,"18 Years and older   (Adult, Older Adult)",Phase 4,0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",IV Acetaminophen,null,null,null,2010-11-01,null,2012-03-08,"UCSD Medical Center (Hillcrest and Thornton), San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT01231191
196,NCT01690546,Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence,BUP/NXT-VIVI,Completed,Has Results,Opiate Dependence,Drug: very low dose naltrexone|Drug: extended release naltrexone|Drug: buprenorphine/naloxone,"Retention in Treatment|Withdrawal Intensity as Measured by the Clinical Opiate Withdrawal Scale (COWS)|Withdrawal Intensity as Measured by the Subjective Opiate Withdrawal Scale (SOWS)|Craving|Illicit Drug Use, Measured by Urine Drug Testing|Satisfaction With Treatment, Measured by a Treatment Satisfaction Questionnaire|Percentage of Participants Who Adhered to Study Visits.|Percentage of Participants With Adherence to Medication (Naltrexone)|Use of Ancillary Medications.|Number of Participants That Self Reported Illicit Drug Use","Paolo Mannelli|Alkermes, Inc.|Duke University",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,38,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00036909,2012-09-01,2015-02-01,2015-02-01,2012-09-21,2016-06-01,2016-06-01,"Duke University Medical Center / Civitan Building, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01690546
197,NCT02464410,Primary Care Intervention to Reduce Prescription Opioid Overdoses,POST,Recruiting,No Results Available,Pain|Drug Overdose|Opioid Use Disorders,Behavioral: Motivational intervention|Behavioral: Psycho-educational control|Other: Long-term opioid therapy informed consent,Overdose risk behaviors|Aberrant opioid use|Prescribed opioid use (total days supply and daily dose) based on pharmacy records and questionnaire|Number of participants with non-fatal overdose experiences|Treatment utilization|Other (non-overdose) injuries from the Revised Injury Behavior Checklist questionnaire|Scores on an opioid storage and disposal knowledge and behaviors questionnaire|Level of oversedation as an opioid side effect|General physical and mental functioning from Short Form-12 questionnaire scores|Pain-specific disability score from an adapted version of Roland-Morris questionnaire,VA Office of Research and Development,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,450,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,IIR 13-322,2016-08-04,2018-12-31,2019-05-31,2015-06-08,null,2018-07-16,"VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT02464410
198,NCT00710385,Abuse Liability of Suboxone Versus Subutex,,Completed,Has Results,Opioid-related Disorders,Drug: Heroin|Drug: Naloxone|Drug: Low Bup Dose|Drug: High Bup Dose|Drug: Low Bup/Nal Dose|Drug: High Bup/Nal Dose|Drug: Placebo (PCB),"Drug's Breakpoint|Drug ""Liking""",New York State Psychiatric Institute|Schering-Plough,All,21 Years to 45 Years   (Adult),Phase 3,19,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science",5518,2007-09-01,2008-08-01,2008-08-01,2008-07-04,2016-12-05,2016-12-05,"New York State Psychiatric Institute/Columbia University, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00710385
199,NCT03002961,Single Ascending Dose Study of RBP-6000,SAD,Completed,No Results Available,Opioid Use Disorder,Drug: RBP-6000|Drug: Suboxone,"Safety will be assessed by the frequency of adverse events (AEs), serious AEs, and discontinuations due to AEs (safety and tolerability) in subjects receiving a single dose of RBP-6000.|Individual, mean and median PK concentrations over time profiles will be plotted for subjects receiving a single dose of RBP-6000 with an adequate number of PK samples collected to derive PK parameters.|The safety of RBP-6000 when administered as a single SC injection after daily dosing of SL Suboxone will be assessed as a measure of the occurrence of AEs, serious AEs and discontinuations due to AEs|Change from baseline of subject suicidal ideation will be reported using the Columbia Suicide Severity Rating Scale (C-SSRS)|Change from baseline of physician reported withdrawal symptoms will be reported by Clinical Opiate Withdrawal Scale (COWS) score|Change from baseline of subject reported withdrawal symptoms will be reported by Visual Analog Scale (VAS) total score",Indivior Inc.,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,48,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RB-US-11-0020,2012-07-01,2013-02-01,2013-10-01,2016-12-26,null,2016-12-26,"Vince and Associates Clinical Research, Overland Park,, Kansas, United States",,https://ClinicalTrials.gov/show/NCT03002961
200,NCT00237406,Interactive Voice Response (IVR) for Methadone Patients,,Completed,No Results Available,Opioid-Related Disorders,Procedure: interactive voice response,,Butler Hospital,All,"18 Years to 75 Years   (Adult, Older Adult)",,50,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,4065-05,2006-01-01,null,2006-10-01,2005-10-12,null,2010-03-25,"Rhode Island Hospital, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT00237406
201,NCT00149539,Abuse Potential of Buprenorphine/Naloxone,,Terminated,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine/naloxone,Opiate withdrawal|opiate agonist symptoms|physiologic measures,National Institute on Drug Abuse (NIDA)|Johns Hopkins University,All,18 Years to 55 Years   (Adult),Phase 2,12,NIH|Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,NIDA-08045-7|R01-08045-7|DPMC,2004-06-01,null,2006-01-01,2005-09-08,null,2017-01-12,"Johns Hopkins University (BPRU) Bayview Campus, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00149539
202,NCT00295308,Clonidine for Relapse Prevention in Buprenorphine-Maintenance Patients,,Completed,No Results Available,Opioid-Related Disorders,Drug: Clonidine|Drug: Placebo,Opiate-negative urine screens|HIV risk behaviors|Craving,National Institute on Drug Abuse (NIDA)|National Institutes of Health Clinical Center (CC),All,18 Years to 50 Years   (Adult),Phase 1,208,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment,999906407|06-DA-N407,2005-11-08,null,2014-07-30,2006-02-23,null,2018-08-14,"National Institute on Drug Abuse, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00295308
203,NCT01642030,Study of the Treatment of Experimental Pain in Opioid Dependent Persons on Methadone or Buprenorphine Maintenance,,Completed,No Results Available,Opioid Dependence|Pain|Addiction,Drug: Placebo|Drug: Hydromorphone|Drug: Buprenorphine,Cold pressor test.|Visual analog scales (VAS) of subjective drug effects.,Johns Hopkins University|National Institute on Drug Abuse (NIDA),All,18 Years to 55 Years   (Adult),Phase 1,132,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",NA_00071459|K23DA029609|1203,2013-08-01,2017-07-01,2017-07-01,2012-07-17,null,2017-09-11,"Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01642030
204,NCT03545516,Wound Infiltration as Part of an Opioid Free Pain Management Pathway Following Cesarean Delivery,,Not yet recruiting,No Results Available,"Pain, Postoperative|Anesthesia, Local|Opioid Use",Drug: Bupivacaine|Drug: Dexmedetomidine|Drug: Placebo,Total number of opioid free Cesarean deliveries|Time to first rescue analgesia|Total opioid consumption|Side effects/Adverse reactions|Postoperative hospital stay|Complications from procedures|Breast feeding capacity,Richmond University Medical Center,Female,18 Years to 55 Years   (Adult),Phase 2,540,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",Post Cesarean Pain Management,2018-07-01,2018-11-01,2018-11-01,2018-06-04,null,2018-06-04,"Richmond University Medical Center, Staten Island, New York, United States",,https://ClinicalTrials.gov/show/NCT03545516
205,NCT03175640,Prescribe to Save Lives,PTSL,Recruiting,No Results Available,Opioid-Related Disorders|Drug Overdose,Behavioral: Implementation intervention,Change in naloxone prescribing behavior|Change in perception about pharmacotherapy for opioid use disorder; 6-month|Change in perception about pharmacotherapy for opioid use disorder; 12-month|Change in prescribing motivation; 6 months|Change in prescribing motivation; 12 months|Change in prescriber training|Change in buprenorphine prescribing behavior,Baystate Medical Center|National Institute on Drug Abuse (NIDA)|The Miriam Hospital|Boston Medical Center|Rhode Island Hospital,All,"Child, Adult, Older Adult",Not Applicable,120,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,BH-15-259|R01DA038082,2017-07-12,2019-12-01,2019-12-01,2017-06-05,null,2018-02-13,"University of Massachusetts Medical School - Baystate, Springfield, Massachusetts, United States|The Miriam Hospital, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT03175640
206,NCT00067184,Fetal Neurobehavioral Development in Methadone Maintained Pregnancies,,Completed,No Results Available,Opioid-Related Disorders,Device: Toitu 320/325,fetal heart rate|fetal movement|neonatal abstinence syndrome,Johns Hopkins University|National Institute on Drug Abuse (NIDA),Female,18 Years to 40 Years   (Adult),,157,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,HBV98112004|R01DA019934|DPMCDA,2002-09-01,2010-08-01,2010-08-01,2003-08-13,null,2018-04-25,"Center for Addiction and Pregnancy, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00067184
207,NCT00061100,HIV Counseling Intervention for Methadone-Maintained Patients - 2,,Completed,No Results Available,Opioid-Related Disorders,Behavioral: Behavior Therapy-RISE|Behavioral: Standard prevention Education,AIDS risk behavior based on the Risk Behavior Assessment,New York State Psychiatric Institute|National Institute on Drug Abuse (NIDA),All,18 Years to 60 Years   (Adult),Phase 1,50,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,#3884|R01DA011444|3884,1999-10-01,2003-10-01,2003-10-01,2003-05-22,null,2018-05-16,"Research Foundation for Mental Hygiene, Inc., New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00061100
208,NCT02272829,Behavioral Consultation for HIV+ Older Adults Prescribed Opioids for Chronic Pain,CHOACOT,Completed,No Results Available,Opioid Misuse|Older Adults|HIV,Behavioral: Choacot: Behavioral Intervention for Chronic Opioid Use|Other: Health Education,opioid use|quality of the patient-provider relationship|pain|problematic use of other substances|antiretroviral adherence|psychosocial functioning,Butler Hospital,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,8,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DA038203,2015-05-01,2017-08-01,2017-08-01,2014-10-23,null,2017-09-18,"Butler Hospital, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT02272829
209,NCT00286052,Impact of Low Dose Naloxone on Fentanyl Requirements in Pediatric ICU Patients,,Completed,No Results Available,Opioid Tolerance,Drug: Low Dose Naloxone,Maximum Cummulative Daily Fentanyl Dose|Number of Rescue Fentanyl Boluses|Number of Rescue Midazolam Boluses|Total Midazolam Dose|Narcotic Withdrawal Scale Score|Modified Motor Activity Assessment Score,University of Texas Southwestern Medical Center,All,"up to 18 Years   (Child, Adult)",Phase 3,128,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,IRB File: 1002-605,2002-12-01,null,2004-08-01,2006-02-02,null,2006-02-02,"Unversity of Texas Southwestern, Children's Medical Center, Dallas, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT00286052
210,NCT02372591,Study of the Treatment of Experimental Pain in Buprenorphine Maintained Persons With Chronic Musculoskeletal Pain,1401,Completed,No Results Available,Opioid-Related Disorders|Chronic Pain,Drug: Buprenorphine|Drug: Hydromorphone|Drug: Placebo,Cold pressor test,Johns Hopkins University|National Institute on Drug Abuse (NIDA),All,18 Years to 55 Years   (Adult),Phase 1,14,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NA_00093537|K23DA029609,2015-08-01,2017-06-01,2017-06-01,2015-02-26,null,2017-09-11,"Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02372591
211,NCT01368562,Compassionate Use Study of Methylnaltrexone,,Completed,No Results Available,Opioid-induced Constipation,Drug: Methylnaltrexone,Number of patients with side effects of opioid-induced constipation.,"Valeant Pharmaceuticals International, Inc.",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,26,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MNTX 901,2003-01-01,2008-06-01,2008-06-01,2011-06-08,null,2011-07-19,"Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States",,https://ClinicalTrials.gov/show/NCT01368562
212,NCT00018226,Effect Of Case Management Following Discharge From Methadone Treatment,,Completed,No Results Available,Opioid-Related Disorders,Behavioral: Case Management,,US Department of Veterans Affairs|VA Office of Research and Development,All,"18 Years and older   (Adult, Older Adult)",Phase 2,null,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ADRD-022-97S,1998-04-01,null,2001-03-01,2001-07-05,null,2009-01-21,"Drug Dependent Treatment Unit, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00018226
213,NCT00000334,Comparison of Buprenorphine and Methadone - 3,,Completed,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine,Withdrawal severity|Opiate agonist symptoms,National Institute on Drug Abuse (NIDA)|Washington D.C. Veterans Affairs Medical Center,Male,23 Years to 45 Years   (Adult),Phase 2,0,NIH|U.S. Fed,Interventional,Primary Purpose: Treatment,NIDA-3-0009-3|Y01-3-0009-3,2002-12-01,2004-11-01,2005-01-15,1999-09-21,null,2017-01-31,"Washington DC VA, Washington, District of Columbia, United States",,https://ClinicalTrials.gov/show/NCT00000334
214,NCT00000300,Feasibility Study of Take-Home LAAM Medication - 3,,Completed,No Results Available,Opioid-Related Disorders,Drug: LAAM,Drug use|Retention|Increased prosocial behaviors|Decreased frequency of HIV related behavior,"University of California, Los Angeles|National Institute on Drug Abuse (NIDA)",All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 4,0,Other|NIH,Interventional,Allocation: Randomized|Primary Purpose: Treatment,NIDA-09260-3|P50DA009260|P50-09260-3,1995-03-01,null,null,1999-09-21,null,2017-11-01,"Friends Research Institute, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT00000300
215,NCT00000298,Buprenorphine Combination Tablet Feasibility - 1,,Completed,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine/naloxone,Withdrawal symptoms|Opiate use|Opiate craving,National Institute on Drug Abuse (NIDA),All,21 Years to 50 Years   (Adult),Phase 2,0,NIH,Interventional,Masking: Double|Primary Purpose: Treatment,NIDA-09260-1|P50-09260-1,1995-08-01,null,null,1999-09-21,null,2005-08-17,"Friends Research Institute, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT00000298
216,NCT00000239,Buprenorphine Pharmacology Related to Addiction Treatment - 21,,Completed,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine,"Drug use|Opioid agonist effects|Opiate withdrawal|Physiological changes in: pupil diameter, blood pressure, heart rate, respiration",National Institute on Drug Abuse (NIDA)|University of Vermont,All,"Child, Adult, Older Adult",Phase 2,0,NIH|Other,Interventional,Primary Purpose: Treatment,NIDA-06969-21|R01-06969-21,null,null,null,1999-09-21,null,2005-08-17,"Treatment Research Center, Burlington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT00000239
217,NCT00000237,Buprenorphine Detoxification - BBDVI - 19,,Completed,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine,Drug use|Retention|Weeks abstinent|Weeks continuous abstinence|Overall treatment outcome|Opioid dependence and psychiatric status,National Institute on Drug Abuse (NIDA)|University of Vermont,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,0,NIH|Other,Interventional,Primary Purpose: Treatment,NIDA-06969-19|R01-06969-19,1997-05-01,null,null,1999-09-21,null,2005-08-17,"Treatment Research Center, Burlington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT00000237
218,NCT00000236,Buprenorphine Pharmacology Related to Addiction Treatment - 18,,Completed,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine/naloxone,"Drug use|Opioid agonist effects|Opiate withdrawal|Psychological changes in: pupil diameter, blood pressure, heart rate, respiration",National Institute on Drug Abuse (NIDA)|University of Vermont,All,"18 Years and older   (Adult, Older Adult)",Phase 2,0,NIH|Other,Interventional,Primary Purpose: Treatment,NIDA-06969-18|R01-06969-18,null,null,null,1999-09-21,null,2005-08-17,"Treatment Research Center, Burlington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT00000236
219,NCT00000235,"Alternate Day Buprenorphine Administration, Phase XII - 17",,Completed,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine,Drug use|Opioid withdrawal|Opioid agonist effects|Dose choice,National Institute on Drug Abuse (NIDA)|University of Vermont,All,"18 Years and older   (Adult, Older Adult)",Phase 2,0,NIH|Other,Interventional,Intervention Model: Crossover Assignment|Primary Purpose: Treatment,NIDA-06969-17|R01-06969-17,null,null,null,1999-09-21,null,2005-08-17,"Treatment Research Center, Burlington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT00000235
220,NCT00000234,"Alternate Day Buprenorphine Administration, Phase XI - 16",,Completed,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine,Drug use|Opioid withdrawal|Opioid agonist effects|Dose choice,University of Vermont|National Institute on Drug Abuse (NIDA),All,25 Years to 51 Years   (Adult),Phase 2,0,Other|NIH,Interventional,Intervention Model: Crossover Assignment|Primary Purpose: Treatment,NIDA-06969-16|R01DA006969|R01-06969-16,null,null,null,1999-09-21,null,2016-05-06,"Treatment Research Center, Burlington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT00000234
221,NCT00000233,"Alternate Day Buprenorphine Administration, Phase X - 15",,Completed,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine,Opioid withdrawal|Subjective dose estimate|Drug effect characteristics: ARCI|Money choice,National Institute on Drug Abuse (NIDA)|University of Vermont,All,34 Years to 51 Years   (Adult),Phase 2,0,NIH|Other,Interventional,Primary Purpose: Treatment,NIDA-06969-15|R01-06969-15,1993-05-01,null,null,1999-09-21,null,2005-08-17,"Treatment Research Center, Burlington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT00000233
222,NCT00000232,"Alternate Day Buprenorphine Administration, Phase IX - 14",,Completed,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine,Drug use|Opioid withdrawal|Opioid agonist effects|Dose identification|Pupil diameter,University of Vermont|National Institute on Drug Abuse (NIDA),All,22 Years to 51 Years   (Adult),Phase 2,0,Other|NIH,Interventional,Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,NIDA-06969-14|R01DA006969|R01-06969-14,1992-03-01,null,null,1999-09-21,null,2016-05-06,"Treatment Research Center, Burlington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT00000232
223,NCT00000231,Buprenorphine Detoxification With Two Types of Treatment. BBD IV - 13,,Completed,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine,Drug use|Retention|Weeks abstinent|Weeks continuous abstinence|Overall treatment outcome|Naltrexone consumption,National Institute on Drug Abuse (NIDA)|University of Vermont,All,"18 Years and older   (Adult, Older Adult)",Phase 2,0,NIH|Other,Interventional,Primary Purpose: Treatment,NIDA-06969-13|R01-06969-13,1992-02-01,null,null,1999-09-21,null,2005-08-17,"Treatment Research Center, Burlington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT00000231
224,NCT00000230,Buprenorphine Detoxification With Two Types of Treatment. BBD III - 12,,Completed,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine,Drug use|Retention|Weeks abstinent|Weeks continuous abstinence|Overall treatment outcome,University of Vermont|National Institute on Drug Abuse (NIDA),All,"18 Years and older   (Adult, Older Adult)",Phase 2,0,Other|NIH,Interventional,Primary Purpose: Treatment,NIDA-06969-12|R01DA006969|R01-06969-12,1995-01-01,null,null,1999-09-21,null,2016-05-06,"Treatment Research Center, Burlington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT00000230
225,NCT00000229,Buprenorphine Detox With Two Types of Treatment. BBD II - 11,,Completed,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine,Drug use|Retention|Weeks abstinent|Weeks continuous abstinence|Overall treatment outcome,University of Vermont|National Institute on Drug Abuse (NIDA),All,"18 Years and older   (Adult, Older Adult)",Phase 2,0,Other|NIH,Interventional,Primary Purpose: Treatment,NIDA-06969-11|R01DA006969|R01-06969-11,1995-10-01,null,null,1999-09-21,null,2016-05-06,"Treatment Research Center, Burlington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT00000229
226,NCT00000228,Buprenorphine Detox With Two Types of Treatment. BBD I - 10,,Completed,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine,Drug use|Retention|Weeks abstinent|Weeks continuous abstinence|Overall treatment outcome,National Institute on Drug Abuse (NIDA)|University of Vermont,All,"18 Years and older   (Adult, Older Adult)",Phase 2,0,NIH|Other,Interventional,Primary Purpose: Treatment,NIDA-06969-10|R01-06969-10,1994-08-01,null,null,1999-09-21,null,2005-08-17,"Treatment Research Center, Burlington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT00000228
227,NCT00000227,Alternate-Day Buprenorphine Administration. Phase VIII - 9,,Completed,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine,Drug use|Opioid withdrawal|Opioid agonist effects|Dose choice,University of Vermont|National Institute on Drug Abuse (NIDA),All,25 Years to 48 Years   (Adult),Phase 2,0,Other|NIH,Interventional,Intervention Model: Crossover Assignment|Primary Purpose: Treatment,NIDA-06969-9|R01DA006969|R01-06969-9,1994-08-01,null,null,1999-09-21,null,2016-05-06,"Treatment Research Center, Burlington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT00000227
228,NCT00000226,Alternate-Day Buprenorphine Administration. Phase VII - 8,,Completed,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine,Drug use|Opioid withdrawal|Opioid agonist effects|Pupil diameter,National Institute on Drug Abuse (NIDA)|University of Vermont,All,21 Years to 48 Years   (Adult),Phase 2,0,NIH|Other,Interventional,Primary Purpose: Treatment,NIDA-06969-8|R01-06969-8,1994-11-01,null,null,1999-09-21,null,2005-06-24,"Treatment Research Center, Burlington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT00000226
229,NCT00000225,Alternate-Day Buprenorphine Administration. Phase VI - 7,,Completed,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine,Drug use|Opioid withdrawal|Opioid agonist effects|Dose identification|Pupil diameter,National Institute on Drug Abuse (NIDA)|University of Vermont,All,21 Years to 51 Years   (Adult),Phase 2,0,NIH|Other,Interventional,Masking: Double|Primary Purpose: Treatment,NIDA-06969-7|R01-06969-7,1992-12-01,null,null,1999-09-21,null,2005-06-24,"Treatment Research Center, Burlington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT00000225
230,NCT00000224,Alternate-Day Buprenorphine. Phase V - 6,,Completed,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine,Drug use|Opioid withdrawal|Subjective dose estimate|Drug effect characteristics: ARCI|Physiological changes in: pupil diameter|Physiological changes in: blood pressure|Physiological changes in: heart rate|Physiological changes in: respiration|Physiological changes in: bup plasma levels,National Institute on Drug Abuse (NIDA)|University of Vermont,All,30 Years to 49 Years   (Adult),Phase 1,0,NIH|Other,Interventional,Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,NIDA-06969-6|R01-06969-6,1993-02-01,null,null,1999-09-21,null,2005-06-24,"Treatment Research Center, Burlington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT00000224
231,NCT00000223,Alternate-Day Buprenorphine Administration. Phase IV - 5,,Completed,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine,Drug use|Opioid withdrawal|Opioid agonist effects|Dose identification|Pupil diameter,National Institute on Drug Abuse (NIDA)|University of Vermont,All,20 Years to 49 Years   (Adult),Phase 2,0,NIH|Other,Interventional,Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,NIDA-06969-5|R01-06969-5,1993-06-01,null,null,1999-09-21,null,2005-06-24,"Treatment Research Center, Burlington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT00000223
232,NCT00000222,Alternate-Day Buprenorphine Administration. Phase II - 4,,Completed,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine,Drug use|Opioid withdrawal|Opioid agonist effects|Dose identification|Pupil diameter,National Institute on Drug Abuse (NIDA)|University of Vermont,All,28 Years to 45 Years   (Adult),Phase 1,0,NIH|Other,Interventional,Intervention Model: Crossover Assignment|Primary Purpose: Treatment,NIDA-06969-4|R01-06969-4,1992-07-01,null,null,1999-09-21,null,2005-06-24,"Treatment Research Center, Burlington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT00000222
233,NCT00000221,Alternate-Day Buprenorphine Administration. Phase I - 3,,Completed,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine,Drug use|Opioid withdrawal|Opioid agonist effects|Dose identification|Pupil diameter,National Institute on Drug Abuse (NIDA)|University of Vermont,All,28 Years to 45 Years   (Adult),Phase 1,0,NIH|Other,Interventional,Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,NIDA-06969-3|R01-06969-3,1992-04-01,null,null,1999-09-21,null,2005-06-24,"Treatment Research Center, Burlington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT00000221
234,NCT00000220,Gradual Vs. Rapid Buprenorphine Detoxification - 2,,Completed,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine,Drug use|Retention|Observed withdrawal rating|Opioid agonist rating|Opioid antagonist rating,National Institute on Drug Abuse (NIDA)|University of Vermont,All,33 Years to 43 Years   (Adult),Phase 1,0,NIH|Other,Interventional,Masking: Double|Primary Purpose: Treatment,NIDA-06969-2|R01-06969-2,1991-06-01,null,2001-07-01,1999-09-21,null,2005-06-24,"Treatment Research Center, Burlington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT00000220
235,NCT00000219,Buprenorphine Dose Alteration Study - 1,,Completed,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine,Opioid withdrawal|Subjective dose estimate|Drug effect characteristics: ARCI|Physiological changes in: pupil diameter|Physiological changes in: blood pressure|Physiological changes in: heart rate|Physiological changes in: respiration|Physiological changes in: skin temperature,University of Vermont|National Institute on Drug Abuse (NIDA),Male,19 Years to 41 Years   (Adult),Phase 1,0,Other|NIH,Interventional,Masking: Double|Primary Purpose: Treatment,NIDA-06969-1|R18DA006969|R01-06969-1,1991-12-01,null,2001-07-01,1999-09-21,null,2016-05-06,"Treatment Research Center, Burlington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT00000219
236,NCT00000209,Buprenorphine Dosing Interval - 5,,Completed,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine,Drug use|Withdrawal symptoms|Opiate and cocaine craving,National Institute on Drug Abuse (NIDA),All,21 Years to 50 Years   (Adult),Phase 2,0,NIH,Interventional,Masking: Single|Primary Purpose: Treatment,NIDA-06082-5|R18-06082-5,1992-11-01,null,null,1999-09-21,null,2005-08-17,"Friends Research Institute, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT00000209
237,NCT00000208,Methadone/Buprenorphine Cross-Over Study - 4,,Completed,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine,Drug use|Withdrawal symptoms|Opiate craving,National Institute on Drug Abuse (NIDA),All,21 Years to 50 Years   (Adult),Phase 2,0,NIH,Interventional,Masking: None (Open Label)|Primary Purpose: Treatment,NIDA-06082-4|R18-06082-4,1992-02-01,null,null,1999-09-21,null,2005-08-17,"Friends Research Institute, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT00000208
238,NCT00000205,Buprenorphine Maintenance Protocol - 1,,Completed,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine,Retention|Opiate use|Opiate craving|Adverse events,"University of California, Los Angeles|National Institute on Drug Abuse (NIDA)",All,21 Years to 50 Years   (Adult),Phase 3,0,Other|NIH,Interventional,Masking: Double|Primary Purpose: Treatment,NIDA-06082-1|R18DA006082|R18-06082-1,1990-10-01,1993-03-01,1993-09-01,1999-09-21,null,2016-07-11,"Friends Research Institute, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT00000205
239,NCT03629197,Improving Communication About Pain and Opioids,,Recruiting,No Results Available,"Pain, Chronic|Communication Research|Opioid Use",Behavioral: Communication skills training|Other: Attention control,Clinician use of targeted communication skills|Compare efficacy of Control vs Intervention by measuring changes in the way pain interfered with patients lives using the Brief Pain Inventory - Pain Interference subscale survey|Compare efficacy of Control vs Intervention by measuring changes in the severity of patients pain using the Brief Pain Inventory - (Short Form) Pain Severity subscale which measures the severity of the patient's pain.|Difficult Doctor-Patient Relationship Questionnaire|Patient experience score|Physicians' overall appraisal of the standardized patient Intervention|Change in physician communication self efficacy,"University of California, Davis|National Institute on Drug Abuse (NIDA)",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,48,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,970014|5K23DA043052|A18-0560,2018-07-12,2019-10-31,2020-01-31,2018-08-14,null,2018-08-14,"University of California Davis Family Medicine Clinic, Sacramento, California, United States|University of California Davis Internal Medicine Clinic, Sacramento, California, United States",,https://ClinicalTrials.gov/show/NCT03629197
240,NCT00142779,Fluoxetine to Reduce Cocaine Use in Cocaine and Opioid Addicts,,Completed,No Results Available,Cocaine-Related Disorders|Opioid-Related Disorders,Drug: Fluoxetine,Cocaine use (measured by urine screen and self-report at Week 19 and 33)|Medication side effects (measured by self-reports throughout Weeks 8 through 19),National Institute on Drug Abuse (NIDA),All,18 Years to 60 Years   (Adult),Not Applicable,220,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,NIDA-10754-2|R01-10754-2|DPMC,2001-04-01,2006-01-01,2006-03-01,2005-09-02,null,2017-01-12,"Johns Hopkins University School of Medicine, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00142779
241,NCT02324725,Biomarkers of Injectable Extended Release Naltrexone Treatment,,"Active, not recruiting",No Results Available,Heroin Dependence|Opioid Dependence,Drug: Naltrexone,Brain response to heroin-related visual cues|Cigarettes smoked per day|Urine toxicology|Injections|Motivational response to opioid-related visual cues measured by self-reported craving for opioids,University of Pennsylvania,All,18 Years to 55 Years   (Adult),Phase 4,32,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,814234,2011-10-01,2018-10-01,2018-10-01,2014-12-24,null,2017-08-08,"Center for the Studies of Addiction, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02324725
242,NCT01645033,Computer-based Cognitive Behavioral Therapy for Risky Behaviors in Opioid Dependent Patients,,Completed,No Results Available,Opioid Dependence|Hepatitis|HIV,Other: computerized Cognitive Behavioral Therapy (CBT)|Other: Treatment as Usual (TAU),"Number of unprotected sexual occurrences, measured by an assessment, the HIV Risk-taking Behavior Scale (HRBS)|Knowledge quiz score (measured as percent correct number of items on a knowledge quiz created for this study)|Knowledge quiz score(measured as percent correct number of items on a knowledge quiz created for this study)",Yale University|National Institute on Drug Abuse (NIDA),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,63,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1111009300|P50DA009241-18,2012-04-01,2013-12-01,2013-12-01,2012-07-19,null,2014-09-12,"Hartford Dispensary, Hartford, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01645033
243,NCT02751762,"A Prospective Investigation of the Risks of Opioid Misuse, Abuse, and Addiction Among Patients Treated With Extended-release/Long Acting (ER/LA) Opioids for the Treatment of Chronic Pain",,Recruiting,No Results Available,Opioid-Related Disorders|Opiate Addiction|Narcotic Abuse|Drug Abuse,"Other: Prescription Opioid Misuse and Abuse Questionnaire (POMAQ).|Other: Psychiatric Research Interview for Substance and Mental Disorders, adapted for assessing addiction to opioid analgesics (PRISM-5-Op).|Other: Events in Medical Records","Prospective Longitudinal study: Prescription Opioid Misuse and Abuse Questionnaire (POMAQ)|Prospective Longitudinal study: Psychiatric Research Interview for Substance and Mental Disorders, adapted for assessing addiction to opioid analgesics (PRISM5Op)|Cross sectional Study: Prescription Opioid Misuse and Abuse Questionnaire (POMAQ)|Cross sectional Study: Psychiatric Research Interview for Substance and Mental Disorders, adapted for assessing addiction to opioid analgesics (PRISM5Op)",Member Companies of the Opioid PMR Consortium,All,"18 Years to 79 Years   (Adult, Older Adult)",,2530,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,Observational Study 2065-1A,2017-11-01,2019-10-01,2019-10-01,2016-04-26,null,2017-11-30,"Center for Health Research, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT02751762
244,NCT03016598,Stimulant Oxytocin Study,SOS,Recruiting,No Results Available,Cocaine Use & Co-occuring Opioid Use Disorders,Drug: Intranasal oxytocin|Drug: Intranasal placebo,quantitative levels of cocaine and metabolites in urine|Working Alliance Inventory (WAI)|Psychophysiological measures|Self-reported stimulant craving|Individual and Group therapy attendance Rates|Stress Biomarkers|Self-reported stress/anxiety,VA Office of Research and Development,All,"18 Years and older   (Adult, Older Adult)",Phase 2,50,U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NURA-014-16S|1IK2CX001495-01,2018-01-26,2019-05-31,2019-05-31,2017-01-10,null,2018-07-23,"San Francisco VA Medical Center, San Francisco, CA, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT03016598
245,NCT01788306,"Project OOPEN: Opioid Overdose Prevention, Education and Intervention",OOPEN,"Active, not recruiting",No Results Available,Opioid Overdose,Drug: OOPEN+BBCC,Opioid overdose|Change in overdose risk|Health care utilization|Health care costs|Change in HIV risk behaviors|Change in overdose risk behaviors and perceptions|Opioid overdose - crossover analysis|Opioid overdose - subgroup analyses,University of Washington|National Institute on Drug Abuse (NIDA),All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,518,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,43874|1R01DA030351,2013-01-01,2019-04-01,2021-04-01,2013-02-11,null,2018-04-03,"Harborview Medical Center, Seattle, Washington, United States|Evergreen Treatment Services, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01788306
246,NCT00000240,Combined Buprenorphine and Behavioral Treatment With and Without Contingent Reinforcement on Opioid and Cocaine Abstinence. - 22,,Completed,No Results Available,Cocaine-Related Disorders|Opioid-Related Disorders,Drug: Buprenorphine,Drug use|Retention|Weeks abstinent|Weeks continuous abstinence|Overall treatment outcome|Opioid dependence and psychiatric status,University of Vermont|National Institute on Drug Abuse (NIDA),All,23 Years to 47 Years   (Adult),Phase 2,0,Other|NIH,Interventional,Masking: None (Open Label)|Primary Purpose: Treatment,NIDA-06969-22|R01DA006969|R01-06969-22,1999-04-01,null,null,1999-09-21,null,2015-06-03,"Treatment Research Center, Burlington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT00000240
247,NCT01108679,Neurocognitive Effects of Buprenorphine Among HIV+ and HIV-Opioid Users,,Unknown status,No Results Available,Opioid-Related Disorders|Buprenorphine|HIV|Cognition|HIV Infections,,"Global Neurocognitive Function|Neurocognitive functioning in the domains of executive functioning, including decision making, processing speed, verbal memory, attention, and motor functioning","Albert Einstein College of Medicine, Inc.|Montefiore Medical Center|Fordham University",All,18 Years to 60 Years   (Adult),,100,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2009-471,2009-12-01,2012-02-01,2012-02-01,2010-04-22,null,2010-05-07,"Fordham University, Bronx, New York, United States|Albert Einstein College of Medicine, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT01108679
248,NCT00829777,Safety Study of Intravenous 6β-Naltrexol (AIKO-150) in Opioid-Dependent Subjects,AIKO-150,Completed,No Results Available,Opiate Addiction,Drug: 6β-Naltrexol escalating doses from 0.05-0.5 mg IV,"- 6β-Naltrexol will have 13 hr half-life. Plasma collected|- 6β-Naltrexol pharmacokinetic profile in opioid-dependent population will be similar in non-opioid-dependent population. Plasma levels collected|-6β-Naltrexol will have a lower potency in precipitating withdrawal and be better tolerated than Naloxone assessed by vital signs, objective/subjective ate Withdrawal Scales, Visual Analog Scales, Pupil Size and GI Motility measures|6β-Naltrexol dose-dependent increases to reverse methadone-induced bowel dysfunction. Plasma levels and Hydrogen Breath Tests",California Pacific Medical Center Research Institute,All,21 Years to 45 Years   (Adult),Phase 1,8,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",28.073-2|PR#0830A|IRB# 26.073-2,2009-03-01,2009-09-01,2009-09-01,2009-01-27,null,2009-09-16,"CPMC Addiction & Pharmacology Research Laboratory (APRL), San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT00829777
249,NCT02657148,Immediate Postpartum Nexplanon Placement in Opioid Dependent Women,,"Active, not recruiting",No Results Available,Opiate Addiction|Pregnancy|Contraceptive Behavior|Sexual Behavior,Drug: Nexplanon (etonogestrel contraceptive implant)|Drug: Standard postpartum contraceptive care,"Consistent contraception|Rapid, repeat pregnancy|Breastfeeding initiation|Postpartum depression|Infant weight gain|Infant development|High-risk sexual behavior",University of Pittsburgh|Merck Sharp & Dohme Corp.,Female,"18 Years and older   (Adult, Older Adult)",,200,Other|Industry,Observational,Observational Model: Case-Control|Time Perspective: Prospective,PRO15070357|IIS#53505,2016-05-01,2018-08-01,2018-08-01,2016-01-15,null,2018-07-03,"Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02657148
250,NCT00249587,Medication Adherence Therapy for Opioid Abusing Pain Patients,,Completed,No Results Available,Pain|Chronic Disease|Prescription Opioid Abuse,Drug: Methadone,Medication compliance and unauthorized drug use|Changes in pain severity and functioning|Satisfaction with services|Therapeutic alliance,National Institute on Drug Abuse (NIDA),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,36,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NIDA-13169-1|R01-13169-1,2000-09-01,2005-09-01,2005-09-01,2005-11-07,null,2017-01-10,"Behavioral Science Research Unit, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00249587
251,NCT01311778,Study to Test the Safety and Efficacy of Cannabidiol as a Treatment Intervention for Opioid Relapse,,Completed,No Results Available,Opiate Addiction,Drug: Cannabidiol|Drug: Fentanyl,To determine the safety of cannabidiol oral administration prior to fentanyl IV administration.|General cannabidiol pharmacokinetics|Cortisol levels|Cannabidiol clearance|Vital signs-BP|Vital signs-HR|Vital signs - RR|Vital signs - O2|Vital signs - temp|Vital signs - EKG|Subjective measures-VAS|Subjective measures-PANAS|Subjective measures-Opiate effect|Subjective measures- OVAS,"Hurd,Yasmin, Ph.D.",All,"21 Years to 65 Years   (Adult, Older Adult)",Phase 1,18,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",R21DA027781,2010-02-01,2011-10-01,2011-10-01,2011-03-10,null,2013-03-22,"Mount Sinai Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01311778
252,NCT03030742,Postpartum Opioid Prescribing Patterns and Patient Utilization,,Recruiting,No Results Available,Postpartum|Opioid Use|Post-operative|Cesarean Delivery,Other: Survey,Postpartum outpatient opioid use|Satisfaction with outpatient pain control|Proper disposal/storage of remaining opioid tablets|High opioid use,Northwestern University|Society for Maternal-Fetal Medicine,Female,"18 Years and older   (Adult, Older Adult)",,700,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,NortherwesternU,2017-06-01,2018-03-01,2018-05-01,2017-01-25,null,2017-07-19,"Northwestern University, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT03030742
253,NCT01015066,Comparison of Buprenorphine/Naloxone With Naltrexone in Opioid Dependent Adolescents,,Withdrawn,No Results Available,Opiate Addiction,Drug: Buprenorphine/naloxone|Drug: Naltrexone,"Retention in treatment: (1-180 days) as measured by the date that participant was last seen by study personnel or date when participant completes study following the date of enrollment.|Opioid craving: (1-10) as measured by a 10 point visual analog scale.|Self-reported drug use: (days to first use and percent days abstinent) as measured by time line follow back.|Urine toxicology: (yes/no) at baseline and monthly at 1, 2, 3, 4, 5, 6 months follow-up.",State University of New York at Buffalo,All,"16 Years to 25 Years   (Child, Adult)",Phase 4,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FMD04405009B,2009-11-01,2014-06-01,2014-06-01,2009-11-17,null,2014-06-10,"UB Department of Family Medicine, Buffalo, New York, United States",,https://ClinicalTrials.gov/show/NCT01015066
254,NCT03268551,MEMO-Medical Marijuana and Opioids Study,,Not yet recruiting,No Results Available,Opioid Use|Marijuana|Chronic Pain|HIV/AIDS,,Opioid analgesic use|Alternative measures of opioid analgesic use|HIV viral load|CD4 count|HIV antiretroviral adherence|HIV risk behaviors|Cannabis use disorder|Illicit drug use|Diversion of medical cannabis|Non-fatal overdose|Death|Accidents/Injuries,"Albert Einstein College of Medicine, Inc.|Fordham University|Columbia University|National Institute on Drug Abuse (NIDA)",All,"18 Years and older   (Adult, Older Adult)",,250,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,2017-7857|1R01DA044171-01A1,2018-08-15,2022-06-30,2022-06-30,2017-08-31,null,2018-08-01,"Montefiore Health System, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT03268551
255,NCT02516436,The Safety of Using Buprenorphine With Naloxone in a Buccal Film to Initiate Treatment of Opioid Dependent Subjects,,Withdrawn,No Results Available,Opioid Dependence,Drug: BEMA Buprenorphine NX|Drug: Buprenorphine,Change from Baseline in COWS total score for BEMA Buprenorphine NX vs BEMA Buprenorphine NX Control,BioDelivery Sciences International,All,18 Years to 55 Years   (Adult),Phase 3,0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BNX-302,null,2017-05-01,2017-05-01,2015-08-05,null,2017-05-04,"Birmingham, Alabama, United States|Orem, Utah, United States|Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT02516436
256,NCT03628846,A Prospective Survey of Opioid Use After Traumatic Injury in Adolescents,,Recruiting,No Results Available,Opioid Use|Traumatic Injury|Adolescent Behavior|Substance Abuse Disorder,,"Prospectively determine drivers of sustained opioid use and prescription opioid misuse.|Identify patient-reported factors for sustained prescription opioid use, including chronic pain and mental health conditions such as PTSD, depression, anxiety, and sleep disorders.|Assess behavioral, social, and clinical predictors of prescription opioid misuse and nonmedical opioid use by longitudinally surveying injured adolescents.",Indiana University,All,"12 Years to 18 Years   (Child, Adult)",,250,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,SURG-NIH-BELL-KL2,2018-07-01,2021-12-31,2021-12-31,2018-08-14,null,2018-08-14,"Indiana University, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT03628846
257,NCT01395784,"Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone",,Completed,Has Results,Opioid Abuse,Drug: pioglitazone,"Subjective Ratings of ""Good"" Drug Effect|Analgesic Responses Using the Cold Pressor Test",New York State Psychiatric Institute|Omeros Corporation,All,21 Years to 45 Years   (Adult),Phase 2,32,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,6106|R01DA09236,2010-08-01,2014-01-01,2014-04-01,2011-07-18,2016-02-23,2016-02-23,"Columbia Univ/ NYSPI Division on Substance Abuse, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01395784
258,NCT03388814,Speeding Recovery From Pain and Opioid Use,,Not yet recruiting,No Results Available,"Pain, Postoperative|Breast Cancer|Opioid Use|Surgery",Drug: Local infiltration of bupivacaine|Drug: Pectoralis Nerve block,Modeled worst pain intensity using the numeric rating scale (NRS)|Area under the curve of the numeric rating scale (NRS)|Opioid use|Length of stay for hospitalization|Readmission rates,Wake Forest University Health Sciences,Female,"18 Years and older   (Adult, Older Adult)",Early Phase 1,80,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention",IRB00047335,2018-11-01,2020-06-01,2020-06-01,2018-01-03,null,2018-08-15,"Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT03388814
259,NCT00429767,Sustained Release d-Amphetamine & Buprenorphine on Drug Seeking Behavior in Opioid & Cocaine Dependent Individuals,,Completed,No Results Available,Heroin Dependence|Opioid-Related Disorders|Cocaine Abuse or Dependence,,,Wayne State University|National Institute on Drug Abuse (NIDA),All,18 Years to 55 Years   (Adult),,16,Other|NIH,Observational,Observational Model: Case-Only|Time Perspective: Prospective,NIDA - 022243|R01DA022243|DPMCDA,2007-01-01,2010-01-01,2010-01-01,2007-02-01,null,2012-06-05,"Wayne State University, Detroit, Michigan, United States",,https://ClinicalTrials.gov/show/NCT00429767
260,NCT03540030,Opioid-Free Shoulder Arthroplasty,,"Active, not recruiting",No Results Available,Opioid Use|Shoulder Osteoarthritis|Avascular Necrosis|Rotator Cuff Tear|Arthritis;Inflammatory,Drug: Gabapentin|Drug: Celecoxib|Drug: toradol|Drug: acetaminophen|Drug: regional block|Drug: propofol|Drug: IV lidocaine|Drug: rocuronium|Drug: vecuronium|Drug: sevoflurane|Drug: desflurane,"Post Op Pain|Additional Post Op Pain|Nausea|Constipation|Continued Pain Medication|Delirium post-operative|Falls|Morphine use|Pain Satisfaction|ASES|Simple Shoulder Test|Veterans RAND 12 Item Health Survey (VR-12©) Physical Health subscore, and Mental Health Subscore","OrthoCarolina Research Institute, Inc.",All,"50 Years and older   (Adult, Older Adult)",Phase 4,65,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00021833,2016-08-01,2018-12-01,2019-06-01,2018-05-30,null,2018-05-30,"OrthoCarolina Research Institute, Charlotte, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT03540030
261,NCT02282306,Phone Interview to Prevent Recurring Opioid Overdoses,TTIP-PRO,Completed,No Results Available,"Overdose|Opioid-related Disorders|Drug Addiction|Drug Abuse|Substance Abuse|Opioid Use, Unspecified|Opioid Dependence|Drug Overdose",Behavioral: TTIP-PRO,"Study Acceptability (proportion of patients who: a). call about the study and b). agree to participate in the study and c). who complete the study.)|Impact of TTIP-PRO on knowledge about Opioid Overdose. (will be assessed with a paired difference test (e.g., paired t-test))",University of Cincinnati,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,2014-2591,2014-09-01,2015-02-01,2015-02-01,2014-11-04,null,2015-05-28,"3131 Harvey Avenue, Suite 104, Cincinnati, Ohio, United States|UC Physicians Company, LLC Opioid Treatment Program, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02282306
262,NCT00142935,Effectiveness of Opiate Replacement Therapy Administered Prior to Release From a Correctional Facility - 1,,Completed,Has Results,HIV Prevention|Opioid-Related Disorders,Behavioral: Pre-release Initiation of MMT|Behavioral: Post Release Initiation of MMT.|Behavioral: Standard of Care Plus,Treatment Engagement|Time to MMT Initiation Post Release Based on Clinic Chart Review|HIV Risk Behaviors - Self Report|Drug Use|Fatal Overdose|Non-fatal Overdose,The Miriam Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,87,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,NIDA-18641-1|R01-DA018641-1|DPMC,2006-09-01,2009-12-01,2009-12-01,2005-09-02,2014-06-06,2014-06-06,"The Miriam Hospital, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT00142935
263,NCT00218010,Methadone Levels in Breast Milk of Women Taking Methadone for Opiate Addiction - 2,,Completed,No Results Available,Breast Feeding|Opioid-Related Disorders,,methadone concentrations in breast milk|methadone concentrations in maternal plasma|methadone concentrations in infant plasma,National Institute on Drug Abuse (NIDA)|Johns Hopkins University,Female,18 Years to 40 Years   (Adult),,25,NIH|Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,NIDA-00495-2,2000-11-01,2005-08-01,2005-09-01,2005-09-22,null,2017-01-12,"Johns Hopkins University (BPRU) Bayview Campus, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00218010
264,NCT00733239,Drug Discrimination in Methadone-Maintained Humans Study 2,OMDD2,Completed,No Results Available,Opioid Dependence,Drug: 2-4 of the drugs listed below,Drug Discrimination Performance|Self-report Ratings|Vital Signs|ECG,University of Arkansas|National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,15,Other|NIH,Interventional,"Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",R01DA010017-02|104881|5R01DA010017-02|DPMCDA,2008-08-01,2010-10-01,2010-10-01,2008-08-13,null,2012-04-18,"University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States",,https://ClinicalTrials.gov/show/NCT00733239
265,NCT00348868,Buprenorphine HIV Care Integration Project,,Completed,No Results Available,HIV Infection|Opioid-Related Disorders,Behavioral: enhanced behavioral motivation counseling|Behavioral: Motivational counseling|Behavioral: Standard counseling,"The three primary outcomes are Cessation of illicit opioid use, Reduction in high risk behavior and Improved HIV therapy adherence",University of Miami|HRSA/Maternal and Child Health Bureau|National Institute on Drug Abuse (NIDA),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,10,Other|U.S. Fed|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A007,2006-07-01,2007-12-01,2007-12-01,2006-07-06,null,2008-03-18,"University of Miami AIDS Clinical Reserach Unit, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT00348868
266,NCT02602795,Distress Tolerance and HIV Prevention With XR-NTX Initiation in Opioid Dependence,,"Active, not recruiting",No Results Available,Opiate Dependence|Sexually Transmitted Diseases|HIV,Behavioral: Acceptance and Commitment Therapy|Behavioral: Information Motivation Behavioral Model,Successful Detoxification|Number of XR-NTX Injections Received|Opioid Drug Use Outcomes|Illicit Drug Use Outcomes|Sex Risk Behavior|Drug Risk Behavior|HIV Risk Behavior,Rhode Island Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,14,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,R34DA037797,2015-12-01,2018-01-01,2018-06-01,2015-11-11,null,2018-04-17,"Rhode Island Hospital, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT02602795
267,NCT03048643,Combining Opioid Addiction Treatment Services With CARe for Infectious Endocarditis,CATS-CARE,Recruiting,No Results Available,"Endocarditis, Bacterial|Opioid-use Disorder|Buprenorphine|Outpatient Parenteral Antibiotic Therapy",Behavioral: Outpatient parenteral antibiotic therapy,Illicit drug use|Completion of recommended IV antibiotic therapy,Laura Fanucchi|University of Kentucky,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,16-1001-F1V,2017-03-29,2018-12-01,2018-12-01,2017-02-09,null,2018-06-18,"University of Kentucky, Lexington, Kentucky, United States",,https://ClinicalTrials.gov/show/NCT03048643
268,NCT02770612,Shared Decision Making for Prescription Opioids After Cesarean Delivery,,Completed,No Results Available,"Pregnancy|Cesarean Section|Prescriptions|Analgesics, Opioid",Other: Prescribed opioids,Pain management and opioid usage measured by telephone questionnaire,Massachusetts General Hospital,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,2016P000251,2016-04-01,2016-09-01,2016-09-01,2016-05-12,null,2016-10-13,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02770612
269,NCT00401362,A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients,,Completed,No Results Available,Advanced Illness Patients With Opioid Induced Constipation,Drug: SC Methylnaltrexone|Drug: SC Placebo,Efficacy of SC MNTX compared with placebo in inducing laxation,"Valeant Pharmaceuticals International, Inc.|Pfizer",All,"18 Years and older   (Adult, Older Adult)",Phase 3,154,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",MNTX 301,2003-02-01,2005-02-01,2005-02-01,2006-11-20,null,2011-07-19,"Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States",,https://ClinicalTrials.gov/show/NCT00401362
270,NCT00913770,"Models of Screening, Brief Intervention With a Facilitated Referral to Treatment (SBIRT) for Opioid Patients in the Emergency Department",,Completed,Has Results,Opiate Addiction,Behavioral: Brief Negotiation Interview (BNI)|Drug: Buprenorphine Initiation,Self-reported Engagement in Formal Substance Abuse Treatment at 30 Days (Verified by Contact With the Treatment Program)|Days of Self-reported Illicit Opioid Use in the Past 7 Days,Yale University|National Institute on Drug Abuse (NIDA),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,329,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",1R01DA025991-01,2008-09-01,2013-08-01,2014-12-01,2009-06-04,2015-05-28,2016-09-15,"Yale University, New Haven, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00913770
271,NCT01556087,Distress Tolerance and Buprenorphine,TRUST,Completed,No Results Available,Opioid Dependence,Behavioral: Distress Tolerance|Behavioral: Health Education,the Client Satisfaction Questionnaire-8|buprenorphine treatment adherence|distress tolerance persistence,Butler Hospital,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,59,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,DA032767,2012-03-01,2014-02-01,2015-08-01,2012-03-16,null,2015-09-10,"Butler Hospital, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT01556087
272,NCT01453374,A Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration,,Completed,Has Results,Opioid Dependence,Drug: VIVITROL 380mg,Incidence of Subject Re-arrest|Incidence of Subject Re-incarceration|Opioid Use|Opioid Overdose|Drug Abuse Treatment Program Entry|Retention in the Community|Opioid Craving|Opioid Dependence|Cocaine Use|Criminal Activity,"Alkermes, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 4,27,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ALK21-028,2011-01-01,2014-05-01,2014-05-01,2011-10-17,2015-07-13,2015-07-13,"Friends Research Institute, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01453374
273,NCT03418636,The Staying Safe Intervention,Ssafe,Recruiting,No Results Available,Hepatitis C|Opioid Use,Behavioral: Staying Safe (Ssafe)|Behavioral: Healthy Living,Injection risk behavior: Syringe-sharing|Injection risk behavior: Syringe-sharing partners|Injection risk behavior: Secondary injection equipment-sharing|Injection risk behavior: Secondary injection equipment-sharing partners|Injection risk behavior: Backloading|Injection risk behavior: Backloading partners|Hepatitis C incidence|Overdose events|Injection frequency|Injection-related complications,"National Development and Research Institutes, Inc.",All,18 Years to 29 Years   (Adult),Not Applicable,456,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,652,2018-01-31,2021-05-31,2021-05-31,2018-02-01,null,2018-05-15,"Staying Safe Study 235 Eldridge Street, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03418636
274,NCT01180647,Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail,,Completed,Has Results,Opiate Dependence,Drug: Extended-Release Naltrexone|Behavioral: Motivational Enhancement Counseling,Post-Release Opioid Relapse|Participation in Community Drug Treatment Post-release|Any Opioid Use Post-release|Injection Drug Use Post-release|Accidental Drug Overdose|Adverse Events and Serious Adverse Events,"New York University School of Medicine|Alkermes, Inc.|New York City Department of Health and Mental Hygiene",All,18 Years to 60 Years   (Adult),Phase 3,48,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NYU IRB Number: 09-0372,2010-05-01,2013-07-01,2013-07-01,2010-08-12,2016-04-07,2016-04-07,"New York University School of Medicine, New York, New York, United States|New York City Department of Correction, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01180647
275,NCT00555425,Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence,,Completed,Has Results,Opiate Dependence,Behavioral: Behavioral: Buprenorphine/naloxone maintenance (Mtn)|Behavioral: Behavioral: Buprenorphine/naloxone detoxification (Dtx),Illicit Opioid Use|Proportion of Patients Protectively Transferred|Retention in Treatment|Reduction in Cocaine Use|Changes in HIV Risk|Patient Satisfaction|Health Status,Yale University|National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,113,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1R01DA020576-01A1|R01DA020576|DPMC,2008-07-01,2013-05-01,2013-05-01,2007-11-08,2017-01-24,2017-03-07,"The APT Foundation, Inc. -- Welch Building, New Haven, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00555425
276,NCT02611752,A Multiple Dose Opioid Challenge Study,,Completed,No Results Available,Moderate or Severe Opioid Use Disorder,Drug: CAM2038,To evaluate the degree of opioid blocking effects of CAM2038 following administration of intramuscular hydromorphone compared to administration of placebo on subjective opioid effects via Visual Analog Scale|Plasma buprenorphine concentration levels at daily time points will be compared to the subjective effects of hydromorphone via Visual Analog Scale|Safety and tolerability will be assessed through TEAEs; hematologic and laboratory parameters; and vital signs measurements.,Braeburn Pharmaceuticals,All,18 Years to 55 Years   (Adult),Phase 2,47,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",HS-13-478,2015-10-01,2016-04-01,2016-04-01,2015-11-23,null,2016-05-11,"Vince and Associates Clinical Research, Overland Park, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|New York Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02611752
277,NCT00634803,Clinical Trial of Integrated Treatment for Pain and Opioid Dependence,POD,Unknown status,No Results Available,Opiate Dependence|Chronic Pain,Behavioral: CBT|Drug: Buprenorphine|Other: Educational Counseling|Other: Physician Management,Pain reduction|Reduced illicit opioid use|Development of a treatment manual|Development and modification of initial therapy training and process rating measures,Yale University,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,91,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HIC0608001776,2009-09-01,2015-05-01,2015-08-01,2008-03-13,null,2014-09-30,"Methadone Research Unit, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00634803
278,NCT00015028,Buprenorphine/Naloxone for Opiate-Dependence Treatment - 1,,Completed,No Results Available,Opioid-Related Disorders|Substance-Related Disorders,Drug: Buprenorphine/naloxone,Craving|Drug use|HIV risk behaviors|Adverse events|Medical evaluation,National Institute on Drug Abuse (NIDA)|Cincinnati MDRU,All,23 Years to 59 Years   (Adult),Phase 2,0,NIH|Other,Interventional,Primary Purpose: Treatment,NIDA-5-0012-1|Y01-5-0012-1,1996-11-01,1996-12-01,1997-01-01,2001-04-18,null,2017-01-16,"Cincinnati MDRU, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00015028
279,NCT00000318,Buprenorphine Maintenance Dose Schedule and Treatment Setting - 1,,Completed,No Results Available,Opioid-Related Disorders|Substance-Related Disorders,Drug: Buprenorphine,Opioid and cocaine use|Social and psychological functioning|AIDS risk behavior,National Institute on Drug Abuse (NIDA)|Yale University,All,21 Years to 55 Years   (Adult),Phase 2,202,NIH|Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NIDA-09803-1|R01-09803-1,1994-12-01,2004-03-01,2007-08-01,1999-09-21,null,2017-01-12,"APT Residential Services Division, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00000318
280,NCT01334580,Cognitive-Behavioral Therapy for Pain and Opioid Dependence in Methadone Maintenance Treatment,,Completed,No Results Available,Chronic Pain|Opiate Dependence,Behavioral: Cognitive-Behavioral Therapy for Pain and Opioid Dependence|Behavioral: Methadone Drug Counseling,Pain reduction|Reduce illicit opioid use|Finalization of treatment manuals|Development and modification of therapy training and process rating measures,Yale University|National Institute on Drug Abuse (NIDA),All,"18 Years and older   (Adult, Older Adult)",Phase 1,40,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,K23DA024050-03,2011-04-01,2014-09-01,2014-09-01,2011-04-13,null,2016-06-29,"Methadone Research Unit, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01334580
281,NCT01895270,Improving Buprenorphine Detoxification Outcomes With Isradipine,,Completed,Has Results,Opioid Dependence,Drug: Isradipine|Drug: Placebo,Change Over Time in Illicit Opioid Use Via Urine Toxicology Screens During Buprenorphine Taper (Wks 5-6),University of Arkansas|National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,28,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R21DA035325,2013-10-01,2016-04-01,2016-04-01,2013-07-10,2017-06-05,2017-06-05,"UAMS Psychiatric Research Institute, Little Rock, Arkansas, United States",,https://ClinicalTrials.gov/show/NCT01895270
282,NCT00158288,The Efficacy of Methadyl Acetate (LAAM) and Contingency Management Procedures for Treating Dual Opioid and Cocaine Abuse - 1,,Completed,No Results Available,Behavior Therapy|Cocaine|Contingency Management|Heroin Dependence|LAAM|Opioid Dependence|Substance-Related Disorders|Alcohol & Drug Use,Behavioral: LAAM,Urine toxicology for cocaine,National Institute on Drug Abuse (NIDA)|Yale University,All,21 Years to 55 Years   (Adult),Phase 2,140,NIH|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,NIDA-09876-1|R01-09876-1,1997-03-01,null,2001-08-01,2005-09-12,null,2017-01-12,"VA Connecticut Healthcare System, West Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00158288
283,NCT03236155,Comparing Opioid Prescription Patterns in Total Joint Arthroplasty Patients,,Recruiting,No Results Available,Postoperative Pain,Drug: opioid pain pills,Number of oxycodone 5 mg tablets taken by patient|Number of tablets received from pharmacy|Postoperative inpatient pain scores|Postoperative inpatient opioid utilization|postoperative outpatient pain scores|Preoperative patient reported outcomes|Compliance|Complications|Postoperative patient reported outcomes,Rush University Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 4,310,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",17030306,2017-07-01,2018-07-01,2019-07-01,2017-08-01,null,2017-08-02,"Rush University Medical Center, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT03236155
284,NCT01315184,Study of Computer-Based Treatment for Drug Dependence,RLSS,Completed,No Results Available,Opioid-Related Disorders|Heroin Dependence,Behavioral: Recovery Line Support System,Opioid Abstinence|Retention|Self Reported Drug Abstinent|system use,Yale University|National Institute on Drug Abuse (NIDA),All,"18 Years and older   (Adult, Older Adult)",Phase 2,36,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,K01DA022398|K01DA022398-01A2,2010-07-01,2011-07-01,2012-07-01,2011-03-15,null,2013-02-15,"APT Foundation, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01315184
285,NCT02433496,Physician Coaching to Reduce Opioid-related Harms,,Completed,Has Results,Substance Abuse|Chronic Pain,Other: Physician coaching,Overall Rate of Opioid Prescribing|Rate of Opioid / Benzodiazepine Co-prescribing|Urine Drug Screening Rate|Mental Health Screening Rate|Use of Pain Management Agreements|High-dose Patients|Provider Drop-out Rate|Participating Patient Demographics|Participating Clinic Characteristics|Participating Staff Characteristics|Intervention Fidelity|Intervention Cost|Proportion With MEDD >120 mg|Average Morphine Equivalent Daily Dose (MEDD),"University of Wisconsin, Madison|National Institute on Drug Abuse (NIDA)|Center for Health Enhancement System Studies",All,"18 Years and older   (Adult, Older Adult)",,53132,Other|NIH,Observational,Observational Model: Case-Control|Time Perspective: Prospective,2015-0280|1R34DA036720-01A1,2014-07-01,2017-06-30,2017-06-30,2015-05-05,2018-07-06,2018-07-06,"University of Wisconsin - Madison, Madison, Wisconsin, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT02433496/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02433496
286,NCT03232346,A Strategy to Improve Success of Treatment Discontinuation in Buprenorphine Responders,,Recruiting,No Results Available,Opioid-use Disorder,Drug: Vivitrol|Drug: Buprenorphine,Percent of patients successfully transitioned off buprenorphine|Percent of patients abstinent from any opioids at 25-week trial endpoint,New York State Psychiatric Institute,All,18 Years to 60 Years   (Adult),Phase 3,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,7522,2017-08-01,2019-08-01,2019-12-01,2017-07-28,null,2018-05-21,"Substance Treatment and Research Service(STARS) Columbia University, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03232346
287,NCT03420313,Interim Buprenorphine Treatment to Bridge Waitlist Delays: Stage II Evaluation,,Recruiting,No Results Available,Opioid-use Disorder,Drug: Buprenorphine/naloxone sublingual tablets,Illicit opioid abstinence,University of Vermont,All,"18 Years and older   (Adult, Older Adult)",Phase 2,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1R01DA042790-01,2018-03-01,2021-07-01,2021-07-01,2018-02-02,null,2018-06-15,"University of Vermont, Burlington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT03420313
288,NCT03365362,A Trial of Directly Observed and Long-term Varenicline,,Not yet recruiting,No Results Available,Tobacco Use Disorder|Opioid-use Disorder,Drug: Long-Term Varenicline|Drug: Short-Term Varenicline|Behavioral: Directly Observed Therapy|Behavioral: Self Administered Therapy,Initial abstinence|Time to lapse|Time to relapse|Durability of tobacco abstinence|Cigarettes smoked per day|Nicotine dependence|Quality of life,"Albert Einstein College of Medicine, Inc.|National Institutes of Health (NIH)|Pfizer|National Institute on Drug Abuse (NIDA)",All,"18 Years and older   (Adult, Older Adult)",Phase 4,450,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2016-6688|R01DA042813,2018-06-01,2021-09-01,2022-01-01,2017-12-07,null,2018-04-18,"Albert Einstein College of Medicine of Yeshiva University, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT03365362
289,NCT03287622,Evaluation of an Interactive Opioid Risk Education Program (STOMP) for Parents,STOMP,Recruiting,No Results Available,"Pain, Postoperative|Medication Adherence|Opioid Use|Knowledge, Attitudes, Practice|Risk Reduction Behavior",Behavioral: Educational Intervention|Behavioral: Nudge,Opioid risk knowledge and perception|Opioid disposal behavior|Pain interference|Analgesic Self-Efficacy|Opioid-related adverse events (OR-ADE)|Analgesic use / adherence|Analgesic decision competency,University of Michigan|National Institute on Drug Abuse (NIDA),All,"21 Years to 99 Years   (Adult, Older Adult)",Not Applicable,840,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",00127009|1R01DA044245-01A1,2017-10-24,2020-07-01,2020-07-01,2017-09-19,null,2017-10-26,"University of Michigan, C.S. Mott Children's Hospital, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT03287622
290,NCT00640835,Safety and Tolerability of Buprenorphine/Naloxone Film Strips,,Completed,Has Results,Opioid-Related Disorders,Drug: Buprenorphine/naloxone Film Strip,"Number of Subjects With Treatment-emergent Adverse Events Associated With the Oral Cavity.|Number of Subjects With Mild, Moderate or Severe Treatment-emergent Adverse Events Associated With the Oral Cavity",Indivior Inc.,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,382,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RB-US-07-0001,2008-02-01,2008-10-01,2008-10-01,2008-03-21,2010-10-26,2012-11-12,"Parkway Medical Center, Birmingham, Alabama, United States|Winston Technology Research LLC, Haleyville, Alabama, United States|Beeches Family Medicine, Jacksonville Beach, Florida, United States",,https://ClinicalTrials.gov/show/NCT00640835
291,NCT01210079,Hyperalgesia in Methadone-Maintained Patients: Can it be Treated?,,Completed,Has Results,Opioid-Induced Hyperalgesia,Drug: Gabapentin;|Drug: Placebo,Change in Pain Threshold Time From Baseline to Week 5,"University of California, Los Angeles",All,21 Years to 55 Years   (Adult),Phase 2,26,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R01 DA 05463,2002-09-01,2008-03-01,2010-05-01,2010-09-28,2012-04-06,2012-04-06,"UCLA School of Nursing, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT01210079
292,NCT03291847,Maternal Buprenorphine-naloxone Treatment and the Infant,,Recruiting,No Results Available,Maternal Opioid Use Disorder|Opioid Exposed Infant,Device: fetal monitoring|Drug: Buprenorphine Naloxone|Drug: Methadone,Fetal Heart Rate (FHR) 24|FHR28|FHR32|FHR36|Neonatal abstinence syndrome severity score (NAS)1|NAS2|NAS3|NAS4,Johns Hopkins University|National Institute on Drug Abuse (NIDA),Female,18 Years to 44 Years   (Adult),Phase 2,80,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,IRB00093171,2018-06-01,2022-06-01,2022-09-01,2017-09-25,null,2018-07-16,"Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT03291847
293,NCT03316859,Naloxegol and Opioid-induced Constipation,,Recruiting,No Results Available,Constipation|Constipation Drug Induced,Drug: Naloxegol 25 MG|Other: Placebo pill,Time to substantial bowel movement|Rescue medications,Angela Fellner|TriHealth Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,280,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",17-020,2017-11-06,2018-10-02,2018-10-02,2017-10-20,null,2017-11-09,"Bethesda North TriHealth Hospital, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03316859
294,NCT03113409,Buprenorphine as Adjunct to Outpatient Induction Onto Vivitrol,,Recruiting,No Results Available,Opioid-use Disorder,Drug: Buprenorphine|Drug: Naltrexone|Drug: Vivitrol,Percentage of patients who receive the second injection of XR-NTX.,New York State Psychiatric Institute,All,18 Years to 60 Years   (Adult),Phase 2|Phase 3,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,#7456,2017-06-01,2018-12-30,2019-03-01,2017-04-13,null,2018-05-21,"Substance Treatment and Research Service (STARS), Columbia University, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03113409
295,NCT02252068,Study of Treatment for Opioid Dependence and Anxiety Disorders,,Recruiting,No Results Available,Anxiety Disorders|Opiate Addiction,Behavioral: I-CBT|Behavioral: IDC,Urine-confirmed self-reported weeks of opioid use|Anxiety symptom severity|Quality of life|Non-opioid substance use|Functional impairment,Mclean Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,K23DA035297,2015-01-01,2019-03-01,2019-03-01,2014-09-29,null,2018-02-15,"McLean Hospital, Belmont, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02252068
296,NCT00406484,Brief Introductory Therapy for Opioid Dependence,,Completed,No Results Available,Opiate Dependence|HIV Infections,Behavioral: Standard drug counseling|Behavioral: BDRC,"Maximum number of consecutive weeks of opiate abstinence achieved during treatment|Overall proportion of opiate negative urines tests in each treatment group|Reduction in HIV risk behaviors|Improvements in social, employment, legal, medical and psychiatric functioning",Yale University|National Institute on Drug Abuse (NIDA),All,"18 Years and older   (Adult, Older Adult)",Phase 2,51,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2R01DA013108-04,2004-09-01,2009-09-01,2010-09-01,2006-12-04,null,2014-01-16,"Methadone Research Unit, The APT Foundation, Inc., New Haven, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00406484
297,NCT01773096,Methylnaltrexone Use for Opioid-induced Postoperative Constipation,,Completed,No Results Available,Constipation,"Drug: Methylnaltrexone|Drug: Senna, docusate sodium, bisacodyl, magnesium hydroxide, Miralax",reduction of post-operative opioid induced constipation|time to ambulation in post-operative pediatric spinal fusion patients,Shriners Hospitals for Children,All,"12 Years to 21 Years   (Child, Adult)",Phase 4,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MNTX-2013,2013-05-01,2015-05-01,2015-05-01,2013-01-23,null,2015-05-19,"Shriners Hospitals for Children- Spokane, Spokane, Washington, United States",,https://ClinicalTrials.gov/show/NCT01773096
298,NCT02093559,Repeated-dose Brief Intervention to Reduce Overdose and Risk Behaviors Among Naloxone Recipients,REBOOT,Completed,No Results Available,Opioid-Related Disorders|Drug Overdose,Behavioral: Brief counseling Intervention,Feasibility of a randomized trial with REBOOT|Acceptability of REBOOT|Influence of egocentric social network characteristics on overdose events and naloxone use,San Francisco Department of Public Health,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,63,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,1R34DA037194-01A1,2014-07-01,2016-12-01,2016-12-01,2014-03-21,null,2017-02-15,"Substance Use Research Unit, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT02093559
299,NCT02674711,Study of Opioid Use After Lumbar and Cervical Spine Surgery,SOULCS,"Active, not recruiting",No Results Available,Low Back Pain|Opiate Addiction|Neck Pain,Behavioral: Educational Video,Number of Opioid Medication Prescriptions|Modified Oswestry Disability Index (ODI)|Numeric Pain Rating Scale (NPRS)|Pain Catastrophizing Scale (PCS)|Fear Avoidance Beliefs Questionnaire (FABQ)|Pittsburgh Sleep Quality Index (PSQI)|Neck Disability Index,Brooke Army Medical Center|Baylor University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,120,U.S. Fed|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",C.2015.048d,2015-08-01,2017-02-01,2018-05-01,2016-02-04,null,2018-02-09,"Brooke Army Medical Center, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT02674711
300,NCT02572089,Pharmacokinetic Evaluation of Intranasal and Intramuscular Naloxone in Healthy Volunteers,,Completed,No Results Available,Drug Overdose|Opioid-Related Disorders,Drug: Naloxone,Maximum Plasma Concentration (Cmax)|Time at Maximum Plasma Concentration (Tmax)|Area Under the Concentration (AUC 0-t)|Area Under Curve (AUC 0-inf)|Half-life|Adverse events|Vital Signs|12-lead electrocardiogram|Nasal Irritation Scoring,"National Institute on Drug Abuse (NIDA)|Vince & Associates Clinical Research, Inc.",All,18 Years to 55 Years   (Adult),Phase 1,30,NIH|Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Naloxone-Phase1a-002,2014-10-01,2015-01-01,2015-01-01,2015-10-08,null,2017-01-12,"Vince Associates Clinical Research, Overland Park, Kansas, United States",,https://ClinicalTrials.gov/show/NCT02572089
301,NCT03427424,Imaging Biomarker for Addiction Treatment Outcome,,Not yet recruiting,No Results Available,Opioid-Related Disorders|Alcohol-Related Disorders,,"For cross-sectional study will be differences in functional connectivity and BOLD signal activation in executive and impulsive neurobehavioral decision systems at various stages of sobriety in relation to control|For the longitudinal study will be differences in baseline and changes over time in functional connectivity circuits, BOLD signal activation in executive and impulsive neurobehavioral decision systems between abstinent and relapsing addicts that...|Phenotypic (performance on behavioral tasks, self-reported measures of cravings, impulsivity and personality traits), genotypic and imaging (structural and spectroscopy) differences between different addiction groups.",National Institute on Drug Abuse (NIDA)|National Institutes of Health Clinical Center (CC),All,"25 Years to 65 Years   (Adult, Older Adult)",,500,NIH,Observational,Observational Model: Cohort|Time Perspective: Other,999918053|18-DA-N053,2018-08-20,2022-12-31,2022-12-31,2018-02-09,null,2018-08-15,"National Institute on Drug Abuse, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT03427424
302,NCT01908062,Comparing Treatments for HIV-Infected Opioid and Alcohol Users in an Integrated Care Effectiveness Study,CHOICES,Completed,No Results Available,Opioid Use Disorder|Alcohol Use Disorder,Drug: Extended Release Naltrexone|Other: Treatment As usual,Treatment initiation|Retention on treatment|HIV Outcomes|Substance Use Outcomes|HIV Care Engagement|Participant Safety,Oregon Health and Science University|National Institute on Drug Abuse (NIDA),All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 3,51,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NIDA-CTN-0055|U10DA015815,2014-06-01,2015-03-01,2015-03-01,2013-07-25,null,2015-10-14,"The CORE Center, Chicago, Illinois, United States|University of British Columbia, Vancouver, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT01908062
303,NCT00548275,Reducing Sex-Related HIV Risk Behaviors in Patients Receiving Treatment for Opioid Dependence,Project RED,Completed,No Results Available,Opiate Dependence|HIV Infections,Behavioral: Enhanced Sexual Risk Management|Behavioral: Standard Sexual Risk Management,proportion of condom use during acts of sexual intercourse|number of unprotected vaginal/anal intercourse acts|number of sexual partners|recent diagnosis of an STD|buprenorphine treatment retention|abstinence from illicit drug use|health status|patient and physician satisfaction,Yale University|Robert Wood Johnson Foundation,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,22,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RWJF57412,2006-07-01,2011-06-01,2011-06-01,2007-10-23,null,2014-07-09,"Methadone Research Unit, The APT Foundation, Inc., New Haven, Connecticut, United States|Yale-New Haven Hospital, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00548275
304,NCT03345173,Facilitating Rapid Naltrexone Initiation,,Recruiting,No Results Available,Opioid Dependence,Drug: CI-581-a|Drug: CI-581-b,XR-NTX Initiation,New York State Psychiatric Institute|National Institute on Drug Abuse (NIDA),All,18 Years to 60 Years   (Adult),Phase 3,100,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",7543,2017-11-25,2021-10-01,2021-10-01,2017-11-17,null,2018-06-15,"New York State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03345173
305,NCT00333242,Hyperalgesia in Methadone Patients: Can it be Treated?,,Unknown status,No Results Available,Opioid-induced Hyperalgesia,Drug: dextromethorphan,Pain tolerance|Pain threshold,National Institute on Drug Abuse (NIDA),All,18 Years to 55 Years   (Adult),Phase 1,40,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",R01DA015463-04,2002-09-01,2006-08-01,null,2006-06-02,null,2017-01-11,"UCLA School of Nursing, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT00333242
306,NCT03402672,AWAITS: A Web-based E-health Application for Active Illicit Opioid Users,AWAITS,Enrolling by invitation,No Results Available,Opioid-use Disorder|IV Drug Usage|Overdose|Drug Addiction|Substance Use Disorders,"Other: self-administered, e-health application","3 sections of the OOTAS (signs of overdose, how to respond to an overdose, and MAT)|Feedback on AWAITS|Acceptance of list of MAT providers",University of Cincinnati,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,2017-1074-2,2017-11-08,2018-11-01,2018-11-01,2018-01-18,null,2018-01-18,"University of Cincinnati Addiction Sciences Division, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03402672
307,NCT02535494,Risks and Benefits of Naloxone Prescribing,,Recruiting,No Results Available,Opioid Overdose,Other: Extensive training,Likelihood of Naloxone Use|Overdose Reversal Outcome,New York State Psychiatric Institute|Indivior Inc.|National Institute on Drug Abuse (NIDA),All,"21 Years to 65 Years   (Adult, Older Adult)",Not Applicable,700,Other|Industry|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research,6723|R01DA035207,2014-03-01,2020-01-01,2020-03-01,2015-08-28,null,2017-10-19,"New York State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02535494
308,NCT01367574,Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction,,Completed,No Results Available,Bowel Dysfunction,Drug: SC MNTX,Number of subjects who have a bowel movement within four hours of dosing|Number of subject with Adverse Events,"Valeant Pharmaceuticals International, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,39,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MNTX 251,2002-04-01,2003-05-01,2003-05-01,2011-06-07,null,2011-07-19,"Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States",,https://ClinicalTrials.gov/show/NCT01367574
309,NCT00991809,Study on the Development of Opioid Induced Hyperalgesia (OIH) After Exposure to Alfentanil,813,Completed,Has Results,Hyperalgesia,Drug: Alfentanil|Drug: Diphenhydramine,Pain Tolerance|Pain Threshold,Johns Hopkins University|National Institute on Drug Abuse (NIDA),Male,18 Years to 55 Years   (Adult),Not Applicable,22,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",NA_00022154|1K24DA023186,2009-02-01,2010-05-01,2010-05-01,2009-10-08,2013-10-14,2017-10-06,"Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00991809
310,NCT01672723,Neuropharmacological Basis of Social Connection: The Role of Opioids,,Completed,Has Results,"Psychology, Social",Drug: Naltrexone,Changes in Self-reported Feelings of Connection During Naltrexone (vs. Placebo)|Daily Self-reported Feelings of Social Connection,"University of California, Los Angeles",All,18 Years to 35 Years   (Adult),Not Applicable,34,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",Opioids and Social Cognition,2012-10-01,2014-02-01,2014-02-01,2012-08-27,2016-01-14,2016-01-14,"University of California, Los Angeles Department of Psychology, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT01672723
311,NCT02710526,Phase II Pharmacokinetics Study of CAM2038,,"Active, not recruiting",No Results Available,Opioid Use Disorder|Chronic Pain,Drug: CAM2038,"AUCss (area under the plasma concentration-time curve during a 7-day dosing interval at steady state) for each injection site, i.e., buttock (reference), abdomen, thigh and back of upper arm.|Css,av (average plasma concentration during a dosing interval at steady state) for each injection site|Css,max (maximum observed plasma concentration during a dosing interval at steady state) for each injection site.|tss,max (time to maximum concentration at steady state) for each injection site|norbuprenorphine/buprenorphine ratios for Area Under the Curve at steady state and at maximum concentration at steady state at each injection site location|Area Under the Curve at steady state (AUC during a 28-day dosing interval at steady state)|Average steady state concentration|Maximum steady state concentration|time to maximum concentration at steady state|Css, 28days (observed plasma concentration 28 days after administration at steady state)|norbuprenorphine/buprenorphine ratios for Area Under the Curve at steady state and at maximum concentration at steady state|Quantify the number of adverse events for both weekly and monthly CAM2038",Braeburn Pharmaceuticals,All,"19 Years to 65 Years   (Adult, Older Adult)",Phase 2,50,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HS-15-549,2015-02-01,2017-03-01,2017-03-01,2016-03-16,null,2016-10-10,"Parkway Medical, Birmingham, Alabama, United States|Hassman Research Institute, Berlin, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT02710526
312,NCT01846481,"A Randomized, 4-sequence, 2-period, Double-blind, Placebo Controlled Study With a DSM-IV-TR Diagnosis of Cocaine Abuse",RBP-8000,Completed,No Results Available,Opioid Dependence|Opioid Related Disorders|Cocaine Dependence,Drug: RBP-8000 100 mg|Drug: Placebo|Drug: Cocaine|Drug: RBP-8000 200 mg,"Maximum plasma concentration (Cmax) of Cocaine, (-)Ecgonine methyl ester and RBP-8000|Time to Maximum Plasma Concentration (Tmax) of Cocaine, (-)Ecgonine methyl ester and RBP-8000|Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUClast) of Cocaine, (-)Ecgonine methyl ester and RBP-8000|Elimination half-life (t1/2) of Cocaine, (-)Ecgonine methyl ester and RBP-8000|Area under the plasma concentration-time curve from time 0 to theoretical infinity (AUC0-inf) of Cocaine, (-)Ecgonine methyl ester and RBP-8000|Distribution half-life (t1/2α) of Cocaine|Clearance (CL) of Cocaine, (-)Ecgonine methyl ester and RBP-8000|Volume of distribution (Vd) of Cocaine, (-)Ecgonine methyl ester and RBP-8000|Elimination rate constant (λz) of Cocaine, (-)Ecgonine methyl ester and RBP-8000|Mean residence time (MRT) of Cocaine, (-)Ecgonine methyl ester and RBP-8000|Behavioral effects - as Measured by the Participant Using the Brief Substance Craving Scale",Indivior Inc.,All,21 Years to 50 Years   (Adult),Phase 2,40,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RB-US-13-0004,2013-04-01,2013-06-01,2013-06-01,2013-05-03,null,2016-09-23,"Vince and Associates Clinical Research, Overland Park,, Kansas, United States",,https://ClinicalTrials.gov/show/NCT01846481
313,NCT01843751,Dane County Drug Court Study for Addicted Offenders,,Unknown status,No Results Available,Opioid Dependence,Drug: buprenorphine/naloxone,Commission of new crime|Ongoing drug use|Treatment uptake and adherence|HIV risk behaviors|Health Services Utilization|Cost benefit,"University of Wisconsin, Madison",All,"18 Years and older   (Adult, Older Adult)",Phase 3,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2012-0226,2013-03-01,2016-02-01,2016-02-01,2013-05-01,null,2015-10-12,"University of Wisconsin, Department of Family Medicine, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT01843751
314,NCT00494598,The Pharmacokinetics of Opioids and Sedative/Hypnotics During Selective Cerebral Perfusion,,Completed,No Results Available,Aortic Aneurysm,Drug: Sufentanil,Pharmacokinetics of intra-carotid opioids and sedatives during selective cerebral perfusion,Columbia University,All,"18 Years and older   (Adult, Older Adult)",,6,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,AAAC2983,2007-03-01,null,2007-06-01,2007-07-02,null,2013-08-01,"Columbia University College of Physicians and Surgeons, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00494598
315,NCT01293994,A Study of Genetic Variation Influencing Pain and Response to Opioid Medications,,Withdrawn,No Results Available,Pain,,Genetic association with various physiologic responses to opioid medication in patients,Stanford University,All,"18 Years to 71 Years   (Adult, Older Adult)",,0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,SU-11222010-7229|IRB #16198,2009-02-01,2012-12-01,2012-12-01,2011-02-11,null,2016-11-22,"Stanford University School of Medicine, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT01293994
316,NCT03579121,Genomic Opioid Optimization of Dosing and Selections (GOODS) Study,,Not yet recruiting,No Results Available,Perioperative/Postoperative Complications,Other: Pharmacogenomic (PGx)|Other: Review results,Change in Overall Benefit of Analgesic Score (OBAS)|Change in prescription pattern for postoperative pain control.|Change in Opioid requirements|Changes in opioid use perioperatively based on pharmacogenomic testing,Mayo Clinic,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Screening,17-006577,2018-07-01,2019-04-01,2019-05-01,2018-07-06,null,2018-07-06,"Mayo Clinic in Arizona, Phoenix, Arizona, United States",,https://ClinicalTrials.gov/show/NCT03579121
317,NCT03415581,Evaluation of Doxazosin to Alter the Abuse of Oxycodone,,Recruiting,No Results Available,Opioid-use Disorder,Drug: Intranasal Oxycodone|Behavioral: Cue Session,Opioid self-administration|Opioid craving,New York State Psychiatric Institute,All,21 Years to 59 Years   (Adult),Phase 2,57,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",7547,2018-02-12,2019-12-30,2020-03-30,2018-01-30,null,2018-02-13,"Jermaine Jones, Manhattan, New York, United States",,https://ClinicalTrials.gov/show/NCT03415581
318,NCT03386591,Comparison of Naloxone Pharmacokinetics,,Completed,No Results Available,Opioid-use Disorder,Drug: Naloxone|Device: Mucosal atomization device and syringe|Device: Narcan|Device: Intramuscular Auto Injector,Pharmacokinetic parameters of naloxone|Safety Assessments,National Institute on Drug Abuse (NIDA),All,18 Years to 55 Years   (Adult),Phase 1,30,NIH,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Naloxone P1a-003,2018-01-03,2018-02-08,2018-03-06,2017-12-29,null,2018-03-09,"Vince and Associates Clinical Research, Overland Park, Kansas, United States",,https://ClinicalTrials.gov/show/NCT03386591
319,NCT01843023,Extended Release Naltrexone for Opioid-Dependent Youth,,"Active, not recruiting",No Results Available,Drug Dependence,Drug: Extended Release Naltrexone|Behavioral: Psychosocial Treatment|Drug: Buprenorphine,Opioid use at 6 month follow-up|Treatment retention|Monetized Economic Form 90 scores as a function of treatment costs|HIV sex risk behaviors,"Friends Research Institute, Inc.|National Institute on Drug Abuse (NIDA)",All,"15 Years to 21 Years   (Child, Adult)",Phase 4,288,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1R01DA033391-01A1|R01DA033391,2013-06-01,2018-01-31,2019-01-01,2013-04-30,null,2018-02-15,"Friends Research Institute, Baltimore, Maryland, United States|Mountain Manor Treatment Center, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01843023
320,NCT03254043,Evaluating a Novel Medication Device for Methadone Dosing,,Recruiting,No Results Available,Opioid-use Disorder,Behavioral: Take-home Dosing Procedures,"Participant willingness to use the MedMinder ""Jon"" electronic pillbox to manage take-home doses of methadone|Participant acceptance of the MedMinder ""Jon"" electronic pillbox to manage take-home doses of methadone|Change in participant satisfaction",Johns Hopkins University|National Institute on Drug Abuse (NIDA),All,"Child, Adult, Older Adult",Not Applicable,54,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,IRB00145200,2018-01-31,2020-09-30,2020-09-30,2017-08-18,null,2018-02-02,"Addiction Treatment Services (ATS), Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT03254043
321,NCT01502644,Opioid Treatment for Chronic Low Back Pain and the Impact of Mood Symptoms,,Completed,Has Results,Chronic Low Back Pain|Degenerative Disc Disease|Depression|Anxiety,Drug: Oxycodone|Drug: Morphine|Drug: Placebo,Percent Change in Average Daily Pain Score,Brigham and Women's Hospital|Arthritis Foundation|National Institute on Drug Abuse (NIDA),All,"21 Years to 75 Years   (Adult, Older Adult)",Phase 4,81,Other|NIH,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2007P-001047|5K23DA020681-05,2009-02-01,2013-01-01,2013-01-01,2012-01-02,2017-06-08,2017-07-11,"Brigham and Women's Hospital, Chestnut Hill, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01502644
322,NCT02230722,Improving Opioid Safety in Veterans Using Collaborative Care and Decision Support,OPTI,Completed,No Results Available,Chronic Pain,Behavioral: Motivational Interviewing|Behavioral: Attention Control,"To evaluate the feasibility, acceptability, and usability of augmenting ATHENA-OT decision support with a Collaborative Care intervention.|To preliminarily evaluate the efficacy of ATHENA-OT decision support plus Collaborative Care (CC) to improve prescription opioid safety and adherence to non-opioid pain management alternatives among primary care patients.",San Francisco Veterans Affairs Medical Center|National Center for Complementary and Integrative Health (NCCIH),All,"18 Years and older   (Adult, Older Adult)",Phase 1,100,U.S. Fed|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",13-11892|R34AT008319-01,2014-11-01,2017-06-12,2017-06-12,2014-09-03,null,2017-07-02,"San Francisco VA Medical Center, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT02230722
323,NCT01040637,A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation,,Completed,No Results Available,Healthy|Opioid-induced Constipation,Drug: TD-1211|Drug: Placebo,Safety and tolerability in healthy subjects and activity in subjects with opioid-induced constipation|Evaluation of the multiple dose pharmacokinetics of TD-1211 following oral administration,"Theravance Biopharma R & D, Inc.|Theravance Biopharma Antibiotics, Inc.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,102,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",67,2010-01-01,2010-10-01,2010-10-01,2009-12-29,null,2014-09-10,"Clinical Research Unit, Pasadena, California, United States|Clinical Research Unit, San Antonio, Texas, United States|Clinical Research Unit, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT01040637
324,NCT00675532,Testing a Primary Care Model for the Treatment of Opioid Dependence Using Long-acting Injectable Naltrexone (Vivitrol).,,Withdrawn,No Results Available,Drug Dependence,Behavioral: Primary Care Counseling|Behavioral: Cognitive-behavioral psychotherapy,"Primary outcomes will be 1) percent of opioid negative urines and 2) treatment compliance as measured by attendance and time in treatment.|Secondary outcomes are opiate craving, opiate withdrawal symptoms, perceived stress scores, severity of addiction problems, and patient satisfaction.",Yale University,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Yale HIC #0708002942,2011-05-01,2013-05-01,2013-08-01,2008-05-09,null,2013-07-22,"Yale New Haven Hospital Primary Care Center, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00675532
325,NCT00988962,Substance Abuse Treatment for High Risk Chronic Pain Patients on Opioid Therapy,,Completed,No Results Available,Substance Abuse,Behavioral: cognitive behavioral training,"Drug Misuse Index: 1) physician ratings of misuse (ABC), 2) structured self-report interview (PDUQ), and 3) urine tox screens|1) Rate of patient dismissal from a pain center, 2) treatment satisfaction ratings",Brigham and Women's Hospital|National Institutes of Health (NIH),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,84,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2007p001732,2009-07-01,2011-06-01,2011-06-01,2009-10-02,null,2011-06-27,"Brigham and Women's Hospital Pain Management Center, Chestnut Hill, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00988962
326,NCT03065049,Transforming Recovery Through Exercise and Community,TREC,Recruiting,No Results Available,Opioid-use Disorder,Behavioral: TREC,Minutes of moderate-to-vigorous physical activity (MVPA)/week|Acceptability of the Intervention assessed with the Client Satisfaction Questionnaire,Butler Hospital|National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,20,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1609-001|1R21DA041553-01A1,2016-09-30,2018-08-31,2018-08-31,2017-02-27,null,2018-07-10,"Stanley Street Treatment and Resources (SSTAR) Lifeline, Fall River, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03065049
327,NCT02942199,MySafeRx & MedicaSafe Open-Label Buprenorphine Induction and Lapse Evaluation (MyMOBILE),,"Active, not recruiting",No Results Available,Opioid Use Disorder,Other: MySafeRx,Feasibility|Usability|Acceptability,"Cambridge Health Alliance|MedicaSafe, Inc.|MySafeRx, Inc|Dartmouth College",All,18 Years to 39 Years   (Adult),Not Applicable,12,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CHA-IRB-1029/03/16,2016-11-01,2018-08-31,2018-08-31,2016-10-24,null,2018-07-27,"Cambridge Health Alliance, Cambridge, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02942199
328,NCT02692157,NT-814: Evaluation of Its Ability to Alter the Abuse Liability of Oxycodone in an Exploratory Clinical Study,NT-814,Recruiting,No Results Available,Opioid Use Disorder,Drug: Placebo|Drug: NT-814 50 mg|Drug: NT-814 100 mg|Drug: NT-814 200 mg,"Percentage of oxycodone choices|Average visual analog scale ratings of ""I like the choice""|Average visual analog scale ratings of ""I want heroin""",New York State Psychiatric Institute|National Institute on Drug Abuse (NIDA),Male,21 Years to 59 Years   (Adult),Phase 1|Phase 2,12,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science",IRB#7173|U54DA037842,2016-02-01,2017-07-01,2017-09-01,2016-02-25,null,2016-10-26,"New York State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02692157
329,NCT00418015,Mu-Opioid Receptor Genetic Polymorphism and Intrathecal Analgesia,,Completed,Has Results,Labor Pain|Post-cesarean Delivery,Procedure: Blood Draw,Duration of Intrathecal Fentanyl Analgesia|Duration of Intrathecal Analgesia Following Cesarean Delivery|Visual Analog Pain Scale (0 to 100) at Analgesia Request Following Intrathecal Intervention|Severity of Pruritus Following Fentanyl|Subjects With Pruritus at 24 Hours Post Morphine,Northwestern University,Female,18 Years to 55 Years   (Adult),,293,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,0524-025,2005-10-01,2007-05-01,2007-06-01,2007-01-04,2011-04-18,2014-04-14,"Northwestern University, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00418015
330,NCT03475862,Nasal Human Abuse Potential of PTI-821,,Completed,No Results Available,Opioid Abuse Nondependent,Drug: PTI-821 capsule Manipulated|Drug: PTI-821 Non-manipulated|Drug: OxyContin|Other: Placebo|Drug: Oxycodone,Drug Liking Emax|Take Drug Again|Drug effects questionnaire|Peak Plasma Concentration (Cmax)|Area under the plasma concentration versus time curve|Time to maximum plasma concentration (Tmax),Pain Therapeutics|PRA Health Sciences,All,18 Years to 55 Years   (Adult),Phase 1,38,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",PTI-821-C08,2017-05-15,2017-07-31,2017-12-15,2018-03-23,null,2018-03-23,"PRA-EDS, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT03475862
331,NCT02334215,A Randomized Trial of Interim Methadone and Patient Navigation Initiated in Jail,SOMATICS FRI,"Active, not recruiting",No Results Available,Opioid Use Disorder,Drug: Methadone|Behavioral: Patient Navigation|Behavioral: Enhanced Treatment as Usual (ETAU),Change in opioid urine test results|Entry into treatment for opioid use disorder on the Methadone Treatment Exposure Form|Opioid Use Disorder as determined by the modified Composite International Diagnostic Interview (CIDI)|Number of arrests|Drug Risk Score on the Risk Assessment Battery (RAB)|Sex Risk Score on the Risk Assessment Battery (RAB)|Physical domain score on the World Health Organization Quality of Life Scale (WHOQOL-BREF)|Psychological domain score on the World Health Organization Quality of Life Scale (WHOQOL-BREF)|Social domain score on the World Health Organization Quality of Life Scale (WHOQOL-BREF)|Environmental domain score on the World Health Organization Quality of Life Scale (WHOQOL-BREF)|Overall quality of life item on the World Health Organization Quality of Life Scale (WHOQOL-BREF)|Retention in treatment for opioid use disorder on the Methadone Treatment Exposure Form|Number of days of criminal activity in the past 30 days on the Addiction Severity Index (ASI|Number of days of illicit opioid use in the past 30 days on the Addiction Severity Index (ASI|Number of days of cocaine use in the past 30 days on the Addiction Severity Index (ASI|Cocaine Use Disorder in the past 30 days on the modified Composite International Diagnostic Interview (CIDI)|Health care utilization on the Economic Form 90 (EF-90)|Cost of substance abuse services on the Substance Abuse Services Cost Analysis Program (SASCAP),"Friends Research Institute, Inc.|National Institute on Drug Abuse (NIDA)|Laura and John Arnold Foundation",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,300,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,3U01DA013636,2014-12-01,2019-05-01,2020-05-01,2015-01-08,null,2018-08-03,"Baltimore City Detention Center, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02334215
332,NCT00015288,Buprenorphine and Naloxone Combination Study - 10,,Completed,No Results Available,Heroin Dependence|Opioid-Related Disorders,Drug: Buprenorphine/naloxone,Physiological measures|Measurements of buprenorphine and naloxone in plasma|Subjective symptoms measures,National Institute on Drug Abuse (NIDA)|New York MDRU,All,21 Years to 50 Years   (Adult),Phase 1,0,NIH|Other,Interventional,Masking: Double|Primary Purpose: Treatment,NIDA-5-0013-10|Y01-5-0013-10,1996-11-01,null,null,2001-04-18,null,2017-01-12,"New York MDRU, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00015288
333,NCT02417038,Postoperative Respiratory Monitoring After Neuraxial Opioid Administration for Cesarean Delivery,,Completed,No Results Available,Respiratory Depression,Device: Capnostream,CO2 monitoring,Stanford University,Female,18 Years to 45 Years   (Adult),,80,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,30189,2015-04-01,2016-04-15,2016-04-15,2015-04-15,null,2017-05-04,"Lucile Packard Children's Hospital, Palo Alto, California, United States",,https://ClinicalTrials.gov/show/NCT02417038
334,NCT02197715,Sex and Female Empowerment,SAFE,Completed,No Results Available,Opioid Use Disorder,Behavioral: Computer-adaptive SAFE|Behavioral: Face-to-face SAFE|Behavioral: Usual Care,Intervention Satisfaction|Contraceptive Consultation Appointment|Intervention Completion|Contraceptive Method Effectiveness|Knowledge of Reproduction|Knowledge of Contraceptive Methods|Contraceptive Self-efficacy Scale|Effective Contraceptive Behavior|Frequency of Use of Barrier Protection in past 30 days|Number of Times Engaged in Unprotected Sex in past 30 days,"University of North Carolina, Chapel Hill|National Institute on Drug Abuse (NIDA)",Female,18 Years to 40 Years   (Adult),Not Applicable,90,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,13-3075|R34DA033442,2014-08-01,2017-08-01,2017-08-01,2014-07-23,null,2017-10-17,"UNC Horizons, Chapel Hill, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT02197715
335,NCT02033746,Opiate Craving Reduction Study Using Post-detox Patients on Suboxone and Use of TEAS as Adjunctive Treatment,,Withdrawn,No Results Available,Opioid-use Disorder,Device: Han's Acupoint Nerve Stimulator,Number of participants who attend all 12 Transdermal Electroacupuncture (TEAS) sessions|Number of participants who experience improvement in mood|Number of participants who experience improvement in sleep|Number of participants who experience improvement in Quality-of-Life|Number of participants who report fewer cravings for drugs and alcohol,Mclean Hospital,All,18 Years to 59 Years   (Adult),Not Applicable,0,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,2013P001595,2015-08-01,2017-08-01,2017-12-01,2014-01-13,null,2018-02-21,"McLean Hospital, Belmont, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02033746
336,NCT02745353,Naloxegol in Cancer Opioid-Induced Constipation,,Recruiting,No Results Available,Constipation,Drug: naloxegol,feasibility,"University of California, San Diego|AstraZeneca",All,"18 Years and older   (Adult, Older Adult)",Phase 2,60,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,160121,2016-05-01,2020-04-01,2021-04-01,2016-04-20,null,2017-03-01,"UCSD Moores Cancer Center, La Jolla, California, United States",,https://ClinicalTrials.gov/show/NCT02745353
337,NCT02790476,Behavioral Insights to Encourage Judicious Prescribing of Opioids,,Recruiting,No Results Available,Substance-Related Disorders,Other: Letters,"Average change over time in dispensed narcotics|Number of opioid prescriptions for ≥ 90 morphine milligram equivalent (MME) and > 50 MME|Number of opioid and benzodiazepine co-prescriptions|Frequency of CURES use|Number of ""new start"" prescriptions",University of Southern California,All,"Child, Adult, Older Adult",Not Applicable,600,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,CHCF-16-00053,2017-01-27,2017-09-27,2017-09-27,2016-06-06,null,2017-04-26,"San Diego County Medical Examiner's Office, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT02790476
338,NCT02219321,Lidocaine Infusion for Chronic Pain in Opioid Dependent Patients,,"Active, not recruiting",No Results Available,Chronic Pain,Drug: Lidocaine infusion|Drug: Saline infusion,Determine the short-term effect of lidocaine infusion on the intensity of pain in opioid dependent chronic pain patients.|Determine the duration of pain relief after lidocaine infusion in opioid dependent chronic pain patients.|Determine the effect of lidocaine infusion on serum cytokine profiles and on cold pressor task,University of Texas Southwestern Medical Center,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",062014-002,2014-12-01,2018-12-01,2018-12-01,2014-08-18,null,2017-12-19,"University of Texas Southwestern Medical Center, Dallas, Texas, United States|Parkland Health Hospital System, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT02219321
339,NCT02964741,Investigation and Modulation of the Mu-Opioid Mechanisms in Migraine (in Vivo),,Recruiting,No Results Available,Migraine,Device: Active Comparator|Device: Sham Comparator,Change in pain intensity level measured by the Visual Analog Scale in migraineurs (active or sham)|Change in mu-opioid receptor non-displaceable binding potential (BPND) in the brains of migraineurs during sustained thermal pain threshold stress challenge subsequent to treatment by HD-tDCS (active or sham).|Change in mu-opioid receptor non-displaceable binding potential (BPND) in the brains of migraineurs at rest subsequent to treatment by HD-tDCS (active or sham).,University of Michigan|National Institute of Neurological Disorders and Stroke (NINDS),All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,90,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HUM00107286|R01NS094413,2017-02-22,2020-04-01,2020-06-01,2016-11-16,null,2018-08-14,"University of Michigan School of Dentistry, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT02964741
340,NCT03063905,The Effects of Opioid Taper on Opioid-Induced Hyperalgesia,,Terminated,No Results Available,Buprenorphine|Pain,Drug: Buprenorphine,Pain Threshold Response (in seconds) - Cold Pressor Test|Pain Tolerance Response (in seconds) - Cold Pressor Test|Pain Threshold Response (in seconds) - Quantitative Sensory Test|Pain Tolerance Response (in seconds) - Quantitative Sensory Test|Improvement in opioid taper,Georgetown University|National Institute on Drug Abuse (NIDA),All,18 Years to 50 Years   (Adult),,15,Other|NIH,Observational,Observational Model: Case-Control|Time Perspective: Other,2016-0028|U01DA029580,2017-01-01,2018-02-28,2018-02-28,2017-02-24,null,2018-03-21,"Avery Road Treatment Center, Rockville, Maryland, United States|Kolmac Clinic, Silver Spring, Maryland, United States",,https://ClinicalTrials.gov/show/NCT03063905
341,NCT01188421,Medications Development for Drug Abuse Disorders,,Completed,Has Results,Opioid Related Disorders|Opioid Dependence|Opioid Addiction,Drug: Buprenorphine/naloxone|Drug: Clonidine|Drug: Tramadol ER,Mean Ratings on Clinical Opiate Withdrawal Scale (COWS) Measure of Withdrawal During Double-blind Taper (7-days) and Post-taper (7-days) Period.,Johns Hopkins University|National Institute on Drug Abuse (NIDA),All,18 Years to 60 Years   (Adult),Phase 1|Phase 2,106,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NIDA-018125|NA_00037871|R01DA018125|DPMC,2010-10-01,2015-06-01,2015-06-01,2010-08-25,2017-07-06,2017-07-06,"Johns Hopkins University (BPRU) Bayview Campus, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01188421
342,NCT01210066,"Pain, Opioids and Pro-Inflammatory Immune Responses",,Terminated,No Results Available,Pro-inflammatory Activity|Immunologic Activity Alteration,Drug: Fentanyl|Other: Cold pressor test|Other: Fentanyl plus cold pressor test,plasma levels of pro-inflammatory cytokine IL-6,"University of California, Los Angeles",All,21 Years to 40 Years   (Adult),Phase 1,21,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,5R21DA027558,2010-07-01,2012-05-01,2012-05-01,2010-09-28,null,2016-12-29,"UCLA School of Nursing, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT01210066
343,NCT00879996,Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients,,Completed,Has Results,Opiate Addiction,Drug: Methadone|Drug: Buprenorphine/naloxone,Number of Participants Retained in Treatment|Numerical Rating Score for Pain|Numerical Rating Score for Functioning|Self-reported Illicit Opioid Use,State University of New York at Buffalo|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institute on Drug Abuse (NIDA),All,"18 Years and older   (Adult, Older Adult)",Phase 4,54,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FMD0350908A|K23AA015616|R03DA029768,2009-04-01,2011-10-01,2011-10-01,2009-04-13,2012-07-09,2012-08-07,"Sheehan Memorial Hospital, Buffalo, New York, United States|Erie County Medical Center, Buffalo, New York, United States",,https://ClinicalTrials.gov/show/NCT00879996
344,NCT03462797,Opioid Physiology Project,OPP,Recruiting,No Results Available,Tolerance|Withdrawal|Addiction|Epigenetic Changes,,Physiological changes|DNA Methlyation changes,University of Tennessee,All,"18 Years and older   (Adult, Older Adult)",,80,Other,Observational,Observational Model: Other|Time Perspective: Prospective,17-05380-XP,2017-08-14,2018-06-01,2018-06-01,2018-03-13,null,2018-03-13,"University of Tennessee College of Dentistry, Memphis, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT03462797
345,NCT00027014,Herb-Opioid Interactions,,Completed,No Results Available,Pain,Drug: St. John's Wort|Drug: oxycodone|Drug: fentanyl,,National Center for Complementary and Integrative Health (NCCIH),All,21 Years to 45 Years   (Adult),Phase 4,54,NIH,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single|Primary Purpose: Diagnostic,R01AT000864-01,2001-09-01,null,2005-05-01,2001-11-16,null,2007-02-08,"Fred Hutchinson Cancer Research Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00027014
346,NCT02747875,Methadone vs. Fentanyl Administration on Postoperative Pain Control in Pediatric Patients Undergoing Cardiac Surgery,CV_RCT_M_F,Recruiting,No Results Available,"Opioid Use, Unspecified",Drug: Methadone|Drug: Fentanyl,"Total opioid dose, in morphine equivalents, in the first 24 hours after pediatric cardiac bypass surgery.|Opioid-related adverse events including: respiratory failure, cardiovascular instability, and postoperative nausea and vomiting",Andrew Waberski|Children's Research Institute,All,2 Years to 7 Years   (Child),Not Applicable,104,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",7364,2016-09-01,2018-12-01,2020-12-01,2016-04-22,null,2018-01-12,"Children's National Health System, Washington, District of Columbia, United States",,https://ClinicalTrials.gov/show/NCT02747875
347,NCT02653144,the Analgesic Duration of Dexmedetomidine Compared to Dexamethasone as Adjuncts to Single Shot Interscalene Block,,Recruiting,No Results Available,"Opioid Use, Unspecified","Drug: Ropivacaine,Dexmedetomidine,Dexamethasone",Opioid requirements (morphine equivalents)|opioid requirements (morphine equivalents)|Time to discharge from PACU|Time to first opioid consumption|Return of motor and sensory function|Side effects encountered,Montefiore Medical Center,All,18 Years to 60 Years   (Adult),Phase 4,105,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",2015-5628,2016-03-01,2018-05-01,2018-09-01,2016-01-12,null,2018-03-29,"Montefiore Medical Center, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT02653144
348,NCT01275599,Drug-Drug Interaction Study Between Telaprevir and Buprenorphine,,Completed,No Results Available,Hepatitis C|Opioid-Related Disorders,Drug: telaprevir|Drug: buprenorphine/naloxone,Blood levels of buprenorphine|Blood levels of norbuprenorphine|Blood levels of naloxone|Blood levels of telaprevir|Safety and tolerability|Buprenorphine withdrawal symtoms,Vertex Pharmaceuticals Incorporated|Tibotec BVBA,All,18 Years to 64 Years   (Adult),Phase 1,16,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,VX10-950-024,2011-01-01,2011-04-01,null,2011-01-12,null,2011-06-08,"Overland Park, Kansas, United States|Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT01275599
349,NCT01895036,Nalrexone Facilitated Discontinuation of Buprenorphine,,Completed,Has Results,Stable Opioid Dependence,Drug: Naltrexone,Successful Discontinuation of Buprenorphine,New York State Psychiatric Institute|National Institute on Drug Abuse (NIDA),All,18 Years to 49 Years   (Adult),Phase 1|Phase 2,6,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,6332,2011-02-01,2013-09-01,2013-09-01,2013-07-10,2017-09-06,2018-06-15,"NYSPI, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01895036
350,NCT01883882,Pilot Trial of Opioid Taper Support,POTS,Completed,No Results Available,Chronic Non-cancer Pain,Behavioral: opioid taper support,mean daily opioid dose over past week|prescription opioid difficulties,University of Washington|National Institute on Drug Abuse (NIDA),All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,35,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,43641-B|R34DA033384,2013-06-01,2016-05-01,2016-06-01,2013-06-21,null,2016-10-24,"University of Washington Center for Pain Relief, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01883882
351,NCT03337009,The Impact of a Web-Based Naloxone Intervention Under Standing Orders to Patients Prescribed Chronic Opioid Therapy,,Recruiting,No Results Available,Overdose|Risk Behavior,Behavioral: Naloxone Navigator (NN),Change in Opioid-Related Risk Behavior|Overdose and Naloxone Knowledge|Rate of Naloxone Dispensings|Patient reported naloxone pick-up|Change in opioid dose|Change in Drug Use Risk Behavior|Change in Hazardous Drinking and Alcohol Use Disorders,Kaiser Permanente|National Institute on Drug Abuse (NIDA),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1000,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,CO-16-2405-01|1R01DA042059,2017-12-21,2020-04-30,2022-04-30,2017-11-08,null,2018-01-16,"Kaiser Permanente Colorado, Denver, Colorado, United States",,https://ClinicalTrials.gov/show/NCT03337009
352,NCT01360450,Clonidine to Treat Iatrogenic-induced Opioid Dependence in Infants,,Terminated,Has Results,Neonatal Abstinence Syndrome,Drug: Clonidine HCL|Drug: saline,Time to Complete Detoxification|Cardiovascular Side-effects Changes HR and BP|Cumulative Dose of Opioid and Benzodiazepine,Johns Hopkins University|National Institute on Drug Abuse (NIDA),All,up to 90 Days   (Child),Phase 2|Phase 3,12,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Clonidine NICU-NAS|R21DA029295-01,2011-07-01,2011-07-01,2014-12-01,2011-05-25,2017-09-13,2017-09-13,"Johns Hopkins Hospital, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01360450
353,NCT02236702,Kappa Opioid Receptor Imaging in Depression (KOR Depression),,Terminated,No Results Available,Major Depressive Disorder|Anhedonia,Other: Positron Emission Tomography (PET) imaging,[11C]LY2795050 volume of distribution (VT) values in specific brain regions of asymptomatic vs mildly symptomatic vs moderately symptomatic vs severely symptomatic individuals,New York University School of Medicine|Yale University,All,18 Years to 55 Years   (Adult),,15,Other,Observational,Observational Model: Case Control|Time Perspective: Cross-Sectional,S14-00643,2014-08-01,2015-03-01,2016-02-01,2014-09-10,null,2016-08-17,"NYU School of Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02236702
354,NCT00833755,Effect of Ketamine on Opioid-Induced Hyperalgesia,,Completed,Has Results,Pain|Chronic Pain|Hyperalgesia,Drug: Ketamine|Drug: Placebos,Change in Temperature of Pain Threshold|Change in Temperature of Pain Tolerance|Change in Duration of Supra-threshold Pain Tolerance,Massachusetts General Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,79,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Health Services Research",2008P 000879,2008-09-01,2013-05-01,2016-04-01,2009-02-02,2017-01-16,2017-01-16,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00833755
355,NCT01050595,Methylnaltrexone for Treatment of Opiate-Induced Constipation in the Intensive Care Unit,MOVE-IT,Unknown status,No Results Available,Opioid-induced Constipation,Drug: Methylnaltrexone Bromide|Drug: Placebo-Normal Saline,A significantly higher incidence of a rescue free laxation with methylnaltrexone within 4 hours +- 45 minutes.|Decreased need for rescue medications to have a bowel movement in the treatment arm vs placebo.,"St. John Health System, Michigan",All,"18 Years and older   (Adult, Older Adult)",Phase 3,80,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",107199,2009-12-01,2010-10-01,2010-12-01,2010-01-15,null,2010-01-15,"Providence Hospital and Medical Center, Southfield, Michigan, United States",,https://ClinicalTrials.gov/show/NCT01050595
356,NCT02237703,Kappa Opioid Receptor Imaging in Post-traumatic Stress Disorder (PTSD),,Terminated,No Results Available,Post-traumatic Stress Disorder (PTSD)|Trauma,Other: Positron emission tomography (PET) imaging,Volume of distribution (VT) of cerebral KOR expression in PTSD and healthy control subjects with and without trauma history using the KOR radioligand [11C]LY2795050 and PET,New York University School of Medicine|Yale University,All,18 Years to 55 Years   (Adult),,17,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,S12-01521,2012-03-01,2015-03-01,2016-08-01,2014-09-11,null,2017-01-20,"NYU School of Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02237703
357,NCT00078130,Buprenorphine/Naloxone - Facilitated Rehabilitation for Opioid Dependent Adolescents - 1,,Completed,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine/naloxone,Opiate abstinence,University of Pennsylvania|National Institute on Drug Abuse (NIDA),All,"14 Years to 21 Years   (Child, Adult)",Phase 3,223,Other,Interventional,Primary Purpose: Treatment,NIDA-CTN-0010-1,2003-07-01,2006-01-01,2006-01-01,2004-02-20,null,2017-01-12,"Mercy Hospital, Portland, Maine, United States|Mountain Manor, Baltimore, Maryland, United States|ASAP, Albuquerque, New Mexico, United States|Duke Addictions Program, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00078130
358,NCT02136784,Analgesic Response to Opioid Analgesics in Buprenorphine-Maintained Individuals,,Unknown status,No Results Available,Analgesic Response,Drug: morphine sulfate|Drug: hydrocodone|Drug: hydromorphone HCI|Drug: oxycodone|Drug: buprenorphine|Drug: oral tablet placebo|Drug: sublingual tablet placebo,Pain detection|Pain tolerance|Pupillometry results,"University of California, Los Angeles|Indivior Inc.",Male,20 Years to 50 Years   (Adult),Not Applicable,12,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant),13-001175,2014-04-01,2014-12-01,2014-12-01,2014-05-13,null,2014-05-13,"UCLA Integrated Substance Abuse Programs Outpatient Clinical Research Center, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT02136784
359,NCT01737073,Comprehensive Opioid Management in Patient Aligned Care Teams,COMPACT,Withdrawn,No Results Available,Chronic Pain,Behavioral: IVR self-management|Behavioral: Opioid monitoring|Other: Enhanced usual care,Brief Pain Inventory|Concordance with opioid treatment practice guidelines,VA Office of Research and Development,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,0,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,CRE 12-006,2017-04-01,2017-04-01,2017-04-01,2012-11-29,null,2017-05-10,"Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis, Indiana, United States|VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT01737073
360,NCT00182598,Applying Web Technology to Buprenorphine Treatment,,Unknown status,No Results Available,Adult Opioid-Dependence,Procedure: computer-based psychoeducational intervention|Procedure: community-based substance abuse counseling,opiate use|treatment retention|other drug use|HIV risk behavior|opiate craving|psychosocial status|feedback on intervention,"National Development and Research Institutes, Inc.",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,90,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R42DA014727,2004-12-01,null,null,2005-09-16,null,2008-08-13,"Dr. Steven Lee, New York, New York, United States|Dr. Tania Taubes, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00182598
361,NCT03337100,The Impact of Co-Dispensing Naloxone to Patients Prescribed Chronic Opioid Therapy,,Recruiting,No Results Available,Overdose|Risk Behavior,Behavioral: Co-Dispensing,Change in Opioid-Related Risk Behavior|Overdose and Naloxone Knowledge|Rate of Naloxone Dispensings|Patient reported naloxone pick-up|Changes in opioid dose|Change in Drug Use Risk Behavior|Change in Hazardous Drinking or Alcohol Use Disorders,Kaiser Permanente|Denver Health and Hospital Authority|National Institute on Drug Abuse (NIDA),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,6,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,CO-16-2405-02|1R01DA042059,2017-11-27,2020-04-30,2022-04-30,2017-11-08,null,2018-01-16,"Denver Health, Denver, Colorado, United States",,https://ClinicalTrials.gov/show/NCT03337100
362,NCT00032942,Lofexidine for Opiate Withdrawal - 1,,Completed,No Results Available,Opioid-Related Disorders,Drug: Lofexidine,Opiate withdrawal symptoms|Potential Abuse Liability,National Institute on Drug Abuse (NIDA)|Britannia Pharmaceuticals Ltd.,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,66,NIH|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,NIDA-CSP-1020-1,2001-04-01,2004-10-01,null,2002-04-08,null,2017-01-12,"UCLA Medical Center, Los Angeles, California, United States|Columbia University, New York, New York, United States|Philadelphia Veterans Medical Center, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00032942
363,NCT02778282,MySafeRx™: An Integrated Mobile Platform for Buprenorphine Adherence,MySafeRx,Recruiting,No Results Available,Opioid Use Disorder,Other: MySafeRx™,Feasibility|Acceptability|Initial Clinical Efficacy-Illicit opioid use|Initial Clinical Efficacy-Medication adherence|Cost efficiency,Dartmouth-Hitchcock Medical Center,All,18 Years to 39 Years   (Adult),Not Applicable,70,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1R34DA040086,2017-03-24,2019-09-01,2019-10-01,2016-05-19,null,2017-11-01,"Hawthorn Recovery Center, Bennington, Vermont, United States|Mount Anthony Primary Care, Bennington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT02778282
364,NCT02225184,Impact of Delta Opioid Receptor Gene (OPRD1) Variations on Treatment Outcome in African Americans,,Enrolling by invitation,No Results Available,Genetic Underpinning of Substance Abuse|Polymorphism-genetic|Drug Abuse/Dependence|Opiod-Related Disorders,,To independently replicate the pharmacogenetic findings of the NIDA CTN START substudy by comparing urine opioid results as a function of rs678849 genotype among opioid-addicted African-Americans treated with either buprenorphine or methadone.,National Institute on Drug Abuse (NIDA)|National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",,81,NIH,Observational,Observational Model: Ecologic or Community|Time Perspective: Other,999914167|14-DA-N167,2014-08-23,2018-12-31,2018-12-31,2014-08-26,null,2018-08-09,"National Institute on Drug Abuse, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02225184
365,NCT02069379,Endogenous Opioid Activity and Affective State in Insulin Resistant Women,,"Active, not recruiting",No Results Available,Depression|Insulin Resistance|Metabolic Syndrome,Drug: Metformin|Drug: Placebo,"Mu-opioid receptor binding potential in left nucleus accumbens, resting state|Mu-opioid receptor binding potential in right nucleus accumbens, resting state|Mu-opioid receptor binding potential in left amygdala, resting state|Mu-opioid receptor binding potential in right amygdala, resting state|Positive and Negative Affect Schedule - positive affective state|Positive and Negative Affect Schedule - negative affective state|Profile of Mood States - overall negative mood|Beck Depression Index",University of Michigan|National Institute of Mental Health (NIMH),Female,18 Years to 40 Years   (Adult),Phase 4,38,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",HUM00066696|K01MH095920,2014-07-01,2019-12-01,2022-12-01,2014-02-24,null,2017-06-16,"University of Michigan Medical School, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT02069379
366,NCT01955902,Using mHealth to Aid Opioid Addicts,,Completed,No Results Available,Opiate Dependency Relapse,,"Attitudes, beliefs and perceptions",Care Team Solutions,All,"21 Years and older   (Adult, Older Adult)",,11,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,271201300015C,2013-08-01,2013-10-01,2013-10-01,2013-10-08,null,2013-11-11,"Care Team Solutions, Lexington, Kentucky, United States",,https://ClinicalTrials.gov/show/NCT01955902
367,NCT00513864,Assessment of Opioid Analgesia in Sickle Cell,,Withdrawn,No Results Available,Sickle Cell Disease,Drug: Dextromethorphan|Drug: Codeine|Drug: Morphine,Pain Tolerance Threshold,Children's Research Institute,All,"7 Years to 18 Years   (Child, Adult)",Phase 4,0,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,3919,2006-11-01,2012-03-01,2012-03-01,2007-08-09,null,2014-12-23,"Children's National Medical Center, Washington, District of Columbia, United States",,https://ClinicalTrials.gov/show/NCT00513864
368,NCT03139240,Opioid Analgesia for MAB,,Completed,No Results Available,MAB|Pain,Drug: Oxycodone 10mg oral|Other: Placebo,Maximum self-reported pain score on a numeric rating scale,Oregon Health and Science University|Society of Family Planning,Female,18 Years to 50 Years   (Adult),Phase 4,172,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",16845,2017-05-01,2018-05-31,2018-05-31,2017-05-03,null,2018-06-20,"Site 1, Beaverton, Oregon, United States",,https://ClinicalTrials.gov/show/NCT03139240
369,NCT01325493,Low Dose Ketamine Study on Opioid Tolerance and Hyperalgesia,KPSF,Completed,Has Results,Idiopathic Scoliosis|Spondylolisthesis,Drug: Ketamine|Drug: Normal Saline,Morphine Equivalent Consumption (mg/kg)|Sedation Score|Pain Score at Rest|Pain Score During Cough.,Julia Finkel|Children's Research Institute,All,"10 Years to 18 Years   (Child, Adult)",Phase 4,54,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",4735,2010-01-01,2012-05-01,2012-09-01,2011-03-29,2015-11-02,2016-01-14,"Children's National Medical Center, Washington, District of Columbia, United States",,https://ClinicalTrials.gov/show/NCT01325493
370,NCT00661674,Palonosetron and Hydroxyzine to Reduce Opioid Withdrawal,,Completed,Has Results,Substance-Related Disorders,Drug: Palonosetron|Drug: Hydroxyzine|Other: Placebo,OOWS Score|SOWS Score,Stanford University,Male,18 Years to 35 Years   (Adult),Not Applicable,10,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",SU-04152008-1099,2008-04-01,2008-08-01,2008-08-01,2008-04-18,2017-06-05,2017-06-05,"Stanford University School of Medicine, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT00661674
371,NCT02189785,Endogenous Opioid Mechanisms for Rejection Sensitivity,,Recruiting,No Results Available,Rejection Sensitivity,,Mu-opioid binding potential|fMRI blood-oxygen-level-dependent (BOLD) response|Plasma cortisol,Stony Brook University|University of Michigan|National Institute of Mental Health (NIMH),All,18 Years to 25 Years   (Adult),,96,Other|NIH,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,R01MH102264,2016-08-01,2020-06-01,2020-06-01,2014-07-15,null,2018-01-02,"University of Michigan, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT02189785
372,NCT02813356,Naloxegol US PMR CV Safety,,Recruiting,No Results Available,Opioid Induced Constipation,Drug: naloxegol|Drug: non-PAMORA,major adverse cardiovascular events,AstraZeneca,All,"Child, Adult, Older Adult",,8800,Industry,Observational,Observational Model: Cohort|Time Perspective: Retrospective,D3820R00008|EUPAS18201,2016-06-24,2022-06-30,2022-06-30,2016-06-27,null,2018-08-06,"Research Site, Wilmington, Delaware, United States|Research Site, Hines, Illinois, United States",,https://ClinicalTrials.gov/show/NCT02813356
373,NCT03023930,Opioid Use Disorder in the Emergency Department: CTN 0069,,Recruiting,No Results Available,Opioid Use Disorder,Other: Standard Dissemination Practice|Other: Implementation Facilitation (IF),Implementation (Considered the Primary Outcome)|Effectiveness|Implementation: Fidelity|Implementation: ED provider Readiness and Preparedness Ruler Score|Implementation: ED Organizational Readiness to Change Assessment (ORCA) Score|Implementation: Community Readiness and Preparedness Ruler Score|Implementation: Community ORCA Score|Effectiveness: Opioid Use|Effectiveness: Overdose Event|Effectiveness: HIV Risk|Effectiveness: Healthcare Service Utilization|Effectiveness: Illicit Opioid Urine Toxicology,Yale University|National Institute on Drug Abuse (NIDA)|The EMMES Corporation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2000,Other|NIH|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,1611018631|5UG1DA015831-15,2017-04-03,2020-07-01,2021-01-01,2017-01-18,null,2018-05-17,"Johns Hopkins Hospital, Baltimore, Maryland, United States|The Mount Sinai Hospital, New York, New York, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Harborview Medical Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT03023930
374,NCT00267332,Modafinil in Opioid Induced Sedation,,Terminated,No Results Available,Cancer|Pain,Drug: Modafinil,Sedation|Pain,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,All,"18 Years and older   (Adult, Older Adult)",Phase 3,90,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,J0502,2006-01-01,null,2006-12-01,2005-12-20,null,2018-05-07,"The Johns Hopkins Hospital, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00267332
375,NCT00698737,Treatment Study: Reducing Cocaine/Heroin Abuse With SR-Amphetamine and Buprenorphine (ARC),ARC,Completed,No Results Available,Heroin Dependence|Opioid-Related Disorders|Cocaine Abuse or Dependence,,,Wayne State University|National Institute on Drug Abuse (NIDA),All,18 Years to 55 Years   (Adult),,22,Other|NIH,Observational,Observational Model: Case-Only|Time Perspective: Prospective,NIDA 022243-2|R01DA022243|DPMCDA,2008-04-01,2012-11-01,2012-11-01,2008-06-17,null,2012-11-22,"Wayne State University, Detroit, Michigan, United States",,https://ClinicalTrials.gov/show/NCT00698737
376,NCT03375645,Montefiore Opioid and Pain Study,MOPS,Recruiting,No Results Available,Acute Pain,Drug: Any oral opioid,Subsequent opioid prescription|Chronic pain in the affected body part|3 item PEG score|Pain description,Montefiore Medical Center,All,"18 Years and older   (Adult, Older Adult)",,462,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2017-8419,2017-11-08,2018-09-01,2019-03-01,2017-12-18,null,2017-12-18,"Montefiore Medical Center, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT03375645
377,NCT00218608,Disulfiram for Treating Cocaine Dependence in Individuals Maintained on Methadone,,Completed,No Results Available,Cocaine-Related Disorders|Opioid-Related Disorders,Drug: Disulfiram,Cocaine use,University of Arkansas|Yale University,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,158,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NIDA-13441-1|R01-13441-1|DPMC,2001-04-01,2007-01-01,2007-01-01,2005-09-22,null,2012-01-31,"University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States",,https://ClinicalTrials.gov/show/NCT00218608
378,NCT00838981,Pharmacotherapy & CM for Opioid and Cocaine Dependence,,Completed,Has Results,Cocaine Dependence,Drug: Modafinil|Drug: Sugar Pill|Behavioral: Contingency Management|Drug: Methadone|Behavioral: cognitive behavioral treatment|Behavioral: Voucher Control,Average Number of Positive Urine Tests|Average Maximum Days Abstinent|Average Number of Days Using a Substance Within Treatment,Yale University|National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,91,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0705002636|R01DA021264|DPMC,2008-05-01,2014-03-01,2014-03-01,2009-02-09,2017-09-12,2017-09-12,"Department of Veterans Affairs, West Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00838981
379,NCT02593474,Medication-Assisted Treatment for Youth With Substance Use Disorders,,Completed,No Results Available,Opioid Use Disorder|Opioid Dependence,Drug: Naltrexone,Retention in treatment at week 9 - the end of the study (this includes 1wk detox and 8 wks of treatment with Vivitrol)|Retention through first administration of Vivitrol (ie number that receive first injection),New York State Psychiatric Institute|National Institute on Drug Abuse (NIDA),All,"16 Years to 25 Years   (Child, Adult)",Phase 1,11,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,#7146|U54DA037842,2015-09-01,2018-04-01,2018-04-01,2015-11-02,null,2018-06-07,"New York State Psychiatric Insitute, New York, New York, United States|New York State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02593474
380,NCT02218775,FASTMAS (Fast-Fail Trials in Mood and Anxiety Spectrum Disorders) Kappa Opioid Receptor Phase 1 Study,KOR1,Withdrawn,No Results Available,Anxiety Disorders,Drug: LY2456302,Primary: Kappa opioid receptor occupancy determined with LY2879788 PET imaging; Mu opioid receptor occupancy determined with [11C]-Carfentanil PET imaging|Peak PET Mu Occupancy|Reward Circuit Engagement Outcome|Clinical Anhedonia Outcome Utilizing the Snaith-Hamilton Pleasure Scale (SHAPS)|Anhedonia Outcome Utilizing the Snaith-Hamilton Pleasure Scale (SHAPS)|Behavioral Anhedonia Outcome as measured by the Probabilistic Reward Task (PRT),Andrew Krystal|Yale University|Duke University,All,"21 Years to 65 Years   (Adult, Older Adult)",Phase 1,0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,Pro00052483|HHSN271201200006I,2014-10-01,2015-04-01,2015-04-01,2014-08-18,null,2015-05-28,"Yale University, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT02218775
381,NCT00015041,Buprenorphine Dose Escalation Trial for Treatment of Non-Dependent Opiate Users - 2,,Completed,No Results Available,Opioid-Related Disorders|Substance-Related Disorders,Drug: Buprenorphine,PK parameters of buprenorphine|Intoxication and withdrawal,National Institute on Drug Abuse (NIDA)|Cincinnati MDRU,All,21 Years to 45 Years   (Adult),Phase 1,0,NIH|Other,Interventional,Primary Purpose: Treatment,NIDA-5-0012-2|Y01-5-0012-2,1996-11-01,1998-06-01,1998-07-01,2001-04-18,null,2017-01-12,"Cincinnati MDRU, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00015041
382,NCT00000357,Buprenorphine Maintenance for Opiate Dependence - 6,,Completed,No Results Available,Opioid-Related Disorders|Substance-Related Disorders,Drug: Buprenorphine,,National Institute on Drug Abuse (NIDA)|University of Pennsylvania,Male,"Child, Adult, Older Adult",Phase 2,0,NIH|Other,Interventional,Primary Purpose: Treatment,NIDA-3-0012-6|Y01-3-0012-6,1992-06-01,1993-08-01,1993-10-01,1999-09-21,null,2017-01-12,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00000357
383,NCT00000356,Evaluation of L-alpha-acetylmethadol (LAAM) in Methadone Patients - 5,,Completed,No Results Available,Opioid-Related Disorders|Substance-Related Disorders,Drug: LAAM,,National Institute on Drug Abuse (NIDA)|University of Pennsylvania,All,"Child, Adult, Older Adult",Phase 2,0,NIH|Other,Interventional,Primary Purpose: Treatment,NIDA-3-0012-5|Y01-3-0012-5,1991-06-01,1992-08-01,1992-10-01,1999-09-21,null,2017-01-12,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00000356
384,NCT00000355,Effects of Buprenorphine and Naloxone in Opiate Addicts - 4,,Completed,No Results Available,Opioid-Related Disorders|Substance-Related Disorders,Drug: Buprenorphine,,National Institute on Drug Abuse (NIDA)|University of Pennsylvania,All,21 Years to 59 Years   (Adult),Phase 1,0,NIH|Other,Interventional,Primary Purpose: Treatment,NIDA-3-0012-4|Y01-3-0012-4,1994-11-01,1996-01-01,1996-03-01,1999-09-21,null,2017-01-12,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00000355
385,NCT00000353,Trial of Buprenorphine/Naloxone for Opiate Dependence - 2,,Completed,No Results Available,Opioid-Related Disorders|Substance-Related Disorders,Drug: Buprenorphine/naloxone,,National Institute on Drug Abuse (NIDA)|University of Pennsylvania,All,19 Years to 57 Years   (Adult),Phase 2,0,NIH|Other,Interventional,Primary Purpose: Treatment,NIDA-3-0012-2|Y01-3-0012-2,1996-10-01,1997-09-01,1997-10-01,1999-09-21,null,2017-01-18,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00000353
386,NCT00000319,Buprenorphine Maintenance Dose Schedule and Treatment Setting - 2,,Completed,No Results Available,Opioid-Related Disorders|Substance-Related Disorders,Drug: Buprenorphine,Depression|Withdrawal symptoms|Opioid and cocaine use|Social and psychological functioning|AIDS risk behavior|Opiate withdrawal symptoms,National Institute on Drug Abuse (NIDA)|Yale University,All,21 Years to 55 Years   (Adult),Phase 2,0,NIH|Other,Interventional,Primary Purpose: Treatment,NIDA-09803-2|R01-09803-2,1996-06-01,null,null,1999-09-21,null,2005-08-17,"APT Residential Services Division, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00000319
387,NCT00000279,Novel Medications for Opiate Detoxification - 4,,Completed,No Results Available,Opioid-Related Disorders|Substance-Related Disorders,Drug: Clonidine,Withdrawal severity,Yale University|National Institute on Drug Abuse (NIDA)|VA Connecticut Healthcare System,All,"18 Years and older   (Adult, Older Adult)",Phase 2,0,Other|NIH|U.S. Fed,Interventional,Primary Purpose: Treatment,NIDA-09250-4|P50DA009250|P50-09250-4,1994-09-01,1999-08-01,1999-08-01,1999-09-21,null,2013-07-25,"VA Connecticut Healthcare System, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00000279
388,NCT00000265,Subjective Effects of Nitrous Oxide in Dental Patients - 17,,Completed,No Results Available,Opioid-Related Disorders|Substance-Related Disorders,,Anxiety scale|Mood scale,University of Chicago|National Institute on Drug Abuse (NIDA),All,"18 Years and older   (Adult, Older Adult)",,46,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,NIDA-08391-17|R01DA008391|R01-08391-17,1997-07-01,2002-01-01,2002-01-01,1999-09-21,null,2015-05-27,"University of Chicago, Anesthesia & Critical Care, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00000265
389,NCT00000264,Subjective/Psychomotor/ Effects of Combined Alcohol & Nitrous Oxide - 16,,Completed,No Results Available,Opioid-Related Disorders|Substance-Related Disorders,Drug: 30% Nitrous oxide|Other: 0.35 g/Kg ethanol|Other: 0.7 g/Kg ethanol|Other: 0 g/Kg ethanol,Mood|Psychomotor performance|Cognitive performance|Choice of nitrous oxide vs placebo,University of Chicago|National Institute on Drug Abuse (NIDA),All,"Child, Adult, Older Adult",Not Applicable,8,Other|NIH,Interventional,"Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)",NIDA-08391-16|R01DA008391|R01-08391-16,1997-09-01,1999-10-01,1999-10-01,1999-09-21,null,2015-05-27,"University of Chicago, Anesthesia & Critical Care, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00000264
390,NCT00000263,Effects of Combined Alcohol and Nitrous Oxide Intake - 15,,Completed,No Results Available,Opioid-Related Disorders|Substance-Related Disorders,Drug: 30% Nitrous oxide|Other: 0.25 g/Kg ethanol|Other: 0.5 g/KG ethanol|Other: 0 g/Kg ethanol,"Pain intensity, pain bothersomeness|Mood|Psychomotor performance|Cognitive performance",University of Chicago|National Institute on Drug Abuse (NIDA),All,"Child, Adult, Older Adult",Not Applicable,11,Other|NIH,Interventional,"Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)",NIDA-08391-15|R01DA008391|R01-08391-15,1997-01-01,1998-10-01,1998-10-01,1999-09-21,null,2015-05-27,"University of Chicago, Anesthesia & Critical Care, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00000263
391,NCT00000262,Effects of Combined Sevoflurane and Nitrous Oxide Inhalation - 14,,Completed,No Results Available,Opioid-Related Disorders|Substance-Related Disorders,Drug: 30% Nitrous oxide|Drug: 0.4% Sevoflurane|Drug: 0.2% sevoflurane|Other: Placebo,"Pain intensity, pain bothersomeness|Mood|Psychomotor performance",University of Chicago|National Institute on Drug Abuse (NIDA),All,"Child, Adult, Older Adult",Not Applicable,20,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",NIDA-08391-14|R01DA008391|R01-08391-14,1996-11-01,1999-02-01,1999-02-01,1999-09-21,null,2015-05-27,"University of Chicago, Anesthesia & Critical Care, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00000262
392,NCT00000260,Effects of Behavioral Contingencies on Effects of Nitrous Oxide - 12,,Completed,No Results Available,Opioid-Related Disorders|Substance-Related Disorders,Drug: Nitrous oxide,Mood|Choice of nitrous oxide vs placebo,University of Chicago|National Institute on Drug Abuse (NIDA),All,"21 Years and older   (Adult, Older Adult)",Not Applicable,18,Other|NIH,Interventional,,NIDA-08391-12|R01DA008391|R01-08391-12,1997-06-01,1998-01-01,1998-01-01,1999-09-21,null,2015-05-27,"University of Chicago, Anesthesia & Critical Care, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00000260
393,NCT00000259,Sevoflurane vs Nitrous Oxide Inhalation at Subanesthetic Concentrations - 11,,Completed,No Results Available,Opioid-Related Disorders|Substance-Related Disorders,Drug: 15 % Nitrous oxide|Drug: 0.3 % Sevoflurane|Drug: 30% Nitrous oxide|Drug: 0.6% Sevoflurane|Other: Placebo,Pain intensity|Psychomotor performance|Cognitive performance,University of Chicago|National Institute on Drug Abuse (NIDA),All,21 Years to 39 Years   (Adult),Not Applicable,12,Other|NIH,Interventional,"Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)",NIDA-08391-11|R01DA008391|R01-08391-11,1996-08-01,1997-11-01,1997-11-01,1999-09-21,null,2015-05-28,"University of Chicago, Anesthesia & Critical Care, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00000259
394,NCT00000258,Role of Instructions in Nitrous Oxide Effects and Choice - 10,,Completed,No Results Available,Opioid-Related Disorders|Substance-Related Disorders,Drug: Nitrous oxide 10% & placebo|Drug: Nitrous oxide 20% & placebo|Drug: Nitrous oxide 30% & placebo|Drug: Nitrous oxide 40% and placebo,Choice of nitrous oxide vs placebo,University of Chicago|National Institute on Drug Abuse (NIDA),All,21 Years to 32 Years   (Adult),Not Applicable,22,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)",NIDA-08391-10|R01DA008391|R01-08391-10,1996-04-01,1997-11-01,1997-11-01,1999-09-21,null,2015-05-28,"University of Chicago, Anesthesia & Critical Care, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00000258
395,NCT00000256,Reinforcing Effects of Brief Exposures to Nitrous Oxide - 8,,Completed,No Results Available,Opioid-Related Disorders|Substance-Related Disorders,Drug: 20% N2O|Drug: 40% N2O|Drug: 60% N2O|Drug: 80% N2O,Choice of nitrous oxide vs placebo,University of Chicago|National Institute on Drug Abuse (NIDA),All,22 Years to 34 Years   (Adult),Not Applicable,11,Other|NIH,Interventional,"Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)",NIDA-08391-8|R01DA008391|R01-08391-8,1995-08-01,1996-11-01,1996-11-01,1999-09-21,null,2015-05-28,"University of Chicago, Anesthesia & Critical Care, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00000256
396,NCT00000255,Differential Acute Tolerance Development to Effects of Nitrous Oxide - 7,,Completed,No Results Available,Opioid-Related Disorders|Substance-Related Disorders,Drug: Nitrous oxide,"Pain intensity, pain bothersomeness",University of Chicago|National Institute on Drug Abuse (NIDA),All,21 Years to 37 Years   (Adult),Phase 2,10,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NIDA-08391-7|R01DA008391|R01-08391-7,1995-04-01,1996-05-01,1996-05-01,1999-09-21,null,2015-05-28,"University of Chicago, Anesthesia & Critical Care, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00000255
397,NCT00000254,Isoflurane at Subanesthetic Concentrations - 6,,Completed,No Results Available,Opioid-Related Disorders|Substance-Related Disorders,Drug: 40% Nitrous oxide|Other: Sham comparator|Drug: 0.2% isoflurane|Drug: 0.4% isoflurane|Drug: 0.6% isoflurane,Pain response,University of Chicago|National Institute on Drug Abuse (NIDA),Male,21 Years to 34 Years   (Adult),Phase 2,10,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,NIDA-08391-6|R01DA008391|R01-08391-6,1995-01-01,1995-09-01,1995-09-01,1999-09-21,null,2015-05-28,"University of Chicago, Anesthesia & Critical Care, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00000254
398,NCT00000253,Effects of Nitrous Oxide: A Dose-Response Analysis - 5,,Completed,No Results Available,Opioid-Related Disorders|Substance-Related Disorders,Drug: 10% N2O|Drug: 20% N2O|Drug: 30% N2O|Drug: 40% N2O,Choice of N2O vs. placebo,University of Chicago|National Institute on Drug Abuse (NIDA),All,21 Years to 37 Years   (Adult),Not Applicable,16,Other|NIH,Interventional,"Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)",NIDA-08391-5|R01DA008391|R01-08391-5,1994-11-01,1996-03-01,1996-03-01,1999-09-21,null,2015-05-28,"University of Chicago, Anesthesia & Critical Care, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00000253
399,NCT00000252,Lack of Acute Tolerance Development to Effects of Nitrous Oxide - 4,,Completed,No Results Available,Opioid-Related Disorders|Substance-Related Disorders,Drug: 0% N2O|Drug: 10% N2O|Drug: 20% N2O|Drug: 30% N2O|Drug: 40% N2O,Psychomotor performance|Cognitive performance,University of Chicago|National Institute on Drug Abuse (NIDA),All,21 Years to 29 Years   (Adult),Phase 2,11,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NIDA-08391-4|R01DA008391|R01-08391-4,1994-06-01,1996-06-01,1996-06-01,1999-09-21,null,2015-05-28,"University of Chicago, Anesthesia & Critical Care, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00000252
400,NCT00000251,Effects of Subanesthetic Concentrations of Isoflurane/Nitrous Oxide - 3,,Completed,No Results Available,Opioid-Related Disorders|Substance-Related Disorders,Drug: 30% N2O|Drug: 0.2% isoflurane|Drug: 0.4% isoflurane|Other: 100% oxygen,Logical reasoning test|Free recall memory test|Auditory reaction time|Digit symbol substitution test,University of Chicago|National Institute on Drug Abuse (NIDA),All,21 Years to 32 Years   (Adult),Phase 2,10,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,NIDA-08391-3|R01DA008391|R01-08391-3,1994-04-01,1996-01-01,1996-01-01,1999-09-21,null,2015-12-02,"University of Chicago, Anesthesia & Critical Care, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00000251
401,NCT00000250,Cold Water Immersion Modulates Reinforcing Effects of Nitrous Oxide - 2,,Completed,No Results Available,Opioid-Related Disorders|Substance-Related Disorders,Drug: 0% N2O|Drug: 40% N2O,Subject's choice of intervention,University of Chicago|National Institute on Drug Abuse (NIDA),All,21 Years to 32 Years   (Adult),Phase 2,12,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,NIDA-08391-2|R01DA008391|R01-08391-2,1993-12-01,1995-05-01,1995-05-01,1999-09-21,null,2015-05-28,"University of Chicago, Anesthesia & Critical Care, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00000250
402,NCT00000249,Effects of Subanesthetic Concentrations of Nitrous Oxide - 1,,Completed,No Results Available,Opioid-Related Disorders|Substance-Related Disorders,Drug: 20% N2O|Drug: 30% N2O|Drug: 40% N2O,Pain intensity,University of Chicago|National Institute on Drug Abuse (NIDA),All,21 Years to 37 Years   (Adult),Phase 2,10,Other|NIH,Interventional,"Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NIDA-08391-1|R01DA008391|R01-08391-1,1993-09-01,1995-06-01,1995-06-01,1999-09-21,null,2015-05-28,"University of Chicago, Anesthesia & Critical Care, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00000249
403,NCT03051945,Endogenous Opioid Modulation by Ketamine,,Enrolling by invitation,No Results Available,Major Depressive Disorder,Drug: Ketamine Hydrochloride|Other: Normal saline,"Montgomery Asberg Depression Rating Scale at 24 hours, change from baseline",University of Utah,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science",87544,2018-06-15,2020-03-01,2021-03-01,2017-02-14,null,2018-05-02,"Huntsman Cancer Institute, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT03051945
404,NCT01591382,Efficacy Study of Ketamine for Postoperative Pain in Opioid Dependent Patients,,Completed,Has Results,Postoperative Pain,Drug: Ketamine|Drug: Placebo|Drug: Hydromorphone PCA,Average Postoperative Pain Score|Worst Postoperative Pain Score|Least Postoperative Pain Score|24-Hour Postoperative Opioid Use|Number of Participants With Treatment Related Adverse Events (AEs),Brigham and Women's Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 4,64,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2008P001126,2008-09-01,2011-06-01,2012-06-01,2012-05-04,2017-03-22,2017-03-22,"Brigham and Women's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01591382
405,NCT03605966,Developing a Method to Objectively Measure Opioid Analgesia,,Recruiting,No Results Available,"Analgesics, Antipyretics and Anti-Inflammatory Drugs Causing Adverse Effects in Therapeutic Use",,Changes in Pupillary Dilation Reflex AUC|Pain Assessment by Visual Analog Scale (VAS)|Pupillary Dilation Reflex Amplitude|Changes in Pupillary Light Reflex Amplitude|Changes in Pupillary Light Reflex Latency|Changes in Pupillary Light Reflex Constriction Velocity,Julia Finkel|Children's Research Institute,All,"7 Years to 21 Years   (Child, Adult)",,40,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,6825,2018-07-01,2019-07-01,2019-12-01,2018-07-30,null,2018-07-30,"Children's National Health System, Washington, District of Columbia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT03605966/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03605966
406,NCT00000306,Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3,,Completed,No Results Available,Cocaine-Related Disorders|Opioid-Related Disorders,Drug: Dextroamphetamine,"Craving|Drug use|Medication compliance|Retention|Addiction severity|Mood indicators|Psychiatric interview|Effectiveness measures including psycho-social variables, side effects, and self-reported measures.",National Institute on Drug Abuse (NIDA)|University of Texas,All,18 Years to 45 Years   (Adult),Phase 2,140,NIH|Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,NIDA-09262-3|P50-09262-3,1994-09-01,null,2001-09-01,1999-09-21,null,2017-01-12,"University of Texas Health Science Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00000306
407,NCT03308188,EMPOWER: Randomized Trial of Online Chronic Pain Management Program to Reduce Reliance on Opioid Analgesic Medications,,Enrolling by invitation,No Results Available,Chronic Pain,Behavioral: E-health program,Decrease in Morphine Equivalent Dose (MED)|Pain Intensity,University of Cincinnati|National Institute on Drug Abuse (NIDA),All,"25 Years to 80 Years   (Adult, Older Adult)",Not Applicable,400,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2017-2301|1R01DA044248-01,2018-02-05,2022-01-01,2022-01-01,2017-10-12,null,2018-03-06,"UC Health Primary Care practices, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03308188
408,NCT02040077,Evaluation of a Computerized Opioid Overdose Prevention Program,,Completed,Has Results,Computer + Fluency|Computer Only|Treatment as Usual,Behavioral: Computer + Fluency|Behavioral: Computer Only|Behavioral: Treatment as Usual,Knowledge Gain|Percent Participants Who Would Recommend the Intervention to a Family Member or Friend.,Johns Hopkins University|National Institute on Drug Abuse (NIDA),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,75,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,Opioid Overdose|R21DA035327,2015-01-01,2015-09-01,2015-09-01,2014-01-20,2017-09-26,2017-11-17,"Johns Hopkins University Bayview Medical Campus, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02040077
409,NCT00149630,Pharmacogenetics of Disulfiram for Cocaine,Disulfiram,Completed,Has Results,Cocaine Dependence|Opioid Dependence,Drug: Disulfiram|Drug: Methadone|Behavioral: CBT|Other: Lactose,Urine Toxicology for Cocaine.|Retention by Treatment Condition.,Baylor College of Medicine|National Institute on Drug Abuse (NIDA)|Yale University,All,18 Years to 64 Years   (Adult),Phase 2,93,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NIDA-18197-2|P50DA018197-02,2005-01-01,2009-12-01,2009-12-01,2005-09-08,2012-12-28,2017-03-15,"Michael E. DeBakey VA Medical Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00149630
410,NCT01870882,Attention Training for Opioid-maintained Cocaine Users,,Completed,No Results Available,Addiction|Cocaine|Methadone|Opiates,Behavioral: Attentional retraining|Behavioral: Control condition,Attentional bias for cocaine cues|Attentional bias for opioid cues|Retention of participants in treatment|Mean duration of sessions with the PED|self-reported craving for cocaine|Self-reported cocaine use|Self-reported opioid use|self-reported craving for opiates|Cocaine urine test results|opioid urine test results,Yale University,All,18 Years to 55 Years   (Adult),Phase 4,8,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",RL001,2013-06-01,2014-12-01,2015-06-01,2013-06-06,null,2015-07-17,"Department of Veterans Affairs Hospital, West Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01870882
411,NCT00558870,Role of Methadone As Co-Opioid Analgesic,,Terminated,Has Results,Pain,Drug: Morphine|Drug: Methadone,Number of Participants With Objective Response (OR)|Dose Escalation Index at Day 15 (+/- 3 Days),M.D. Anderson Cancer Center,All,"18 Years and older   (Adult, Older Adult)",Phase 2,5,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2006-0641|NCI-2012-01553,2007-11-01,2015-01-01,2015-01-01,2007-11-15,2016-04-05,2016-04-05,"University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00558870
412,NCT03173131,Opioid Consumption After Orthopaedic Surgery,,Enrolling by invitation,No Results Available,Orthopedic Disorder,Behavioral: Pre-operative opioid counseling,Post operative opioid consumption,Thomas Jefferson University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,280,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Supportive Care",17D.131,2017-06-01,2017-09-01,2017-10-01,2017-06-01,null,2017-06-01,"Thomas Jefferson University, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03173131
413,NCT02496403,Buprenorphine and Substance Abuse Services for Prescription Opioid Dependence,,"Active, not recruiting",No Results Available,Opiate Substitution Treatment,Behavioral: Standard Medical Management (SMM),Adherence to buprenorphine/naloxone using MPR|Abstinence using ASI|Health care utilization costs using ICER|Adherence to buprenorphine/naloxone using drug testing|Chronic Pain using the pain Interference scale|Quality of Life using PROMIS Global Health scale|Mental health using PHQ-9,Kaiser Permanente|National Institute on Drug Abuse (NIDA),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,239,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,CN-13-1592-H|R01DA036603,2015-12-01,2019-05-01,2019-05-01,2015-07-14,null,2018-06-08,"Kaiser Sacramento Chemical Dependency Recovery Program, Sacramento, California, United States",,https://ClinicalTrials.gov/show/NCT02496403
414,NCT03299920,Opioid Consumption After Knee Arthroscopy,,Recruiting,No Results Available,"Surgical Procedure, Unspecified|Orthopedic Disorder",Other: Standardized instructions|Other: Conventional instructions,Number of opioid medication doses taken,Giorgio Veneziano|Nationwide Children's Hospital,All,"up to 20 Years   (Child, Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB17-00710,2017-09-18,2019-12-31,2019-12-31,2017-10-03,null,2017-10-03,"Nationwide Children's Hospital, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03299920
415,NCT02240797,Kappa Opioid Receptor Imaging in Anorexia,,Terminated,No Results Available,Anorexia Nervosa,Other: Positron emission tomography (PET) imaging,"Volume of distribution (VT) (i.e., KOR binding) using [11C]PKAB and PET imaging",New York University School of Medicine|Yale University|Icahn School of Medicine at Mount Sinai,Female,18 Years to 55 Years   (Adult),,7,Other,Observational,Observational Model: Case Control|Time Perspective: Cross-Sectional,S13-00990,2014-09-01,2016-03-01,2016-03-01,2014-09-16,null,2016-08-17,"NYU School of Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02240797
416,NCT03588910,Ambulatory Gynecologic Surgery: Finding the Optimal Opioid Prescription,,Not yet recruiting,No Results Available,Surgery,Drug: Acetaminophen|Drug: Ibuprofen 600 mg|Drug: Oxycodone,Number of oxycodone tablets used as reported by participants 1 day after surgery|Number of oxycodone tablets used as reported by participants 1 week after surgery|Self reported pain score on post operative day 1|Self reported pain score on post operative day 7|Additional contacts with provider,Montefiore Medical Center,Female,"18 Years and older   (Adult, Older Adult)",Phase 2,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2018-8755,2018-08-01,2019-01-01,2019-01-01,2018-07-17,null,2018-07-17,"Montefiore Medical Center, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT03588910
417,NCT02132221,Cessation of Long-term Opioid Therapy in Chronic Pain Patients,,Unknown status,No Results Available,Chronic Non-cancer Pain,Behavioral: Cognitive Behavioral Therapy,"Number of participants with daily opioid dose below 50% of initial dose|signs of hyperalgesia on Quantitative Sensory Testing (QST)|signs of hyperalgesia on QST|number of patients who are not prescribed opioids on daily basis (""full taper"")|Time to reach >50% taper.|Pain scores (Brief Pain Inventory)|Absolute opioid dose reduction|Functional Impairment|Number of patients who reach a full taper amongst those having not reached this outcome at 10 weeks.|Anxiety and depression (HADS).|Withdrawal (COWS measure).|Hedonic tone (SHAPS).",Massachusetts General Hospital|Brigham and Women's Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Partners IRB 2013P000881,2013-10-01,2014-11-01,2015-03-01,2014-05-07,null,2014-05-07,"Massachusetts General Hospital Center for Pain Medicine, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02132221
418,NCT01559454,Buprenorphine and Methadone for Opioid-dependent Chronic Back Pain Patients,,Completed,Has Results,Low Back Pain,Drug: Methadone|Drug: Buprenorphine/naloxone,Analgesia|Illicit Drug Use|Cravings|Functioning|Depression|Treatment Retention,State University of New York at Buffalo,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,19,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FMD0600908A,2012-02-01,2014-05-01,2014-05-01,2012-03-21,2017-02-20,2017-02-20,"UB/MD Family Medicine, Inc., Amherst, New York, United States",,https://ClinicalTrials.gov/show/NCT01559454
419,NCT03575377,"Opioid Use, Storage, and Disposal Among Pediatric Patients After Surgery",,Enrolling by invitation,No Results Available,Tonsillitis|Sleep Disordered Breathing|Hernia|Hydrocele|Hypospadias|Undescended Testicle|Circumcision,Other: Disposal Aid,Proper disposal of unused opioids|Quantity of opioid used after surgery|Quantity of opioid leftover after surgery|Opioid refill occurrence|Proper storage of opioids|Barriers to opioid disposal,Nationwide Children's Hospital|Ohio State University,All,1 Year to 17 Years   (Child),Not Applicable,192,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,IRB18-00157,2018-06-07,2019-05-31,2019-06-30,2018-07-02,null,2018-07-02,"Jennifer Cooper, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03575377
420,NCT01728909,Methadone Oxytocin Option,MOO,Completed,No Results Available,Substance Abuse|Opioid Dependence|Methadone Treatment,Drug: Oxytocin|Drug: Saline Nasal Spray,Computerized Social Cognition Tasks|Craving Questionnaires,"University of California, San Francisco|San Francisco Veterans Affairs Medical Center",Male,"18 Years and older   (Adult, Older Adult)",Early Phase 1,64,Other|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",11-07691,2012-05-01,2014-10-01,2014-10-01,2012-11-20,null,2016-05-12,"San Francisco VA Medical Center, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT01728909
421,NCT01821430,Increased Sensitivity to Pain Caused by Opioids in People Who Have Abused Prescription Opioids,,Terminated,No Results Available,Chronic Pain,Drug: Pregabalin|Drug: Placebo,"Improved Pain Response, threshold and tolerance|Improvement in pain severity and daily functionality",Georgetown University|National Institute on Drug Abuse (NIDA),All,"21 Years to 65 Years   (Adult, Older Adult)",Phase 2,4,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Pro00000669|U01DA029580,2013-03-01,2016-02-01,2016-02-01,2013-04-01,null,2017-02-09,"Georgetown University, Washington, District of Columbia, United States",,https://ClinicalTrials.gov/show/NCT01821430
422,NCT03096353,Sensory and Opioid Mechanisms of Affective Touch,,Recruiting,No Results Available,Pain|Anxiety,,Effect of naloxone on touch pleasantness,National Center for Complementary and Integrative Health (NCCIH)|National Institutes of Health Clinical Center (CC),All,18 Years to 50 Years   (Adult),,30,NIH,Observational,Observational Model: Case-Crossover|Time Perspective: Cross-Sectional,170075|17-AT-0075,2017-08-01,2018-10-17,2019-10-17,2017-03-30,null,2018-08-09,"National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT03096353
423,NCT03422211,A Prospective Assessment of Opioid Utilization Post-operatively in Sports Orthopaedic Surgeries,Opioids,Recruiting,No Results Available,"Narcotic Use|Postoperative Pain|Narcotic Abuse|Opioid Use|Opioid Abuse, Uncomplicated|Opioids; Harmful Use|Analgesic Drug Dependence|Orthopedic Disorder",Other: Questionnaire,Number of narcotic analgesics consumed,St. Louis University,All,"10 Years to 100 Years   (Child, Adult, Older Adult)",,300,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,28494,2017-11-16,2018-07-30,2018-11-30,2018-02-05,null,2018-02-05,"Cardinal Glennon, Saint Louis, Missouri, United States|Anheuser Busch Institute, Saint Louis, Missouri, United States|SSM Health St. Mary's Hospital - St. Louis, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT03422211
424,NCT00706576,Treatment of Unresectable Hepatocellular Cancer With Opioid Growth Factor,,Completed,No Results Available,Hepatocellular Cancer,Drug: Infusion of opioid growth factor,Number of participants with opioid growth factor toxicity|Change in plasma opioid growth factor levels,University of Missouri-Columbia|Penn State University,All,"18 Years and older   (Adult, Older Adult)",Phase 1,14,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,26336,2008-06-01,2013-07-01,2013-07-01,2008-06-27,null,2017-08-02,"Penn State Hershey Medical Center, Hershey, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00706576
425,NCT03090152,Minimal Opioid Use After Total Hip Replacement (THR),,Recruiting,No Results Available,"Osteoarthritis, Hip",Procedure: Periarticular injection (Deep injection)|Procedure: Periarticular injection (Superficial injection)|Drug: Bupivacaine|Drug: Placebo,Opioid use|Pain at rest|Pain with activity|Opioid side effects|Patient satisfaction|Post-operative pain|Neuropathic pain|Quality of recovery|Readiness for discharge time,"Hospital for Special Surgery, New York",All,"50 Years to 75 Years   (Adult, Older Adult)",Phase 4,180,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",2016-0721,2017-03-08,2018-12-31,2018-12-31,2017-03-24,null,2018-02-16,"Hospital for Special Surgery, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03090152
426,NCT02964000,Phoenix Thera-Lase for Treating Chronic Pain in Patients Taking Opioid on a PRN Basis,,Recruiting,No Results Available,Pain,Device: Low level 1 Watt|Device: Phoenix Thera-Lase System 42|Device: Phoenix Thera-Lase System 74,Reduce chronic pain|reduce of opioid analgesic dosage.|Level of physical activity|Quality of sleep,"Phoenix Thera-lase Systems, LLC",All,"25 Years to 65 Years   (Adult, Older Adult)",Not Applicable,75,Industry,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20162211,2016-11-01,2017-12-01,2017-12-01,2016-11-15,null,2017-02-23,"Phoenix Thera-Lase Systems, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT02964000
427,NCT00580294,A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation),,Completed,Has Results,Pain,Drug: Oxymorphone,Change in Patient Global Impression of Change|Brief Pain Inventory,Icahn School of Medicine at Mount Sinai|Endo Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,12,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GCO 07-0464,2007-11-01,2008-08-01,2008-08-01,2007-12-24,2016-02-03,2016-02-03,"Icahn School of Medcine at Mount Sinai, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00580294
428,NCT01100437,Safety Study to Assess Opiate Withdrawal Signs and Symptoms in Opioid Dependent Patients,,Terminated,Has Results,Chronic Pain,Drug: EMBEDA™ (morphine sulfate/naltrexone hydrochloride) crush|Drug: EMBEDA™ (morphine sulfate/naltrexone hydrochloride) whole,Number of Participants With Clinical Opiate Withdrawal Scale (COWS) Score Greater Than or Equal to (≥) 13 in the Treatment Phase|Average Numeric Pain Rating Scale (NPRS) in Titration/Stabilization and Maintenance Phases|Time to Reach Maximum Observed Plasma Concentration (Tmax) During the Treatment Phase|Maximum Observed Plasma Concentration (Cmax) During the Treatment Phase|Minimum Observed Plasma Concentration (Cmin) During the Treatment Phase|Apparent Oral Clearance (CL/F) During the Treatment Phase|Volume of Distribution (Vd/F)During the Treatment Phase|Plasma Decay Half-Life (t1/2) During the Treatment Phase|Area Under the Curve From Time Zero to End of Dosing Interval (AUC0-τ) During the Treatment Phase|Area Under the Curve From Time Zero to the Time of Last Measurable Concentration (AUC0-last) During the Treatment Phase|Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] During the Treatment Phase,Pfizer,All,"21 Years and older   (Adult, Older Adult)",Phase 4,14,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)",ALO-01-09-111|B4541002,2010-04-01,2011-03-01,2011-03-01,2010-04-09,2012-03-28,2012-07-13,"Lifetree Clinical Research, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT01100437
429,NCT02473354,Predictors of Opioid-Induced Respiratory Depression (OIRD),(OIRD),Recruiting,No Results Available,Respiratory Depression,Drug: Remifentanil|Drug: Oxygen|Drug: Carbon dioxide,"Hypercapnic Ventilatory Response (HCVR) gradient based upon ETCO2 and Minute Volume|The proportion of subjects who are classified as low, medium, or high risk for Opioid Induced Respiratory Depression (OIRD).",Duke University,All,18 Years to 50 Years   (Adult),Phase 1,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,Pro00060429,2015-04-01,2019-06-01,2019-06-01,2015-06-16,null,2018-06-08,"Duke University Health Systems, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT02473354
430,NCT03229447,Facilitating MAT Acceptance & Implementation in Problem Solving & Felony Courts,,Recruiting,No Results Available,Improving Treatment for Opioid Use Disorder in Courts,Behavioral: eLearning Modules|Behavioral: Change Team Intervention,Enrollment in Medication Assisted Treatment|MAT referrals|MAT knowledge/attitudes|Willingness to refer clients to MAT|Barriers to MAT,"National Development and Research Institutes, Inc.|Treatment Alternatives for Safe Communities",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,96,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NationalDRI|R34DA038799,2016-04-15,2018-04-01,2018-04-01,2017-07-25,null,2017-07-25,"National Development and Research Institutes, Inc., New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03229447
431,NCT00308555,Opioid and Cannabinoid Pharmacokinetic Interactions,,Completed,Has Results,Pain,Drug: Cannabis,Disposition Kinetics of Morphine and Oxycodone Before and After Cannabis Use,"University of California, San Francisco|National Institute on Drug Abuse (NIDA)",All,"18 Years and older   (Adult, Older Adult)",Phase 1,24,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CC # 064|1R21DA020831-01,2006-05-01,2009-03-01,2009-03-01,2006-03-29,2013-07-22,2016-12-09,"Community Consortium, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT00308555
432,NCT02276989,Evaluation of a Compliance Marker in Prescription Opioid Abusers With Chronic Pain,,Withdrawn,No Results Available,Compliance|Chronic Pain,Drug: acetazolamide|Drug: Quinine|Drug: Riboflavin,"Pharmacokinetic profiles for each medication/tracer (assayed from blood and urine samples) and will include parameters such as AUC, CMAX, TMax, and t1/2.",Georgetown University,All,18 Years to 50 Years   (Adult),Phase 2,0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,2013-0751,2014-12-01,2016-01-01,2016-01-01,2014-10-28,null,2017-02-10,"Georgetown University, Washington, District of Columbia, United States",,https://ClinicalTrials.gov/show/NCT02276989
433,NCT00529230,Prevalence of Secondary Hypogonadism in Male Patients on Chronic Opioid Therapy for Cancer-Related Pain Syndromes,,Terminated,No Results Available,Advanced Cancer|Hypogonadism|Pain,Behavioral: Questionnaire|Other: Blood draws to assess gonadal function,Prevalence of secondary hypogonadism in male patients on chronic opioid therapy for cancer-related pain syndromes,M.D. Anderson Cancer Center,Male,"18 Years and older   (Adult, Older Adult)",,46,Other,Observational,Observational Model: Case Control|Time Perspective: Prospective,ID01-451,2001-12-01,2004-12-01,2004-12-01,2007-09-14,null,2012-08-01,"U.T.M.D. Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00529230
434,NCT00659035,Use of Driving Tests to Evaluate Patient Performance on Oral Opioids,OpDrive,"Active, not recruiting",No Results Available,Chronic Pain,,"Weaving, measured as standard deviation of lateral position.|Reaction time",Asokumar Buvanendran|Rush University Medical Center,All,"18 Years to 80 Years   (Adult, Older Adult)",,450,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,ABuv111407,2008-04-01,2018-07-01,2018-07-01,2008-04-16,null,2017-09-27,"Rush University Medical Center, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00659035
435,NCT00383682,Efficacy of Opioids and Mexiletine for the Treatment of Postamputation Pain,,Completed,No Results Available,Amputation|Chronic Pain,Drug: morphine and mexiletine,Pain intensity (0-10 numerical rating scale)|Pain relief (0-100%)|Functional activity (Multidimensional Pain Inventory activity and interference subscales,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,60,NIH,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,"P01HD033990|Project 2, P01HD33990",1997-07-01,null,2003-04-01,2006-10-03,null,2006-10-03,"Johns Hopkins Hospital, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00383682
436,NCT02226601,Aprepitant to Mitigate Opioids' Cognitive Side Effects,,Unknown status,No Results Available,Cognitive Dysfunction,Drug: Aprepitant|Drug: Placebo,cognitive function,University of Arizona,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CognAp,2014-10-01,2016-10-01,null,2014-08-27,null,2015-06-02,"University of Arizona Medical Center, Tucson, Arizona, United States",,https://ClinicalTrials.gov/show/NCT02226601
437,NCT02818036,An fMRI Study of Opioid-related Changes in Neural Activity,,Completed,No Results Available,Social Acceptance,Drug: Naltrexone|Drug: Placebo,"Neural activity (fMRI) in response to the scanner tasks (reading sentences and viewing pictures of known and unknown people)|self-reported feelings of connection (i.e. average of how connected, touched, warm did you feel) in response to the scanner tasks",University of Pittsburgh,All,18 Years to 35 Years   (Adult),Not Applicable,82,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",PRO15010292,2016-08-01,2018-06-21,2018-06-21,2016-06-29,null,2018-07-09,"University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02818036
438,NCT03137030,A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults,,Withdrawn,No Results Available,"Opioid-Related Disorders|Pain, Acute|Pain, Postoperative",Drug: GRT7014 - Abuse Deterrend Tablet|Drug: Norco 5Mg-325Mg Tablet,"Maximum Plasma Concentration (Cmax) GRT7014 (1 and 10 Tablets)|Area under the plasma concentration curve from timepoint 0 to t (AUC0-t) GRT7014 (1 and 10 Tablets)|Area under the plasma concentration curve from timepoint 0 to infinity (AUC) GRT7014 (1 and 10 Tablets)|Maximum Plasma Concentration (Cmax) GRT7014 and Norco (1, 5 (optional) and 10 Tablets)|Area under the plasma concentration curve from timepoint 0 to t (AUC0-t) GRT7014 and Norco (1, 5 (optional) and 10 Tablets)|Area under the plasma concentration curve from timepoint 0 to infinity (AUC) GRT7014 and Norco (1, 5 (optional) and 10 Tablets)",Grünenthal GmbH,All,18 Years to 55 Years   (Adult),Phase 1,0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HP7014-02|U1111-1184-8922,2017-09-01,2018-01-01,2018-01-01,2017-05-02,null,2017-07-21,"US001: PRA Health Sciences, Lenexa, Kansas, United States",,https://ClinicalTrials.gov/show/NCT03137030
439,NCT03137017,A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of a New and a Marketed Tablet Formulation Under Fasted and Fed Conditions in Healthy Adults,,Withdrawn,No Results Available,"Opioid-Related Disorders|Pain, Acute|Pain, Postoperative",Drug: Norco 5Mg-325Mg Tablet|Drug: GRT7014 - Abuse Deterrent Tablet,Maximum Plasma Concentration (Cmax)|Area under the plasma concentration curve from timepoint 0 to t (AUC0-t)|Area under the plasma concentration curve from timepoint 0 to infinity (AUC),Grünenthal GmbH,All,18 Years to 55 Years   (Adult),Phase 1,0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HP7014-01|U1111-1183-5343,2017-09-01,2017-11-01,2017-11-01,2017-05-02,null,2017-07-21,"US001: PRA Health Sciences, Lenexa, Kansas, United States",,https://ClinicalTrials.gov/show/NCT03137017
440,NCT02509312,Prospective Effect of Intravenous Ketorolac on Opioid Use and Complications Following Cesarean Delivery,,"Active, not recruiting",No Results Available,"Analgesia, Obstetrical",Drug: Ketorolac|Drug: Epidural Morphine|Drug: Hydromorphone,"Opioid use|Estimated blood loss (EBL)/Post-operative hemoglobin|Anti-emetic use|Blood pressure|Post-partum Hemorrhage (PPH)|PPH EBL|PPH treatment drugs|Post-partum reoperation|Pain score|Need for opioid side-effect reducing drugs including Diphenhydramine, Nalbuphine and Naloxone.",University Hospitals Cleveland Medical Center,Female,18 Years to 50 Years   (Adult),Phase 4,69,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Ketorolac-1,2016-05-01,2017-12-01,2018-08-01,2015-07-28,null,2018-05-07,"University Hospitals Case Medical Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02509312
441,NCT00907192,Self Reported Deviations From Opioid Analgesic Prescription,,Completed,No Results Available,Advanced Cancers,Behavioral: Personal Interview|Behavioral: Questionnaire,Number of Persons with Advanced Cancer who Self-report Opioid Analgesics Over/Under,M.D. Anderson Cancer Center,All,"18 Years and older   (Adult, Older Adult)",,201,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,2009-0019,2009-05-01,2012-06-01,2012-06-01,2009-05-22,null,2013-06-18,"UT MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00907192
442,NCT02009722,Intrathecal Opioids for Pain Control After Cesarean Delivery: Determining the Optimal Dose,,Completed,Has Results,"Analgesia, Obstetrical|Cesarean Section",Drug: Morphine|Drug: Hydromorphone,Dose of IT Morphine and IT Hydromorphone for Adequate Analgesia (Pain Score Less Than or Equal to 3) in 90% of Patients|Side Effects: Pruritus|Side Effects: Nausea|Side Effects: Sedation|Pruritus|Nausea|Treatment for Nausea|Treatment for Pruritus,Mayo Clinic,Female,"18 Years and older   (Adult, Older Adult)",Phase 4,84,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",13-008490,2014-01-01,2014-12-01,2015-04-01,2013-12-12,2016-05-20,2016-07-25,"Rochester Methodist Hospital, Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02009722
443,NCT00672438,Heritability of Opioid Effects: A Twin Study,,Completed,Has Results,Pain,Drug: Alfentanil|Other: Saline placebo infusion,Heat Pain Threshold|Cold Pain Threshold|Cold Pain Tolerance|Respiratory Rate|Transcutaneous Partial Pressure of Carbon Dioxide|Sedation|Average Nausea|Maximum Nausea|Average Pruritis|Maximum Pruritis|Average Drug Liking|Maximum Drug Liking|Maximum Drug Disliking|Sedation by Patient Report,Martin Angst|SRI International|Stanford University,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,242,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)",SU-04212008-1119|13018,2008-05-01,2010-06-01,2010-06-01,2008-05-06,2016-07-21,2017-01-06,"Stanford University School of Medicine, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT00672438
444,NCT01380197,Choosing Opioid Management for Pain and Analyzing Acute Chest Syndrome (ACS) Rates Equally,COMPARE,Completed,Has Results,Pain|Sickle Cell Disease,Drug: Morphine|Drug: Nubain,Acute Chest Syndrome|Number of Participants Who Experienced Pain Relief,Children's Healthcare of Atlanta|Atlanta Clinical and Translational Science Institute,All,"6 Years to 19 Years   (Child, Adult)",Phase 3,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",09-076,2010-05-26,2014-01-14,2016-10-18,2011-06-27,2015-02-16,2018-02-20,"Children's Healthcare of Atlanta, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT01380197
445,NCT00000244,Effects of Dynorphin 1-13 on Heroin Addiction - 1,,Completed,No Results Available,Opioid-Related Disorders|Substance Withdrawal Syndrome,Drug: Dynorphin 1 - 13,Craving scale,University of Minnesota - Clinical and Translational Science Institute|National Institute on Drug Abuse (NIDA),All,18 Years to 55 Years   (Adult),Phase 2,0,Other|NIH,Interventional,Masking: Double|Primary Purpose: Treatment,NIDA-08067-1|R01DA008067|R01-08067-1,1994-08-01,1997-03-01,1997-03-01,1999-09-21,null,2015-05-27,"U of Minnesota School of Medicine, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00000244
446,NCT01546948,Intraoperative Opioids and Postoperative Recovery After Hepatobiliary or Foregut Surgery,,"Active, not recruiting",No Results Available,Postoperative Pain,Drug: Methadone|Drug: Hydromorphone,Postoperative pain medication used (hydromorphone)|Postoperative pain scores|The presence or absence of nausea and vomiting|Level of sedation,NorthShore University HealthSystem Research Institute,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EH11-232,2011-08-01,2019-12-01,2019-12-01,2012-03-07,null,2018-05-30,"NorthShore University HealthSystem, Evanston, Illinois, United States",,https://ClinicalTrials.gov/show/NCT01546948
447,NCT02735629,Antagonism of Opioid-Induced Respiratory Depression by CX1739 With Preservation of Opioid Analgesia,,Unknown status,No Results Available,Opiate Induced Respiratory Depression,Drug: CX1739 - 300 mg|Drug: CX1739 - 600 mg|Drug: CX1739 - 900 mg|Drug: Placebo,Respiratory depression|Pain tolerance threshold|Maintenance of sedation|The number of patients that experience an adverse drug reaction upon ingestion of CX1739 when used alone or in conjunction with remifentanil|Change in pupil size,RespireRx|Duke University,Male,18 Years to 50 Years   (Adult),Phase 2,18,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",CRTX-05,2016-03-01,2016-08-01,2016-09-01,2016-04-13,null,2016-07-28,"Duke Clinical Research Unit, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT02735629
448,NCT03298269,Behavioral Interventions for Chronic Pain and Opioid-Related Problems,,Recruiting,No Results Available,Chronic Pain,Behavioral: Mindfulness-Oriented Recovery Enhancement|Behavioral: Supportive Counseling,Change in pain symptoms|Change in aberrant drug-related behaviors|Change in emotional distress|Change in opioid dose|Change in opioid craving|Change in interoceptive awareness|Change in reappraisal|Change in savoring|Change in meditative experiences|Change in body sensations,University of Utah,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,1618,2017-09-26,2021-08-01,2021-08-01,2017-10-02,null,2017-10-02,"College of Social Work, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT03298269
449,NCT03271151,Effect of Duloxetine on Opioid Use After Total Knee Arthroplasty,,Enrolling by invitation,No Results Available,"Joint Disease|Pain, Acute|Pain, Chronic",Drug: Cymbalta|Other: Placebo,Opioid Use|Pain Scores|Pain Phenotype,"Hospital for Special Surgery, New York",All,"25 Years to 75 Years   (Adult, Older Adult)",Phase 4,175,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2017-0655,2017-09-28,2018-12-01,2019-12-01,2017-09-01,null,2017-10-18,"Hospital for Special Surgery, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03271151
450,NCT03545893,Overnight Pain Treatment Investigating Opioids vs. Nonopioids,OPTION,Recruiting,No Results Available,Abortion Second Trimester,Drug: Ibuprofen 600 mg|Drug: OxyCODONE 5 Mg Oral Tablet,Maximum pain score,University of Pennsylvania,Female,"18 Years and older   (Adult, Older Adult)",Phase 4,70,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,829723,2018-06-19,2019-02-01,2019-02-01,2018-06-04,null,2018-08-01,"Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03545893
451,NCT02543944,Improving Treatment Outcomes for Prescription Opioid Dependence,GBN,Recruiting,No Results Available,Drug Dependence,Drug: Gabapentin|Drug: Buprenorphine|Drug: Clonidine|Drug: Naltrexone (oral)|Drug: Naltrexone (depot)|Drug: Placebo,Changes in Illicit Opioid-positive Urine samples over time,University of Arkansas|National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,200,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",203970|R01DA039088,2016-02-01,2020-06-01,2020-06-01,2015-09-07,null,2018-04-04,"University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States",,https://ClinicalTrials.gov/show/NCT02543944
452,NCT03592459,Rectal Administration of Opioids Using the Macy Catheter in Reducing Pain in Participants With Advanced Cancer,,Recruiting,No Results Available,Advanced Malignant Neoplasm|Pain,Device: Macy Catheter|Procedure: Pain Therapy|Other: Questionnaire Administration|Other: Survey Administration,Feasibility of using the device 'Macy catheter' for rectal administration of opioids for comfort in cancer patients on palliative care|Episodes of confusion (delirium) assessed by primary caregiver survey|Hospice nurse experience assessed by survey,M.D. Anderson Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2018-0321|NCI-2018-01344|P30CA016672,2018-08-08,2019-12-31,2020-12-31,2018-07-19,null,2018-08-09,"M D Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03592459
453,NCT03437967,Effect of LASER Photobiomodulation Therapy on Chronic Pain and Opioid Weaning,,Not yet recruiting,No Results Available,Chronic Pain,Device: LightForce EXPi,Compliance with Medical Opioid Use Reduction Protocol|Self-reported measure of Pain.|Self-reported measure of Quality of Life.|Self-reported measure of Depression.|Self-reported measure of Anxiety.|Self-reported measure of Sleep Quality.|Urine screening,LiteCure LLC,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,48,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",PBMT for Chronic Pain,2018-03-01,2018-11-01,2019-03-01,2018-02-19,null,2018-02-19,"Sharp Alison DeRose Rehabilitation Center, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT03437967
454,NCT02824276,Sensory Effects of Oral Opioid Treatment in Patients With Chronic Low Back Pain,,Recruiting,No Results Available,Low Back Pain,Drug: Oxycodone or morphine sulfate immediate release (MSIR)|Drug: Placebo Treatment,Changes in Pain Sensitivity (Quantitative Sensory Testing),Brigham and Women's Hospital|National Institute on Drug Abuse (NIDA),All,"25 Years to 65 Years   (Adult, Older Adult)",Phase 1,100,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",2016P000725,2017-01-06,2019-09-30,2019-09-30,2016-07-06,null,2017-07-06,"Brigham and Women's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02824276
455,NCT01875848,Buprenorphine vs. Opioid Dose Escalation Among Patients With Chronic Pain,Bup,Terminated,Has Results,Pain,Drug: buprenorphine/naloxone|Drug: opioid dose escalation,Change in Numeric Rating Scale of Pain Severity|Patient Global Impression of Change (PGIC),VA Office of Research and Development,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PPO 13-184,2013-12-01,2015-06-01,2015-06-01,2013-06-12,2016-12-21,2016-12-21,"VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01875848
456,NCT03579446,Levorphanol as A Second Line Opioid in Reducing Pain in Participants With Cancer,,Not yet recruiting,No Results Available,Malignant Neoplasm|Metastatic Malignant Neoplasm|Pain,Drug: Levorphanol|Other: Questionnaire Administration,Proportion of successful opioid rotation (OR) from morphine equivalent daily dose (MEDD) to levorphanol|Opioid rotation ratio (ORR)|Change of Exercise Self-Efficacy Scale (ESES) pain score|Incidence of levorphanol related side effects|Personalized pain goal (PPG),M.D. Anderson Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,86,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2017-0925|NCI-2018-01139|P30CA016672,2018-09-07,2019-03-07,2019-03-07,2018-07-06,null,2018-07-09,"M D Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03579446
457,NCT03544112,Emergency Department Connection to Care With Buprenorphine for Opioid Use Disorder,ED-CONNECT,Recruiting,No Results Available,Opioid-use Disorder,Behavioral: Employ a multifaceted approach to facilitate clinical protocol implementation|Drug: Initiate BUP (SL-BUP or XR-BUP) in the ED,Receipt of ED-initiated BUP (binary) and will be abstracted from the health record.|Proportion of patients who received ED-initiated BUP who are engaged in formal addiction treatment 30 days after the index ED visit.,New York University School of Medicine|National Institute on Drug Abuse (NIDA),All,"18 Years and older   (Adult, Older Adult)",,390,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,17-01513,2018-06-11,2019-02-01,2019-05-01,2018-06-01,null,2018-07-12,"Valley Regional Healthcare, Claremont, New Hampshire, United States|Catholic Medical Center, Manchester, New Hampshire, United States|Bellevue Hospital Center, New York, New York, United States|New York University School of Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03544112
458,NCT01605539,Acute and Short-term Effects of Cannabidiol Admin on Cue-induced Craving in Drug-abstinent Heroin Dependent Humans,,Completed,Has Results,Opiate Addiction,Drug: Cannabidiol 400|Drug: Cannabidiol 800|Drug: Control,Changes in Cue-Induced In-Clinic Craving (From Baseline to Post-cue or Post-neutral - Via the Visual Analog Scale for Craving (VASC)|Changes in Out-of-Clinic Craving (From Pre-Dose to Approximately 6 Hours Post-Dose for Test Visits I and II; and From Pre-Dose Test Visit I to Pre-Cue Test Visit IV) - Via the Heroin Craving Questionnaire (HCQ)|Vital Signs - Blood Pressure|Visual Analog Scale for Anxiety (VASA)|The Positive and Negative Affect Schedule (PANAS) - Positive Affect Schedule (PAS) Data|The Positive and Negative Affect Schedule (PANAS) - Negative Affect Schedule (NAS) Data|Vital Signs - Heart Rate|Vital Signs - Respiratory Rate|Vital Signs - Temperature,"Hurd,Yasmin, Ph.D.",All,"21 Years to 65 Years   (Adult, Older Adult)",Phase 2,10,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",R21 DA027781(2),2012-05-01,2013-10-01,2013-10-01,2012-05-25,2016-11-28,2016-11-28,"Mount Sinai Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01605539
459,NCT01967381,Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse,,"Active, not recruiting",No Results Available,Methamphetamine Abuse|Methamphetamine Dependence,Drug: Methamphetamine (Desoxyn®),Reinforcing Effects|Subjective Effects|Physiological and Side Effects,University of Kentucky|National Institute on Drug Abuse (NIDA),All,18 Years to 55 Years   (Adult),Early Phase 1,24,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Basic Science",R01DA033394,2013-10-01,2018-09-01,2018-09-01,2013-10-22,null,2018-07-11,"University of Kentucky Medical Center, Lexington, Kentucky, United States",,https://ClinicalTrials.gov/show/NCT01967381
460,NCT00718835,Incentive-based Smoking Cessation for Methadone Patients,,Completed,No Results Available,Cigarette Smoking Among Patients Currently Receiving Methadone or Buprenorphine Treatment for Opioid Dependence,Behavioral: incentive-based contingency management,percent of subjects abstinent during the second week of the two-week monitoring period|mean days of continuous abstinence achieved during the 2-week abstinence monitoring period and mean number days abstinent (non-continuous),University of Vermont Medical Center|National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,170,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R01DA019550,2007-06-01,2013-06-01,2013-06-01,2008-07-21,null,2014-02-21,"Substance Abuse Treatment Center, University of Vermont, Burlington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT00718835
461,NCT02061774,Postoperative Opioid Use and Pain Scores in Patients Undergoing Transforaminal Lumbar Interbody Fusion,,Completed,No Results Available,Low Back Pain,Drug: Acetaminophen|Drug: Placebo comparator,VAS|Sedation|Vital signs,Texas Tech University Health Sciences Center,All,"18 Years and older   (Adult, Older Adult)",Phase 4,29,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",L14-015,2013-10-01,2018-01-11,2018-01-11,2014-02-13,null,2018-04-06,"Texas Tech University Health Science Center, Lubbock, Texas, United States",,https://ClinicalTrials.gov/show/NCT02061774
462,NCT00398034,Analgesic Efficacy of Testosterone Replacement in Hypogonadal Opioid-Treated Chronic Pain Patients: A Pilot Study.,,Unknown status,No Results Available,Pain|Hypogonadism,Drug: Testosterone Gel,"• To determine if testosterone replacement can improve pain control in opioid-treated, hypogonadal men with chronic pain.|In opioid-treated, hypogonadal men with chronic pain, to determine whether testosterone replacement therapy (TRT) will:|reduce the opioid requirement.|improve fatigue|improve depression|improve sexual function.|Improve cognition|To determine the proportion of responders to the analgesic effects of TRT",James J. Peters Veterans Affairs Medical Center|Solvay Pharmaceuticals,Male,18 Years to 60 Years   (Adult),Phase 2,62,U.S. Fed|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,2192-06-049,2006-11-01,null,2008-10-01,2006-11-10,null,2006-11-10,"James J. Peters VAMC, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT00398034
463,NCT02643355,Utility of Olanzapine in the Treatment of Opioid Withdrawal in the ED,,Recruiting,No Results Available,Substance Withdrawal Syndrome,Drug: Olanzapine|Drug: Clonidine,Need for rescue medication for withdrawal symptoms|Clinical Opiate Withdrawal Scale,Minneapolis Medical Research Foundation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,70,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HSR# 15-4004,2015-11-01,2017-11-01,2017-11-01,2015-12-31,null,2017-10-06,"Hennepin County Medical Center, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02643355
464,NCT00497068,Tobacco Use in Opioid Agonist Treated Pregnant Women,ROSE,Completed,No Results Available,Nicotine Dependence,Behavioral: tobacco abstinent contingent|Behavioral: non-contingent|Behavioral: control,Percent of tobacco-free urine samples submitted and Neonatal Abstinence Score|tobacco use measures • treatment compliance• Neonatal measures include:Birth parameters,Johns Hopkins University|National Institute on Drug Abuse (NIDA),Female,18 Years to 50 Years   (Adult),Phase 2|Phase 3,210,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R01DA012403|DPMCDA,2005-01-01,2009-09-01,2010-06-01,2007-07-06,null,2013-03-05,"Johns Hopkins Bayview Medical Center, Center for Addiction and Pregnancy, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00497068
465,NCT00495404,Health Outcomes From Opioid Therapy for Chronic Pain,,Completed,No Results Available,"Chronic Pain|Behavior, Addictive",Behavioral: Physician Treatment Guidelines,"Measure: Pain Relief (Visual Analogue Scales of pain variables and relief measures); Measure: Quality of Life (Oswestry Disability Index); Measure: Addictive Behaviors (Prescription Drug Use Questionnaire, Addiction Behaviors Checklist, Reason for Opioid|Medication Use; Stability of Use; Treatment Satisfaction; Mood; Illness Beliefs; Health Care Utilization",US Department of Veterans Affairs|VA Office of Research and Development,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,135,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Health Services Research,IIR 98-149,2001-08-01,null,2005-03-01,2007-07-03,null,2015-04-07,"VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT00495404
466,NCT01681264,Effect of Guanfacine on Opioid-induced Hyperalgesia (OIH) and Tolerance,,Recruiting,No Results Available,Chronic Pain,Drug: Morphine|Drug: Guanfacine 1mg|Drug: Guanfacine 2mg|Drug: Placebo,Quantitative Sensory Testing (QST)|Heat Pain Threshold|Heat Pain Tolerance|Temporal Pain Summation|Detecting Diffuse Noxious Inhibitory Control (DNIC)|Heat Sensation,Massachusetts General Hospital|National Institutes of Health (NIH)|National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,200,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2013P-001510|1R01DA036564-01,2013-11-01,2018-12-01,2019-03-01,2012-09-07,null,2018-06-13,"Center for Translational Pain Research, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01681264
467,NCT01236521,Care Management for the Effective Use of Opioids,CAMEO,Completed,Has Results,Low Back Pain|Pain,Drug: Pharmacological (PHARM)|Behavioral: Behavioral treatment (BEH),"Brief Pain Inventory Total Score at Baseline and Change Score From Baseline at 3, 6, 9, and 12 Months|Brief Pain Inventory Pain Intensity Score at Baseline and Each Follow-up Time Point|Brief Pain Inventory Pain Interference Scale Score|Pain Catastrophizing Scale|Roland Morris Disability Scale|Patient Health Questionnaire-9|Generalized Anxiety Disorder 7-item (GAD-7) Scale|AUDIT-C|Current Opioid Misuse Measure (COMM)|SF-36 General Health Perception|SF-36 Vitality Scale|SF-36 Social Functioning Scale",VA Office of Research and Development,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,261,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,IIR 10-128,2011-12-01,2015-12-01,2015-12-01,2010-11-08,2018-06-08,2018-07-11,"Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT01236521
468,NCT03567603,Differences in Brain Activity Measures by Electroencephalogram (EEG) in Babies With Opioid Exposure,,Not yet recruiting,No Results Available,Neonatal Abstinence Syndrome,,Percent with neonates with auditory cortical processing deficiencies,University of Rochester,All,up to 20 Days   (Child),,40,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,RSRB#72329,2018-08-01,2019-06-30,2019-07-30,2018-06-25,null,2018-06-26,"University of Rochester Medical Center, Rochester, New York, United States",,https://ClinicalTrials.gov/show/NCT03567603
469,NCT02192398,Effect of Guanfacine on the Reversal of Opioid-induced Hyperalgesia (OIH),,Recruiting,No Results Available,Chronic Pain,Drug: Guanfacine|Drug: Placebo,Quantitative Sensory Testing (QST)|Heat Pain Threshold|Heat Pain Tolerance|Temporal Pain Summation|Detecting Diffuse Noxious Inhibitory Control (DNIC)|Heat Sensation,Massachusetts General Hospital|National Institutes of Health (NIH)|National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,120,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2014P-001377|1R01DA036564-01,2014-09-01,2018-12-01,2019-12-01,2014-07-16,null,2018-03-22,"MGH Center for Translational Pain Research, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02192398
470,NCT02794597,Improving Reproductive Health for Women in Opioid Medication-Assisted Treatment (OMAT),,Recruiting,No Results Available,Contraception,Behavioral: Intervention,Develop a sustainable behavioral patient-centered peer-led sexual health intervention|Assess the feasibility and efficacy of the intervention|Explore the relationship of Health Belief Model and LARC uptake,Denver Health and Hospital Authority|National Institute on Drug Abuse (NIDA),Female,18 Years to 44 Years   (Adult),Not Applicable,200,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,15-1236|1R34DA039381-01A1,2016-08-01,2019-07-01,2019-07-01,2016-06-09,null,2018-03-27,"Denver Health and Hospital Authority, Denver, Colorado, United States",,https://ClinicalTrials.gov/show/NCT02794597
471,NCT01884233,Cell Phone Technology Targeting ART Adherence and Drug Use,TXT-CBT,Unknown status,No Results Available,HIV|Opioid Abuse,Behavioral: Standard Care|Behavioral: Text Messaging CBT (TXT-CBT),Substance Use Measures|HIV Risk|Adherence Measures|Quality of life,"University of California, Los Angeles|National Institute on Drug Abuse (NIDA)",All,"18 Years and older   (Adult, Older Adult)",Phase 2,50,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1R34DA033196,2012-12-01,2016-01-01,2016-01-01,2013-06-21,null,2015-11-13,"UCLA Isap Ocrc, Los Angeles, California, United States|UCLA ISAP Outpatient Clinical Research Center, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT01884233
472,NCT00618631,Effects of Smoking on Opioid Receptor Binding: A PET Study,,Completed,No Results Available,Substance-related Discorder,Drug: Nicotine|Drug: Carfentanil,Changes in carfentanil binding.|Cardiovascular and subjective responses to smoking one cigarette.,National Institute on Drug Abuse (NIDA)|Johns Hopkins University|National Institutes of Health Clinical Center (CC),All,21 Years to 50 Years   (Adult),Phase 1,26,NIH|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Screening,999908060|08-DA-N060,2008-01-17,null,2015-01-08,2008-02-20,null,2018-04-05,"National Institute on Drug Abuse, Baltimore, Maryland, United States|Johns Hopkins Medical Institute, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00618631
473,NCT03135886,Project I Test: Implementing HIV Testing in Opioid Treatment Programs,,Recruiting,No Results Available,HIV/AIDS|Hepatitis C|Substance Use Disorders|Opioid-use Disorder,Other: Information Control|Other: HIV and HCV Testing Practice Coaching Intervention|Other: HIV Testing Practice Coaching Intervention,Proportion of OTP patients HIV tested at 6 months post intervention or control|Proportion of OTP patients HIV tested at 12 months post intervention or control,"Columbia University|National Institute on Drug Abuse (NIDA)|Weill Medical College of Cornell University|University of Miami|Johns Hopkins University|Boston Medical Center|Medical University of South Carolina|Research Foundation for Mental Hygiene, Inc.|San Francisco Department of Public Health|Aspire Health Partners",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,51,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,AAAQ9986|R01DA043130,2017-06-12,2020-08-01,2020-08-01,2017-05-02,null,2018-04-24,"Columbia University Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03135886
474,NCT02673684,"Effects of Neuro-Stim System on Pain, Sleep, and Opioid Use",NSS,Terminated,No Results Available,"Pain (Visceral, Somatic, or Neuropathic)",Device: Experimental NSS|Device: Sham NSS,"Pain Measured via the Defense and Veterans Pain Scale v2.0 (DVPRS)|Modified PROMIS for pain, pain interference, and sleep|Opioid Use",Defense and Veterans Center for Integrative Pain Management|Innovative Health Solutions,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,11,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",390805,2016-02-01,2016-05-01,2016-05-01,2016-02-04,null,2017-02-09,"Walter Reed National Military Medical Center, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02673684
475,NCT02641340,Fentanyl Sublingual Spray in Opioid Naive Participants,,Completed,No Results Available,Pharmacology,Drug: Fentanyl Sublingual Spray|Drug: Fentanyl Citrate IV,"Maximum concentration (Cmax)|Time to reach peak or maximum concentration following drug administration (Tmax)|Area under the concentration-time curve|Apparent elimination rate constant in the terminal phase by non-compartmental analysis|Corresponding half-life (t1/2)|Trough concentration during multiple dosing prior to next dose (Ctrough)|Accumulation ratios|Dose normalized Cmax|Dose normalized AUC|Participants with respiratory depression requiring the use of naloxone|Participants with hypoxia requiring oxygen administration|Participants needing noninvasive respiratory maneuvers (e.g., jaw thrust, bag-valve mask) to improve respiratory status at any point during the study|Participants with hypotension requiring intervention",INSYS Therapeutics Inc,All,18 Years to 55 Years   (Adult),Phase 1,96,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,INS002-15-050,2016-01-01,2016-03-01,2016-03-01,2015-12-29,null,2016-03-30,"Lotus Clinical Research, Inc., Pasadena, California, United States",,https://ClinicalTrials.gov/show/NCT02641340
476,NCT00662363,Lubiprostone (Amitiza®) Vs. Standard Care in Opioid-induced Constipation After Surgery in Inpatient Rehabilitation,,Completed,Has Results,Constipation,Drug: Lubiprostone|Drug: Senna,Change in Patient Assessment of Constipation (PAC) - Symptoms (Sym)|Change in Patient Assessment of Constipation - Quality of Life,"Shirley Ryan AbilityLab|Takeda Pharmaceuticals North America, Inc.",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,64,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",STU00001168,2008-04-01,2011-10-01,2011-10-01,2008-04-21,2013-02-21,2013-03-06,"Rehabilitation Institute of Chicago, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00662363
477,NCT03375216,Quantitative Sensory Testing in Chronic Pain Patients Undergoing Opioid Treatment and Opioid Tapering,,Recruiting,No Results Available,Analgesic Drug Dependence|Sensory Deficit,"Behavioral: sensory testing (Heat, cold, and pressure)|Behavioral: Promis Survey",Heat threshold measurements|Cold threshold measurements|Pressure threshold measurements|PROMIS surveys,"The University of Texas Medical Branch, Galveston",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,90,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,17-0195,2017-12-22,2018-12-18,2020-12-18,2017-12-15,null,2018-07-06,"University of Texas Medical Branch, Galveston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03375216
478,NCT01246401,Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations,NewHope,Completed,Has Results,HIV|AIDS|Opioid Dependence|Drug Dependence,Drug: Extended-Release Naltrexone,Participants Who Had Undetectable HIV-1 RNA Levels at Less Than 400 Copies/mL at Six Month|Particpants Who Had Undetectable HIV-1 RNA Levels at Less Than 50 Copies/mL|CD4 Cell Count (Cells/mL)|Time to Opioid Relapse or End of Intervention|Addiction Severity|Craving for Opioids|Antiretroviral Therapy (ART) Adherence 100%|Participants With Opiate Abstinence Via By Doing Urine Toxicology Test|Opioid Abstinence at 6 Months for Those With More Than 4 Injections|ART Adherence for 4 or More Injections XR-NTX Versus Placebo and 3 or Less Injections of XR-NTX,Yale University|Baystate Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,151,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1007007169,2011-03-01,2016-03-01,2016-07-01,2010-11-23,2017-07-17,2017-07-17,"Yale University, Hartford, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Baystate Medical Center, Springfield, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01246401
479,NCT01749826,Inflammatory Responses to Acute and Chronic Opioid Exposure in Humans,,Suspended,No Results Available,Inflammation,Drug: Morphine Sulfate,Changes in Cytokine Release|Laser Doppler Images|Peltier Device-Heat Pain|Mechanical Pain Stimuli,Stanford University,All,18 Years to 60 Years   (Adult),Not Applicable,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention",SU-10212009-4201,2010-01-01,2013-07-01,2016-12-01,2012-12-17,null,2016-02-10,"Stanford University School of Medicine, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT01749826
480,NCT00499460,Effects of Garlic Supplements on Opioids in Healthy Volunteers,,Completed,Has Results,"Healthy, No Evidence of Disease",Dietary Supplement: garlic powder tablets|Drug: oxycodone,Oxycodone Oral Clearance|Cold Pressor Tolerance AUC|Somatic Side Effects Total Score|Cognitive-Affective Side Effects Total Score|Oral Midazolam Test|Oral Digoxin Test,Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI),All,21 Years to 45 Years   (Adult),Phase 4,15,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,2040.00|IR-6130|CDR0000551927|R21CA118334,2006-11-01,2008-08-01,2008-08-01,2007-07-11,2017-04-07,2017-04-07,"Fred Hutchinson Cancer Research Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00499460
481,NCT02929589,Ibuprofen to Decrease Opioid Use and Post-operative Pain Following Unilateral Inguinal Herniorrhaphy,,Not yet recruiting,No Results Available,Pain|Hernia,Drug: Ibuprofen|Drug: Opioid Medication|Drug: Placebo|Drug: Ibuprofen + Opioid medication,The primary outcome measure is morphine equivalent units to measure pain intensity difference and total pain relief.,Mike O'Callaghan Military Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 3,185,U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",FWH20160095H,2018-04-01,2018-12-01,2018-12-01,2016-10-11,null,2018-02-08,"Mike O'Callaghan Federal Medical Center, Nellis Air Force Base, Nevada, United States",,https://ClinicalTrials.gov/show/NCT02929589
482,NCT02558010,Perioperative Methadone Use to Decrease Opioid Requirement in Pediatric Spinal Fusion Patients,,Recruiting,No Results Available,Scoliosis|Pain,Drug: Methadone|Other: Normal Saline|Drug: Morphine,"Post-operative Pain Score on the verbal numeric pain scale|Itching as assessed by number of doses of benadryl required post-operatively|Patient satisfaction as assessed by the question ""How satisfied were you with your pain management?""|Nausea as assessed by number of doses of ondansetron required post-operatively|Constipation as assessed by number of days to first bowel movement",Medical College of Wisconsin,All,10 Years to 17 Years   (Child),Phase 3,44,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CHW-Methadone-001,2016-05-01,2018-08-31,2018-12-31,2015-09-23,null,2018-03-19,"Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02558010
483,NCT01775995,Meditation-CBT for Opioid-treated Chronic Low Back Pain,,Completed,Has Results,Chronic Pain|Low Back Pain,Behavioral: Meditation-CBT Intervention + Usual Care|Other: Usual Care Alone,Health-Related Quality of Life: Averaged Pain Severity|Health-Related Quality of Life: Physical Function|Opioid Dose,"University of Wisconsin, Madison",All,"21 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,35,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2012-0656,2013-01-01,2013-12-01,2013-12-01,2013-01-25,2014-12-04,2016-05-16,"University of Wisconsin-Madison, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT01775995
484,NCT01542645,The Effect of Choice of Intraoperative Opioid on Postoperative Pain,,Completed,Has Results,"Pain, Postoperative|Chronic Pain",Drug: Methadone|Drug: Fentanyl,Total Opioid Consumption in the Postoperative Period|Postoperative Pain Scores|Chronic Postoperative Pain Scores|Marker of Myocardial Injury (Troponin I),NorthShore University HealthSystem Research Institute,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 4,164,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ENH10-256,2010-09-01,2013-11-01,2014-09-01,2012-03-02,2014-05-26,2014-10-02,"NorthShore University HealthSystem, Evanston, Illinois, United States",,https://ClinicalTrials.gov/show/NCT01542645
485,NCT03359031,Effects of Perioperative Patient Education Regarding Compartment Syndrome on Post-operative Opioid Consumption,,Enrolling by invitation,No Results Available,Compartment Syndrome of Leg,Other: Patient education,narcotic consumption,Rothman Institute Orthopaedics,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,134,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2017-Krieg,2017-11-13,2018-11-01,2018-11-01,2017-12-02,null,2017-12-02,"Rothman Institute, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03359031
486,NCT02437188,Preventing Persistent Post-Surgical Pain and Opioid Use In At-Risk Veterans: Effect of ACT,PreACT,Unknown status,No Results Available,Persistent Post-surgical Pain|Acceptance and Commitment Therapy|Substance Use Disorder,Behavioral: ACT (Acceptance and Commitment Therapy),"Number and % of veterans willing and able to receive the ACT workshops and individual ""booster"" sessions|Amount of pain|Amount of opioid use|Length of pain|Length of opioid use|Barriers and facilitators to receiving the ACT intervention and utilizing the skills taught",University of Iowa,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,72,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,R34AT008349-01,2015-02-01,2016-08-01,2016-08-01,2015-05-07,null,2015-05-07,"Iowa City VAMC, Iowa City, Iowa, United States",,https://ClinicalTrials.gov/show/NCT02437188
487,NCT01563718,Pre-Release VIVITROL for Opioid Dependent Inmates,,Completed,No Results Available,Substance-Related Disorders,Drug: naltrexone for extended release injectable suspension,Proportion of opioid-free days,"Rhode Island Hospital|National Institute on Drug Abuse (NIDA)|Alkermes, Inc.",All,18 Years to 60 Years   (Adult),Phase 4,26,Other|NIH|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RIH VIVITROL -01|3R01DA024549-03S1,2012-03-01,2015-08-01,2015-08-01,2012-03-27,null,2015-10-22,"Rhode Island Hospital, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT01563718
488,NCT03445988,Cognitive Behavioral Therapy and Chronic Pain Self-Management Within the Context of Opioid Reduction,,Recruiting,No Results Available,Chronic Pain,Behavioral: Cognitive Behavioral Therapy|Behavioral: Chronic Pain Self Management Program|Other: Usual Care,Opioid use|Patient-Reported Outcomes Measurement Information Systems (PROMIS) Pain Intensity,Stanford University|Patient-Centered Outcomes Research Institute,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,1365,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,44918,2018-07-24,2022-11-01,2022-11-01,2018-02-26,null,2018-08-03,"Stanford University, Palo Alto, California, United States",,https://ClinicalTrials.gov/show/NCT03445988
489,NCT01673594,Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist,,Completed,Has Results,ADHD|Stimulant-Induced Euphoria,Drug: SODAS MPH|Drug: Naltrexone,Change in Score on AISRS From Baseline to Week 6|Safety,Massachusetts General Hospital|United States Department of Defense,All,18 Years to 30 Years   (Adult),Phase 4,37,Other|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2012-P-000918,2012-09-01,2015-06-01,2015-06-01,2012-08-28,2016-11-30,2016-11-30,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01673594
490,NCT03390283,"A Survey of Parent/Caregiver Practices on the Storage, Use, and Disposal of Opioids in a Comprehensive Cancer Center",,Recruiting,No Results Available,Other Specified Personal Exposures and History Presenting Hazards to Health,Behavioral: Survey,"Proportions of Unsafe Storage of Opioids|Associations Between the Unsafe Use, Storage, and Disposal of Opioids",M.D. Anderson Cancer Center,All,"18 Years and older   (Adult, Older Adult)",,150,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2017-0396,2017-12-20,2019-12-01,2020-12-01,2018-01-04,null,2018-02-08,"University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03390283
491,NCT02470728,Optimal Management of Pain in Hospitalized Patients - Opioid Tolerant Populations.,,Recruiting,No Results Available,Pain|Acute Pain|Postoperative Pain,Other: New Clinical Pathway,Returns to Acute Care|Opioid Analgesic Use|Opioid Tolerance Status|Pain at Discharge|Hospital Length of Stay|Latency to Hospital Readmission|Healthcare Expenditures|Use of Rescue Drugs,"Duke University|Massachusetts Institute of Technology|University of California, Irvine",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,Pro00076402,2016-01-01,2024-11-01,2025-11-01,2015-06-12,null,2018-06-25,"University of California, Irvine Medical Center, Orange, California, United States|Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT02470728
492,NCT00825370,Protocolized vs Discretionary Use of Opioids in Acute Pain,,Completed,Has Results,Pain,Drug: Hydromorphone|Drug: IV opioid,Percentage of Patients With Successful Treatment|Percentage of Patients Who Did Not Want Additional Pain Medication at 15 Minutes|Percentage of Patients Who Did Not Want Additional Pain Medication at 60 Minutes|Changes in Pain Intensity From Baseline to Other Pain Assessment Times (15 and 60 Minutes).,Montefiore Medical Center,All,21 Years to 64 Years   (Adult),Phase 3,350,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MMC 0808278,2008-10-01,2009-05-01,2009-05-01,2009-01-21,2018-04-19,2018-06-12,"Montefiore Medical Center Emergency Department, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT00825370
493,NCT01967433,Diphenhydramine as an Adjunctive Sedative in Patients on Chronic Opioids,,"Active, not recruiting",No Results Available,Colonoscopy|Adjunct Anesthesia Medication,Drug: Diphenhydramine|Drug: Placebo,Dosage of Fentanyl and Midazolam|Quality of sedation|Duration of Procedure|Adverse events|24 hour follow up,University of Oklahoma,All,18 Years to 64 Years   (Adult),Phase 4,150,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care",DAASIPCO,2013-12-01,2017-06-01,2017-06-01,2013-10-22,null,2017-04-11,"Veterans Affairs Medical Center, Oklahoma City, Oklahoma, United States",,https://ClinicalTrials.gov/show/NCT01967433
494,NCT02846649,A Text Messaging Program to Help Prevent Early Opioid Relapse,PIER1,Completed,No Results Available,Substance-Related Disorders,Behavioral: PIER,SMS query completion rate|Number of intentional opioid uses|Number of opioid overdoses|Ratings of usefulness,University of Pittsburgh,All,18 Years to 60 Years   (Adult),Not Applicable,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,PRO15120183,2016-08-01,2016-12-01,2016-12-01,2016-07-27,null,2017-05-05,"University of Pittsburgh Medical Center Emergency Department, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02846649
495,NCT02840240,Effect of Gabapentin Enacarbil on Opioid Consumption and Pain Scores,,Recruiting,No Results Available,Pain,Drug: Gabapentin enacarbil|Drug: Placebo,Time weighted average pain score in numerical rating scores|Cumulative postoperative opioid consumption,The Cleveland Clinic,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",15-479,2016-01-01,2019-01-01,2019-01-01,2016-07-21,null,2018-04-06,"Cleveland Clinic, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02840240
496,NCT00593125,Levetiracetam (Keppra) Tolerability in Cocaine Abusing Methadone-maintained Patients.,Keppra,Completed,No Results Available,Cocaine Dependence|Opioid Dependence,Drug: levetiracetam,Medication emergent side-effects|Thrice weekly urine toxicology|Weekly self-report of cocaine and opioid use,Yale University|National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,15,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yale-0508000534|UBC,Inc|VA HSS GG 0004",2007-01-01,2007-08-01,2008-08-01,2008-01-14,null,2017-01-12,"VA CT Healthcare System, West Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00593125
497,NCT01006707,Functional Magnetic Resonance Imaging of Opioid Withdrawal in Healthy Human Volunteers,,Completed,Has Results,Substance-Related Disorders,Drug: Ondansetron,Brain Regions With Increases or Decreases in Amplitude of Low Frequency Fluctuations (ALFF) Associated With Ondansetron Administration|Objective Opioid Withdrawal Scale Score 5 Minutes Following Ondansetron or Placebo Administration|Objective Opioid Withdrawal Scale Score 15 Minutes Following Ondansetron or Placebo Administration|Subjective Opioid Withdrawal Scale (SOWS) Score 20 Minutes Following Ondansetron or Placebo Administration,Stanford University,Male,18 Years to 35 Years   (Adult),Not Applicable,15,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",SU-10212009-4200,2010-11-01,2013-07-01,2013-07-01,2009-11-03,2017-11-17,2017-11-17,"Stanford University School of Medicine, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT01006707
498,NCT00319241,Relational Parenting Group for Opioid-Addicted Mothers,,Completed,No Results Available,Substance Abuse|Child Abuse,Behavioral: Parenting Intervention,Mother's risk for maltreating her child|Mother's affective and instrumental parenting|Mother's psychosocial adjustment|Children's psychosocial adjustment|Mother's substance abuse,"Yale University|APT Foundation, Inc.",Female,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R01DA011498,1998-01-01,2003-10-01,2003-11-01,2006-04-27,null,2008-06-18,"The APT Foundation, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00319241
499,NCT01825655,Study of Using Long Acting Antihistamine to Treat Opioid Induced Itching,,Terminated,No Results Available,Pruritus,Drug: Cetirizine|Drug: Placebo or sugar pill,Itch score,Virginia Commonwealth University,All,"6 Years to 18 Years   (Child, Adult)",Phase 4,3,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",HM20003779|IIS2012-003,2014-09-01,2017-11-01,2017-11-01,2013-04-05,null,2017-11-08,"Children's Hospital of Richmond at VCU, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01825655
500,NCT02151513,Pilot Study on the Effect of Intrathecal Opioids on Immune Function in Humans With Cancer Pain,,Enrolling by invitation,No Results Available,Cancer-associated Pain,Device: Intrathecal Pump Placement,Change in biomarker values|Quality of Life,University of Utah,All,"18 Years and older   (Adult, Older Adult)",,30,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,IRB_00057738,2014-04-01,2018-05-01,2018-05-01,2014-05-30,null,2017-11-07,"Huntsman Cancer Hosptial, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT02151513
501,NCT02075411,Opioid Use in Single Shot Nerve Block vs Continuous Peripheral Nerve Infusion in Anterior Cruciate Ligament (ACL) Repair,,Terminated,Has Results,Injury of Anterior Cruciate Ligament,Drug: bupivacaine|Device: continuous perineural infusion catheter,Opioid Pain Medication|Duration of Analgesia in the Single Injection Nerve Block and the Continuous Peripheral Neural Infusion Group,Children's Hospital of Philadelphia,All,"14 Years to 18 Years   (Child, Adult)",Phase 3,1,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,12-009320,2014-03-01,2015-02-01,2015-02-01,2014-03-03,2016-05-18,2016-05-18,"The Children's Hospital Of Philadelphia, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02075411
502,NCT02459964,Compare Fentanyl Nasal Spray With Intravenous Opioids to Treat Severe Pain,,"Active, not recruiting",No Results Available,Advanced Cancers|Pain,Drug: Fentanyl Nasal Spray|Drug: Hydromorphone Hydrochloride|Behavioral: Phone Call,Non-Inferiority of Nasal Fentanyl versus Hydromorphone Hydrochloride: mean change in Numeric Rating Scale (NRS) pain scores|Change in Numeric Rating Scale (NRS) Pain Scores,M.D. Anderson Cancer Center,All,"Child, Adult, Older Adult",Phase 4,84,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2015-0086|NCI-2015-01509,2015-09-14,2019-09-01,2019-09-01,2015-06-02,null,2017-09-21,"University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02459964
503,NCT03088306,Improving Pain and Reducing Opioid Use (IPaRO) in Lumbar Spine Surgery Patients,IPaRO,Recruiting,No Results Available,Lumbar Spinal Stenosis|Lumbar Spinal Instability|Lumbar Spine Degeneration,Drug: Standard analgesia use [Oxygen]|Drug: Standard analgesia use [Hydromorphone]|Drug: Standard analgesia use [Volatile Anesthesia]|Drug: Standard analgesia use [Fentanyl]|Drug: Multi-modal pain management [Acetaminophen + Gabapentin]|Drug: Multi-modal pain management [Fentanyl]|Drug: Multi-modal pain management [Intravenous Ketamine]|Drug: Multi-modal pain management [Valium + Gabapentin],"Number of participants undergoing lumbar spine surgery with complete follow-up|Patient controlled analgesia (PCA) pump use|Opioid medication use|Patient Reported Outcomes Measurement Information System (PROMIS) Pain|PROMIS Physical Function|PROMIS Fatigue|PROMIS Anxiety|PROMIS Depression|PROMIS Sleep Disturbance|PROMIS Satisfaction with Social Roles|Health status (Medical Outcome Study Short Form 12, version 2)|Oswestry Disability Index (ODI)",Johns Hopkins University|North American Spine Society,All,"18 Years to 100 Years   (Adult, Older Adult)",Early Phase 1,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",IRB00113816,2017-07-01,2018-05-31,2018-07-31,2017-03-23,null,2018-06-29,"Johns Hopkins University School of Medicine, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT03088306
504,NCT02324933,Post-Operative Pain Control in Opioid Tolerant Patients: Fentanyl Challenge Protocol Versus Standard of Care,,Withdrawn,No Results Available,"Pain, Postoperative",Drug: Fentanyl,Pain Score|Events requiring intervention for respiratory depression|Number of dose adjustments required,Bassett Healthcare,All,"18 Years and older   (Adult, Older Adult)",Phase 4,0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1064,2014-08-01,2016-01-01,null,2014-12-24,null,2015-11-02,"Bassett Healthcare Network, Cooperstown, New York, United States",,https://ClinicalTrials.gov/show/NCT02324933
505,NCT02290223,Patient Activation to Address Chronic Pain and Opioid Management in Primary Care,,"Active, not recruiting",No Results Available,Chronic Pain,Behavioral: Behavioral Based Treatment Model,Patient Activation|Satisfaction with care|Patterns of opioid use and long-term goals for opioid use|Opioid Misuse|Pain coping|Health Care Utilization|Self-Efficacy|Pain Severity and Functional Status.|Quality of Life|Patient Provider Communication,Kaiser Permanente|Patient-Centered Outcomes Research Institute,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,377,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CN-14-1928-H,2015-06-01,2017-08-06,2018-09-01,2014-11-14,null,2017-09-07,"Kaiser Permanente, San Jose Medical Center, San Jose, California, United States|Kaiser Permanente, Santa Clara Medical Center, Santa Clara, California, United States",,https://ClinicalTrials.gov/show/NCT02290223
506,NCT03274453,A Comparison of Ketamine Infusion Versus Placebo in Opioid Tolerant and Opioid Naive Patients After Spinal Fusion,,Completed,Has Results,Spinal Fusion,Drug: Ketamine|Drug: Saline,Hydromorphone Use/24 Hours postOP in mg/kg,New York University School of Medicine,All,"16 Years and older   (Child, Adult, Older Adult)",Phase 2,129,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",12-02202,2012-11-01,2014-11-01,2017-09-01,2017-09-07,2018-06-14,2018-06-14,"New York University School of Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03274453
507,NCT02639273,Title: Effect of Opioid Receptor Modulation on Alcohol Self-Administration and Neural Response to Alcohol Cues in Heavy Drinkers: Role of OPRM1 Gene Variation,,Recruiting,No Results Available,Alcohol Drinking,Drug: Nalmefene|Other: Placebo,"Nalmefene-induced BOLD signal changes in neural regions associated with alcohol reward processing, including ventral striatum, amygdala, and insula|Nalmefene-induced changes in IV alcohol self-administration|Nalmefene-induced BOLD signal changes in neural processing of aversive stimuli during fMRI|Genotypic modulation (at the OPRM1 118 location) of Nalmafene's effects on primary outcome measures (BOLD signal change during alcohol reward processing and IV alcohol self-administration).",National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institutes of Health Clinical Center (CC),All,21 Years to 60 Years   (Adult),Phase 1,60,NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other",160037|16-AA-0037,2016-05-11,2018-07-31,2020-12-31,2015-12-24,null,2018-07-06,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02639273
508,NCT01576276,A Brain Imaging Study of Opioid (Morphine) and Non-opioid (Ketorolac) Conditioning Effects,,Completed,Has Results,Healthy Controls,Radiation: Integrated MR-PET scan|Drug: Ketorolac,fMRI Signal Changes|Pain Ratings,Massachusetts General Hospital,All,21 Years to 50 Years   (Adult),Not Applicable,51,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other,2011P000358,2012-04-01,2017-02-01,2017-02-01,2012-04-12,2018-05-28,2018-06-29,"Massachusetts General Hospital, Charlestown, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT01576276/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01576276
509,NCT02940509,Ketamine and Magnesium in Post-operative Pain Control in Patients Treated With Opioids,,Recruiting,No Results Available,Chronic Pain,Drug: Ketamine plus Magnesium sulfate|Drug: Placebo,Post-operative pain score using the Numeric Rating Scale (NRS)|Post-operative opioid use|Recovery Questionnaire|Intraoperative fentanyl use|Nausea Scores using PONV Impact Scale Score|Length of Hospital Stay,Milton S. Hershey Medical Center,Female,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,128,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",STUDY00006048,2017-07-01,2020-03-01,2020-04-01,2016-10-21,null,2018-06-20,"Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02940509
510,NCT02541396,A Study Of The Effectiveness Of Wafermine Alone And In Combination With Opioids In Subjects Undergoing Bunionectomy,,Completed,No Results Available,Acute Pain,Drug: Wafermine|Drug: Oxycodone|Drug: Placebo,"Total Pain Relief (TOTPAR)|Percent with maximum Pain Relief|Proportion of Subjects requiring ""Rescue Medication""|Time to onset of perceptible and meaningful pain relief|Time to onset of complete pain relief (Peak Relief)|Time to maximum reduction in pain intensity|Time for pain intensity to return to baseline|Time to rescue medication|Percentage of Maximum Total Pain Relief (TOTPAR)|Sum of Pain Intensity Differences (SPID)|Responder Rates (30% and 50%)|Safety (treatment emergent adverse events, significant changes in physical examination findings as well as vital sign measurements)|Tolerability (judged by subject answers on oral symptoms questionnaire)",iX Biopharma Ltd.|Jean Brown Research,All,"18 Years and older   (Adult, Older Adult)",Phase 2,72,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",KET009,2015-10-01,2015-12-01,2015-12-01,2015-09-04,null,2016-02-23,"Jean Brown Research, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT02541396
511,NCT01498510,"Web-based Cognitive-behavior Therapy (CBT) for Opioid-treated, Chronic Pain Patients With Aberrant Behavior",WebCBTPain,Completed,No Results Available,Chronic Pain,Behavioral: Web-based CBT for chronic pain,"pain severity, as measured by the Multidimensional Pain Inventory (MPI)|pain interference, as measured by the Multidimensional Pain Inventory (MPI)|aberrant drug-related behavior, assessed via the Current Opioid Misuse Measure (COMM)|pain catastrophizing, measured by the Pain Catastrophizing Scale (PCS)|Emergency Department visits for pain","National Development and Research Institutes, Inc.|National Institute on Drug Abuse (NIDA)|Beth Israel Medical Center",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,110,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,WebCBTPain618|R01DA026887,2012-02-01,2014-12-01,2015-01-01,2011-12-23,null,2017-05-25,"Mount Sinai Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01498510
512,NCT01222091,Study on the Effect of a Beta Blocker on Increased Sensitivity to Pain in Humans Caused by Opioids,,Completed,Has Results,Hyperalgesia,Drug: Propranolol|Drug: Placebo to Match Propranolol|Drug: Remifentanil,"Percent Change From Baseline in Size (Area) of Secondary Hyperalgesia After Cessation of Remifentanil Infusion, a Measure of Opioid-induced Hyperalgesia (OIH).|Objective Opioid Withdrawal Scale (OOWS)",Stanford University,Male,18 Years to 45 Years   (Adult),Phase 2,10,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",SU-10062010-7050,2009-02-01,2011-05-01,2011-06-01,2010-10-18,2018-06-15,2018-06-15,"Stanford University School of Medicine, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT01222091
513,NCT03401450,Optimal Location of Nerve Block to Minimize Perioperative Opioid Administration in ACL Surgery: Comparing True Adductor Canal to Proximal Block,,Recruiting,No Results Available,ACL Surgery,Drug: ACB within true AC with bupivacaine 0.5% 20cc|Drug: ACB proximal to true AC with bupivacaine 0.5% 20cc,Total opioid consumption intraop measured by amount of morphine administered|Total opioid consumption postop by amount of morphine administered,New York University School of Medicine,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,17-01602,2018-02-01,2020-03-01,2020-03-01,2018-01-17,null,2018-02-06,"New York University School of Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03401450
514,NCT02951884,Effect of Local Anesthetic Injection and Hemarthrosis Aspiration on Pain and Narcotic/Opioid Analgesia Use-Tibial Plateau Fractures,,Recruiting,No Results Available,Tibial Fractures|Pain|Analgesia|Aspiration,Procedure: Aspiration Knee Joint|Drug: Bupivacaine with Epinephrine,Numerical Rating Scale (NRS) pain scores|Visual Analog Scale (VAS)|Use of supplemental analgesia (pain medicine),Loyola University,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 4,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,208755,2017-09-02,2019-12-01,2020-12-01,2016-11-01,null,2017-12-11,"Loyola University Medical Center, Maywood, Illinois, United States",,https://ClinicalTrials.gov/show/NCT02951884
515,NCT00945919,A Pilot Study of Ultra Rapid Opioid Rotation and Titration of Oxymorphone,,Unknown status,No Results Available,Chronic Nociceptive Pain|Neuropathic Pain|Non-cancer Pain,Drug: Oxymorphone ER,The safety of rapid Opioid rotation,Icahn School of Medicine at Mount Sinai|Endo Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,12,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,GCO# 08-1423,2009-07-01,2010-12-01,2011-05-01,2009-07-24,null,2009-07-24,"Mount Sinai School of Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00945919
516,NCT02342977,Effects of Lacosamide on Post-operative Opioid Requirements After a Total Hip Arthroplasty:,,Withdrawn,No Results Available,Osteoarthritis|Rheumatoid Arthritis|Avascular Necrosis,Drug: Placebo|Drug: Lacosamide,Opioid use in Post anesthesia care unit|Pain scores|Nausea and Vomiting|Total opioid use|Time to PACU discharge readiness|Pain scores and opioid use at 3 month discharge|Time to hospital discharge|Possible side effects from Lacosamide,Indiana University School of Medicine|VA Office of Research and Development|Indiana University,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,0,Other|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",1408905316,2014-11-01,2016-08-01,2016-08-01,2015-01-21,null,2016-08-26,"Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT02342977
517,NCT01761110,Pilot Test of a Community-based Buprenorphine Treatment Intervention,,Completed,No Results Available,Opioid Dependence|Injection Drug Use,Behavioral: Community-based buprenorphine treatment (CBBT) intervention,initiation of buprenorphine treatment|opioid use,"Albert Einstein College of Medicine, Inc.|National Institute on Drug Abuse (NIDA)|The City University of New York|Washington Heights Corner Project",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,77,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2012-381|R34DA031066,2012-12-01,2014-02-01,2014-02-01,2013-01-04,null,2018-04-23,"Washington Heights Corner Project, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01761110
518,NCT03031340,Evaluating the Role of Pregabalin in Reducing Opioid Requirement in Spinal Fusion Surgeries of Two or More Vertebrae,,Terminated,No Results Available,Spinal Fusion,Drug: Pregabalin|Other: placebo,Postoperative opioid requirement|Pain using the visual analog scale (VAS) pain score|Incidence of 48 hours post operative nausea and vomiting|Post operative cognitive function|Pre-operative anxiety|Anesthesia satisfaction,Montefiore Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 3,3,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",11-01-004,2012-05-01,2012-09-01,2012-09-01,2017-01-25,null,2018-03-05,"Montefiore Medical Center, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT03031340
519,NCT00275249,Evolution of Analgesic Tolerance With Opioids,,Completed,No Results Available,Chronic Pain,Drug: levorphanol,,"University of California, San Francisco",All,"21 Years to 80 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double,H5612-23841,2001-03-01,2004-10-01,2005-12-01,2006-01-11,null,2011-04-14,"UCSF Pain Clinical Research Center, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT00275249
520,NCT00693160,Effect of Spinal Ketorolac After Acute Opioid Exposure,,Terminated,Has Results,Healthy,Drug: ketorolac|Drug: placebo|Drug: remifentanil|Drug: Capsaicin,Hyperalgesia|Cerebrospinal Fluid (CSF) Prostaglandin E2 (PGE2) Concentration,Wake Forest University|National Institute of General Medical Sciences (NIGMS)|Wake Forest University Health Sciences,All,18 Years to 55 Years   (Adult),Phase 2,30,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",IRB00002457|GM48085,2007-12-01,2010-10-01,2011-01-01,2008-06-06,2014-04-14,2017-11-08,"Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00693160
521,NCT00109941,Opioid Growth Factor in Treating Patients With Advanced Pancreatic Cancer That Cannot Be Removed By Surgery,OGF,Completed,No Results Available,Pancreatic Cancer,"Biological: opioid growth factor|Biological: metenkephalin, OGF-opioid growth factor","Survival|Response (progressive disease, stable disease, partial response, complete response)|Tumor size|Quality of life|Depression|Opioid growth factor markers",Jill P. Smith|Penn State University,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,25,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDR0000425404|FD-R-0002391|M01RR010732,2003-10-01,2007-09-01,2009-04-01,2005-05-04,null,2013-05-17,"Penn State Cancer Institute at Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00109941
522,NCT00656942,Pain Responses in Patients on Long-Term Opioid Therapy for Chronic Pain,,"Active, not recruiting",No Results Available,Chronic Pain,Device: Quantitative Sensory Testing (QST),Response to warm/cold temperature,Massachusetts General Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",,419,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,2003P 000110|MGH Fund # 1200-204727,2006-07-01,2013-10-01,2018-12-01,2008-04-14,null,2018-08-15,"MGH Center for Translational Pain Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00656942
523,NCT01402375,Comparing the Efficacy of Oral Opioids for Outpatient Acute Pain Management After ED Discharge Discharge,,Completed,Has Results,Analgesia After ED Discharge for Extremity Injuries,Drug: Hydrocodone (first trial)|Drug: Codeine (first trial)|Drug: Oxycodone (for second trial)|Drug: Codeine (for second trial)|Drug: Oxycodone (third trial)|Drug: Hydrocodone (third trial),Difference in Pain Intensity Score Before and After Last Dose.|Overall Satisfaction With the Pain Medicine,Montefiore Medical Center,All,21 Years to 64 Years   (Adult),Phase 3,720,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care",11-02-066,2012-01-01,2014-11-01,2014-11-01,2011-07-26,2018-05-01,2018-05-01,"Montefiore Medical Center, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT01402375
524,NCT00980044,Efficacy of Extended Release Tramadol for Treating Prescription Opioid Withdrawal,,Completed,Has Results,Substance Withdrawal Syndrome,Drug: Tramadol|Drug: Placebo,Subjective Opioid Withdrawal Total Adjective Score|Total Number of Breakthrough Withdrawal Medication Doses Taken Week 1|Subjective Opioid Withdrawal Adjective Total Score Week 2|Total Number of Breakthrough Withdrawal Medication Doses Taken Week 2,Michelle Lofwall|National Institute on Drug Abuse (NIDA)|University of Kentucky,All,18 Years to 55 Years   (Adult),Phase 2|Phase 3,53,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",09-0489|R01DA027068,2009-10-01,2012-02-01,2012-03-01,2009-09-18,2014-12-03,2017-04-05,"University of Kentucky, Lexington, Kentucky, United States",,https://ClinicalTrials.gov/show/NCT00980044
525,NCT02977286,Naloxegol to Prevent Lower Gastrointestinal Paralysis in Critically Ill Adults Administered Opioids,,Recruiting,No Results Available,Constipation,Drug: Naloxegol Oral Tablet|Drug: Placebo Oral Tablet|Drug: Docusate Sodium 100 Mg oral capsule [Colace]|Drug: Senna 217 Mg Oral Tablet|Drug: Polyethylene Glycols|Drug: Bisacodyl 10 mg Suppository|Drug: Magnesium Citrate Oral Liquid Product|Drug: Methylnaltrexone,Time to first spontaneous bowel movement (SBM) administration|Time to first SBM|ICU days without a SBM|Occurrence of lower GI tract paralysis (≥3 days without a SBM)|Average daily opioid requirement [in IV fentanyl equivalents (mcg)]|Daily characterization of each SBM for size and consistency|Daily characterization of use of the study laxative protocol|Enteral nutrition administered/% of daily goal reached|Daily fluid balance|Daily maximal pain scale score|Daily maximal Sedation Assessment Scale (SAS) score|Daily presence of delirium using the Intensive Care Delirium Screening Checklist (ICDSC)|Occurrence of lower GI tract paralysis requiring GI/surgical consultation|Days without mechanical ventilation support and duration of ICU stay|Abdominal pressure measurement every 8 hours|Daily presence of diarrhea (time from study drug initiation to first episode of diarrhea; days without a diaper or rectal tube)|Daily difference in the pre-dose and post-dose Clinical Opioid Withdrawal Scale (COWS) score (as evaluated by the bedside nurse before and 2 hours after the administration of the daily study drug dose),Tufts Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 4,36,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",11200,2016-11-01,2018-07-01,2018-07-01,2016-11-30,null,2017-12-06,"Tufts Medical Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02977286
526,NCT02469077,Reduced Opioid Analgesic Requirements Via Improved Endogenous Opioid Function,,Recruiting,No Results Available,Chronic Pain,Behavioral: exercise|Drug: Placebo|Drug: Morphine|Drug: naloxone,"Change in Morphine dosage (in mg) required to achieve 25% reduction in thermal evoked pain responses relative to baseline (pre-intervention) placebo condition responses|Change in mean 5-day electronic diary ratings of low back pain intensity|Placebo condition ratings of acute thermal pain intensity on the McGill Pain Questionnaire-Short Form|Difference between naloxone and placebo condition ratings of acute thermal pain intensity on the McGill Pain Questionnaire-Short Form|Pre-drug ratings of low back pain intensity on the McGill Pain Questionnaire-Short Form|Difference between naloxone and placebo condition pre-post drug changes in ratings of low back pain intensity on the McGill Pain Questionnaire-Short Form|Ratings of Negative Affect|Morphine subjective non-analgesic effects on Visual Analog Opioid Effects scale|Morphine subjective non-analgesic effects on Drug Effects, Liking, and Take Again scale",Vanderbilt University|National Institute on Drug Abuse (NIDA)|Vanderbilt University Medical Center,All,18 Years to 55 Years   (Adult),Not Applicable,116,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",141862|R01DA037891,2015-08-01,2019-05-01,2020-05-01,2015-06-11,null,2018-01-29,"Rush University, Chicago, Illinois, United States|Vanderbilt University, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT02469077
527,NCT02576353,Fentanyl Sublingual Spray and Fentanyl Citrate Intravenous (IV) in Opioid Naive Subjects,,Completed,No Results Available,Pharmacokinetics and Pharmacodynamics,Drug: Fentanyl|Drug: Fentanyl Citrate,Maximum concentration|Time to maximum concentration|Area under the plasma concentration-time curve from 0 to the final time with a concentration at or above the limit of quantitation (LoQ)|Area under the plasma concentration-time curve from 0 to infinity|Apparent elimination rate constant in the terminal phase by noncompartmental analysis|Elimination half-life|Apparent oral clearance of drug following extravascular administration|Volume of distribution during terminal phase following extravascular administration,INSYS Therapeutics Inc,All,18 Years to 55 Years   (Adult),Phase 1,50,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,INS002-15-049,2015-10-01,2015-11-01,2015-11-01,2015-10-15,null,2015-12-02,"Lotus Clinical Research, Pasadena, California, United States",,https://ClinicalTrials.gov/show/NCT02576353
528,NCT01840345,The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain,,Completed,Has Results,Neuropathic Pain,Drug: N-acetyl-l-cysteine,Opioid Use|Pain|Mood|Stress,Virginia Commonwealth University,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,11,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HM14748,2014-01-01,2017-03-01,2017-04-01,2013-04-25,2018-05-14,2018-05-14,"Virginia Commonwealth University, Richmond, Virginia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT01840345/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01840345
529,NCT00781898,Treatment Study Using Depot Naltrexone (1/6) Philadelphia Coord/Data Mgmt Site,,Completed,Has Results,Opiate Addiction,Drug: Depot naltrexone|Other: Treatment as Usual (TAU),Relapse,University of Pennsylvania|National Institute on Drug Abuse (NIDA),All,18 Years to 60 Years   (Adult),Phase 2|Phase 3,308,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,808422|R01DA024553,2008-06-01,2015-08-01,2015-08-01,2008-10-29,2017-10-23,2017-10-23,"Treatment Research Center, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00781898
530,NCT02218021,"A Study of the Abuse Liability Potential of Samidorphan in Healthy, Non-Dependent, Recreational Opioid Users",,Completed,No Results Available,Healthy Volunteers,Drug: Samidorphan|Drug: Placebo|Drug: Oxycodone,Pharmacodynamics: Abuse potential measured by visual analog scales (VAS)|Safety: Incidence of adverse events (AEs)|Pharmacokinetics: Plasma concentrations of samidorphan and metabolite,"Alkermes, Inc.",All,18 Years to 55 Years   (Adult),Phase 1,59,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ALK33-012,2014-08-01,2014-11-01,2014-11-01,2014-08-15,null,2014-12-02,"Alkermes Investigational Site, Overland Park, Kansas, United States",,https://ClinicalTrials.gov/show/NCT02218021
531,NCT00000323,Therapeutic Potential of Kappa-Opioids Against Cocaine - 1,,Completed,No Results Available,Cocaine-Related Disorders,,,National Institute on Drug Abuse (NIDA),All,21 Years to 50 Years   (Adult),,10,NIH,Observational,,NIDA-10753-1|R01-10753-1,1996-07-01,null,1998-12-01,1999-09-21,null,2017-01-12,"Johns Hopkins University (BPRU) Bayview Campus, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00000323
532,NCT00321347,Intravenous (IV) Lidocaine for Opioid-refractory Pain,,Withdrawn,No Results Available,Neoplasms|Pain,Drug: Lidocaine,Comparison of current pain scores before and after the 30 minute randomized intervention|Preliminary assessment of the safety of intravenous lidocaine|Identify parameters that positively or negatively predict response to lidocaine,San Diego Hospice & Palliative Care,All,"18 Years and older   (Adult, Older Adult)",Phase 2,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CPS-05-002-MI,2006-05-01,null,2009-05-01,2006-05-03,null,2012-06-22,"San Diego Hospice & Palliative Care, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT00321347
533,NCT01194089,Nicotine Administration and Post-operative Opioid Use With Bariatric Surgery,,Completed,Has Results,"Pain, Postoperative",Drug: Nasal Nicotine Spray|Drug: Nasal Normal Saline Spray,"Postoperative Opioid Use During the Postanesthesia Care Unit (PACU) Stay, and the First 24 Hours Postoperatively|Number of Participants Who Needed to Use Antiemetic Medication in the PACU|Numeric Pain Score",Toby Weingarten|Mayo Clinic,Female,18 Years to 60 Years   (Adult),Phase 4,95,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",10-002241,2010-08-01,2014-04-01,2014-04-01,2010-09-02,2015-06-03,2015-07-09,"Mayo Clinic in Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT01194089
534,NCT01632982,Mobile Psychosocial Interventions for MMT Clients,MobileMMT,"Active, not recruiting",No Results Available,Opioid Abuse|Substance Abuse,Behavioral: standard treatment|Behavioral: MTS (Mobile Therapeutic System)|Behavioral: mobile control,treatment retention|opioid use|other substance use|coping skills|readiness to change drug use|heroin/opioid craving|HIV risk behavior|psychiatric and psychosocial functioning,"National Development and Research Institutes, Inc.|National Institute on Drug Abuse (NIDA)",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,219,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Mobile631|R01DA029630,2013-07-01,2016-11-01,2018-09-01,2012-07-04,null,2017-09-14,"Bridge Plaza Treatment and Rehabilitation Clinic, Long Island City, New York, United States",,https://ClinicalTrials.gov/show/NCT01632982
535,NCT01046539,Phase 1 Study to Evaluate RDC-0313 Coadministered With Buprenorphine to Opioid-Experienced Healthy Adults,,Completed,No Results Available,Substance-Related Disorders,Drug: RDC-0313 + Buprenorphine|Drug: Placebo,Pharmacodynamics (PD) of study drug|VAS Scores|Pupuillometry Assessments|Subjective Symptoms|To determine pharmacokinetics (PK) and evaluate safety and tolerability of study drug|Max plasma concentration|Time to maximum plasma concentration|Area under the concentration time curve (AUC)|Additional PK parameters may be analyzed,"National Institute on Drug Abuse (NIDA)|Alkermes, Inc.",All,18 Years to 55 Years   (Adult),Phase 1,12,NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ALK33-008,2010-01-01,2010-03-01,2010-07-01,2010-01-12,null,2017-01-11,"Langley Porter Psychiatric Hospital, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT01046539
536,NCT02276911,Safety and Efficacy of Pre-incisional Intravenous Ibuprofen to Reduce Postoperative Pain and Opioid Dependence After Posterior Cervical or Lumbar Instrumented Spine Surgery,,Unknown status,No Results Available,Cervical Spondylosis|Lumbar Spondylosis,Drug: Ibuprofen|Other: normal saline,Change in pain level|Change in overall health/function|Fusion rates,"St. Joseph's Hospital and Medical Center, Phoenix",All,"18 Years and older   (Adult, Older Adult)",Phase 2,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",13BN033,2015-03-01,2017-06-01,2017-12-01,2014-10-28,null,2016-08-29,"SJHMC/Barrow Neurosurgical Associates, Phoenix, Arizona, United States",,https://ClinicalTrials.gov/show/NCT02276911
537,NCT03012087,Using m-Health Tools to Reduce the Misuse of Opioid Pain Relievers,,Completed,No Results Available,Prescription Drug Abuse,Behavioral: MyHealthyChoices|Other: Health Risk Assessment,"Change in Self-Reported Preference for Opioid Pain Reliever|Change in Knowledge about Prescription Pain Medication Side Effects and Safe Practices for Taking, Storing and Disposing Prescription Pain Medications|Self-Reported Prescription Drug Storage and Disposal Behaviors",Johns Hopkins Bloomberg School of Public Health|West Virginia University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,123,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,MyHealthyChoices,2016-09-01,2017-04-01,2017-06-01,2017-01-06,null,2017-08-22,"Johns Hopkins Hospital Emergency Department, Baltimore, Maryland, United States|West Virginia University Emergency Department, Morgantown, West Virginia, United States",,https://ClinicalTrials.gov/show/NCT03012087
538,NCT01475604,"Impact of Noninvasive Targeted Pulsed Electromagnetic Field (tPEMF) on Opioid Use, Pain, and Joint Function Following Total Knee Arthroplasty",,Terminated,No Results Available,"Osteoarthritis, Knee",Device: Ivivi Torino II,"The average daily morphine equivalent dose consumption at 2 weeks post-surgery.|Post-surgical opioid use during hospitalization and following discharge at 1 and 4 weeks post-surgery.|Knee pain severity assessed on a 10 cm visual analogue scale (VAS)|The measurement of knee joint circumference|Range of motion of the knee joint, assessed using the knee flexion technique|OA-related medication use including analgesics, anti-inflammatories, and other non-opioids|Adverse Events collected and analyzed for confirmation of device safety","Amp Orthopedics, Inc.",All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 4,23,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IOH-TKA-001,2011-11-01,2012-07-01,2012-07-01,2011-11-21,null,2012-07-10,"Anderson Orthopaedic Research Institute, Alexandria, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01475604
539,NCT00486902,Does a Single Intravenous Dose of Ketamine Reduce the Need for Supplemental Opioids in Post-Cesarean Section Patients?,,Completed,Has Results,"Ketamine Adverse Reaction|Effects of; Anesthesia, Spinal and Epidural, in Pregnancy|Complication of Labor and/or Delivery",Drug: Ketamine|Drug: Placebo,Number of Subjects Requiring Supplemental Analgesia in the First 24 Hours Following Cesarean Delivery|Verbal Pain Scores (0 to 10) at First Analgesia Request|Cumulative Hydrocodone/Acetaminophen for Supplemental Analgesia to Treat Breakthrough Pain|Postoperative Nausea|Postoperative Vomiting|Postperative Pruritus|Disturbing Dreams,Northwestern University,Female,18 Years to 60 Years   (Adult),Not Applicable,188,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",0524-030,2006-07-01,2008-10-01,2008-10-01,2007-06-15,2011-05-06,2014-04-14,"Northwestern University, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00486902
540,NCT02462811,"A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Acute Pain and Opioid-Induced Nausea and Vomiting (OINV)",,Completed,No Results Available,Pain|Nausea|Vomiting,"Drug: CL-108 (hydrocodone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg)|Drug: Placebo|Drug: Norco (hyrdocodone 7,5 mg, acetaminophen 325 mg)","The occurrence of opioid-induced nausea and vomiting (OINV) as assessed by an OINV questionnaire comparing CL-108 to Norco® over 48 hours.|The relief of moderate to severe pain, assessed by visual analog pain intensity scale, comparing CL-108 to placebo over 48 hours (SPID48).|The severity of opioid-induced nausea, comparing CL-108 to Norco® over 48 hours|The occurrence of vomiting, comparing CL-108 to Norco® over 48 hours|The use of anti-emetics, comparing CL-108 to Norco® over 48 hours.|Incidence of post-discharge nausea and vomiting (PDNV), comparing CL-108 to placebo over days 3-5|The relief of post-operative nausea and vomiting (PONV), comparing CL-108 to placebo over 48 hours|The relief of severe pain, comparing CL-108 to Norco® over 48 hours, i.e., summed pain intensity differences over 48 hours (SPID48)","Joseph Hazelton|Charleston Laboratories, Inc",All,"18 Years and older   (Adult, Older Adult)",Phase 3,552,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CLCL-003,2014-09-01,2015-07-01,2015-08-01,2015-06-04,null,2016-11-03,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02462811
541,NCT01733693,Neurocognitive Effects of Opiate Agonist Treatment,NEO,Completed,No Results Available,Opioid-Related Disorders|HIV|HIV Infections,Drug: Buprenorphine|Drug: Methadone,"Global Neurocognitive Function|Domain-Specific Neurocognitive Function (i.e. in the domains of executive functioning, learning, memory, attention/working memory, processing speed, motor, and verbal functioning).","Albert Einstein College of Medicine, Inc.|National Institute on Drug Abuse (NIDA)|Montefiore Medical Center|Fordham University",All,"18 Years to 68 Years   (Adult, Older Adult)",Phase 4,135,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2012-433|1R01DA032552-01A1,2013-01-01,2017-06-01,2017-06-01,2012-11-27,null,2017-07-06,"Fordham University, The Bronx, New York, United States|Albert Einstein College of Medicine of Yeshiva University, The Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT01733693
542,NCT00000273,A Laboratory Model for Heroin Abuse Medications - 8,,Completed,No Results Available,Heroin Dependence|Opioid-Related Disorders|Substance-Related Disorders,Drug: opiates,Amount drug self-administered|Subjective responses,New York State Psychiatric Institute|National Institute on Drug Abuse (NIDA),All,18 Years to 45 Years   (Adult),Phase 2,8,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,#4857/5982R|5P50DA009236-18,1995-08-01,2005-11-01,2005-11-01,1999-09-21,null,2017-07-05,"Columbia University, New York, New York, United States|New York State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00000273
543,NCT01825447,"A Study to Characterize the Abuse Liability of Intravenous Oxycodone Alone or in Combination With Intravenous Naltrexone in Healthy, Non-Dependent, Recreational Opioid Users",,Completed,No Results Available,Healthy,Drug: Placebo|Drug: Oxycodone + Naltrexone|Drug: Oxycodone,Drug Liking: Area Under Effect Curve (AUE) From 0-2 Hours|Drug Liking: Peak Effect (Emax)|High: Area Under Effect Curve (AUE) From 0-2 Hours|High: Peak Effect (Emax)|Drug Liking: Area Under Effect Curve (AUE) From 0-1 Hour|Drug Liking: Area Under Effect Curve (AUE) From 0-8 Hours|High: Area Under Effect Curve (AUE) From 0-1 Hour|High: Area Under Effect Curve (AUE) From 0-8 Hours|Take Drug Again: Peak Effect (Emax)|Take Drug Again: Mean Effect (Emean)|Overall Drug Liking: Peak Effect (Emax)|Overall Drug Liking: Mean Effect (Emean)|Any Drug Effects: Area Under Effect Curve (AUE) From 0-1 Hour|Any Drug Effects: Area Under Effect Curve (AUE) From 0-2 Hours|Any Drug Effects: Area Under Effect Curve (AUE) From 0-8 Hours|Good Drug Effects: Area Under Effect Curve (AUE) From 0-1 Hour|Good Drug Effects: Area Under Effect Curve (AUE) From 0-2 Hours|Good Drug Effects: Area Under Effect Curve (AUE) From 0-8 Hours|Bad Drug Effects: Area Under Effect Curve (AUE) From 0-1 Hour|Bad Drug Effects: Area Under Effect Curve (AUE) From 0-2 Hours|Bad Drug Effects: Area Under Effect Curve (AUE) From 0-8 Hours|Feel Sick: Area Under Effect Curve (AUE) From 0-1 Hour|Feel Sick: Area Under Effect Curve (AUE) From 0-2 Hours|Feel Sick: Area Under Effect Curve (AUE) From 0-8 Hours|Nausea: Area Under Effect Curve (AUE) From 0-1 Hour|Nausea: Area Under Effect Curve (AUE) From 0-2 Hours|Nausea: Area Under Effect Curve (AUE) From 0-8 Hours|Sleepy: Area Under Effect Curve (AUE) From 0-1 Hour|Sleepy: Area Under Effect Curve (AUE) From 0-2 Hours|Sleepy: Area Under Effect Curve (AUE) From 0-8 Hours|Dizzy: Area Under Effect Curve (AUE) From 0-1 Hour|Dizzy: Area Under Effect Curve (AUE) From 0-2 Hours|Dizzy: Area Under Effect Curve (AUE) From 0-8 Hours|Any Drug Effects: Peak Effect (Emax)|Good Drug Effects: Peak Effect (Emax)|Bad Drug Effects: Peak Effect (Emax)|Feel Sick: Peak Effect (Emax)|Nausea: Peak Effect (Emax)|Sleepy: Peak Effect (Emax)|Dizzy: Peak Effect (Emax)|Pupillometry: Area Under Effect Curve (AUE) From 0-1 Hour|Pupillometry: Area Under Effect Curve (AUE) From 0-2 Hours|Pupillometry: Area Under Effect Curve (AUE) From 0-8 Hours|Pupillometry: Peak Effect (Emax)|Pupillometry: Time to Maximum (Peak) Effect (TEmax)|Drug Liking: Time to Maximum (Peak) Effect (TEmax)|High: Time to Maximum (Peak) Effect (TEmax)|Any Drug Effects: Time to Maximum (Peak) Effect (TEmax)|Good Drug Effects: Time to Maximum (Peak) Effect (TEmax)|Bad Drug Effects: Time to Maximum (Peak) Effect (TEmax)|Sleepy: Time to Maximum (Peak) Effect (TEmax)|Dizzy: Time to Maximum (Peak) Effect (TEmax)|Nausea: Time to Maximum (Peak) Effect (TEmax)|Feel Sick: Time to Maximum (Peak) Effect (TEmax)|Plasma Concentration of Oxycodone 5 Minutes Post-Dose (C5min)|Plasma Concentration of Oxymorphone 5 Minutes Post-Dose (C5min)|Plasma Concentration of Noroxycodone 5 Minutes Post-Dose (C5min)|Plasma Concentration of Naltrexone 5 Minutes Post-Dose (C5min)|Plasma Concentration of 6-beta-naltrexol 5 Minutes Post-Dose (C5min)|Plasma Decay Half-Life (t1/2) of Oxycodone|Plasma Decay Half-Life (t1/2) of Oxymorphone|Plasma Decay Half-Life (t1/2) of Noroxycodone|Plasma Decay Half-Life (t1/2) of Naltrexone|Plasma Decay Half-Life (t1/2) of 6-beta-naltrexol|Area Under the Oxycodone Concentration-Time Curve (AUC0-1h)|Area Under the Oxymorphone Concentration-Time Curve (AUC0-1h)|Area Under the Noroxycodone Concentration-Time Curve (AUC0-1h)|Area Under the Naltrexone Concentration-Time Curve (AUC0-1h)|Area Under the 6-beta-naltrexol Concentration-Time Curve (AUC0-1h)|Area Under the Oxycodone Concentration-Time Curve (AUC0-2h)|Area Under the Oxymorphone Concentration-Time Curve (AUC0-2h)|Area Under the Noroxycodone Concentration-Time Curve (AUC0-2h)|Area Under the Naltrexone Concentration-Time Curve (AUC0-2h)|Area Under the 6-beta-naltrexol Concentration-Time Curve (AUC0-2h)|Area Under the Oxycodone Concentration-Time Curve (AUC0-8h)|Area Under the Oxymorphone Concentration-Time Curve (AUC0-8h)|Area Under the Noroxycodone Concentration-Time Curve (AUC0-8h)|Area Under the Naltrexone Concentration-Time Curve (AUC0-8h)|Area Under the 6-beta-naltrexol Concentration-Time Curve (AUC0-8h)|Area Under the Curve From Time Zero to Last Quantifiable Oxycodone Concentration (AUClast)|Area Under the Curve From Time Zero to Last Quantifiable Oxymorphone Concentration (AUClast)|Area Under the Curve From Time Zero to Last Quantifiable Noroxycodone Concentration (AUClast)|Area Under the Curve From Time Zero to Last Quantifiable Naltrexone Concentration (AUClast)|Area Under the Curve From Time Zero to Last Quantifiable 6-beta-naltrexol Concentration (AUClast)|Area Under the Curve From Time Zero Extrapolated to Infinity (AUCinf) for Oxycodone|Area Under the Curve From Time Zero Extrapolated to Infinity (AUCinf) for Oxymorphone|Area Under the Curve From Time Zero Extrapolated to Infinity (AUCinf) for Noroxycodone|Area Under the Curve From Time Zero Extrapolated to Infinity (AUCinf) for Naltrexone|Area Under the Curve From Time Zero Extrapolated to Infinity (AUCinf) for 6-beta-naltrexol|Systemic Clearance (Cl) of Oxycodone|Systemic Clearance (Cl) of Oxymorphone|Systemic Clearance (Cl) of Noroxycodone|Systemic Clearance (Cl) of Naltrexone|Systemic Clearance (Cl) of 6-beta-naltrexol|Volume of Distribution at Steady State (Vss) for Oxycodone|Volume of Distribution at Steady State (Vss) for Oxymorphone|Volume of Distribution at Steady State (Vss) for Noroxycodone|Volume of Distribution at Steady State (Vss) for Naltrexone|Volume of Distribution at Steady State (Vss) for 6-beta-naltrexol,"Pfizer|Lifetree Clinical Research Center, Salt Lake City, Utah",All,18 Years to 55 Years   (Adult),Phase 1,89,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",B4981002,2013-07-01,2013-09-01,2013-09-01,2013-04-05,null,2013-10-08,"Pfizer Investigational Site, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT01825447
544,NCT00388401,Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus,,Completed,No Results Available,Ileus,Drug: Alvimopan,acceleration of gastrointestinal recovery|time until ready for discharge based upon recovery of GI function|severity of GI symptoms|pain|opioid consumption|time to tolerate solid food|need for reinsertion of nasogastric tube|time until discharge order is written,Cubist Pharmaceuticals LLC|GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 3,510,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,14CL313,2002-01-01,2003-06-01,2003-06-01,2006-10-16,null,2015-07-20,"Adolor Corporation, Exton, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00388401
545,NCT00388258,Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus,,Completed,No Results Available,Ileus,Drug: Alvimopan,acceleration of gastrointestinal recovery|time until ready for discharged based upon recovery of GI function|severity of GI symptoms|pain|opioid consumption|time to tolerate solid food|need for reinsertion of nasogastric tube|time until discharge order is written,Cubist Pharmaceuticals LLC|GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 3,451,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,3753-015|14CL302,2001-03-01,2002-12-01,2002-12-01,2006-10-16,null,2017-08-22,"Various, Exton, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00388258
546,NCT00388479,Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/ Postoperative Ileus,,Completed,No Results Available,Ileus,Drug: Alvimopan,Acceleration of gastrointestinal recovery|Time until ready for discharge based upon recovery of GI function|Severity of GI symptoms|Pain|Opioid Consumption|Time to tolerate liquids|Need for reinsertion of nasogastric tube|Time until discharge order is written,Cubist Pharmaceuticals LLC|GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 3,666,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,14CL308,2001-12-01,2003-11-01,2003-11-01,2006-10-16,null,2015-07-20,"Various, Exton, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00388479
547,NCT00153192,Study to Evaluate the Efficacy of Dronabinol (Marinol) as Add-On Therapy for Patients on Opioids for Chronic Pain,,Completed,No Results Available,Chronic Pain,Drug: Marinol (dronabinol),Single-Dose Phase|- Total pain relief (TOTPAR) at 8 hours|Multi-Dose Phase|- Change in pain score from baseline|- Sum of pain intensity differences at 8 hours|- Pain and pain relief at all prespecified time points|- SPID for pain bothersomeness at 8 hours|- Side effects scale|- Addiction Research Center Inventory scale of abuse liability|- Patient global assessment at 8 hours|- Changes in mood|- Evoked pain at all prespecified timepoints|- SPID for evoked pain at 8 hours|- Drop outs due to need for rescue analgesia during the 8 hour study phase|- Least squares mean change in pain score by ANCOVA.|- Plasma levels of THC vs. effect of study drug|- Time-weighted average of weekly pain assessments collected during study visits and by telephone|- Patient global assessment|- Adverse events|- Quality of life (SF-36) compared to baseline on aggregate score and subscales.|- Sleep scale,Brigham and Women's Hospital|Solvay Pharmaceuticals,All,"Child, Adult, Older Adult",Phase 2|Phase 3,30,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,2001-P-000474|BN7894973,2001-04-01,2006-04-01,2006-04-01,2005-09-12,null,2013-04-26,"Brigham and Women's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00153192
548,NCT00293020,Study of the Safety of BEMA™ Fentanyl Use for Breakthrough Pain in Cancer Subjects on Chronic Opioid Therapy,,Completed,Has Results,Pain|Cancer,Drug: BEMA Fentanyl,Percentage of Participants With Adverse Events.,BioDelivery Sciences International,All,"18 Years and older   (Adult, Older Adult)",Phase 3,244,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FEN-202,2006-02-01,2008-06-01,2008-06-01,2006-02-17,2012-10-05,2012-10-05,"ResearchPoint, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT00293020
549,NCT00205842,Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus,,Completed,No Results Available,Ileus,Drug: alvimopan,"Time to recovery of GI function, which will be the time to Recovery of both upper GI function (tolerating solid food), and lower GI recovery (first bowel movement). Referred to as GI2.|Time to discharge order written, time to actual discharge, time to tolerate solid food and time to first bowel movement",Cubist Pharmaceuticals LLC|GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 3,660,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,3753-001|14CL314,2004-06-01,2005-12-01,2005-12-01,2005-09-21,null,2016-01-11,"50 Sites, Exton, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00205842
550,NCT02156154,Effect of Intravenous Acetaminophen on Postoperative Opioid-related Complications,,Recruiting,No Results Available,Postoperative Pain,Drug: Intravenous Acetaminophen,Pulseoxymeter,The Cleveland Clinic,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 3,528,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",14-241,2014-12-01,2018-12-01,2018-12-01,2014-06-05,null,2018-01-17,"Cleveland Clinic Foundation, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02156154
551,NCT01822132,Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade,,Completed,No Results Available,Methamphetamine Abuse|HIV,Drug: Extended release naltrexone|Drug: Placebo,Discounting Tasks|Neural Mapping|Methamphetamine use|HIV risk behaviors|Antiretroviral adherence,Oregon Health and Science University|National Institute on Drug Abuse (NIDA),All,18 Years to 55 Years   (Adult),Not Applicable,62,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)",ALKIIT-KOR-034|1R21DA033182-01A1,2013-05-01,2015-03-01,2015-03-01,2013-04-02,null,2015-04-28,"Oregon Health & Science University, Portland, Oregon, United States|Portland VA Medical Center, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT01822132
552,NCT00020605,Naloxone in Treating Constipation in Patients Who Are Receiving Opioids for Chronic Pain,,Unknown status,No Results Available,"Constipation, Impaction, and Bowel Obstruction|Unspecified Adult Solid Tumor, Protocol Specific",Drug: naloxone hydrochloride,,Dana-Farber Cancer Institute|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 3,null,Other,Interventional,Primary Purpose: Supportive Care,CDR0000068671|DFCI-NAL-0597|BWH-1999-P-002415/10|BWH-97-08658|ROXANE-NAL-0597,2000-05-01,null,null,2004-04-05,null,2009-05-12,"Brigham and Women's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00020605
553,NCT01741350,Testing a Community-Friendly Risk Reduction Intervention for Injection Drug Users,,Completed,Has Results,HIV|Opioid Dependence,Behavioral: Community-friendly Health Recovery Program|Behavioral: Time-and-Attention-Matched Control Condition,Demonstrated Drug Risk Reduction Skills (0-100%)|Safer Drug Use (0-4)|Drug-related HIV-risk Reduction Knowledge (0-1)|Personal Motivation to Reduce Drug-related HIV-Risk Behavior (1-5)|Social Motivation to Reduce Drug-related HIV-Risk Behavior (1-5)|Self-efficacy to Reduce Drug-related HIV-Risk Behavior (1-5)|Female Condom Skills (0-100%)|Male Condom Skills (0-100%)|Condom Use (0-4)|Sex-related HIV-risk Reduction Knowledge (0-1)|Personal Motivation to Reduce Sex-related HIV- Risk Behavior (1-5)|Social Motivation to Reduce Sex-related HIV- Risk Behavior (1-5)|Self-efficacy to Reduce Sex-related HIV- Risk Behavior (1-5),"University of Connecticut|National Institute on Drug Abuse (NIDA)|APT Foundation, Inc.",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,304,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H06-215|1R01DA022122-01A1,2006-09-01,2011-05-01,2012-06-01,2012-12-04,2014-02-27,2014-02-27,"APT Foundation, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01741350
554,NCT03372382,Ibuprofen and Acetaminophen Versus Ibuprofen and Acetaminophen Plus Hydrocodone for Analgesia After Cesarean Section,IVY,Completed,No Results Available,"Opioid Use|Pain, Postoperative",Drug: Ibuprofen|Drug: Acetaminophen|Drug: Norco,pain level|patient satisfaction,"The University of Texas Health Science Center, Houston",Female,18 Years to 50 Years   (Adult),Phase 4,170,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HSC-MS-17-0777,2017-12-13,2018-04-10,2018-04-10,2017-12-13,null,2018-07-27,"The University of Texas Health Science Center at Houston, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03372382
555,NCT00330343,Optimal Dose of Prophylactic Naloxone in Reducing Opioid-Induced Side Effects in Children/Adolescents,,Completed,Has Results,Pain|Nausea|Pruritus,Drug: naloxone,Number of Participants With Naloxone Side Effects,Johns Hopkins University,All,7 Years to 17 Years   (Child),Phase 2,75,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,04-03-31-02,2004-05-01,2009-06-01,2009-06-01,2006-05-26,2017-07-19,2017-07-19,"John Hopkins Hospital, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00330343
556,NCT00459277,Efficacy & Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids,,Completed,No Results Available,Cancer Pain,"Drug: Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)","Summed pain intensity difference at 30 min|SPID, Pain intensity, Pain intensity difference, Pain relief and Total pain relief",Archimedes Development Ltd,All,"18 Years and older   (Adult, Older Adult)",Phase 3,73,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",CPO43/06/FCNS,2006-12-01,2008-07-01,2008-08-01,2007-04-11,null,2012-01-25,"Beth Israel Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00459277
557,NCT03221309,"Hepatitis C Treatment to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior",ANCHOR,Enrolling by invitation,No Results Available,HCV|Burpenorphine|PreP,Other: Evaluate model of care for HCV-infected adults with on-going injection drug use,SVR12|Uptake of Prep|Adherence of Prep|Uptake of buprenorphine|Retention in buprenorphine program,University of Maryland,All,"18 Years and older   (Adult, Older Adult)",,200,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,HP-00071577,2017-05-01,2020-12-01,2020-12-01,2017-07-18,null,2018-08-14,"HIPS, Washington, District of Columbia, United States|University of Maryland Drug Treatment Center, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT03221309
558,NCT02250664,"Project 2, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in Opioid Abusers",P2S2,Recruiting,No Results Available,Tobacco Use Disorder,Other: Very low nicotine content cigarettes,Cigarettes per day,University of Vermont|National Institute on Drug Abuse (NIDA)|Johns Hopkins University,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,282,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",P50DA036114:P2S2|P50DA036114,2016-10-01,2019-10-01,2019-10-01,2014-09-26,null,2016-10-06,"Johns Hopkins University, Baltimore, Maryland, United States|University of Vermont, Burlington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT02250664
559,NCT00618397,Pharmacokinetics of Low Dose Ketamine Infusion,,Terminated,No Results Available,Sedation|Opioid Tolerance,Drug: Ketamine,"To establish if continuous infusions of ketamine in doses of 0.01mg/kg/hr, 0.1mg/kg/hr and 0.5mg/kg/hr cause serum levels > 1 mcg/ml.|To define the pharmacokinetics of continuous infusion ketamine in doses of 0.01mg/kg/hr, 0.1mg/kg/hr and 0.5mg/kg/hr.",University of Texas Southwestern Medical Center,All,"3 Years to 18 Years   (Child, Adult)",Phase 1,5,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),42006035,2006-06-01,2015-06-01,2015-06-01,2008-02-20,null,2016-10-26,"Children's Medical Center Dallas, University of Texas Southwestern, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT00618397
560,NCT03586934,Multimodal Analgesia in Shoulder Arthroplasty,,Recruiting,No Results Available,Shoulder Pain|Opioid Use,Drug: Acetaminophen|Drug: Celecoxib 200mg|Drug: Celecoxib 400 mg|Drug: Ropivacaine|Drug: Ketorolac|Drug: Acetaminophen Injectable Product|Drug: Oxycodone|Drug: Tramadol|Drug: Morphine Injectable Solution|Drug: hydrocodone bitartrate and acetaminophen|Drug: Morphine|Drug: Oxycodone Hydrochloride|Drug: Meloxicam,Number of Oxycodone tablets|Patient Reported Outcome Measures|Shoulder range of motion and strength testing|Complications|Pain Score|Postoperative Inpatient Opioid Utilization|Long-term Pain Scores,Rush University Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 3,74,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ORA 17071004,2018-06-01,2020-06-01,2020-09-01,2018-07-16,null,2018-07-17,"Rush University Medical Center, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT03586934
561,NCT03319277,A Randomized-controlled Trial of Post-operative Opiate Quantities After Urogynecologic Surgery,,Recruiting,No Results Available,Postoperative Pain|Opioid Use,Other: Decreased opiate prescription|Other: Routine opiate prescription,Patient satisfaction with pain control|Number of opiate tablets used by patients|Patient willingness to destroy remaining tablets,The Cleveland Clinic,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,118,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17-1012,2017-10-13,2019-06-30,2019-06-30,2017-10-24,null,2018-07-17,"Cleveland Clinic, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03319277
562,NCT00000311,Combining Behavioral Treatment With Agonist Maintenance - 1,,Completed,No Results Available,Cocaine-Related Disorders|Opioid-Related Disorders|Substance-Related Disorders,Drug: Buprenorphine|Drug: methadone,Depression|Withdrawal symptoms|Opioid and cocaine use|Social and psychological functioning|AIDS risk behavior,Yale University|National Institute on Drug Abuse (NIDA),All,"Child, Adult, Older Adult",Phase 3,168,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double|Primary Purpose: Treatment,NIDA-09413-1|R01DA009413|R01-09413-1,1995-02-01,1999-02-01,1999-02-01,1999-09-21,null,2018-01-17,"APT Residential Services Division, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00000311
563,NCT03020966,IV vs. Oral Acetaminophen as a Component of Multimodal Analgesia After Total Hip Arthroplasty,IV Tylenol,Recruiting,No Results Available,"Pain, Postoperative|Opioid Use",Drug: Acetaminophen,Pain with physical therapy on post-operative day 1|Opioid Use|Opioid side effects,"Hospital for Special Surgery, New York|Mallinckrodt",All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 4,154,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2016-209,2017-02-16,2018-09-16,2018-11-16,2017-01-13,null,2018-03-29,"Hospital for Special Surgery, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03020966
564,NCT03547882,Addiction Treatment in Primary Care Expansion,APEX,Enrolling by invitation,No Results Available,Opioid Use Disorder (OUD)|Chronic Pain,,Number of patients who receive mediation assisted treatment for opioid use disorder (by facility and community based clinic)|Ratio of patients receiving medication assisted treatment for opioid use disorder to the number of patients with opioid use disorder (by facility and community based clinic)|Change in number of providers prescribing medication assisted treatment for opioid use disorder and patients receiving medication assisted treatment (by facility)|Patients receiving medication assisted treatment (by facility),"VA Office of Research and Development|VA Eastern Colorado Health Care System|University of Colorado, Denver|University of Utah",All,"Child, Adult, Older Adult",,6,U.S. Fed|Other,Observational,Observational Model: Other|Time Perspective: Other,PIX 18-002|PII 18-181,2018-05-01,2019-04-30,2019-04-30,2018-06-06,null,2018-06-06,"VA Eastern Colorado Health Care System, Denver, CO, Denver, Colorado, United States|VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT03547882
565,NCT01820442,Pharmacokinetic & Pharmacodynamic Interaction of Lofexidine and Buprenorphine in Buprenorphine Maintained Patients,,Completed,No Results Available,Opioid Dependence|Buprenorphine Withdrawal Syndrome,Drug: Lofexidine HCl|Drug: Lofexidine-matching sugar pill,Changes in QTc Interval|Change from baseline in the Short Opioid Withdrawal Scale (SOWS)|Change from Baseline in the Clinical Opiate Withdrawal Scale (COWS)|Buprenorphine Area Under the Curve (AUC)|Lofexidine Area Under the Curve (AUC)|Change in Adverse Events|Change in Vital Signs,US WorldMeds LLC|National Institute on Drug Abuse (NIDA),All,18 Years to 60 Years   (Adult),Phase 1,30,Industry|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",USWM-LX1-1006|5U01DA030916-03,2013-03-01,2013-09-01,2013-09-01,2013-03-28,null,2018-02-23,"Lifetree Clinical Research, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT01820442
566,NCT00913484,Disulfiram for Cocaine Abuse in Buprenorphine Treatment,,Completed,No Results Available,Cocaine Dependence|Opioid Dependency,Drug: Disulfiram|Drug: Placebo,Cocaine abstinence|Opioid abstinence,Yale University|National Institute on Drug Abuse (NIDA),All,18 Years to 45 Years   (Adult),Phase 2,177,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1R01DA012979,2000-10-01,2004-02-01,2004-02-01,2009-06-04,null,2009-06-04,"The APT Foundation MRU, New Haven, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00913484
567,NCT01650649,Main Study of Lofexidine and Methadone Pharmacodynamic Interaction in Methadone Maintained Patients,,Completed,No Results Available,Opioid Dependence|Methadone Withdrawal Syndrome,Drug: Lofexidine HCl|Drug: Lofexidine-matching sugar pill,Changes in QTc Interval|Change from Baseline in the Short Opioid Withdrawal Scale (SOWS)|Change from Baseline in the Clinical Opiate Withdrawal Scale (COWS)|Methadone Area Under the Curve (AUC)|Lofexidine Area Under the Curve (AUC)|Change in Vital Signs|Change in Adverse Events,US WorldMeds LLC|National Institute on Drug Abuse (NIDA),All,18 Years to 60 Years   (Adult),Phase 1,27,Industry|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",USWM-LX1-1005-2|1U01DA030916-01,2012-07-01,2012-12-01,2012-12-01,2012-07-26,null,2017-10-26,"Lifetree Clinical Research, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT01650649
568,NCT01558934,Pilot Study of Lofexidine and Methadone Pharmacodynamic Interaction in Methadone Maintained Patients,,Completed,No Results Available,Opioid Dependence|Methadone Withdrawal Syndrome,Drug: Lofexidine HCl,Changes in QTc Interval|Change from Baseline in the Short Opioid Withdrawal Scale (SOWS)|Change from Baseline in the Clinical Opiate Withdrawal Scale (COWS)|Methadone Area Under the Curve (AUC)|Lofexidine Area Under the Curve (AUC)|Change in Vital Signs|Change in Adverse Events,US WorldMeds LLC|National Institute on Drug Abuse (NIDA),All,18 Years to 60 Years   (Adult),Phase 1,6,Industry|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,USWM-LX1-1005-1|1U01DA030916-01,2012-02-01,2012-04-01,2012-04-01,2012-03-20,null,2018-02-23,"Lifetree Clinical Research, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT01558934
569,NCT01871285,Evaluation of the Tolerability of Switching Subjects on Chronic ATC Opioid Therapy to Buprenorphine HCl Buccal Film,,Completed,Has Results,Pain,Drug: Buprenorphine|Drug: Placebo film|Drug: Oxycodone|Drug: Morphine sulfate|Drug: Placebo capsule,"Number of Responders|Maximum COWS Total Score|Change From Baseline in Maximum COWS Total Score|Change From Baseline in COWS Total Score Over Time|Change From Baseline in ""Pain Now"" Over Time Using NRS",BioDelivery Sciences International,All,18 Years to 60 Years   (Adult),Phase 2,39,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",EN3409-204,2013-06-01,2014-07-01,2014-07-01,2013-06-06,2016-02-03,2017-02-27,"Vince and Associates Clinical Research, Inc., Overland Park, Kansas, United States|CRI Lifetree, Philadelphia, Pennsylvania, United States|CRI Lifetree (Lifetree Clinical Research), Salt Lake, Utah, United States",,https://ClinicalTrials.gov/show/NCT01871285
570,NCT00218426,Addiction Treatment in Russia: Oral vs. Naltrexone Implant,,"Active, not recruiting",No Results Available,Heroin Dependence|Opioid-Related Disorders,Drug: naltrexone implant|Drug: Oral naltrexone|Drug: placebo oral and placebo implant,"Relapse to heroin addiction (measured at Months 1 and 6)|Time to dropout for treatment|positive opioid urine test|use of alcohol and other drugs|psychiatric symptoms|HIV risk (measured at Months 1, 6, 9, and 12)","University of Pennsylvania|National Institute on Drug Abuse (NIDA)|St. Petersburg State Pavlov Medical University|Leningrad Addiction Treatment & Research Center, Leningrad Region, Russia",All,18 Years to 50 Years   (Adult),Phase 2|Phase 3,306,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NIDA-17317-1|R01DA017317|R01-17317-1|DPMC,2006-07-01,2017-07-01,2018-10-01,2005-09-22,null,2018-02-26,"University of Pennsylvania, Philadelphia, Pennsylvania, United States|Pavlov Medical University, St. Petersburg, Russian Federation",,https://ClinicalTrials.gov/show/NCT00218426
571,NCT03495869,Feasibility and Validation of a Standard Phenotyping Assessment Battery,PhAB,Recruiting,No Results Available,Opioid-use Disorder|Cocaine Use Disorder,,Retention|Time to complete battery|Non-completers of the Battery and Platform Instruments,Virginia Commonwealth University|National Institute on Drug Abuse (NIDA),All,"18 Years to 70 Years   (Adult, Older Adult)",,180,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,HM20012559|U54DA038999,2018-06-21,2018-10-01,2018-10-01,2018-04-12,null,2018-06-27,"VCU Institute for Drug and Alcohol Studies, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT03495869
572,NCT01802515,A Drug Treatment for Cocaine Users Who Are Also on Methadone Maintenance Treatment,,Terminated,Has Results,Cocaine Dependence|Opiate Dependence,"Drug: Atomoxetine, low dose|Drug: Atomoxetine, high dose|Drug: Placebo",Treatment Retention|Change Score in the Center for Epidemiological Studies-Depression (CES-D) Scale,Yale University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,14,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",1206010407,2012-12-01,2014-03-01,2014-03-01,2013-03-01,2016-12-06,2016-12-06,"Department of Veterans Affairs Hospital, West Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01802515
573,NCT03279562,Patient Driven Recovery With Nalmefene and Coaching,,Recruiting,No Results Available,"Opioid-use Disorder|Harmful; Use, Alcohol",Drug: Nalmefene,Duration of abstinence from illicit opioids|Treatment retention,"Yale University|First Pavlov State Medical University in St. Petersburg, Russia",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,30,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1610018492,2017-09-01,2018-06-30,2018-06-30,2017-09-12,null,2017-09-12,"Yale University, Department, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT03279562
574,NCT00877591,Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications,,Completed,No Results Available,Opioid Dependency|HIV Infections,Drug: Fosamprenavir/Ritonavir|Drug: Darunavir/Ritonavir|Drug: Rifampin|Drug: Rifabutin|Drug: Buprenorphine,Effect of ARV or Tuberculosis Medication on Buprenorphine,"University of California, San Francisco|State University of New York at Buffalo|University of Utah",All,"18 Years and older   (Adult, Older Adult)",Phase 1,63,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R01DA013004,2008-04-01,2013-04-01,2013-04-01,2009-04-08,null,2014-05-06,"San Francisco General Hospital, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT00877591
575,NCT00669175,Safety and Efficacy of a Low Dose Naloxone Infusion in NICU Patients,,Completed,No Results Available,Opioid Tolerance|Pain,,"The primary outcome variable will be a change in N-PASS scores. N-PASS scores will be compared before, during, and after administration of naloxone.|The secondary outcome variable will be any changes in dosing of opioids within four hours of initiating or increasing naloxone infusion. Vital signs will be recorded per NICU protocol and closely monitored for changes.",Children's Mercy Hospital Kansas City,All,up to 30 Days   (Child),,25,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,08 01-003,2008-02-01,null,2011-06-01,2008-04-29,null,2011-07-21,"Children's Mercy Hospital, Kansas City, Missouri, United States",,https://ClinicalTrials.gov/show/NCT00669175
576,NCT02025855,Adjunct Methadone to Decrease the Duration of Mechanical Ventilation in the Medical Intensive Care Unit,,Unknown status,No Results Available,"Opioid Use, Unspecified With Withdrawal|Opioid-Induced Disorders|Delirium",Drug: Methadone|Drug: Placebo,Time to extubation|Cumulative opioid consumption|Level of sedation|Corrected QT interval|Cumulative Antipsychotic Use|Cumulative benzodiazepine consumption,Henry Ford Health System,All,"18 Years and older   (Adult, Older Adult)",Phase 4,46,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Smoot_8503,2014-01-01,2015-03-01,2015-03-01,2014-01-01,null,2014-01-17,"Henry Ford Hospital, Detroit, Michigan, United States",,https://ClinicalTrials.gov/show/NCT02025855
577,NCT00577005,Efficacy of Levetiracetam in Cocaine-Abusing Methadone Maintained Patients,Keppra-DB,Completed,Has Results,Cocaine Dependence|Opioid Dependency,Drug: levetiracetam|Drug: Placebo,Change of Thrice Weekly Cocaine Free Urine Toxicology From Week 1 to 13|Change of Thrice Weekly Opioid Free Urine Toxicology From Week 1 to 13|Treatment Retention|Cocaine Craving,Yale University|National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,28,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",0707002832|5R01DA017782-04|NIDA-5R01DA017782-04|Yale-0508000534|VA-gg0006,2007-07-01,2008-06-01,2008-10-01,2007-12-19,2017-04-24,2018-01-17,"VA CT Healthcare System, West Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00577005
578,NCT00420771,Gabapentin Treatment of Benzodiazepine Abuse in Methadone Maintenance Patients,,Completed,Has Results,Benzodiazepine Dependence|Opioid Dependence,Drug: Gabapentin|Drug: Placebo,Mean Reduction Change in Benzodiazepine Use Per Day Based on Time Line Follow Back,New York State Psychiatric Institute|National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,19,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",4906/#5998R|K23DA021209,2007-01-01,2011-01-01,2011-01-01,2007-01-11,2018-07-12,2018-07-12,"Bridge Plaza Treatment and Rehabilitation Clinic, Long Island City, New York, United States",,https://ClinicalTrials.gov/show/NCT00420771
579,NCT00061087,Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) in Methadone Patients - 1,,Completed,No Results Available,ADHD|Opioid-Related Disorders|Cocaine Dependence,Drug: Methylphenidate|Drug: Bupropion|Other: Placebo,Cocaine use based on urine toxicology|ADHD symptom severity based on the ADHD Rating scale score,New York State Psychiatric Institute|National Institute on Drug Abuse (NIDA),All,18 Years to 60 Years   (Adult),Phase 2|Phase 3,115,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NIDA-011444-1,#4184R|R01DA011444|4184R",1998-02-01,2004-10-01,2004-10-01,2003-05-22,null,2018-05-16,"Research Foundation for Mental Hygiene, Inc., New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00061087
580,NCT02423772,Pilot Study of Combined Treatment for Veterans With Chronic Pain & Opiate Misuse,,Recruiting,No Results Available,Chronic Pain|Problematic Opioid Use,Behavioral: Acceptance and Commitment Therapy + Mindfulness-Based Relapse Prevention + Treatment as Usual (TAU),Patient Reported Outcomes Measurement Information System (PROMIS) - Pain Behavior|Patient Reported Outcomes Measurement Information System (PROMIS) - Pain Interference|Current Opioid Misuse Measure (COMM),University of New Mexico,All,"21 Years to 65 Years   (Adult, Older Adult)",Not Applicable,120,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",AT008398-01,2014-08-01,2018-07-01,2018-07-01,2015-04-22,null,2017-11-09,"Raymond G. Murphy VA Medical Center, Albuquerque, New Mexico, United States",,https://ClinicalTrials.gov/show/NCT02423772
581,NCT02665429,A Quality Improvement Project to Investigate Individual Provider Variation in Opioid Prescribing From the Emergency Department,,Completed,No Results Available,"Analgesics, Opioid|Delivery of Health Care|Drug Prescribing|Over Prescribing|Prescribing Patterns, Physician|Practice Management, Medical|Practice Guidelines as Topic",Behavioral: Individual prescribing data profile and self-assessment,Change in number of opioid prescriptions per hundred patients seen|Change in percentage of total prescriptions written that are opioids|Change in median quantity of pills dispensed per opioid prescription|Change in number of prescriptions for long-acting opioid formulations,"University of Massachusetts, Worcester|UMass Memorial Health Care",All,"Child, Adult, Older Adult",Not Applicable,109,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,H00009241,2016-02-01,2017-03-01,2017-03-01,2016-01-27,null,2017-06-27,"UMass Clinton Hospital, Clinton, Massachusetts, United States|UMass Memorial Marlborough Hospital, Marlborough, Massachusetts, United States|UMass Memorial Medical Center, Worcester, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02665429
582,NCT02483468,The Effects of Cognitive Behavioral Therapy and Transcranial Current Stimulation (tDCS) on Chronic Lower Back Pain,,Recruiting,No Results Available,"Chronic Low Back Pain|Opioid Use, Unspecified",Behavioral: Cognitive Behavioral Therapy for Pain|Device: Transcranial Direct Current Stimulation|Device: Sham Transcranial Direct Current Stimulation,Pain perception|Opioid misuse|Psychiatric functioning,Medical University of South Carolina,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,120,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Pro00036590,2015-01-01,2020-01-01,2020-06-01,2015-06-29,null,2018-05-02,"Medical University of South Carolina, Charleston, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT02483468
583,NCT00246532,Opiate-Induced Tolerance & Hyperalgesia in Pain Patients,,Completed,No Results Available,Chronic Low Back Pain|Opioid-induced Hyperalgesia,Drug: Morphine|Drug: Placebo,Pain Tolerance|Pain Threshold|Opioid Titration|Pain Intensity|Roland-Morris Disability Index|Beck Depression Inventory|Follow-Up Survey,National Institute of General Medical Sciences (NIGMS),All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,139,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic",5K23GM071400-02,2005-10-01,2008-12-01,2009-08-01,2005-10-31,null,2012-04-30,"Stanford University School of Medicine, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT00246532
584,NCT03586219,Postoperative Opioid Consumption After Urogyneocologic Surgery,,Recruiting,No Results Available,Pelvic Organ Prolapse,Behavioral: Opioid-specific educational patient pamphlets,2 week postoperative opioid consumption|Modified Surgical Pain Score|Preoperative Patient Survey answers|Postoperative Patient Survey answers|Additional opioid prescriptions|Intraoperative complications|Postoperative complications|Postoperative Oral Morphine Equivalents Prior to Discharge,"University of California, Irvine|Kaiser Permanente",Female,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,146,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,2017-11833,2017-12-21,2019-06-30,2020-12-31,2018-07-13,null,2018-07-13,"Kaiser Permanente Orange County - Anaheim, Anaheim, California, United States|Kaiser Permanente Orange County-Irvine Medical Center, Irvine, California, United States|University of California Irvine Medical Center, Orange, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT03586219/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT03586219/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03586219
585,NCT01433081,The Effect of Magnesium Sulfate Infusion on the Quality of Recovery of Ambulatory Patients,,Completed,Has Results,"Pain|Opioid Use, Unspecified, Uncomplicated",Drug: Placebo infusion of .9 normal saline|Drug: administration of magnesium sulfate,Quality of Recovery Scores Post Operative|Opioid Consumption,Northwestern University,Female,18 Years to 64 Years   (Adult),Not Applicable,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",STU00032878,2011-02-01,2013-04-01,2013-04-01,2011-09-13,2014-04-02,2014-04-02,"Prentice Womens Hospital, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT01433081
586,NCT03454555,Integrated Health Services to Reduce Opioid Use While Managing Chronic Pain,,Not yet recruiting,No Results Available,Chronic Pain,Behavioral: Shared Decision Making|Behavioral: Motivational Interviewing and Cognitive Behavioral Therapy for Chronic Pain,Reduction of opioid use|Time to discontinuation of opioid use|Physical functioning|Pain interference on functioning|Pain status|Emotional distress|Depressive symptoms|Self-efficacy to manage and cope with pain|Satisfaction with pain care,RTI International|Patient-Centered Outcomes Research Institute|University of North Carolina Health Care System|Duke University Health System|Vanderbilt University Health System,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,1060,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PCORI-OPD-1610-37006,2019-01-31,2022-09-30,2022-09-30,2018-03-06,null,2018-03-06,"University of North Carolina Health Care System, Chapel Hill, North Carolina, United States|Duke University Health System, Durham, North Carolina, United States|Vanderbilt University Health System, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT03454555
587,NCT03532256,Post-op Crowd Sourcing Health Data Via Text-messaging,,Not yet recruiting,No Results Available,Orthopedic Surgery|Opioid Use|Acute Injuries Knee|Neurosurgery|Surgery,Behavioral: Observation,Number of opioid tablets taken at 7 days|Number of opioid tablets prescribed and number remaining|Perceived ability to manage pain,University of Pennsylvania,All,"18 Years and older   (Adult, Older Adult)",,200,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,827461,2018-08-01,2019-08-31,2020-04-30,2018-05-22,null,2018-05-22,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03532256
588,NCT02898792,Remifentanil in Adults With OSA,AROSA,Recruiting,No Results Available,"Apnea, Sleep",Drug: Targeted infusion of remifentanil,The relationship between remifentanil concentration and miotic effect,Washington University School of Medicine,All,"18 Years to 70 Years   (Adult, Older Adult)",Early Phase 1,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,201605158,2016-07-01,2018-10-01,2018-12-01,2016-09-13,null,2018-08-02,"Washington University St Louis School of Medicine, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT02898792
589,NCT00135759,Addition of Naltrexone to Methadone Taper,,Completed,No Results Available,Heroin Dependence|Opioid-Related Disorders|Substance-Related Disorders,Drug: Naltrexone|Drug: Placebo comparator|Drug: naltrexone,Withdrawal intensity|Retention in treatment,National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,174,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",NIDA-15469-1|R21-15469-1|DPMC,2005-04-01,null,2006-07-01,2005-08-26,null,2017-01-12,"Duke University, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00135759
590,NCT00780702,Aripiprazole for Prevention of Relapse to Cocaine Use in Methadone-Maintenance Patients,,Completed,No Results Available,Cocaine Dependence|Cocaine-Related Disorders|Opioid-Related Disorders,Drug: Airipiprazole|Drug: Placebo,Time to relapse|Cocaine use|HIV risk behaviors,National Institute on Drug Abuse (NIDA)|National Institutes of Health Clinical Center (CC),All,18 Years to 60 Years   (Adult),Phase 1,41,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment,999908426|08-DA-N426,2008-05-08,2013-04-16,2013-04-16,2008-10-28,null,2018-08-03,"National Institute on Drug Abuse, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00780702
591,NCT00023283,Counseling Conditions for Buprenorphine in a Primary Care Clinic - 1,,Unknown status,No Results Available,"Heroin Dependence|Opioid-Related Disorders|Substance Abuse, Intravenous",Drug: Buprenorphine,Self-reported frequency of illicit opioid use|Percentage of opioid-negative urine specimens|Maximum number of weeks abstinent from illicit opioids,National Institute on Drug Abuse (NIDA)|Yale University,All,21 Years to 55 Years   (Adult),Phase 2,0,NIH|Other,Interventional,Allocation: Randomized|Primary Purpose: Treatment,NIDA-9803-1|R01-9803-1,null,null,null,2001-08-31,null,2009-01-01,"APT Residential Services Division, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00023283
592,NCT00634010,Morphine Versus Methadone As First Line Strong Opioid for Cancer Pain,,Terminated,Has Results,Advanced Cancer|Solid Tumors,Drug: Morphine|Drug: Methadone,Participant Pain Severity Score Measured Using Brief Pain Inventory,M.D. Anderson Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 3,36,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2007-0477|1R01CA124481-01A1|NCI-2012-02126,2008-02-01,2015-01-01,2015-01-01,2008-03-12,2016-05-09,2016-05-09,"LBJ General Hospital, Houston, Texas, United States|The Michael E. DeBakey V.A. Medical Center, Houston, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00634010
593,NCT00000261,Effects of Alcohol History on Effects of Sevoflurane and Nitrous Oxide - 13,,Completed,No Results Available,Alcohol-Related Disorders|Opioid-Related Disorders|Substance-Related Disorders,Drug: 30% Nitrous oxide|Other: Placebo|Drug: 0.2% sevoflurane|Drug: 0.4% sevoflurane|Drug: 0.6% sevoflurane,Mood|Psychomotor performance|Choice of drug vs placebo,University of Chicago|National Institute on Drug Abuse (NIDA),All,"Child, Adult, Older Adult",Phase 2,14,Other|NIH,Interventional,"Intervention Model: Single Group Assignment|Masking: Double (Participant, Care Provider)",NIDA-08391-13|R01DA008391|R01-08391-13,1997-11-01,1998-10-01,1998-10-01,1999-09-21,null,2015-05-27,"University of Chicago, Anesthesia & Critical Care, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00000261
594,NCT00000257,Effects of Alcohol History on Effects of Nitrous Oxide - 9,,Completed,No Results Available,Alcohol-Related Disorders|Opioid-Related Disorders|Substance-Related Disorders,Drug: 0% N2O and 10% N2O|Drug: 0% N2O and 20% N2O|Drug: 0% N2O and 30% N2O|Drug: 0% N2O and 40% N2O,Choice of nitrous oxide vs placebo,University of Chicago|National Institute on Drug Abuse (NIDA),All,21 Years to 37 Years   (Adult),Not Applicable,19,Other|NIH,Interventional,"Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)",NIDA-08391-9|R01DA008391|R01-08391-9,1995-09-01,1997-04-01,1997-04-01,1999-09-21,null,2015-05-28,"University of Chicago, Anesthesia & Critical Care, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00000257
595,NCT02709317,Preventing Risky Drinking in Veterans Treated With Prescription Opioids,,Recruiting,No Results Available,Pain|Opiates|Alcohol Drinking,Behavioral: Prevention Intervention|Behavioral: Brief Intervention,"Rates of Risky Drinking 3 months|Rates of Risky Drinking, 6 months|Rates of Risky Drinking, 9 months|Rates of Risky Drinking, 12 months|Rates of Risky Drinking, 18 months",University of Pennsylvania|United States Department of Defense|Corporal Michael J. Crescenz VA Medical Center|Medical University of South Carolina|VA Pittsburgh Healthcare System,All,"18 Years to 88 Years   (Adult, Older Adult)",Phase 2,300,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,818671,2014-04-01,2018-09-01,2018-10-01,2016-03-16,null,2017-10-11,"Philadelphia VA Medical Center, Philadelphia, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|VA Pittsburgh Health System, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02709317
596,NCT02244099,Controlled Substance Treatment Agreements in an Internal Medicine Residents' Clinic,,Completed,No Results Available,"Anxiety|Chronic Pain|Opioid Use, Unspecified",Other: Controlled Substance,Percentage of Patients Adhering to Controlled Substance Agreement|Discrepancy on urine drug screen|Morphine Equivalent Review|Healthcare Utilization,Ohio State University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,96,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,2014H0102,2014-09-01,2015-01-01,2015-03-01,2014-09-18,null,2015-09-24,"The Ohio State University, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02244099
597,NCT02839889,"Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)",,Completed,No Results Available,Cancer|Constipation|Pain,Drug: Naloxegol|Drug: Placebo,Adverse Events|Numerical Rating Scale (NRS) for Pain change from Baseline|Daily Opioid Use change from Baseline|Adverse Events associated with Blood Laboratory result changes from Baseline|Electrocardiogram (ECG) Interval and Rate Change from Baseline|Vital Signs changes from Baseline|Rescue Free Bowel Movements (RFBM) Responder Rate|Time to First Post-dose Rescue Free Laxation|Bristol Stool Scale (BSS) Score|Patient Assessment of Constipation Symptoms (PAC-SYM)|Patient Assessment of Constipation Quality of Life (PAC-QOL)|Degree of Straining question with each Bowel Movement|Complete Evacuation question with each Bowel Movement,"Hospice of Henderson County, Inc.|AstraZeneca",All,"18 Years and older   (Adult, Older Adult)",Phase 4,12,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D3820C00041,2016-09-01,2018-01-11,2018-01-11,2016-07-21,null,2018-05-09,"MJHS Institute for Innovation in Palliative Care, New York, New York, United States|Hospice of Henderson County, Inc, Flat Rock, North Carolina, United States|Hospice of the Western Reserve, Inc., Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02839889
598,NCT02997644,Impact of Different Educational Approaches on Post-operative Opiate Utilization After Elective Lower Extremity Surgery,OpiateLEO,Recruiting,No Results Available,Knee Injuries and Disorders|Hip Injuries and Disorders|Opiate Addiction,Behavioral: Video Education|Behavioral: Usual Care Group,Opiate Prescriptions|Numeric Pain Rating Scale|PROMIS-29,Brooke Army Medical Center,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,100,U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",C.2016.142d,2016-06-01,2018-05-01,2019-05-01,2016-12-20,null,2018-02-09,"Brooke Army Medical Center, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT02997644
599,NCT00130819,Comparison of HIV Clinic-based Treatment With Buprenorphine Versus Referred Care in Heroin-dependent Participants,,Completed,No Results Available,Opiate Dependence|HIV Seropositivity|HIV Infections,Behavioral: Clinic-based substance abuse treatment with buprenorphine|Behavioral: Case management and referred substance abuse treatment,Retention to substance abuse treatment|Visit attendance with primary medical provider|Urine drug screen positivity for opioids and other drugs|Use of and adherence to highly active antiretroviral therapy (HAART)|HIV RNA changes|CD4 cell count changes|Self-reported HIV transmission risk behaviors|Costs and resource utilization,Johns Hopkins University|The New York Academy of Medicine,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H97HA03794|HRSA-04-078,2005-11-01,2009-04-01,2009-04-01,2005-08-16,null,2015-04-15,"Johns Hopkins HIV Clinic, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00130819
600,NCT02321319,Open-Label Safety and PK Study of ER Hydromorphone Tablets in Opioid-Tolerant Pediatric Chronic Pain Patients,,Recruiting,No Results Available,Chronic Pain,Drug: Hydromorphone HCl ER Tablets,"Safety ( based on vital signs, pulse oximetry, clinical laboratory assessments, and AEs)",Mallinckrodt,All,7 Years to 17 Years   (Child),Phase 3,100,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,COV02520124,2014-12-01,2019-01-01,2019-01-01,2014-12-22,null,2017-06-06,"Jackson Memorial Hospital, University of Miami, Miami, Florida, United States|Medical Professional Clinical Research, Miami, Florida, United States|Clinical Pharmacology Services, Inc., Tampa, Florida, United States",,https://ClinicalTrials.gov/show/NCT02321319
601,NCT01596673,A Study to Assess the Abuse Potential of Hydrocodone Extended-Release Tablet in Recreational Opioid Users,,Completed,No Results Available,Drug Abuse,Drug: 45-mg hydrocodone bitartrate extended-release tablet (crushed or intact)|Drug: Placebo,Drug Liking and Effects Questionnaire (DLEQ)|Overall drug liking visual analog scale (VAS) score|Pharmacokinetic maximum observed (Cmax) plasma concentrations|Take drug again Visual Analog Scale|Price Value Assessment Questionnaire|Addiction Research Center Inventory (ARCI): Morphine Benzedrine Group (MBG) Subscale|Addiction Research Center Inventory (ARCI): Lysergic Acid Diethylamide (LSD) Subscale|Addiction Research Center Inventory (ARCI): Pentobarbital Chlorpromazine Alcohol Group (PCAG) Subscale|Pupillometry|Time to maximum observed drug concentration (tmax)|Area under the plasma concentration by time curve (AUC) from time 0 to maximum drug concentration time - Immediate release product|Area under the plasma concentration by time curve (AUC) from time 0 to maximum drug concentration time - Extended release product intact|Area under the plasma concentration by time curve (AUC) from time 0 to maximum drug concentration time - Extended release product crushed|Area under the plasma concentration by time curve (AUC) from time 0 to last measureable drug concentration|Area under the plasma concentration by time curve (AUC) from time 0 to infinity|Apparent plasma terminal elimination rate constant and associated elimination half-life,Cephalon|Teva Pharmaceutical Industries,All,18 Years to 50 Years   (Adult),Phase 1,100,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",C33237/1085,2012-03-01,2012-05-01,2012-05-01,2012-05-11,null,2012-11-21,"Cephalon Investigational Site 001, Salt Lake City, Utah, United States|Cephalon Investigational Site 100, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01596673
602,NCT03398265,Treatment Navigation for Opioid Use Disorder,,Recruiting,No Results Available,Opioid-use Disorder,Behavioral: Treatment Navigation (Intervention)|Other: Control,Feasibility|Criminal activity|Hospitalizations|Treatment enrollment|Relapse prevention medication prescriptions,University of Washington,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STUDY00000227,2017-03-20,2018-07-01,2018-12-01,2018-01-12,null,2018-01-12,"DOC Community Field Office, Auburn, Washington, United States|DOC Community Field Office, Burien, Washington, United States|DOC Community Field Office, Federal Way, Washington, United States|DOC Community Field Office, Kent, Washington, United States|DOC Community Field Office, Renton, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT03398265/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT03398265
603,NCT00939887,"A Study Of Kappa Opioid Receptor Occupancy Of PF-04455242, Using PET (Positron Emission Tomography)",,Terminated,No Results Available,Bipolar Disorder|Depression,Drug: PF-04455242,Overall kappa opioid receptor occupancy of PF 04455242.|Binding potential (BP) of [11C] PF 04767135.|Kappa opioid receptor occupancy of PF 04455242 at regions of interest in man.|Relationship between plasma PF 04455242 concentration and kappa opioid receptor occupancy (IC50).,Pfizer,All,18 Years to 55 Years   (Adult),Phase 1,12,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,B1071003,2009-09-01,2009-12-01,2009-12-01,2009-07-15,null,2010-02-08,"Pfizer Investigational Site, New Haven, Connecticut, United States|Pfizer Investigational Site, New Haven, Connecticut, United States|Pfizer Investigational Site, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00939887
604,NCT02730403,TAU Opioid Use Outcomes Following Discharge From Detoxification and Short Term Residential Programs Affiliated With CTN-0051,,Completed,No Results Available,Opioid Use Disorder,Other: Treatment As Usual,"Days to first use|Percent days of use during the first eight weeks post-discharge|number of positive, negative and missing UDSs at weeks 1, 4 and 8",New York University School of Medicine,All,"18 Years and older   (Adult, Older Adult)",,211,Other,Observational,Observational Model: Other|Time Perspective: Prospective,16-00090,2016-06-01,2017-01-30,2017-01-30,2016-04-06,null,2017-05-16,"Tarzana Treatment Centers, Tarzana, California, United States|Gateway Community Services, Inc., Jacksonville, Florida, United States|Stanley Street Treatment and Resources, Fall River, Massachusetts, United States|Bellevue Hospital, New York, New York, United States|Maryhaven, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02730403
605,NCT00987961,Linking Hospitalized Injection Drug Users to Buprenorphine,,Completed,No Results Available,Opiate Dependence,Behavioral: Linkage,opioid use|HIV risk behavior|reduction in injection-related medical conditions|reduction in emergency department and hospital utilization,Butler Hospital|Boston Medical Center,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,147,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1R01DA026223,2009-09-01,2014-03-01,2015-09-01,2009-10-01,null,2015-11-11,"Boston Medical Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00987961
606,NCT00499746,The Discriminative Effects of Tramadol in Humans,,Completed,Has Results,Opioid Abuse|Opioid Addiction|Stimulant Abuse|Stimulant Addiction,Drug: tramadol|Drug: placebo|Drug: Hydromorphone|Drug: Methylphenidate,Acquisition of Discrimination Assessed by Accuracy of the Discrimination Test|Discrimination Effects Assessed by Operant Responses|Discrimination Effects Assessed by Point Distribution|Discrimination Effects Assessed by Discrete Choice|Physiologic Effects Assessed by the Pharmacological Class Questionnaire|Physiological Effects Assessed by Peak Change From Baseline Pupil Diameter|Peak Change From Baseline Opioid Agonist Effects Assessed by the Visual Analog Scale (VAS)|Peak Change From Baseline Stimulant Effects Assessed by the Visual Analog Scale (VAS),National Institute on Drug Abuse (NIDA),All,"21 Months to 55 Years   (Child, Adult)",Phase 1|Phase 2,20,NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",NIDA-18125-3|R01DA018125|DPMCDA,2007-11-01,2010-04-01,2011-08-01,2007-07-11,2017-10-17,2017-10-17,"Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00499746
607,NCT03134092,The Life STORRIED Study,,Recruiting,No Results Available,Opioid Dependence|Communication|Risk Behavior|Narrative Medicine,Other: Narrative Enhanced Risk Tool (NERT)|Other: probabilistic risk communication tool (PRT),Risk Awareness and Recall|Patient reported use of opioid medication|Reported use of non opioid pain medication|Functional Ability/Return to Usual Activities|Functional Ability/Return to Usual Activities for back pain patients|Patient Reported Shared Decision Making|Satisfaction with Pain Treatment|Trust in Provider|Patient Preference for Treatment Plan|Treatment Plan Agreement between Patient Preference and Provider Decision,University of Pennsylvania|Patient-Centered Outcomes Research Institute,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,1100,Other,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,826673,2017-06-28,2018-09-01,2019-09-30,2017-04-28,null,2017-10-31,"Mayo Clinic, Rochester, Minnesota, United States|Northwell Health, Manhasset, New York, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03134092
608,NCT00982696,Treatment of Advanced Head and Neck Cancer,,Terminated,No Results Available,"Carcinoma, Squamous Cell of Head and Neck",Biological: Opioid Growth Factor,Progression of tumor measured with CT scan|Metastatic development using CT scan,Milton S. Hershey Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 2,5,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PSU 23429,2008-02-01,2011-11-01,2011-11-01,2009-09-23,null,2014-09-30,"Penn State College of Medicine, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00982696
609,NCT00930943,Effect of Extended-release Oxymorphone Taking With or Without Food on Cognitive Functioning,,Completed,No Results Available,Chronic Pain,Drug: Oxymorphone ER (Opana ER),Rapid Visual Information Processing Test|Spatial Recognition Memory test|Spatial Working Memory Test|Verbal Recognition Memory Test,MedVadis Research Corporation,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,30,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2009-133A,2009-05-01,2009-11-01,2009-11-01,2009-07-02,null,2011-09-09,"MedVadis Research Corporation, Wellesley Hills, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00930943
610,NCT00263458,Integrating Buprenorphine Into the SFGH AIDS Program,BHIVES-SF,Completed,No Results Available,HIV|Buprenorphine|Opioid Dependence,Other: Integrated office-based buprenorphine treatment for opioid dependence in an HIV primary care setting,"Substance use outcomes at 0, 1, 3, 6, 9 and 12 months.|HIV care outcomes at 0, 1, 3, 6, 9 and 12 months.|HIV-related health|Quality of life|Social functioning|Quality of HIV care.|Patient satisfaction at 3 months.","University of California, San Francisco|San Francisco Department of Public Health|The New York Academy of Medicine|Health Resources and Services Administration (HRSA)",All,"19 Years and older   (Adult, Older Adult)",Phase 4,37,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H97HA03799,2005-12-01,2009-06-01,2009-06-01,2005-12-08,null,2011-09-12,"UCSF Positive Health Program, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT00263458
611,NCT00227357,The CORE Buprenorphine Project - An HIV Primary Care Program Demonstration,BUP,Completed,No Results Available,HIV Infections|AIDS|Opiate Dependence|Post-Traumatic Stress Disorders,Drug: On-site - buprenorphine/naloxone (Suboxone)|Drug: Off-site - methadone or no agonist,,Ruth M. Rothstein CORE Center|Health Resources and Services Administration (HRSA)|The New York Academy of Medicine,All,"18 Years and older   (Adult, Older Adult)",,101,Other|U.S. Fed,Observational,Time Perspective: Prospective,1-H97HA03796-01-00,2005-07-01,2008-12-01,2008-12-01,2005-09-28,null,2010-06-07,"The CORE Center, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00227357
612,NCT03472521,Postpartum Analgesic Management of Patients at Risk for Prolonged Pain and Analgesic Use,,Not yet recruiting,No Results Available,Opioid Use|Postpartum Disorder|Chronic Pain Syndrome,Drug: Gabapentin|Drug: Placebo,Opioid Utilization|Pain Report|Functional recovery,Stanford University,Female,"18 Years and older   (Adult, Older Adult)",Phase 4,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IRB-43964,2019-04-01,2021-03-31,2021-03-31,2018-03-21,null,2018-05-17,"Lucille Packard Children's Hospital, Palo Alto, California, United States",,https://ClinicalTrials.gov/show/NCT03472521
613,NCT03495245,Identification of Potential Biomarkers for Pain,,Recruiting,No Results Available,Fibromyalgia,,Serum protein levels as a marker for pain|Determine if correlation may be established between impact of fibromyalgia and opioid doses|Determine if correlation may be established between sleep index and opioid doses,Rowan University|American Osteopathic Association,All,"18 Years and older   (Adult, Older Adult)",,200,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,Pro2017001740,2018-05-01,2019-09-30,2021-09-30,2018-04-11,null,2018-04-11,"Rowan University School of Osteopathic Medicine, Stratford, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT03495245
614,NCT03241771,Impact of Direct Outreach to Expand Access to Naloxone in the Context of Standing Orders,,"Active, not recruiting",No Results Available,Opioid Abuse|Overdose|Risk Behavior,Behavioral: Naloxone Navigator 1.0,Risk Behavior|Patient Knowledge|Naloxone Dispensings|Opioid dose|Drug Use Risk Behavior|Alcohol Use Risk Behavior,Kaiser Permanente|Denver Health and Hospital Authority|National Institute on Drug Abuse (NIDA),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,300,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,CO-16-2405|1R01DA042059-01,2017-08-14,2018-07-31,2018-07-31,2017-08-07,null,2018-08-09,"Denver Health, Denver, Colorado, United States",,https://ClinicalTrials.gov/show/NCT03241771
615,NCT03467230,Performance Assessment of the PMD-200 Under General Anesthesia,,Recruiting,No Results Available,Pain|Opioid Use|Intraoperative Complications,Device: NoL Index,The primary efficacy objective: Correlation of NoL Index with noxious stimulation/analgesic use|the secondary efficacy objective: Correlation of NoL Index with changes in heart rate|the secondary efficacy objective: Correlation of NoL Index with blood pressure|Safety objective: Any adverse reaction related to device,University of Vermont,All,"18 Years and older   (Adult, Older Adult)",,80,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,18-0302,2018-03-15,2018-11-01,2019-06-01,2018-03-15,null,2018-08-10,"University of Vermont Medical Center, Burlington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT03467230
616,NCT02583243,Project BEST: Buprenorphine Entry Into Substance Abuse Treatment,,Completed,No Results Available,"Opioid-related Disorders|HIV Infections|Hepatitis C, Chronic|Depression",Behavioral: MET/CBT based individualized counseling|Drug: Buprenorphine,,Yale University,All,"18 Years to 65 Years   (Adult, Older Adult)",,209,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,SAMHSA 15767|SAMHSA TCE/HIV 15767,2005-05-01,2008-08-01,2008-08-01,2015-10-22,null,2015-10-22,"Yale University, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT02583243
617,NCT01973452,Placebo Controlled Clinical Trial of the Postoperative Opioid Sparing Effects of Intraoperative Dexmedetomidine Infusion for Thoracic Surgery,,"Active, not recruiting",No Results Available,Pain,Drug: Dexmedetomidine|Drug: Placebo,total opioid administered|Improves analgesia|Results in fewer cumulative episodes of nausea or antiemetic doses and/or sedation,Memorial Sloan Kettering Cancer Center,All,"21 Years and older   (Adult, Older Adult)",Phase 3,332,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",13-163,2013-10-01,2019-10-01,2019-10-01,2013-10-31,null,2018-02-08,"Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center 1275 York Avenue, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01973452
618,NCT01770314,Study to Test the Efficacy of Online Education to Increase Safe Use of Opioid Medication.,,Completed,Has Results,Medication Adherence,Behavioral: Experimental,Self-efficacy - 8 Item Measure Taps Into Key Concepts Associated With Confidence for Managing Opioid Medications|Satisfaction With the Program,"Inflexxion, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,176,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,MedSafetyStudy|Endo Pharmaceuticals,2012-09-01,2013-04-01,2013-09-01,2013-01-17,2014-05-19,2014-05-19,"Inflexxion Inc, Newton, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01770314
619,NCT02599818,Navigation Services to Avoid Rehospitalization (NavSTAR),NavSTAR,Enrolling by invitation,No Results Available,Opioid-use Disorder|Cocaine Use Disorder|Alcohol Use Disorder,Behavioral: NavSTAR,Time-to-Rehospitalization|30-day rehospitalization rate|Cumulative days of inpatient hospitalization|Mortality|Emergency Department utilization rate|Emergency Department visits|addiction treatment entry|medical follow-up care|quality of life|alcohol use (self-report)|opioid use (self-report)|cocaine use (self-report)|opioid use (urine test)|cocaine use (urine test)|alcohol use disorder criteria|opioid use disorder criteria|cocaine use disorder criteria,"Friends Research Institute, Inc.|National Institute on Drug Abuse (NIDA)|University of Maryland|RTI International",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,420,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,14-07-224|R01DA037942-01A1,2016-03-15,2019-02-01,2019-02-01,2015-11-09,null,2017-08-31,"University of Maryland Medical Center, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02599818
620,NCT01123486,Hydromorphone Pharmacokinetic-Pharmacodynamic Fingerprint,,Withdrawn,No Results Available,Pain|Ventilatory Depression,Drug: hydromorphone,Opioid induced analgesia|Opioid induced ventilatory depression|Opioid induced miosis|Opioid induced EEG changes,Northwestern University,All,21 Years to 30 Years   (Adult),Not Applicable,0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STU00013543,2015-01-01,2015-01-01,2015-01-01,2010-05-14,null,2015-04-22,"Northwestern Memorial Hospital, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT01123486
621,NCT00792415,Validation of a Pediatric-Specific Abstinence Syndrome Assessment Tool,,Unknown status,No Results Available,Substance Withdrawal Syndrome,,Total scores of abstinence syndrome symptoms|Expert opinion on abstinence syndrome,Banner Health,All,"up to 18 Years   (Child, Adult)",,75,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,BHRI#05-08-0074,2009-11-01,2010-04-01,2010-12-01,2008-11-18,null,2010-04-26,"Cardon Children's Medical Center, Mesa, Arizona, United States",,https://ClinicalTrials.gov/show/NCT00792415
622,NCT00999544,Aprepitant Effects on Oxycodone Response,,Completed,Has Results,Narcotic Abuse,"Drug: Aprepitant 0mg|Drug: Aprepitant 40mg|Drug: Aprepitant 200mg|Drug: Oxycodone 0mg, p.o.|Drug: Oxycodone 20mg, p.o.|Drug: Oxycodone 40mg, p.o.|Drug: Oxycodone 0mg, IN|Drug: Oxycodone 15mg, IN|Drug: Oxycodone 30mg, IN",Abuse Liability Proxy|Respiration Depression,Sharon Walsh|National Institute on Drug Abuse (NIDA)|Merck Sharp & Dohme Corp.|University of Kentucky,All,18 Years to 55 Years   (Adult),Not Applicable,9,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",09-0446|R01DA027031,2009-10-01,2011-04-01,2011-04-01,2009-10-21,2013-08-23,2017-09-01,"University of Kentucky, Lexington, Kentucky, United States",,https://ClinicalTrials.gov/show/NCT00999544
623,NCT03295097,Characteristics and Clinical Implications of a Clinical Decision Support System,,Recruiting,No Results Available,Chronic Illness|Opioid Use|Palliative Care,Other: Clinical Decision Support System,Clinician Feasibility|Patient Quality of Life|Clinician Usability|Patient Pain|Patient Satisfaction,"Hospice of Henderson County, Inc.|Tabula Rasa HealthCare",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,TRHC2017-SERD101,2018-03-08,2019-11-01,2020-02-01,2017-09-27,null,2018-03-12,"MJHS Hospice and Palliative Care, New York, New York, United States|Hospice of Henderson County, Inc. d/b/a Four Seasons Compassion for Life, Flat Rock, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT03295097
624,NCT00929253,Efficacy of Computer Delivered Community Reinforcement Approach (CRA) (Bup II),CAT,Completed,No Results Available,Opiate Addiction,Drug: Suboxone|Behavioral: CRA|Behavioral: Therapy|Behavioral: CM,Abstinence defined as the longest documented period of continuous abstinence from opioids and cocaine for each participant|Delay discounting measures and other non-normal or ordinal outcomes measures will be compared across treatment groups based on nonparametric rank tests.,Virginia Polytechnic Institute and State University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,206,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB 31695,2007-09-01,2010-04-01,2010-04-01,2009-06-29,null,2016-05-02,"University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States",,https://ClinicalTrials.gov/show/NCT00929253
625,NCT03583138,"HIV, Buprenorphine, and the Criminal Justice System (STRIDE2)",,Completed,No Results Available,Human Immunodeficiency Virus|Acquired Immunodeficiency Syndrome|Opiate Addiction|Drug Dependence,Drug: buprenorphine,VL <400|CD4+ cell count|HIV risk behaviors|Retention in HIV care|Opioid use|Medically assisted therapy retention,Yale University|National Institute on Drug Abuse (NIDA)|George Mason University|Howard University,All,"18 Years and older   (Adult, Older Adult)",Phase 4,112,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,1011007631b,2014-06-23,2015-12-15,2017-06-30,2018-07-11,null,2018-07-11,"Howard University, Washington, District of Columbia, United States",,https://ClinicalTrials.gov/show/NCT03583138
626,NCT00899600,Intra-operative Ketamine Infusions in Opioid-dependent Patients With Chronic Lower Back Pain,,Completed,Has Results,Chronic Low Back Pain,Drug: Ketamine|Other: Normal saline,Morphine Consumption in the First 48 Hours After Surgery|Hospital Duration|Mortality|Hemodynamic Changes|Complications Related to Ketamine,Dartmouth-Hitchcock Medical Center,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,102,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",100674,2007-02-01,2009-04-01,2009-04-01,2009-05-12,2013-04-11,2013-05-07,"Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States",,https://ClinicalTrials.gov/show/NCT00899600
627,NCT01465191,Effect of Mu-opioid Receptor Genetics on 3 Doses of Spinal Morphine for Postoperative Analgesia After Cesarean Section,,Unknown status,No Results Available,Postoperative Pain,Drug: Morphine,"Milligrams of intravenous morphine used by patient in first 24 hours postoperatively|Pain scores at 6, 12, 18, and 24 hours|nausea|itching|patient satisfaction with analgesia",Columbia University,Female,18 Years to 45 Years   (Adult),Phase 4,300,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AAAI2804,2011-11-01,2016-11-01,2016-11-01,2011-11-04,null,2015-01-19,"George Washington University Medical Center, Washington, District of Columbia, United States|Columbia University Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01465191
628,NCT00015171,Buprenorphine and Naloxone for the Treatment of Opiate Dependence - 1,,Completed,No Results Available,Heroin Dependence|Substance-Related Disorders,Drug: Buprenorphine/naloxone,Craving|Drug use|Retention|Opioid withdrawal|Subjective rating,National Institute on Drug Abuse (NIDA)|New York MDRU,All,18 Years to 59 Years   (Adult),Phase 3,0,NIH|Other,Interventional,Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,NIDA-5-0013-1|Y01-5-0013-1,1996-04-01,1997-05-01,1997-06-01,2001-04-18,null,2017-01-16,"New York MDRU, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00015171
629,NCT01530542,A Clinical Study To Characterize The Pharmacokinetics And The Effects Of Food On Oxycodone In Healthy Volunteers,,Completed,No Results Available,Analgesia|Acute Pain|Chronic Pain|Narcotic Abuse|Opioid-related Disorders,Drug: oxycodone hydrochloride|Drug: marketed oxycodone hydrochloride,"Maximum Observed Plasma Concentration (Cmax)|Time to Reach Maximum Observed Plasma Concentration (Tmax)|Area under the Concentration-Time Curve (AUC)|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)|Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Percentage of participants with treatment-emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)|Change from Baseline in Diastolic Blood Pressure at each Post-Dose Assessment|Change from Baseline in Systolic Blood Pressure at each Post-Dose Assessment|Change from Baseline to each Post-Dose Assessment in Heart Rate|Change from Baseline to each Post-Dose Assessment in Respiratory Rate|Change from Baseline to each Post-Dose Assessment in Pulse Oximetry (SpO2, %)|Change from Screening to End-of-Study Assessment in Hematology Parameters|Change from Screening to End-of-Study Assessment in Chemistry Parameters|Change from Screening to End-of-Study Assessment in Urinalysis Parameters|Change from Screening to End-of-Study Assessment in ECG Measurements",Pfizer,All,18 Years to 55 Years   (Adult),Phase 1,35,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,K234-10-1001|B4501006,2010-07-01,2010-09-01,2010-09-01,2012-02-10,null,2012-02-24,"Pfizer Investigational Site, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT01530542
630,NCT00783172,Opioid Growth Factor (OGF) and Gemcitabine: Novel Treatment for Pancreatic Cancer,,Terminated,No Results Available,Pancreatic Cancer,Drug: Gemcitabine|Biological: Opioid Growth Factor (OGF),progression measured with CT scan,Jill P. Smith|Milton S. Hershey Medical Center|National Institutes of Health (NIH)|National Cancer Institute (NCI)|Penn State University,All,"18 Years and older   (Adult, Older Adult)",Phase 1,4,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PSU-20978 and 35686EP|1R03CA129581,2009-01-01,2010-08-01,2011-10-01,2008-10-31,null,2013-02-13,"Lehigh Valley Hospital and Health Network, Allentown, Pennsylvania, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00783172
631,NCT02452437,Opioids in Chronic Kidney Disease Patients Undergoing Hemodialysis,OCKD,Unknown status,No Results Available,Chronic Kidney Disease,Drug: Oxycodone,Oxycodone's intradialytic mass transfer coefficient,Emerio & Lourdes Linares Research and Education Center,All,30 Years to 60 Years   (Adult),Phase 4,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,ELLHDM-001,2015-05-01,2015-09-01,2015-12-01,2015-05-22,null,2015-05-22,"Oscar A. Linares, MD, Dearborn, Michigan, United States",,https://ClinicalTrials.gov/show/NCT02452437
632,NCT00249470,The Therapeutic Workplace Initiation Study,,Completed,Has Results,"Cocaine-Related Disorders|Opioid-Related Disorders|Heroin Dependence|Substance Abuse, Intravenous",Behavioral: Abstinence & Work|Behavioral: Work Only,Cocaine Abstinence|Percent Opiate Negative|HIV Risk Behaviors,Johns Hopkins University|National Institute on Drug Abuse (NIDA),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,117,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,WIRB 2162|R01DA012564,2003-04-01,2004-05-01,2004-10-01,2005-11-07,2016-12-16,2017-12-27,"The Center for Learning and Health, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00249470
633,NCT01878006,"Mu Opioid Receptor Genes, Remifentanil, and Pain Sensitivity",,Completed,No Results Available,Polymorphism-Genetic|Pain|Allelic Frequencies of Genetic Markers,Genetic: OPRM1 AA118|Drug: Morphine|Drug: Placebo|Genetic: OPRM1 GX118,"Differences 11C raclopride displacement in ventral striatum based on genotype for OPRM1|Differences in subjective perceptions of morphine intoxication and opiate effects based on genotype for OPRM1|Differences in pupillary constriction, respiratory rate, pain response based on genotype for OPRM1|Differences in neuroendocrine measures (ACTH, cortisol) based on genotype for OPRM1",National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institute on Drug Abuse (NIDA)|National Institutes of Health Clinical Center (CC),Male,21 Years to 55 Years   (Adult),Phase 2,15,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other,130061|13-AA-0061,2013-06-13,2017-04-27,2017-04-27,2013-06-14,null,2017-10-19,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01878006
634,NCT02373254,NSAIDS Versus Opioids in Acute SER II Ankle Fractures,,Completed,No Results Available,Ankle Fracture,Drug: Ibuprofen|Drug: Acetaminophen/hydrocodone,fracture healing as measured by radiographic evaluation|pain level improvement as measured by VAS score|functional improvement as measured by AAOS score,"University of California, Davis",All,18 Years to 60 Years   (Adult),Early Phase 1,1,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,656916,2015-01-01,2015-10-01,2015-10-01,2015-02-26,null,2017-07-14,"University of California Davis, Sacramento, California, United States",,https://ClinicalTrials.gov/show/NCT02373254
635,NCT03026790,Veterans' Pain Care Organizational Improvement Comparative Effectiveness Study,VOICE,Enrolling by invitation,No Results Available,Chronic Pain,Other: Medication management|Other: Non-pharmacological pain management|Drug: Buprenorphine-Naloxone,Change in Brief Pain Inventory (BPI) total score from 0 to 12 months|Change in opioid daily dose from 0 to 12 months|Number with both 30% improvement in BPI and 50% reduction in opioid dose,University of Minnesota - Clinical and Translational Science Institute|Patient-Centered Outcomes Research Institute,All,"21 Years and older   (Adult, Older Adult)",Phase 2,1400,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,OPD-1511-33052,2017-10-19,2020-10-01,2020-10-01,2017-01-20,null,2017-10-31,"Minneapolis VA Health Care System, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT03026790
636,NCT00149669,Employment-based Reinforcement of Naltrexone Ingestion and Abstinence,,Completed,Has Results,"Cocaine-Related Disorders|Heroin Dependence|Opioid-Related Disorders|Substance Abuse, Intravenous",Behavioral: employment-based reinforcement,Percentage of Urine Samples Positive for Naltrexone|Percentage of Urine Samples Negative for Cocaine|Percentage of Urine Samples Negative for Opiates,Johns Hopkins University|National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,67,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NA_00039284|R01DA019386,2005-12-01,2010-12-01,2010-12-01,2005-09-08,2017-08-16,2017-09-14,"The Center for Learning and Health, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00149669
637,NCT03576781,Developing rTMS Treatment Strategies for Pain in Opiate Dependence,,Recruiting,No Results Available,Pain|Chronic Pain|Opioid Dependence|Opioid Use,Device: Real iTBS|Device: Sham iTBS|Device: Real cTBS|Device: Sham cTBS,iTBS to the left DLPFC vs. cTBS to the left MPFC|Changes in pain threshold|Changes in opiate pain and craving inventory,Medical University of South Carolina|South Carolina Clinical & Translational Research Institute (SCTR),All,"18 Years to 65 Years   (Adult, Older Adult)",Early Phase 1,78,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",61328,2017-02-09,2019-12-01,2019-12-01,2018-07-03,null,2018-07-23,"Medical University of South Carolina, Charleston, South Carolina, United States|Ralph H Johnson Veterans Medical Center, Charleston, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT03576781
638,NCT03467750,Effect of Ketorolac on Post Adenotonsillectomy Pain,,Recruiting,No Results Available,Obstructive Sleep Apnea,Drug: Ketorolac|Drug: Standard of Care,"Post-Anesthesia Care Unit (PACU) Morphine Requirements|Face, Legs, Activity, Cry, Consolability (FLACC) Scale Score|Post-Anesthesia Care Unit (PACU) Recovery Time|Incidence of Post-Tonsillectomy Bleeding|Pain Medication Administration",Emory University,All,"2 Years to 18 Years   (Child, Adult)",Phase 4,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Supportive Care,IRB00097738,2018-07-19,2020-08-24,2020-08-24,2018-03-16,null,2018-07-25,"Childrens Healthcare of Atlanta, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT03467750
639,NCT01409044,Effect of Music on Pain and Anxiety After Surgery,,Terminated,No Results Available,Postop Adult ICU Patients,Other: Music,"Opiate use|Pain, anxiety and distress outcome measures",National Institutes of Health Clinical Center (CC),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,62,NIH,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,110201|11-CC-0201,2011-06-17,2013-05-09,2017-08-08,2011-08-03,null,2017-08-10,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01409044
640,NCT02867124,Long-acting Naltrexone for Pre-release Prisoners,,Recruiting,No Results Available,Opiate Addiction,Drug: XR-NTX|Other: place of residence|Other: opioid treatment program,treatment adherence|Any illicit opioid used|re-arrest|re-incarceration|criminal activity|Injection drug use and HIV sexual risk factors|Treatment Group Equilibration,"Friends Research Institute, Inc.|National Institute on Drug Abuse (NIDA)",All,"18 Years and older   (Adult, Older Adult)",Phase 3,240,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FriendsResearch|R01DA040636,2017-01-01,2020-08-01,2021-08-01,2016-08-15,null,2018-02-07,"Maryland Department of Public Safety and Correctional Services, Towson, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02867124
641,NCT02863601,Impact of Pregnancy on Buprenorphine Pharmacokinetics and Pharmacodynamics,,Recruiting,No Results Available,Opiate Addiction|Pregnancy,,Exposure to BUP (AUC) during pregnancy and the post-partum state,University of Pittsburgh,Female,18 Years to 45 Years   (Adult),,40,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,PRO15120442,2016-08-01,2020-06-01,2021-06-01,2016-08-11,null,2018-07-26,"Univerity of Pittsburgh Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT02863601/Prot_SAP_009.pdf|""Informed Consent Form: Adult Version"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT02863601/ICF_010.pdf|""Informed Consent Form: Minor Version"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT02863601/ICF_011.pdf",https://ClinicalTrials.gov/show/NCT02863601
642,NCT02539823,Acute and Short-term Effects of CBD on Cue-induced Craving in Drug-abstinent Heroin-dependent Humans,,Completed,No Results Available,Opiate Addiction,Drug: CBD 400 mg|Drug: CBD 800 mg|Drug: Control (placebo),"Changes in Cue-Induced In-Clinic Craving (from baseline to post-cue (30 minutes), and from test visit 1 through test visit 4 (1 week)) - via the Visual Analog Scale for Craving (VASC)|Changes in Out-of-Clinic Craving (from pre-dose to approximately 4-6 hours post-dose; and from test visit 1 to test visit 4 or 1 week) - via the Heroin Craving Questionnaire (HCQ)|Vital Signs","Hurd,Yasmin, Ph.D.|GW Research Ltd",All,"21 Years to 65 Years   (Adult, Older Adult)",Phase 2,45,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",MSBI HSM# 087-14,2015-09-01,2017-05-24,2017-05-24,2015-09-03,null,2018-02-21,"Mount Sinai Beth Israel, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02539823
643,NCT02477267,Study of Buprenorphine-Naloxone Sublingual Spray and Suboxone® Sublingual Film in Healthy Volunteers,,Completed,No Results Available,Opiate Dependence,Drug: SL spray|Drug: SL film,Maximum plasma concentration (Cmax)|Time to Cmax (Tmax)|Elimination rate constant|Elimination half-life (T½)|Area under the curve to the final sample with a concentration greater than the limit of quantification (LOQ [AUClast])|Area under the curve extrapolated to infinity (AUCinf),INSYS Therapeutics Inc,All,18 Years to 45 Years   (Adult),Phase 1,47,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,INS009-15-033,2015-06-01,2015-07-01,2015-07-01,2015-06-22,null,2015-09-03,"Worldwide Clinical Trials Early Phase Services, LLC, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT02477267
644,NCT02052258,Oxytocin in Opiate Dependence: A Pilot Study of the Effects of Intranasal Oxytocin on Emotional Processes and Stress Responses in Patients With Opiate Dependence,,Unknown status,No Results Available,Opiate Dependence,Drug: Oxytocin,Cold Pressor Task,"MacDonald, Kai, M.D.",Male,"18 Years and older   (Adult, Older Adult)",Phase 1,null,Other,Interventional,,120283,2013-01-01,2015-12-01,null,2014-02-03,null,2014-09-15,"UCSD Medical Center, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT02052258
645,NCT02525731,Targeting Effective Analgesia in Clinics for HIV - Patient Cohort,TEACH,"Active, not recruiting",No Results Available,HIV Infection|Pain|Drug Dependence,,Pain severity in the past week (Brief Pain Inventory)|Opioid misuse (Current Opioid Misuse Measure)|Pain interference in the past week (Brief Pain Inventory)|Any emergency department visit to seek opioids (medical chart review and interview)|Number of days of drug use in the past 30 days (Addiction Severity Index)|Trust in provider (Physician Trust Scale)|Satisfaction with COT (questions created),Boston Medical Center|National Institute on Drug Abuse (NIDA)|Emory University|Grady Health System,All,"18 Years and older   (Adult, Older Adult)",,170,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,H-33343|R01DA037768,2015-07-01,2018-11-01,2018-11-01,2015-08-17,null,2018-07-10,"Emory University, Atlanta, Georgia, United States|Boston Medical Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02525731
646,NCT01230515,Opioid Titration in the Hospice Setting: Barriers Assessment and Modification of the Model Order Sheet and Protocol,,Completed,No Results Available,Cancer Pain,"Other: Individual patient interview, focus group and structured survey|Other: interview, focus group and structured survey",Adequate pain control,Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI),All,"21 Years and older   (Adult, Older Adult)",,65,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,VICC SUPP 0566|P30CA068485,2006-01-01,2007-11-01,2008-03-01,2010-10-29,null,2012-09-10,"Vanderbilt-Ingam Cancer Center, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT01230515
647,NCT01779973,Remote Observed Dosing to Increase Suboxone Compliance,RODISC,Completed,No Results Available,Opiate Dependence,Behavioral: Remote Observed Dosing,The number of suboxone dose taken during the course of the study. The number of opiate-negative urine samples provided during the study.|Patterns of missed doses including visit times and frequency impact.,University of Pennsylvania,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,9,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,816651,2013-02-01,2013-09-01,2013-09-01,2013-01-30,null,2017-11-07,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01779973
648,NCT03407638,PRimary Care Opioid Use Disorders Treatment (PROUD) Trial,PROUD,Recruiting,No Results Available,Opioid-use Disorder,Other: PROUD Intervention,Patient-days of OUD medication treatment|Acute care utilization,Kaiser Permanente|National Institute on Drug Abuse (NIDA)|The EMMES Corporation,All,"16 Years to 90 Years   (Child, Adult, Older Adult)",Not Applicable,175000,Other|NIH|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,CTN-0074|UG1DA040314,2018-02-28,2021-02-01,2021-02-01,2018-01-23,null,2018-04-02,"University of Miami Health System, Miami, Florida, United States|Henry Ford Health System, Detroit, Michigan, United States|Montefiore Medical Center, Bronx, New York, United States|Harris Health System, Houston, Texas, United States|Kaiser Permanente Washington, Seattle, Washington, United States|MultiCare Health System, Tacoma, Washington, United States",,https://ClinicalTrials.gov/show/NCT03407638
649,NCT01040338,Effects of Nicotine on Brain Opioid Receptors,,Terminated,No Results Available,Nicotine Dependence,Drug: Nicotine,MOR binding potential|Subjective reward/liking and cravings to smoke,University of Pennsylvania|National Institute on Drug Abuse (NIDA),All,18 Years to 50 Years   (Adult),,15,Other|NIH,Observational,Observational Model: Case-Crossover|Time Perspective: Prospective,809187|R21DA027066,2010-02-01,2011-03-01,2011-03-01,2009-12-29,null,2013-07-19,"Center for Interdisciplinary Research on Nicotine Addiction, University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01040338
650,NCT01416584,A Bridge to Treatment: The Therapeutic Workplace and Methadone Treatment,,Completed,Has Results,Opiate Dependence,Behavioral: methadone contingency|Behavioral: Methadone & Abstinence Contingency,"Percentage of Months in Methadone Treatment|Percentage of Monthly Urine Sample Negative for Opiates|Percentage of Monthly Urine Samples Negative for Cocaine|Percentage of M,W,F Urine Samples Negative for Cocaine|Percentage of M,W,F Urine Samples Negative for Opiates",Johns Hopkins University|National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,98,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NA_00020746|R01DA023864,2008-10-01,2013-10-01,2014-04-01,2011-08-15,2017-09-29,2017-12-05,"Center for Learning and Health, Johns Hopkins Bayview Medical Campus, 5200 Eastern Ave., Suite W142, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01416584
651,NCT00712036,Entry Into Comprehensive Methadone Treatment Via Interim Maintenance,,Completed,No Results Available,Opiate Dependence,Behavioral: Interim|Behavioral: Comprehensive|Behavioral: Restored,Opioid positive drug tests|HIV risk behavior|Treatment Retention|Cost-benefit|Cocaine positive tests,"Friends Research Institute, Inc.|National Institute on Drug Abuse (NIDA)",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,230,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DA R01 13636|R01DA013636,2008-06-01,2011-01-01,2011-01-01,2008-07-09,null,2015-01-09,"Friends Research Institute, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00712036
652,NCT03248947,Buprenorphine Physician-Pharmacist Collaboration in the Management of Patients With Opioid Use Disorder: CTN 0075,Pharm-OUD-Care,Recruiting,No Results Available,Opioid Use Disorder,Drug: buprenorphine/naloxone|Other: Pharmacist-administered buprenorphine/naloxone maintenance care,Recruitment rate|Treatment retention|Opioid and other substance use|Medication compliance|Treatment fidelity|Treatment satisfaction|Participant safety|Pharmacists' use of the Prescription Drug Monitoring Program (PDMP)|Pharmacists' use of electronic health records (EHRs)|Use of the EHR to compare treatment outcome measures,Duke University|National Institute on Drug Abuse (NIDA)|The EMMES Corporation,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,70,Other|NIH|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00083544|UG1DA040317,2018-03-28,2019-03-01,2019-03-01,2017-08-15,null,2018-04-06,"Duke Outpatient Clinic, Durham, North Carolina, United States|Josefs Pharmacy, Durham, North Carolina, United States|Changes by Choice, Durham, North Carolina, United States|Clinic Pharmacy, Durham, North Carolina, United States|Carolina Performance, Raleigh, North Carolina, United States|Health Park Pharmacy, Raleigh, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT03248947
653,NCT00684788,Employment-Based Depot Naltrexone Clinical Trial,,Completed,Has Results,Opiate Dependence,Combination Product: employment-based reinforcement,"Percentage of Depot Naltrexone Doses Received|The Time to the First Missed Dose of Depot Naltrexone|Percentage of 30-day Assessments Urine Samples Negative for Opiates|Percentage of Monday, Wednesday, Friday Urine Samples Negative for Opiates|Percentage of 30-day Assessments Urine Samples Negative for Cocaine|Percentage of Monday, Wednesday, Friday Urine Samples Negative for Cocaine|HIV Risk Behaviors",Johns Hopkins University|National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,35,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NA_00000928-1|R01DA019497,2006-05-01,2009-05-01,2009-05-03,2008-05-28,2017-12-26,2017-12-26,"The Center for Learning and Health, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00684788
654,NCT00684775,Employment-Based Depot Naltrexone Clinical Trial II,,Completed,Has Results,Opiate Dependence,Combination Product: Work Plus Naltrexone Contingency,"Naltrexone Injections Received|Time to the First Missed Dose|Percentage of 30-day Urine Samples Negative for Opiates|Percentage of M-W-F Samples Negative for Cocaine|Average Percentage of 30-day Urine Samples Negative for Cocaine|HIV Risk Behaviors|Percentage of M,W,F Urine Samples Negative for Opiates",Johns Hopkins University|National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,38,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NIDA-19497-2|R01DA019497-02|NA_00000928,2008-05-01,2010-04-30,2010-04-30,2008-05-28,2017-12-26,2018-01-23,"The Center for Learning and Health, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00684775
655,NCT00622596,Prospective Cohort of Opiate Dependent Patients on Buprenorphine/Naloxone for Maintenance,Project BEST,Completed,No Results Available,Opiate Dependence,Other: Mobile Access,"Attendance|Opioid free urine toxicology|Access to other health care, incarceration, hospitalization acceptability of the site of care from both patient and provider perspectives, and attendance and adherence to counseling.",Yale University,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,504027630,2003-10-01,2008-09-01,2008-09-01,2008-02-25,null,2016-08-24,"Yale University School of Medicine, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00622596
656,NCT00439036,Acceptance Therapy During Methadone Detoxification,,Completed,No Results Available,Opiate Dependence,Behavioral: Behavior Therapy|Behavioral: Drug Counseling,Substance use|HIV/HCV risk behaviors|Retention|Client adherence|Psychosocial functioning|Treatment satisfaction,"The University of Texas Health Science Center, Houston|National Institute on Drug Abuse (NIDA)",All,25 Years to 60 Years   (Adult),Phase 1,56,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DA019436-01|R01DA019436-01|DCNBR,2006-07-01,2010-08-01,2012-12-01,2007-02-22,null,2013-05-06,"University of Texas Medical School- Houston; Department of Psychiatry; Mental Sciences Institute, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00439036
657,NCT00787735,Improving Delivery of Mental Health Services for Patients With Drug Use and Other Behavioral and Emotional Problems,,Completed,No Results Available,Study Focusing on Integrated Versus Non-integrated Psychiatric Care in|Opioid-dependent and Methadone Treated Patients With Other Psychiatric|Diagnoses,Behavioral: Counseling compliance,Days to first psychiatric appointment|Overall psychiatric counseling attendance compliance rate|Psychiatrist session attendance compliance rate|Individual and group psychiatric session attendance compliance rate|Level of psychiatric distress|Urinalysis results,Johns Hopkins University|National Institute on Drug Abuse (NIDA),All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,380,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R01DA016375,2004-01-01,2009-06-01,2009-06-01,2008-11-07,null,2017-03-06,"Addiction Treatment Services, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00787735
658,NCT00253890,Insomnia and Drug Relapse Risk,,Completed,Has Results,Poor Quality Sleep|Opiate Addiction,Drug: Trazodone|Drug: Placebo,"Sleep Quality, as Measured by Total Sleep Time",Butler Hospital|National Institute on Drug Abuse (NIDA),All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,137,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R01DA020479|R01DA020479-01,2005-10-01,2010-05-01,2010-05-01,2005-11-15,2013-12-11,2013-12-11,"Butler Hospital, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT00253890
659,NCT00737737,Hormone Function in Men Treated for Pain With Opioids or Placebo,,Completed,Has Results,Chronic Pain|Osteoarthritis,Drug: MS Contin|Drug: Placebo,"Is Chronic Opioid Treatment Associated With Changes in Adrenocorticotropic Hormone (ACTH), Cortisol, Luteinizing Hormone (LH) and Testosterone Secretion?|Is Placebo Analgesia Associated With a Similar Hormonal Response as Elicited by an Opioid Analgesic?",National Institute of Nursing Research (NINR)|National Institutes of Health Clinical Center (CC),Male,"30 Years to 65 Years   (Adult, Older Adult)",Phase 4,8,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",080190|08-NR-0190,2008-08-01,2013-09-01,2014-04-01,2008-08-20,2015-04-29,2015-04-29,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00737737
660,NCT02413281,"A Study of the Abuse Liability Potential of ALKS 5461 in Healthy, Non-Dependent, Recreational Opioid Users",,Completed,No Results Available,Healthy,Drug: ALKS 5461|Drug: Buprenorphine|Drug: Placebo,Pharmacodynamics: Abuse potential measured by visual analog scales (VAS)|Safety: Incidence of adverse events (AEs)|Pharmacokinetics: Plasma concentrations of ALKS 5461,"Alkermes, Inc.",All,18 Years to 55 Years   (Adult),Phase 1,56,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ALK5461-212,2015-03-01,2015-09-01,2015-09-01,2015-04-09,null,2015-11-10,"Alkermes Investigational Site, Overland Park, Kansas, United States",,https://ClinicalTrials.gov/show/NCT02413281
661,NCT02252432,The Effects of Ketamine and Methadone on Postoperative Pain for Laminectomy,,Recruiting,No Results Available,Laminectomy,Drug: Ketamine|Drug: Methadone|Drug: Ketamine + methadone,Opioid consumption obtained from the recorded data|Postoperative pain using a Verbal Rating Scale|Nausea and vomiting will be measured with follow up|Constipation (Ileus) will be measured with follow up,Cedars-Sinai Medical Center,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,114,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Pro00030109,2013-02-01,2018-12-01,2020-10-01,2014-09-30,null,2018-02-02,"Cedars Sinai Medical Center, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT02252432
662,NCT01598701,Intravenous Acetaminophen in Craniotomy,,Completed,Has Results,Postoperative Pain,Drug: Acetaminophen|Drug: Placebo,Post-Operative Opioid Requirement|Post-Operative Pain|Post-Operative Side Effects|Time to Extubation at Emergence From Anesthesia|Time for Patient to Meet Post-anesthesia Care Unit (PACU) Discharge Criteria,"The University of Texas Health Science Center, Houston|Mallinckrodt",All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 4,100,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",HSC-MS-12-0055,2012-05-02,2016-03-30,2016-03-30,2012-05-15,2018-06-19,2018-06-19,"Memorial Hermann Hospital - Texas Medical Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01598701
663,NCT00956254,Fentanyl Sublingual Spray in Treating Opioid-tolerant Cancer Patients With or Without Oral Mucositis,,Completed,Has Results,"Mucositis|Pain|Unspecified Adult Solid Tumor, Protocol Specific",Drug: Fentanyl sublingual spray,Cmax of Fentanyl|Tmax of Fentanyl|AUC0-last of Fentanyl,INSYS Therapeutics Inc,All,"18 Years and older   (Adult, Older Adult)",Phase 3,18,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,INS-09-011|CDR0000647007,2009-10-01,2010-10-01,2010-10-01,2009-08-11,2013-09-05,2013-09-05,"InSys Therapeutics, Incorporated, Scottsdale, Arizona, United States",,https://ClinicalTrials.gov/show/NCT00956254
664,NCT02564341,Targeting Effective Analgesia in Clinics for HIV - Intervention,TEACH,"Active, not recruiting",No Results Available,HIV Infection|Pain|Drug Dependence,Behavioral: Collaboration with an IT enabled nurse care manager|Behavioral: Education and academic detailing|Behavioral: Facilitated access to a specialist in addictions,"Patient receipt of ≥2 UDT (Electronic Medical Record (EMR) extraction)|% of patients who have ≥1 early refill (i.e., any early refills) (EMR extraction)|Physician satisfaction managing HIV-infected patients on COT for pain (Physician self-report)|≥3 primary care visits in infectious disease clinic (EMR extraction)|% of patients who had a discontinuation of their narcotic prescriptions (EMR extraction)|Opioid treatment agreement (EMR extraction)|% of physicians who self-report consulting the state Prescription Monitoring Program (Physician self-report)|Number (continuous measure) of early refills at 12 months (EMR extraction)|Patient aberrant use (Patient self-report)|Number of patients who have visited the emergency department to seek opioids (EMR extraction and patient self-report)|Patient pain severity and interference (Patient self-report)|Patient addiction severity (Patient self-report)|Physician confidence in prescribing COT (Physician self-report)|Patient satisfaction with COT (Patient self-report)|Patient trust in physician (Patient self-report)",Boston Medical Center|National Institute on Drug Abuse (NIDA)|Emory University|Grady Health System,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,41,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,H-33269|R01DA037768,2015-09-01,2018-11-01,2018-11-01,2015-09-30,null,2018-07-11,"Emory University, Atlanta, Georgia, United States|Boston Medical Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02564341
665,NCT03083626,The Effects of Water Temperature on the Cold Pressor Test,,Completed,No Results Available,Chronic Pain,Other: Cold pressor test,Improved Pain Threshold Response|Improved Pain Tolerance Response|Improved Pain Recovery Response,Georgetown University,All,"21 Years to 65 Years   (Adult, Older Adult)",,20,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,2014-1378,2015-05-01,2017-03-31,2017-03-31,2017-03-20,null,2017-04-20,"Georgetown University Medical Center, Washington, D.C., District of Columbia, United States",,https://ClinicalTrials.gov/show/NCT03083626
666,NCT00015340,Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14,,Completed,No Results Available,Opioid Dependence|Substance-Related Disorders,Drug: Buprenorphine/naloxone,Craving|Retention|Opioid withdrawal|Subjective rating,National Institute on Drug Abuse (NIDA)|New York MDRU,All,18 Years to 59 Years   (Adult),Phase 4,582,NIH|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NIDA-5-0013-14|Y01-5-0013-14,1999-08-01,2001-08-01,2001-09-01,2001-04-18,null,2017-01-12,"University of California, Los Angeles, California, United States|VA Medical Center, Tampa, Florida, United States|VA Medical Center, Hines, Illinois, United States|New York VAMC, New York, New York, United States|VA PUget Sound Helath Care System, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00015340
667,NCT00799201,Enteral Naloxone Versus a Traditional Bowel Regimen for the Prevention of Opioid Induced Constipation in Trauma Patients,,Terminated,No Results Available,Constipation|Analgesia,Drug: Naloxone and Docusate,Number of hours until first bowel movement|Residual volume/toleration of feeds|Average number of bowel movements per day|Escalation of opioid dose due to impaired analgesia,CAMC Health System,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,3,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,07-01-1897,2007-08-01,2012-10-01,2012-10-01,2008-11-27,null,2015-07-29,"Charleston Area Medical Center, General Hospital, Charleston, West Virginia, United States",,https://ClinicalTrials.gov/show/NCT00799201
668,NCT01442493,Reengineering Methadone Treatment Study of Patient-centered Methadone Treatment,,Completed,Has Results,Opiate Dependence,Other: Patient-Centered Methadone Treatment|Other: Methadone Treatment as usual,Number of Participants With Opiate Positive Urine Tests|Number of Participants With Cocaine Positive Urine Tests|Drug Use HIV Risk Behavior|Criminal Behavior|Global Score on the World Health Organization Quality of Life Measure|Number of Participants Meeting DSM-IV Opiate Dependence Criteria|Number of Participants Meeting DSM-IV Cocaine Dependence Criteria,"Friends Research Institute, Inc.",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,300,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,2R01DA015842,2011-09-01,2015-04-01,2015-08-01,2011-09-28,2017-09-18,2017-12-29,"Institutes for Behavior Resources REACH, Baltimore, Maryland, United States|University of Maryland Drug Treatment Center, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01442493
669,NCT01366001,ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With Cocaine,,Completed,No Results Available,Cocaine Abuse,Drug: ALKS 33-BUP|Drug: ALKS 33|Drug: Placebo,The primary outcome measures are safety and pharmacokinetics (PK)/ pharmacodynamics (PD),"Alkermes, Inc.|National Institute on Drug Abuse (NIDA)",All,21 Years to 50 Years   (Adult),Phase 1,33,Industry|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",ALK33BUP-101|R01DA031000,2011-08-01,2012-02-01,2012-02-01,2011-06-03,null,2012-03-09,"Alkermes Study Site, Overland Park, Kansas, United States",,https://ClinicalTrials.gov/show/NCT01366001
670,NCT01191242,Methadone Monitoring for Insights Into Adverse Events,MEMORIES,Completed,Has Results,Pain|Opiate Addiction,,"Total Methadone Peak Plasma Concentration|Total Methadone Trough Plasma Concentration|(S)- Methadone Peak Plasma Concentration|(S)- Methadone Trough Plasma Concentration|(R)-Methadone Peak Plasma Concentration|(R)-Methadone Trough Plasma Concentration|Total 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidene (EDDP) Peak Plasma Concentration|Total EDDP Trough Plasma Concentration|(S)-EDDP Peak Plasma Concentration|(S)-EDDP Trough Plasma Concentration|(R)-EDDP Peak Plasma Concentration|(R)-EDDP Trough Plasma Concentration","Intermountain Health Care, Inc.",All,"18 Years and older   (Adult, Older Adult)",,31,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,154-08,2010-08-01,2011-03-01,2011-05-01,2010-08-30,2017-02-17,2017-03-29,"Intermountain Medical Center, Murray, Utah, United States|Discovery House, Taylorsville, Utah, United States",,https://ClinicalTrials.gov/show/NCT01191242
671,NCT00595764,Counseling for Primary Care Office-based Buprenorphine,,Completed,Has Results,Opiate Dependence,Behavioral: Manual-guided Physician Management (PM)|Behavioral: Physician Management (PM) combined with on-site manual-guided Cognitive Behavioral Therapy (CBT),Illicit Opioid Abstinence|Treatment Completion|Cocaine Abstinence|Criminal Activity- Addiction Severity Index (ASI) Legal Composite Score.|Overall Health- Short Form (36) Health Survey,Yale University|National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,141,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,5R01DA019511,2005-08-01,2011-02-01,2011-02-01,2008-01-16,2014-10-06,2014-10-06,"The APT Foundation, Inc. -- Welch Building, New Haven, Connecticut, United States|Yale New Haven Hospital Primary Care Center, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00595764
672,NCT01075087,"The Effect of Pre-Operative Transversus Abdominis Plane (TAP) Block in the Post Operative Opioid Consumption in Morbid Obese Patients Undergoing Laparoscopic Gastric Bypass Surgery: A Prospective,Randomized, Blinded Study",,Completed,Has Results,Pain|Obesity|Surgery,Drug: Placebo|Drug: (study group) will receive a bilateral TAP block using 20 cc of 0.5% ropivacaine on each side.,Quality of Recovery 40 Score|24 Hour Total Opioid Consumption.,Northwestern University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,19,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",STU00023482,2010-03-01,2012-07-01,2012-08-01,2010-02-24,2014-06-26,2014-06-26,"Northwestern Memorial Hospital, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT01075087
673,NCT01140724,Personalizing Perioperative Analgesia in Children,,"Active, not recruiting",No Results Available,Postoperative Pain,,"Look at polymorphisms in genes that regulate pain perception, opioid transport and opioid receptor signaling to see if there is a higher susceptibility to pain and morphine requirement.|Evaluate relationship of pupil reaction and response to 5% carbon dioxide to adverse effects of morphine","Indiana University|Children's Hospital Medical Center, Cincinnati|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,6 Years to 15 Years   (Child),,1200,Other|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,1707325115|7R01HD089458-02,2008-04-01,2018-04-01,2018-04-01,2010-06-09,null,2017-12-20,"Riley Hospital for Children, Indianapolis, Indiana, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01140724
674,NCT00007527,Determine the Safety of a Sublingual Tablet Formulation of Buprenorphine and Naloxone by Extending the Combination Tablet Availability to Physicians in Office-Based Practice,,Completed,No Results Available,Opiate Dependence,Drug: naloxone|Drug: buprenorphine,,US Department of Veterans Affairs|National Institute on Drug Abuse (NIDA)|Reckitt and Colman|VA Office of Research and Development,All,"15 Years and older   (Child, Adult, Older Adult)",Phase 4,600,U.S. Fed|NIH|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1018,1999-08-01,null,2002-01-01,2001-01-01,null,2009-01-21,"Paul Casadonte, M.D. VAMC New York, New York, New York, United States|Andrew Saxon, M.D.-Addictions Treatment (116ATC), Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00007527
675,NCT01519063,Naltrexone and Memantine Effects on Alcohol Drinking Behaviors,,Completed,No Results Available,Alcohol Drinking,Drug: Naltrexone and memantine|Drug: Naltrexone and Placebo,number of drinks consumed|Stimulation and sedation responses to alcohol,Yale University|National Institute on Alcohol Abuse and Alcoholism (NIAAA),All,21 Years to 55 Years   (Adult),Phase 2,75,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other",1005006779|P50AA012870,2012-01-01,2017-03-29,2017-05-01,2012-01-26,null,2017-05-17,"Sac, Cmhc, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01519063
676,NCT03448016,[C-11]NOP-1A and Alcohol Use Disorder,,Recruiting,No Results Available,Alcohol Use Disorder,Radiation: [C-11]|Drug: NOP-1A,[C-11]NOP-1A VT,Rajesh Narendran|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|University of Pittsburgh,All,18 Years to 55 Years   (Adult),Early Phase 1,80,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,PRO16030103 & PRO13080387|R01AA025247,2016-05-27,2022-12-31,2022-12-31,2018-02-27,null,2018-02-28,"University of PIttsburgh PET Facility, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03448016
677,NCT03039725,Vaccination Compliance,,Completed,No Results Available,Vaccine Compliance,Other: Observational,compliance with the 2016 ACIP recommendations,"Jaye Shyken, MD|St. Louis University",Female,"14 Years to 55 Years   (Child, Adult)",,99,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,27919,2017-05-01,2017-08-28,2017-08-28,2017-02-01,null,2017-11-21,"St. Mary's Health Center, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT03039725
678,NCT03348384,[11C]NOP-1A and Cocaine Use Disorders,,Recruiting,No Results Available,Cocaine Use Disorder,Radiation: [C-11]|Drug: NOP-1A,[C-11]NOP-1A VT,University of Pittsburgh|National Institute on Drug Abuse (NIDA),All,18 Years to 50 Years   (Adult),Early Phase 1,80,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,PRO14080588|R01DA026472,2014-10-30,2021-12-31,2021-12-31,2017-11-20,null,2017-11-21,"University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03348384
679,NCT01760473,Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone,,Completed,Has Results,Heroin Dependence,Drug: Intranasal challenge drug,Drug Self-administration|SOWS,New York State Psychiatric Institute|Indivior Inc.,All,21 Years to 45 Years   (Adult),Phase 3,27,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science",#5879,2009-05-01,2014-12-01,2014-12-01,2013-01-04,2017-09-08,2017-09-08,"New York State Psychiatric Institute and Columbia University, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01760473
680,NCT01264965,Non-cancer Pain and Cognitive Impairment: A Disabling Relationship,,Terminated,No Results Available,Arthritis|Pain|Cognitive Impairment,Drug: long acting oxycodone|Drug: extra strength acetaminophen,"pain self-report on the brief pain inventory and WOMAC|discontinuation of study drug, short physical performance battery",University of Chicago,All,65 Years and older   (Older Adult),Phase 4,25,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",10-238-B,2011-01-01,2014-02-01,2014-02-01,2010-12-22,null,2014-11-14,"University of Chicago Medical Center Outpatient Senior Health Center South Shore, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT01264965
681,NCT01903005,"Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence",,Completed,Has Results,"Opioid Dependence, on Agonist Therapy",Drug: Higher bioavailability BNX sublingual tablets,"Number of Patients Reporting Treatment-Emergent Adverse Events|Number of Patients Reporting Treatment-Related, Treatment-Emergent Adverse Events|Number of Patients Reporting Treatment-Emergent Serious Adverse Events|Number of Patient Discontinuations Due to Treatment-Emergent Adverse Events|Retention in Treatment in the Safety Population|Mean Change From Primary Study Baseline (OX219-006 or OX219-007) in Clinical Opioid Withdrawal Scale (COWS) Score|Mean Change From Primary Study Baseline (OX219-006 or OX219-007) in Subjective Opioid Withdrawal Scale (SOWS) Score|Mean Change From Primary Study Baseline (OX219-006 and OX219-007) in Visual Analog Scale (VAS) Craving Scores|Percent Change From Primary Study Baseline (OX219-006 or OX219-007) for Question 1 of the Work Productivity/Activity Impairment: 6-Question Specific Health Problem Questionnaire (WPAI:SHP)|Mean Change From Primary Study Baseline (OX219-006 or OX219-007) for Questions 2-4 of the WPAI:SHP|Mean Change From Primary Study Baseline (OX219-006 or OX219-007) for Questions 5-6 of the WPAI:SHP",Orexo AB|Worldwide Clinical Trials,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,668,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OX219-008,2013-07-01,2014-09-01,2014-09-01,2013-07-19,2015-10-28,2015-10-28,"Jefferson County, Alabama, United States|Marion County, Alabama, United States|Winston County, Alabama, United States|Maricopa County, Arizona, United States|Los Angeles County, California, United States|San Diego County, California, United States|Broward County, Florida, United States|Columbia County, Florida, United States|Duval County, Florida, United States|Jacksonville metropolitan area, Florida, United States|Miami-Dade County, Florida, United States|Orlando metropolitan area, Florida, United States|Osceola County, Florida, United States|Palm Beach County, Florida, United States|DeKalb County, Georgia, United States|Chicago metropolitan area, Illinois, United States|Baltimore County, Maryland, United States|Bristol County, Massachusetts, United States|Rankin County, Mississippi, United States|St. Louis metropolitan area, Missouri, United States|Warren County, New Jersey, United States|Oklahoma County, Oklahoma, United States|Portland metropolitan area, Oregon, United States|Delaware County, Pennsylvania, United States|Philadelphia County, Pennsylvania, United States|Charleston County, South Carolina, United States|Salt Lake County, Utah, United States|Benton County, Washington, United States",,https://ClinicalTrials.gov/show/NCT01903005
682,NCT02926482,Intervention to Expand Opioid Use Disorder Treatment Pharmacotherapy Prescribers,,"Active, not recruiting",No Results Available,Expanding Buprenorphine & Injectable Naltrexone Capacity,Behavioral: Prescriber Recruitment Bundle (PRB),Buprenorphine slots and extended naltrexone capacity survey|Organizational survey|Physician Satisfaction|Qualitative surveys,"University of Wisconsin, Madison|National Institute on Drug Abuse (NIDA)",All,"Child, Adult, Older Adult",Not Applicable,73,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,2016-0486|1R01DA041415,2016-04-01,2020-04-01,2020-04-01,2016-10-06,null,2017-11-21,"Florida Alcohol and Drug Abuse Association, Tallahassee, Florida, United States|Ohio Department of Mental Health and Addiction Services, Columbus, Ohio, United States|Center for Health Enhancement Systems, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02926482
683,NCT03608696,Buprenorphine Pharmacometric Open Label Research Study of Drug Exposure,B-PHORE,Not yet recruiting,No Results Available,Neonatal Abstinence Syndrome|Neonatal Opiate Withdrawal Syndrome,Drug: Buprenorphine,Buprenorphine pharmacokinetics,Thomas Jefferson University|Chiesi Farmaceutici S.p.A.,All,up to 4 Weeks   (Child),Phase 1|Phase 2,10,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,18C.272,2018-08-29,2018-12-21,2018-12-21,2018-08-01,null,2018-08-01,"Thomas Jefferson University Hosptial, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03608696
684,NCT00716807,Efficacy of Nalbuphine and Naloxone Administered as Nose Sprays in the Treatment of Orofacial Pain,,Terminated,Has Results,Temporomandibular Joint Dysfunction Syndrome|Burning Mouth Syndrome,Drug: nalbuphine plus naloxone|Drug: nalbuphine plus placebo,Pain Intensity as Measured on a Visual Analogue Scale (VAS) Ranging From Zero to 100.,"University of California, San Francisco",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,46,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",NIH/NIDCR R01 DE018526-1|1R01DE018526-01,2008-01-01,2010-06-01,2010-06-01,2008-07-16,2013-10-22,2016-05-20,"University of California, San Francisco, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT00716807
685,NCT03604861,An Observational Study of Environmental and SocioEconomic Factors in Opioid Recovery,RECOVER®,"Active, not recruiting",No Results Available,Opioid-use Disorder|Opioid-related Disorders,Other: Not applicable - no defined intervention,"Percentage of Participants Who Reported Abstinent From Opioids For the Previous 7 Days and Previous 28 Days at Month 24|Change from Baseline in Percentage of Participants Who Reported Abstinent From Opioids For the Previous 7 Days At Months 3, 6, 9, 12, 15, 18, 21, 24|Change from Baseline in Percentage of Participants Who Reported Abstinent From Opioids For the Previous 28 Days At Months 3, 6, 9, 12, 15, 18, 21, 24|Percentage of Participants Who Reported Abstinent From Opioids For the Previous 7 Days and Confirmed by Urine Drug Screen (UDS) at Month 24|Change from Baseline in Percentage of Participants Who Reported Abstinent From Opioids For the Previous 7 Days and Confirmed by UDS At Months 3, 6, 9, 12, 15, 18, 21, 24",Indivior Inc.,All,"18 Years to 65 Years   (Adult, Older Adult)",,534,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,INDV-6000-N01,2015-08-01,2019-03-01,2019-03-01,2018-07-30,null,2018-07-30,"Winston Technology Research LLC, Haleyville, Alabama, United States|Boyett Health Services, Hamilton, Alabama, United States|Woodland International Research Group, Little Rock, Arkansas, United States|Behavioral Research Specialists, Glendale, California, United States|Collaborative Neuroscience Networks, Inc., Long Beach, California, United States|Synergy Research Center, National City, California, United States|North County Clinical Research, Oceanside, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Amit Vijapura, Jacksonville, Florida, United States|Meridien Research, Lakeland, Florida, United States|Try Research, Maitland, Florida, United States|Innovative Clinical Research, Miami, Florida, United States|Scientific Clinical Research, Miami, Florida, United States|Research Centers of America, Oakland Park, Florida, United States|Louisiana Research Associates, New Orleans, Louisiana, United States|Louisiana Clinical Research, Shreveport, Louisiana, United States|Stanley Street Treatment and Resources, Fall River, Massachusetts, United States|Adams Clinical Trials, Watertown, Massachusetts, United States|Precise Research Centers, Inc., Flowood, Mississippi, United States|St. Louis Clinical Trials, Saint Louis, Missouri, United States|Altea Research Institute, Las Vegas, Nevada, United States|Hassman Research Institute, Berlin, New Jersey, United States|Center for Emotional Fitness, Cherry Hill, New Jersey, United States|The Medical Research Network, LLC, New York, New York, United States|Neuro-behavioral Clinical Research, Canton, Ohio, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|Charak Clinical Research Center, Garfield Heights, Ohio, United States|Oklahoma Clinical Research Center, Oklahoma City, Oklahoma, United States|Pahl Pharmaceutical Professionals, Oklahoma City, Oklahoma, United States|CODA, Portland, Oregon, United States|Tipton Medical and Diagnostic Center aka Clinical Research Associates of Central PA, Altoona, Pennsylvania, United States|UPenn Treatment Research Center, Philadelphia, Pennsylvania, United States|Carolina Clinical Trials, Charleston, South Carolina, United States|Pillar Clinic Research, LLC, Dallas, Texas, United States|InSite Clinical Research, DeSoto, Texas, United States",,https://ClinicalTrials.gov/show/NCT03604861
686,NCT00630201,Extension to Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence,PRO-807,Completed,No Results Available,Opioid Dependence,Drug: Probuphine (buprenorphine implant),Number of subjects with adverse events as a measure of safety|Buprenorphine concentration in plasma|Percent of urine samples that are negative for illicit opioids|Percent of subjects retained as a measure of efficacy|Percent of subjects reporting illicit drug use as a measure of efficacy|Average daily dose of supplemental sublingual buprenorphine as a measure of efficacy|Mean total score on SOWS as a measure of efficacy|Mean total score on COWS as a measure of efficacy|Mean subjective opioid cravings scores as a measure of efficacy|Mean composite score Drug Problems area of Addiction Severity Index|Patient-rated Opioid use and Problems Responder Analysis as a measure of efficacy|Physician-rated severity of opioid use and symptoms Responder Analysis as a measure of efficacy,Braeburn Pharmaceuticals,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,62,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PRO-807,2007-10-01,2009-02-01,2009-02-01,2008-03-06,null,2017-06-14,"David Geffen School of Medicine at UCLA, Los Angeles, California, United States|Synergy Clinical Research Center, National City, California, United States|Amit Vijapura, MD, Jacksonville, Florida, United States|Fidelity Clinical Research, Inc., Lauderhill, Florida, United States|Scientific Clinical Research, Inc., North Miami, Florida, United States|Behavioral Biology Research Unit, Johns Hopkins Bayview Campus, Baltimore, Maryland, United States|Dual Diagnosis Unit, SSTAR: Stanley Street Treatment and Resources, Inc., Fall River, Massachusetts, United States|Wayne State Univ. School of Medicine, Dept of Psychiatry & Behavioral Neuroscience, Detroit, Michigan, United States|Psych Care Consultants Research, Saint Louis, Missouri, United States|New York VA Medical Center, NYU School of Medicine, New York, New York, United States|Duke Addictions Program, Durham, North Carolina, United States|Pahl Pharmaceutical Research, LLC, Oklahoma City, Oklahoma, United States|University of Pennsylvania, Treatment Research Center, Philadelphia, Pennsylvania, United States|Providence Behavioral Health Services, Everett, Washington, United States|Puget Sound Health CareSystem, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00630201
687,NCT00609297,Pain Control in Hospice Patients With Cancer-Related Pain,,Completed,No Results Available,Pain|Solid Tumor,Other: medical chart review|Other: questionnaire administration|Other: survey administration,Description of standard pain management methods and outcomes in the hospice setting,Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI),All,"21 Years and older   (Adult, Older Adult)",,22,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,VICC SUPP 0731|VU-VICC-SUPP-0731|VU-VICC-070605,2007-07-01,2008-03-01,2011-05-01,2008-02-07,null,2012-10-24,"Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT00609297
688,NCT02210936,SCOSI-M: Preventing Prescription Drug Problems,,"Active, not recruiting",No Results Available,Prescription Drug Problems,Other: Educational Intervention,Use of SCRIPTS,Brandeis University|University of South Carolina|Medical University of South Carolina|Moncrief Army Community Hospital|William Jennings Bryan Dorn VA Medical Center,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,93,Other|U.S. Fed,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,14047,2014-07-01,2019-05-01,2019-05-01,2014-08-07,null,2018-07-10,"Brandeis University, Waltham, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02210936
689,NCT00447564,Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence,,Completed,No Results Available,Opioid Dependence,Drug: Probuphine|Drug: placebo,The cumulative distribution function (CDF) of the percent of urine samples negative for illicit opioids|Mean percent urines negative for illicit opioids|Proportion (percent) of study completers|Total number of weeks of abstinence|Mean maximal period in weeks of continuous abstinence|Mean total score on the SOWS|Mean total score on the COWS|Mean subjective opioid cravings assessment (VAS)|Patient-rated Clinical Global Impression|Physician-rated Clinical Global Impression,Braeburn Pharmaceuticals,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,163,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",PRO-805,2006-10-01,2008-07-01,2008-07-01,2007-03-14,null,2017-06-14,"David Geffen School of Medicine at UCLA, Los Angeles, California, United States|Synergy Clinical Research Center, National City, California, United States|North County Clinical Research, Oceanside, California, United States|Amit Vijapura, MD and Associates, Jacksonville, Florida, United States|Fidelity Clinical Research, Lauderhill, Florida, United States|Scientific Clinical Research, Inc, North Miami, Florida, United States|Northwest Behavioral Research Center, Roswell, Georgia, United States|Behavioral Biology Research Unit, Johns Hopkins Bayview Campus, Baltimore, Maryland, United States|Dual Diagnosis Unit, SSTAR: Stanley Street Treatment and Resources, Inc., Fall River, Massachusetts, United States|Wayne State University Department of Psychiatry and Behavioral Neurosciences, Detroit, Michigan, United States|Psych Care Consultants Research, Saint Louis, Missouri, United States|New York VA Medical Center, NYU School of Medicine, New York, New York, United States|Addiction Institute of New York, New York, New York, United States|Duke University Medical Center Addictions Program, Durham, North Carolina, United States|Pahl Pharmaceutical Research, LLC, Oklahoma City, Oklahoma, United States|University of Pennsylvania Treatment Research Center, Philadelphia, Pennsylvania, United States|Providence Behavioral Health Services, Everett, Washington, United States|Puget Sound Health Care Systems, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00447564
690,NCT00947284,Effect of Nalbuphine and Naloxone on Experimentally Induced Skin Sensitivity,,Terminated,Has Results,Healthy,Drug: nalbuphine plus naloxone|Drug: nalbuphine plus saline|Drug: naloxone plus saline,Change in Skin Sensitivity as Measured by a Visual Analog Scale,"University of California, San Francisco",All,18 Years to 40 Years   (Adult),Not Applicable,3,Other,Interventional,"Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",NIH/NIDCR R01 DE018526-2|5R01DE018526-02,2010-01-01,2012-06-01,2012-06-01,2009-07-28,2013-10-23,2016-05-20,"University of California, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT00947284
691,NCT03525977,Impact of Fascia Iliaca Block in Hip Fracture Patients,,Recruiting,No Results Available,Hip Fractures (i.e. Femoral Neck or Intertrochanteric Hip Fractures),Procedure: Fascia iliaca block arm,Pain control|Ambulation distance,"Texas Tech University Health Sciences Center, El Paso",All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E18046,2018-02-20,2019-03-31,2019-03-31,2018-05-16,null,2018-05-16,"University Medical Center, El Paso, Texas, United States",,https://ClinicalTrials.gov/show/NCT03525977
692,NCT01848054,Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence,,Completed,Has Results,Opioid-Related Disorders|Opiate Dependence,Drug: Buprenorphine/naloxone sublingual tablets|Drug: Buprenorphine,Retention in Treatment in the Per Protocol Population|Area Under the Curve (AUC) in Clinical Opiate Withdrawal Scale (COWS) Total Score on Days 1 to 3 Inclusive|AUC in Subjective Opiate Withdrawal Scale (SOWS) Total Score on Days 1 to 3 Inclusive|AUC in Visual Analog Scale (VAS) Score for Craving on Days 1 to 3 Inclusive|Mean Change From Baseline in COWS Total Score After Day 3 (Maintenance Phase)|Mean Change From Baseline in SOWS Total Score After Day 3 (Maintenance Phase)|Mean Change From Baseline in the VAS Score for Cravings After Day 3 (Maintenance Phase)|Retention in Treatment in the Full Analysis Population,Orexo AB|Worldwide Clinical Trials,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,313,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",OX219-007,2013-06-01,2014-01-01,2014-01-01,2013-05-07,2015-06-24,2017-05-10,"Birmingham, Alabama, United States|Haleyville, Alabama, United States|National City, California, United States|Oceanside, California, United States|Jacksonville, Florida, United States|Maitland, Florida, United States|North Miami, Florida, United States|Baltimore, Maryland, United States|Fall River, Massachusetts, United States|Flowood, Mississippi, United States|Philadelphia, Pennsylvania, United States|Charleston, South Carolina, United States|Houston, Texas, United States|Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT01848054
693,NCT00000210,Treatment Efficacy for Drug Abuse and AIDS Prevention - 1,,Completed,No Results Available,Cocaine-Related Disorders|Heroin Dependence,Drug: Buprenorphine,,National Institute on Drug Abuse (NIDA)|Mclean Hospital,Male,26 Years to 41 Years   (Adult),Phase 2,0,NIH|Other,Interventional,Primary Purpose: Treatment,NIDA-06116-1|R18-06116-1,1989-09-01,1996-02-01,1996-02-01,1999-09-21,null,2017-01-12,"McLean Hospital, Dept. of Psychiatry, Belmont, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00000210
694,NCT02935621,Behavioral Interventions for Active Duty Service Members and Veterans With Chronic Pain,,Recruiting,No Results Available,Chronic Pain,Behavioral: Mindfulness-Oriented Recovery Enhancement (MORE)|Behavioral: Support Group,Change in opioid misuse|Change in pain severity and interference|Change in opioid craving|Change in psychological distress|Change in opioid dose (in morphine equivalents)|Change in post-traumatic stress|Change in resilience,University of Utah|United States Department of Defense,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,260,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,91781,2017-04-01,2021-08-01,2021-08-01,2016-10-17,null,2018-02-05,"George Wahlen VA Hospital, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT02935621
695,NCT02935465,Effects of Behavioral Interventions on Mechanisms of Pain Regulation and Hedonic Regulation,,Recruiting,No Results Available,"Chronic, Non-neuropathic Back Pain",Behavioral: Mindfulness-Oriented Recovery Enhancement (MORE)|Behavioral: Support Group,"Changes in endogenous opioid system function in response to pain challenge|Changes in fMRI activity level during natural reward processing|Pain sensitivity as a measure of volume of hypertonic saline|Self-report affect ratings|Significant correlation between PET and fMRI measures with improvements in clinical pain, affect, and opioid use",University of Utah|National Center for Complementary and Integrative Health (NCCIH),All,21 Years to 60 Years   (Adult),Not Applicable,140,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,93561,2016-09-01,2021-08-01,2021-08-01,2016-10-17,null,2016-10-17,"College of Social Work, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT02935465
696,NCT00700596,Effects of Salvinorin A in Healthy Controls,,"Active, not recruiting",No Results Available,Healthy,Drug: Salvinorin A|Drug: Placebo,"Positive and Negative Syndrome Scale, Clinician Administered Dissociative Symptoms Scale, Visual Analog Scale, Assessment of Opioid Effects, Cognitive Testing",Yale University|National Alliance for Research on Schizophrenia and Depression,All,18 Years to 45 Years   (Adult),Phase 1,41,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",707002884,2009-01-01,2019-08-01,2019-08-01,2008-06-18,null,2018-06-06,"VA Connecticut Healthcare System, West Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00700596
697,NCT03195205,Identification to Elimination in HCV-Infected Individuals,,Recruiting,No Results Available,Hepatitis C,Diagnostic Test: OraQuick HCV Rapid Antibody Test,Positivity rates|Linked to care|Treatment,TruCare Internal Medicine & Infectious Disease|Gilead Sciences,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,3000,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,GSI-2016-09-APR,2017-06-01,2019-12-01,2020-06-01,2017-06-22,null,2018-04-27,"TruCare Internal Medicine & Infectious Diseases, DuBois, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03195205
698,NCT02862691,Percocet vs. Bupivicaine for Toothaches in the ED,,Terminated,No Results Available,Toothache,Drug: Acetaminophen/Oxycodone (Oral analgesic)|Drug: Bupivicaine (Injectable local anesthetic),Percentage of patients with significant pain relief at the end of the study period|Absolute change in pain severity|The time to a 50% reduction in pain severity,Stony Brook University,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,901314-2,2016-08-01,2017-08-01,2017-08-01,2016-08-11,null,2018-04-25,"Stony Brook University Hospital, Stony Brook, New York, United States",,https://ClinicalTrials.gov/show/NCT02862691
699,NCT00733720,Buprenorphine Naltrexone-P1 A-Cocaine,,Completed,No Results Available,Cocaine-related Disorders,Drug: Suboxone,Opioid Effects of study drug|Adverse Events,National Institute on Drug Abuse (NIDA),All,18 Years to 55 Years   (Adult),Phase 1,8,NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",N01DA-6-8867,2008-08-01,2008-12-01,2009-01-01,2008-08-13,null,2017-01-12,"Drug Dependence Research Center, San Fransisco, California, United States",,https://ClinicalTrials.gov/show/NCT00733720
700,NCT00003000,Morphine for the Treatment of Pain in Patients With Breast Cancer,,Completed,No Results Available,Pain,Drug: fentanyl citrate|Drug: morphine sulfate,,Roswell Park Cancer Institute,All,"up to 120 Years   (Child, Adult, Older Adult)",,18,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,CDR0000065555|RPCI-DS-92-13,1992-05-01,2001-01-01,2001-06-01,2004-07-30,null,2015-10-14,"Roswell Park Cancer Institute, Buffalo, New York, United States",,https://ClinicalTrials.gov/show/NCT00003000
701,NCT02357901,Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine,,Completed,Has Results,Opioid Dependence|Opioid Related Disorders,Drug: SUBOXONE|Drug: RBP-6000|Drug: Placebo,"Cumulative Distribution Function (CDF) of the Percentage of Urine Samples Negative for Opioids Combined With Self-Reports Negative for Illicit Opioid Use Collected From Week 5 Through Week 24|Percentage of Participants Considered A Treatment Success|Cumulative Distribution Function (CDF) of the Percentage of Urine Samples Negative for Opioids From Week 5 Through Week 24|Cumulative Distribution Function (CDF) of the Percentage of Self-Reports Negative for Illicit Opioid Use From Week 5 Through Week 24|Change From Baseline in the Opioid Craving Visual Analog Scale (VAS) Prior to Injections From Week 5 Through Week 24 Analyzed by Mixed Model for Repeated Measures|Participants Who Complete the Week 24 Visit (""Completers"")|Participants Who Are Abstinent at Week 24|Change From Baseline in the Clinical Global Impression - Improvement Scale (CGI-I) Prior to Injections From Week 5 Through Week 24 Analyzed by Mixed Model for Repeated Measures|Change From Baseline in the Clinical Global Impression - Severity Scale (CGI-S) Prior to Injections From Week 5 Through Week 24 Analyzed by Mixed Model for Repeated Measures|Change From Baseline in the Clinical Opiate Withdrawal Scale (COWS) Through Week 24 Analyzed by Mixed Model for Repeated Measures|Change From Baseline in the Subjective Opiate Withdrawal Scale (SOWS) Through Week 24 Analyzed by Mixed Model for Repeated Measures|Total Number of Weeks of Abstinence as Assessed From Urine Samples Negative for Opioids Combined With Self-Reports Negative for Illicit Opioid Use Collected From Week 5 Through Week 24|Participants With Adverse Events During the Treatment Period|Worst Injection Site Pain From Injections 1-6 as Measured by Participant-Reported Visual Analog Scale (VAS)|Suicidality Using the Columbia Suicide Severity Rating Scale (C-SSRS) From Week 2 - 24",Indivior Inc.,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,665,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",RB-US-13-0001,2015-01-28,2016-04-29,2016-04-29,2015-02-06,2018-02-20,2018-02-20,"Haleyville Clinical Research, Haleyville, Alabama, United States|Boyett Health Services, Hamilton, Alabama, United States|Woodland International Research Group, Little Rock, Arkansas, United States|Collaborative Neuroscience Network, Garden Grove, California, United States|Behavioral Research Specialists, Glendale, California, United States|Synergy Clinical Research Center, National City, California, United States|North County Clinical Research, Oceanside, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Care Practice, San Francisco, California, United States|Southern California Research, Thousand Oaks, California, United States|Amit Vijapura, Jacksonville, Florida, United States|Meridien Research, Lakeland, Florida, United States|Innovative Clinical Research, Lauderhill, Florida, United States|Florida Clinical Research Center, Maitland, Florida, United States|Try Research, Maitland, Florida, United States|Scientific Clinical Research, North Miami, Florida, United States|Research Centers of America, Oakland Park, Florida, United States|Behavioral Health Care Associates, Schaumburg, Illinois, United States|Phoenix Medical Research, Prairie Village, Kansas, United States|Louisiana Research Associates, New Orleans, Louisiana, United States|Louisiana Clinical Research, Shreveport, Louisiana, United States|Stanley Street Treatment and Resources, Fall River, Massachusetts, United States|Adams Clinical Trials, Watertown, Massachusetts, United States|Precise Research Centers, Inc., Flowood, Mississippi, United States|St Louis Clinical Trials, Saint Louis, Missouri, United States|Altea Research, Las Vegas, Nevada, United States|Comprehensive Clinical Research, Berlin, New Jersey, United States|Neuro-behavioral Clinical Research, Canton, Ohio, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|Charak Clinical Research Center, Garfield Heights, Ohio, United States|Oklahoma Clinical Research Center, Oklahoma City, Oklahoma, United States|Pahl Pharmaceutical Professionals, Oklahoma City, Oklahoma, United States|CODA, Portland, Oregon, United States|Tipton Medical and Diagnostic Center aka Clinical Research Associates of Central PA, Altoona, Pennsylvania, United States|UPenn Treatment Research Center, Philadelphia, Pennsylvania, United States|Carolina Clinical Trials, Charleston, South Carolina, United States|Pillar Clinical Research, Dallas, Texas, United States|InSite Clinical Research, DeSoto, Texas, United States",,https://ClinicalTrials.gov/show/NCT02357901
702,NCT02510014,Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder,,Completed,Has Results,Opioid Use Disorder|Opioid-related Disorders,Drug: SUBOXONE sublingual film|Drug: RBP-6000,Participants With Treatment-Emergent Adverse Events (TEAE) During the Treatment Period|Percentage Change From Baseline to End of Study (Weeks 25 and 49) in Vital Signs|Shifts in Suicidality Using the Columbia Suicide Severity Rating Scale (C-SSRS) From Baseline to Most Severe Assessment During the Treatment Period|Worst Local Injection Site Pain From Injections as Measured by Participant-Reported Visual Analog Scale (VAS)|Change From Baseline in the Clinical Opiate Withdrawal Scale (COWS) at End of Study (Weeks 25 and 49)|Change From Baseline in the Subjective Opiate Withdrawal Scale (SOWS) at End of Study (Weeks 25 and 49)|Change From Baseline in the Opioid Craving Visual Analog Scale (VAS) at End of Study (Weeks 25 and 49)|Cumulative Distribution Function (CDF) of the Percentage Abstinence Collected From Week 1 Through End of Study (Weeks 25 and 49),Indivior Inc.,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,775,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RB-US-13-0003,2015-07-27,2017-01-31,2017-01-31,2015-07-28,2018-03-29,2018-03-29,"Haleyville Clinical Research, Haleyville, Alabama, United States|Boyett Health Services, Hamilton, Alabama, United States|Woodland International Research Group, Little Rock, Arkansas, United States|Collaborative Neuroscience Network, Garden Grove, California, United States|Behavioral Research Specialists, Glendale, California, United States|Synergy Clinical Research Center, National City, California, United States|Pacific Research Partners, Oakland, California, United States|North County Clinical Research, Oceanside, California, United States|Neuropsychiatric Research Center of Orange County, Orange, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Amit Vijapura, Jacksonville, Florida, United States|Sarkis Clinical Trials, Lake City, Florida, United States|Meridien Research, Lakeland, Florida, United States|Innovative Clinical Research, Lauderhill, Florida, United States|Florida Clinical Research Center, Maitland, Florida, United States|Try Research, Maitland, Florida, United States|Scientific Clinical Research, North Miami, Florida, United States|Research Centers of America, Oakland Park, Florida, United States|Atlanta Institute of Medicine and Research, Alpharetta, Georgia, United States|Phoenix Medical Research, Prairie Village, Kansas, United States|Louisiana Research Associates, New Orleans, Louisiana, United States|Louisiana Clinical Research, Shreveport, Louisiana, United States|Stanley Street Treatment and Resources, Fall River, Massachusetts, United States|Adams Clinical Trials, Watertown, Massachusetts, United States|Precise Research Centers, Inc., Flowood, Mississippi, United States|St Louis Clinical Trials, Saint Louis, Missouri, United States|Altea Research, Las Vegas, Nevada, United States|Comprehensive Clinical Research, Berlin, New Jersey, United States|Center for Emotional Fitness, Cherry Hill, New Jersey, United States|The Medical Research Network, LLC, New York, New York, United States|Neuro-behavioral Clinical Research, Canton, Ohio, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|Charak Clinical Research Center, Garfield Heights, Ohio, United States|Oklahoma Clinical Research Center, Oklahoma City, Oklahoma, United States|Pahl Pharmaceutical Professionals, Oklahoma City, Oklahoma, United States|CODA, Portland, Oregon, United States|Tipton Medical and Diagnostic Center aka Clinical Research Associates of Central PA, Altoona, Pennsylvania, United States|UPenn Treatment Research Center, Philadelphia, Pennsylvania, United States|Carolina Clinical Trials, Charleston, South Carolina, United States|Pillar Clinical Research, Dallas, Texas, United States|InSite Clinical Research, DeSoto, Texas, United States|Aspen Clinical Research, LLC, Orem, Utah, United States","""Study Protocol: Original"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT02510014/Prot_000.pdf|""Study Protocol: Amendment 1"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT02510014/Prot_001.pdf|""Study Protocol: Amendment 2"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT02510014/Prot_002.pdf|""Study Protocol: Amendment 3"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT02510014/Prot_003.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT02510014/SAP_004.pdf|""Study Protocol: Amendment 4"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT02510014/Prot_005.pdf",https://ClinicalTrials.gov/show/NCT02510014
703,NCT00046709,Marijuana for Cancer Pain,,Terminated,No Results Available,Neoplasms,Drug: Smoked Marijuana,Change in level of cancer pain as recorded on a 100mm Visual Analog Scale.|Change in level of experimentally induced pain on a 100mm Visual Analog Scale.|Change in nausea and emesis in participants exhibiting these symptoms.|Change in disposition kinetics of opioid analgesics.,"Center for Medicinal Cannabis Research|University of California, San Francisco",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,16,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C00-SF-108|CC#057,2002-09-01,null,2004-10-01,2002-10-02,null,2013-10-10,"University of California, San Francisco, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT00046709
704,NCT01994785,Use of Capnography in EGD and Colonoscopy With Moderate Sedation.,,Completed,Has Results,Hypoxia|Apnea|Hypotension|Hypopnea,Diagnostic Test: Capnographic Monitoring,Number of Participants Experiencing Hypoxia During Capnography Monitoring.,The Cleveland Clinic|American College of Gastroenterology,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,452,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Other",CC-13-792,2013-11-01,2015-02-01,2015-05-01,2013-11-26,2017-07-02,2017-07-02,"Cleveland Clinic, Independence, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01994785
705,NCT01977937,Pain Control in Pediatric Posterior Spine Fusion Patients: The Effect of Gabapentin,,Completed,No Results Available,"Pain, Postoperative",Drug: Gabapentin|Drug: Simple Syrup,Difference in pain control when adding gabapentin to a multimodal pain management protocol in pediatric post-operative posterior spinal fusion patients.|Determine if opiate usage is less in the gabapentin group versus control.,Oregon Health and Science University,All,"10 Years to 19 Years   (Child, Adult)",Phase 4,57,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IRB00009681,2013-11-01,2018-03-01,2018-03-01,2013-11-07,null,2018-04-05,"Oregon Health and Science University, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT01977937
706,NCT03029468,Computerized Cognitive Behavioral Therapy Assisted Life Management for Pain in Sickle Cell Disease,CALM-SCD,Recruiting,No Results Available,Sickle Cell Disease|Chronic Pain,Behavioral: cognitive behavioral therapy|Behavioral: eEducation,Acceptability|Feasibility|Pain intensity|Pain interference|Depressive symptoms|Anxiety symptoms|Pain Catastrophizing Scale|Sickle Cell Self-efficacy Scale|ASCQ-Me,"University of Pittsburgh|University of Toronto|University of Washington|Duke University|Vanderbilt University|National Heart, Lung, and Blood Institute (NHLBI)",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PRO17010378|K23HL135396,2018-03-28,2020-09-01,2020-09-01,2017-01-24,null,2018-05-10,"University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03029468
707,NCT01977352,Efficacy of Interscalene Brachial Plexus Block With Liposomal Bupivacaine for Arthroscopic Shoulder Surgery,,Completed,Has Results,Shoulder Pain|Rotator Cuff Tear,Drug: Liposomal bupivacaine|Drug: Bupivacaine 0.25%,Total Opioid Consumption|Quality of Analgesia|Sensory and Motor Block|Time to First Pain Medicine|Time to Discharge Home|Incidence of Postoperative Nausea and Vomiting|Sleep Quality,St. Luke's-Roosevelt Hospital Center,All,"17 Years and older   (Child, Adult, Older Adult)",Phase 4,42,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",13-0064,2014-01-01,2015-02-01,2015-02-01,2013-11-06,2018-04-02,2018-04-02,"St. Luke's Roosevelt Hospital Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01977352
708,NCT03480620,Post Discharge Online Telerehabilitation Program,OTP,Recruiting,No Results Available,"Pain, Chronic",Other: Online Telerehabilitation Platform Access|Other: Usual care,Adherence to post-discharge home exercise recommendations|PROMIS Measure - Physical Function - Short Form 8b|PROMIS Measure - Pain Interference - Short Form 4a|PROMIS Measure - Self-Efficacy for Managing Symptoms - Short Form 8a|PROMIS Measure - Self-Efficacy for Managing Emotions - Short Form 8a|Technology Acceptance Model Questionnaire|Patient Satisfaction,"Brooks Rehabilitation|Florida Physical Therapy Association|Yoga, Fitness, Mindfulness|ReadyOp",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,BRCRC2017_001,2018-02-09,2020-03-01,2020-03-01,2018-03-29,null,2018-03-29,"Brooks Rehabilitation, Jacksonville, Florida, United States",,https://ClinicalTrials.gov/show/NCT03480620
709,NCT03004222,A Study to Determine the Effectiveness of Utilizing Intraperitoneal Bupivacaine,,Completed,No Results Available,Laparoscopic Appendectomy,Drug: Bupivacaine|Drug: Placebos,"Total narcotic use following surgery until the time of discharge from the hospital.|Time to Discharge|Pain Level Scores at 1, 2, 4, and 12 hours postoperatively","Metro Health, Michigan",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,137,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,Appendectomy Study,2015-07-01,2017-11-01,2017-11-01,2016-12-28,null,2018-01-18,"Metro Health Hospital, Wyoming, Michigan, United States",,https://ClinicalTrials.gov/show/NCT03004222
710,NCT01644864,Can Post-operative TAP Block Improve Quality of Recovery After C-sections in Patients on Methadone Maintenance?,TAP,Withdrawn,No Results Available,Uncontrolled Postoperative Pain,Drug: 0.375% ROPIVACAINE|Drug: placebo,Quality of Recovery after TAP block,Thomas Jefferson University,Female,18 Years to 40 Years   (Adult),Phase 4,0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care",12D.37,2012-07-01,2013-11-01,2013-11-01,2012-07-19,null,2017-05-08,"Thomas Jefferson University, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01644864
711,NCT02219087,Liposomal Bupivacaine Versus Standard of Care in Total Knee Surgery,,Completed,Has Results,"Osteoarthritis, Knee",Drug: Liposomal bupivacaine|Drug: Standard of Care,"Number Physical Therapy Sessions Necessary for Discharge|Mean Visual Analog Scale (VAS) Pain Scores During Hospital Stay|Length of Stay (LOS, in Days)|Opioid Consumption in Oral Morphine Equivalents (OMEs, in Milligrams)|Number of Participants With Opioid-related Adverse Events (ORAEs) During Hospital Stay|Total Cost of Care (Dollars)|Hospital Readmission Not Including Admissions Planned Procedures",OhioHealth,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,14-0024,2014-08-01,2016-03-01,2016-03-01,2014-08-18,2018-01-02,2018-01-02,"OhioHealth Grant Medical Center Bone and Joint Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02219087
712,NCT02351700,Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors,,Completed,No Results Available,Pituitary Tumor|Pain,Drug: IV Caldolor (IV Ibuprofen)|Drug: IV Ibuprofen placebo,"Comparison of pain scores between two arms|Breakthrough narcotic requirement|Total number of doses and type of any anti-emetic required post-operatively in both groups|The number of patients who do not have a bowel movement during hospitalization in both groups|The number of patients in both groups with opioid-associated adverse events, such as respiratory depression or sedation, using Pasero Opioid-Induced Sedation Scale (POSS)|Total cost of hospital charges compared between two arms|Other adverse events|Cost of pharmacy charges compared between two arms|Length of stay in hospital compared between two arms","St. Joseph's Hospital and Medical Center, Phoenix",All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 4,62,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care",14BN090,2015-02-01,2016-03-01,2016-04-01,2015-01-30,null,2017-04-14,"St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States",,https://ClinicalTrials.gov/show/NCT02351700
713,NCT02684968,Effects of Continuous Bilateral QL Analgesia After Open Abdominal Surgery,,Recruiting,No Results Available,"Pain, Postoperative",Procedure: Colorectal surgery,Pain Score|Opioid Consumption,The Cleveland Clinic,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,126,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",15-1273,2016-03-01,2020-02-01,2020-02-01,2016-02-18,null,2018-05-07,"Cleveland Clinic, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02684968
714,NCT01232439,A Study of Brain Receptor Occupancy in Healthy Subjects,,Completed,No Results Available,Alcohol Dependence,Drug: opioid receptor kappa antagonist,"Change in brain kappa opioid receptor occupancy (RO) by positron emission tomography (PET)|Pharmacokinetics, area under the curve (AUC)|Number of participants with clinically significant effects|Pharmacokinetics, concentration maximum (Cmax)",Eli Lilly and Company,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,13,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,12511|I2Z-MC-LAFC,2010-12-01,2011-04-01,2011-04-01,2010-11-02,null,2011-05-09,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01232439
715,NCT02028715,Efficacy of IV Acetaminophen for Pain Management,,Completed,No Results Available,Post-operative Pain,Drug: Placebo (normal saline)|Drug: IV acetaminophen,Amount of opioid rescue needed|Time to return of bowel function (passage of flatus)|Patient Satisfaction|Cost Effectiveness,Aultman Health Foundation,Female,"18 Years to 85 Years   (Adult, Older Adult)",Phase 4,67,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,2013.08.22.F2,2014-01-01,2016-07-01,2016-07-01,2014-01-07,null,2016-07-12,"Aultman Health Foundation, Canton, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02028715
716,NCT01839552,An Assessment of the Ability of Fentanyl Citrate Nasal Spray to Manage Breakthrough Pain in Cancer Patients.,FCNS,Withdrawn,No Results Available,Pain,Drug: Fentanyl Citrate Nasal Spray (FCNS),Pain Intensity|Pain Management Satisfaction,University of Louisville|James Graham Brown Cancer Center,All,"18 Years and older   (Adult, Older Adult)",Phase 4,0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,BCC-CA-12,2014-10-01,2017-04-01,2018-04-01,2013-04-25,null,2018-03-05,"James Graham Brown Cancer Center, Louisville, Kentucky, United States",,https://ClinicalTrials.gov/show/NCT01839552
717,NCT00218595,DBT Compared to I/GDC for the Treatment of Opiate Addiction in Emotionally Dysregulated Patients. - 1,,Completed,No Results Available,Dialectical Behavior Therapy|Individual and Group Drug Counseling,Behavioral: DBT|Behavioral: I/GDC,Psychological assessment interview|Urinalysis|Pre- and post-session therapist and client questionnaires,Duke University|National Institute on Drug Abuse (NIDA),All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,39,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,Pro00010957|5R01DA026454-03|R01-17372-1,2004-08-01,2009-06-01,2009-06-01,2005-09-22,null,2014-08-01,"Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00218595
718,NCT02403830,Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine,,Completed,Has Results,Coronary Artery Disease,Drug: Methylnaltrexone|Other: Placebo|Drug: Morphine|Drug: Ticagrelor,Platelet Reactivity Measured by VerifyNow P2Y12|Platelet Reactivity Measured by VASP|AUC of Ticagrelor Plasma Levels,University of Florida,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",AZ 10583 IISR,2015-08-01,2016-05-01,2016-05-01,2015-03-31,2017-04-27,2017-05-30,"University of Florida, Jacksonville, Florida, United States",,https://ClinicalTrials.gov/show/NCT02403830
719,NCT02525718,Selective Intraoperative Administration of Local Anesthesia in Breast Reconstruction,,Recruiting,No Results Available,Breast Cancer,"Drug: Saline|Drug: 0.25 % bupivacaine (2.5 mg/ml) w/ 1:100,000 epinephrine & 4 mg dexamethasone",Modified Quality of Recovery Survey|Pain using PROMIS scale,Northwestern University,Female,"18 Years to 79 Years   (Adult, Older Adult)",Phase 2,46,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",STU00200903,2015-06-01,2017-12-01,2018-12-01,2015-08-17,null,2017-02-24,"Northwestern University, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT02525718
720,NCT00591448,Study in the Use of Virtual Reality as an Adjunct to Pain Control in Burn Patients,,Completed,No Results Available,Burn,Other: Virtual Reality (VR),Improved pain scores|There are no secondary outcomes,"University of Wisconsin, Madison",All,"6 Years and older   (Child, Adult, Older Adult)",Not Applicable,10,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,H-2006-0380,2007-10-01,2008-08-01,2008-08-01,2008-01-11,null,2012-10-17,"United States, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00591448
721,NCT00670800,Study of Brain Function in Women With Insulin Resistant Polycystic Ovary Syndrome,,Completed,Has Results,Polycystic Ovary Syndrome,Drug: Metformin,Mu-opioid Binding Potential Measured in Left Nucleus Accumbens|Mu-opioid Binding Potential Measured in Right Nucleus Accumbens|Mu-opioid Binding Potential Measured in Left Amygdala|Mu-opioid Binding Potential Measured in Right Amygdala,University of Michigan,Female,21 Years to 40 Years   (Adult),Not Applicable,14,Other,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2276|HUM00008330,2008-01-01,2009-08-01,2009-08-01,2008-05-02,2014-05-15,2014-05-21,"University of Michigan, Michigan Clinical Research Unit, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT00670800
722,NCT01367561,Naloxone and Intravenous Methylnaltrexone Effects on Bladder Function,,Completed,No Results Available,Healthy Males,Drug: Naloxone|Drug: IV Methylnaltrexone (MNTX)|Drug: Placebo,Maximal force of detrusor contraction (Pdet) after administration of MNTX,"Valeant Pharmaceuticals International, Inc.",null,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,15,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,MNTX 206,2002-10-01,2003-05-01,2003-05-01,2011-06-07,null,2011-07-19,"Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States",,https://ClinicalTrials.gov/show/NCT01367561
723,NCT02886286,Patient Controlled Intrathecal Analgesia With Bupivacaine for Chronic Low Back Pain,,Completed,No Results Available,"Pain, Intractable|Breakthrough Pain|Chronic Pain",Drug: Bupivacaine|Drug: Opioid,Change in the numerical rating pain scale|Oswestry Disability Index|Global Impression of Change|painDETECT|Average Weekly Pain Score (NRS)|Treatment Satisfaction,University Hospitals Cleveland Medical Center,All,"31 Years to 90 Years   (Adult, Older Adult)",Phase 4,17,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2/16/24,2016-05-01,2017-12-01,2017-12-01,2016-09-01,null,2018-06-14,"University Hospitals Case Medical Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02886286
724,NCT01587274,A Randomized Study of Three Medication Regimens for Acute Low Back Pain,,Completed,Has Results,Acute Low Back Pain,Drug: Naproxen|Drug: Cyclobenzaprine|Drug: Oxycodone/ acetaminophen,Change in Functional Disability as Measured by the Roland Morris Disability Questionnaire,Montefiore Medical Center,All,21 Years to 64 Years   (Adult),Phase 4,323,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",11-10-379,2012-04-01,2014-10-01,2014-12-01,2012-04-30,2018-07-31,2018-07-31,"Montefiore Medical Center, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT01587274
725,NCT00352664,The Effect of Donepezil on Sedation and Other Symptoms,,Terminated,Has Results,Advanced Cancer,Drug: Donepezil|Drug: Placebo,Sedation Mean Scores at 1-Week,M.D. Anderson Cancer Center|Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,27,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2003-0425,2003-11-01,2007-07-01,2007-07-01,2006-07-14,2009-12-29,2016-05-09,"U.T. M.D. Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00352664
726,NCT01993940,Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation,,Completed,Has Results,Opioid-induced Constipation,Drug: Naldemedine|Drug: Placebo,Percentage of Participants With a Spontaneous Bowel Movement (SBM) Response|Change From Baseline to the Last 2 Weeks of the Treatment Period in the Number of Spontaneous Bowel Movements Per Week|Change From Baseline to Week 1 in the Number of Spontaneous Bowel Movements Per Week|Change From Baseline to the Last 2 Weeks of the Treatment Period in the Number of Complete Spontaneous Bowel Movements Per Week|Change From Baseline to the Last 2 Weeks of the Treatment Period in the Number of Spontaneous Bowel Movements With No Straining Per Week,Shionogi|Shionogi Inc.,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,553,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1315V9232|2013-002948-91,2013-11-04,2015-06-09,2015-06-09,2013-11-25,2017-05-30,2017-05-30,"Shionogi Research Site, Birmingham, Alabama, United States|Shionogi Research Site, Homewood, Alabama, United States|Shionogi Research Site, Goodyear, Arizona, United States|Shionogi Research Site, Little Rock, Arkansas, United States|Shionogi Research Site, Anaheim, California, United States|Shionogi Research Site, Buena Park, California, United States|Shionogi Research Site, Corona, California, United States|Shionogi Research Site, Gold River, California, United States|Shionogi Research Site, Los Angeles, California, United States|Shionogi Research Site, Modesto, California, United States|Shionogi Research Site, Pasadena, California, United States|Shionogi Research Site, Coral Gables, Florida, United States|Shionogi Research Site, Hialeah, Florida, United States|Shionogi Research Site, Jacksonville, Florida, United States|Shionogi Research Site, Miami Beach, Florida, United States|Shionogi Research Site, Miami, Florida, United States|Shionogi Research Site, Plantation, Florida, United States|Shionogi Research Site, Columbus, Georgia, United States|Shionogi Research Site, Evansville, Indiana, United States|Shionogi Research Site, Indianapolis, Indiana, United States|Shionogi Research Site, West Des Moines, Iowa, United States|Shionogi Research Site, Edgewood, Kentucky, United States|Shionogi Research Site, Crowley, Louisiana, United States|Shionogi Research Site, Kalamazoo, Michigan, United States|Shionogi Research Site, Traverse City, Michigan, United States|Shionogi Research Site, Butte, Montana, United States|Shionogi Research Site, Omaha, Nebraska, United States|Shionogi Research Site, Las Vegas, Nevada, United States|Shionogi Research Site, Omaha, Nevada, United States|Shionogi Research Site, Albuquerque, New Mexico, United States|Shionogi Research Site, Hopewell Junction, New York, United States|Shionogi Research Site, Mooresville, North Carolina, United States|Shionogi Research Site, Winston-Salem, North Carolina, United States|Shionogi Research Site, Dayton, Ohio, United States|Shionogi Research Site, Marion, Ohio, United States|Shionogi Research Site, Media, Pennsylvania, United States|Shionogi Research Site, Spartanburg, South Carolina, United States|Shionogi Research Site, Knoxville, Tennessee, United States|Shionogi Research Site, Tullahoma, Tennessee, United States|Shionogi Research Site, Channelview, Texas, United States|Shionogi Research Site, Fort Worth, Texas, United States|Shionogi Research Site, Groesbeck, Texas, United States|Shionogi Research Site, Houston, Texas, United States|Shionogi Research Site, Plano, Texas, United States|Shionogi Research Site, San Antonio, Texas, United States|Shionogi Research Site, Chesapeake, Virginia, United States|Shionogi Research Site, Chester, Virginia, United States|Shionogi Research Site, Tacoma, Washington, United States|Shionogi Research Site, Clarksburg, West Virginia, United States",,https://ClinicalTrials.gov/show/NCT01993940
727,NCT01965158,Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation,,Completed,Has Results,Opioid-induced Constipation,Drug: Naldemedine|Drug: Placebo,Percentage of Participants With a Spontaneous Bowel Movement (SBM) Response|Change From Baseline to the Last 2 Weeks of the Treatment Period in the Number of Spontaneous Bowel Movements Per Week|Change From Baseline to Week 1 in the Number of Spontaneous Bowel Movements Per Week|Change From Baseline to the Last 2 Weeks of the Treatment Period in the Number of Complete Spontaneous Bowel Movements Per Week|Change From Baseline to the Last 2 Weeks of the Treatment Period in the Number of Spontaneous Bowel Movements With No Straining Per Week,Shionogi|Shionogi Inc.,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,547,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1314V9231|2013-002241-11,2013-08-29,2015-01-22,2015-01-22,2013-10-18,2017-05-30,2017-05-30,"Shionogi Research Site, Birmingham, Alabama, United States|Shionogi Research Site, Phoenix, Arizona, United States|Shionogi Research Site, Fresno, California, United States|Shionogi Research Site, Long Beach, California, United States|Shionogi Research Site, National City, California, United States|Shionogi Research Site, North Hollywood, California, United States|Shionogi Research Site, Oceanside, California, United States|Shionogi Research Site, Golden, Colorado, United States|Shionogi Research Site, Miami Springs, Florida, United States|Shionogi Research Site, Miami, Florida, United States|Shionogi Research Site, Orlando, Florida, United States|Shionogi Research Site, Sarasota, Florida, United States|Shionogi Research Site, West Palm Beach, Florida, United States|Shionogi Research Site, Winter Park, Florida, United States|Shionogi Research Site, Marietta, Georgia, United States|Shionogi Research Site, Shreveport, Louisiana, United States|Shionogi Research Site, Caro, Michigan, United States|Shionogi Research Site, Flint, Michigan, United States|Shionogi Research Site, Hazelwood, Missouri, United States|Shionogi Research Site, Las Vegas, Nevada, United States|Shionogi Research Site, Belvidere, New Jersey, United States|Shionogi Research Site, East Brunswick, New Jersey, United States|Shionogi Research Site, Albuquerque, New Mexico, United States|Shionogi Research Site, Great Neck, New York, United States|Shionogi Research Site, Hollis, New York, United States|Shionogi Research Site, New Windsor, New York, United States|Shionogi Research Site, Winston-Salem, North Carolina, United States|Shionogi Research Site, Cincinnati, Ohio, United States|Shionogi Research Site, Oklahoma City, Oklahoma, United States|Shionogi Research Site, Medford, Oregon, United States|Shionogi Research Site, West Reading, Pennsylvania, United States|Shionogi Research Site, Chattanooga, Tennessee, United States|Shionogi Research Site, Arlington, Texas, United States|Shionogi Research Site, Austin, Texas, United States|Shionogi Research Site, Dallas, Texas, United States|Shionogi Research Site, Houston, Texas, United States|Shionogi Research Site, San Antonio, Texas, United States|Shionogi Research Site, St. Poelten, Austria|Shionogi Research Site, Vienna, Austria|Shionogi Research Site, Hradec Kralove, Czechia|Shionogi Research Site, Liberec, Czechia|Shionogi Research Site, Pardubice, Czechia|Shionogi Research Site, Prague, Czechia|Shionogi Research Site, Vysoke Myto, Czechia|Shionogi Research Site, Berlin, Germany|Shionogi Research Site, Eichstaett, Germany|Shionogi Research Site, Frankfurt am Main, Germany|Shionogi Research Site, Bialystok, Poland|Shionogi Research Site, Bydgoszcz, Poland|Shionogi Research Site, Czeladź, Poland|Shionogi Research Site, Gorzów Wielkopolski, Poland|Shionogi Research Site, Warszawa, Poland|Shionogi Research Site, Alicante, Spain|Shionogi Research Site, Cádiz, Spain|Shionogi Research Site, Madrid, Spain|Shionogi Research Site, Belfast, United Kingdom|Shionogi Research Site, Bexhill-on-Sea East Sussex, United Kingdom|Shionogi Research Site, Crownhill Plymouth, United Kingdom|Shionogi Research Site, Fowey Cornwall, United Kingdom|Shionogi Research Site, Liskeard Cornwall, United Kingdom|Shionogi Research Site, London, United Kingdom|Shionogi Research Site, Penzance Cornwall, United Kingdom|Shionogi Research Site, Soham Ely Cambs, United Kingdom|Shionogi Research Site, St Austell Cornwall, United Kingdom|Shionogi Research Site, Tomairt, United Kingdom",,https://ClinicalTrials.gov/show/NCT01965158
728,NCT02123979,Study to Assess Dopamine Receptor Modulation With Rotigotine to Enhance Morphine Analgesia in the Dental Model,,Unknown status,No Results Available,Post-op Pain,Drug: Neupro® transdermal patch/placebo,Sum of pain intensity difference scores|Analgesic tablets taken postoperatively,East Carolina University,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",14-000723|112101 668916,2015-11-01,2016-11-01,2017-01-01,2014-04-28,null,2015-08-07,"School of Dental Medicine At East Carolina University, Greenville, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT02123979
729,NCT01452789,Blinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence Syndrome,,Completed,No Results Available,Neonatal Abstinence Syndrome,Drug: sublingual buprenorphine|Drug: oral morphine,Length of treatment|Length of hospitalization|Number of patients requiring supplemental phenobarbital treatment.|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Buprenorphine blood concentration|Morphine blood concentration,Thomas Jefferson University|National Institute on Drug Abuse (NIDA),All,"Child, Adult, Older Adult",Phase 3,62,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",11F.193|R01DA029076-01A1,2011-11-01,2016-06-01,2016-06-01,2011-10-17,null,2017-02-07,"Thomas Jefferson University Hosptial, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01452789
730,NCT02391571,A Study to Evaluate Withdrawal Effects Following Dosing of Oxycodone/Naltrexone in Methadone-Maintained Subjects,,Completed,No Results Available,Withdrawal Symptoms,Drug: Oxycodone/Naltrexone Capsules|Drug: Oxycodone|Drug: Placebo,Primary: Onset of Withdrawal measured by Subjective Opioid Withdrawal Scale(SOWS)|Primary: Onset of Withdrawal measured by Clinician-Rated Opioid Withdrawal Scale (COWS)|Secondary: Pharmacokinetic Profile of Naltrexone and 6β-Naltrexol in Subjects receiving Oxycodone/Naltrexone|Secondary: Subjective Pharmacodynamic Effects through the use of Visual Analog Scales (VAS)|Secondary: Objective Pharmacodynamic Effects through the use of Pupillometry measurements,"Elite Laboratories, Inc",All,18 Years to 55 Years   (Adult),Phase 3,26,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)",ELI-004-2015,2015-02-01,2015-03-01,2015-03-01,2015-03-18,null,2016-08-10,"Vince and Associates, Overland Park, Kansas, United States",,https://ClinicalTrials.gov/show/NCT02391571
731,NCT00440830,Nicotine Patch as an Analgesic Adjuvant After Surgery,,Completed,Has Results,Pain,Drug: nicotine patch|Drug: placebo,Postoperative Pain Score One Hour After Surgery|Postoperative Pain Score Five Days After Surgery|Nausea Assessment by Patient|Sedation|Pain Medication Used|Systolic Blood Pressure|Diastolic Blood Pressure|Heart Rate,Columbia University,All,18 Years to 60 Years   (Adult),Phase 4,68,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AAAB5945,2005-12-01,2008-12-01,2008-12-01,2007-02-27,2010-10-27,2010-11-11,"New York Presbyterian, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00440830
732,NCT00001952,Using a Narcotic to Enhance the Numbing Effect of the Local Anesthetic Lidocaine on Inflamed Molar Teeth,,Completed,No Results Available,Healthy|Inflammation|Mouth Disease|Pain,,,National Institute of Dental and Craniofacial Research (NIDCR)|National Institutes of Health Clinical Center (CC),All,"Child, Adult, Older Adult",,275,NIH,Observational,,000017|00-D-0017,1999-11-01,null,2002-12-01,2000-01-19,null,2008-03-04,"National Institute of Dental And Craniofacial Research (NIDCR), Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00001952
733,NCT02774954,Change the Cycle: An RCT to Prevent Injection Initiation,CTC,"Active, not recruiting",No Results Available,"Substance Abuse, Intravenous|HIV|Heroin Dependence|Opioid Dependence|Cocaine Dependence|Amphetamine Dependence",Behavioral: Change the Cycle,Number of non-injectors initiated into drug injection|Number of request to initiate someone into drug injection,University of Southern California|National Institute on Drug Abuse (NIDA)|RTI International|University of Toronto,All,"18 Years and older   (Adult, Older Adult)",Phase 3,972,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,HS-15-00243|R01DA038965,2016-06-01,2018-09-01,2019-06-01,2016-05-17,null,2017-12-05,"University of Southern California, Los Angeles, California, United States|RTI International, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT02774954
734,NCT00335972,The Effects of Dexmedetomidine and Remifentanil on Carotid Patients,,Terminated,Has Results,Carotid Artery Stenosis,Drug: Remifentanil|Drug: Dexmedetomidine,Mean Arterial Pressure|Visual Analogue Scale (VAS) Pain Score|Intravenous Morphine Equivalents During Post-anesthesia Care Unit (PACU) After Surgery,The Cleveland Clinic,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 4,142,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",10/27/05,2006-06-01,2008-05-01,2008-05-01,2006-06-12,2017-08-11,2017-08-11,"Cleveland Clinic, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00335972
735,NCT00402038,Study of Methylnaltrexone (MNTX) for the Relief of Constipation,,Completed,No Results Available,Advance Illness Patients With OIC,Drug: SC Methylnaltrexone|Drug: SC Placebo,Laxation within four hours of a single dose of SC MNTX and efficacy of SC MNTX every other day over a 1 week period.,"Valeant Pharmaceuticals International, Inc.|Wyeth is now a wholly owned subsidiary of Pfizer",All,"18 Years and older   (Adult, Older Adult)",Phase 3,134,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",MNTX 302,2004-02-01,2005-10-01,2005-10-01,2006-11-22,null,2011-07-19,"Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States",,https://ClinicalTrials.gov/show/NCT00402038
736,NCT03198208,Intraoperative Fentanyl Dose on Respiratory Complications,,"Active, not recruiting",No Results Available,Fentanyl|Opioid Use|Surgery|Respiratory Complication,Drug: Fentanyl dose administration,Postoperative respiratory complications,Massachusetts General Hospital,All,"18 Years and older   (Adult, Older Adult)",,183396,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2017P000825,2007-01-01,2015-12-31,2018-06-30,2017-06-26,null,2017-06-26,"The Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03198208
737,NCT00672139,Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness,,Completed,Has Results,Opioid-Induced Constipation,Drug: Methylnaltrexone bromide,Number of Laxations Per Subject Within 24 Hours of Dosing Per Week.,"Valeant Pharmaceuticals International, Inc.|Progenics Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 4,156,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3200K1-4001|B2541006,2008-07-01,2013-01-01,2013-05-01,2008-05-06,2018-03-07,2018-03-07,"Salix Investigational Site, Mobile, Alabama, United States|Salix Investigational Site, Laguna Hills, California, United States|Salix Investigational Site, Lancaster, California, United States|Salix Investigational Site, Aurora, Colorado, United States|Salix Investigational Site, Auburndale, Florida, United States|Salix Investigational Site, Hudson, Florida, United States|Salix Investigational Site, Lakeland, Florida, United States|Salix Investigational Site, Lakeland, Florida, United States|Salix Investigational Site, Miami Springs, Florida, United States|Salix Investigational Site, Ruskin, Florida, United States|Salix Investigational Site, Sebring, Florida, United States|Salix Investigational Site, Tampa, Florida, United States|Salix Investigational Site, Tampa, Florida, United States|Salix Investigational Site, Tampa, Florida, United States|Salix Investigational Site, Temple Terrace, Florida, United States|Salix Investigational Site, Orange, New Jersey, United States|Salix Investigational Site, Flat Rock, North Carolina, United States|Salix Investigational Site, Winston-Salem, North Carolina, United States|Salix Investigational Site, Cleveland, Ohio, United States|Salix Investigational Site, Philadelphia, Pennsylvania, United States|Salix Investigational Site, Austin, Texas, United States|Salix Investigational Site, Houston, Texas, United States|Salix Investigational Site, American Fork, Utah, United States|Salix Investigational Site, Orem, Utah, United States|Salix Investigational Site, Provo, Utah, United States|Salix Investigational Site, Madison, Wisconsin, United States|Salix Investigational Site, Coburg, Victoria, Australia|Salix Investigational Site, East Melbourne, Victoria, Australia|Salix Investigational Site, Adelaide, Australia|Salix Investigational Site, Leuven, Belgium|Salix Investigational Site, Edmonton, Alberta, Canada|Salix Investigational Site, Edmonton, Alberta, Canada|Salix Investigational Site, Hamilton, Ontario, Canada|Salix Investigational Site, London, Ontario, Canada|Salix Investigational Site, Montreal, Quebec, Canada|Salix Investigational Site, Quebec, Canada|Salix Investigational Site, Montpellier, France|Salix Investigational Site, Berlin, Germany|Salix Investigational Site, L'Aquila, Italy|Salix Investigational Site, Milano, Italy|Salix Investigational Site, Milan, Italy|Salix Investigational Site, Roma, Italy|Pfizer Investigational Site, Mexico City DF, Mexico|Salix Investigational Site, Almada, Portugal|Salix Investigational Site, Porto, Portugal|Salix Investigational Site, Cheltenham, Gloucestershire, United Kingdom",,https://ClinicalTrials.gov/show/NCT00672139
738,NCT00474799,"Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of MNS075 (Intranasal Morphine)",,Completed,No Results Available,Healthy,Drug: MNS075,"To characterize the repeat dosing plasma profile, extent of accumulation and repeat dose pharmacokinetics of morphine, morphine-3-glucuronide, and morphine-6-glucuronide during administration of MNS075.",Javelin Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 1,32,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),MOR-PK-006,2007-01-01,2007-02-01,2007-02-01,2007-05-17,null,2008-01-14,"CEDRA Corporation, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT00474799
739,NCT01928953,Longitudinal Study of Patients With Opioid-Induced Constipation,,Completed,No Results Available,Patients With Opioid Induced Constipation,,"Rate of LIR among the OIC population|Rate of inadequate response to first and second-line laxative treatment for OIC (1x LIR and 2x LIR).|Baseline demographic and clinical characteristics of patients with OIC (prior health status, comorbidities, GI symptoms, and concomitant medications).|Drug utilization and self-management of OIC at baseline and changes from baseline over the 24-week follow-up period.|Healthcare resource utilization profiles pre- and post-baseline|Cost of illness related to the diagnosis, treatment, and general management of OIC (including laxative use) and events attributed to OIC, including both direct and indirect costs.|Baseline constipation-associated GI symptoms and changes from baseline over the 24-week follow-up period (PAC-SYM and additional symptom questions).|Baseline health-related quality of life (PAC-QOL and EQ-5D) and changes from baseline over the 24-week follow-up period (PAC-QOL).|Loss of productivity (WPAI-SHP score) at baseline and changes from baseline over the 24-week follow-up period.|Persistence on opioid therapy at baseline and changes from baseline over the 24-week follow-up period|Treatment satisfaction with laxative use at baseline and changes from baseline over the 24-week follow-up period, for all patients taking laxatives.|Physician-reported awareness of OIC and symptoms, and understanding of patient reported impact of OIC at baseline.",AstraZeneca,All,"18 Years to 85 Years   (Adult, Older Adult)",,520,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,12AST11894/A-12292,2012-10-01,2014-12-01,2014-12-01,2013-08-27,null,2015-07-08,"Alliance Clinical Research, Birmingham, Alabama, United States|Horizon Research Group, Inc, Mobile, Alabama, United States|HOPE Research Institute, Phoenix, Arizona, United States|Advanced Rx Clinical Research, Artelia, California, United States|TriWest Research Associates, LLC, El Cajon, California, United States|Akkiance Research Centers, Laguna Hills, California, United States|Primecare Clinical Research, Lajuna Hills, California, United States|Samaritan Center for Medical Research, Los Gatos, California, United States|Precision Research Institute, LLC, San Diego, California, United States|Southeast Clinical Research, LLC, Jacksonville, Florida, United States|Physician Care Clinical Research, LLC, Sarasota, Florida, United States|Soth Miami Clinical Research, South Miami, Florida, United States|Chicago Anesthesia Pain Specialists, Chicago, Illinois, United States|ActivMed Practices & Research, Newington, New Hampshire, United States|Atco Medical Associates, P.C., Atco, New Jersey, United States|DiGiovanna Institute for medical Education and Research, North Massapequa, New York, United States|Gaffnew Health Services, Charlotte, North Carolina, United States|Clinical Inquest Center LTD, Beavercreek, Ohio, United States|Ohio Clinical Research Partners, LLC, Canton, Ohio, United States|Clinical Inquest Center, Ltd., Dayton, Ohio, United States|NPC Research, Oklahoma City, Oklahoma, United States|Pain Research of Charleston, Charleston, South Carolina, United States|Family Medicine of SayeBrook, Myrtle Beach, South Carolina, United States|Highland Clinical Research, Salt Lake City, Utah, United States|University of Calgary, Calgary, Alberta, Canada|Paradise Medical Clinic, Paradise, Newfoundland and Labrador, Canada|Aviva Clinical Trial Group Inc., Burlington, Ontario, Canada|SKDS Research Inc., Newmarket, Ontario, Canada|Taunton Health Centre, Oshawa, Ontario, Canada|Pro-Recherche, St. Romuald, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01928953
740,NCT00672477,Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness,,Completed,Has Results,Opioid-Induced Constipation,Drug: Methylnaltrexone|Drug: Placebo,The Proportion of Subjects Who Have a Rescue-free Laxation Response Within 4 Hours After at Least 2 of the First 4 Doses|Time to First Rescue-free Laxation (Following the First Dose of Study Drug).,"Valeant Pharmaceuticals International, Inc.|Progenics Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 4,237,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",3200K1-4000|B2541005,2008-06-01,2013-02-01,2013-02-01,2008-05-06,2018-03-08,2018-03-08,"Salix Investigational Site, Mobile, Alabama, United States|Salix Investigational Site, Laguna Hills, California, United States|Salix Investigational Site, Lancaster, California, United States|Salix Investigational Site, Aurora, Colorado, United States|Salix Investigational Site, Auburndale, Florida, United States|Salix Investigational Site, Hudson, Florida, United States|Salix Investigational Site, Lakeland, Florida, United States|Salix Investigational Site, Lakeland, Florida, United States|Salix Investigational Site, Miami Springs, Florida, United States|Salix Investigational Site, Ruskin, Florida, United States|Salix Investigational Site, Sebring, Florida, United States|Salix Investigational Site, Tampa, Florida, United States|Salix Investigational Site, Tampa, Florida, United States|Salix Investigational Site, Tampa, Florida, United States|Salix Investigational Site, Temple Terrace, Florida, United States|Salix Investigational Site, West Palm Beach, Florida, United States|Salix Investigational Site, Orange, New Jersey, United States|Salix Investigational Site, Albuquerque, New Mexico, United States|Salix Investigational Site, Flat Rock, North Carolina, United States|Salix Investigational Site, Winston-Salem, North Carolina, United States|Salix Investigational Site, Cleveland, Ohio, United States|Salix Investigational Site, Philadelphia, Pennsylvania, United States|Salix Investigational Site, Austin, Texas, United States|Salix Investigational Site, Houston, Texas, United States|Salix Investigational Site, American Fork, Utah, United States|Salix Investigational Site, Orem, Utah, United States|Salix Investigational Site, Provo, Utah, United States|Salix Investigational Site, Salt Lake City, Utah, United States|Salix Investigational Site, Madison, Wisconsin, United States|Salix Investigational Site, Darlinghurst, New South Wales, Australia|Salix Investigational Site, Coburg, Victoria, Australia|Salix Investigational Site, East Melbourne, Victoria, Australia|Salix Investigational Site, Leuven, Belgium|Salix Investigational Site, Liberdade, Sao Paulo, Brazil|Salix Investigational Site, Sao Paulo, SP, Brazil|Salix Investigational Site, Edmonton, Alberta, Canada|Salix Investigational Site, Winnipeg, Manitoba, Canada|Salix Investigational Site, Hamilton, Ontario, Canada|Salix Investigational Site, Montreal, Quebec, Canada|Salix Investigational Site, Montreal, Quebec, Canada|Salix Investigational Site, Quebec, Canada|Salix Investigational Site, Besancon, France|Salix Investigational Site, Bordeaux, France|Salix Investigational Site, Bordeaux, France|Salix Investigational Site, Grenoble, France|Salix Investigational Site, Montpellier, France|Salix Investigational Site, Villejuif, France|Salix Investigational Site, Aachen, Germany|Salix Investigational Site, Berlin, Germany|Salix Investigational Site, Muenchen, Germany|Salix Investigational Site, L'Aquila, Italy|Salix Investigational Site, Milano, Italy|Salix Investigational Site, Milan, Italy|Pfizer Investigational Site, Mexico City DF, Mexico|Salix Investigational Site, Barcelona, Spain|Salix Investigational Site, L'Hospitalet De Llobregat, Spain|Salix Investigational Site, Sevilla, Spain|Salix Investigational Site, Kungsbacka, Sweden|Salix Investigational Site, Norrköping, Sweden|Salix Investigational Site, Cheltenham, Gloucestershire, United Kingdom",,https://ClinicalTrials.gov/show/NCT00672477
741,NCT00262678,Efficacy and Safety of Sublingual Fentanyl Tablets in Treatment of Breakthrough Pain in Cancer Patients.,,Completed,No Results Available,Pain|Cancer,Drug: EN3267,,Prostrakan Pharmaceuticals,All,"17 Years and older   (Child, Adult, Older Adult)",Phase 3,null,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,EN3267-005,2005-12-01,2008-12-01,2009-01-01,2005-12-07,null,2009-06-04,"Carolinas Pain Institute, Winston-Salem, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00262678
742,NCT00485225,"Open Label, Safety Study of EN3270 in Patients With Moderate to Severe Non-malignant, Chronic Pain",,Completed,No Results Available,"Chronic, Non Malignant Pain",Drug: EN3270,Safety and minimum titration period,Durect,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,77,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EN3270-201,2007-06-01,2008-04-01,2008-07-01,2007-06-12,null,2012-02-23,"Comprehensive Clinical Research, Berlin, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT00485225
743,NCT03151226,OSA Screen Negative With Spinal Duramorph,,Terminated,Has Results,Respiratory Depression,Device: Capnography monitoring,Respiratory Depression/Suppression,Wake Forest University Health Sciences,Female,18 Years to 50 Years   (Adult),Not Applicable,3,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,15-330,2015-08-03,2015-10-01,2015-10-01,2017-05-12,2018-03-08,2018-04-11,"Novant Health Forsyth Medical Center, Winston-Salem, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT03151226
744,NCT01443403,A Study of Naldemedine (S-297995) for the Treatment of Opioid-Induced Constipation in Adults With Non-Malignant Chronic Pain Receiving Opioid Therapy,,Completed,Has Results,Opioid-induced Constipation,Drug: Placebo|Drug: Naldemedine,"Change From Baseline to Last 2 Weeks of the Treatment Period in the Number of Spontaneous Bowel Movements Per Week|Change From Baseline to Weeks 1, 2, 3, and 4 in the Number of Spontaneous Bowel Movements Per Week|Change From Baseline to the Last 2 Weeks of the Treatment Period in the Number of Bowel Movements (BMs) Per Week|Change From Baseline to Weeks 1, 2, 3, and 4 in the Number of Bowel Movements Per Week|Change From Baseline to the Last 2 Weeks of the Treatment Period in the Number of Complete Bowel Movements (CBMs) Per Week|Change From Baseline to Weeks 1, 2, 3, and 4 in the Number of Complete Bowel Movements Per Week|Change From Baseline to the Last 2 Weeks of the Treatment Period in the Number of Complete Spontaneous Bowel Movements (CSBMs) Per Week|Change From Baseline to Weeks 1, 2, 3, and 4 in the Number of Complete Spontaneous Bowel Movements Per Week|Percentage of Participants With an SBM Response in the Last 2 Weeks of the Treatment Period|Percentage of Participants With an SBM Response at Weeks 1, 2, 3 and 4|Percentage of Participants With a CSBM Response in the Last 2 Weeks of the Treatment Period|Percentage of Participants With a CSBM Response at Weeks 1, 2, 3, and 4|Change From Baseline to the Last 2 Weeks of the Treatment Period in Number of Days Per Week With SBMs|Change From Baseline to Weeks 1, 2, 3 and 4 in Number of Days Per Week With SBMs|Change From Baseline to the Last 2 Weeks of the Treatment Period in Number of Days Per Week With CSBMs|Change From Baseline to Weeks 1, 2, 3 and 4 in Number of Days Per Week With CSBMs|Time to the First Spontaneous Bowel Movement|Time to the First Complete Spontaneous Bowel Movement|Percentage of Participants With SBMs Within 4, 8, 12, and 24 Hours After the Initial Administration of Study Drug|Percentage of Participants With CSBMs Within 4, 8, 12, and 24 Hours After the Initial Administration of Study Drug|Change From Baseline to the Last 2 Weeks of the Treatment Period in Number of SBMs Per Week Rated as 3 or 4 on the Bristol Stool Scale|Change From Baseline to Weeks 1, 2, 3, and 4 in Number of SBMs Rated as 3 or 4 on the Bristol Stool Scale Per Week|Change From Baseline to the Last 2 Weeks of the Treatment Period in Number of SBMs Per Week With no Straining|Change From Baseline to Weeks 1, 2, 3, and 4 in the Number of SBMs Per Week Without Straining|Change From Baseline to the Last 2 Weeks of the Treatment Period in Number of False Start BMs Per Week|Change From Baseline to the Last 2 Weeks of the Treatment Period in Rescue Use of Laxative Agents Per Week|Mean Rescue Laxative Use Per Week During the Treatment Period|Change From Baseline to the Last 2 Weeks of the Treatment Period in Abdominal Bloating|Change From Baseline to Weeks 1, 2, 3, and 4 in Abdominal Bloating|Change From Baseline to the Last 2 Weeks of the Treatment Period in Abdominal Discomfort|Change From Baseline to Weeks 1, 2, 3, and 4 in Abdominal Discomfort|Subject Global Satisfaction at End of Treatment|Maximum Observed Plasma Concentration (Cmax) of Naldemedine and Metabolite Nor-S-297995|Time to Maximum Concentration (Tmax) of Naldemedine and Metabolite Nor-S-297995|Area Under the Concentration-time Curve From Hour 0 to the Time Point of the Last Measurable Concentration Within the Dose Interval (AUC0-τ)|Number of Participants With Treatment-emergent Adverse Events (TEAEs)",Shionogi|Shionogi Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,244,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1107V9221,2011-08-17,2012-08-22,2012-08-22,2011-09-29,2017-05-30,2017-06-26,"Shionogi Research Site, Phoenix, Arizona, United States|Shionogi Research Site, Sun Lakes, Arizona, United States|Shionogi Research Site, Little Rock, Arkansas, United States|Shionogi Research Site, Anaheim, California, United States|Shionogi Research Site, Fresno, California, United States|Shionogi Research Site, Lincoln, California, United States|Shionogi Research Site, Lomita, California, United States|Shionogi Research Site, Denver, Colorado, United States|Shionogi Research Site, Brandon, Florida, United States|Shionogi Research Site, Kissimmee, Florida, United States|Shionogi Research Site, New Port Richey, Florida, United States|Shionogi Research Site, North Miami, Florida, United States|Shionogi Research Site, Ocala, Florida, United States|Shionogi Research Site, Orlando, Florida, United States|Shionogi Research Site, Ormond Beach, Florida, United States|Shionogi Research Site, Port Orange, Florida, United States|Shionogi Research Site, Sarasota, Florida, United States|Shionogi Research Site, South Miami, Florida, United States|Shionogi Research Site, West Palm Beach, Florida, United States|Shionogi Research Site, Atlanta, Georgia, United States|Shionogi Research Site, Decatur, Georgia, United States|Shionogi Research Site, Marietta, Georgia, United States|Shionogi Research Site, Evansville, Indiana, United States|Shionogi Research Site, Lexington, Kentucky, United States|Shionogi Research Site, Shreveport, Louisiana, United States|Shionogi Research Site, Owings Mills, Maryland, United States|Shionogi Research Site, Watertown, Massachusetts, United States|Shionogi Research Site, Worcester, Massachusetts, United States|Shionogi Research Site, Traverse City, Michigan, United States|Shionogi Research Site, Edina, Minnesota, United States|Shionogi Research Site, Las Vegas, Nevada, United States|Shionogi Research Site, Newington, New Hampshire, United States|Shionogi Research Site, Berlin, New Jersey, United States|Shionogi Research Site, Willingboro, New Jersey, United States|Shionogi Research Site, Hartsdale, New York, United States|Shionogi Research Site, North Syracuse, New York, United States|Shionogi Research Site, Williamsville, New York, United States|Shionogi Research Site, Wilmington, North Carolina, United States|Shionogi Research Site, Winston-Salem, North Carolina, United States|Shionogi Research Site, Canton, Ohio, United States|Shionogi Research Site, Columbus, Ohio, United States|Shionogi Research Site, Perrysburg, Ohio, United States|Shionogi Research Site, Eugene, Oregon, United States|Shionogi Research Site, Philadelphia, Pennsylvania, United States|Shionogi Research Site, Greer, South Carolina, United States|Shionogi Research Site, Austin, Texas, United States|Shionogi Research Site, Dallas, Texas, United States|Shionogi Research Site, Orem, Utah, United States|Shionogi Research Site, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT01443403
745,NCT00399659,Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.,,Terminated,No Results Available,Opioid-induced Constipation,Drug: Tegaserod,"Long term safety of tegaserod|Change from baseline assessment of OIC symptoms, at week 24 and 52|Change from baseline assessment of opioid-induced mid/upper GI symptoms, at week 24 and 52|Patients' weekly assessment of intensity of pain for which opioids were prescribed, at week 24 and 52",Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 3,360,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CHTF919N2201E1,2006-11-01,2007-04-01,2007-04-01,2006-11-15,null,2012-05-01,"Investigative Site, Mobile, Alabama, United States|Investigative Site, Phoenix, Arizona, United States|Investigative Site, Phoenix, Arizona, United States|Investigative Site, Tucson, Arizona, United States|Investigative Site, North Little Rock, Arkansas, United States|Investigative Site, Buena Park, California, United States|Investigative Site, Downey, California, United States|Investigative Site, Encinitas, California, United States|Investigative Site, Fountain Valley, California, United States|Investigative Site, La Jolla, California, United States|Investigative Site, Los Angeles, California, United States|Investigative Site, Mission Viejo, California, United States|Investigative Site, Monroe, California, United States|Investigative Site, San Diego, California, United States|Investigative Site, San Diego, California, United States|Investigative Site, San Francisco, California, United States|Investigative Site, Torrance, California, United States|Investigative Site, Northglenn, Colorado, United States|Investigative Site, Bristol, Connecticut, United States|Investigative Site, DeLande, Florida, United States|Investigative Site, Jacksonville, Florida, United States|Investigative Site, Largo, Florida, United States|Investigative Site, Miami, Florida, United States|Investigative Site, New Smyrna Beach, Florida, United States|Investigative Site, Sarasota, Florida, United States|Investigative Site, Springhill, Florida, United States|Investigative Site, Tampa, Florida, United States|Investigative Site, Belleville, Illinois, United States|Investigative Site, Chicago, Illinois, United States|Investigative Site, Avon, Indiana, United States|Investigative Site, Evansville, Indiana, United States|Investigative Site, Indianapolis, Indiana, United States|Investigative Site, Overland Park, Kansas, United States|Investigative Site, Prairie Village, Kansas, United States|Investigative Site, Topeka, Kansas, United States|Investigative Site, Shreveport, Louisiana, United States|Investigative Site, Boston, Massachusetts, United States|Investigative Site, Boston, Massachusetts, United States|Investigative Site, Wellesley Hills, Massachusetts, United States|Investigative Site, Omaha, Nebraska, United States|Investigative Site, Omaha, Nebraska, United States|Investigative Site, Pahrump, Nevada, United States|Investigative Site, New York City, New York, United States|Investigative Site, New York, New York, United States|Investigative Site, North Massapequa, New York, United States|Investigative Site, Charlotte, North Carolina, United States|Investigative Site, Greensboro, North Carolina, United States|Investigative Site, Winston Salem, North Carolina, United States|Investigative Site, Oklahoma City, Oklahoma, United States|Investigative Site, Levittown, Pennsylvania, United States|Investigative Site, Chattanooga, Tennessee, United States|Investigative Site, Beaumont, Texas, United States|Investigative Site, Corsicana, Texas, United States|Investigative Site, Houston, Texas, United States|Investigative Site, Salt Lake City, Utah, United States|Investigative Site, Charlottesville, Virginia, United States|Investigative Site, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00399659
746,NCT02270983,"Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain",,Completed,No Results Available,Opioid-Induced Constipation,Drug: Linaclotide 145 micrograms|Drug: Linaclotide 290 micrograms|Drug: Placebo,Change from baseline in the 8-week Spontaneous Bowel Movement (SBM) frequency rate (SBMs/week) during the Treatment Period|Time to first Spontaneous Bowel Movement (SBM) after the first dose of investigational product|6/8 Week Spontaneous Bowel Movement (SBM) 3 + 1 responder|Change from baseline in 8-week stool consistency (Bristol Stool Form Scale)|Change from baseline in 8-week straining|Change from baseline in 8-week abdominal bloating,"Forest Laboratories|Ironwood Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,254,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",LIN-MD-40,2014-10-01,2015-08-01,2015-10-01,2014-10-22,null,2016-08-09,"Forest Investigative Site 002, Anniston, Alabama, United States|Forest Investigative Site 001, Foley, Alabama, United States|Forest Investigative Site 007, Phoenix, Arizona, United States|Forest Investigative Site 008, Tucson, Arizona, United States|Forest Investigative Site 003, North Little Rock, Arkansas, United States|Forest Investigative Site 018, Anaheim, California, United States|Forest Investigative Site 014, Fountain Valley, California, United States|Forest Investigative Site 019, Fresno, California, United States|Forest Investigative Site 017, Garden Grove, California, United States|Forest Investigative Site 010, Gold River, California, United States|Forest Investigative Site 009, Lincoln, California, United States|Forest Investigative Site 012, North Hollywood, California, United States|Forest Investigative Site 011, Orange, California, United States|Forest Investigative Site 016, Sacramento, California, United States|Forest Investigative Site 013, San Diego, California, United States|Forest Investigative Site 015, Santa Ana, California, United States|Forest Investigative Site 020, Colorado Springs, Colorado, United States|Forest Investigative Site 021, Bristol, Connecticut, United States|Forest Investigative Site 035, Boynton Beach, Florida, United States|Forest Investigative Site 038, Bradenton, Florida, United States|Forest Investigative Site 024, DeLand, Florida, United States|Forest Investigative Site 027, Gainesville, Florida, United States|Forest Investigative Site 023, Jacksonville, Florida, United States|Forest Investigative Site 036, Jupiter, Florida, United States|Forest Investigative Site 037, Lauderdale Lakes, Florida, United States|Forest Investigative Site 028, Miami, Florida, United States|Forest Investigative Site 040, Orlando, Florida, United States|Forest Investigative Site 022, Oviedo, Florida, United States|Forest Investigative Site 034, Port Orange, Florida, United States|Forest Investigative Site 029, Seminole, Florida, United States|Forest Investigative Site 031, Tampa, Florida, United States|Forest Investigative Site 033, Tampa, Florida, United States|Forest Investigative Site 030, Tampa, Florida, United States|Forest Investigative Site 039, West Palm Beach, Florida, United States|Forest Investigative Site 032, Weston, Florida, United States|Forest Investigative Site 041, Marietta, Georgia, United States|Forest Investigative Site 042, Woodstock, Georgia, United States|Forest Investigative Site 043, Chicago, Illinois, United States|Forest Investigative Site 044, Evansville, Indiana, United States|Forest Investigative Site 045, Madisonville, Kentucky, United States|Forest Investigative Site 046, Metairie, Louisiana, United States|Forest Investigative Site 048, Hagerstown, Maryland, United States|Forest Investigative Site 047, Watertown, Massachusetts, United States|Forest Investigative Site 050, Chesterfield, Michigan, United States|Forest Investigative Site 049, Flint, Michigan, United States|Forest Investigative Site 058, Omaha, Nebraska, United States|Forest Investigative Site 057, Omaha, Nebraska, United States|Forest Investigative Site 059, Williamsville, New York, United States|Forest Investigative Site 082, Asheboro, North Carolina, United States|Forest Investigative Site 054, Chapel Hill, North Carolina, United States|Forest Investigative Site 088, Davidson, North Carolina, United States|Forest Investigative Site 051, Flat Rock, North Carolina, United States|Forest Investigative Site 052, Greensboro, North Carolina, United States|Forest Investigative Site 055, Greensboro, North Carolina, United States|Forest Investigative Site 053, Winston Salem, North Carolina, United States|Forest Investigative Site 056, Fargo, North Dakota, United States|Forest Investigative Site 062, Cincinnati, Ohio, United States|Forest Investigative Site 061, Columbus, Ohio, United States|Forest Investigative Site 060, Mentor, Ohio, United States|Forest Investigative Site 087, Wadsworth, Ohio, United States|Forest Investigative Site 064, Oklahoma City, Oklahoma, United States|Forest Investigative Site 063, Oklahoma City, Oklahoma, United States|Forest Investigative Site 065, Tulsa, Oklahoma, United States|Forest Investigative Site 066, Medford, Oregon, United States|Forest Investigative Site 067, Levittown, Pennsylvania, United States|Forest Investigative Site 080, Philadelphia, Pennsylvania, United States|Forest Investigative Site 068, Cumberland, Rhode Island, United States|Forest Investigative Site 070, Charleston, South Carolina, United States|Forest Investigative Site 083, Richardson, Texas, United States|Forest Investigative Site 074, San Antonio, Texas, United States|Forest Investigative Site 073, San Antonio, Texas, United States|Forest Investigative Site 071, San Antonio, Texas, United States|Forest Investigative Site 075, Logan, Utah, United States|Forest Investigative Site 084, Ogden, Utah, United States|Forest Investigative Site 076, West Jordan, Utah, United States|Forest Investigative Site 078, Christiansburg, Virginia, United States|Forest Investigative Site 079, Bellevue, Washington, United States",,https://ClinicalTrials.gov/show/NCT02270983
747,NCT02267772,IV Acetaminophen vs IV Morphine for Pain Control in Pregnant Women,,Recruiting,No Results Available,Pain Management in Pregnant Women,Drug: IV Acetaminophen|Drug: IV Morphine,"Pain intensity|Pain relief based on a 5 point verbal scale at 15 minutes, 1, 2, 6 and 24 hours|The time to first rescue medication|3. The quantity of rescue medication over 24 hours or hospital stay|4. Total amount of either acetaminophen, morphine or other analgesics over 24 hours|5. Patient's global satisfaction at 24 hours. This will be patient reported.|6. Reports of maternal adverse effects such as nausea, vomiting, pruritus, headache, pyrexia, insomnia, sedation|7. Effects on fetal heart rate tracing including acceleration, decelerations, change in baseline and variability. This will occur about 30 minutes after the medication is given with a range of ± 30 minutes.","The University of Texas Health Science Center, Houston",Female,18 Years to 60 Years   (Adult),Not Applicable,330,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,HSC-MS-13-0763,2014-01-01,2018-02-01,2018-06-01,2014-10-17,null,2017-05-03,"Lyndon B Johnson Hospital, Houston, Texas, United States|Memorial Hermann Hospital, Texas Medical Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02267772
748,NCT01666119,An Open Label Study To Assess The Safety And Tolerability Of BEMA® Buprenorphine NX In Opioid Dependent Subjects,,Completed,Has Results,Opioid Dependence,Drug: BEMA Buprenorphine NX films,Adverse Events|Urine Drug Screen,BioDelivery Sciences International,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,249,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BNX-201,2012-08-01,2013-01-01,2013-01-01,2012-08-16,2017-04-04,2017-04-04,"Birmingham, Alabama, United States|Haleyville, Alabama, United States|Jacksonville, Florida, United States|Maitland, Florida, United States|North Miami, Florida, United States|Prairie Village, Kansas, United States|Baltimore, Maryland, United States|Fall River, Massachusetts, United States|Belvidere, New Jersey, United States|Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT01666119
749,NCT01309841,Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation,,Completed,Has Results,Opioid-Induced Constipation (OIC),Drug: NKTR-118|Drug: Placebo,Response (Responder/Non-responder) to Study Drug During Weeks 1 to 12|Response (Responder/Non-responder) to Study Drug in the LIR Subgroup During Weeks 1 to 12|Time (in Hours) to First Post-dose Laxation Without the Use of Rescue Laxatives Within the Previous 24 Hours|Change From Baseline in Mean Number of Days Per Week With at Least 1 SBM During Weeks 1 to 12|Change From Baseline in Degree of Straining|Change From Baseline in Stool Consistency (Bristol Stool Scale)|Change From Baseline in Percent Numbers of Days With a CSBM (Complete Spontaneous Bowel Movement)|Change From Baseline in Mean Spontaneous Bowel Movements/Week|Time (in Hours) to First Post-dose Laxation Without the Use of Rescue Laxatives Within the Previous 24 Hours in the Laxative Inadequate Response (LIR) Subgroup|Change From Baseline in Patient Assessment of Constipation Symptoms Questionnaire (PAC-SYM)|Change From Baseline in Patient Assessment of Constipation Quality of Life (PAC-QOL) Satisfaction Domain,AstraZeneca,All,"18 Years to 84 Years   (Adult, Older Adult)",Phase 3,652,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D3820C00004|2011-001987-24,2011-03-01,2012-08-01,2012-08-01,2011-03-07,2015-06-01,2015-06-01,"Research Site, Birmingham, Alabama, United States|Research Site, Calera, Alabama, United States|Research Site, Glendale, Arizona, United States|Research Site, Mesa, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Hot Springs, Arkansas, United States|Research Site, Malvern, Arkansas, United States|Research Site, Anaheim, California, United States|Research Site, Beverly Hills, California, United States|Research Site, Burbank, California, United States|Research Site, Garden Grove, California, United States|Research Site, Laguana Hills, California, United States|Research Site, Laguna Hills, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Gatos, California, United States|Research Site, Montebello, California, United States|Research Site, National City, California, United States|Research Site, Norwalk, California, United States|Research Site, Paramount, California, United States|Research Site, Sacramento, California, United States|Research Site, San Diego, California, United States|Research Site, Santa Ana, California, United States|Research Site, Denver, Colorado, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Brooksville, Florida, United States|Research Site, Deland, Florida, United States|Research Site, Fort Myers, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Inverness, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jackson, Florida, United States|Research Site, Jupiter, Florida, United States|Research Site, Maitland, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Naples, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Ormond Beach, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Plantation, Florida, United States|Research Site, Tamarac, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Venice, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Winter Park, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Decatur, Georgia, United States|Research Site, Boise, Idaho, United States|Research Site, Bloomington, Illinois, United States|Research Site, Rockford, Illinois, United States|Research Site, Evansville, Indiana, United States|Research Site, Greenfield, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, West Des Moines, Iowa, United States|Research Site, Pikesville, Maryland, United States|Research Site, Brockton, Massachusetts, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Biloxi, Mississippi, United States|Research Site, St Joseph, Missouri, United States|Research Site, St Louis, Missouri, United States|Research Site, Missoula, Montana, United States|Research Site, Omaha, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Trenton, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, New York, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Hickory, North Carolina, United States|Research Site, High Point, North Carolina, United States|Research Site, Morrisville, North Carolina, United States|Research Site, Beavercreek, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Medord, Oregon, United States|Research Site, Feasterville, Pennsylvania, United States|Research Site, Huntingdon Valley, Pennsylvania, United States|Research Site, Levittown, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Yardley, Pennsylvania, United States|Research Site, Cumberland, Rhode Island, United States|Research Site, Charleston, South Carolina, United States|Research Site, Greer, South Carolina, United States|Research Site, Orangeburg, South Carolina, United States|Research Site, Clarksville, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Doral, Texas, United States|Research Site, Houston, Texas, United States|Research Site, North Richland Hills, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Spokane, Washington, United States|Research Site, Broadmeadow, New South Wales, Australia|Research Site, Darlinghurst, New South Wales, Australia|Research Site, Port Kembla, New South Wales, Australia|Research Site, Westmead, New South Wales, Australia|Research Site, Greenslopes, Queensland, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, Fremantle, Western Australia, Australia|Research Site, Nedlands, Western Australia, Australia|Research Site, Berlin, BE, Germany|Research Site, Potsdam, BR, Germany|Research Site, Dietzenbach, HE, Germany|Research Site, Huttenberg, HE, Germany|Research Site, Wetzlar, HE, Germany|Research Site, Hamburg, HH, Germany|Research Site, Schwerin, MV, Germany|Research Site, Celle, NI, Germany|Research Site, Hannover, NI, Germany|Research Site, Essen, NW, Germany|Research Site, Mainz, RP, Germany|Research Site, Kiel, SH, Germany|Research Site, Dresden, SN, Germany|Research Site, Leipzig, SN, Germany|Research Site, Banska Bystrica, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Kosice, Slovakia|Research Site, Presov, Slovakia",,https://ClinicalTrials.gov/show/NCT01309841
750,NCT01262261,Re-Treatment Study of Probuphine in Opioid Addiction,,Completed,No Results Available,Opioid Dependency,Drug: Probuphine (buprenorphine implant),Number of subjects with Adverse Events (AEs) as a measure of safety|Pharmacokinetic analyses through plasma buprenorphine concentration in subjects as a measure of efficacy|Percent of subjects retained as a measure of efficacy|Percent of subjects reporting illicit drug use as a measure of efficacy|Average daily dose of supplemental sublingual buprenorphine as a measure of efficacy|Mean total score on SOWS as a measure of efficacy|Mean total score on COWS as a measure of efficacy|Mean subjective opioid cravings scores as a measure of efficacy|Mean total score on Beck Depression Inventory (BDI-II) as a measure of efficacy|Patient-rated opioid use and problems Responder Analysis as a measure of efficacy|Physician-rated severity of opioid use and symptoms Responder Analysis as a measure of efficacy|Overall satisfaction with treatment reported on Patient Satisfaction Survey,Braeburn Pharmaceuticals,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,85,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PRO-811,2010-11-01,2011-11-01,2011-11-01,2010-12-17,null,2017-06-14,"David Geffen School of Medicine at UCLA, Los Angeles, California, United States|Synergy Clinical Research Center, National City, California, United States|North County Clinical Research, Oceanside, California, United States|Friends Research Institute, Torrance, California, United States|Amit Vijapura, MD, Jacksonville, Florida, United States|Operation PAR, Inc. - TC Campus, Largo, Florida, United States|Fidelity Clinical Research, Lauderhill, Florida, United States|Scientific Clinical Research, Inc., North Miami, Florida, United States|BPRU, Behavioral Biology Research Center, Baltimore, Maryland, United States|Stanley Street Treatment and Resources, Inc, Fall River, Massachusetts, United States|Precise Research Centers, Flowood, Mississippi, United States|Psych Care Consultants Research, Saint Louis, Missouri, United States|St. Luke's Roosevelt Hospital Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Carolina Clinical Trials, Inc., Charleston, South Carolina, United States|University of Vermont, Burlington, Vermont, United States|Providence Behavioral Health Services, Everett, Washington, United States",,https://ClinicalTrials.gov/show/NCT01262261
751,NCT01863186,"Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal",,Completed,No Results Available,Opioid Dependence|Acute Opioid Withdrawal Syndrome,Drug: Lofexidine HCl|Drug: Placebo|Drug: Open Label Lofexidine HCL,Area under the curve based on Short Opiate Withdrawal Scale (SOWS) scores|Completion of initial double-blind treatment phase,US WorldMeds LLC|National Institute on Drug Abuse (NIDA),All,"18 Years and older   (Adult, Older Adult)",Phase 3,603,Industry|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",USWM-LX1-3003-1|1U01DA033276-01A1,2013-06-01,2014-11-01,2014-12-01,2013-05-27,null,2018-02-26,"Clovis, California, United States|Escondido, California, United States|San Diego, California, United States|Miami, Florida, United States|Orlando, Florida, United States|Atlanta, Georgia, United States|Oak Park, Illinois, United States|Lake Charles, Louisiana, United States|Baltimore, Maryland, United States|Flowood, Mississippi, United States|Saint Louis, Missouri, United States|Dayton, Ohio, United States|Mason, Ohio, United States|Austin, Texas, United States|Dallas, Texas, United States|DeSoto, Texas, United States|Orem, Utah, United States|Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT01863186
752,NCT00020618,Inhaled Morphine Compared With Morphine By Mouth in Treating Cancer Patients With Breakthrough Pain,,Completed,No Results Available,"Pain|Unspecified Adult Solid Tumor, Protocol Specific",Drug: morphine sulfate|Procedure: quality-of-life assessment,,Dana-Farber Cancer Institute|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 2,null,Other,Interventional,Primary Purpose: Supportive Care,DFCI-MOR-00-01|CDR0000068672|ARADIGM-MOR-00-01|BWH-2000-P-001516,2001-03-01,null,2004-02-01,2004-02-27,null,2013-07-18,"Brigham and Women's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00020618
753,NCT00223366,In Vitro Studies on Pharmacological Regulation and Genetic Risk Factors of Peripheral Human Nociceptors,,"Active, not recruiting",No Results Available,Pain,,Effects of inflammation in periradicular tissues.|Altered pain reports.,The University of Texas Health Science Center at San Antonio|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS),All,"16 Years to 90 Years   (Child, Adult, Older Adult)",,2000,Other|NIH,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,HSC20020071H|R01NS058655,2001-10-01,2019-08-01,2019-08-01,2005-09-22,null,2018-06-20,"The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00223366
754,NCT01384292,Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain,,Terminated,Has Results,Opioid-Induced Constipation,Drug: NKTR-118|Drug: Placebo,Response (Responder/Non-responder) to Study Drug,AstraZeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 3,14,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D3820C00006|2011-001985-16,2011-06-01,2012-09-01,2012-09-01,2011-06-29,2015-06-01,2015-06-01,"Research Site, Huntsville, Alabama, United States|Research Site, Casa Grande, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Fort Smith, Arkansas, United States|Research Site, Hot Springs, Arkansas, United States|Research Site, North Little Rock, Arkansas, United States|Research Site, Encino, California, United States|Research Site, Fountain Valley, California, United States|Research Site, Gilroy, California, United States|Research Site, Laguna Hills, California, United States|Research Site, Montebello, California, United States|Research Site, Orange, California, United States|Research Site, Riverside, California, United States|Research Site, San Bernandino, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Baypines, Florida, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Celebration, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Coral Gables, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Lake Worth, Florida, United States|Research Site, Lakeland, Florida, United States|Research Site, Miami Lakes, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Naples, Florida, United States|Research Site, Plantation, Florida, United States|Research Site, Tavares, Florida, United States|Research Site, Albany, Georgia, United States|Research Site, Marietta, Georgia, United States|Research Site, Riverdale, Georgia, United States|Research Site, Roswell, Georgia, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Chicago, Illinois, United States|Research Site, Springfield, Illinois, United States|Research Site, Anderson, Indiana, United States|Research Site, Evansville, Indiana, United States|Research Site, Owensboro, Kentucky, United States|Research Site, Lafayette, Louisiana, United States|Research Site, Elkridge, Maryland, United States|Research Site, Hollywood, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Fairhaven, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Southaven, Mississippi, United States|Research Site, Jefferson City, Missouri, United States|Research Site, St. Louis, Missouri, United States|Research Site, Missoula, Montana, United States|Research Site, Omaha, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Toms River, New Jersey, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Great Neck, New York, United States|Research Site, Syracuse, New York, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Flat Rock, North Carolina, United States|Research Site, Morrisville, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Winston-salem, North Carolina, United States|Research Site, Bismarck, North Dakota, United States|Research Site, Akron, Ohio, United States|Research Site, Beavercreek, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Middleton, Ohio, United States|Research Site, Danville, Pennsylvania, United States|Research Site, East Providence, Rhode Island, United States|Research Site, Charleston, South Carolina, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Beaumont, Texas, United States|Research Site, Bellaire, Texas, United States|Research Site, Corpus Christi, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Lubbock, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Sugarland, Texas, United States|Research Site, Fairfax, Virginia, United States|Research Site, Broadmeadow, New South Wales, Australia|Research Site, Frankston, Victoria, Australia|Research Site, Malvern, Victoria, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Fremantle, Western Australia, Australia|Research Site, Brussels, Belgium|Research Site, Edegem, Belgium|Research Site, Mons, Belgium|Research Site, Wetteren, Belgium|Research Site, Haskovo, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Ruse, Bulgaria|Research Site, Shumen, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Zagreb, Croatia|Research Site, Benesov, Czech Republic|Research Site, Ceske Budejovice, Czech Republic|Research Site, Praha 2, Czech Republic|Research Site, Berlin, BE, Germany|Research Site, Wiesbaden, HE, Germany|Research Site, Hamburg, HH, Germany|Research Site, Offenbach, Germany|Research Site, Brzozow, Poland|Research Site, Bydgoszcz, Poland|Research Site, Gdansk, Poland|Research Site, Gliwice, Poland|Research Site, Poznan, Poland|Research Site, Warsaw, Poland|Research Site, Wroclaw, Poland|Research Site, Ponce, Puerto Rico|Research Site, Craiova, Dolj, Romania|Research Site, Ploiesti, Prahova, Romania|Research Site, Baia Mare, Romania|Research Site, Braila, Romania|Research Site, Brasov, Romania|Research Site, Bucuresti, Romania|Research Site, Cluj-napoca, Romania|Research Site, Onesti, Romania|Research Site, Bardejov, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Kosice, Slovakia|Research Site, Presov, Slovakia|Research Site, Port Elizabeth, Eastern Cape, South Africa|Research Site, Bloemfontein, Free State, South Africa|Research Site, Benoni, Gauteng, South Africa|Research Site, Pretoria, Gauteng, South Africa|Research Site, Vereeniging, Gauteng, South Africa|Research Site, Durban, Kz-natal, South Africa|Research Site, Goodwood, W Cape, South Africa|Research Site, Sevilla, Andalucia, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, A Coruna, Galicia, Spain|Research Site, Penarth, CRF, United Kingdom|Research Site, Norwich, Norfolk, United Kingdom|Research Site, Guildford, Surrey, United Kingdom|Research Site, Chippenham, Wilts, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01384292
755,NCT02381717,Ultrasound Guided Femoral Nerve Block,,Recruiting,No Results Available,Hip Fracture,Other: ultra-sound guide|Drug: bupivacaine|Drug: morphine,pain intensity reduction,Beth Israel Deaconess Medical Center,All,"18 Years to 101 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2014P000304,2015-08-01,2019-01-01,2019-01-01,2015-03-06,null,2017-09-26,"Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|St. Vincent's Hospital, Worcester, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02381717
756,NCT02696434,Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL,,Completed,No Results Available,Opioid Use Disorder,Drug: Naltrexone|Drug: Placebo|Drug: Buprenorphine,"Proportion of subjects who receive and tolerate a VIVITROL injection on Day 8|Proportion of days with COWS peak score </=12 during the treatment period prior to the VIVITROL injection|Proportion of post-VIVITROL days (Days 9-11) in which subjects in each group demonstrate mild opioid withdrawal|Mean peak COWS scores during the Treatment Period and VIVITROL Induction and Post-VIVITROL Observation Period|Area under the curve (AUC) for COWS scores during the Treatment Period and VIVITROL Induction and Post-VIVITROL Observation Period|Mean score for ""desire for opioids"" Visual Analog Scale (VAS) during the Treatment Period and VIVITROL Induction and Post-VIVITROL Observation Period|Incidence of adverse events","Alkermes, Inc.",All,18 Years to 60 Years   (Adult),Phase 3,101,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ALK6428-A302,2016-04-01,2017-11-01,2017-11-30,2016-03-02,null,2017-12-27,"Segal Institute for Clinical Research, Lauderhill, Florida, United States|Research Centers of America, LLC, Oakland Park, Florida, United States|Neuroscience Research Institute, Inc., Winfield, Illinois, United States|John Hopkins School of Medicine, Baltimore, Maryland, United States|Hassman Research Institute, Berlin, New Jersey, United States|New York State Psychiatric Institute, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Pennsylvania Treatment Research Center, Philadelphia, Pennsylvania, United States|Western Psychiatric Institute and Clinic of University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02696434
757,NCT01181843,Incidence of Respiratory Depression in Cesarean Section,,Terminated,No Results Available,Respiratory Depression|Postoperative Pain,,RESPIRATORY DEPRESSION,Wake Forest University|Forsyth Medical Center|Wake Forest University Health Sciences,Female,18 Years to 55 Years   (Adult),,100,Other,Observational,Observational Model: Other|Time Perspective: Prospective,FMC IRB 2010.200,2010-07-01,2014-06-01,2014-06-01,2010-08-13,null,2017-11-08,"Forsyth Medical Center-Dept of OB Anesthesia, Winston-Salem, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01181843
758,NCT01336205,Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation,,Completed,Has Results,Opioid-Induced Constipation (OIC),Drug: NKTR-118|Drug: Usual care,Incidence of Patients Experiencing at Least One Adverse Event (AE)|Incidence of Patients Experiencing AEs That Resulted in Discontinuation of Investigational Product (IP)|Incidence of Patients Experiencing Severe Adverse Events (SAEs),AstraZeneca,All,"18 Years to 84 Years   (Adult, Older Adult)",Phase 3,844,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D3820C00008,2011-04-01,2012-12-01,2012-12-01,2011-04-15,2014-10-20,2014-10-20,"Research Site, Athens, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Pell City, Alabama, United States|Research Site, Garden Grove, Arizona, United States|Research Site, Goodyear, Arizona, United States|Research Site, Mesa, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Tuscon, Arizona, United States|Research Site, Jonesboro, Arkansas, United States|Research Site, Little Rock, Arkansas, United States|Research Site, North Little Rock, Arkansas, United States|Research Site, Sherwood, Arkansas, United States|Research Site, Arcadia, California, United States|Research Site, Chino, California, United States|Research Site, Encino, California, United States|Research Site, Fremont, California, United States|Research Site, Garden Grove, California, United States|Research Site, Huntington Park, California, United States|Research Site, La Mesa, California, United States|Research Site, Laguna Hills, California, United States|Research Site, Lakewood, California, United States|Research Site, Long Beach, California, United States|Research Site, Oceanside, California, United States|Research Site, Orange, California, United States|Research Site, Pasadena, California, United States|Research Site, Riverside, California, United States|Research Site, San Bernardino, California, United States|Research Site, San Diego, California, United States|Research Site, San Francisco, California, United States|Research Site, Santa Ana, California, United States|Research Site, Walnut Creek, California, United States|Research Site, Whittier, California, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Stamford, Connecticut, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Bradenton, Florida, United States|Research Site, Brooksville, Florida, United States|Research Site, Chiefland, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Crystal River, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Debary, Florida, United States|Research Site, Deerfield Beach, Florida, United States|Research Site, Delray Beach, Florida, United States|Research Site, Edgewater, Florida, United States|Research Site, Eustis, Florida, United States|Research Site, Fort Myers, Florida, United States|Research Site, Inverness, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jackson, Florida, United States|Research Site, Jupiter, Florida, United States|Research Site, Largo, Florida, United States|Research Site, Lauderhill, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Naples, Florida, United States|Research Site, North Miami, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Orange City, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Oviedo, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Pinellas Park, Florida, United States|Research Site, Plantation, Florida, United States|Research Site, Port Orange, Florida, United States|Research Site, Port St. Lucie, Florida, United States|Research Site, South Miami, Florida, United States|Research Site, St. Doral, Florida, United States|Research Site, St. Petersburg, Florida, United States|Research Site, Tamarac, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, West Palm, Florida, United States|Research Site, Winter Park, Florida, United States|Research Site, Alpharetta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Columbus, Georgia, United States|Research Site, Marietta, Georgia, United States|Research Site, Suwanee, Georgia, United States|Research Site, Tucker, Georgia, United States|Research Site, Boise, Idaho, United States|Research Site, Bloomington, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Peoria, Illinois, United States|Research Site, Schaumburg, Illinois, United States|Research Site, Evansville, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Council Bluffs, Iowa, United States|Research Site, Kansas City, Kansas, United States|Research Site, Lansing, Kansas, United States|Research Site, Overland Park, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Louisville, Kentucky, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Columbia, Maryland, United States|Research Site, Hollywood, Maryland, United States|Research Site, Pikesville, Maryland, United States|Research Site, Reisterstown, Maryland, United States|Research Site, Watertown, Massachusetts, United States|Research Site, Calamazoo, Michigan, United States|Research Site, Traverse City, Michigan, United States|Research Site, St Louis, Missouri, United States|Research Site, St. Louis, Missouri, United States|Research Site, Bellevue, Nebraska, United States|Research Site, Fremont, Nebraska, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Henderson, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Clifton, New Jersey, United States|Research Site, Freehold, New Jersey, United States|Research Site, Lumberton, New Jersey, United States|Research Site, Toms River, New Jersey, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Willingboro, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Great Neck, New York, United States|Research Site, Hartsdale, New York, United States|Research Site, New York, New York, United States|Research Site, North Massapequa, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Elkin, North Carolina, United States|Research Site, Flat Rock, North Carolina, United States|Research Site, Harrisburg, North Carolina, United States|Research Site, Mooresville, North Carolina, United States|Research Site, Morganton, North Carolina, United States|Research Site, Morrisville, North Carolina, United States|Research Site, Winston-salem, North Carolina, United States|Research Site, Akron, Ohio, United States|Research Site, Beavercreek, Ohio, United States|Research Site, Centerville, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Downingtown, Pennsylvania, United States|Research Site, Jenkintown, Pennsylvania, United States|Research Site, Norristown, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pottstown, Pennsylvania, United States|Research Site, Anderson, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Greer, South Carolina, United States|Research Site, Myrtle Beach, South Carolina, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Clarksville, Tennessee, United States|Research Site, Jackson, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Milan, Tennessee, United States|Research Site, New Tazewell, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Hurst, Texas, United States|Research Site, Lexington, Texas, United States|Research Site, Marshall, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Sugarland, Texas, United States|Research Site, Victoria, Texas, United States|Research Site, Clinton, Utah, United States|Research Site, Ogden, Utah, United States|Research Site, Saint George, Utah, United States|Research Site, Salt Lake City, Utah, United States|Research Site, West Jordan, Utah, United States|Research Site, Richmond, Virginia, United States|Research Site, Springfield, Virginia, United States|Research Site, Virginia Beach, Virginia, United States|Research Site, Middleton, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT01336205
759,NCT01114308,A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid Addiction,,Completed,No Results Available,Opioid Dependency,Drug: Probuphine (buprenorphine implant)|Drug: placebo implant|Drug: Buprenorphine,CDF of the percent of urine samples negative for opioids in Probuphine and Placebo groups from weeks 1-24|CDF of the percent of urine samples negative for opioids from weeks 1-24 with imputation based on illicit drug use self-report data for Probuphine and placebo groups|CDF of the percent of urine samples negative for opioids from weeks 1-16|CDF of the percent of urine samples negative for opioids from weeks 17-24|Difference of proportion of urine samples negative for illicit opioids over 24 weeks of treatment for Probuphine vs. SL BPN,Braeburn Pharmaceuticals|National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,287,Industry|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PRO-806|1RC2DA028910-01,2010-04-01,2011-05-01,2011-05-01,2010-05-03,null,2017-06-14,"David Geffen School of Medicine at UCLA, Los Angeles, California, United States|Synergy Clinical Research Center, National City, California, United States|North County Clinical Research, Oceanside, California, United States|Friends Research Institute, Torrance, California, United States|Amit Vijapura, MD, Jacksonville, Florida, United States|Operation PAR, Inc. - TC Campus, Largo, Florida, United States|Fidelity Clinical Research, Inc., Lauderhill, Florida, United States|Scientific Clinical Research, Inc., North Miami, Florida, United States|BPRU, Behavioral Biology Research Center, Baltimore, Maryland, United States|SSTAR: Stanley Street Treatment and Resources, Inc., Fall River, Massachusetts, United States|Precise Research Centers, Flowood, Mississippi, United States|PsychCare Consultants Research, Saint Louis, Missouri, United States|New York VA Medical Center, NYU School of Medicine, New York, New York, United States|St. Luke's Roosevelt Hospital Center, New York, New York, United States|Duke University, Duke Addictions Program, Durham, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Carolina Clinical Trials, Inc., Charleston, South Carolina, United States|University of Vermont, Burlington, Vermont, United States|Providence Behavioral Health Services, Everett, Washington, United States",,https://ClinicalTrials.gov/show/NCT01114308
760,NCT01323790,Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation,,Completed,Has Results,Opioid-Induced Constipation (OIC),Drug: NKTR-118|Drug: Placebo,Response (Responder/Non-responder) to Study Drug During Weeks 1 to 12|Response (Responder/Non-responder) to Study Drug in the LIR Subgroup During Weeks 1 to 12|Time (in Hours) to First Post-dose Laxation Without the Use of Rescue Laxatives Within the Previous 24 Hours|Change From Baseline in Mean Number of Days Per Week With at Least 1 SBM During Weeks 1 to 12|Change From Baseline in Degree of Straining|Change From Baseline in Stool Consistency (Bristol Stool Scale)|Change From Baseline in Percent Numbers of Days With a CSBM (Complete Spontaneous Bowel Movement)|Change From Baseline in Mean Spontaneous Bowel Movements/Week|Time (in Hours) to First Post-dose Laxation Without the Use of Rescue Laxatives Within the Previous 24 Hours in the Laxative Inadequate Response (LIR) Subgroup|Change From Baseline in Patient Assessment of Constipation Symptoms Questionnaire (PAC-SYM)|Change From Baseline in Patient Assessment of Constipation Quality of Life (PAC-QOL) Satisfaction Domain,AstraZeneca,All,"18 Years to 84 Years   (Adult, Older Adult)",Phase 3,700,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D3820C00005|2011-001986-41,2011-03-01,2012-09-01,2012-09-01,2011-03-28,2015-06-02,2015-06-02,"Research Site, Mobile, Alabama, United States|Research Site, Pell City, Alabama, United States|Research Site, Mesa, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Sun Lakes, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Jonesboro, Arkansas, United States|Research Site, Little Rock, Arkansas, United States|Research Site, North Little Rock, Arkansas, United States|Research Site, Sherwood, Arkansas, United States|Research Site, Chino, California, United States|Research Site, La Jolla, California, United States|Research Site, Lincoln, California, United States|Research Site, Modesto, California, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Stamford, Connecticut, United States|Research Site, Bradenton, Florida, United States|Research Site, Delray Beach, Florida, United States|Research Site, Gainesville, Florida, United States|Research Site, Miami Springs, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Sanford, Florida, United States|Research Site, St. Petersburg, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Conyers, Georgia, United States|Research Site, John's Creek, Georgia, United States|Research Site, Peoria, Illinois, United States|Research Site, Council Bluffs, Iowa, United States|Research Site, Wichita, Kansas, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Chestnut Hill, Massachusetts, United States|Research Site, Watertown, Massachusetts, United States|Research Site, Livonia, Michigan, United States|Research Site, St. Clair Shores, Michigan, United States|Research Site, Florissant, Missouri, United States|Research Site, Henderson, Nevada, United States|Research Site, Freehold, New Jersey, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Willingboro, New Jersey, United States|Research Site, Great Neck, New York, United States|Research Site, Hartsdale, New York, United States|Research Site, North Massapequa, New York, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Morrisville, North Carolina, United States|Research Site, Winston-salem, North Carolina, United States|Research Site, Bellevue, Ohio, United States|Research Site, Downingtown, Pennsylvania, United States|Research Site, Jenkintown, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pottstown, Pennsylvania, United States|Research Site, Anderson, South Carolina, United States|Research Site, Myrtle Beach, South Carolina, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Jackson, Tennessee, United States|Research Site, Milan, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Hurst, Texas, United States|Research Site, Marshall, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Sugarland, Texas, United States|Research Site, Clinton, Utah, United States|Research Site, Saint George, Utah, United States|Research Site, West Jordan, Utah, United States|Research Site, Antwerpen, Belgium|Research Site, Edegem, Belgium|Research Site, Leuven, Belgium|Research Site, Moerkerke, Belgium|Research Site, Mouscron, Belgium|Research Site, Roeselare, Belgium|Research Site, Bjelovar, Croatia|Research Site, Osijek, Croatia|Research Site, Susak, Croatia|Research Site, Zagreb, Croatia|Research Site, Chocen, Czech Republic|Research Site, Pardubice, Czech Republic|Research Site, Prague, Czech Republic|Research Site, Praha, Czech Republic|Research Site, Zlin, Czech Republic|Research Site, Baja, Hungary|Research Site, Budapest, Hungary|Research Site, Kecskemet, Hungary|Research Site, Miskolc, Hungary|Research Site, Pusztaszer, Hungary|Research Site, Satoraljaujhely, Hungary|Research Site, Szeged, Hungary|Research Site, Szikszo, Hungary|Research Site, Urhida, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Malaga, Andalucia, Spain|Research Site, L' Hospitalet de Llobregat, Catalu?a, Spain|Research Site, VIC, Catalu?a, Spain|Research Site, Barcelona, Cataluna, Spain|Research Site, Centelles (barcelona), Cataluna, Spain|Research Site, Fuenlabrada, Comunidad de Madrid, Spain|Research Site, Almeria, Spain|Research Site, Lleida, Spain|Research Site, Madrid, Spain|Research Site, Santiago de Compostela, Spain|Research Site, Valencia, Spain|Research Site, Valladolid, Spain|Research Site, Goteborg, Sweden|Research Site, Lund, Sweden|Research Site, Stockholm, Sweden|Research Site, Vallingby, Sweden|Research Site, Ayrshire, AYR, United Kingdom|Research Site, Chesterfield, Derby, United Kingdom|Research Site, Plymouth, Devon, United Kingdom|Research Site, London, Gt Lon, United Kingdom|Research Site, Royton, Lancashire, United Kingdom|Research Site, Thornton-cleveleys, Lancashire, United Kingdom|Research Site, Norwich, Norflk, United Kingdom|Research Site, Barry, S Glam, United Kingdom|Research Site, Bath, Somer, United Kingdom|Research Site, Glasgow, Strath, United Kingdom|Research Site, Coventry, Warwks, United Kingdom|Research Site, Derby, United Kingdom",,https://ClinicalTrials.gov/show/NCT01323790
761,NCT03060512,To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation,,Completed,Has Results,Opioid Induced Constipation,Drug: Polyethylene Glycol 3350|Drug: Movantik,Patient Reported Preference for Movantik or PEG 3350 for Opioid-induced Constipation (OIC) Treatment|Patient Reported Preference for Movantik or PEG 3350 for OIC Treatment by Treatment Sequence|Patient Reported Influence of Each Medication Characteristic Median Scores That Contributed to Their Overall Preference for Movantik or PEG 3350|Patient Reported Influence of Each Medication Characteristic Individual Category Results That Contributed to Their Overall Preference for Movantik or PEG 3350|Patient Global Impression of Change (PGIC) Questionnaire to Compare the Impact of Movantik and PEG 3350 on OIC Symptoms|PGIC Questionnaire Individual Item Results to Compare the Impact of Movantik and PEG 3350 on OIC Symptoms|Mean Change From Baseline at Visit 3/5 in Bowel Function Index (BFI) Questionnaire Scores to Compare the Impact of Movantik and PEG 3350 on OIC Symptoms,"AstraZeneca|QuintilesIMS, Inc.",All,"18 Years to 84 Years   (Adult, Older Adult)",Phase 4,276,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D3820L00017,2017-03-02,2017-08-23,2017-08-23,2017-02-23,2018-07-13,2018-07-13,"Research Site, Huntsville, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Anaheim, California, United States|Research Site, Anaheim, California, United States|Research Site, Lincoln, California, United States|Research Site, Los Gatos, California, United States|Research Site, North Hollywood, California, United States|Research Site, Orange, California, United States|Research Site, San Diego, California, United States|Research Site, Westminster, California, United States|Research Site, DeLand, Florida, United States|Research Site, Fort Myers, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jupiter, Florida, United States|Research Site, Lake City, Florida, United States|Research Site, Miami Springs, Florida, United States|Research Site, Miami, Florida, United States|Research Site, North Miami Beach, Florida, United States|Research Site, Ormond Beach, Florida, United States|Research Site, Plantation, Florida, United States|Research Site, Port Orange, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Decatur, Georgia, United States|Research Site, Marietta, Georgia, United States|Research Site, Bloomington, Illinois, United States|Research Site, Brownsburg, Indiana, United States|Research Site, Pikesville, Maryland, United States|Research Site, Waltham, Massachusetts, United States|Research Site, Troy, Michigan, United States|Research Site, Wyoming, Michigan, United States|Research Site, Biloxi, Mississippi, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Omaha, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Trenton, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Endwell, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, High Point, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Beavercreek, Ohio, United States|Research Site, Edmond, Oklahoma, United States|Research Site, Collegeville, Pennsylvania, United States|Research Site, Levittown, Pennsylvania, United States|Research Site, Greer, South Carolina, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Kingsport, Tennessee, United States|Research Site, West Jordan, Utah, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT03060512/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT03060512/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03060512
762,NCT01395524,A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation,,Completed,Has Results,Opioid-Induced Constipation (OIC),Drug: NKTR-118|Drug: Placebo,Incidence of Patients Experiencing at Least One Adverse Event (AE)|Incidence of Patients Experiencing AEs That Resulted in Discontinuation of Investigational Product (IP)|Incidence of Patients Experiencing Severe Adverse Events (SAEs)|Change From Baseline in Patient Assessment of Constipation Symptoms Questionnaire (PAC-SYM)|Change From Baseline in Patient Assessment of Constipation Quality of Life (PAC-QOL),AstraZeneca,All,"18 Years to 84 Years   (Adult, Older Adult)",Phase 3,302,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D3820C00007,2011-07-01,2012-09-01,2012-09-01,2011-07-15,2015-06-17,2017-02-23,"Research Site, Birmingham, Alabama, United States|Research Site, Calera, Alabama, United States|Research Site, Glendale, Arizona, United States|Research Site, Mesa, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Hot Springs, Arkansas, United States|Research Site, Malvern, Arkansas, United States|Research Site, Anaheim, California, United States|Research Site, Beverly Hills, California, United States|Research Site, Burbank, California, United States|Research Site, Garden Grove, California, United States|Research Site, Laguana Hills, California, United States|Research Site, Laguna Hills, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Gatos, California, United States|Research Site, Montebello, California, United States|Research Site, National City, California, United States|Research Site, Norwalk, California, United States|Research Site, Paramount, California, United States|Research Site, Sacramento, California, United States|Research Site, San Diego, California, United States|Research Site, Santa Ana, California, United States|Research Site, Denver, Colorado, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Brooksville, Florida, United States|Research Site, Crystal River, Florida, United States|Research Site, Deland, Florida, United States|Research Site, Fort Myers, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jupiter, Florida, United States|Research Site, Maitland, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Naples, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Ormond Beach, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Plantation, Florida, United States|Research Site, Tamarac, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Venice, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Winter Park, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Decatur, Georgia, United States|Research Site, Boise, Idaho, United States|Research Site, Bloomington, Illinois, United States|Research Site, Rockford, Illinois, United States|Research Site, Avon, Indiana, United States|Research Site, Evansville, Indiana, United States|Reserach Site, Indianapolis, Indiana, United States|Research Site, West Des Moines, Iowa, United States|Research Site, Pikesville, Maryland, United States|Research Site, Brockton, Massachusetts, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Biloxi, Mississippi, United States|Research Site, St Joseph, Missouri, United States|Research Site, St Louis, Missouri, United States|Research Site, Missoula, Montana, United States|Research Site, Omaha, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Trenton, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, New York, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Hickory, North Carolina, United States|Research Site, High Point, North Carolina, United States|Research Site, Morrisville, North Carolina, United States|Research Site, Beavercreek, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Medord, Oregon, United States|Research Site, Feasterville, Pennsylvania, United States|Research Site, Huntingdon Valley, Pennsylvania, United States|Research Site, Levittown, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Yardley, Pennsylvania, United States|Research Site, Cumberland, Rhode Island, United States|Research Site, Charleston, South Carolina, United States|Research Site, Greer, South Carolina, United States|Research Site, Orangeburg, South Carolina, United States|Research Site, Clarksville, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Doral, Texas, United States|Research Site, Houston, Texas, United States|Research Site, North Richland Hills, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Spokane, Washington, United States|Research Site, Broadmeadow, New South Wales, Australia|Research Site, Darlinghurst, New South Wales, Australia|Research Site, Port Kembla, New South Wales, Australia|Research Site, Westmead, New South Wales, Australia|Research Site, Greenslopes, Queensland, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, Fremantle, Western Australia, Australia|Research Site, Nedlands, Western Australia, Australia|Research Site, Potsdam, BR, Germany|Research Site, Dietzenbach, HE, Germany|Research Site, Huttenberg, HE, Germany|Research Site, Wetzlar, HE, Germany|Research Site, Hamburg, HH, Germany|Research Site, Schwerin, MV, Germany|Research Site, Celle, NI, Germany|Research Site, Hannover, NI, Germany|Research Site, Essen, NW, Germany|Research Site, Mainz, RP, Germany|Research Site, Kiel, SH, Germany|Research Site, Leipzig, SN, Germany|Research Site, Berlin, Germany|Research Site, Dresden, Germany|Research Site, Banska Bystrica, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Kosice, Slovakia|Research Site, Presov, Slovakia",,https://ClinicalTrials.gov/show/NCT01395524
763,NCT01100151,ALK37-003: A Study of RDC-1036 (ALKS 37) in Adults With Opioid-induced Constipation (OIC),,Completed,No Results Available,Opioid-induced Constipation,Drug: RDC-1036 (ALKS 37)|Drug: Placebo,Change in frequency of spontaneous bowel movement (SBM) from pre-treatment period to treatment period|Number of subjects reporting treatment-emergent adverse events (TEAEs)|Change in rescue laxative use from pre-treatment to treatment period|Study drug dose prior to first SBM after randomization|Scores to study-related questionnaires,"Alkermes, Inc.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,60,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ALK37-003,2010-04-01,2010-12-01,2010-12-01,2010-04-08,null,2011-08-23,"Alkermes Investigational Site, Sheffield, Alabama, United States|Alkermes Investigational Site, Anaheim, California, United States|Alkermes Investigational Site, Pasadena, California, United States|Alkermes Investigational Site, Walnut Creek, California, United States|Alkermes Investigational Site, DeLand, Florida, United States|Alkermes Investigative Site, New Smyrna Beach, Florida, United States|Alkermes Investigational Site, Boise, Idaho, United States|Alkermes Investigational Site, New Orleans, Louisiana, United States|Alkermes Investigational Site, Winston-Salem, North Carolina, United States|Alkermes Investigational Site, Dayton, Ohio, United States|Alkermes Investigational Site, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT01100151
764,NCT02537574,Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension),,Completed,No Results Available,Opioid Use Disorder,Drug: NTX/BUP|Drug: NTX/PBO-B|Drug: PBO-N/PBO-B,Proportion of subjects who receive and tolerate a VIVITROL injection|Proportion of days with COWS peak score of less than or equal to 12 during the treatment period prior to the VIVITROL injection|Mean peak COWS score during treatment period prior to VIVITROL injection|Area under the curve (AUC) COWS score during the treatment period prior to VIVITROL injection|Mean score for desire of opioids during treatment period prior to VIVITROL injection|Incidence of Adverse Effects|Area under the curve SOWS score during the treatment period prior to the VIVITROL injection,"Alkermes, Inc.",All,18 Years to 60 Years   (Adult),Phase 3,380,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ALK6428-A301,2015-08-01,2016-10-27,2017-01-09,2015-09-01,null,2018-02-02,"North Country Clinical Research, Oceanside, California, United States|NRC Research Institute, Orange, California, United States|Atlantic Shores Hospital, Lauderhill, Florida, United States|TRY Research, Maitland, Florida, United States|Research Centers of America, Oakland Park, Florida, United States|CNS Healthcare, Orlando, Florida, United States|Neuroscience Research Institute, Winfield, Illinois, United States|John Hopkins University School of Medicine, Baltimore, Maryland, United States|Comprehensive Clinical Research, Berlin, New Jersey, United States|PRA Health Sciences, Marlton, New Jersey, United States|New York State Psychiatric Institute/ Columbia University, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Neuro-Behavioral Clinical Research, Inc., Canton, Ohio, United States|Midwest Clinical Research Center, LLC, Dayton, Ohio, United States|University Of Pennsylvania - Treatment Research Center, Philadelphia, Pennsylvania, United States|Western Psychiatric Institute and Clinic of UPMC, Pittsburgh, Pennsylvania, United States|Community Clinical Research, Inc., Austin, Texas, United States|Insite Clinical Research, DeSoto, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Pharmaceutical Research Associates Inc., Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT02537574
765,NCT00600119,"A Phase 2, Double-Blind, Multiple-Dose Escalation Study to Evaluate NKTR-118 (Oral PEG-Naloxol) in Patients With Opioid-Induced Constipation (OIC)",,Completed,Has Results,Opioid Induced Constipation (OIC),Drug: placebo|Drug: NKTR-118,Change From Baseline in Spontaneous Bowel Movements (SBMs) Per Week During Week 1|Change From Baseline in SBMs/Week Across the 28-day Double-blind Period|Change From Baseline in Patient Assessment of Constipation-Quality of Life (PAC-QOL) Questionnaire|Change From Baseline in Patient Assessment of Constipation-Symptoms (PAC-SYM) Questionnaire,AstraZeneca|Nektar Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 2,207,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",07-IN-NX003,2007-12-01,2009-03-01,2009-04-01,2008-01-24,2015-06-12,2015-06-12,"Tennessee Valley Pain Consultants / Center for Pain Management, Huntsville, Alabama, United States|Deerfoot Internal Medicine, Pinson, Alabama, United States|Genova Clinical Research, Inc., Tucson, Arizona, United States|Therapeutic Research Institute of Orange County, Laguna Hills, California, United States|San Diego Managed Care Group, San Diego, California, United States|Arapahoe Gastroenterology, PC, Littleton, Colorado, United States|Southeast Clinical Research, Chiefland, Florida, United States|Osler Medical, Inc. / Osler Clinical Research, Melbourne, Florida, United States|Palm Beach Research Center, West Palm Beach, Florida, United States|Gold Coast Research LLC, Weston, Florida, United States|PMI Health Research Group, Atlanta, Georgia, United States|Northwest Clinical Trials, Boise, Idaho, United States|Millennium Pain Center, Bloomington, Illinois, United States|Pain & Rehabilitation Clinic of Chicago, Chicago, Illinois, United States|Investigative Clinical Research of Indiana, LLC, Indianapolis, Indiana, United States|Pain Treatment Center of the Bluegrass, Lexington, Kentucky, United States|Gulf Coast Reserach, Baton Rouge, Louisiana, United States|Centennial Medical Group, Elkridge, Maryland, United States|MAPS Applied Research Center, Edina, Minnesota, United States|Midwest Pharmaceutical Research, Inc., St. Peters, Missouri, United States|Lovelace Scientific Resources, Inc., Albuquerque, New Mexico, United States|Long Island Gastrointestinal Research Group, Great Neck, New York, United States|Four Seasons Hospice and Palliative Care, Flat Rock, North Carolina, United States|The Center for Clinical Research, LLC, Winston Salem, North Carolina, United States|Gabrail Cancer Center, Canton, Ohio, United States|Riverhills Healthcare Research Division, Cincinnati, Ohio, United States|Options Health Research, Tulsa, Oklahoma, United States|Medford Medical Clinic, Medford, Oregon, United States|Anderson Gastroenterology Associates, LLC, Anderson, South Carolina, United States|Singleton Health Center, Orangeburg, South Carolina, United States|ClinSearch, LLC, Chattanooga, Tennessee, United States|Lifetree Clinical Research, Salt Lake City, Utah, United States|Spokane Internal Medicine, Spokane, Washington, United States",,https://ClinicalTrials.gov/show/NCT00600119
766,NCT00249457,Employment-based Reinforcement to Motivate Drug Abstinence in the Treatment of Drug Addiction. - 2,,Completed,No Results Available,"Behavior, Addictive|Cocaine Abuse|Cocaine Dependence|Heroin Dependence|Opioid Dependence",Behavioral: Contingency management,Percentage of urine samples at the assessments that were negative for cocaine|Percentage of urine samples at the assessments that were negative for opiates|Percentage of urine samples at the assessments that were negative for cocaine and opiates|HIV risk behaviors|Percentage of participants employed each month|Number of days employed each month|Percentage of participants to self-report abstinence at all time points,Johns Hopkins University,Female,18 Years to 50 Years   (Adult),Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NIDA-13107-2,1996-10-01,2006-01-01,2006-01-01,2005-11-07,null,2017-10-30,"The Center for Learning and Health, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00249457
767,NCT02672111,Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder,,Completed,No Results Available,Opioid Use Disorder,Drug: CAM2038 (buprenorphine FluidCrystal® once-weekly injection depot)|Drug: CAM2038 (buprenorphine FluidCrystal® once-monthly injection depot),"Safety and tolerability of CAM2038 products in 100 adult outpatients with opioid use disorder via safety assessments.|Evaluate efficacy of CAM2038 through several efficacy parameters, including urine toxicology, signs and symptoms of withdrawal and cravings in 100 adult outpatients with opioid use disorder.",Braeburn Pharmaceuticals,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,228,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HS-14-499,2015-11-01,2017-05-01,2017-05-01,2016-02-03,null,2017-06-14,"Parkway Medical Center, Birmingham, Alabama, United States|Haleyville Clinical Research LLC, Haleyville, Alabama, United States|Boyett Health Services Inc, Hamilton, Alabama, United States|Dr Vijapura and Associates, Jacksonville, Florida, United States|TRY Research, Maitland, Florida, United States|Stanley Street Treatment and Resources Inc, Fall River, Massachusetts, United States|Wellness and Research Center, Belvidere, New Jersey, United States|Comprehensive Clinical Research, Berlin, New Jersey, United States|STARS/Columbia University, New York, New York, United States|Frost Medical Group, LLC, Conshohocken, Pennsylvania, United States|Royal Prince Alfred Hospital, Camperdown Nsw, Australia|South Eastern Sydney Local Health District (SESLHD), New Surrey Hills Surry Hills, Australia|Newcastle Community Health Services, Newcastle, Australia|Drug & Alcohol Services SA Drug and Alcohol Services, Norwood, Australia|Center for Misbrugsbehandling, Sumatravej 3, Aarhus, Denmark|Behandlingscenter Odense, Grønlandsgade 13 A, Odense, Denmark|Gemeinschaftspraxis Schnaitmann/Schaffert Salzstrasse, Baden-Wurttemberg, Heilbronn, Germany|Studikum - Zentrum fur Klinische Studien im Praxiszentrum Friedrichsplatz, Friedrichsplatz 2-3, Kassel, Germany|Klinik fur Abhangiges Verhalten und Suchtmedizin Zentralinstitut, Baden-Wurttemberg Mannheim, Mannheim, Germany|Psychosoziale Begleitung - Praxis Boniakowski, Koenigswiesenweg 21, Regensburg, Germany|Praxisgemeinschaft, Schwabstrasse 59, Stuttgart, Germany|XVI. Kerület Kertvárosi Egészségügyi Szolgálata, Addiktológia, Gábor, Budapest, Hungary|Clinexpert Kft, Kaszasdulo u. 5., Budapest, Hungary|Metadonsektionen, Beroendecentrum Tantogatan 8, Stockholm, Sweden|Centrallasarettet Vasteras, Stockholmsvägen, Västerås, Sweden|China Medical University Hospita, North District, Taichung, Taiwan|Jinan Psychiatric Center, Ministry of Health and Welfa, Jen-Te Hsien, Tainan County, Taiwan|Taipei City Hospital, Datong District, Taipei, Taiwan|Blackberry Centre Blackberry Hill Hospital, Fishponds, Bristol, United Kingdom|NHS Tayside, DD at Ninewells Hospital and Medical School, Dundee, United Kingdom|Lambeth Drug and Alcohol Service Lorraine Hewitt House, Brighton Terrace, London, United Kingdom|Hellesdon Hospital The Weavers Centre, Hellesdon, Norwich, United Kingdom",,https://ClinicalTrials.gov/show/NCT02672111
768,NCT02651584,"Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence",,Completed,No Results Available,Opioid Use Disorders,Drug: CAM2038 subcutaneous injection|Drug: SL BPN tablets|Drug: placebo subcutaneous (SC) injections|Drug: SL placebo tablets,"The primary outcome measure will be the response rate, denoted by response rate (Weeks 1-24).|Secondary efficacy endpoints will include response rate over 24 weeks of treatment for the following outcome measures:|Secondary efficacy endpoints will include response rate over 24 weeks of treatment for the following outcome measures|Secondary safety endpoints will be measured by clinical laboratory parameters, electrocardiogram, physical, and injection site examinations, concomitant medications, vital signs and C-SSRS.",Braeburn Pharmaceuticals,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,429,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",HS-11-421,2015-12-01,2016-10-01,2016-11-01,2016-01-11,null,2016-11-21,"Parkway Medical Center, Birmingham, Alabama, United States|Haleyville Clinical Research LLC, Haleyville, Alabama, United States|Boyett Health Services Inc, Hamilton, Alabama, United States|Synergy East, Lemon Grove, California, United States|North County Clinical Research, Oceanside, California, United States|Asclepes Research, Panorama City, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Care Practice, San Francisco, California, United States|Synergist Research, West Hollywood, California, United States|Dr Vijapura and Associates, Jacksonville, Florida, United States|Innovative Clinical Research Inc, Lauderhill, Florida, United States|TRY Research, Maitland, Florida, United States|Tellus Clinical Research, Inc., Miami, Florida, United States|Scientific Clinical Research, Inc., North Miami, Florida, United States|Professional Research Network of Kansas, LLC, Wichita, Kansas, United States|University of Kentucky Medical Center, Lexington, Kentucky, United States|Stanley Street Treatment and Resources Inc, Fall River, Massachusetts, United States|Novex Clinical Research, New Bedford, Massachusetts, United States|Precise Research Centers, Flowood, Mississippi, United States|PsychCare Consultants Research, St. Louis, Missouri, United States|St. Louis Clinical Trials, St. Louis, Missouri, United States|Wellness and Research Center, Belvidere, New Jersey, United States|Comprehensive Clinical Research, Berlin, New Jersey, United States|STARS/Columbia University, New York, New York, United States|Neuro-Behavioral Clinical Research Center, Canton, Ohio, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|North Star Medical Research, Middleburg Heights, Ohio, United States|Rivus Wellness & Research Institute, Oklahoma City, Oklahoma, United States|Frost Medical Group, Conshohocken, Pennsylvania, United States|The University of Pennsylvania Health System Treatment Research Center, Philadelphia, Pennsylvania, United States|Lincoln Research, Lincoln, Rhode Island, United States|Carolina Clinical Trials, Inc, Charleston, South Carolina, United States|InSite Clinical Research, Dallas, Texas, United States|Aspen Clinical Research, Orem, Utah, United States|University of Vermont, Burlington, Vermont, United States|Swedish Health Services, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT02651584
769,NCT02032433,Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment,,Completed,Has Results,Opioid Use Disorder,Drug: Extended-Release Naltrexone|Drug: Buprenorphine-Naloxone,"Time to Relapse (Intent to Treat Population)|Time to Relapse (Per Protocol Population)|Number Successfully Inducted Onto Assigned Study Medication|Adverse Events Related to Study Medications|Opioid Abstinence Over Time While on Study Medication (Subjective)|Alcohol and Other Drug Use, Over Time|Cigarette Smoking|Opioid Craving Over Time|Subacute Withdrawal Symptoms Over Time|Problems Related to Drug Abuse|HIV Risk Behavior Over Time|Cognitive Function|Opioid Abstinence Over Time While on Study Medication (Objective)",New York University School of Medicine|National Institute on Drug Abuse (NIDA)|The EMMES Corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 4,570,Other|NIH|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12-03133|UG1DA013035,2014-01-29,2017-01-25,2017-01-31,2014-01-10,2018-01-19,2018-07-06,"Tarzana Treatment Centers, Tarzana, California, United States|Gateway Community Services, Inc., Jacksonville, Florida, United States|Avery Road Treatment Center, Rockville, Maryland, United States|Stanley Street Treatment and Resources, Fall River, Massachusetts, United States|Turquoise Lodge Hospital, Albuquerque, New Mexico, United States|Bellevue Hospital Center, New York, New York, United States|Maryhaven, Columbus, Ohio, United States|Evergreen Treatment Services, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT02032433/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT02032433/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02032433
770,NCT00858754,Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects,,Withdrawn,No Results Available,Opioid-Induced Constipation,Drug: methylnaltrexone|Drug: placebo,"Bowel movement within 4 hours after the first dose. Collection of adverse events, vital signs measurements, and laboratory assessments.|1. Bowel movements within 4 hours after at least 2 of the first 4 doses. 2. Bowel movements within 4 hours after all doses. 3. The time to bowel movement after the first dose.","Valeant Pharmaceuticals International, Inc.|Progenics Pharmaceuticals, Inc.",All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 4,340,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3200K1-4006,2009-03-01,2009-08-01,2009-08-01,2009-03-10,null,2011-07-25,"Pfizer Investigational Site, Laguna Hills, California, United States|Pfizer Investigational Site, Lancaster, California, United States|Pfizer Investigational Site, Flat Rock, North Carolina, United States|Pfizer Investigational Site, Madison, Wisconsin, United States|Pfizer Investigational Site, Edmonton, Alberta, Canada|Pfizer Investigational Site, Villejuif Cedex, France|Pfizer Investigational Site, El Palmar, Murcia/Spain, Spain|Pfizer Investigational Site",,https://ClinicalTrials.gov/show/NCT00858754
771,NCT01298219,Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL),,Completed,No Results Available,Opioid-induced Bowel Dysfunction,Drug: Lubiprostone|Drug: Placebo,"Overall SBM response rate|Change from baseline in SBM frequency|First post-dose SBM (percentage of patients)|Responder rates|Mean changes from baseline in straining, stool consistency, constipation severity, abdominal bloating, abdominal discomfort, bowel habit regularity|Treatment effectiveness|Health related quality of life","Sucampo Pharmaceuticals, Inc.|Takeda|Sucampo Pharma Americas, LLC",All,"18 Years and older   (Adult, Older Adult)",Phase 3,447,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",OBD1033,2010-12-01,2011-11-01,2011-11-01,2011-02-17,null,2013-02-05,"North Alabama Research Center, Athens, Alabama, United States|Innovative Clinical Trials, Inc., Birmingham, Alabama, United States|Achieve Clinical Research, Birmingham, Alabama, United States|Alabama Clinical Therapeutics, Birmingham, Alabama, United States|G&L Research, LLC, Foley, Alabama, United States|Healthscan Research, Montgomery, Alabama, United States|River Region Research, Tallassee, Alabama, United States|Anasazi Internal Medicine PC, Phoenix, Arizona, United States|Aureas Research, Inc, Little Rock, Arkansas, United States|Certified Clinical Research, Carmichael, California, United States|California Clinical Research, Inc., Davis, California, United States|Family Medical Center, Foothill Ranch, California, United States|South Orange County Surgical Medical Group, Laguna Hills, California, United States|Clinical Trials Research, Lincoln, California, United States|Clear Vision Research, Long Beach, California, United States|Long Beach VA Medical Center, Long Beach, California, United States|Clear Vision Research, Los Angelos, California, United States|Facey Medical Foundation, Mission Hills, California, United States|North County Clinical Research, Oceanside, California, United States|SDS Clinical Trials, Inc., Orange, California, United States|Probe Clinical Research Corporation, Riverside, California, United States|Probe Clinical Research Corporation - Santa Ana, Santa Ana, California, United States|Westlake Medical Research, Westlake Village, California, United States|Mountain View Clinical Research, Denver, Colorado, United States|Meridien Research, Bradenton, Florida, United States|Coastal Orthopedics & Pain Management, Bradenton, Florida, United States|Florida Research & Testing, LLC, Clearwater, Florida, United States|Avail Clinical Research, DeLand, Florida, United States|S&W Clinical Research, Fort Lauderdale, Florida, United States|Palm Springs Research Institute, Hialeah, Florida, United States|Kendall South Medical Center, Inc., Miami, Florida, United States|Gastroenterology Group of Naples, Naples, Florida, United States|Physicians Regional Medical Group, Naples, Florida, United States|Ocala Rheumatology Research Center, Ocala, Florida, United States|Paddock Park Clinical Research, Ocala, Florida, United States|Journey Research, Inc., Oldsmar, Florida, United States|Compass Research, Orlando, Florida, United States|Andres Patron, DO, PA, Pembroke Pines, Florida, United States|Advent Clinical Research Centers, Pinellas Park, Florida, United States|Gold Coast Research, LLC, Plantation, Florida, United States|Orthopedic Research Institite, Royal Palm Beach, Florida, United States|IC Research, Sanford, Florida, United States|Sarasota Memorial Pain Care Center, Sarasota, Florida, United States|Tampa Clinical Research, Tampa, Florida, United States|Southeastern Regional Research Group, Columbus, Georgia, United States|Better Health Clinical Research, Newnan, Georgia, United States|Clinical Research Atlanta, Stockbridge, Georgia, United States|Advanced Clinical Research, Boise, Idaho, United States|Sonora Clinical Research, Boise, Idaho, United States|Nautical Clinical Research, Meridian, Idaho, United States|Anesthesia/Pain Control Indiana University School of Medicine, Chicago, Illinois, United States|Knight Center for Integrated Health, Peoria, Illinois, United States|Ridge Family Practice, Council Bluffs, Iowa, United States|Lee Research Institute, Lenexa, Kansas, United States|Kentucky Medical Research Center, Lexington, Kentucky, United States|Bluegrass Internal Medicine, Owensboro, Kentucky, United States|Horizon Research Group, Baton Rouge, Louisiana, United States|Miray Medical Center, Brockton, Massachusetts, United States|The Research Institute, Springfield, Massachusetts, United States|Coastal Research, Weymouth, Massachusetts, United States|Ashok Jain, MD, Dearborn, Michigan, United States|Shores Medical Associates, St. Clair Shores, Michigan, United States|Mid-America Clinical Research LLC, St. Louis, Missouri, United States|Montana Medical Research, Inc., Missoula, Montana, United States|Independent Clinical Researchers, Las Vegas, Nevada, United States|AB Clinical Trials, Las Vegas, Nevada, United States|Clinical Research of South Nevada, Las Vegas, Nevada, United States|Clinical Research Advantage, Inc., Las Vegas, Nevada, United States|Lab2Marche, Las Vegas, Nevada, United States|Aloha Medical Center, Las Vegas, Nevada, United States|Edison Medical Group, Edison, New Jersey, United States|Clinical Research Program, Marlton, New Jersey, United States|Albuquerque Clinical Trials, Albuquerque, New Mexico, United States|Drug Trials America, Hartsdale, New York, United States|Family Health Medical Services PLLC, Jamestown, New York, United States|U of Rochester, Rochester, New York, United States|Medical Frontiers, Carlisle, Ohio, United States|Hightop Medical Research Center, Cincinnati, Ohio, United States|Community Research, Cincinnati, Ohio, United States|Community Research, Cincinnati, Ohio, United States|Rapid Medical Research, Inc., Cleveland, Ohio, United States|Parsons Avenue Medical Center, Columbus, Ohio, United States|Hometown Urgent Care, Groveport, Ohio, United States|Northstar Medical Research, LLC, Middleburg Heights, Ohio, United States|Pharmacotherpy Research Associates Inc, Zanesville, Ohio, United States|COR Clinical Research, LLC, Oklahoma City, Oklahoma, United States|Sooner Clinical Research, Oklahoma City, Oklahoma, United States|Sunstone Medical Research, Medford, Oregon, United States|Fanno Creek Clinic, Portland, Oregon, United States|McMillen & Magargle, Mechanicsburg, Pennsylvania, United States|Omega Medical Research, Warwick, Rhode Island, United States|Hartwell Research Group, Anderson, South Carolina, United States|Degarmo Institute of Medical Research, Greer, South Carolina, United States|Pain Specialists of Charleston, North Charleston, South Carolina, United States|Health Concepts, Rapid City, South Dakota, United States|InvestiClin Research, Brentwood, Tennessee, United States|SCRI Research Center, Germantown, Tennessee, United States|Prevention & Strengthening Solutions, Inc., Humboldt, Tennessee, United States|FutureSearch Trials of Neurology & Sleep Lab, Austin, Texas, United States|Jaron Winston, MD, Austin, Texas, United States|KRK Medical Research, Dallas, Texas, United States|FutureSearch Trials of Dallas, LP, Dallas, Texas, United States|Pillar Clinical Research, LLC, Dallas, Texas, United States|Galenos Research, Dallas, Texas, United States|Diversified Medical Practice, P.A., Houston, Texas, United States|Clinical Trial Network, Houston, Texas, United States|Dependable Clinical Research, Houston, Texas, United States|Pioneer Research Solutions, Inc., Houston, Texas, United States|Bobby Huynh, Richardson, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|Pioneer Research Solutions, Sugar Land, Texas, United States|Spring Clinical Research, Sugarland, Texas, United States|Lifetree Clinical Research, Salt Lake City, Utah, United States|ACR Research Salt Lake City, West Jordan, Utah, United States|Virginia Research Center, LLC, Midlothian, Virginia, United States|Pain Clinic-Heilig Hart Ziekenhuis Roeselare, Roeselare, Westlaan 123, Belgium|Huisartsenpraktijk De Regenboog, Deurne (Antwerpen), Belgium|Dr Capiau - GP Practice, Wetteren, Belgium|St. Anne's University Hospital - centrum pro, Brno, Czech Republic|Nemocnice Jablonec nad Nisou, p.o., Jablonec nad Nisou, Czech Republic|Ambulance bolesti, Krajska nemocnice Liberec, Liberec, Czech Republic|Klaudianova nemocnice Mlada Boleslav, Mlada Boleslav, Czech Republic|Clintrial s.r.o., Praha 10, Czech Republic|Neurologicka ambulance, Praha 6, Czech Republic|Regional Hospital T. B., a.s., Zlin, Czech Republic|Schmerzzentrum Berlin, Berlin, Germany|Schmerztherapeutische- Ärztezentrum Nordstadt, Hannover, Germany|Schmerz und Palliativzentrum, Wiesbaden, Germany|NZOZ Dom Sue Ryder prowadzony przez Pallmed Sp. z o.o., Bydgoszcz, Poland|Hagakliniken, Gothenburg, Sweden|Karolinska University Hospita- Dept of Anaesthesia, Pain Div., Stockholm, Sweden|S3 Clinical Research Centers, Vällingby, Sweden|ElyBridge Surgery, ELY, Cardiff, United Kingdom|Randalstown Medical Practice, Randalstown, Co Antrim, United Kingdom|Sea Road Surgery, Bexhill on Sea, E.Sussex, United Kingdom|Sheepcot Medical Centre,, Watford, Herts, United Kingdom|Fylde Coast Clinical Research Ltd, Blackpool, Lancsashire, United Kingdom|Ballygomartin Group Practice, Belfast, Northern Ireland, United Kingdom|Mortimer Surgery, Mortimer, Reading, United Kingdom|The Waterfront Medical Centre, Barry, Wales, United Kingdom|Valleyfield Health Center, Fife, United Kingdom|Frome Medical Practice, Frome, United Kingdom",,https://ClinicalTrials.gov/show/NCT01298219
772,NCT00726830,"Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer",,Terminated,Has Results,"Brain and Central Nervous System Tumors|Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Lymphoproliferative Disorder|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Pain|Precancerous Condition|Unspecified Adult Solid Tumor, Protocol Specific",Drug: methadone hydrochloride|Drug: morphine sulfate|Drug: oxycodone hydrochloride,Number of Participants With at Least a 3-point Reduction in Pain Score on the M.D. Anderson Symptom Inventory (MDASI)|Number of Participants With 30% Reduction in Total Summary Score for the Individual Composite Drug Toxicity Score (CDTS) Items,M.D. Anderson Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2007-0791|MDA-2007-0791|CDR0000598283,2009-03-01,2010-09-01,2010-10-01,2008-08-01,2012-12-06,2012-12-06,"Palmetto Hematology Oncology, PC at Gibbs Regional Cancer Center, Spartanburg, South Carolina, United States|M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00726830
773,NCT01376570,Project FIRST - Financial Incentives to Reduce Substance Use and Improve Treatment,Project FIRST,Completed,No Results Available,HIV|Opiate Dependence,Behavioral: Abstinence-reinforcing contingency management intervention|Behavioral: Performance Feedback intervention,"HIV viral load|CD4 count|Abstinence from opiates, oxycodone, and cocaine|Antiretroviral adherence","Albert Einstein College of Medicine, Inc.|National Institute on Drug Abuse (NIDA)",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,242,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2010-553|R01DA032110,2012-06-01,2017-08-10,2017-08-10,2011-06-20,null,2018-04-20,"Montefiore's Community Clinics (Montefiore Medical Group), Bronx, New York, United States|Albert Einstein College of Medicine Division of Substance Abuse clinics, Bronx, New York, United States|Montefiore Infectious Disease Clinic, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT01376570
774,NCT01382797,ALK37-005: A Study of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC),,Completed,No Results Available,Opioid-induced Constipation,Drug: ALKS 37|Drug: Placebo,"Dose response relationship among five doses of study drug (4 doses of ALKS 37 and placebo), defined as an increasing proportion of patients exhibiting overall response.","Alkermes, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,157,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ALK37-005,2011-08-01,2012-04-01,2012-04-01,2011-06-27,null,2012-06-13,"Alkermes Study Site, Mesa, Arizona, United States|Alkermes Study Site, Phoenix, Arizona, United States|Alkermes Study Site, National City, California, United States|Alkermes Study Site, Oceanside, California, United States|Alkermes Study Site, Pasadena, California, United States|Alkermes Study Site, Denver, Colorado, United States|Alkermes Investigational Site, De Land, Florida, United States|Alkermes Study Site, Ormond Beach, Florida, United States|Alkermes Study Site, St. Petersburg, Florida, United States|Alkermes Study Site, Stockbridge, Georgia, United States|Alkermes Study Site, Boise, Idaho, United States|Alkermes Study Site, New Orleans, Louisiana, United States|Alkermes Study Site, Kalamazoo, Michigan, United States|Alkermes Study Site, Las Vegas, Nevada, United States|Alkermes Study Site, Belvidere, New Jersey, United States|Alkermes Study Site, Brooklyn, New York, United States|Alkermes Study Site, Cincinnati, Ohio, United States|Alkermes Study Site, Oklahoma City, Oklahoma, United States|Alkermes Study Site, Medford, Oregon, United States|Alkermes Study Site, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT01382797
775,NCT00620061,Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone,,Completed,No Results Available,Opioid-Induced Bowel Dysfunction,Drug: Lubiprostone,"Evaluation of overall safety, including AEs; clinical laboratory evaluations; vital signs; 12-lead resting electrocardiograms; and physical examination results.|Change from baseline in spontaneous bowel movement (SBM) and bowel movement (BM) frequency|Frequency of SBMs and BMs|Responder rates|Mean change from baseline in straining associated with SBMs; stool consistency of SBMs; constipation severity; treatment effectiveness; abdominal bloating; and abdominal discomfort.|Mean change from baseline in bowel habit regularity","Sucampo Pharmaceuticals, Inc.|Takeda|Sucampo Pharma Americas, LLC",All,"18 Years and older   (Adult, Older Adult)",Phase 3,440,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OBD06S1,2007-11-01,2009-09-01,2009-09-01,2008-02-21,null,2013-02-05,"Alabama Orthopedic Clinic, Mobile, Alabama, United States|Clinical Research Advantage, Inc./ Mesa Family Medical Center, Mesa, Arizona, United States|Clinical Research Advantage, Inc. / East Valley Family Physicians, PLC, Tempe, Arizona, United States|Clinical Research Advantage, Inc., Tempe, Arizona, United States|Premiere Pharamaceutical Research, LLC, Tempe, Arizona, United States|Advanced Clinical Therapeutics, LLC, Tucson, Arizona, United States|Wilson and Charani, Tucson, Arizona, United States|Advanced Clinical Research Institute, Anaheim, California, United States|Northern California Research Corporation, Sacramento, California, United States|Clinicos, LLC, Colorado Springs, Colorado, United States|Clinical Physiology Associates/Clinical Study Center, Fort Meyers, Florida, United States|Century Clinical Research, Holly Hill, Florida, United States|Florida Institute of Medical Research, Jacksonville, Florida, United States|Accord Clinical Research, LLC, Port Orange, Florida, United States|Clinical Research of West Florida, Inc., Tampa, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Best Clinical Research, Decatur, Georgia, United States|Millenium Pain Center, Bloomington, Illinois, United States|Columbia Medical Practice/ RxTrials, Inc., Columbia, Maryland, United States|MedVadis Research Corporation, Wellesley Hills, Massachusetts, United States|Center for Digestive Health, Troy, Michigan, United States|Montana Neuroscience Institute Foundation / Montana Spine and Pain Center, Missoula, Montana, United States|Office of Stephen H. Miller, MD, Las Vegas, Nevada, United States|Long Island Gastrointestinal Research Group, Great Neck, New York, United States|COR Clinical Research, LLC, Oklahoma City, Oklahoma, United States|Memorial Clinical Research, Oklahoma City, Oklahoma, United States|Medford Medical Clinic, LLP, Medford, Oregon, United States|Trident Institute of Medical Research, LLC, North Charleston, South Carolina, United States|Southeastern Clinical Research, Chattanooga, Tennessee, United States|Comprehensive Pain Specialists, PLLC, Hendersonville, Tennessee, United States|New River Valley Research Institute, Christianburg, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00620061
776,NCT00597428,Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone,OPAL,Completed,Has Results,Opioid-Induced Bowel Dysfunction,Drug: Lubiprostone|Drug: Placebo,"Change From Baseline in Mean Weekly Spontaneous Bowel Movement (SBM) Frequency in Subjects Without Dose Reduction Prior to Week 8|Change From Baseline in Mean Weekly SBM Frequency|First Post-dose SBM|Responder Rate|Mean Changes From Baseline in Straining, Stool Consistency, Constipation Severity, Abdominal Bloating, Abdominal Discomfort, and Bowel Habit Regularity|Treatment Effectiveness","Sucampo Pharmaceuticals, Inc.|Takeda|Sucampo Pharma Americas, LLC",All,"18 Years and older   (Adult, Older Adult)",Phase 3,437,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",OBD0632,2007-08-01,2009-03-01,2009-03-01,2008-01-18,2015-12-07,2015-12-07,"Tuscaloosa VA Medical Center, Tuscaloosa, Alabama, United States|Carl T Hayden VA Medical Center, Phoenix, Arizona, United States|Redpoint Research, Phoenix, Arizona, United States|HOPE Research Institute, LLC, Phoenix, Arizona, United States|Clinical Research Advantage, Inc. / East Valley Family Physicians, PLC, Tempe, Arizona, United States|Premiere Pharamaceutical Research, LLC, Tempe, Arizona, United States|Harmony Clinical Research, Inc., Tucson, Arizona, United States|Martin Bowen Hefley Knee, Little Rock, Arkansas, United States|Advanced Pain Institute, Arcadia, California, United States|Pain Institute of CA, Bakersfield, California, United States|Catalina Research Institute, LLC, Chino, California, United States|California Pain Center, Huntington Beach, California, United States|Shreenath Clinical Service, Laguna Hills, California, United States|Loma Linda University Physicians Medical Group, Loma Linda, California, United States|VA Long Beach Healthcare System, Long Beach, California, United States|Rider Research Group, San Francisco, California, United States|Clinicos, LLC, Colorado Springs, Colorado, United States|Rocky Mountain Gastroenterology Associates, Lakewood, Colorado, United States|Arapahoe Gastroenterology, PC, Littleton, Colorado, United States|Metro Clinical Research, LLC, Littleton, Colorado, United States|Clinical Trial Management of Boca Raton, Inc., Boca Raton, Florida, United States|Florida Institute of Medical Research, Jacksonville, Florida, United States|Drug Study Institute, Jupiter, Florida, United States|Gastroenterology Group of Naples, Naples, Florida, United States|Kenneth W. Ponder, MD PA, Niceville, Florida, United States|North Miami Research, Inc., North Miami, Florida, United States|Renstar Inc., Ocala, Florida, United States|Peninsula Research, Inc, Ormond Beach, Florida, United States|DMI Research, Inc., Pinellas Park, Florida, United States|Sunrise Medical Research, Inc., Plantation, Florida, United States|Accord Clinical Research, LLC, Port Orange, Florida, United States|Lovelace Scientific Resources, Inc., Sarasota, Florida, United States|Meridien Research, St. Petersburg, Florida, United States|Clinical Research of West Florida, Inc., Tampa, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Advanced Pain Management, Augusta, Georgia, United States|Global Research Partners & Consultants, Incs., Calhoun, Georgia, United States|Q Clinical Research, Decatur, Georgia, United States|Apex Medical Research, AMR, Inc., Chicago, Illinois, United States|Claude Mandel Medical Center, Chicago, Illinois, United States|Advanced Pain Care Clinic, Evansville, Indiana, United States|MediSphere Medical Research Center, Evansville, Indiana, United States|Davis Clinic, PC, Indianapolis, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Louisville, Louisville, Kentucky, United States|Gulf Coast Research, LLC, Lafayette, Louisiana, United States|Delta Research Partners, LLC, Monroe, Louisiana, United States|Louisiana Research Center, LLC, Shreveport, Louisiana, United States|Rehabilitation Team West, PA, Baltimore, Maryland, United States|Columbia Medical Practice/ RxTrials, Inc., Columbia, Maryland, United States|Washington County Hospital Association - The Center for Clinical Research, Hagerstown, Maryland, United States|Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States|MedVadis Research Corporation, Wellesley Hills, Massachusetts, United States|Clinical Research Institute of Michigan, LLC, Chesterfield, Michigan, United States|Professional Clinical Research, Inc., Interlochen, Michigan, United States|PCM Medical Services, Lansing, Michigan, United States|Women's Health Care Specialists, PC, Paw Paw, Michigan, United States|Medical Research Associates, Traverse City, Michigan, United States|Center for Digestive Health, Troy, Michigan, United States|MAPS Applied Research Center, Edina, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Precise Research, Inc., Flowood, Mississippi, United States|Medex Healthcare Research, St. Louis, Missouri, United States|Montana Neuroscience Institute Foundation / Montana Spine and Pain Center, Missoula, Montana, United States|Creighton University Medical Center, Omaha, Nebraska, United States|Advanced Biomedical Research of America, Las Vegas, Nevada, United States|Lovelace Scientific Resources, Inc., Las Vegas, Nevada, United States|Gastroenterology Research Associates, Cedar Knolls, New Jersey, United States|Central Jersey Medical Research Center, Elizabeth, New Jersey, United States|Holy Name Hospital, Institute for Clinical Research, Teaneck, New Jersey, United States|Advanced Pain Consultants, Voorhees, New Jersey, United States|Medex Healthcare Research, Inc., New York, New York, United States|New York University Pain Management Center, New York, New York, United States|Research Across America, New York, New York, United States|North American Partners, Valley Stream, New York, United States|Upstate Clinical Research Associates, Williamsville, New York, United States|Randolph Medical Associates, Asheboro, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Carolina Research, Greenville, North Carolina, United States|Carolina Digestive Health Associates, Harrisburg, North Carolina, United States|Peters Medical Research, LLC, High Point, North Carolina, United States|Triangle Medical Research, Lexington, North Carolina, United States|Southern Gastroenterology Associates, New Bern, North Carolina, United States|Valley Medical Primary Care, Centerville, Ohio, United States|Glenway Family Medicine, Cincinnati, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|Urgent Care Specialists, Dayton, Ohio, United States|RAS Health Ltd., Marion, Ohio, United States|University of Toledo - Health Science Campus, Toledo, Ohio, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Paradigm Research Professionals, LLP, Oklahoma City, Oklahoma, United States|Memorial Clinical Research, Oklahoma City, Oklahoma, United States|Medford Medical Clinic, LLP, Medford, Oregon, United States|Lehigh Valley Hospital - Neurosciences and Pain Research, Allentown, Pennsylvania, United States|Einstein Pain Institute, Philadelphia, Pennsylvania, United States|Jeffry A. Lindenbaum DO, PC, Yardley, Pennsylvania, United States|Baptist Medical Tower Suite 740, Knoxville, Tennessee, United States|Integrity Clinical Research, LLC, Milan, Tennessee, United States|Texas Familicare Clinical Research, Hurst, Texas, United States|DCOL Center for Clinical Research, Longview, Texas, United States|Bexar Clinical Trials, LLC, Richardson, Texas, United States|Advance Research Institute, Ogden, Utah, United States|Highland Clinical Research, Salt Lake City, Utah, United States|University of Utah, Salt Lake City, Utah, United States|New River Valley Research Institute, Christianburg, Virginia, United States|Hampton Roads Institute for Performance and Sports Medicine (HIPS), Portsmouth, Virginia, United States|McGuire Research Institute, Richmond, Virginia, United States|Northwest Gastroenterology Associates, Bellevue, Washington, United States|Daniel R. Coulston, Spokane, Washington, United States|Hermitage Medicentre, Edmonton, Alberta, Canada|Health Sciences Centre, Winnipeg, Manitoba, Canada|St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada|Pharmaceutical Integrated Research Company, London, Ontario, Canada|DHC Research, Richmond Hill, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00597428
777,NCT00595946,Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone,OPAL,Completed,Has Results,Opioid-Induced Bowel Dysfunction,Drug: Lubiprostone|Drug: Placebo,"Change From Baseline in Mean Weekly Spontaneous Bowel Movement Frequency|First Post-dose Spontaneous Bowel Movement|Responder Rate|Mean Changes From Baseline in Straining, Stool Consistency, Constipation Severity, Abdominal Bloating, Abdominal Discomfort, and Bowel Habit Regularity|Treatment Effectiveness (Patient Reported Outcome)","Sucampo Pharmaceuticals, Inc.|Takeda|Sucampo Pharma Americas, LLC",All,"18 Years and older   (Adult, Older Adult)",Phase 3,439,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",OBD0631,2007-08-01,2009-03-01,2009-03-01,2008-01-16,2016-02-03,2016-02-03,"The Birmingham Pain Center, Birmingham, Alabama, United States|Simon Williamson Clinic, PC, Hueytown, Alabama, United States|Alabama Orthopedic Clinic, Mobile, Alabama, United States|Clinical Research Advantage, Inc./ Mesa Family Medical Center, Mesa, Arizona, United States|Clinical Research Advantage, Inc., Tempe, Arizona, United States|Harmony Clinical Research, Inc., Tucson, Arizona, United States|Verona Clinical Research, Inc., Tucson, Arizona, United States|Quality of Life Medical & Research Center, LLC, Tucson, Arizona, United States|Pusch Ridge Family Medicine / WC Clinical Research, Tucson, Arizona, United States|Genova Clinical Research, Inc., Tuscon, Arizona, United States|Advanced Clinical Research Institute, Anaheim, California, United States|Orange County Clinical Trials, Inc., Anaheim, California, United States|Gregory J. Wiener, MD PC, Chula Vista, California, United States|Digestive and Liver Disease Specialists, Garden Grove, California, United States|RX Clinical Research, Inc, Garden Grove, California, United States|Physicians Clinical Research Corporation, Laguna Hills, California, United States|Loma Linda University Physicians Medical Group, Loma Linda, California, United States|HealthCare Partners Medical Group, Long Beach, California, United States|Impact Clinical Trials, Los Angeles, California, United States|The Regents of the University of California, Los Angeles, Los Angeles, California, United States|Pasadena Rehabilitation Institute, Pasadena, California, United States|Northern California Research Corporation, Sacramento, California, United States|SB Family Medicine, Solana Beach, California, United States|Lynn Institute of the Rockies, Colorado Springs, Colorado, United States|Lynn Institute of Pueblo, Pueblo, Colorado, United States|Advanced Diagnostic Pain Treatment Center, New Haven, Connecticut, United States|International Research Clinicians of Conneticut, Ridgefield, Connecticut, United States|New England Research Associates, LLC, Trumbull, Connecticut, United States|Meridien Research, Brooksville, Florida, United States|South Lake Pain Institute, Clermont, Florida, United States|Century Clinical Research, Daytona Beach, Florida, United States|International Medical Research, Daytona Beach, Florida, United States|Clinical Physiology Associates/Clinical Study Center, Fort Meyers, Florida, United States|Southeaster Integrated Medical, PL d/b/a Florida Medical Research Institute, Gainesville, Florida, United States|Palm Beach Research Center, West Palm Beach, Florida, United States|North Georgia Premier Research, Dawsonville, Georgia, United States|Best Clinical Research, Decatur, Georgia, United States|Drug Studies America, Marietta, Georgia, United States|Pinnacle Trials Inc., Stockbridge, Georgia, United States|Rosemark Women Care Specialists, Idaho Falls, Idaho, United States|Saltzer Medical Group, Nampa, Idaho, United States|Millenium Pain Center, Bloomington, Illinois, United States|University of Illinois Medical Center, Chicago, Illinois, United States|Redhead Research Inc., dba Research Associates of Central Illinois, Peoria, Illinois, United States|Integrated Clinical Trial Services, Inc., West Des Moines, Iowa, United States|The Pain Treatment Center of the Bluegrass and Ballard Wright, MD PSC, Lexington, Kentucky, United States|Gulf Coast Research, LLC, Baton Rouge, Louisiana, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|The Willis-Knighton Pain Management Center, Shreveport, Louisiana, United States|Pain and Rehabilitation Medicine, Bethesda, Maryland, United States|The Brigham and Women's Hospital, Boston, Massachusetts, United States|Professional Clinical Research, Benzonia, Benzonia, Michigan, United States|Center for Clinical Studies, Dearborn, Michigan, United States|Apex Medical Research, AMR, Inc., Flint, Michigan, United States|Digestive Health Specialists, PA, Tupelo, Mississippi, United States|Impact Clinical Trials, Las Vegas, Las Vegas, Nevada, United States|Office of Stephen H. Miller, MD, Las Vegas, Nevada, United States|University of Nevada, Reno, Nevada, United States|Cooper Health System, Camden, New Jersey, United States|UMDNJ, Stratford, New Jersey, United States|Partners in Primary Care, Voorhees, New Jersey, United States|Abraham D. Morganoff, MD PA, Watchung, New Jersey, United States|Northway Medical Associates, Fulton, New York, United States|Long Island Clinical Research Associates, LLP, Great Neck, New York, United States|Long Island Gastrointestinal Research Group, Great Neck, New York, United States|University of Rochester, Rochester, New York, United States|Diversified Research, Durham, North Carolina, United States|Medoff Medical/ Vital re:Search, Greensboro, North Carolina, United States|Carolina Pharmaceutical Research, Statesville, North Carolina, United States|Center for Clinical Research, LLC, Winston-Salem, North Carolina, United States|St. Alexius Medical Center, Bismarck, North Dakota, United States|Cleveland Clinic, Cleveland, Ohio, United States|COR Clinical Research, LLC, Oklahoma City, Oklahoma, United States|Pain Research of Oregon, LLC, Eugene, Oregon, United States|Affinity Research, Portland, Oregon, United States|Private Practice of Dr. Hasan, Allentown, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Preferred Primary Care Physicians, Uniontown, Pennsylvania, United States|Partners in Clinical Research, Cumberland, Rhode Island, United States|University Gastroenterology, Providence, Rhode Island, United States|Trident Institute of Medical Research, LLC, North Charleston, South Carolina, United States|Southeastern Clinical Research, Chattanooga, Tennessee, United States|Comprehensive Pain Specialists, PLLC, Hendersonville, Tennessee, United States|Vanderbilt University - Interventional Pain Center, Nashville, Tennessee, United States|Integrity Clinical Research, LLC, Savannah, Tennessee, United States|Dallas VA Research Corporation, Inc., Dallas, Texas, United States|Bexar Clinical Trials, LLC, Dallas, Texas, United States|Permian Research Foundation, Odessa, Texas, United States|Bexar Clinical Trials, LLC, Richardson, Texas, United States|Salt Lake Research, PLLC, Salt Lake City, Utah, United States|Digestive and Liver Disease Specialists, Norfolk, Virginia, United States|General Clinical Research Center, Virginia Commonwealth University, North Hospital, Richmond, Virginia, United States|Metro Physicians a Division of Wheaton Franciscan Medical Group, Milwaukee, Wisconsin, United States|Clement J. Zablocki VA Medical Center, Milwaukee, Wisconsin, United States|Health Sciences Center, Hamilton, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00595946
778,NCT00577408,Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone,Depot-BNT,Completed,Has Results,Opiate Dependence|Heroin Dependence,Drug: depot naltrexone|Drug: Oral Naltrexone,Treatment Retention,New York State Psychiatric Institute|National Institute on Drug Abuse (NIDA),All,18 Years to 60 Years   (Adult),Phase 3,60,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",#5307|R01DA010746,2007-09-01,2011-08-01,2011-08-01,2007-12-20,2017-08-25,2017-08-25,"New York State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00577408
779,NCT00552578,Buprenorphine as a Treatment in Opiate Dependent Pain Patients,,Terminated,Has Results,Opiate Addiction|Refractory Pain,Drug: buprenorphine/naloxone,Relapse to Substance Abuse|Number of Participants With Better Overall Quality of Life at Six Months as Compared to Baseline.|Treatment Retention.,State University of New York at Buffalo,All,"18 Years and older   (Adult, Older Adult)",Phase 4,12,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FMD0400907A,2007-10-01,2008-10-01,2008-10-01,2007-11-02,2009-07-07,2011-02-17,"Erie County Medical Center, Buffalo, New York, United States",,https://ClinicalTrials.gov/show/NCT00552578
780,NCT00539123,Drug Counseling and Abstinent-Contingent Take-Home Buprenorphine in Malaysia,,Unknown status,No Results Available,Opiate Dependence,Behavioral: behavioral drug and HIV risk reduction counseling (BDRC)|Behavioral: abstinence-contingent take-home buprenorphine (ACB)|Behavioral: Physician Management (PM),reductions in heroin use|reductions in drug- and sex-related HIV risk|retention|reductions in other illicit drug use|changes in functional status,Yale University|National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,240,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2R01DA014718-05A1,2007-09-01,2012-09-01,2012-09-01,2007-10-04,null,2009-06-04,"Yale University School of Medicine, New Haven, Connecticut, United States|Substance Abuse Research Center, Muar, Johor, Malaysia",,https://ClinicalTrials.gov/show/NCT00539123
781,NCT00021996,Valdecoxib in Treating Chronic Pain in Cancer Patients,,Completed,No Results Available,"Pain|Unspecified Adult Solid Tumor, Protocol Specific",Drug: valdecoxib,,Dana-Farber Cancer Institute|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,null,Other,Interventional,Primary Purpose: Supportive Care,DFCI-N91-00-02-040|CDR0000068670|BWH-2000-P-000984/7|SC-N91-00-02-040,2001-01-01,null,2004-02-01,2004-02-27,null,2013-07-18,"Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00021996
782,NCT01393392,Developing a Smoking Cessation Intervention for Methadone Maintained Smokers,,Completed,No Results Available,Nicotine Dependence|Opiate Dependence,"Behavioral: Intensive, tailored intervention|Behavioral: NJ Quitline Referral",seven-day point prevalence of smoking abstinence|mean number of cigarettes smoked per day during the past week|any quit attempts since enrollment|readiness for quitting|self-efficacy for quitting|nicotine dependence|three-month prolonged smoking abstinence,"Rutgers, The State University of New Jersey|National Institute on Drug Abuse (NIDA)",All,"18 Years and older   (Adult, Older Adult)",Phase 1,91,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,K23DA025049,2011-10-01,2014-05-01,2014-05-01,2011-07-13,null,2015-05-06,"Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT01393392
783,NCT02896296,Open-Label Treatment Extension Study,,Completed,No Results Available,Opioid Use Disorder|Opioid-related Disorders,Drug: Low dose RBP-6000|Drug: High dose RBP-6000,Number of participants with adverse events as a measure of safety and tolerability,Indivior Inc.,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,208,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,INDV-6000-301,2016-08-17,2017-08-23,2017-08-23,2016-09-12,null,2018-01-17,"Boyett Health Services, Hamilton, Alabama, United States|Woodland International Research Group, Little Rock, Arkansas, United States|Collaborative Neuroscience Network, Long Beach, California, United States|Pacific Research Partners, Oakland, California, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|Amit Vijapura, Jacksonville, Florida, United States|Meridien Research, Lakeland, Florida, United States|Innovative Clinical Research, Lauderhill, Florida, United States|Scientific Clinical Research, North Miami, Florida, United States|Phoenix Medical Research, Prairie Village, Kansas, United States|Louisiana Research Associates, New Orleans, Louisiana, United States|Louisiana Clinical Research, Shreveport, Louisiana, United States|Stanley Street Treatment and Resources, Fall River, Massachusetts, United States|Adams Clinical Trials, Watertown, Massachusetts, United States|Precise Research Centers, Inc., Flowood, Mississippi, United States|St Louis Clinical Trials, Saint Louis, Missouri, United States|Altea Research, Las Vegas, Nevada, United States|Hassman Research Institute, Berlin, New Jersey, United States|Center for Emotional Fitness, Cherry Hill, New Jersey, United States|Neuro-behavioral Clinical Research, Canton, Ohio, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|Charak Clinical Research Center, Garfield Heights, Ohio, United States|Pahl Pharmaceutical Professionals, Oklahoma City, Oklahoma, United States|SP Research, PLLC, Oklahoma City, Oklahoma, United States|CODA, Portland, Oregon, United States|Keystone Clinical Solutions, Altoona, Pennsylvania, United States|Carolina Clinical Trials, Charleston, South Carolina, United States|Pillar Clinical Research, Dallas, Texas, United States|InSite Clinical Research, DeSoto, Texas, United States",,https://ClinicalTrials.gov/show/NCT02896296
784,NCT03115359,Strategies to Assist With Management of Pain,STAMP,Recruiting,No Results Available,Chronic Low Back Pain,Behavioral: Mindfulness Meditation|Behavioral: Cognitive Behavioral Therapy,Pain Intensity|Physical Function|Quality of Life|Daily Opioid Dose,"University of Wisconsin, Madison|Patient-Centered Outcomes Research Institute",All,"21 Years and older   (Adult, Older Adult)",Not Applicable,766,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,2017-0353,2017-06-30,2021-06-30,2021-07-15,2017-04-14,null,2017-09-01,"Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Utah, Salt Lake City, Utah, United States|University of Wisconsin-Madison, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT03115359
785,NCT03328208,Nonpharmacologic Reduction of Periprocedural Distress and Drug Use,,Recruiting,No Results Available,Dental Anxiety|Pain|Drug Use|Opioid Use,Other: Comfort Talk® app|Other: White Noise app,Study design feasibility|Enrollment ability|Follow-up feasibility,"Hypnalgesics, LLC|Tufts University",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,72,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",R43AT009517,2017-11-22,2018-10-30,2018-12-31,2017-11-01,null,2017-11-27,"Tufts University School of Dental Medicine, Boston, Massachusetts, United States|Hypnalgesics, LLC, Brookline, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03328208
786,NCT00238914,Opiate Dependence: Combined Naltrexone/Behavior Therapy - 1,,Completed,No Results Available,Heroin Dependence,Drug: Naltrexone|Behavioral: Behavioral Naltrexone Therapy (BNT)|Behavioral: Compliance Enhancement (CE),Relapse to heroin addiction,New York State Psychiatric Institute|National Institute on Drug Abuse (NIDA),All,18 Years to 60 Years   (Adult),Phase 2,12,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,#4260R|R01DA010746|R01-10746-1,1999-08-01,2002-07-01,2002-07-01,2005-10-14,null,2012-01-13,"New York State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00238914
787,NCT00218621,The Effects of Methadone and Buprenorphine on Fetal Neurobehavior and Infant Neonatal Abstinence Syndrome - 1,,Completed,No Results Available,Opiate Dependence|Pregnancy,Procedure: Buprenorphine / methadone,Fetal heart rate|Fetal movement|Neonatal abstinence syndrome,Johns Hopkins University|National Institute on Drug Abuse (NIDA),Female,18 Years to 40 Years   (Adult),,20,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,04032202|R01DA019934|NIDA R01DA019934|DPMCDA,2005-09-01,2009-02-01,2009-02-01,2005-09-22,null,2013-02-21,"The Center for Addiction and Pregnancy, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00218621
788,NCT00218036,Pharmacotherapy Dosing Regimen in Cocaine and Opiate Dependent Individuals - 8,,Unknown status,No Results Available,Cocaine Abuse|Opiate Dependence,Drug: Modafinil 200mg|Drug: Modafinil 400mg|Drug: Citalopram 20mg|Drug: Citalopram 40mg|Drug: Placebo,Confirmed abstinence from cocaine|Retention|Medication Compliance,University of Texas|National Institute on Drug Abuse (NIDA),All,22 Years to 50 Years   (Adult),Phase 2,200,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NIDA-09262-8|P50DA009262-08|DPMC,2006-07-01,2010-07-01,2011-07-01,2005-09-22,null,2009-12-15,"University of Texas Health Science Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00218036
789,NCT00668265,Anxiety in Recovering Opiate Dependence,,Terminated,Has Results,Generalized Anxiety Disorder|Comorbid Opiate Dependence in Remission|Status Post Methadone-Maintenance Treatment,Drug: Quetiapine,Hamilton Anxiety Scale at 16 Weeks|Beck Depression Inventory at 16 Weeks,Beth Israel Medical Center|AstraZeneca,All,"21 Years to 65 Years   (Adult, Older Adult)",Phase 4,14,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",IRB # (112-07)|IRUSQUET0443,2008-01-01,2011-08-01,2011-08-01,2008-04-29,2013-02-18,2013-02-18,"Su Casa Methadone-to-Abstinence Rehabilitation, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00668265
790,NCT00580827,Clinical Efficacy of Disulfiram in LAAM-Maintained Cocaine Abusers,,Completed,No Results Available,Cocaine-Related Disorder|Opiate Dependence,Drug: Placebo|Drug: Disulfiram,Reductions in cocaine use as measured by urine toxicology and self-report|Predictors of treatment efficacy using DBH genotyping for disulfiram will be tested.,Yale University|National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,126,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R01DA013441|NIDA R01 DA13441,2003-09-01,2004-03-01,null,2007-12-27,null,2007-12-27,"West Haven VA, West Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00580827
791,NCT00566969,Cocaine Withdrawal and Pharmacotherapy Response,Carvedilol,Completed,Has Results,Cocaine Dependence|Opiate Dependence,Drug: sugar pill|Drug: Carvedilol 25 mg|Drug: Carvedilol 50 mg,Percent Days Abstinent From Cocaine - Self Report,Yale University|National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,106,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Health Services Research",NIDA R01DA014537|R01DA014537|DPMC,2007-09-01,2012-12-01,2013-01-01,2007-12-04,2016-10-10,2018-02-13,"Veterans Hospital, West Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00566969
792,NCT00475878,SSRI and Buprenorphine,,Completed,Has Results,Opiate Dependence|Depression,Drug: escitalopram|Drug: placebo,Percentage of Participants Who Dropped Out of Buprenorphine Treatment|Depressive Symptoms,Butler Hospital,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,147,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",DA022207|0807-002,2006-12-01,2009-09-01,2009-09-01,2007-05-21,2012-04-03,2012-04-03,"Butler Hospital, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT00475878
793,NCT01965652,Long Term Safety of Naldemedine,,Completed,Has Results,Opioid-induced Constipation,Drug: Naldemedine|Drug: Placebo,Number of Participants With Adverse Events|Change From Baseline in the Number of Bowel Movements Per Week|Percentage of Participants Meeting Each Criterion of Laxative Use|Change From Baseline in the Overall Score for Patient Assessment of Constipation Symptoms|Change From Baseline in the PAC-SYM Abdominal-symptoms Domain Score|Change From Baseline in the PAC-SYM Rectal-symptoms Domain Score|Change From Baseline in the PAC-SYM Stool-symptoms Domain Score|Change From Baseline in the Patient Assessment of Constipation Quality of Life Overall Score|Change From Baseline in the Physical Discomfort Domain of PAC-QOL|Change From Baseline in the Psychosocial Discomfort Domain of PAC-QOL|Change From Baseline in the Worries and Concerns Domain of PAC-QOL|Change From Baseline in the Satisfaction Domain of PAC-QOL|Participant Global Satisfaction,Shionogi|Shionogi Inc.,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,1246,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1326V9235,2013-09-24,2016-01-12,2016-01-12,2013-10-18,2017-05-30,2018-04-18,"Shionogi Research Site, Birmingham, Alabama, United States|Shionogi Research Site, Mobile, Alabama, United States|Shionogi Research Site, Chandler, Arizona, United States|Shionogi Research Site, Glendale, Arizona, United States|Shionogi Research Site, Goodyear, Arizona, United States|Shionogi Research Site, Mesa, Arizona, United States|Shionogi Research Site, Phoenix, Arizona, United States|Shionogi Research Site, Tucson, Arizona, United States|Shionogi Research Site, Fountain Valley, California, United States|Shionogi Research Site, Garden Grove, California, United States|Shionogi Research Site, Glendale, California, United States|Shionogi Research Site, Long Beach, California, United States|Shionogi Research Site, Los Angeles, California, United States|Shionogi Research Site, Oceanside, California, United States|Shionogi Research Site, Sacramento, California, United States|Shionogi Research Site, Santa Ana, California, United States|Shionogi Research Site, Upland, California, United States|Shionogi Research Site, Colorado Springs, Colorado, United States|Shionogi Research Site, Boynton Beach, Florida, United States|Shionogi Research Site, Brandon, Florida, United States|Shionogi Research Site, Brooksville, Florida, United States|Shionogi Research Site, Clearwater, Florida, United States|Shionogi Research Site, Fort Myers, Florida, United States|Shionogi Research Site, Jacksonville, Florida, United States|Shionogi Research Site, Lake City, Florida, United States|Shionogi Research Site, Lakeland, Florida, United States|Shionogi Research Site, Orlando, Florida, United States|Shionogi Research Site, Saint Petersburg, Florida, United States|Shionogi Research Site, South Miami, Florida, United States|Shionogi Research Site, Tampa, Florida, United States|Shionogi Research Site, Atlanta, Georgia, United States|Shionogi Research Site, Blue Ridge, Georgia, United States|Shionogi Research Site, Decatur, Georgia, United States|Shionogi Research Site, Savannah, Georgia, United States|Shionogi Research Site, Boise, Idaho, United States|Shionogi Research Site, Aurora, Illinois, United States|Shionogi Research Site, Bloomington, Illinois, United States|Shionogi Research Site, Decatur, Illinois, United States|Shionogi Research Site, Rockford, Illinois, United States|Shionogi Research Site, Schaumburg, Illinois, United States|Shionogi Research Site, Evansville, Indiana, United States|Shionogi Research Site, Lafayette, Indiana, United States|Shionogi Research Site, Valparaiso, Indiana, United States|Shionogi Research Site, Augusta, Kansas, United States|Shionogi Research Site, Newton, Kansas, United States|Shionogi Research Site, Wichita, Kansas, United States|Shionogi Research Site, Hartford, Kentucky, United States|Shionogi Research Site, Eunice, Louisiana, United States|Shionogi Research Site, Lake Charles, Louisiana, United States|Shionogi Research Site, Mandeville, Louisiana, United States|Shionogi Research Site, Brockton, Massachusetts, United States|Shionogi Research Site, Fall River, Massachusetts, United States|Shionogi Research Site, New Bedford, Massachusetts, United States|Shionogi Research Site, Rochester, Michigan, United States|Shionogi Research Site, Saginaw, Michigan, United States|Shionogi Research Site, Traverse City, Michigan, United States|Shionogi Research Site, Biloxi, Mississippi, United States|Shionogi Research Site, Fremont, Nebraska, United States|Shionogi Research Site, Omaha, Nebraska, United States|Shionogi Research Site, Henderson, Nevada, United States|Shionogi Research Site, Las Vegas, Nevada, United States|Shionogi Research Site, Trenton, New Jersey, United States|Shionogi Research Site, Albuquerque, New Mexico, United States|Shionogi Research Site, New York, New York, United States|Shionogi Research Site, Greensboro, North Carolina, United States|Shionogi Research Site, Wilmington, North Carolina, United States|Shionogi Research Site, Winston-Salem, North Carolina, United States|Shionogi Research Site, Akron, Ohio, United States|Shionogi Research Site, Canton, Ohio, United States|Shionogi Research Site, Columbus, Ohio, United States|Shionogi Research Site, Groveport, Ohio, United States|Shionogi Research Site, Kettering, Ohio, United States|Shionogi Research Site, Lebanon, Ohio, United States|Shionogi Research Site, Marion, Ohio, United States|Shionogi Research Site, Munroe Falls, Ohio, United States|Shionogi Research Site, Oklahoma City, Oklahoma, United States|Shionogi Research Site, Tulsa, Oklahoma, United States|Shionogi Research Site, Portland, Oregon, United States|Shionogi Research Site, Huntingdon Valley, Pennsylvania, United States|Shionogi Research Site, Jenkintown, Pennsylvania, United States|Shionogi Research Site, Lansdale, Pennsylvania, United States|Shionogi Research Site, Charleston, South Carolina, United States|Shionogi Research Site, Greer, South Carolina, United States|Shionogi Research Site, Myrtle Beach, South Carolina, United States|Shionogi Research Site, Summerville, South Carolina, United States|Shionogi Research Site, Bristol, Tennessee, United States|Shionogi Research Site, Milan, Tennessee, United States|Shionogi Research Site, Nashville, Tennessee, United States|Shionogi Research Site, Austin, Texas, United States|Shionogi Research Site, Dallas, Texas, United States|Shionogi Research Site, Houston, Texas, United States|Shionogi Research Site, Hurst, Texas, United States|Shionogi Research Site, Sugar Land, Texas, United States|Shionogi Research Site, Bountiful, Utah, United States|Shionogi Research Site, Salt Lake City, Utah, United States|Shionogi Research Site, South Ogden, Utah, United States|Shionogi Research Site, Richmond, Virginia, United States|Shionogi Research Site, Bellevue, Washington, United States|Shionogi Research Site, Edmonds, Washington, United States|Shionogi Research Site, Adelaide, Australia|Shionogi Research Site, Bedford Park, Australia|Shionogi Research Site, Camperdown, Australia|Shionogi Research Site, Carina Heights, Australia|Shionogi Research Site, Caulfield South, Australia|Shionogi Research Site, Malvern East, Australia|Shionogi Research Site, Nambour, Australia|Shionogi Research Site, Sherwood, Australia|Shionogi Research Site, St Leonards, Australia|Shionogi Research Site, Linz, Austria|Shionogi Research Site, Vienna, Austria|Shionogi Research Site, Zams, Austria|Shionogi Research Site, London, Canada|Shionogi Research Site, Mirabel, Canada|Shionogi Research Site, Sarnia, Canada|Shionogi Research Site, Sherbrooke, Canada|Shionogi Research Site, Toronto, Canada|Shionogi Research Site, Vancouver, Canada|Shionogi Research Site, Benesov, Czechia|Shionogi Research Site, Olomouc, Czechia|Shionogi Research Site, Ostrava, Czechia|Shionogi Research Site, Pardubice, Czechia|Shionogi Research Site, Pribram V- Zdabor, Czechia|Shionogi Research Site, Glostrup, Denmark|Shionogi Research Site, Hellerup, Denmark|Shionogi Research Site, Odense, Denmark|Shionogi Research Site, Soulaine Sur Aubance, France|Shionogi Research Site, Berlin, Germany|Shionogi Research Site, Dresden, Germany|Shionogi Research Site, Halle, Germany|Shionogi Research Site, Hamburg, Germany|Shionogi Research Site, Hannover, Germany|Shionogi Research Site, Kassel, Germany|Shionogi Research Site, Leipzig, Germany|Shionogi Research Site, Luenen, Germany|Shionogi Research Site, Mainz, Germany|Shionogi Research Site, Muenster, Germany|Shionogi Research Site, Stadtroda, Germany|Shionogi Research Site, Balatonfuered, Hungary|Shionogi Research Site, Budapest, Hungary|Shionogi Research Site, Debrecen, Hungary|Shionogi Research Site, Hatvan, Hungary|Shionogi Research Site, Szikszo, Hungary|Shionogi Research Site, Beer Sheva, Israel|Shionogi Research Site, Haifa, Israel|Shionogi Research Site, Tel Aviv, Israel|Shionogi Research Site, Tel Hashomer, Israel|Shionogi Research Site, Asti, Italy|Shionogi Research Site, Catania, Italy|Shionogi Research Site, Chieti, Italy|Shionogi Research Site, Firenze, Italy|Shionogi Research Site, Napoli, Italy|Shionogi Research Site, Rionero in Vulture, Italy|Shionogi Research Site, Roma, Italy|Shionogi Research Site, Rome, Italy|Shionogi Research Site, Chorzów, Poland|Shionogi Research Site, Gdańsk, Poland|Shionogi Research Site, Katowice, Poland|Shionogi Research Site, Lublin, Poland|Shionogi Research Site, Alberton, South Africa|Shionogi Research Site, Lyttelton Centurion, South Africa|Shionogi Research Site, Muckleneuk Pretoria, South Africa|Shionogi Research Site, Pretoria West Pretoria, South Africa|Shionogi Research Site, Worcester, South Africa|Shionogi Research Site, Barcelona, Spain|Shionogi Research Site, Girona, Spain|Shionogi Research Site, Sevilla, Spain|Shionogi Research Site, Skene, Sweden|Shionogi Research Site, Stockholm, Sweden|Shionogi Research Site, Bath, United Kingdom|Shionogi Research Site, Belfast, United Kingdom|Shionogi Research Site, Bexhill On Sea East Sussex, United Kingdom|Shionogi Research Site, Chesterfield, United Kingdom|Shionogi Research Site, Chestfield Kent, United Kingdom|Shionogi Research Site, Daventry Northants, United Kingdom|Shionogi Research Site, Devon, United Kingdom|Shionogi Research Site, Epworth Doncaster, United Kingdom|Shionogi Research Site, Harrogate, United Kingdom|Shionogi Research Site, Hinckley, United Kingdom|Shionogi Research Site, Liverpool, United Kingdom|Shionogi Research Site, Norwich, United Kingdom|Shionogi Research Site, Oldham, United Kingdom|Shionogi Research Site, Peterborough, United Kingdom|Shionogi Research Site, Randalstown, County Antrim, United Kingdom|Shionogi Research Site, Spiro Close, Pulborough West Sussex, United Kingdom|Shionogi Research Site, Wellingborough Northamptonshire, United Kingdom|Shionogi Research Site, York, United Kingdom",,https://ClinicalTrials.gov/show/NCT01965652
794,NCT03275350,Comparing Treatments for HIV-Infected Opioid Users in an Integrated Care Effectiveness Study (CHOICES) Scale-Up,,Recruiting,No Results Available,Opioid-use Disorder|Hiv,Drug: Naltrexone Injectable Suspension|Other: Treatment as usual,HIV Viral Suppression|Veterans Aging Cohort Study (VACS) Index|Cluster of Differentiation 4 (CD4)|Engagement in HIV Care: Antiretroviral Therapy Prescribed|Engagement in HIV Care: Antiretroviral Therapy Adherence|Engagement in HIV Care: Retention in HIV Care|Engagement in HIV Care: HIV Risk Behaviors|Engagement in HIV Care: Quality of Life|Antiretroviral Therapy Adherence Mediation Variables: Days of Opioid Use|Antiretroviral Therapy Adherence Mediation Variables: Opioid Abstinence,Oregon Health and Science University|National Institute on Drug Abuse (NIDA)|Johns Hopkins University|University of Kentucky|Whitman-Walker Health|Jackson Health System|Florida Department of Health|Tarzana Treatment Centers|Ruth M. Rothstein CORE Center,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,350,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Clinical Trials Network-0067,2018-02-05,2020-03-06,2020-03-06,2017-09-07,null,2018-07-31,"Tarzana Treatment Centers, Tarzana, California, United States|Whitman-Walker Health, Washington, District of Columbia, United States|Jackson Memorial Hospital, Miami, Florida, United States|Florida Department of Health - Sunshine Care Clinic, Orlando, Florida, United States|Ruth M. Rothstein CORE Center, Chicago, Illinois, United States|University of Kentucky Bluegrass Care Clinic, Lexington, Kentucky, United States|Johns Hopkins University, Bartlett Specialty Clinic, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT03275350
795,NCT00332228,Behavioral Naltrexone Therapy: A Novel Treatment for Heroin Dependence,,Completed,No Results Available,Opiate Dependence,Drug: depot naltrexone|Behavioral: Compliance enhancement (CE)|Drug: BNT,proportion of patients relapsing to illicit opiates based on urine toxicology and self report.|proportion of patients retained in treatment,New York State Psychiatric Institute|National Institute on Drug Abuse (NIDA),All,18 Years to 60 Years   (Adult),Phase 2,125,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",5004-R|R01DA010746,2002-06-01,2007-12-01,2007-12-01,2006-06-01,null,2012-10-26,"New York State Psychiatric Institute, New York, New York, United States|STARS, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00332228
796,NCT00316277,Prescription Opioid Addiction Treatment Study (POATS),,Completed,Has Results,Opiate Dependence|Substance-related Disorders|Opioid-related Disorders,Behavioral: Standard Medical Management (SMM) of Prescription Opiate Abuse|Behavioral: Enhanced Medical Management (EMM) of Prescription Opiate Abuse,"The Number of Participants Attaining Successful Opioid Use Outcome by Counseling Condition at End of Phase 1|The Number of Participants Attaining Successful Opioid Use Outcome by Counseling Condition, Phase 2 End of Treatment|The Number of Participants Attaining Successful Opioid Use Outcome by Counseling Condition Phase 2, 8-week Posttreatment Follow-up|The Number of Participants Attaining Successful Opioid Use Outcomes in Phase 1 by Chronic Pain Condition|The Number of Participants Attaining Successful Opioid Use Outcomes in Phase 2 by Chronic Pain Condition|The Number of Participants With and Without Any Lifetime Use of Heroin Attaining Successful Opioid Use Outcomes in Phase 1|The Number of Participants With and Without Any Lifetime Use of Heroin Attaining Successful Opioid Use Outcomes in Phase 2","Mclean Hospital|University of California, Los Angeles",All,"18 Years and older   (Adult, Older Adult)",Phase 3,653,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NIDA-CTN-0030,2006-05-01,2009-07-01,2013-01-01,2006-04-20,2012-07-27,2013-02-06,"Integrated Substance Abuse Programs, Los Angeles, California, United States|San Francisco General Hospital, San Francisco, California, United States|East Indiana Treatment Center, Lawrenceburg, Indiana, United States|McLean Hospital, Alcohol and Drug Abuse Treatment Program, Belmont, Massachusetts, United States|North Shore - Long Island Jewish Health Systems, Glen Oaks, New York, United States|Bellevue Hospital Center, New York, New York, United States|St. Luke's Roosevelt Hospital Center, New York, New York, United States|ADAPT, Inc., Roseburg, Oregon, United States|Behavioral Health Services of Pickens County, Pickens, South Carolina, United States|Homeward Bound, Inc., Dallas, Texas, United States|Providence Behavioral Health Service, Everett, Washington, United States|Chestnut Ridge Hospital, Morgantown, West Virginia, United States",,https://ClinicalTrials.gov/show/NCT00316277
797,NCT00271219,RCT Comparing Methadone and Buprenorphine in Pregnant Women,,Completed,Has Results,Opioid Related Disorders|Pregnancy|Opioid Dependence,Drug: Methadone|Drug: Buprenorphine,Child's Head Circumference Measurement (Measured at Birth)|Child's Length of Hospital Stay|Number of Children Requiring Treatment for Neonatal Abstinence Signs (NAS)|Child's Peak Daily Total NAS Score|Total Amount of Morphine Sulfate That a Neonate Receives to Treat NAS|Mother's Self-report of Drug Use (Measured Monthly by Time Line Follow Back)|Mother's HIV Risk Behaviors (Measured Monthly by Risk Behavior Assessment)|Mother's Measures of Dose Adequacy and Acceptance Over Time (Measured Weekly by Dose Adequacy Measure)|Mother's Psychosocial Functioning at Delivery as Measured by the Addiction Severity Index Psychosocial Index Score,Johns Hopkins University|National Institute on Drug Abuse (NIDA),Female,18 Years to 41 Years   (Adult),Phase 3,175,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R01DA15764-1|R01DA015764|DPMC,2005-07-01,2009-08-01,2010-06-01,2005-12-30,2015-08-05,2015-08-05,"Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Wayne State University, Detroit, Michigan, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Brown University, Providence, Rhode Island, United States|Vanderbilt University, Nashville, Tennessee, United States|University of Vermont, Burlington, Vermont, United States|Medical University of Vienna, Vienna, Austria|St. Joseph's Health Centre, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00271219
798,NCT01160614,Pharmacokinetics and Safety of ORF Tablets in Pediatric Patients,,Completed,Has Results,Opioid Analgesia,Drug: Oxycodone hydrochloride controlled-release (ORF) tablets,Single-dose PK Metric: Area Under the Plasma Concentration-time Curve From Hour 0 to the Last Measurable Plasma Concentration [AUCt]|Single-dose PK Metric: Area Under the Plasma Concentration-time Curve Extrapolated to Infinity (AUCinf)|Single-dose PK Metric: Maximum Observed Plasma Concentration (Cmax)|Single-dose PK Metric: Time to Maximum Plasma Concentration (Tmax)|Single-dose PK Metric: Apparent Terminal Phase Rate Constant (Lamda z)|Single-dose PK Metric: Apparent Plasma Terminal Phase Half/Life (t1/2z)|Single-dose PK Metric: Lag Time Was Estimated as the Time Point Immediately Prior to the First Measurable Plasma Concentration Value (Tlag)|Single- and Multiple-dose PK Metric: Mean Area Under the Plasma Concentration During Each Dosing Interval-time Curve From Hour 0 to 12 Hours of the First Dose of ORF (AUC 0-12)|Single- and Multiple-dose PK Metric: Maximum Observed Plasma Concentration From Hour 0 to 12 Hours of the First Dose of ORF (Cmax 0-12)|Single- and Multiple-dose PK Metric: Time to Maximum Plasma Concentration From Hour 0 to 12 Hours of the First Dose of ORF (Tmax 0-12)|Single- and Multiple-dose PK Metric: Lag Time Estimated as the Time Point Immediately Prior to the First Measurable Plasma Concentration Value From Hour 0 to 12 Hours of the First Dose of ORF (Tlag 0-12)|The Number of Patients With Adverse Events as a Measure of Safety|Multiple-dose PK Metric: Minimum Observed Plasma Concentration Just Prior to the Next Dose (Cmin),Purdue Pharma LP,All,6 Years to 16 Years   (Child),Phase 1,30,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),OTR1020|2010-020510-29,2010-07-01,2011-08-01,2011-08-01,2010-07-12,2012-08-21,2012-10-15,"Maricopa Medical Center, Phoenix, Arizona, United States|Arkansas Childrens Hospital, Little Rock, Arkansas, United States|LS Packard Children's Hospital, Palo Alto, California, United States|The Children's Hospital Association, Aurora, Colorado, United States|Research Facility, Miami, Florida, United States|F3900 C.S. Mott Children's Hospital, Ann Arbor, Michigan, United States|Akron Children's Hospital, Akron, Ohio, United States|The Children's Hospital at OUMC, Oklahoma City, Oklahoma, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Children's Med Center of Dallas, Dallas, Texas, United States|Scott & White Memorial Hospital & Clinic, Temple, Texas, United States|University of Washington School of Medicine - Harborview Medical Center, Seattle, Washington, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|The Royal Children's Hospital, Parkville, Australia|Helsinki University Central Hospital/Children and Adolescent Hospital, Helsinki, Finland|Kuopio University Hospital/Operative Services and Intensive Care, Kuopio, Finland|Waikato Clinical Research (2008) Ltd, Hamilton, New Zealand",,https://ClinicalTrials.gov/show/NCT01160614
799,NCT03044522,Use of a Nurse Pain Educator for Patients With Chronic Pain,,Completed,No Results Available,Chronic Pain|Opioid Use|Nurse's Role,Other: Opioid Education,Change in Opioid Consumption|Change Opioid Consumption|Change in Current Opioid Misuse Measure (COMM)|Change in Pain Medicine Questionnaire (PMQ)|Change in SF-36|Change in Quality of Life Scale,"NEMA Research, Inc.|Food and Drug Administration (FDA)",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,183,Industry|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,NEMA-SUPeR-001,2016-11-14,2017-09-21,2017-11-21,2017-02-07,null,2017-12-11,"Headache and Pain Management Center of SWFL, Fort Myers, Florida, United States|Gold Coast Research, Plantation, Florida, United States|Mid America Physiatrists, Overland Park, Kansas, United States|Piedmont Family Practice, Warrenton, Virginia, United States",,https://ClinicalTrials.gov/show/NCT03044522
800,NCT02741076,Structured Discontinuation vs Continued Therapy in Suboptimal and Optimal Responders to High-dose Long-term Opioids for Chronic Pain,,"Active, not recruiting",No Results Available,Opioid-Related Disorders|Opiate Addiction|Narcotic Abuse|Drug Abuse,Drug: Morphine Sulfate ER|Drug: Oxycodone ER|Drug: Oxymorphone ER,Change in the mean Average Pain Intensity (PI) score on the 0-10 Numerical Ratings Scale (NRS)|Change from baseline in the Average Pain Intensity (PI) score on the 0-10 Numerical Ratings Scale (NRS) over 1 week prior to each visit.|Percentage of patients whose Pain Intensity (PI) score has improved since baseline.|Change from baseline in physical function (RMDQ)|Change from baseline in the Worst Pain Intensity (PI) score on the 0-10 Numerical Ratings Scale over 1 week prior to each visit|Percentage of patients whose Pain Intensity (PI) score has worsened since baseline.|Change from baseline on impact of pain on function (BPI-SF)|Change from baseline on pain quality (PQAS)|Change from baseline on pain spread (Regional Pain Scale)|Change from baseline on sleep quality (MOS Sleep Scale)|Change from baseline on mood (PHQ-8)|Change from baseline on quality of life (EQ-5D-5L)|Change from baseline on work productivity (WPAI),Member Companies of the Opioid PMR Consortium,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,820,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2065-5,null,2019-02-01,null,2016-04-18,null,2018-07-04,"G & L Research, Foley, Alabama, United States|Horizon Research Partners, Mobile, Alabama, United States|Healthscan Clinical Trials, Montgomery, Alabama, United States|Center for Pain and Supportive Care, Phoenix, Arizona, United States|The Pain Center of Arizona, Phoenix, Arizona, United States|Quality of Life Medical and Research Centers, Tucson, Arizona, United States|Coastal Pain and Spinal Diagnostics, Carlsbad, California, United States|Aviva Research, Escondido, California, United States|Global Clinical Trials, Irvine, California, United States|The Helm Center for Pain Management, Laguna Woods, California, United States|Alexander Ford, MD, Los Angeles, California, United States|Samaritan Center for Medical Research, Los Gatos, California, United States|Catalina Research Institute, Montclair, California, United States|North Country Clinical Research, Oceanside, California, United States|Westview Clinical Research, Placentia, California, United States|Foothills Pain Management Clinic, Pomona, California, United States|Northern California Research, Sacramento, California, United States|Breakthrough Clinical Trials, San Bernardino, California, United States|Optimus Medical Group, San Francisco, California, United States|Mountain View Clinical Research, Denver, Colorado, United States|Care Research Center, Doral, Florida, United States|Direct Helpers Research Center, Hialeah, Florida, United States|Eastern Research, Hialeah, Florida, United States|Empire Clinical Research, Miami Lakes, Florida, United States|Finlay Medical Research, Miami, Florida, United States|Future Clinical Research, Miami, Florida, United States|South Florida Clinical Research, Miami, Florida, United States|Martin E Hale, MD, Plantation, Florida, United States|Florida Medical Pain Management, Saint Petersburg, Florida, United States|Clinical Research of West Florida, Tampa, Florida, United States|Palm Beach Research Center, West Palm Beach, Florida, United States|Georgia Institute for Clinical Research, Marietta, Georgia, United States|Sestron Clinical Research, Marietta, Georgia, United States|Healthcare Research Network II, Blue Island, Illinois, United States|Indiana Pain and Spine Clinic, South Bend, Indiana, United States|Mid-American Psysiatrists, Overland Park, Kansas, United States|WK River Cities Clinical Research Center, Shreveport, Louisiana, United States|MedVadis Research Corporation, Watertown, Massachusetts, United States|Oakland Medical Research, Troy, Michigan, United States|Healthcare Research Network, Hazelwood, Missouri, United States|St Louis Clinical Trials, Saint Louis, Missouri, United States|Red Rock Clinical Research, Las Vegas, Nevada, United States|OnSite Clinical Solutions, Mooresville, North Carolina, United States|Clinical Trials of America, Winston-Salem, North Carolina, United States|The Center for Clinical Research, Winston-Salem, North Carolina, United States|Prestige Clinical Research, Franklin, Ohio, United States|North Star Medical Research, Middleburg Heights, Ohio, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|Medical Research International, Oklahoma City, Oklahoma, United States|SP Research, Oklahoma City, Oklahoma, United States|Brandywine Clinical Research, Downingtown, Pennsylvania, United States|Founders Research Corporation, Philadelphia, Pennsylvania, United States|Carolina Center for Advanced Management of Pain, Spartanburg, South Carolina, United States|Healthy Concepts, Rapid City, South Dakota, United States|Comprehensive Pain Specialists, Hendersonville, Tennessee, United States|New Phase Research and Development, Knoxville, Tennessee, United States|Biopharma Informatic Research Center, Houston, Texas, United States|Coastal Medical Group, Houston, Texas, United States|Highland Clinical Research, Salt Lake City, Utah, United States|Interventional Pain and Spine Specialists, Chester, Virginia, United States|Healing Hands of Virginia, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02741076
801,NCT01908842,Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults,ISTART,Completed,Has Results,"Opioid Dependence, on Agonist Therapy",Drug: BNX sublingual tablets|Drug: BNX sublingual film|Drug: Buprenorphine,Primary Endpoints of Retention in Treatment at Days 3 and 15|Clinical Opiate Withdrawal Scale (COWS) Scores: Induction|COWS Total Scores: Stabilization/Maintenance|Subjective Opiate Withdrawal Scale (SOWS) Scores: Induction|SOWS Total Scores: Stabilization/Maintenance|Visual Analog Scale (VAS) Cravings: Induction|VAS Craving Scores: Stabilization/Maintenance,Orexo AB|Worldwide Clinical Trials,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,759,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",OX219-006 Protocol Amendment 4,2013-08-01,2014-04-01,2014-04-01,2013-07-26,2015-05-22,2017-05-10,"Baldwin County, Alabama, United States|Houston County, Alabama, United States|Maricopa, Arizona, United States|Beverly Hills, California, United States|Los Angeles County, California, United States|Riverside County, California, United States|San Diego County, California, United States|Broward County, Florida, United States|Colombia County, Florida, United States|Duval County, Florida, United States|Greater Metro Orlando, Florida, United States|Lake County, Florida, United States|Miami-Dade County, Florida, United States|Osceola County, Florida, United States|Palm Beach County, Florida, United States|DeKalb County, Georgia, United States|Chicagoland, Illinois, United States|Johnson County, Kansas, United States|Kenton County, Kentucky, United States|Caddo Parish, Louisiana, United States|Baltimore County, Maryland, United States|Bristol County, Massachusetts, United States|St. Louis Metro Area, Missouri, United States|Camden County, New Jersey, United States|Warren County, New Jersey, United States|Warren County, Ohio, United States|Oklahoma County, Oklahoma, United States|Portland metropolitan area, Oregon, United States|Allegheny County, Pennsylvania, United States|Delaware County, Pennsylvania, United States|Philadelphia County, Pennsylvania, United States|Charleston County, South Carolina, United States|Dallas County, Texas, United States|Salt Lake County, Utah, United States|Charlottesville metropolitan area, Virginia, United States|Benton County, Washington, United States",,https://ClinicalTrials.gov/show/NCT01908842
802,NCT00078117,Suboxone: (Buprenorphine/Naloxone) Comparison of Two Taper Schedules - 1,,Completed,No Results Available,Opioid-Related Disorders,Drug: Buprenorphine,Opiate abstinence,"University of California, Los Angeles|National Institute on Drug Abuse (NIDA)",All,"15 Years to 99 Years   (Child, Adult, Older Adult)",Phase 3,516,Other,Interventional,Primary Purpose: Treatment,NIDA-CTN-0003-1,2003-06-01,2005-05-01,2005-05-01,2004-02-20,null,2017-01-12,"Addiction Research & Treatment Services (ARTS), Denver, Colorado, United States|Denver Health & Hospitals Authority, Denver, Colorado, United States|Hartford Dispensary, Hartford, Connecticut, United States|Connecticut Counseling Centers, Waterbury, Connecticut, United States|LI Jewish Health System, Glen Oaks, New York, United States|New York VA Medical Center, New York, New York, United States|South Light-Wakeview Clinic, Raleigh, North Carolina, United States|Coastal Horizons Center, Inc., Wilmington, North Carolina, United States|CODA, Portland, Oregon, United States|Norfolk CSB, Norfolk, Virginia, United States|Providence Behavioral Health Services, Everett, Washington, United States",,https://ClinicalTrials.gov/show/NCT00078117
803,NCT03366805,A Patient Education Video Program for Post-Operative Recovery After Upper Extremity Surgery,,Recruiting,No Results Available,"Analgesics, Opioid|Orthopedic Surgery|Ambulatory Surgery|Education, Patient|Injuries and Wounds",Behavioral: Pain Management Patient Education Video|Behavioral: Wound Care Patient Education Video,Quality of Recovery 15 Score|PROMIS|number of narcotic pills used|daily pain level|patient-reported satisfaction and feeling of control - pain management|patient-reported satisfaction and feeling of control- wound care|patient-reported satisfaction and feeling of control - pain management satisfaction|number of pain-related calls/visits to a healthcare provider|use of non-narcotic adjunct pain relief medication and modalities|incidence of high risk activities - sedating medication polytherapy|incidence of high risk activities - NSAID polytherapy|incidence of high risk activities - overdosing|incidence of side effects and adverse events - Nausea/V omitting|incidence of side effects and adverse events - Dizziness/balance problems|incidence of side effects and adverse events - fatigue or sedation|incidence of side effects and adverse events - headache|incidence of side effects and adverse events - visual changes|incidence of side effects and adverse events - stomach pain|incidence of side effects and adverse events - constipation|incidence of side effects and adverse events - diarrhea|incidence of side effects and adverse events - fever|incidence of side effects and adverse events - rash|incidence of side effects and adverse events - hives|incidence of side effects and adverse events - swelling|incidence of side effects and adverse events - difficulty breathing/shortness of breath|incidence of side effects and adverse events - heart palpitations/arrythmia/heart racing|incidence of side effects and adverse events - anaphylaxis|incidence of side effects and adverse events - ringing in ears|incidence of side effects and adverse events - other|demonstrated patient knowledge|prevalence of chronic opioid use,Carilion Clinic,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,400,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Supportive Care,2266,2017-11-30,2018-11-29,2019-12-12,2017-12-08,null,2017-12-08,"Institute for Orthopedics and Neurosciences, Roanoke, Virginia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT03366805/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT03366805/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03366805
804,NCT02657317,Establishing Efficacy of a Functional-Restoration Based CAM Pain Management Program in Post-9/11 Veterans,,Recruiting,No Results Available,Chronic Pain|Traumatic Brain Injury|Posttraumatic Stress Disorder|Depression|Opioid Use Disorder,Behavioral: FORT-A|Other: VA Treatment as Usual,Change in Oswestry Disability Index|Change in Lifting Capacity|Change in Aerobic Capacity|Change in Gait|Change in Range of Motion|Timeline Followback Interview for Opioid Medication Use (dose frequency)|Timeline Followback Interview for Opioid Medication Use (# pills),The University of Texas Health Science Center at San Antonio|South Texas Veterans Health Care System,All,"18 Years to 72 Years   (Adult, Older Adult)",Not Applicable,130,Other|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R01AT008422-01|HSC20140396,2016-01-01,2019-08-01,2019-08-01,2016-01-15,null,2017-09-19,"South Texas Veterans Health Care System, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT02657317
805,NCT00326235,Effects of Buspirone in Opiate Withdrawal,,Completed,No Results Available,Heroin Dependence,Drug: Buspirone,,National Institute on Drug Abuse (NIDA),All,25 Years to 55 Years   (Adult),Phase 4,null,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,R01DA013264,2002-01-01,null,2004-07-01,2006-05-16,null,2017-01-12,"VA New York Harbor Healthcare System - Brooklyn Campus, Brooklyn, New York, United States",,https://ClinicalTrials.gov/show/NCT00326235
806,NCT03557632,University of Houston Drug Abuse Research Development Program II,UHDARDP-II,Recruiting,No Results Available,Heroin Dependence,Behavioral: Virtual Reality Cue Exposure Therapy|Behavioral: Relapse Prevention Drug Education,Self-reported reactivity to cues|Lab-based reactivity to cues|Number of times of self-reported drug use in vivo during the week between lab sessions.,University of Houston|National Institute on Drug Abuse (NIDA),All,18 Years to 64 Years   (Adult),Not Applicable,100,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,5R24DA019798-08 REVISED|5R24DA019798,2014-08-01,2019-08-31,2020-03-31,2018-06-15,null,2018-08-06,"University of Houston Virtual Reality Clinical Research Lab, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03557632
807,NCT00414024,Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.,,Terminated,No Results Available,Opioid-induced Constipation,Drug: Tegaserod,To evaluate the long term safety of tegaserod|Change from baseline assessment of OIC symptoms at weeks 24 and 52|Change from baseline assessment of opioid-induced mid/upper GI symptoms at weeks 24 and 52|Patients weekly assessment of intensity of pain for which opioids were prescribed at weeks 24 and 52,Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 3,11,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CHTF919N2302,2007-02-01,2007-05-01,2007-05-01,2006-12-20,null,2012-04-20,"60 Investigative Sites, East Hanover, New Jersey, United States|2 Investigative Sites, Hong Kong, China|6 Investigative Sites, Egypt, Egypt|1 Investigative Site, Singapore, Singapore|2 Investigative Sites, Taiwan, Taiwan|4 Investigative Sites, Venezuela, Venezuela",,https://ClinicalTrials.gov/show/NCT00414024
808,NCT00124358,Buprenorphine and Integrated HIV Care Evaluation,,Unknown status,No Results Available,Opioid-Related Disorders|HIV Infections|AIDS,Drug: Buprenorphine|Behavioral: Integrated HIV care and office-based opioid dependence treatment,"Substance use outcomes at 1, 3 and 6 months measured by self-report|Urine toxicology results at 1, 3, 6, and 12 months|Retention in and adherence to HIV care at 1, 3, 6, and 12 months|Quality of life at 1, 3, 6, 9, and 12 months|HIV-related health outcomes at 1, 3, 6, 9, and 12 months","The New York Academy of Medicine|Health Resources and Services Administration (HRSA)|El Rio Santa Cruz Neighborhood Health Center|Organization to Achieve Solutions in Substance Abuse (OASIS)|Oregon Health and Science University|Montefiore Medical Center|University of Miami|Brown University|University of California, San Francisco|Johns Hopkins University|CORE Center, Cook County Bureau of Health Services|Yale University",All,"18 Years and older   (Adult, Older Adult)",Phase 4,1350,Other|U.S. Fed,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,063005|H97HA03795,2005-08-01,null,2008-12-01,2005-07-27,null,2007-03-27,"El Rio Santa Cruz Neighborhood Health Center, Tucson, Arizona, United States|Organization to Achieve Solutions in Substance Abuse, Oakland, California, United States|University of California San Francisco, San Francisco, California, United States|Yale University School of Medicine AIDS Program, New Haven, Connecticut, United States|University of Miami School of Medicine, Miami, Florida, United States|The CORE Center, Chicago, Illinois, United States|Johns Hopkins University, Baltimore, Maryland, United States|Montefiore Medical Center, New York, New York, United States|Oregon Health & Science University, Portland, Oregon, United States|The Miriam Hospital, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT00124358
809,NCT01422837,ALK21-025: Vivitrol's Cost and Treatment Outcomes Registry,VICTORY,Completed,No Results Available,Opioid Dependence,,,"Alkermes, Inc.",All,"18 Years and older   (Adult, Older Adult)",,403,Industry,Observational,Time Perspective: Prospective,ALK21-025,2011-08-01,2013-10-01,2013-10-01,2011-08-24,null,2014-08-07,"Assisted Recovery Centers of America, Phoenix, Arizona, United States|Arkansas Psychiatric Clinc, Little Rock, Arkansas, United States|Amy Solomon, MD, Ben Lomond, California, United States|Touchstone Medical Group, Clovis, California, United States|Kenneth C. Russ, MD, Palm Springs, California, United States|Tarzana Treatment Centers, Tarzana, California, United States|The NeuroBehavioral Institute of Colorado, PC, Lone Tree, Colorado, United States|Psychotherapy Services, Etc., Groton, Connecticut, United States|Jacqueline Boutrouille, MD, Tamarac, Florida, United States|Alliance Clinical Research, Winter Park, Florida, United States|Atlanta Institute of Medicine and Research, Atlanta, Georgia, United States|PACT Atlanta, Decatur, Georgia, United States|Gosnold-Thorne Counseling Center, Centerville, Massachusetts, United States|Dr. Li's Clinic, Milford, Massachusetts, United States|Assisted Recovery Centers of America, St. Louis, Missouri, United States|Dent Neurologic Institute, Amherst, New York, United States|Dr. Michael Sanders, Great Neck, New York, United States|Fakhouri Medical, Hopewell Junction, New York, United States|Parallax Center, New York, New York, United States|Healing Comfort Clinic, Corvalis, Oregon, United States|Jasper Health, Media, Pennsylvania, United States|Institute of Addiction Medicine, Plymouth Meeting, Pennsylvania, United States|Innovation Laboratory/PEARL, Johnson City, Tennessee, United States|Urschel Recovery Science Institute, Dallas, Texas, United States|Holiner Psychiatric Group, Dallas, Texas, United States|Lenae White, MD, PA, Dallas, Texas, United States|Utah Addiction Medicine & Counseling, Bountiful, Utah, United States|Adolescent and Family Health Center, PC, Midlothian, Virginia, United States|Chessen and Associates, Newport News, Virginia, United States|Creekside Center for Integrative Medicine, Bellevue, Washington, United States|Child and Adolescent Psychiatry, Bothell, Washington, United States",,https://ClinicalTrials.gov/show/NCT01422837
810,NCT02218736,Fast-Fail Trials in Mood and Anxiety Spectrum Disorders; Kappa Opioid Receptor Phase 2a,FASTMAS_Kor2,Completed,No Results Available,ANXIETY DISORDERS (or Anxiety and Phobic Neuroses),Drug: CERC-501|Drug: placebo,Functional MRI evaluation of task-related ventral striatal activation occurring with reward and anticipation during the Monetary Incentive Delay Task|Clinical Anhedonia measured by the Snaith-Hamilton Pleasure Scale (SHAPS; total score)|Behavioral measure of anhedonia using the Probabilistic Reward Task,Duke University|Yale University|Baylor College of Medicine|Indiana University|Icahn School of Medicine at Mount Sinai|Case Western Reserve University,All,"21 Years to 65 Years   (Adult, Older Adult)",Phase 2,89,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research",Pro00052485|HHSN271201200006I,2015-06-01,2017-11-01,2017-12-01,2014-08-18,null,2018-03-26,"Yale University, New Haven, Connecticut, United States|Andrew Goddard, MD, Indianapolis, Indiana, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|CaseWestern Reserve University, Cleveland, Ohio, United States|Baylor College of Medicine, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02218736
811,NCT00757744,Behavioral Drug and HIV Risk Reduction Counseling in Methadone Patients in China,,Completed,No Results Available,Opiate Dependence|HIV Infections,Behavioral: Behavioral Drug and HIV Risk Reduction Counseling (BDRC)|Behavioral: Drug counseling,Reductions of illicit opiate use|Reductions in HIV risk behaviors,Yale University|National Institute on Drug Abuse (NIDA),All,"20 Years and older   (Adult, Older Adult)",Phase 3,45,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R01DA014718-05A1S1|NIDA grant R01DA014718-05A1S1,2007-09-01,2010-01-01,2010-09-01,2008-09-23,null,2011-05-18,"Yale University School of Medicine - CMHC, New Haven, Connecticut, United States|Wuhan Center for Disease Control and Prevention, Wuhan, Hubei, China",,https://ClinicalTrials.gov/show/NCT00757744
812,NCT00383045,HIV Risk Reduction and Drug Abuse Treatment in Malaysia,,Completed,No Results Available,Opiate Dependence,Drug: Buprenorphine/Subutex|Drug: Naltrexone|Procedure: Drug counseling,Time to resumption of heroin use|Time to relapse|Maximum consecutive weeks of opiate abstinence|Reduction of HIV risks|Addiction-related functional status|Adverse events,Yale University|National Institute on Drug Abuse (NIDA),Male,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,180,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double|Primary Purpose: Treatment,R01DA014718-04,2003-04-01,null,2007-08-01,2006-10-02,null,2009-02-24,"Yale University School of Medicine, New Haven, Connecticut, United States|Substance Abuse Research Center, Muar, Johor, Malaysia",,https://ClinicalTrials.gov/show/NCT00383045
813,NCT01592461,Starting Treatment With Agonist Replacement Therapies Follow-up Study,,Completed,No Results Available,Opioid Dependence,,Opioid use as determined by the Timeline Follow Back measure|mortality,"University of California, Los Angeles|National Institute on Drug Abuse (NIDA)",All,"18 Years and older   (Adult, Older Adult)",,877,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,CTN-0050|U10DA013045,2010-09-01,2016-08-01,2016-08-01,2012-05-07,null,2016-08-08,"Matrix Institute on Addictions, Los Angeles, California, United States|Bi-Valley Medical Clinic, Inc., Sacramento, California, United States|BAART Programs, San Francisco, California, United States|Hartford Dispensary, Hartford, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States|CODA, Inc., Portland, Oregon, United States|NET Steps, Philadelphia, Pennsylvania, United States|Evergreen Treatment Services, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01592461
814,NCT00241930,Integrating Buprenorphine Into HIV Treatment,,Unknown status,No Results Available,Opiate Dependence|HIV Infections,Behavioral: Integrating drug treatment into HIV services,"1.Impact of integrated care vs nonintegrated care on:|a. Substance use and high-risk transmission behaviors|b. Medical engagement and outcomes|c. Psychosocial indices, such as criminal justice, employment, housing, and education|1. Acceptability of HIV treatment-based buprenorphine therapy|2. Health services utilization",Organization to Achieve Solutions in Substance Abuse (OASIS),All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 4,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H97HA03792|1 H97HA03792-01-00,2005-09-01,null,2009-02-01,2005-10-19,null,2005-10-25,"Alameda County Medical Center HIV Clinic, Oakland, California, United States|OASIS, Oakland, California, United States|Fairmont Hospital HIV Clinic, San Leandro, California, United States",,https://ClinicalTrials.gov/show/NCT00241930
815,NCT02363998,"Open-Label, Safety Study of Lofexidine",NU LEAF,Completed,No Results Available,Opioid Withdrawal,Drug: Lofexidine,Occurrence of Adverse Events (AEs)|Vital Signs|12-Lead Electrocardiograms|Pharmacokinetic Sampling|Physical Examination|Columbia Suicide Severity Rating Scale (C-SSRS)|Short Opiate Withdrawal Scale of Gossop (SOWS-Gossop)|Clinical Opiate Withdrawal Scale (COWS)|Assessment of Completion of Pre-Defined Withdrawal Treatment Goal|Evaluation of subject treatment status 30 days after last dose|Concomitant medication administration|Clinical laboratory tests,US WorldMeds LLC|National Institute on Drug Abuse (NIDA),All,"18 Years and older   (Adult, Older Adult)",Phase 3,286,Industry|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,USWM-LX1-3003-2|1U01DA033276-01A1,2015-02-01,2015-09-01,2015-10-01,2015-02-16,null,2018-02-26,"Little Rock, Arkansas, United States|Springdale, Arkansas, United States|San Diego, California, United States|Fort Lauderdale, Florida, United States|Hollywood, Florida, United States|Orlando, Florida, United States|Atlanta, Georgia, United States|Winfield, Illinois, United States|Lake Charles, Louisiana, United States|Rockville, Maryland, United States|Flowood, Mississippi, United States|Saint Louis, Missouri, United States|New York, New York, United States|Dayton, Ohio, United States|Portland, Oregon, United States|Pittsburgh, Pennsylvania, United States|North Charleston, South Carolina, United States|Orem, Utah, United States",,https://ClinicalTrials.gov/show/NCT02363998
816,NCT03187080,Enhanced Recovery Strategies in Elective Breast Surgery,,Recruiting,No Results Available,"Pain, Acute|Nausea|Vomiting, Postoperative|Opioid Use|Satisfaction",Procedure: Paravertebral block procedure using either local anesthetic (0.25% bupivacaine) or sterile saline|Other: Enhanced recovery after breast surgery (ERABS) strategies|Procedure: Sham paravertebral block using saline|Drug: Paravertebral block using local anesthetic,"Numerical Pain Scores, rated by patient on 0-10 scale|Time spent in each phase of care prior to discharge|Time to discharge to home|Analgesic requirements (pain medication quantity)|Post-operative nausea and vomiting (subjective report)|Anti-emetic requirements (anti-nausea medication quantity)|Patients' assessment of perceived quality of recovery using Modified Quality of Recovery Survey (MQOR-40)","University of Wisconsin, Madison",Female,"18 Years and older   (Adult, Older Adult)",Phase 4,296,Other,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",UW 2016-1388,2017-09-01,2021-09-01,2021-12-30,2017-06-14,null,2017-09-01,"University of Wisconsin Madison, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT03187080
817,NCT01558973,FMRI of Stress and Addictive Disorders,,Completed,No Results Available,Cocaine Dependence|Opioid Dependence|Alcoholism|Pathological Gamblers|Adolescents,,Neural responses to change will be measured.,Yale University|National Institutes of Health (NIH)|National Institute on Drug Abuse (NIDA),All,"13 Years to 50 Years   (Child, Adult)",,108,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,0405026787|2P50DA016556-08,2005-08-01,2015-12-01,null,2012-03-20,null,2016-11-30,"Yale Stress Center, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01558973
818,NCT02334111,RESPECT-PLUS: Services for Infants With Prenatal Opiate Exposure,RESPECT-Plus,Completed,No Results Available,Opioid Use Disorder|Neonatal Abstinence Syndrome|Child Development|Child Abuse|Child Neglect,Behavioral: RESPECT-Plus,"Time to Change in Custody|Improvements in parental resilience and parenting aligned with the Strengthening Families model (parental resilience, knowledge of parenting and child development, concrete supports, social connections, and child well-being)",Boston Medical Center,All,up to 21 Days   (Child),Not Applicable,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,HHS-2012-ACF-ACYF-CB-0286,2013-07-01,2016-09-01,2016-09-01,2015-01-08,null,2017-01-16,"Boston Medical Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02334111
819,NCT02801357,Study to Evaluate the Exposures of Lofexidine and Its Major Metabolites in Subjects Seeking Buprenorphine Dose Reduction,,Completed,No Results Available,Substance Withdrawal Syndrome|Opiate Addiction|Opiate Dependence,Drug: lofexidine administration in subjects seeking buprenorphine dose reduction,"Predose and peak metabolite (N-[2- aminoethyl-2-[2,6-dichlorophenoxy] propanamide [LADP], 2-[2,6-dichlorophenoxy] propionic acid [LDPA] and 2,6-Dichlorophenol [2,6-DCP]) plasma concentration to lofexidine (parent) ratios on each day of treatment|Modified Clinical Global Impression - subject and observer|Visual Analog Scale for Efficacy|Columbia Suicide Severity Rating Scale (C-SSRS)|Holter ECGs|Blood pressure and pulse (sitting and standing)|Laboratory Assessments|Oral temperature and respiration|12-Lead ECG|Adverse Events Assessment|Urine drug screening|Concomitant medications|Physical exam",US WorldMeds LLC,All,18 Years to 64 Years   (Adult),Phase 1,10,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,USWM- LX1-1013,2016-06-01,2016-08-01,2016-08-01,2016-06-15,null,2017-10-26,"Overland Park, Kansas, United States",,https://ClinicalTrials.gov/show/NCT02801357
820,NCT00609089,Community Reinforcement and Family Training for Drug Abuse Treatment Retention/HIV Risk Reduction,,Unknown status,No Results Available,Heroin Dependence|Opiate Dependence|Substance Dependence,Behavioral: CRAFT-T|Behavioral: Treatment as usual,"The primary outcome is retention in drug abuse treatment, specifically time to first drop from services for at least 3 weeks duration.|The Identified Patient's engagement in behaviors that increase the risk of contracting HIV, as measured by the RAB|The concerned significant other's (CSO's) engagement in behaviors that increase the risk of contracting HIV, as measured by the RAB,|The identified patient's successful completion of drug abuse treatment episode|The portion of available treatment sessions attended during each assessment period including,|Substance use (defined as days of self-reported substance use, with partial confirmation by urinalysis and breathalyzer) during the active study phase and through the 3 month and 6-month follow-ups.|The identified patient's substance use as reported by the CSO (collateral reports of drug use).|Changes in concerned significant other and identified patient function as measured using the Brief Symptom Inventory. Specifically, the Global Severity Index (GSI) score.|Concerned significant other and identified patient's relationship satisfaction (the score on the General Happiness Scale of the RHS).|Marital satisfaction as measured by the KMS for the sub-sample of concerned significant others who are married to their identified patient's.|The identified patient's (IP) retention in any substance abuse specific intervention, including self-help, as reported by the IP on the Treatment tracking form.|The identified patient's retention in any substance abuse specific intervention, including self-help, as reported by CSO on the Treatment Tracking form.|Identified patient (IP) attendance at self-help groups (i.e., AA, NA, CA) (defined as the number of times that the IP has attended a self-help group as assessed on the Treatment Services Review).|Identified patient's use of professional services, other than substance abuse treatment, as reported on the TSR.|Concerned significant others satisfaction with treatment as measured by the Participant Satisfaction Form.|Identified patient's satisfaction with treatment as measured by the Participant Satisfaction",University of Cincinnati|National Institute on Drug Abuse (NIDA)|Maryhaven,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,104,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,5K23DA021512-02,2008-03-01,2012-06-01,2013-06-01,2008-02-06,null,2012-08-14,"Maryhaven, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00609089
821,NCT00804141,Study Evaluating Long-Term Safety Of MOA-728 In Subjects With Opioid-Induced Constipation,,Completed,No Results Available,Constipation,Drug: N-methylnaltrexone bromide (MOA-728),"collection of safety data & assessments to include monitoring of treatment emergent adverse events, safety laboratory measurements, electrocardiograms and changes in the physical exam including vital signs while on therapy|change in bowel function compared to baseline","Valeant Pharmaceuticals International, Inc.|Pfizer",All,"18 Years and older   (Adult, Older Adult)",Phase 3,1040,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3200K1-3358,2008-12-01,2010-09-01,2010-09-01,2008-12-08,null,2014-09-01,"Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Chandler, Arizona, United States|Pfizer Investigational Site, Mesa, Arizona, United States|Pfizer Investigational Site, Mesa, Arizona, United States|Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Tempe, Arizona, United States|Pfizer Investigational Site, Tucson, Arizona, United States|Pfizer Investigational Site, Tucson, Arizona, United States|Pfizer Investigational Site, Hot Spings, Arkansas, United States|Pfizer Investigational Site, Garden Grove, California, United States|Pfizer Investigational Site, Laguna Hills, California, United States|Pfizer Investigational Site, Los Gatos, California, United States|Pfizer Investigational Site, Newport Beach, California, United States|Pfizer Investigational Site, Newport Beach, California, United States|Pfizer Investigational Site, Colorado Springs, Colorado, United States|Pfizer Investigational Site, Boca Raton, Florida, United States|Pfizer Investigational Site, Brandon, Florida, United States|Pfizer Investigational Site, Chiefland, Florida, United States|Pfizer Investigational Site, Clearwater, Florida, United States|Pfizer Investigational Site, Daytona Beach, Florida, United States|Pfizer Investigational Site, Fort Myers, Florida, United States|Pfizer Investigational Site, Gainesville, Florida, United States|Pfizer Investigational Site, Jacksonville, Florida, United States|Pfizer Investigational Site, Jacksonville, Florida, United States|Pfizer Investigational Site, Jupiter, Florida, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, Ocala, Florida, United States|Pfizer Investigational Site, Ocala, Florida, United States|Pfizer Investigational Site, Ocala, Florida, United States|Pfizer Investigational Site, Orlando, Florida, United States|Pfizer Investigational Site, Ormond Beach, Florida, United States|Pfizer Investigational Site, Port Orange, Florida, United States|Pfizer Investigational Site, Sarasota, Florida, United States|Pfizer Investigational Site, Sarasota, Florida, United States|Pfizer Investigational Site, Tampa, Florida, United States|Pfizer Investigational Site, Tampa, Florida, United States|Pfizer Investigational Site, Vero Beach, Florida, United States|Pfizer Investigational Site, Winter Park, Florida, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, Rockford, Illinois, United States|Pfizer Investigational Site, Avon, Indiana, United States|Pfizer Investigational Site, Evansville, Indiana, United States|Pfizer Investigational Site, Indianapolis, Indiana, United States|Pfizer Investigational Site, Indianapolis, Indiana, United States|Pfizer Investigational Site, West Des Moines, Iowa, United States|Pfizer Investigational Site, Madisonville, Kentucky, United States|Pfizer Investigational Site, Hagerstown, Maryland, United States|Pfizer Investigational Site, Hollywood, Maryland, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Brockton, Massachusetts, United States|Pfizer Investigational Site, Watertown, Massachusetts, United States|Pfizer Investigational Site, Bingham Farms, Michigan, United States|Pfizer Investigational Site, Chesterfield, Michigan, United States|Pfizer Investigational Site, Kalamazoo, Michigan, United States|Pfizer Investigational Site, Traverse City, Michigan, United States|Pfizer Investigational Site, Edina, Minnesota, United States|Pfizer Investigational Site, Biloxi, Mississippi, United States|Pfizer Investigational Site, Jackson, Mississippi, United States|Pfizer Investigational Site, Springfield, Missouri, United States|Pfizer Investigational Site, Omaha, Nebraska, United States|Pfizer Investigational Site, Henderson, Nevada, United States|Pfizer Investigational Site, Las Vegas, Nevada, United States|Pfizer Investigational Site, Las Vegas, Nevada, United States|Pfizer Investigational Site, Las Vegas, Nevada, United States|Pfizer Investigational Site, Elizabeth, New Jersey, United States|Pfizer Investigational Site, Albuquerque, New Mexico, United States|Pfizer Investigational Site, Great Neck, New York, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, Charlotte, North Carolina, United States|Pfizer Investigational Site, Raleigh, North Carolina, United States|Pfizer Investigational Site, Fargo, North Dakota, United States|Pfizer Investigational Site, Centerville, Ohio, United States|Pfizer Investigational Site, Dayton, Ohio, United States|Pfizer Investigational Site, Oklahoma City, Oklahoma, United States|Pfizer Investigational Site, Medford, Oregon, United States|Pfizer Investigational Site, Portland, Oregon, United States|Pfizer Investigational Site, Altoona, Pennsylvania, United States|Pfizer Investigational Site, Levittown, Pennsylvania, United States|Pfizer Investigational Site, Yardley, Pennsylvania, United States|Pfizer Investigational Site, Cranston, Rhode Island, United States|Pfizer Investigational Site, Huntingdon, Tennessee, United States|Pfizer Investigational Site, Austin, Texas, United States|Pfizer Investigational Site, Beaumont, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Hurst, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, Salt Lake City, Utah, United States|Pfizer Investigational Site, Christiansburg, Virginia, United States|Pfizer Investigational Site, Bellevue, Washington, United States|Pfizer Investigational Site, Broadmeadow, New South Wales, Australia|Pfizer Investigational Site, Edmonton, Alberta, Canada|Pfizer Investigational Site, Kelowna, British Columbia, Canada|Pfizer Investigational Site, Vancouver, British Columbia, Canada|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, Mount Pearl, Newfoundland and Labrador, Canada|Pfizer Investigational Site, Dartmouth, Nova Scotia, Canada|Pfizer Investigational Site, Hamilton, Ontario, Canada|Pfizer Investigational Site, London, Ontario, Canada|Pfizer Investigational Site, Oshawa, Ontario, Canada|Pfizer Investigational Site, Sarnia, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Mirabel, Quebec, Canada|Pfizer Investigational Site, Sainte-Foy, Quebec, Canada|Pfizer Investigational Site, Sherbrooke, Quebec, Canada|Pfizer Investigational Site, St-Romuald, Quebec, Canada|Pfizer Investigational Site, Trois-Rivieres, Quebec, Canada|Pfizer Investigational Site, Quebec, Canada|Pfizer Investigational Site, Barranquilla, Atlantico, Colombia|Pfizer Investigational Site, Bogota, Cundinamarca, Colombia|Pfizer Investigational Site, Suwon, Kyonggi-do, Korea, Republic of|Pfizer Investigational Site, Seoul, Seoul/Korea, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Badalona, Barcelona/Spain, Spain|Pfizer Investigational Site, Madrid, Madrid/Spain, Spain",,https://ClinicalTrials.gov/show/NCT00804141
822,NCT00529087,Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain,,Completed,Has Results,Constipation,Drug: N-methylnaltrexone bromide (MOA-728)|Other: placebo,"Percentage of Patients Having a Rescue-free Bowel Movement (RFBM) Within 4 Hours of the First Dose|Percentage of Active Injections Resulting in Any Rescue-free Bowel Movement (RFBM) Within 4 Hours of Injection During the Double-blind Period|Time to the First Rescue-free Bowel Movement (RFBM) After First Dose|Change From Baseline in Weekly Number of Rescue-free Bowel Movements (RFBM) for the Double-blind Period at 4 Weeks|Weekly Number of Rescue-free Bowel Movements (RFBM) (Open-label Period)|Percentage of Patients Achieving at Least 3 Rescue-free Bowel Movements (RFBM) Per Week in Double-blind Period|Percentage of Active Injections Resulting in Any Rescue-free Bowel Movement (RFBM) Within 1, 2, 3 and 6 Hour(s) in Double-blind Period|Percentage of Injections Resulting in Any Rescue-free Bowel Movement (RFBM) Within 1, 2, 3, 4 and 6 Hours in Double-blind Period|Percentage of Patients With a Weekly Rescue-free Bowel Movement (RFBM) Rate ≥ 3 and an Increase of at Least 1 in the Weekly RFBM Rate From Baseline for the Double-blind Period|Percentage of Patients With an Increase of at Least 1 in the Weekly Rescue-free Bowel Movement (RFBM) Rate From Baseline for the Double-blind Period at 4 Weeks|Change in Weekly Number of Bowel Movements During Double-blind Period|Change From Baseline in Weekly Number of Quality Rescue-free Bowel Movements (RFBM)|Change in Weekly Number of Complete Rescue-free Bowel Movements (RFBM)|Change in Bristol Stool Form Scale Score for Rescue-free Bowel Movements (RFBM)|Change in Straining Scale Score of Rescue-free Bowel Movements (RFBM) From Baseline During Double-blind Period|Percentage of Patients With Improvement in Bristol Stool Form Scale Score for Rescue-free Bowel Movements (RFBM) by 1 Point During Open Label Period|Percentage of Patients With Improvement in Straining Scale Score for Rescue-free Bowel Movements (RFBM) by 1 Point During Open Label Period|Change in Percentage of Rescue-free Bowel Movements (RFBM) With Bristol Stool Form Scale in Type 3 or Type 4 From Baseline During Double-blind Period|Change in Percentage of Rescue-free Bowel Movements (RFBM) Classified as Diarrhea or Watery Stools From Baseline During Double-blind Period|Percentage of Patients With Any Diarrhea or Watery Rescue-free Bowel Movements (RFBM) During Open-label Period.|Change in Percentage of Rescue-free Bowel Movements (RFBM) With Straining Scale Scores of 0 or 1 (no, or Mild) From Baseline During Double-blind Period|Change in Percentage of Rescue-free Bowel Movements (RFBM) With a Sensation of Complete Evacuation From Baseline During Double-blind Period","Valeant Pharmaceuticals International, Inc.|Progenics Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,460,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3200K1-3356,2007-08-01,2008-12-01,2008-12-01,2007-09-14,2010-05-11,2011-09-12,"Mobile, Alabama, United States|Mobile, Alabama, United States|Sun City, Arizona, United States|Tucson, Arizona, United States|Tucson, Arizona, United States|Hot Springs, Arkansas, United States|Anaheim, California, United States|Garden Grove, California, United States|Hawaiian Gardens, California, United States|Long Beach, California, United States|Los Angeles, California, United States|San Diego, California, United States|Brandon, Florida, United States|Cheifland, Florida, United States|Clearwater, Florida, United States|Gainesville, Florida, United States|Jacksonville, Florida, United States|Jupiter, Florida, United States|Largo, Florida, United States|Miami, Florida, United States|Naples, Florida, United States|Ocala, Florida, United States|Ocala, Florida, United States|Orlando, Florida, United States|Ormond Beach, Florida, United States|Spring Hill, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Winter Park, Florida, United States|Atlanta, Georgia, United States|Marietta, Georgia, United States|Stockbrige, Georgia, United States|Chicago, Illinois, United States|Dekalb, Illinois, United States|Avon, Indiana, United States|Indianapolis, Indiana, United States|West Des Moines, Iowa, United States|Shreveport, Louisiana, United States|Sunset, Louisiana, United States|Elkridge, Maryland, United States|Boston, Massachusetts, United States|Brockton, Massachusetts, United States|Cadillac, Michigan, United States|Paw Paw, Michigan, United States|Traverse City, Michigan, United States|Biloxi, Mississippi, United States|Ocean Springs, Mississippi, United States|Nixa, Missouri, United States|Kalispell, Montana, United States|Missoula, Montana, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Albuquerque, New Mexico, United States|Great Neck, New York, United States|Valley Stream, New York, United States|Charlotte, North Carolina, United States|Raleigh, North Carolina, United States|Winston-Salem, North Carolina, United States|Dayton, Ohio, United States|Toledo, Ohio, United States|Oklahoma City, Oklahoma, United States|Medford, Oregon, United States|Portland, Oregon, United States|Levittown, Pennsylvania, United States|Chattanooga, Tennessee, United States|Austin, Texas, United States|Beaumont, Texas, United States|Colleyville, Texas, United States|Dallas, Texas, United States|Dallas, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|Alexandria, Virginia, United States|Christiansburg, Virginia, United States|Hampton, Virginia, United States|Spokane, Washington, United States|Spokane, Washington, United States|Charleston, West Virginia, United States",,https://ClinicalTrials.gov/show/NCT00529087
823,NCT00365820,Efficacy and Safety of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain,,Terminated,No Results Available,Constipation,Drug: Tegaserod,Change from baseline in the number of bowel movements over weeks 1-4|Change from baseline in the number of bowel movements over weeks 1-12|Change from baseline in abdominal distension/bloating over weeks 1-12|Change from baseline in abdominal discomfort/pain over weeks 1-12,Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,670,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CHTF919N2201,2006-07-01,2007-04-01,2007-04-01,2006-08-18,null,2012-04-20,"Investigative Site, Mobile, Alabama, United States|Investigative Site, Phoenix, Arizona, United States|Investigative Site, Phoenix, Arizona, United States|Investigative Site, Tucson, Arizona, United States|Investigative Site, North Little Rock, Arkansas, United States|Investigative Site, Buena Park, California, United States|Investigative Site, Downey, California, United States|Investigative Site, Encinitas, California, United States|Investigative Site, Fountain Valley, California, United States|Investigative Site, La Jolla, California, United States|Investigative Site, Los Angeles, California, United States|Investigative Site, Mission Viejo, California, United States|Investigative Site, San Diego, California, United States|Investigative Site, San Francisco, California, United States|Investigative Site, Torrance, California, United States|Investigative Site, Northglenn, Colorado, United States|Investigative Site, Bristol, Connecticut, United States|Investigative Site, DeLand, Florida, United States|Investigative Site, Jacksonville, Florida, United States|Investigative Site, Largo, Florida, United States|Investigative Site, Miami, Florida, United States|Investigative Site, New Smyrna Beach, Florida, United States|Investigative Site, Springhill, Florida, United States|Investigative Site, Tampa, Florida, United States|Investigative Site, Belleville, Illinois, United States|Investigative Site, Chicago, Illinois, United States|Investigative Site, Avon, Indiana, United States|Investigative Site, Evansville, Indiana, United States|Investigative Site, Indianapolis, Indiana, United States|Investigative Site, Overland Park, Kansas, United States|Investigative Site, Prairie Village, Kansas, United States|Investigative Site, Shreveport, Louisiana, United States|Investigative Site, Boston, Massachusetts, United States|Investigative Site, Boston, Massachusetts, United States|Investigative Site, Omaha, Nebraska, United States|Investigative Site, Omaha, Nebraska, United States|Investigative Site, Pahrump, Nevada, United States|Novartis Pharmaceutical Corporation, East Hanover, New Jersey, United States|Investigative Site, New York City, New York, United States|Investigative Site, New York, New York, United States|Investigative Site, North Massapequa, New York, United States|Investigative Site, Charlotte, North Carolina, United States|Investigative Site, Greensboro, North Carolina, United States|Investigative Site, Monroe, North Carolina, United States|Investigative Site, Winston Salem, North Carolina, United States|Investigative Site, Dayton, Ohio, United States|Investigative Site, Oklahoma City, Oklahoma, United States|Investigative Site, Portland, Oregon, United States|Investigative Site, Hershey, Pennsylvania, United States|Investigative Site, Levittown, Pennsylvania, United States|Investigative Site, Chattanooga, Tennessee, United States|Investigative Site, Beaumont, Texas, United States|Investigative Site, Colleyville, Texas, United States|Investigative Site, Corsicana, Texas, United States|Investigative Site, Houston, Texas, United States|Investigative Site, San Antonio, Texas, United States|Investigative Site, Salt Lake City, Utah, United States|Investigative Site, Charlottesville, Virginia, United States|Investigative Site, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00365820
824,NCT00292136,"Real Time Assessment of Drug Craving, Use, and Abstinence During Outpatient: A Development and Feasibility Study",,Completed,No Results Available,Cocaine Addiction|Opiate Addiction,,,National Institute on Drug Abuse (NIDA)|National Institutes of Health Clinical Center (CC),All,"18 Years to 65 Years   (Adult, Older Adult)",,230,NIH,Observational,Time Perspective: Prospective,999903385|03-DA-N385,2003-08-15,null,2013-06-11,2006-02-15,null,2018-04-05,"National Institute on Drug Abuse, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00292136
825,NCT00117741,Evaluation of DBT Compared to Drug Counseling for Opiate Addicts,,Completed,No Results Available,Opiate Addiction|Borderline Personality Disorder,Behavioral: Dialectical Behavior Therapy|Behavioral: Drug Counseling,"Urinalysis|Suicidal Behavior|Depression, anxiety, Axis I diagnostic remission",University of Washington|National Institute on Drug Abuse (NIDA),All,18 Years to 60 Years   (Adult),Not Applicable,86,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,R01DA014997,2004-06-01,2008-10-01,2010-04-01,2005-07-08,null,2012-02-02,"University of Washington, Behavioral Research and Therapy Clinics, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00117741
826,NCT01924182,Intrathecal Morphine Compared to Conventional Medical Management for Pain Control and Opioid-related Side Effects,CONVERT-TDD,Terminated,Has Results,Chronic Pain,Device: SynchroMed Infusion System and Intrathecal Morphine Sulfate|Other: Conventional Medicine,Clinical Success|Pain Assessment|Opioid-Related Side Effects,MedtronicNeuro,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,7,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1664 - CONVERT-TDD,2013-10-01,2015-07-01,2015-07-01,2013-08-16,2016-03-07,2018-03-29,"Pain Management Services PC, Homewood, Alabama, United States|Napa Pain Institute and Neurovations, Napa, California, United States|IPM Medical Group (Interventional Pain Medical Group), Walnut Creek, California, United States|Compass Research, Orlando, Florida, United States|The Center for Clinical Research, Winston-Salem, North Carolina, United States|University of Virginia Pain Management Center, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01924182
827,NCT00834080,ALK21-021: A Safety Study of Medisorb® Naltrexone (VIVITROL®) Administered to Health Care Professionals,,Completed,Has Results,Opiate Dependence,Drug: Medisorb naltrexone 380 mg,Number of Subjects Reporting at Least 1 Treatment-emergent Adverse Event (TEAE) While on Study.,"Alkermes, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,38,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ALK21-021,2009-03-01,2012-05-01,2012-05-01,2009-02-03,2013-07-29,2013-07-29,"Alkermes Clinical Study Site, Colton, California, United States|Alkermes Clinical Study Site, Oceanside, California, United States|Alkermes Clinical Study Site, Lauderhill, Florida, United States|Alkermes Clinical Study Site, Hoffman Estates, Illinois, United States|Alkermes Clinical Study Site, St. Louis, Missouri, United States|Alkermes Clinical Study Site, Elmsford, New York, United States|Alkermes Clinical Study Site, Canton, Ohio, United States|Alkermes Clinical Study Site, Philadelphia, Pennsylvania, United States|Alkermes Clinical Study Site, Philadelphia, Pennsylvania, United States|Alkermes Clinical Study Site, Austin, Texas, United States|Alkermes Clinical Study Site, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT00834080
828,NCT00135577,Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects,,Completed,No Results Available,Cancer|Bowel Dysfunction,Drug: alvimopan|Drug: placebo,"Incidence of reported adverse events, including serious adverse events|Incidence of treatment-limiting toxicities, changes in pain intensity, patient satisfaction, health outcome measures",Cubist Pharmaceuticals LLC|GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 2,67,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ABD101684,2004-09-01,2007-04-01,2007-04-01,2005-08-26,null,2015-09-02,"GSK Investigational Site, Duarte, California, United States|GSK Investigational Site, Fountain Valley, California, United States|GSK Investigational Site, La Verne, California, United States|GSK Investigational Site, Sacramento, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, New Port Richey, Florida, United States|GSK Investigational Site, Tampa, Florida, United States|GSK Investigational Site, West Des Moines, Iowa, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Worcester, Massachusetts, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Hendersonville, North Carolina, United States|GSK Investigational Site, Tacoma, Washington, United States|GSK Investigational Site, Winnipeg, Manitoba, Canada|GSK Investigational Site, Saint John's, Newfoundland and Labrador, Canada|GSK Investigational Site, Kitchener, Ontario, Canada|GSK Investigational Site, Sudbury, Ontario, Canada|GSK Investigational Site, Bonaventure, Quebec, Canada|GSK Investigational Site, Chandler, Quebec, Canada|GSK Investigational Site, Sherbrooke, Quebec, Canada|GSK Investigational Site, Helsinki, Finland|GSK Investigational Site, Bordeaux Cedex, France|GSK Investigational Site, Strasbourg, France|GSK Investigational Site, Vandoeuvre-Les-Nancy, France|GSK Investigational Site, Villejuif Cedex, France|GSK Investigational Site, Kwun Tong, Hong Kong|GSK Investigational Site, Wellington, New Zealand|GSK Investigational Site, Lahore, Pakistan|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Bialystok, Poland|GSK Investigational Site, Lublin, Poland|GSK Investigational Site, Olsztyn, Poland|GSK Investigational Site, Otwock, Poland|GSK Investigational Site, Poznan, Poland|GSK Investigational Site, Lisboa, Portugal|GSK Investigational Site, Lisboa, Portugal|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Alcorcon, Spain|GSK Investigational Site, Nottingham, United Kingdom",,https://ClinicalTrials.gov/show/NCT00135577
829,NCT03461120,Improving Postamputation Functioning by Decreasing Phantom Pain With Perioperative Continuous Peripheral Nerve Blocks: A Department of Defense Funded Multicenter Study,,Recruiting,No Results Available,Lower Extremity Surgical Amputation|Post-amputation Phantom Limb Pain,Drug: Experimental continuous peripheral nerve blocks|Drug: Control continuous peripheral nerve blocks,Locomotor Capabilities Index-5|World Health Organization Disability Assessment Schedule 2.0|Beck Depression Inventory|Phantom limb pain|Residual limb pain|Opioid consumption|Non-painful phantom limb sensations frequency|Non-painful phantom limb sensations duration|Phantom limb pain frequency|Phantom limb pain average duration|Residual limb pain frequency|Residual limb pain duration|Masking assessment,"University of California, San Diego|United States Department of Defense|United States Naval Medical Center, San Diego|The Cleveland Clinic|University of Texas MD Anderson|Walter Reed National Military Medical Center|Johns Hopkins University|Wake Forest Medical Center|VA Pittsburgh Healthcare System",All,"18 Years and older   (Adult, Older Adult)",Phase 4,218,Other|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",Phantom pain PREVENTION (DoD),2018-03-23,2020-09-01,2021-09-01,2018-03-09,null,2018-05-30,"University California San Diego, San Diego, California, United States|Naval Medical Center San Diego, San Diego, California, United States|Cleveland Clinic, Cleveland, Ohio, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03461120
830,NCT01983306,Dose-ranging Study to Assess Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC),OIC,Completed,No Results Available,Constipation,Drug: SP-333 1 mg|Drug: SP-333 3 mg|Drug: SP-333 6 mg|Drug: Placebo,Change from baseline in the number of spontaneous bowel movements during Week 4 of the 4-week treatment period|To assess safety and tolerability of SP-333 in the treatment of non-malignant OIC,Synergy Pharmaceuticals Inc.,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,260,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SP333201-01,2013-11-01,2014-09-01,2015-04-01,2013-11-13,null,2017-10-04,"Synergy Research Site, Huntsville, Alabama, United States|Synergy Research Site, Mobile, Alabama, United States|Synergy Research Site, Phoenix, Arizona, United States|Synergy Research Site, Artesia, California, United States|Synergy Research Site, Laguna Hills, California, United States|Synergy Research Site, Oceanside, California, United States|Synergy Research Site, Sacramento, California, United States|Synergy Research Site, San Diego, California, United States|Synergy Research Site, San Diego, California, United States|Synergy Research Site, San Francisco, California, United States|Synergy Research Site, Hialeah, Florida, United States|Synergy Research Site, Miami Beach, Florida, United States|Synergy Research Site, Miami, Florida, United States|Synergy Research Site, Plant City, Florida, United States|Synergy Research Site, Plantation, Florida, United States|Synergy Research Site, Port Orange, Florida, United States|Synergy Research Site, Sarasota, Florida, United States|Synergy Research Site, West Palm Beach, Florida, United States|Synergy Research Site, Winter Haven, Florida, United States|Synergy Research Site, Atlanta, Georgia, United States|Synergy Research Site, Bloomington, Illinois, United States|Synergy Research Site, Traverse City, Michigan, United States|Synergy Research Site, Saint Louis, Missouri, United States|Synergy Research Site, Las Vegas, Nevada, United States|Synergy Research Site, Great Neck, New York, United States|Synergy Research Site, New York, New York, United States|Synergy Research Site, Concord, North Carolina, United States|Synergy Research Site, Greensboro, North Carolina, United States|Synergy Research Site, Salisbury, North Carolina, United States|Synergy Research Site, Winston-Salem, North Carolina, United States|Synergy Research Site, Dayton, Ohio, United States|Synergy Research Site, Oklahoma City, Oklahoma, United States|Synergy Research Site, Oklahoma City, Oklahoma, United States|Synergy Research Site, Oklahoma City, Oklahoma, United States|Synergy Research Site, Medford, Oregon, United States|Synergy Research Site, Orangeburg, South Carolina, United States|Synergy Research Site, Chattanooga, Tennessee, United States|Synergy Research Site, Arlington, Texas, United States|Synergy Research Site, Dallas, Texas, United States|Synergy Research Site, Dallas, Texas, United States|Synergy Research Site, Houston, Texas, United States|Synergy Research Site, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT01983306
831,NCT00315458,Buprenorphine Transdermal Patch in Subjects With Osteoarthritis Pain Requiring Opioids. Includes a 52-Week Safety Extension.,,Terminated,Has Results,Osteoarthritis,Drug: Buprenorphine transdermal patch|Drug: Placebo transdermal patch,Number of Participants With Adverse Events (AEs) as a Measure of Safety,Purdue Pharma LP,All,"40 Years and older   (Adult, Older Adult)",Phase 3,107,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BUP3011 and BUP3011S,2003-12-01,2005-03-01,2005-03-01,2006-04-18,2010-09-23,2012-09-03,"Parkway Medical Center, Birmingham, Alabama, United States|Clinical Research Consultants, Birmingham, Alabama, United States|Winston Physician Services, Inc, Haleyville, Alabama, United States|Private Practice, Muscle Shoals, Alabama, United States|Clinic for Rheumatic Diseases, Tuscaloosa, Alabama, United States|Radiant Research, Phoenix, Arizona, United States|Arizona Research Center, Phoenix, Arizona, United States|ACRC/Arizona Clinical Research, Tuscon, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Southbay Pharma Research, Buena Park, California, United States|Torrence Clinical Research, Torrance, California, United States|Comprehensive Neuroscience Inc, Boynton Beach, Florida, United States|Chiefland Medical Center, Chiefland, Florida, United States|University Clinical Research Deland, Deland, Florida, United States|Florida Medical Research Institute, Gainesville, Florida, United States|Drug Study Institute, Jupiter, Florida, United States|Coastal Medical Research, Orange City, Florida, United States|Ormond Medical Arts Pharmaceutical Res Ctr, Ormond Beach,, Florida, United States|The Arthritis Center, Palm Harbor, Florida, United States|Avancia Research, Pembroke Pines, Florida, United States|Coastal Medical Research, Port Orange, Florida, United States|Palm Beach Research Center, West Palm Beach, Florida, United States|Gold Coast Research LLC, Weston, Florida, United States|Georgia Medical Research Institute, Marietta, Georgia, United States|Internal Medicine Northwest, Gurnee, Illinois, United States|MediSphere Medical Research Center, Evansville, Indiana, United States|University of Louisville Medical/Rheumatology, Louisville, Kentucky, United States|Clinical Trials Management, LLC, Metairie, Louisiana, United States|Future Care Studies, Springfield, Massachusetts, United States|Bay Area Health Clinic, Bay City, Michigan, United States|Medex Healthcare Research Inc, St Louis, Missouri, United States|Beth Israel Medical Center, New York, New York, United States|Health Research Institute, Oklahoma City, Oklahoma, United States|Keystone Clinical Solutions, Altoona, Pennsylvania, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|BioMedical Research Associates, Shippensburg, Pennsylvania, United States|University Orthopedics Center, State College, Pennsylvania, United States|Omega Medical Research, Warwick, Rhode Island, United States|Low Country Rheumatology, Charleston, South Carolina, United States|Brown Clinic, Watertown, South Dakota, United States|Holston Medical Group, Bristol, Tennessee, United States|CSS Research, Memphis, Tennessee, United States|Prime Care Medical Center, Selmer, Tennessee, United States|Team Research of Central Texas, Harker Heights, Texas, United States|Quality Research, San Antonio, Texas, United States|Advanced Pain Management and Rehab Hilltop Med Center, Virginia Beach, Virginia, United States|Sentara Medical Group, Virginia Beach, Virginia, United States|Physicians Clinic of Spokane, Spokane, Washington, United States",,https://ClinicalTrials.gov/show/NCT00315458
832,NCT01958476,Improving Outcomes in Neonatal Abstinence Syndrome,,"Active, not recruiting",No Results Available,Neonatal Abstinence Syndrome|Neonatal Opioid Withdrawal,Drug: Neonatal Morphine Solution|Drug: Methadone|Drug: Phenobarbital,Length of hospital stay|Total opioid days|Maximum daily dose of replacement opioid|Mean Finnegan Score|Need for a second NAS medication|Growth Outcome Weight|Growth Outcome Head Circumference|Maximum Finnegan Score|Growth Outcome Length,Tufts Medical Center,All,"Child, Adult, Older Adult",Phase 3,184,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1R01DA032889-01A1,2013-09-01,2018-08-01,2018-08-01,2013-10-09,null,2017-12-12,"Shands Jacksonville Medical Center, Jacksonville, Florida, United States|Maine Medical Center, Portland, Maine, United States|Tufts Medical Center, Boston, Massachusetts, United States|Boston Medical Center, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Women and Infant's Hospital of Rhode Island, Providence, Rhode Island, United States|Vanderbilt University, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT01958476
833,NCT01495611,Multicenter Perioperative Opioid Pharmacogenetic Study,,Completed,No Results Available,Pain,,Safety Outcomes|Efficacy Outcome Measures - Opioid interventions|Efficacy Outcome Measures - Opioid requirement|Efficacy Outcome Measures - Pain Scores,"Children's Hospital Medical Center, Cincinnati|Texas Children's Hospital|Ochsner Health System|Children's Hospital Colorado|Children's Hospital Los Angeles|C.S. Mott Children's Hospital|St. Christopher's Hospital for Children|St. Louis Children's Hospital|Boston Children’s Hospital|Seattle Children's Hospital|Ann & Robert H Lurie Children's Hospital of Chicago|UW Health American Family Children's Hospital/University of Wisconsin|University of Miami|Johns Hopkins University|Stanford University|Phoenix Children's Hospital|University of Michigan|University of Utah|Shanghai Children's Hospital",All,6 Years to 17 Years   (Child),,1000,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,2010-1353,2010-11-01,2016-01-01,2017-04-30,2011-12-20,null,2017-01-31,"Children's Hospital of Los Angeles, Los Angeles, California, United States|Stanford University Medical Center, Palo Alto, California, United States|The Children's Hospital, Denver, Denver, Colorado, United States|University of Miami - Miller School of Medicine, Miami, Florida, United States|Children's Memorial Hospital, Chicago, Illinois, United States|Ochsner Medical Center for Children, New Orleans, Louisiana, United States|The Johns Hopkins Hospital, Baltimore, Maryland, United States|Boston Children's Hospital, Boston, Massachusetts, United States|C.S. Mott Children's Hospital, Ann Arbor, Michigan, United States|St. Louis Children's Hospital, St. Louis, Missouri, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States|Texas Children's Hospital, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|UW Health-American Family Children's Hospital, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT01495611
834,NCT01913535,Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression,RAPID KOR,Terminated,Has Results,Treatment Resistant Depression,Drug: CERC-501|Drug: Placebo,"Change in Hamilton Rating Scale for Depression - 6 Items (HAM-D-6)|Change in Hamilton Rating Scale for Depression - 6 Items (HAM-D-6), Day 20|Number of Participants With Response on Hamilton Rating Scale for Depression - 6 Items (HAM-D-6)|Change in Montgomery-Asberg Depression Rating Scale (MADRS)|Change in Clinical Global Impression -Severity (CGI-S)|Clinical Global Impression-Improvement (CGI-I)|Change in Symptoms of Depression Questionnaire (SDQ)|Change in Perceived Stress Scale (PSS)|Change in Positive Affect Scale (PAS)|Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Satisfaction With Participation in Social Roles and Discretionary Activities|Change in the Columbia-Suicide Severity Rating Scale (C-SSRS)|Number of Participants With Clinically Significant Abnormal ECG|Number of Participants With Clinically Significant Abnormal Labs",Massachusetts General Hospital|National Institute of Mental Health (NIMH)|Butler Hospital|Rush University|Temple University|University of Kansas,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,8,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RAP-002|271201100006I-0-27100007-1,2013-09-12,2016-01-22,2016-01-22,2013-08-01,2017-07-02,2017-07-02,"Rush University, Chicago, Illinois, United States|University of Kansas, Wichita, Kansas, United States|Temple University, Philadelphia, Pennsylvania, United States|Brown University-Butler Hospital, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT01913535
835,NCT01358526,Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain,,Completed,Has Results,Low Back Pain,Drug: Oxycodone/Naloxone Controlled-release|Drug: Placebo,"The ""Average Pain Over the Last 24 Hours"" at Week 12 of the Double-blind Period|The Sleep Disturbance Subscale of the MOS Sleep Scale at Weeks 4, 8, and 12|Patient Global Impression of Change (PGIC)",Purdue Pharma LP,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1095,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ONU3701,2011-05-01,2012-10-01,2012-11-01,2011-05-23,2014-09-03,2015-11-11,"Alabama Orthopaedic Center, PC, Birmingham, Alabama, United States|Alliance Clinical Research, Birmingham, Alabama, United States|Winston Technology Research, LLC, Haleyville, Alabama, United States|Monte Sano Clinical Research, LLC, Huntsville, Alabama, United States|Research Facility, Mobile, Alabama, United States|Radiant Research, Inc., Chandler, Arizona, United States|Dedicated Clinical Research, Phoenix, Arizona, United States|Arizona Research Center, Phoenix, Arizona, United States|Clinical Research Advantage, Inc./Tatum Highlands Medical Associates, PLLC, Phoenix, Arizona, United States|Quality of Life Medical & Research Center, LLC, Tucson, Arizona, United States|Ortho Surgeons, Little Rock, Arkansas, United States|Orange County Research Institute, Anaheim, California, United States|Physician Alliance Research Center, Anaheim, California, United States|Advanced Pain Research Institute, Arcadia, California, United States|Southbay Pharma Research, Buena Park, California, United States|Providence Clinical Research, Burbank, California, United States|Med Center, Carmichael, California, United States|Advanced Pain Management and Rehabilitation Medical Group, Inc., Castro Valley, California, United States|Catalina Research Institute, LLC, Chino, California, United States|Synergy Clinical Research of Escondido, Escondido, California, United States|Valley Research, Fresno, California, United States|RX Clinical Research, Inc., Garden Grove, California, United States|TriWest Research Associates, La Mesa, California, United States|Pacific Coast Pain Management Center, Laguna Hills, California, United States|South Orange County Surgical Medical Group, Laguna Hills, California, United States|Clinical Trials Research, Lincoln, California, United States|L.A. Pain and Wellness Institute, Los Angeles, California, United States|Newport Beach Clinical Research Associates, Inc., Newport Beach, California, United States|Lotus Clinical Research, Pasadena, California, United States|Northern California Clinical Research Center, Redding, California, United States|Probe Clinical Research Corporation, Riverside, California, United States|Northern California Research, Sacramento, California, United States|Probe Clinical Research Corporation, Santa Ana, California, United States|Denver Internal Medicine Group, Denver, Colorado, United States|Front Range Clinical Research, Wheat Ridge, Colorado, United States|New England Research Associates, LLC, Trumbull, Connecticut, United States|Orthopedic Research Institute, Boynton Beach, Florida, United States|Coastal Orthopedics & Pain Management, Bradenton, Florida, United States|Southeast Clinical Research, LLC, Chiefland, Florida, United States|Innovative Research of West Florida, Inc., Clearwater, Florida, United States|Clinical Research of West Florida, Inc., Clearwater, Florida, United States|Omega Research Consultants, LLC, Debary, Florida, United States|S & W Clinical Research, Fort Lauderdale, Florida, United States|Southeastern Integrated Medical, PL, Gainesville, Florida, United States|Health Care Family Rehab & Research Center, Hialeah, Florida, United States|Eastern Research, Inc., Hialeah, Florida, United States|Southeast Clinical Research, LLC, Jacksonville, Florida, United States|Florida Institute of Medical Research, Jacksonville, Florida, United States|Drug Study Institute, Jupiter, Florida, United States|Pharma Care Research, Inc., Miami, Florida, United States|Advanced Pharma CR, LLC, Miami, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Peninsula Research, Inc., Ormond Beach, Florida, United States|Sarasota Clinical Research, LLC, Sarasota, Florida, United States|Sarasota Pain Medicine Research, Sarasota, Florida, United States|Vita Research Solutions & Medical Center, Inc., Tamarac, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Advanced Research Institute, Inc., Trinity, Florida, United States|Palm Beach Research Center, West Palm Beach, Florida, United States|National Pain Research Institute, LLC, Winter Park, Florida, United States|Independent Neurodiagnostic Clinic, Atlanta, Georgia, United States|In-Quest Medical Research, LLC, Duluth, Georgia, United States|Georgia Institute for Clinical Research, LLC, Marietta, Georgia, United States|Research Facility, Marietta, Georgia, United States|Better Health Clinical Research, Inc., Newnan, Georgia, United States|SouthCoast Medical Group, Savannah, Georgia, United States|Georgia Clinical Research, LLC, Snellville, Georgia, United States|The Pain Center, Boise, Idaho, United States|Clinical Investigation Specialists, Inc., Gurnee, Illinois, United States|Destiny Clinical Research, LLC, Evansville, Indiana, United States|MediSphere Medical Research Center, LLC, Evansville, Indiana, United States|Northwest Indiana Center for Clinical Research, Valparaiso, Indiana, United States|International Clinical Research Institute, Inc., Leawood, Kansas, United States|Clinical Trials Technology, Inc. CTT Consultants, Inc., Prairie Village, Kansas, United States|The Pain Treatment Center of the Bluegrass, Lexington, Kentucky, United States|Louisiana Research Associates, Inc., New Orleans, Louisiana, United States|Research Facility, New Orleans, Louisiana, United States|Mid-Atlantic Medical Research Centers, Hollywood, Maryland, United States|MidAtlantic Pain Medicine Center, Pikesville, Maryland, United States|Beacon Clinical Research, LLC, Brockton, Massachusetts, United States|ActivMed Practices and Research, Haverhill, Massachusetts, United States|Medvadis Research Corporation, Watertown, Massachusetts, United States|Great Lakes Research Group, Inc., Bay City, Michigan, United States|Great Lakes Family Care, Cadillac, Michigan, United States|Great Lakes Research Group, Inc., Pinconning, Michigan, United States|Medex Healthcare Research, Inc., Saint Louis, Missouri, United States|Mercy Health Research, St. Louis, Missouri, United States|Sundance Clinical Research, LLC, St. Louis, Missouri, United States|Meridian Clinical Research, LLC, Omaha, Nebraska, United States|Research Facility, Las Vegas, Nevada, United States|South Jersey Medical Associates, P.A., Blackwood, New Jersey, United States|University of Medicine & Dentistry of New Jersey - School of Osteopathic Medicine (UMDNJ), Stratford, New Jersey, United States|Five Towns Neuroscience Research/Five Towns Neurology, Cedarhurst, New York, United States|Long Island Gastrointestinal Research Group, LLP, Great Neck, New York, United States|Medex Healthcare Research, Inc., New York, New York, United States|Research Across America, New York, New York, United States|Upstate Clinical Research Associates, LLC, Williamsville, New York, United States|Gaffney Health Services, Charlotte, North Carolina, United States|Box Arthritis & Rheumatology of the Carolinas, PLLC, Charlotte, North Carolina, United States|PharmQuest, Greensboro, North Carolina, United States|Peters Medical Research, High Point, North Carolina, United States|Plains Medical Clinic, LLC, Fargo, North Dakota, United States|Clinical Inquest Center Ltd., Beavercreek, Ohio, United States|Community Research, Cincinnati, Ohio, United States|Columbus Clinical Research, Inc., Columbus, Ohio, United States|Hometown Urgent Care and Research, Dayton, Ohio, United States|Prestige Clinical Research, Franklin, Ohio, United States|Hometown Urgent Care and Research, Springfield, Ohio, United States|J L Clinical Research, Tiffin, Ohio, United States|Bone Joint and Spine Surgeons, Inc., Toledo, Ohio, United States|Pharmacotherapy Research Associates, Inc., Zanesville, Ohio, United States|Neuropsychiatric Center and NPC Research, Oklahoma City, Oklahoma, United States|Health Research Institute, Oklahoma City, Oklahoma, United States|Paradigm Research Professionals, LLC, Oklahoma City, Oklahoma, United States|Bend Memorial Clinic, Bend, Oregon, United States|Pain Consultants of Oregon, Eugene, Oregon, United States|Willamette Valley Clinical Studies, Eugene, Oregon, United States|Sunstone Medical Research, LLC, Medford, Oregon, United States|Allegheny Pain Management, PC, Altoona, Pennsylvania, United States|Paramount Clinical Research, Bridgeville, Pennsylvania, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Central Pennsylvania Clinical Research, Mechanicsburg, Pennsylvania, United States|CRI Worldwide, LLC, Philadelphia, Pennsylvania, United States|Dairyland Medical Center, Red Lion, Pennsylvania, United States|New England Center for Clinical Research, Inc, Cranston, Rhode Island, United States|Hartwell Research Group, LLC, Anderson, South Carolina, United States|Greenville Pharmaceutical Research, Inc., Greenville, South Carolina, United States|Internal Medicine of Greer, Greer, South Carolina, United States|Meridian Clinical Research, Dakota Dunes, South Dakota, United States|Health Concepts Wellness Center, Rapid City, South Dakota, United States|Integrity Clinical Research, LLC, Huntingdon, Tennessee, United States|FutureSearch Trials of Neurology, Austin, Texas, United States|Austin Center for Clinical Research, Austin, Texas, United States|Corpus Christi Pain Medicine, Corpus Christi, Texas, United States|FutureSearch Trials of Dallas, Dallas, Texas, United States|Pineloch Medical Clinic, Houston, Texas, United States|Clinical Trial Network, Houston, Texas, United States|Southwest Clinical Trials, Houston, Texas, United States|Protenium Clinical Research, LLC, Hurst, Texas, United States|TEAM Research of Central Texas, Killeen, Texas, United States|West Texas Medical Associates, San Angelo, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|Research Facility, Bountiful, Utah, United States|Summit Pain Management, Murray, Utah, United States|Alpine Medical Group, Salt Lake City, Utah, United States|Highland Clinical Research, Salt Lake City, Utah, United States|Virginia Research Center, Midlothian, Virginia, United States|Hilltop Medical Center, Virginia Beach, Virginia, United States|Independence Family Medicine, Virginia Beach, Virginia, United States|Universal Research Group, Tacoma, Washington, United States",,https://ClinicalTrials.gov/show/NCT01358526
836,NCT03303664,Inpatient Multimodal Path to RecOVEry,IMPROVE,Withdrawn,No Results Available,Pain|Opioid Use,Other: IMPROVE Protocol,Use of Opioid Overdose Reversal Treatment|Pain|Oversedation without naloxone|Multimodal Therapy|Average Daily MME,Carolinas Healthcare System,All,"Child, Adult, Older Adult",Not Applicable,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,Pro00022455,2017-07-11,2018-02-26,2018-02-26,2017-10-06,null,2018-02-28,"Carolinas Healthcare System - Stanly, Albemarle, North Carolina, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Carolinas Healthcare System - Mercy, Charlotte, North Carolina, United States|Carolinas Healthcare System - Pineville, Charlotte, North Carolina, United States|Carolinas Healthcare System - University, Charlotte, North Carolina, United States|Carolinas Healthcare System - NorthEast, Concord, North Carolina, United States|Carolinas Healthcare System - Kings Mountain, Kings Mountain, North Carolina, United States|Carolinas Healthcare System - Lincoln, Lincolnton, North Carolina, United States|Carolinas Healthcare System - Union, Monroe, North Carolina, United States|Carolinas Healthcare System - Blue Ridge, Morganton, North Carolina, United States|Carolinas Healthcare System - Cleveland, Shelby, North Carolina, United States|Carolinas Healthcare System - Anson, Wadesboro, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT03303664
837,NCT02081391,An Efficacy and Safety Study of Tapentadol in the Treatment of Post-operative Acute Pain Requiring Opioid Treatment in Pediatric Participants,,Recruiting,No Results Available,Acute Pain,Drug: Tapentadol 4 mg/mL|Drug: Tapentadol 20 mg/mL|Other: Placebo,"For US: The total amount of supplemental opioid analgesic medication used within the first 12 hours after first intake of investigational medicinal product (IMP) [tapentadol oral solution or placebo] in participants aged from birth to less than 17 years|For Europe: The total amount of supplemental opioid analgesic (pain killer) medication used within the first 24 hours after first intake of IMP in participants aged from 2 years to less than 18 years|The total amount of supplemental opioid analgesic medication used within the first 12 hours after the first intake of IMP in participants from 2 years to less than 18 years|The total amount of supplemental opioid analgesic medication used within the first 24 hours after the first intake of IMP in participants aged from birth to less than 17 years|The total amount of supplemental opioid analgesic medication received, assessed in 12 hour intervals from 24 hours to 96 hours after the first dose of IMP|Palatability of IMP in participants aged 2 years to less than 18 years assessed using facial 5-point hedonic scale|Acceptability of IMP in participants aged 2 years to less than 18 years assessed using facial 5-point hedonic scale|Change from baseline in the Face, Leg, Activity, Cry, and Consolability (FLACC) total score in participants aged less than 6 years|Change from baseline in the Faces Pain Scale-Revised (FPS-R) pain intensity score in participants aged 6 to less than 12 years|Change from baseline in the Visual Analog Scale (VAS) pain intensity score in participants aged 12 to less than 18 years|Clinical Global Impression of Change (CGIC)|Patient Global Impression of Change (PGIC)|Time to receive first and second patient or nurse controlled analgesia after the first dose of IMP|Time from first dose of IMP until treatment discontinuation due to lack of efficacy",Grünenthal GmbH|Depomed,All,"up to 18 Years   (Child, Adult)",Phase 3,200,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",KF5503/65|2012-004359-35,2015-01-01,2018-12-01,2018-12-01,2014-03-07,null,2018-01-24,"US013, Phoenix, Arizona, United States|US008, Little Rock, Arkansas, United States|US004, Stanford, California, United States|US010, Washington, District of Columbia, United States|US011, Miami, Florida, United States|US012, Louisville, Kentucky, United States|US009, Saint Paul, Minnesota, United States|US001, Bronx, New York, United States|US018, Bronx, New York, United States|US006, Durham, North Carolina, United States|US016, Cincinnati, Ohio, United States|US015, Philadelphia, Pennsylvania, United States|US014, Pittsburgh, Pennsylvania, United States|US002, Nashville, Tennessee, United States|US003, Dallas, Texas, United States|US005, Houston, Texas, United States|US007, Milwaukee, Wisconsin, United States|AT001, Graz, Austria|BG003, Pleven, Bulgaria|BG001, Plovdiv, Bulgaria|BG004, Sevlievo, Bulgaria|BG005, Sofia, Bulgaria|BG002, Stara Zagora, Bulgaria|HR002, Rijeka, Croatia|HR003, Split, Croatia|HR001, Zagreb, Croatia|CZ004, Karviná, Czechia|CZ003, Olomouc, Czechia|CZ002, Ostrava, Czechia|CZ001, Praha 4 - Krč, Czechia|FR002, La Tronche, France|FR001, Lille, France|FR004, Limoges, France|FR003, Toulouse, France|DE001, Freiburg, Germany|DE003, Homburg/Saar, Germany|DE006, Sankt Augustin, Germany|DE007, Stuttgart, Germany|DE004, Wuppertal, Germany|HU004, Budapest, Hungary|HU003, Debrecen, Hungary|HU002, Gyor, Hungary|HU001, Gyula, Hungary|HU005, Pecs, Hungary|PL011, Bydgoszcz, Poland|PL010, Gdansk, Poland|PL006, Katowice, Poland|PL005, Lodz, Poland|PL002, Lublin, Poland|PL009, Olsztyn, Poland|PL014, Rzeszow, Poland|PL007, Torun, Poland|PL004, Warszawa, Poland|PL008, Warszawa, Poland|PL003, Łódź, Poland|PR001, San Juan, Puerto Rico|ES010, Baracaldo, Spain|ES001, Barcelona, Spain|ES002, Barcelona, Spain|ES008, Granada, Spain|ES003, Madrid, Spain|ES005, Madrid, Spain|ES004, Madrid, Spain|ES007, Madrid, Spain|ES009, Santiago de Compostela, Spain|ES006, Valladolid, Spain|GB003, Bristol, United Kingdom|GB004, Glasgow, United Kingdom|GB002, London, United Kingdom|GB001, Sheffield, United Kingdom",,https://ClinicalTrials.gov/show/NCT02081391
838,NCT02067442,"Prospective, Randomized, Double Blind Study Comparing IV vs PO Acetaminophen in Patients Undergoing Lumbar Discectomy",,Unknown status,No Results Available,Pain,Drug: oral acetaminophen|Drug: intravenous acetaminophen,Postoperative pain scores|Quantity of intraoperative and postoperative opioids administered.,Thomas Jefferson University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",12D.685,2013-08-01,2015-07-01,null,2014-02-20,null,2015-03-18,"Thomas Jefferson University Hopsital, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02067442
839,NCT01177982,Reinforcement-Based Treatment for Pregnant Drug Abusers,HOME II,Completed,No Results Available,Drug Use Disorders During Pregnancy,Behavioral: Usual RBT (t-RBT)|Behavioral: Reduced RBT (r-RBT)|Behavioral: Abbreviated RBT (a-RBT)|Behavioral: Enhanced RBT (e-RBT)|Behavioral: Early compliant t-RBT|Behavioral: Early non-compliant t-RBT|Behavioral: Early compliant r-RBT|Behavioral: Early non-compliant r-RBT,Treatment Completion|Substance use|Alcohol|Maternal Obstetrical Course/Outcome|Birth outcomes|Length of Hospital Stay|APGAR scores,National Institute on Drug Abuse (NIDA)|Johns Hopkins University,Female,18 Years to 46 Years   (Adult),Phase 2|Phase 3,220,NIH|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,DA14979-06|R01DA014979|DCNBR,2009-07-01,2014-01-01,2015-05-01,2010-08-09,null,2017-01-11,"Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01177982
840,NCT01280331,Comparison of the Safety of Q8003 Versus Morphine Equivalent Doses of Its Components (Oxycodone and Morphine) in Bunionectomy Patients,,Completed,No Results Available,Postoperative Pain,Drug: Q8003 (morphine sulfate and oxycodone hydrochloride)|Drug: Morphine sulfate|Drug: Oxycodone HCl,Differences in desaturation events per standardized time unit|Difference in efficacy between Q8003 and its components (morphine and oxycodone)|Differences in the absence of emesis without the use of an anti-emetic (emesis complete response),QRxPharma Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 3,375,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Q8003-022,2011-01-01,2011-04-01,2011-04-01,2011-01-20,null,2012-05-17,"Investigational site, Anaheim, California, United States|Investigational site, Owings Mills, Maryland, United States|Investigational site, Pasadena, Maryland, United States|Investigational Site, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT01280331
841,NCT01427270,Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain,,Completed,No Results Available,Low Back Pain,Drug: Oxycodone/Naloxone controlled-release|Drug: Oxycodone HCl controlled-release|Drug: Placebo,Overall complete spontaneous bowel movement (CSBM) responder rates|CSBM Responder at least 50% of the weeks in the double-blind period|Laxative-free Responder at least 50% of the weeks in the double-blind period,Purdue Pharma LP,All,"18 Years and older   (Adult, Older Adult)",Phase 3,455,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ONU3704|2011-005060-26,2011-08-01,2014-10-01,2014-10-01,2011-09-01,null,2014-11-07,"Investigational Site, Alabaster, Alabama, United States|Investigational Site, Birmingham, Alabama, United States|Investigational Site, Gulf Shores, Alabama, United States|Investigational Site, Homewood, Alabama, United States|Investigational Site, Huntsville, Alabama, United States|Investigational Site, Mobile, Alabama, United States|Investigational Site, Goodyear, Arizona, United States|Investigational Site, Goodyear, Arizona, United States|Investigational Site, Phoenix, Arizona, United States|Investigational Site, Phoenix, Arizona, United States|Investigational Site, Tempe, Arizona, United States|Investigational Site, Tucson, Arizona, United States|Investigational Site, Hot Springs, Arkansas, United States|Investigational Site, Little Rock, Arkansas, United States|Investigational Site, Anaheim, California, United States|Investigational Site, Anaheim, California, United States|Investigational Site, Anaheim, California, United States|Investigational Site, Chino, California, United States|Investigational Site, Fresno, California, United States|Investigational Site, Fresno, California, United States|Investigational Site, Glendale, California, United States|Investigational Site, La Mesa, California, United States|Investigational Site, Laguna Hills, California, United States|Investigational Site, Long Beach, California, United States|Investigational Site, Los Angeles, California, United States|Investigational Site, Los Angeles, California, United States|Investigational Site, Los Angeles, California, United States|Investigational Site, Los Gatos, California, United States|Investigational Site, National City, California, United States|Investigational Site, North Hollywood, California, United States|Investigational Site, Oceanside, California, United States|Investigational Site, Paramount, California, United States|Investigational Site, Richmond, California, United States|Investigational Site, Roseville, California, United States|Investigational Site, Sacramento, California, United States|Investigational Site, Sacramento, California, United States|Investigational Site, San Diego, California, United States|Investigational Site, Santa Ana, California, United States|Investigational Site, Santa Clarita, California, United States|Investigational Site, Valley Village, California, United States|Investigational Site, Golden, Colorado, United States|Investigational Site, New Haven, Connecticut, United States|Investigational Site, Waterbury, Connecticut, United States|Investigational Site, Aventura, Florida, United States|Investigational Site, Boynton Beach, Florida, United States|Investigational Site, Bradenton, Florida, United States|Investigational Site, Clearwater, Florida, United States|Investigational Site, Clermont, Florida, United States|Investigational Site, Coral Gables, Florida, United States|Investigational Site, Daytona Beach, Florida, United States|Investigational Site, Ft. Lauderdale, Florida, United States|Investigational Site, Hialeah, Florida, United States|Investigational Site, Hialeah, Florida, United States|Investigational Site, Inverness, Florida, United States|Investigational Site, Jacksonville, Florida, United States|Investigational Site, Jacksonville, Florida, United States|Investigational Site, Jupiter, Florida, United States|Investigational Site, Miami Lakes, Florida, United States|Investigational Site, Miami, Florida, United States|Investigational Site, Miami, Florida, United States|Investigational Site, Miami, Florida, United States|Investigational Site, Miami, Florida, United States|Investigational Site, Miami, Florida, United States|Investigational Site, Naples, Florida, United States|Investigational Site, Naples, Florida, United States|Investigational Site, New Port Richey, Florida, United States|Investigational Site, North Miami Beach, Florida, United States|Investigational Site, Orlando, Florida, United States|Investigational Site, Oviedo, Florida, United States|Investigational Site, Pinellas Park, Florida, United States|Investigational Site, Pinellas Park, Florida, United States|Investigational Site, Plantation, Florida, United States|Investigational Site, Port Orange, Florida, United States|Investigational Site, Sanford, Florida, United States|Investigational Site, South Miami, Florida, United States|Investigational Site, Tamarac, Florida, United States|Investigational Site, Tampa, Florida, United States|Investigational Site, Tampa, Florida, United States|Investigational Site, Wellington, Florida, United States|Investigational Site, Austell, Georgia, United States|Investigational Site, Blue Ridge, Georgia, United States|Investigational Site, Canton, Georgia, United States|Investigational Site, Columbus, Georgia, United States|Investigational Site, Johns Creek, Georgia, United States|Investigational Site, Marietta, Georgia, United States|Investigational Site, Perry, Georgia, United States|Investigational Site, Savannah, Georgia, United States|Investigational Site, Boise, Idaho, United States|Investigational Site, Meridian, Idaho, United States|Investigational Site, Bloomington, Illinois, United States|Investigational Site, Chicago, Illinois, United States|Investigational Site, Evansville, Indiana, United States|Investigational Site, Kansas City, Kansas, United States|Investigational Site, Wichita, Kansas, United States|Investigational Site, Lexington, Kentucky, United States|Investigational Site, Madisonville, Kentucky, United States|Investigational Site, Baton Rouge, Louisiana, United States|Investigational Site, Covington, Louisiana, United States|Investigational Site, Marrero, Louisiana, United States|Investigational Site, Metairie, Louisiana, United States|Investigational Site, Hollywood, Maryland, United States|Investigational Site, Fall River, Massachusetts, United States|Investigational Site, North Attleboro, Massachusetts, United States|Investigational Site, Bay City, Michigan, United States|Investigational Site, Pinconning, Michigan, United States|Investigational Site, Rochester, Michigan, United States|Investigational Site, Troy, Michigan, United States|Investigational Site, Hazelwood, Missouri, United States|Investigational Site, St. Louis, Missouri, United States|Investigational Site, St. Louis, Missouri, United States|Investigational Site, Las Vegas, Nevada, United States|Investigational Site, Stratford, New Jersey, United States|Investigational Site, Toms River, New Jersey, United States|Investigational Site, Voorhees, New Jersey, United States|Investigational Site, Albuquerque, New Mexico, United States|Investigational Site, Cedarhurst, New York, United States|Investigational Site, Great Neck, New York, United States|Investigational Site, New Windsor, New York, United States|Investigational Site, New York, New York, United States|Investigational Site, North Massapequa, New York, United States|Investigational Site, Williamsville, New York, United States|Investigational Site, Elkin, North Carolina, United States|Investigational Site, Winston-Salem, North Carolina, United States|Investigational Site, Beavercreek, Ohio, United States|Investigational Site, Cincinnati, Ohio, United States|Investigational Site, Cleveland, Ohio, United States|Investigational Site, Columbus, Ohio, United States|Investigational Site, Columbus, Ohio, United States|Investigational Site, Franklin, Ohio, United States|Investigational Site, Groveport, Ohio, United States|Investigational Site, Toledo, Ohio, United States|Investigational Site, Oklahoma City, Oklahoma, United States|Investigational Site, Altoona, Pennsylvania, United States|Investigational Site, Jenkintown, Pennsylvania, United States|Investigational Site, Johnstown, Pennsylvania, United States|Investigational Site, Philadelphia, Pennsylvania, United States|Investigational Site, Phoenixville, Pennsylvania, United States|Investigational Site, Tipton, Pennsylvania, United States|Investigational Site, Warwick, Rhode Island, United States|Investigational Site, Myrtle Beach, South Carolina, United States|Investigational Site, Spartanburg, South Carolina, United States|Investigational Site, Franklin, Tennessee, United States|Investigational Site, New Tazewell, Tennessee, United States|Investigational Site, Arlington, Texas, United States|Investigational Site, Athens, Texas, United States|Investigational Site, Austin, Texas, United States|Investigational Site, Dallas, Texas, United States|Investigational Site, Dallas, Texas, United States|Investigational Site, Houston, Texas, United States|Investigational Site, Houston, Texas, United States|Investigational Site, Houston, Texas, United States|Investigational Site, Houston, Texas, United States|Investigational Site, Houston, Texas, United States|Investigational Site, Houston, Texas, United States|Investigational Site, Houston, Texas, United States|Investigational Site, Houston, Texas, United States|Investigational Site, Humble, Texas, United States|Investigational Site, North Richland Hills, Texas, United States|Investigational Site, Plano, Texas, United States|Investigational Site, San Antonio, Texas, United States|Investigational Site, San Antonio, Texas, United States|Investigational Site, Sugar Land, Texas, United States|Investigational Site, Tomball, Texas, United States|Investigational Site, Clinton, Utah, United States|Investigational Site, Salt Lake City, Utah, United States|Investigational Site, Salt Lake City, Utah, United States|Investigational Site, West Jordan, Utah, United States|Investigational Site, Richmond, Virginia, United States|Investigational Site, Richmond, Virginia, United States|Investigational Site, Virginia Beach, Virginia, United States|Investigational Site, Brno, Czech Republic|Investigational Site, Hradec Kralove, Czech Republic|Investigational Site, Most, Czech Republic|Investigational Site, Olomouc, Czech Republic|Investigational Site, Praha 10, Czech Republic|Investigational Site, Praha 4 - Krc, Czech Republic|Investigational Site, Praha 6, Czech Republic|Investigational Site, Rychnov nad Kneznou, Czech Republic|Investigational Site, Sternberk, Czech Republic|Investigational Site, Vysoke Myto, Czech Republic|Investigational Site, Zlin, Czech Republic|Investigational Site, Znojmo, Czech Republic|Investigational Site, Catania, Italy|Investigational Site, Bielsko-Biala, Poland|Investigational Site, Bydgoszcz, Poland|Investigational Site, Bydgoszcz, Poland|Investigational Site, Gdansk, Poland|Investigational Site, Gdansk, Poland|Investigational Site, Gdynia, Poland|Investigational Site, Katowice, Poland|Investigational Site, Katowice, Poland|Investigational Site, Lublin, Poland|Investigational Site, Lublin, Poland|Investigational Site, Torun, Poland",,https://ClinicalTrials.gov/show/NCT01427270
842,NCT01192295,Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids,,Completed,Has Results,Pain,Drug: Oxycodone HCl controlled-release tablets,The Number of Participants With Adverse Events as a Measure of Safety.|Pain Right Now Assessment by Patients Aged 6 to < 12 Years|Pain Right Now Assessment by Patients Aged ≥ 12 to ≤ 16 Years|Use of Supplemental Pain Medication|Parent/ Caregiver-Assessed Global Impression of Change (PGIC)|Parent/ Caregiver Assessed Functional Disability Inventory (FDI) for Patients Aged 6 to < 12 Years|Parent/ Caregiver Assessed Functional Disability Inventory (FDI) for Patients Aged ≥ 12 to ≤ 16 Years|Pharmacokinetics (PK) Data of Oxycodone Hydrochloride Controlled-release Tablets,Purdue Pharma LP,All,6 Years to 16 Years   (Child),Phase 3,155,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OTR3001|2010-020471-23,2010-11-01,2014-07-01,2014-07-01,2010-09-01,2015-02-06,2017-10-18,"Children's Hospital of Alabama, Birmingham, Alabama, United States|University of South Alabama, Children's and Women's Hospital, Mobile, Alabama, United States|Phoenix Children's Hospital, Phoenix, Arizona, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Children's Hospital of Orange County, Orange, California, United States|LS Packard Children's Hospital, Palo Alto, California, United States|Bayview Research Group, LLC, Paramount, California, United States|Shriners Hospitals for Children Northern California, Sacramento, California, United States|The Children's Hospital, Aurora, Colorado, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States|Memorial Regional Hospital, Hollywood, Florida, United States|Jackson Memorial Hospital/University of Miami, Miami, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|Children's Memorial Hospital, Chicago, Illinois, United States|University of Kentucky, Lexington, Kentucky, United States|Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States|St. John's Mercy Medical Center, Saint Louis, Missouri, United States|New York University Langone Medical Center, New York, New York, United States|Stony Brook University Hospital, Stony Brook, New York, United States|Presbyterian Blume Pediatric Hematology and Oncology Clinic, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Akron Children's Hospital, Akron, Ohio, United States|Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|The Children's Hospital at OUMC, Oklahoma City, Oklahoma, United States|Legacy Emanuel Children's Hospital, Portland, Oregon, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, United States|Children's Medical Ctr of Dallas, Dallas, Texas, United States|Research Facility, The Woodlands, Texas, United States|Primary Children's Medical Center, Salt Lake City, Utah, United States|Children's Hospital of the King's Daughters, Norfolk, Virginia, United States|Pediatric Hematology and Oncology, Virginia Commonwealth University Health System, Richmond, Virginia, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|Agia Sophia Children's Hospital, Athens, Greece|Aglaia Kyriakou - Elpida Children's Oncology Unit, Athens, Greece|Semmelweis Egyetem, II. sz. Gyermekgyogyaszati Klinika, Budapest, Hungary|Soroka University Medical Center, Beersheba, Israel|Mayer Children Hospital, Rambam Medical Center, Haifa, Israel|Hadassah Medical Organization, Ein Kerem, Jerusalem, Israel|Schneider Children Medical Center of Israel, Petaẖ Tiqwa, Israel|Sheba Medical Center, Ramat Gan, Israel|Starship Children's Health, Grafton, Auckland, New Zealand|Spitalul Clinic Judetean de Urgenta Targu Mures, Clinica pediatrie I, Targu Mures, Romania|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Sheffield Children's Hospital, Sheffield, United Kingdom",,https://ClinicalTrials.gov/show/NCT01192295
843,NCT02811302,PRediction of Opioid-induced Respiratory Depression In Patients Monitored by capnoGraphY,PRODIGY,Completed,No Results Available,Respiratory Depression,Device: Capnostream Monitor,Identify subjects at risk of having respiratory depression,Medtronic - MITG,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1496,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,COVMOPO0560,2017-04-07,2018-05-07,2018-05-07,2016-06-23,null,2018-06-11,"University of Colorado Hospital, Aurora, Colorado, United States|Emory University Hospital, Atlanta, Georgia, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Beaumont Hospital - Royal Oak, Royal Oak, Michigan, United States|Buffalo General Medical Center, Buffalo, New York, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Providence Regional Medical Center Everett, Everett, Washington, United States|Hospital Foch, Suresnes, France|University Hospital Bonn, Bonn, Germany|Okayama University Hospital, Okayama, Japan|The Jikei University School of Medicine Hospital, Tokyo, Japan|Maastricht UMC+, Maastricht, Limburg, Netherlands|National University Hospital, Singapore, Singapore|Hospital Clínico Universitario de Valencia, Valencia, Spain",,https://ClinicalTrials.gov/show/NCT02811302
844,NCT00366431,Study Evaluating Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction (OIBD) in Subjects With Chronic Non-Malignant Pain,,Completed,No Results Available,Constipation,Drug: MOA-728,The effect of the interventional treatment will be measured by the change from baseline in the number of bowel movements per week during the double-blind treatment period.,"Valeant Pharmaceuticals International, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,420,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,3200A3-200,2006-08-01,null,2007-03-01,2006-08-21,null,2011-07-25,"Birmingham, Alabama, United States|Birmingham, Alabama, United States|Mobile, Alabama, United States|Phoenix, Arizona, United States|Tucson, Arizona, United States|Tucson, Arizona, United States|Tucson, Arizona, United States|Hot Springs, Arkansas, United States|Anaheim, California, United States|Anaheim, California, United States|Bakersfield, California, United States|Foothill Ranch, California, United States|Garden Grove, California, United States|Los Gatos, California, United States|Orange, California, United States|Sacramento, California, United States|San Diego, California, United States|San Diego, California, United States|San Diego, California, United States|Trumbull, Connecticut, United States|Hollywood, Florida, United States|Jacksonville, Florida, United States|Jupiter, Florida, United States|Largo, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Ocala, Florida, United States|Ormond Beach, Florida, United States|St. Cloud, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Dawsonville, Georgia, United States|Marietta, Georgia, United States|Marietta, Georgia, United States|Bloomington, Illinois, United States|Chicago, Illinois, United States|Indianapolis, Indiana, United States|Elkridge, Maryland, United States|Boston, Massachusetts, United States|Brockton, Massachusetts, United States|Saginaw, Michigan, United States|Traverse City, Michigan, United States|Picayune, Mississippi, United States|Independence, Missouri, United States|Missoula, Montana, United States|Omaha, Nebraska, United States|Reno, Nevada, United States|Haddon Heights, New Jersey, United States|Albuquerque, New Mexico, United States|Great Neck, New York, United States|Lake Success, New York, United States|Charlotte, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Dayton, Ohio, United States|Clinton, Oklahoma, United States|Chattanooga, Tennessee, United States|Beaumont, Texas, United States|Colleyville, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|Alexandria, Virginia, United States|Christiansburg, Virginia, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00366431
845,NCT00226421,Efficacy and Safety of Oxymorphone Extended Release in Opioid-Experienced Patients With Chronic Non-Malignant Pain,,Completed,No Results Available,Chronic Pain,Drug: Oxymorphone Extended Release,Change in pain intensity from baseline (pre-randomization) to last assessment.|- Time to early discontinuation due to lack of efficacy|- Patient's Global Assessment of Pain Medication|- Physician's Global Assessment of Pain Medication|- Pain Quality Assessment Scale|- Safety as measured by AEs,Endo Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 3,120,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,EN3202-032,2004-10-01,null,2005-08-01,2005-09-27,null,2010-02-15,"Southern Drug Research, Hueytown, Alabama, United States|Phoenix Center for Clinical Research, Phoenix, Arizona, United States|Arizona Research, Phoenix, Arizona, United States|Express Care Clinical Research, Colorado Springs, Colorado, United States|Glasgow Family Practice, Newark, Delaware, United States|Radiant Research, Daytona Beach, Florida, United States|University Clinical Research, Deland, Florida, United States|LCFP Inc., Fort Myers, Florida, United States|Century Clinical Research, Holly Hill, Florida, United States|Ocala Rheumatology Research Center, Ocala, Florida, United States|The Arthritis Center, Palm Harbor, Florida, United States|Radiant Research, Pinellas Park, Florida, United States|Park Place Therapeutic Center, Plantation, Florida, United States|Comprehensive Neurology Specialists, Atlanta, Georgia, United States|Comprehensive Neuroscience, Atlanta, Georgia, United States|Pain Specialists of Greater Chicago, Burr Ridge, Illinois, United States|Mid-America Physiatrists, Overland Park, Kansas, United States|Research Medical Center, Kansas City, Missouri, United States|Radiant Research, St. Louis, Missouri, United States|Comprehensive Clinical Research, Berlin, New Jersey, United States|Piedmont Anesthesia, Winston-Salem, North Carolina, United States|Health Research Institute, Oklahoma City, Oklahoma, United States|Pain Consultants of Oregon, Eugene, Oregon, United States|Keystone Medical Research, Altoona, Pennsylvania, United States|Perkiomen Valley Family Practice, Collegeville, Pennsylvania, United States|Feasterville Family Health Center, Feasterville, Pennsylvania, United States|Fleetwood Clinical Research, Fleetwood, Pennsylvania, United States|Paragon Clinical Research, Cranston, Rhode Island, United States|Waccamaw Pain Management, Murrells Inlet, South Carolina, United States|KRK Medical Research, Richardson, Texas, United States|Jean Brown Research, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT00226421
846,NCT01427283,A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain,,Completed,No Results Available,Low Back Pain,Drug: Oxycodone/Naloxone controlled-release|Drug: Oxycodone HCl controlled-release|Drug: Placebo,Overall complete spontaneous bowel movement (CSBM) responder rates|CSBM Responder at least 50% of the weeks in the double-blind period|Laxative-free Responder at least 50% of the weeks in the double-blind period,Purdue Pharma LP,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ONU3705|2011-005061-20,2011-08-01,2014-10-01,2014-10-01,2011-09-01,null,2015-02-12,"Investigational Site, Alabaster, Alabama, United States|Investigational Site, Birmingham, Alabama, United States|Investigational Site, Birmingham, Alabama, United States|Investigational Site, Foley, Alabama, United States|Investigational Site, Mobile, Alabama, United States|Investigational Site, Mesa, Arizona, United States|Investigational Site, Phoenix, Arizona, United States|Investigational Site, Phoenix, Arizona, United States|Investigational Site, Sun Lakes, Arizona, United States|Investigational Site, Tucson, Arizona, United States|Investigational Site, Tucson, Arizona, United States|Investigational Site, Little Rock, Arkansas, United States|Investigational Site, Sherwood, Arkansas, United States|Investigational Site, Anaheim, California, United States|Investigational Site, Anaheim, California, United States|Investigational Site, Artesia, California, United States|Investigational Site, Cerritos, California, United States|Investigational Site, Chino, California, United States|Investigational Site, El Cajon, California, United States|Investigational Site, Encino, California, United States|Investigational Site, Fountain Valley, California, United States|Investigational Site, Fresno, California, United States|Investigational Site, Garden Grove, California, United States|Investigational Site, Garden Grove, California, United States|Investigational Site, Laguna Hills, California, United States|Investigational Site, Lakewood, California, United States|Investigational Site, Lincoln, California, United States|Investigational Site, Lomita, California, United States|Investigational Site, Long Beach, California, United States|Investigational Site, Oceanside, California, United States|Investigational Site, Orange, California, United States|Investigational Site, Paramount, California, United States|Investigational Site, Sacramento, California, United States|Investigational Site, San Bernardino, California, United States|Investigational Site, San Diego, California, United States|Investigational Site, San Diego, California, United States|Investigational Site, Thousand Oaks, California, United States|Investigational Site, Torrance, California, United States|Investigational Site, Colorado Springs, Colorado, United States|Investigational Site, Colorado Springs, Colorado, United States|Investigational Site, Denver, Colorado, United States|Investigational Site, Golden, Colorado, United States|Investigational Site, Aventura, Florida, United States|Investigational Site, Bradenton, Florida, United States|Investigational Site, Chiefland, Florida, United States|Investigational Site, Clermont, Florida, United States|Investigational Site, Daytona Beach, Florida, United States|Investigational Site, Deland, Florida, United States|Investigational Site, Edgewater, Florida, United States|Investigational Site, Ft. Lauderdale, Florida, United States|Investigational Site, Ft. Myers, Florida, United States|Investigational Site, Hialeah, Florida, United States|Investigational Site, Hialeah, Florida, United States|Investigational Site, Inverness, Florida, United States|Investigational Site, Jacksonville, Florida, United States|Investigational Site, Jacksonville, Florida, United States|Investigational Site, Jacksonville, Florida, United States|Investigational Site, Miami Beach, Florida, United States|Investigational Site, Miami, Florida, United States|Investigational Site, Miami, Florida, United States|Investigational Site, Miami, Florida, United States|Investigational Site, Miami, Florida, United States|Investigational Site, Miami, Florida, United States|Investigational Site, Miami, Florida, United States|Investigational Site, Miami, Florida, United States|Investigational Site, Miami, Florida, United States|Investigational Site, Miami, Florida, United States|Investigational Site, Miami, Florida, United States|Investigational Site, Naples, Florida, United States|Investigational Site, Naples, Florida, United States|Investigational Site, New Smyrna Beach, Florida, United States|Investigational Site, North Miami, Florida, United States|Investigational Site, Oldsmar, Florida, United States|Investigational Site, Orlando, Florida, United States|Investigational Site, Oviedo, Florida, United States|Investigational Site, Plantation, Florida, United States|Investigational Site, Tamarac, Florida, United States|Investigational Site, Tampa, Florida, United States|Investigational Site, West Palm Beach, Florida, United States|Investigational Site, Atlanta, Georgia, United States|Investigational Site, Austell, Georgia, United States|Investigational Site, Snellville, Georgia, United States|Investigational Site, Boise, Idaho, United States|Investigational Site, Boise, Idaho, United States|Investigational Site, Chicago, Illinois, United States|Investigational Site, Chicago, Illinois, United States|Investigational Site, Chicago, Illinois, United States|Investigational Site, Evansville, Indiana, United States|Investigational Site, Indianapolis, Indiana, United States|Investigational Site, Michigan City, Indiana, United States|Investigational Site, Wichita, Kansas, United States|Investigational Site, Edgewood, Kentucky, United States|Investigational Site, Lake Charles, Louisiana, United States|Investigational Site, Monroe, Louisiana, United States|Investigational Site, New Orleans, Louisiana, United States|Investigational Site, Pikesville, Maryland, United States|Investigational Site, Brockton, Massachusetts, United States|Investigational Site, Worcester, Massachusetts, United States|Investigational Site, Florissant, Missouri, United States|Investigational Site, Las Vegas, Nevada, United States|Investigational Site, Atco, New Jersey, United States|Investigational Site, Great Neck, New York, United States|Investigational Site, Kew Gardens, New York, United States|Investigational Site, New York, New York, United States|Investigational Site, Rochester, New York, United States|Investigational Site, Williamsville, New York, United States|Investigational Site, Durham, North Carolina, United States|Investigational Site, Elkin, North Carolina, United States|Investigational Site, High Point, North Carolina, United States|Investigational Site, Winston Salem, North Carolina, United States|Investigational Site, Winston-Salem, North Carolina, United States|Investigational Site, Columbus, Ohio, United States|Investigational Site, Dayton, Ohio, United States|Investigational Site, Moraine, Ohio, United States|Investigational Site, Toledo, Ohio, United States|Investigational Site, Oklahoma City, Oklahoma, United States|Investigational Site, Oklahoma City, Oklahoma, United States|Investigational Site, Oklahoma City, Oklahoma, United States|Investigational Site, Eugene, Oregon, United States|Investigational Site, Jenkintown, Pennsylvania, United States|Investigational Site, Levittown, Pennsylvania, United States|Investigational Site, Mechanicsburg, Pennsylvania, United States|Investigational Site, Pittsburgh, Pennsylvania, United States|Investigational Site, Red Lion, Pennsylvania, United States|Investigational Site, State College, Pennsylvania, United States|Investigational Site, Warwick, Rhode Island, United States|Investigational Site, Charleston, South Carolina, United States|Investigational Site, Myrtle Beach, South Carolina, United States|Investigational Site, Rapid City, South Dakota, United States|Investigational Site, Jackson, Tennessee, United States|Investigational Site, Allen, Texas, United States|Investigational Site, Austin, Texas, United States|Investigational Site, Dallas, Texas, United States|Investigational Site, Dallas, Texas, United States|Investigational Site, Dallas, Texas, United States|Investigational Site, Dallas, Texas, United States|Investigational Site, Houston, Texas, United States|Investigational Site, Houston, Texas, United States|Investigational Site, Houston, Texas, United States|Investigational Site, Houston, Texas, United States|Investigational Site, McKinney, Texas, United States|Investigational Site, North Richland Hills, Texas, United States|Investigational Site, Tomball, Texas, United States|Investigational Site, Orem, Utah, United States|Investigational Site, Salt Lake City, Utah, United States|Investigational Site, Salt Lake City, Utah, United States|Investigational Site, Danville, Virginia, United States|Investigational Site, Midlothian, Virginia, United States|Investigational Site, Richmond, Virginia, United States|Investigational Site, Bothell, Washington, United States",,https://ClinicalTrials.gov/show/NCT01427283
847,NCT00765856,Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects,,Terminated,No Results Available,Chronic Pain,Drug: Oxymorphone IR - Opioid,"Change in pain intensity from baseline to last assessment using the FPS-R.|Assessment of AEs, vital signs, and physical examinations.",Endo Pharmaceuticals,All,6 Years to 17 Years   (Child),Phase 3,27,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EN3202 036,2008-10-01,2010-02-01,2010-02-01,2008-10-03,null,2015-06-12,"Arkansas Childrens's Hospital-Division of Pediatric Anestesia and Pain Medicine, Little Rock, Arkansas, United States|Stanford University School of Medicine, Stanford, California, United States|The Children's Hospital, Aurora, Colorado, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|Children's National Medical Center, Washington, District of Columbia, United States|Florida Institute of Medical Research, Jacksonville, Florida, United States|Tukoi Clinical Research, Miami, Florida, United States|St. Joseph's Children's Hospital of Tampa, Tampa, Florida, United States|Taylor Research, LLC, Marietta, Georgia, United States|Rehabilitation Associates of Indiana, Indianapolis, Indiana, United States|University of Louisville Reserach Foundation, Inc., Louisville, Kentucky, United States|The Center for Clinical Research, Winston-Salem, North Carolina, United States|Hershey Medical Center, Hershey, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00765856
848,NCT00256932,Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain,,Completed,No Results Available,Bowel Dysfunction|Constipation,Drug: alvimopan|Drug: Placebo,"to compare alvimopan with placebo for efficacy in the treatment of OBD|Safety and tolerability, quality of life, pharmacokinetics, pharmacogenetics (dependent on results from other data)",Cubist Pharmaceuticals LLC|GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 3,518,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SB-767905/012,2005-08-01,null,2006-05-01,2005-11-22,null,2015-09-02,"GSK Investigational Site, Birmingham, Alabama, United States|GSK Investigational Site, Birmingham, Alabama, United States|GSK Investigational Site, Calera, Alabama, United States|GSK Investigational Site, Muscle Shoals, Alabama, United States|GSK Investigational Site, Tallassee, Alabama, United States|GSK Investigational Site, Glendale, Arizona, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Sun City, Arizona, United States|GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Hot Springs, Arkansas, United States|GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Anaheim, California, United States|GSK Investigational Site, Anaheim, California, United States|GSK Investigational Site, Beuna Park, California, United States|GSK Investigational Site, Burbank, California, United States|GSK Investigational Site, Duarte, California, United States|GSK Investigational Site, Fountain Valley, California, United States|GSK Investigational Site, Huntington Beach, California, United States|GSK Investigational Site, Mission Viejo, California, United States|GSK Investigational Site, Orange, California, United States|GSK Investigational Site, Redlands, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, Vista, California, United States|GSK Investigational Site, Waterbury, Connecticut, United States|GSK Investigational Site, Newark, Delaware, United States|GSK Investigational Site, Brandon, Florida, United States|GSK Investigational Site, Brooksville, Florida, United States|GSK Investigational Site, Deland, Florida, United States|GSK Investigational Site, Fort Meyers, Florida, United States|GSK Investigational Site, Gainsville, Florida, United States|GSK Investigational Site, Hollywood, Florida, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Jupiter, Florida, United States|GSK Investigational Site, Largo, Florida, United States|GSK Investigational Site, Melbourne, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Niceville, Florida, United States|GSK Investigational Site, North Miami, Florida, United States|GSK Investigational Site, Ocala, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Ormond Beach, Florida, United States|GSK Investigational Site, Sarasota, Florida, United States|GSK Investigational Site, St. Petersburg, Florida, United States|GSK Investigational Site, Tampa, Florida, United States|GSK Investigational Site, West Palm Beach, Florida, United States|GSK Investigational Site, Winter Park, Florida, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Dawsonville, Georgia, United States|GSK Investigational Site, Decatur, Georgia, United States|GSK Investigational Site, Decatur, Georgia, United States|GSK Investigational Site, Marietta, Georgia, United States|GSK Investigational Site, Bloomington, Illinois, United States|GSK Investigational Site, Rockford, Illinois, United States|GSK Investigational Site, Elkhart, Indiana, United States|GSK Investigational Site, Evansville, Indiana, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Newburgh, Indiana, United States|GSK Investigational Site, Lexington, Kentucky, United States|GSK Investigational Site, Louisville, Kentucky, United States|GSK Investigational Site, Shreveport, Louisiana, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Elkridge, Maryland, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Detroit, Michigan, United States|GSK Investigational Site, Portage, Michigan, United States|GSK Investigational Site, Saginaw, Michigan, United States|GSK Investigational Site, Chaska, Minnesota, United States|GSK Investigational Site, Picayune, Mississippi, United States|GSK Investigational Site, Fenton, Missouri, United States|GSK Investigational Site, Manchester, Missouri, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Incline Village, Nevada, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Elizabeth, New Jersey, United States|GSK Investigational Site, Haddon Heights, New Jersey, United States|GSK Investigational Site, Princeton, New Jersey, United States|GSK Investigational Site, East Syracuse, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Valley Stream, New York, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Concord, North Carolina, United States|GSK Investigational Site, Greensboro, North Carolina, United States|GSK Investigational Site, Salisbury, North Carolina, United States|GSK Investigational Site, Wilmington, North Carolina, United States|GSK Investigational Site, Winston-Salem, North Carolina, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Dayton, Ohio, United States|GSK Investigational Site, Dayton, Ohio, United States|GSK Investigational Site, Maumee, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Eugene, Oregon, United States|GSK Investigational Site, Medford, Oregon, United States|GSK Investigational Site, Oregon City, Oregon, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Bala Cynwyd, Pennsylvania, United States|GSK Investigational Site, Nazareth, Pennsylvania, United States|GSK Investigational Site, Whitehall, Pennsylvania, United States|GSK Investigational Site, Wyomissing, Pennsylvania, United States|GSK Investigational Site, Warwick, Rhode Island, United States|GSK Investigational Site, Woonsocket, Rhode Island, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Murrells Inlet, South Carolina, United States|GSK Investigational Site, Spartanburg, South Carolina, United States|GSK Investigational Site, Arlington, Texas, United States|GSK Investigational Site, Brownwood, Texas, United States|GSK Investigational Site, Colleyville, Texas, United States|GSK Investigational Site, Galveston, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Lake Jackson, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Alexandria, Virginia, United States|GSK Investigational Site, Chesapeake, Virginia, United States|GSK Investigational Site, Christiansburg, Virginia, United States|GSK Investigational Site, Danville, Virginia, United States|GSK Investigational Site, Virginia Beach, Virginia, United States|GSK Investigational Site, Bellingham, Washington, United States|GSK Investigational Site, Edmonds, Washington, United States|GSK Investigational Site, Lacey, Washington, United States|GSK Investigational Site, Spokane, Washington, United States|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Edmonton, Alberta, Canada|GSK Investigational Site, Kelowna, British Columbia, Canada|GSK Investigational Site, Langley, British Columbia, Canada|GSK Investigational Site, Saint John's, Newfoundland and Labrador, Canada|GSK Investigational Site, Halifax, Nova Scotia, Canada|GSK Investigational Site, Brampton, Ontario, Canada|GSK Investigational Site, Kitchener, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Chandler, Quebec, Canada|GSK Investigational Site, Mirabel, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Sherbrooke, Quebec, Canada|GSK Investigational Site, Hvidovre, Denmark|GSK Investigational Site, Ishoj, Denmark|GSK Investigational Site, Odense C, Denmark|GSK Investigational Site, Tallinn, Estonia|GSK Investigational Site, Helsinki, Finland|GSK Investigational Site, Fellbach, Baden-Wuerttemberg, Germany|GSK Investigational Site, Freiburg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Villingen-Schwenningen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Weinheim, Baden-Wuerttemberg, Germany|GSK Investigational Site, Augsburg, Bayern, Germany|GSK Investigational Site, Nuernberg, Bayern, Germany|GSK Investigational Site, Huettenberg, Hessen, Germany|GSK Investigational Site, Wiesbaden, Hessen, Germany|GSK Investigational Site, Schwerin, Mecklenburg-Vorpommern, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Viersen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Witten, Nordrhein-Westfalen, Germany|GSK Investigational Site, Chemnitz, Sachsen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Kiel, Schleswig-Holstein, Germany|GSK Investigational Site, Pinneberg, Schleswig-Holstein, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Cork, Ireland|GSK Investigational Site, Gdansk, Poland|GSK Investigational Site, Krakow, Poland|GSK Investigational Site, Wroclaw, Poland|GSK Investigational Site, Reading, Berkshire, United Kingdom|GSK Investigational Site, Slough, Berkshire, United Kingdom|GSK Investigational Site, Cardiff, Glamorgan, United Kingdom|GSK Investigational Site, Glasgow, Lanarkshire, United Kingdom|GSK Investigational Site, Glasgow, Lanarkshire, United Kingdom|GSK Investigational Site, Blackpool, Lancashire, United Kingdom|GSK Investigational Site, Ashford, Middlesex, United Kingdom|GSK Investigational Site, Sunbury-on-Thames, Middlesex, United Kingdom|GSK Investigational Site, Coventry, Warwickshire, United Kingdom|GSK Investigational Site, Bexhill-on-Sea, East Sussex, United Kingdom|GSK Investigational Site, Leeds, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Yaxley, Peterborough, United Kingdom|GSK Investigational Site, York, United Kingdom",,https://ClinicalTrials.gov/show/NCT00256932
849,NCT00259922,Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain,,Completed,No Results Available,Bowel Dysfunction|Constipation,Drug: Placebo|Drug: Alvimopan|Drug: Alviompan,"To compare alvimopan with placebo for efficacy in the treatment of OBD|Safety and tolerability, quality of life, pharmacogenetics (dependent on results from other data)",Cubist Pharmaceuticals LLC|GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 3,485,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SB-767905/013,2005-08-01,2006-06-01,null,2005-12-01,null,2015-09-02,"GSK Investigational Site, Birmingham, Alabama, United States|GSK Investigational Site, Birmingham, Alabama, United States|GSK Investigational Site, Huntsville, Alabama, United States|GSK Investigational Site, Mobile, Alabama, United States|GSK Investigational Site, Northport, Alabama, United States|GSK Investigational Site, Mesa, Arizona, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Tempe, Arizona, United States|GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Bakersfield, California, United States|GSK Investigational Site, Beverly Hills, California, United States|GSK Investigational Site, Long Beach, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Los Gatos, California, United States|GSK Investigational Site, Northridge, California, United States|GSK Investigational Site, Orange, California, United States|GSK Investigational Site, Palm Springs, California, United States|GSK Investigational Site, Pasadena, California, United States|GSK Investigational Site, Sacramento, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, San Rafael, California, United States|GSK Investigational Site, Santa Ana, California, United States|GSK Investigational Site, Stamford, Connecticut, United States|GSK Investigational Site, Waterbury, Connecticut, United States|GSK Investigational Site, Washington, District of Columbia, United States|GSK Investigational Site, Chiefland, Florida, United States|GSK Investigational Site, Clearwater, Florida, United States|GSK Investigational Site, Deerfield Beach, Florida, United States|GSK Investigational Site, Destin, Florida, United States|GSK Investigational Site, Fort Myers, Florida, United States|GSK Investigational Site, Hollywood, Florida, United States|GSK Investigational Site, Hollywood, Florida, United States|GSK Investigational Site, Largo, Florida, United States|GSK Investigational Site, Margate, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Ocala, Florida, United States|GSK Investigational Site, Ormond Beach, Florida, United States|GSK Investigational Site, St. Cloud, Florida, United States|GSK Investigational Site, Tampa, Florida, United States|GSK Investigational Site, West Palm Beach, Florida, United States|GSK Investigational Site, Winterhaven, Florida, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Cumming, Georgia, United States|GSK Investigational Site, Marietta, Georgia, United States|GSK Investigational Site, Stockbridge, Georgia, United States|GSK Investigational Site, Meridian, Idaho, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Libertyville, Illinois, United States|GSK Investigational Site, Oak Forest, Illinois, United States|GSK Investigational Site, Oakbrook Terrace, Illinois, United States|GSK Investigational Site, Evansville, Indiana, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Lexington, Kentucky, United States|GSK Investigational Site, Louisville, Kentucky, United States|GSK Investigational Site, Sunset, Louisiana, United States|GSK Investigational Site, Pasadena, Maryland, United States|GSK Investigational Site, Rockville, Maryland, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Brockton, Massachusetts, United States|GSK Investigational Site, Wellesley Hills, Massachusetts, United States|GSK Investigational Site, Portage, Michigan, United States|GSK Investigational Site, Waterford, Michigan, United States|GSK Investigational Site, Olive Branch, Mississippi, United States|GSK Investigational Site, Independence, Missouri, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, Missoula, Montana, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Dover, New Hampshire, United States|GSK Investigational Site, Blackwood, New Jersey, United States|GSK Investigational Site, Egg Harbor Township, New Jersey, United States|GSK Investigational Site, Albuquerque, New Mexico, United States|GSK Investigational Site, Mineola, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Rochester, New York, United States|GSK Investigational Site, Asheville, North Carolina, United States|GSK Investigational Site, Greensboro, North Carolina, United States|GSK Investigational Site, Hickory, North Carolina, United States|GSK Investigational Site, Raleigh, North Carolina, United States|GSK Investigational Site, Winston-Salem, North Carolina, United States|GSK Investigational Site, Centerville, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Dayton, Ohio, United States|GSK Investigational Site, Perrysburg, Ohio, United States|GSK Investigational Site, Eugene, Oregon, United States|GSK Investigational Site, Medford, Oregon, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Salem, Oregon, United States|GSK Investigational Site, Levittown, Pennsylvania, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Reading, Pennsylvania, United States|GSK Investigational Site, Cranston, Rhode Island, United States|GSK Investigational Site, Greer, South Carolina, United States|GSK Investigational Site, Kingsport, Tennessee, United States|GSK Investigational Site, New Tazewell, Tennessee, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Corpus Christi, Texas, United States|GSK Investigational Site, Galveston, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Richardson, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Salt Lake City, Utah, United States|GSK Investigational Site, Norfolk, Virginia, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Spokane, Washington, United States|GSK Investigational Site, Tacoma, Washington, United States|GSK Investigational Site, Yakima, Washington, United States|GSK Investigational Site, Charleston, West Virginia, United States|GSK Investigational Site, La Crosse, Wisconsin, United States|GSK Investigational Site, Broadmeadow, New South Wales, Australia|GSK Investigational Site, Newcastle, New South Wales, Australia|GSK Investigational Site, St Leonards, New South Wales, Australia|GSK Investigational Site, Carina Heights, Queensland, Australia|GSK Investigational Site, Kippa Ring, Queensland, Australia|GSK Investigational Site, Bedford Park, South Australia, Australia|GSK Investigational Site, Port Lincoln, South Australia, Australia|GSK Investigational Site, Toorak Gardens, South Australia, Australia|GSK Investigational Site, Box Hill, Victoria, Australia|GSK Investigational Site, Carlton, Victoria, Australia|GSK Investigational Site, Fremantle, Western Australia, Australia|GSK Investigational Site, Nedlands, Western Australia, Australia|GSK Investigational Site, Coquitlam, British Columbia, Canada|GSK Investigational Site, Winnipeg, Manitoba, Canada|GSK Investigational Site, Moncton, New Brunswick, Canada|GSK Investigational Site, St. John's, Newfoundland and Labrador, Canada|GSK Investigational Site, Mississauga, Ontario, Canada|GSK Investigational Site, North Bay, Ontario, Canada|GSK Investigational Site, North York, Ontario, Canada|GSK Investigational Site, Sudbury, Ontario, Canada|GSK Investigational Site, Bonaventure, Quebec, Canada|GSK Investigational Site, Saint Romuald, Quebec, Canada|GSK Investigational Site, Trois-Rivieres, Quebec, Canada|GSK Investigational Site, Boulogne, France|GSK Investigational Site, Grenoble, France|GSK Investigational Site, Montpellier Cedex 5, France|GSK Investigational Site, Paris Cedex 4, France|GSK Investigational Site, Paris, France|GSK Investigational Site, Paris, France|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Csongrád, Hungary|GSK Investigational Site, Heves, Hungary|GSK Investigational Site, Alkmaar, Netherlands|GSK Investigational Site, Breda, Netherlands|GSK Investigational Site, Roosendaal, Netherlands|GSK Investigational Site, Rotterdam, Netherlands|GSK Investigational Site, Utrecht, Netherlands|GSK Investigational Site, Christchurch, New Zealand|GSK Investigational Site, Hamilton, New Zealand|GSK Investigational Site, Tauranga, New Zealand|GSK Investigational Site, Oslo, Norway|GSK Investigational Site, Oslo, Norway|GSK Investigational Site, Paradis, Norway|GSK Investigational Site, Rådahl, Norway|GSK Investigational Site, Skien, Norway|GSK Investigational Site, Athlone, Cape Town, South Africa|GSK Investigational Site, Erasmuskloof, Pretoria, South Africa|GSK Investigational Site, Fourways, Johannesburg, South Africa|GSK Investigational Site, Kempton Park, South Africa|GSK Investigational Site, Kenilworth, Cape Town, South Africa|GSK Investigational Site, Lynnwood, Pretoria, South Africa|GSK Investigational Site, Tygervalley, South Africa|GSK Investigational Site, Westridge, Mitchells Plain, South Africa|GSK Investigational Site, Alcorcon, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, El Ferrol, Spain|GSK Investigational Site, Granada, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Santander, Spain|GSK Investigational Site, Valencia, Spain|GSK Investigational Site, Jönköping, Sweden|GSK Investigational Site, Karlstad, Sweden|GSK Investigational Site, Linköping, Sweden|GSK Investigational Site, Stockholm, Sweden|GSK Investigational Site, Bern, Switzerland|GSK Investigational Site, Nottwil, Switzerland",,https://ClinicalTrials.gov/show/NCT00259922
850,NCT00241722,Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain,,Completed,No Results Available,Bowel Dysfunction|Constipation,Drug: Alvimopan|Drug: Placebo,"To compare alvimopan with placebo for long-term safety and tolerability|Quality of life, pharmacokinetics, pharmacogenetics (dependent on results from other data)",Cubist Pharmaceuticals LLC|GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 3,805,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3753-013|SB-767905/014,2005-08-01,2007-02-01,2007-02-01,2005-10-19,null,2017-08-30,"GSK Investigational Site, Birmingham, Alabama, United States|GSK Investigational Site, Birmingham, Alabama, United States|GSK Investigational Site, Birmingham, Alabama, United States|GSK Investigational Site, Huntsville, Alabama, United States|GSK Investigational Site, Mobile, Alabama, United States|GSK Investigational Site, Muscle Shoals, Alabama, United States|GSK Investigational Site, Northport, Alabama, United States|GSK Investigational Site, Glendale, Arizona, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Sun City, Arizona, United States|GSK Investigational Site, Tempe, Arizona, United States|GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Hot Springs, Arkansas, United States|GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Anaheim, California, United States|GSK Investigational Site, Anaheim, California, United States|GSK Investigational Site, Bakersfield, California, United States|GSK Investigational Site, Beverly Hills, California, United States|GSK Investigational Site, Buena Park, California, United States|GSK Investigational Site, Burbank, California, United States|GSK Investigational Site, Los Gatos, California, United States|GSK Investigational Site, Orange, California, United States|GSK Investigational Site, Palm Springs, California, United States|GSK Investigational Site, Pismo Beach, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, Torrance, California, United States|GSK Investigational Site, Vista, California, United States|GSK Investigational Site, Stratford, Connecticut, United States|GSK Investigational Site, Trumbull, Connecticut, United States|GSK Investigational Site, Brandon, Florida, United States|GSK Investigational Site, Chiefland, Florida, United States|GSK Investigational Site, Clearwater, Florida, United States|GSK Investigational Site, Clearwater, Florida, United States|GSK Investigational Site, Deerfield Beach, Florida, United States|GSK Investigational Site, DeLand, Florida, United States|GSK Investigational Site, Fort Myers, Florida, United States|GSK Investigational Site, Gainesville, Florida, United States|GSK Investigational Site, Holly Hill, Florida, United States|GSK Investigational Site, Hollywood, Florida, United States|GSK Investigational Site, Jupiter, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Ocala, Florida, United States|GSK Investigational Site, Ocala, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Ormond Beach, Florida, United States|GSK Investigational Site, Saint Cloud, Florida, United States|GSK Investigational Site, West Palm Beach, Florida, United States|GSK Investigational Site, Dawsonville, Georgia, United States|GSK Investigational Site, Marietta, Georgia, United States|GSK Investigational Site, Stockbridge, Georgia, United States|GSK Investigational Site, Suwanee, Georgia, United States|GSK Investigational Site, Boise, Idaho, United States|GSK Investigational Site, Meridian, Idaho, United States|GSK Investigational Site, Arlington Heights, Illinois, United States|GSK Investigational Site, Bloomington, Illinois, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Rockford, Illinois, United States|GSK Investigational Site, Elkhart, Indiana, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Louisville, Kentucky, United States|GSK Investigational Site, Louisville, Kentucky, United States|GSK Investigational Site, Madisonville, Kentucky, United States|GSK Investigational Site, Baton Rouge, Louisiana, United States|GSK Investigational Site, Shreveport, Louisiana, United States|GSK Investigational Site, Pasadena, Maryland, United States|GSK Investigational Site, Rockville, Maryland, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Brockton, Massachusetts, United States|GSK Investigational Site, Wellesley Hills, Massachusetts, United States|GSK Investigational Site, Detroit, Michigan, United States|GSK Investigational Site, Grand Blanc, Michigan, United States|GSK Investigational Site, Portage, Michigan, United States|GSK Investigational Site, Traverse City, Michigan, United States|GSK Investigational Site, Chaska, Minnesota, United States|GSK Investigational Site, Olive Branch, Mississippi, United States|GSK Investigational Site, Manchester, Missouri, United States|GSK Investigational Site, Nixa, Missouri, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, Missoula, Montana, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Henderson, Nevada, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Dover, New Hampshire, United States|GSK Investigational Site, Blackwood, New Jersey, United States|GSK Investigational Site, Elizabeth, New Jersey, United States|GSK Investigational Site, Albuquerque, New Mexico, United States|GSK Investigational Site, Lake Success, New York, United States|GSK Investigational Site, Asheville, North Carolina, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Concord, North Carolina, United States|GSK Investigational Site, Greensboro, North Carolina, United States|GSK Investigational Site, Greensboro, North Carolina, United States|GSK Investigational Site, Hickory, North Carolina, United States|GSK Investigational Site, Raleigh, North Carolina, United States|GSK Investigational Site, Winston-Salem, North Carolina, United States|GSK Investigational Site, Centerville, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Dayton, Ohio, United States|GSK Investigational Site, Dayton, Ohio, United States|GSK Investigational Site, Dayton, Ohio, United States|GSK Investigational Site, Clinton, Oklahoma, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Medford, Oregon, United States|GSK Investigational Site, Oregon City, Oregon, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Carnegie, Pennsylvania, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Reading, Pennsylvania, United States|GSK Investigational Site, Woonsocket, Rhode Island, United States|GSK Investigational Site, Chattanooga, Tennessee, United States|GSK Investigational Site, Clarksville, Tennessee, United States|GSK Investigational Site, Kingsport, Tennessee, United States|GSK Investigational Site, Arlington, Texas, United States|GSK Investigational Site, Brownwood, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Grand Prairie, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Lake Jackson, Texas, United States|GSK Investigational Site, Lancaster, Texas, United States|GSK Investigational Site, Richardson, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Salt Lake City, Utah, United States|GSK Investigational Site, Salt Lake City, Utah, United States|GSK Investigational Site, Norfolk, Virginia, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Virginia Beach, Virginia, United States|GSK Investigational Site, Bellingham, Washington, United States|GSK Investigational Site, Edmonds, Washington, United States|GSK Investigational Site, Spokane, Washington, United States|GSK Investigational Site, Tacoma, Washington, United States|GSK Investigational Site, Charleston, West Virginia, United States|GSK Investigational Site, Broadmeadow, New South Wales, Australia|GSK Investigational Site, St Leonards, New South Wales, Australia|GSK Investigational Site, Carina Heights, Queensland, Australia|GSK Investigational Site, Kippa Ring, Queensland, Australia|GSK Investigational Site, Bedford Park, South Australia, Australia|GSK Investigational Site, Port Lincoln, South Australia, Australia|GSK Investigational Site, Toorak Gardens, South Australia, Australia|GSK Investigational Site, Box Hill, Victoria, Australia|GSK Investigational Site, Carlton, Victoria, Australia|GSK Investigational Site, Fremantle, Western Australia, Australia|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Calgary, Alberta, Canada|GSK Investigational Site, Edmonton, Alberta, Canada|GSK Investigational Site, Coquitlam, British Columbia, Canada|GSK Investigational Site, Kelowna, British Columbia, Canada|GSK Investigational Site, Langley, British Columbia, Canada|GSK Investigational Site, Winnipeg, Manitoba, Canada|GSK Investigational Site, Moncton, New Brunswick, Canada|GSK Investigational Site, Saint John's, Newfoundland and Labrador, Canada|GSK Investigational Site, Halifax, Nova Scotia, Canada|GSK Investigational Site, Brampton, Ontario, Canada|GSK Investigational Site, Hamilton, Ontario, Canada|GSK Investigational Site, Kitchener, Ontario, Canada|GSK Investigational Site, Mississauga, Ontario, Canada|GSK Investigational Site, North Bay, Ontario, Canada|GSK Investigational Site, North York, Ontario, Canada|GSK Investigational Site, Sudbury, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Charlottetown, Prince Edward Island, Canada|GSK Investigational Site, Bonaventure, Quebec, Canada|GSK Investigational Site, Chandler, Quebec, Canada|GSK Investigational Site, Drummondville, Quebec, Canada|GSK Investigational Site, Mirabel, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Saint Romuald, Quebec, Canada|GSK Investigational Site, Sherbrooke, Quebec, Canada|GSK Investigational Site, Trois-Rivieres, Quebec, Canada|GSK Investigational Site, Ishoj, Denmark|GSK Investigational Site, Helsinki, Finland|GSK Investigational Site, Kowloon, Hong Kong|GSK Investigational Site, Kwun Tong, Hong Kong|GSK Investigational Site, Pokfulam, Hong Kong|GSK Investigational Site, Shatin, Hong Kong|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Cork, Ireland|GSK Investigational Site, Roosendaal, Netherlands|GSK Investigational Site, Utrecht, Netherlands|GSK Investigational Site, Christchurch, New Zealand|GSK Investigational Site, Hamilton, New Zealand|GSK Investigational Site, Tauranga, New Zealand|GSK Investigational Site, Gdansk, Poland|GSK Investigational Site, Krakow, Poland|GSK Investigational Site, Wroclaw, Poland|GSK Investigational Site, Alcorcon, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, El Ferrol, Spain|GSK Investigational Site, Granada, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Santander, Spain|GSK Investigational Site, Valencia, Spain|GSK Investigational Site, Jönköping, Sweden|GSK Investigational Site, Karlstad, Sweden|GSK Investigational Site, Linköping, Sweden|GSK Investigational Site, Stockholm, Sweden|GSK Investigational Site, Bern, Switzerland|GSK Investigational Site, Tainan, Taiwan|GSK Investigational Site, Taipei, Taiwan|GSK Investigational Site, Taipei, Taiwan|GSK Investigational Site, Reading, Berkshire, United Kingdom|GSK Investigational Site, Slough, Berkshire, United Kingdom|GSK Investigational Site, Cardiff, Glamorgan, United Kingdom|GSK Investigational Site, Glasgow, Lanarkshire, United Kingdom|GSK Investigational Site, Glasgow, Lanarkshire, United Kingdom|GSK Investigational Site, Sunbury-on-Thames, Middlesex, United Kingdom|GSK Investigational Site, Coventry, Warwickshire, United Kingdom|GSK Investigational Site, Bexhill-on-Sea, East Sussex, United Kingdom|GSK Investigational Site, Leeds, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Yaxley, Peterborough, United Kingdom",,https://ClinicalTrials.gov/show/NCT00241722
851,NCT03305055,RCT: Fentanyl Plus Ketamine Versus Fentanyl Alone for Acute Burn Pain,,Not yet recruiting,No Results Available,Acute Pain|Wound Care|Posttraumatic Stress Disorder,Drug: ketamine|Drug: Fentanyl,"Mean Wound Care Pain|PTSD symptoms, symptom clusters and diagnosis",Johns Hopkins University|United States Department of Defense|Congressionally Directed Medical Research Programs,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,150,Other|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IRB00089761|NTI-NTRR15-13,2017-11-01,2018-06-30,2018-06-30,2017-10-09,null,2017-10-09,"Johns Hopkins Burn Center, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT03305055
852,NCT00666211,Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain,,Completed,Has Results,"Brain and Central Nervous System Tumors|Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Lymphoproliferative Disorder|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Pain|Precancerous Condition|Unspecified Adult Solid Tumor, Protocol Specific",Other: educational intervention|Other: Titrated pain management|Other: questionnaire administration,Pain Intensity|Pain-related Distress|Pain Duration|Ability to Engage in Activities of Daily Living (ADL)|Interference in Daily Life Due to Pain|Mood Disturbance|Quality of Life,Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI),All,"21 Years and older   (Adult, Older Adult)",Phase 3,98,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,VICC SUPP 0424|P30CA068485|VU-VICC-SUPP-0424|VU-VICC-040410,2005-05-01,2010-01-01,2010-05-01,2008-04-24,2012-09-06,2012-09-06,"Jennie Stuart Medical Center, Hopkinsville, Kentucky, United States|Mitchell Memorial Cancer Center at Owensboro Medical Health System, Owensboro, Kentucky, United States|Erlanger Health System, Chattanooga, Tennessee, United States|Tennessee Plateau Oncology, Crossville, Tennessee, United States|Center for Biomedical Research, Knoxville, Tennessee, United States|The Jones Clinic, Memphis, Tennessee, United States|Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States|Meharry Medical College, Nashville, Tennessee, United States|Veterans Affairs Medical Center - Nashville, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT00666211
853,NCT02362672,Efficacy and Safety Study of NKTR-181 in Opioid-Naive Subjects With Low Back Pain,SUMMIT-07,Completed,No Results Available,Low Back Pain|Chronic Pain,Drug: NKTR-181 BID tablets|Drug: Placebo to match NKTR-181 BID tablets,Change in Pain,Nektar Therapeutics,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,610,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",14-181-07,2015-03-11,2016-12-01,2017-02-01,2015-02-13,null,2018-03-06,"Investigator Site - Saraland, Saraland, Alabama, United States|Investigator Site - Phoenix, Phoenix, Arizona, United States|Investigator Site - Tempe, Tempe, Arizona, United States|Investigator Site - Little Rock, Little Rock, Arkansas, United States|Investigator Site - Stamford, Stamford, Connecticut, United States|Investigator Site - Clearwater, Clearwater, Florida, United States|Investigator Site - Fort Lauderdale, Fort Lauderdale, Florida, United States|Investigator Site - Jacksonville, Jacksonville, Florida, United States|Investigator Site - Orlando, Orlando, Florida, United States|Investigator Site - Ormond Beach, Ormond Beach, Florida, United States|Investigator Site - Plantation, Plantation, Florida, United States|Investigator Site - Tampa, Tampa, Florida, United States|Investigator Site - West Palm Beach, West Palm Beach, Florida, United States|Investigator Site - Atlanta, Atlanta, Georgia, United States|Investigator Site - Blue Ridge, Blue Ridge, Georgia, United States|Investigator Site - Marietta, Marietta, Georgia, United States|Investigator Site - Norcross, Norcross, Georgia, United States|Investigator Site - Gurnee, Gurnee, Illinois, United States|Investigator Site - West Des Moines, West Des Moines, Iowa, United States|Investigator Site - Wichita, Wichita, Kansas, United States|Investigator Site - Louisville, Louisville, Kentucky, United States|Investigator Site - Bossier, Bossier City, Louisiana, United States|Investigator Site - New Orleans, New Orleans, Louisiana, United States|Investigator Site - Shreveport, Shreveport, Louisiana, United States|Investigator Site - Bay City, Bay City, Michigan, United States|Investigator Site - Pinconning, Pinconning, Michigan, United States|Investigator Site - Biloxi, Biloxi, Mississippi, United States|Investigator Site - Saint Louis 1, Saint Louis, Missouri, United States|Investigator Site - Saint Louis 2, Saint Louis, Missouri, United States|Investigator Site - Omaha, Omaha, Nebraska, United States|Investigator Site - Las Vegas 2, Las Vegas, Nevada, United States|Investigator Site - Las Vegas 1, Las Vegas, Nevada, United States|Investigator Site - Rochester, Rochester, New York, United States|Investigator Site - Williamsville, Williamsville, New York, United States|Investigator Site - Greensboro, Greensboro, North Carolina, United States|Investigator Site - Winston Salem, Winston-Salem, North Carolina, United States|Investigator Site - Fargo, Fargo, North Dakota, United States|Investigator Site - Beavercreek, Beavercreek, Ohio, United States|Investigator Site - Cincinnati 1, Cincinnati, Ohio, United States|Investigator Site - Cincinnati 2, Cincinnati, Ohio, United States|Investigator Site - Columbus, Columbus, Ohio, United States|Investigator Site - Duncansville, Duncansville, Pennsylvania, United States|Investigator Site - Jenkintown, Jenkintown, Pennsylvania, United States|Investigator Site - Rapid City, Rapid City, South Dakota, United States|Investigator Site - Memphis, Memphis, Tennessee, United States|Investigator Site - Arlington, Arlington, Texas, United States|Investigator Site - Austin, Austin, Texas, United States|Investigator Site - Killeen, Killeen, Texas, United States|Investigator Site - San Antonio, San Antonio, Texas, United States|Investigator Site - Salt Lake City, Salt Lake City, Utah, United States|Investigator Site - West Jordan, West Jordan, Utah, United States|Investigator Site - Midlothian, Midlothian, Virginia, United States|Investigator Site - Norfolk, Norfolk, Virginia, United States|Investigator Site - Kenosha, Kenosha, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02362672
854,NCT01633944,Efficacy Study to Evaluate Buprenorphine HCl Buccal Film in Opioid-Naive Subjects,,Completed,Has Results,Low Back Pain,Drug: Buprenorphine|Drug: Placebo,Change From Baseline to Week 12 in Average Daily Pain Intensity Scores|Number of Participants With Response to Treatment (Responder) Using NRS Scale|Number of Subjects With Rescue Medication Use|Time to Optimal Dose of Open-label Study Medication|Percentage of Participants With Treatment Failure in the Double-blind Treatment Phase (up to 12 Weeks)|Patient Global Impression of Change|Change From Baseline to Week 12 in Roland Morris Disability Questionnaire|Change From Baseline to Week 12 in Medical Outcomes Score Sleep Subscale,BioDelivery Sciences International,All,"18 Years and older   (Adult, Older Adult)",Phase 3,752,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",EN3409-308,2012-08-01,2013-12-01,2013-12-01,2012-07-06,2016-02-03,2017-02-27,"Horizon Research Group, Inc./Alabama Orthopedic Clinic, Mobile, Alabama, United States|Arizona Research Center, Phoenix, Arizona, United States|Global Research, Anaheim, California, United States|Catalina Research Institute, LLC, Chino, California, United States|Synergy Clinical Research Center of Escondido, Escondido, California, United States|Adam D. Karns MD, Los Angeles, California, United States|Stamford Therapeutics Consortium, Stamford, Connecticut, United States|Clinical Research of West Florida - Clearwater, Clearwater, Florida, United States|Century Clinical Research, Inc., Daytona Beach, Florida, United States|Avail Clinical Research, LLC, Deland, Florida, United States|Florida Health Center, Ft. Lauderdale, Florida, United States|Eastern Research, Inc., Hialeah, Florida, United States|Florida Institute of Medical Research, Jacksonville, Florida, United States|Drug Study Institute, Jupiter, Florida, United States|Health Awareness, Inc., Jupiter, Florida, United States|NEMA Research, Inc., Naples, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Peninsula Research, Ormond Beach, Florida, United States|Gold Coast Research, L.L.C., Plantation, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Clinical Research of West Florida - Tampa, Tampa, Florida, United States|National Pain Research Institute, LLC, Winter Park, Florida, United States|Atlanta Research Center, Atlanta, Georgia, United States|River Birch Research Alliance, LLC, Blue Ridge, Georgia, United States|Drug Studies America, Marietta, Georgia, United States|Georgia Institute for Clinical Research, LLC, Marietta, Georgia, United States|Taylor Research, LLC, Marietta, Georgia, United States|MediSphere Medical Research Center, LLC, Evansville, Indiana, United States|Integrated Clinical Trial Services, Inc., West Des Moines, Iowa, United States|International Clinical Research Institute, Inc., Overland Park, Kansas, United States|Willis-Kinghton Physician Network/River Interventional Pain Specialist, Bossier City, Louisiana, United States|Clinical Trials Management, LLC, Metairie, Louisiana, United States|Best Clinical Trials, Inc., New Orleans, Louisiana, United States|River Cities Clinical Research Center, Shreveport, Louisiana, United States|MedVadis Research Corp., Watertown, Massachusetts, United States|Great Lakes Research Group, Inc., Bay City, Michigan, United States|The Center for Clinical Trials, Biloxi, Mississippi, United States|Office of Robert Kaplan, DO, Las Vegas, Nevada, United States|Long Island Gastrointestinal Research Group, Great Neck, New York, United States|Upstate Clinical Research Associates LLC, Williamsville, New York, United States|PharmQuest, LLC, Greensboro, North Carolina, United States|The Center for Clinical Research, Winston Salem, North Carolina, United States|Plains Medical Clinic, LLC, Fargo, North Dakota, United States|Clinical Inquest Center, Ltd., Beavercreek, Ohio, United States|New Horizons Clinical Research, Cincinnati, Ohio, United States|Optimed Research, Ltd., Columbus, Ohio, United States|Prestige Clinical Research, Franklin, Ohio, United States|Health Research Institute, Oklahoma City, Oklahoma, United States|NPC Research, Oklahoma City, Oklahoma, United States|Brandywine Clinical Research, Downingtown, Pennsylvania, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Health Concepts, Rapid City, South Dakota, United States|FutureSearch Clinical Trials - Austin, Austin, Texas, United States|KRK Medical Research, Dallas, Texas, United States|FutureSearch Trials of Dallas, LP, Dallas, Texas, United States|Advanced Clinical Research of Houston, Houston, Texas, United States|Clinical Trial Network, Houston, Texas, United States|Innovative Clinical Trials, San Antonio, Texas, United States|Highland Clinical Research, Salt Lake City, Utah, United States|Clinical Investigations Specialists, Inc., Kenosha, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT01633944
855,NCT01675167,Efficacy Study to Evaluate Buprenorphine HCl Buccal Film in Opioid-Experienced Subjects,,Completed,Has Results,Low Back Pain,Drug: Buprenorphine|Drug: Placebo,Change From Baseline to Week 12 in Average Daily Pain Intensity Scores|Number of Participants With Response to Treatment (Responder) Using NRS Scale|Number of Subjects With Opioid Rescue Medication Use|Time to Optimal Dose of Open-label Study Medication|Percentage of Participants With Treatment Failure in the Double-blind Treatment Phase (up to 12 Weeks)|Patient Global Impression of Change|Change From Baseline to Week 12 in Roland Morris Disability Questionnaire|Change From Baseline to Week 12 in Medical Outcome Score Sleep Subscale|Medical Outcomes Score Sleep Subscale - Quantity of Sleep/Optimal Sleep,BioDelivery Sciences International,All,"18 Years and older   (Adult, Older Adult)",Phase 3,815,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",EN3409-307,2012-09-01,2014-06-01,2014-06-01,2012-08-29,2016-02-03,2017-02-27,"Parkway Medical Center, Birmingham, Alabama, United States|Haleyville Clinical Research LLC, Haleyville, Alabama, United States|Horizon Research Group. Inc / Alabama Orthopedice, Mobile, Alabama, United States|Arizona Research Center, Phoenix, Arizona, United States|Global Research, Anaheim, California, United States|Catalina Research Institute, LLC, Chino, California, United States|Synergy Clinical Research Center of Escondido, Escondido, California, United States|RX Clinical Research, Inc., Garden Grove, California, United States|Adam D. Karns, MD, Los Angeles, California, United States|Stamford Therapeutics Consortium, Stamford, Connecticut, United States|Century Clinic Research, Daytona Beach, Florida, United States|Avail Clinical Research, LLC, Deland, Florida, United States|Florida Health Center, Ft. Lauderdale, Florida, United States|Eastern Research, Inc., Hialeah, Florida, United States|Florida Institute of Medical Research, Jacksonville, Florida, United States|Drug Study Institute, Jupiter, Florida, United States|Health Awareness, Inc., Jupiter, Florida, United States|FPA Clinical Research, Kissimmee, Florida, United States|Try Research, Inc., Maitland, Florida, United States|NEMA Research, Inc., Naples, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Peninsula Research, Inc., Ormond Beach, Florida, United States|Gold Coast Research, LLC, Plantation, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Clinical Research of West Florida, Inc., Tampa, Florida, United States|Palm Beach Research Center, West Palm Beach, Florida, United States|National Pain Research Institute, LLC, Winter Park, Florida, United States|Atlanta Research Center, Atlanta, Georgia, United States|River Birch Research Alliance, LLC, Blue Ridge, Georgia, United States|Drug Studies America, Marietta, Georgia, United States|Georgia Institute for Clinical Research, LLC, Marietta, Georgia, United States|Taylor Research, LLC, Marietta, Georgia, United States|Georgia Pain & Spine Care & Better Health Clinical Research, Newnan, Georgia, United States|Clinical Investigations Specialists, Inc., Gurnee, Illinois, United States|MediSphere Medical Research, LLC, Evansville, Indiana, United States|Integrated Clinical Trial Services, Inc, West Des Moines, Iowa, United States|International Clinical Research Institute, Inc., Overland Park, Kansas, United States|Willis-Kinghton Physician Network / River Cities International Pain Specialist, Bossier City, Louisiana, United States|Clinical Trials Management, LLC, Metairie, Louisiana, United States|Best Clinical Trials, LLC, New Orleans, Louisiana, United States|River Cities Clinical Research Center, Shreveport, Louisiana, United States|MedVadis Research Corp., Watertown, Massachusetts, United States|Great Lakes Research Group, Inc., Bay City, Michigan, United States|The Center for Clinical Trials, Biloxi, Mississippi, United States|Office of Robert Kaplan, DO, Las Vegas, Nevada, United States|Comprehensive Clinical Research, Berlin, New Jersey, United States|Long Island Gastrointestinal Research Group, Great Neck, New York, United States|Upstate Clinical Research Associates, Williamsville, New York, United States|PharmQuest, LLC, Greensboro, North Carolina, United States|The Center for Clinical Research, Winston-Salem, North Carolina, United States|Plains Medical Clinic, LLC, Fargo, North Dakota, United States|Clinical Inquest Center, Ltd, Beavercreek, Ohio, United States|New Horizons Health Research, Cincinnati, Ohio, United States|Prestige Clinical Research, Franklin, Ohio, United States|Health Research Institute, Oklahoma City, Oklahoma, United States|Neuropsychiatric Research Center Research, Oklahoma City, Oklahoma, United States|Brandywine Clinical Research, Downingtown, Pennsylvania, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Health Concepts, Rapid City, South Dakota, United States|FutureSearch Clinical Trials, Austin, Texas, United States|KRK Medical Research, Dallas, Texas, United States|Future Search Trials of Dallas, LP, Dallas, Texas, United States|Advanced Clinical Research of Houston, Houston, Texas, United States|Clinical Trial Network, Houston, Texas, United States|Innovative Clinical Trials, San Antonio, Texas, United States|Highland Clinical Research, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT01675167
856,NCT00105287,Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients,,Completed,No Results Available,Pain|Cancer,Drug: OraVescent fentanyl (OVF),,Cephalon|Teva Pharmaceutical Industries,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,100,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C25608/3039/BP/US,2005-01-01,2006-09-01,2007-09-01,2005-03-14,null,2014-05-09,"Cullman Oncology and Hematology, Cullman, Alabama, United States|Advanced Clinical Research Institute, Anaheim, California, United States|Pacific Cancer Medical Center, Anaheim, California, United States|Compassionate Cancer Care Medical Group, Corona, California, United States|Compassionate Cancer Center, Fountain Valley, California, United States|Clinical Trials & Research Associates, Inc., Montebello, California, United States|San Diego Hospice & Palliative Care, San Diego, California, United States|Pacific Clinical Research, Santa Monica, California, United States|Lovelace Scientific Resources, Miami, Florida, United States|Gulf Coast Pain Specialists, Pensacola, Florida, United States|Hematology Oncology Associates of Treasure Coast, Port St. Lucie, Florida, United States|Center for Prospective Outcome, Marietta, Georgia, United States|Iowa Pain Management Clinic, PC, Des Moines, Iowa, United States|Donald Berdeaux, Great Falls, Montana, United States|Great Falls Clinic, LLP, Great Falls, Montana, United States|Southern Nevada Cancer Research, Las Vegas, Nevada, United States|NYU Pain Management Center, New York, New York, United States|Research Across America, New York, New York, United States|Brody School of Medicine, Greenville, North Carolina, United States|Gabrail Cancer Center, Canton, Ohio, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Charleston Hematology Oncology, PA, Charleston, South Carolina, United States|University of Rochester, San Antonio, Texas, United States|Lifetree Clinical Research, Salt Lake City, Utah, United States|Cache Valley Cancer Treatment and Research Clinic, Inc., West Point, Utah, United States",,https://ClinicalTrials.gov/show/NCT00105287
857,NCT00444158,"Double-Blind, Double-Dummy, 2-Period Crossover of a 20-Minute Versus a 4-hour IV of MOA-728 in Stable Methadone Subjects",,Completed,No Results Available,Constipation,Drug: MOA-728,It is not known if the activity of MOA-728 is related to the peak concentration or the overall exposure (AUC). This study is designed to evaluate the PK and PD effect of MOA-728 administered either as a 20-minute or 4-hour infusion.,"Valeant Pharmaceuticals International, Inc.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,24,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,3200L2-1108,2007-03-01,null,2007-07-01,2007-03-07,null,2011-07-26,"Gainesville, Florida, United States",,https://ClinicalTrials.gov/show/NCT00444158
858,NCT00105937,OraVescent Fentanyl (OVF) for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients,,Completed,No Results Available,Pain|Cancer,Drug: OraVescent fentanyl citrate,Tolerability and safety of OraVescent fentanyl when used long-term|Assess the effectiveness of OraVescent fentanyl|Assess the development of incremental tolerance,Cephalon|Teva Pharmaceutical Industries,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,300,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,099-15,2004-04-01,null,2006-11-01,2005-03-21,null,2012-06-29,"Center for Pain Management, Huntsville, Alabama, United States|Outcomes Research International, Tucson, Arizona, United States|Arizona Clinical Research Center, Tucson, Arizona, United States|Hot Spring Pain Clinic, Hot Springs, Arkansas, United States|Saint Joseph's Mercy Cancer Center, Hot Springs, Arkansas, United States|Arkansas Cancer Institute, Pine Bluff, Arkansas, United States|City of Hope National Medical Center, Duarte, California, United States|The Cancer Prevention and Treatment Center, Soquel, California, United States|Northwestern Connecticut Oncology & Hematology Associates, Torrington, Connecticut, United States|Florida Institute of Medical Research, Jacksonville, Florida, United States|University of Florida Shands Cancer Center at Jacksonville, Jacksonville, Florida, United States|Hematology Oncology Associates, Lake Worth, Florida, United States|Innovative Medical Research of South Florida, Miami Shores, Florida, United States|Gulf Coast Oncology Association, St. Petersburg, Florida, United States|Clinical Pharmacology Services, Inc, Tampa, Florida, United States|Palm Beach Research, West Palm Beach, Florida, United States|Florida Medical Clinic, PA, Zephyrhills, Florida, United States|Southeastern Gynecologic Oncology, LLC, Atlanta, Georgia, United States|North Shore Cancer Research Association, Skokie, Illinois, United States|Kentucky Cancer Clinic, Hazard, Kentucky, United States|Southwest Oncology Associates, Lafayette, Louisiana, United States|Hematology and Oncology Specialists, New Orleans, Louisiana, United States|St. Agnes Healthcare, Baltimore, Maryland, United States|Huron Medical Center, Port Huron, Michigan, United States|Providence Cancer Institute, Southfield, Michigan, United States|Bond Clinic, Inc, Rolla, Missouri, United States|HealthCare Research, LLC, St. Louis, Missouri, United States|North Shore University Hospital, Manhasset, New York, United States|Beth Israel Medical Center, New York, New York, United States|The Center for Clinical Research, LLC, Winston-Salem, North Carolina, United States|PETC Research Group, Inc., Tulsa, Oklahoma, United States|Oncology Associates of Oregon, Eugene, Oregon, United States|Allegheny Pain Management, PC, Altoona, Pennsylvania, United States|St. Mary Medical Center, Langhorne, Pennsylvania, United States|Mohamed Haq, Pasadena, Texas, United States|Cancer Care Centers of South Texas, San Antonio, Texas, United States|UTHCT (ATTN: Clinical Research), Tyler, Texas, United States|Hunstman Cancer Institute, Salt Lake City, Utah, United States|Palliative Care and Pain Medicine, Salt Lake City, Utah, United States|Great Basin Clinical Research, West Point, Utah, United States|Cancer Outreach Associates, PC, Abingdon, Virginia, United States|MedSource Inc, Richmond, Virginia, United States|University of Wisconsin Medical School, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00105937
859,NCT01100320,A Study to Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets,,Completed,Has Results,Healthy Volunteers,Drug: Reformulated OXY (oxycodone HCl)|Drug: Original OxyContin® (OXY) (oxycodone HCl),Cmax - Maximum Observed Plasma Concentration|AUC0-inf - Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (Extrapolated)|AUC0-t - Area Under Plasma Concentration-time Curve From Time Zero to Time of Last Non-zero Plasma Concentration,Purdue Pharma LP,All,18 Years to 50 Years   (Adult),Phase 1,88,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),OTR1004,2007-01-01,2007-03-01,2007-07-01,2010-04-08,2010-05-06,2010-05-11,"Covance Clinical Research Unit - Austin, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT01100320
860,NCT01100086,A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets,,Completed,Has Results,Healthy Volunteers,Drug: Reformulated OXY (oxycodone HCl)|Drug: Original OxyContin® (OXY) (oxycodone HCl),Cmax - Maximum Observed Plasma Concentration|AUC0-inf - Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (Extrapolated)|AUC0-t - Area Under Plasma Concentration-time Curve From Time Zero to Time of Last Non-zero Plasma Concentration,Purdue Pharma LP,All,18 Years to 50 Years   (Adult),Phase 1,84,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),OTR1003,2007-01-01,2007-03-01,2007-06-01,2010-04-08,2010-05-06,2010-05-25,"Covance Clinical Research Unit Madison, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT01100086
861,NCT01099709,A Study to Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets,,Completed,Has Results,Healthy Volunteers,Drug: Reformulated OXY (oxycodone HCl)|Drug: Original OxyContin® (OXY) (oxycodone HCl),Cmax - Maximum Observed Plasma Concentration|AUC0-inf - Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (Extrapolated)|AUC0-t - Area Under Plasma Concentration-time Curve From Time Zero to Time of Last Non-zero Plasma Concentration,Purdue Pharma LP,All,18 Years to 50 Years   (Adult),Phase 1,85,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),OTR1002,2007-01-01,2007-03-01,2007-08-01,2010-04-07,2010-05-06,2010-05-06,"Covance Clinical Research Unit, Honolulu, Hawaii, United States",,https://ClinicalTrials.gov/show/NCT01099709
862,NCT00000211,Treatment Efficacy for Drug Abuse and AIDS Prevention - 2,,Completed,No Results Available,Cocaine-Related Disorders|Heroin Dependence,Drug: Buprenorphine,,National Institute on Drug Abuse (NIDA)|Mclean Hospital,Male,26 Years to 41 Years   (Adult),Phase 2,0,NIH|Other,Interventional,Primary Purpose: Treatment,NIDA-06116-2|R18-06116-2,1989-09-01,1996-02-01,1996-02-01,1999-09-21,null,2017-01-12,"McLean Hospital, Dept. of Psychiatry, Belmont, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00000211
863,NCT00545129,A Study Of Tanezumab as Add-On Therapy to Opioid Medication In Patients With Pain Due To Cancer That Has Spread To Bone,,Completed,No Results Available,Neoplasm Metastasis|Palliative Care,Drug: Tanezumab 10 mg IV|Drug: IV Placebo for tanezumab,"Change from Baseline to Week 6 in daily average pain intensity measured by the 11 point Pain Intensity Numerical Rating Scale (NRS; 0-10). Baseline is the average daily Pain NRS score during Stabilization Phase prior to Randomization (3 days).|Physical examination at Screening, Week 6 and Week 16 (or at early termination).|Change from Baseline to Weeks 1, 2, 4, 8, 12 and 16 in the daily average pain intensity NRS score.|Change from Baseline to Weeks 1, 2, 4, 6, 8, 12 and 16 in the daily worst pain intensity NRS score.|Average number of doses of rescue medication required per week (up to Week 16).|Clinical laboratory assessments (hematology, blood chemistry, PT/PTT, urinalysis) at Screening, Baseline, and Weeks 2, 4, 6, 12 and 16 (or at early termination).|Change in Patient's Global Assessment of Disease (Cancer Pain) Activity at Weeks 1, 2, 4, 6, 8, 12 and 16.|Response as defined by a ≥30/50/70/90% reduction from Baseline in the daily average pain intensity NRS score.|Vital sign measurements at Screening, Baseline, and Weeks 2, 4, 6, 12, and 16 (or at early termination).|Neurologic examination at Screening, Baseline, and Weeks 2, 4, 6, 12, and 16 (or at early termination).|Weight measurements at Screening, Week 6 and Week 16 (or at early termination).|Change from Baseline to Weeks 1, 2, 4, 6, 8, 12 and 16, in the BPI worst pain scores obtained at study visits.|Change in the weekly Opioid Related Symptom Distress Scale at Weeks 2, 4, 6, 12 and 16.|Change from Baseline to Weeks 1, 2, 4, 6, 8, 12 and 16, in the Brief Pain Inventory (BPI) average pain scores obtained at study visits.|Anti-Drug Antibody testing at Baseline and Weeks 4, 6, 12 and 16 (or at early termination).|Adverse events from time of first dose of study treatment through the last patient visit.|Patient's Global Evaluation of Study Medication at Weeks 1, 2, 4, 6, 8, 12 and 16.|Average daily opioid consumption (up to Week 16).|ECG at Baseline (predosing and 1 hr post-dose) and Weeks 4 and 16 (or at early termination).",Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 2,59,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A4091003,2009-04-01,2011-12-01,2012-02-01,2007-10-17,null,2013-01-18,"Pfizer Investigational Site, La Jolla, California, United States|Pfizer Investigational Site, La Jolla, California, United States|Pfizer Investigational Site, South Bend, Indiana, United States|Pfizer Investigational Site, Shreveport, Louisiana, United States|Pfizer Investigational Site, Shreveport, Louisiana, United States|Pfizer Investigational Site, Charleston, South Carolina, United States|Pfizer Investigational Site, Salt Lake City, Utah, United States|Pfizer Investigational Site, Graz, Austria|Pfizer Investigational Site, Linz, Austria|Pfizer Investigational Site, Senftenberg, Austria|Pfizer Investigational Site, Banja Luka, Bosnia and Herzegovina|Pfizer Investigational Site, Sarajevo, Bosnia and Herzegovina|Pfizer Investigational Site, Varazdin, Croatia|Pfizer Investigational Site, Villejuif, France|Pfizer Investigational Site, Budapest, Hungary|Pfizer Investigational Site, Budapest, Hungary|Pfizer Investigational Site, Szekesfehervar, Hungary|Pfizer Investigational Site, Miraj, Maharashtra, India|Pfizer Investigational Site, Nagpur, Maharashtra, India|Pfizer Investigational Site, Nashik, Maharashtra, India|Pfizer Investigational Site, Lucknow, Uttar Pradesh, India|Pfizer Investigational Site, New Delhi, India|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Riga, Latvia|Pfizer Investigational Site, Mexico, Distrito Federal, Mexico|Pfizer Investigational Site, Lima, Lima L13, Peru|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Bydgoszcz, Poland|Pfizer Investigational Site, Gdansk, Poland|Pfizer Investigational Site, Poznan, Poland|Pfizer Investigational Site, Wloclawek, Poland|Pfizer Investigational Site, Banska Bystrica, Slovakia|Pfizer Investigational Site, Bratislava, Slovakia",,https://ClinicalTrials.gov/show/NCT00545129
864,NCT01223365,Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of Time,,Completed,Has Results,Chronic Pain,Drug: Hydrocodone ER,Participants With Adverse Experiences|Participants With Potentially Clinically Significant (PCS) Abnormal Laboratory Values During the Open-Label Treatment Period by Participant Status|Participants With Potentially Clinically Significant Abnormal Vital Signs Values by Participant Status|Shifts in Electrocardiogram (ECG) Findings From Baseline to Overall Study by Participant Status|Participants With Clinically Significant (CS) Hearing Changes From Baseline in Pure Tone Audiometry Test Results by Patient Status|Participant Global Assessment (PGA) of the Method of Pain Control by Participant Status|Participants by Risk Category for Aberrant Drug Misuse Based on the Total Score in the Screener and Opioid Assessment for Patients With Pain - Revised (SOAPP-R)|Addiction Behavior Checklist (ABC) Total Scores During Both the Open-Label Titration and Open-Label Treatment Periods by Participant Status|Current Opioid Misuse Measure (COMM) Scores During Both the Open-Label Titration and Open-Label Treatment Periods by Participant Status,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,330,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C33237/3080,2010-10-01,2012-09-01,2012-09-01,2010-10-19,2017-04-05,2017-06-05,"Horizon Research Group, LLC, Mobile, Alabama, United States|Physician Alliance Research Center, Anaheim, California, United States|Adam D. Karns, MD, Beverly Hills, California, United States|Associated Pharmaceutical Research Center, Inc., Buena Park, California, United States|Providence Clinical Research, Burbank, California, United States|Research Center of Fresno, Inc., Fresno, California, United States|Pacific Coast Pain Management Center, Laguna Hills, California, United States|South Orange County Surgical Medical Group, Laguna Hills, California, United States|Accelovance, Inc., San Diego, California, United States|Bayview Research Group, LLC, Valley Village, California, United States|Clinical Research of West Florida, Inc., Clearwater, Florida, United States|Avail Clinical Research, LLC, DeLand, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Sarasota Pain Medicine Research LLC, Sarasota, Florida, United States|Gold Coast Research LLC, Weston, Florida, United States|Drug Studies America, Marietta, Georgia, United States|Georgia Institute for Clinical Research, LLC, Marietta, Georgia, United States|Taylor Research, LLC, Marietta, Georgia, United States|Better Health Clinical Research, Inc., Newnan, Georgia, United States|Millennium Pain Center, Bloomington, Illinois, United States|Rehabilitation Associates of Indiana, Indianapolis, Indiana, United States|International Clinical Research, Inc., Overland Park, Kansas, United States|Community Research, Crestview Hills, Kentucky, United States|Willis Knighton River Cities Clinical Research Center, Shreveport, Louisiana, United States|MidAtlantic Pain Medicine Center, Pikesville, Maryland, United States|Beacon Clinical Research, LLC, Brockton, Massachusetts, United States|HealthCare Research, Florissant, Missouri, United States|Sundance Clinical Research, LLC, Saint Louis, Missouri, United States|Meridian Clinical Research, Omaha, Nebraska, United States|Clinical Research Center of Nevada, Las Vegas, Nevada, United States|Advanced Pain Consultants, Voorhees, New Jersey, United States|Upstate Clinical Research Associates, Williamsville, New York, United States|Wake Research Associates, Raleigh, North Carolina, United States|Sterling Research Group, Ltd., Cincinnati, Ohio, United States|Columbus Clinical Research, Columbus, Ohio, United States|SP Research, Oklahoma City, Oklahoma, United States|Pain Research of Oregon, Eugene, Oregon, United States|Summit Research Network Inc., Portland, Oregon, United States|Brandywine Clinical Research, Downingtown, Pennsylvania, United States|AMH Feasterville Family Health Care Center, Feasterville-Trevose, Pennsylvania, United States|Tipton Medical and Diagnostic Center, Tipton, Pennsylvania, United States|Clinical Research Center of Reading, LLP, West Reading, Pennsylvania, United States|Omega Medical Research, Warwick, Rhode Island, United States|Greenville Pharmaceutical Research, Greenville, South Carolina, United States|Trident Institute of Medical Research, LLC, North Charleston, South Carolina, United States|S. Carolina Pharmaceutical Research, Spartanburg, South Carolina, United States|KRK Medical Research, Dallas, Texas, United States|Radiant Research, Dallas, Texas, United States|Renaissance Clinical Research & Hypertension of Texas, PLLC, Dallas, Texas, United States|Medstar Clinical Research, Houston, Texas, United States|Benchmark Research, San Angelo, Texas, United States|DCT-Sugarland, LLC dba Discovery Clinical Trials, Sugar Land, Texas, United States|Hillcrest Family Health Centers, Waco, Texas, United States|Aspen Clinical Research, LLC, Orem, Utah, United States",,https://ClinicalTrials.gov/show/NCT01223365
865,NCT00236041,Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP),,Completed,No Results Available,Cancer|Breakthrough Pain,Drug: ACTIQ®,"Pain intensity differences as measured by the FPS-R|Time to adequate analgesia|Duration of analgesia|Percentage of BTP episodes requiring rescue medication, or for which oversedation occurs|Amount of rescue medication|Distribution of optimal doses",Cephalon|Teva Pharmaceutical Industries,All,3 Years to 15 Years   (Child),Phase 2,38,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,C8278b/202/BP/US-CA,2004-04-01,null,2006-08-01,2005-10-12,null,2014-05-09,"Children's Hospital of Arkansas, Little Rock, Arkansas, United States|UCLA Pediatric Pain Program, Los Angeles, California, United States|Childrens Hospital of Orange, Orange, California, United States|Lucille Packard Childrens Hospital, Palo Alto, California, United States|Connecticut Childrens Medical Center, Hartford, Connecticut, United States|Children's National Medical Center, Washington, District of Columbia, United States|Nemours Childrens Clinic, Jacksonville, Florida, United States|St. Joseph's Children's Hospital, Tampa, Florida, United States|Scottish Rite Children's Medical Center, Atlanta, Georgia, United States|Kapi'olani Medical Center, Honolulu, Hawaii, United States|Children's Memorial Center, Chicago, Illinois, United States|Children's Memorial Hospital, Chicago, Illinois, United States|University Hospitals of Iowa, Iowa City, Iowa, United States|Cardinal Glennon Children's Hospital, St. Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|University of New Mexico, Albuquerque, New Mexico, United States|Children's Hospital at Montefiore, Bronx, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Duke University Hospital, Durham, North Carolina, United States|Akron Children's Hospital, Akron, Ohio, United States|Tod Children's Hospital, Youngstown, Ohio, United States|Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical, Nashville, Tennessee, United States|Children's Cancer and Blood Disorders Center, San Antonio, Texas, United States|Methodist Hospital, San Antonio, Texas, United States|Sacred Heart Medical Center, Spokane, Washington, United States|West Virginia University, Morgantown, West Virginia, United States|Childrens Hospital of Wisconsin, Milwaukee, Wisconsin, United States|San Jorge Childrens Medical, San Juan, Puerto Rico",,https://ClinicalTrials.gov/show/NCT00236041
866,NCT00828490,Electronic Pharmacotherapy Risk Management,ePRM,Completed,No Results Available,Asthma|Mental Health|Pain,Behavioral: provider feedback|Behavioral: patient intervention|Behavioral: Process-level,,University of Utah|Utah Department of Health,All,"Child, Adult, Older Adult",,174000,Other,Observational,Time Perspective: Retrospective,24987|7570516-1,2007-07-01,2010-03-01,2010-03-01,2009-01-26,null,2010-03-23,"Multi-clinic site, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT00828490
867,NCT00228605,Evaluating the Safety and Tolerability of OraVescent Fentanyl for Opioid Tolerant Patients With Noncancer Related Breakthrough Pain,,Completed,No Results Available,Low Back Pain|Migraine|Diabetic Neuropathies|Osteoarthritis,Drug: OraVescent Fentanyl,Safety and tolerability when used over a 12-month period for the management of breakthrough pain in opioid tolerant patients|Assess the patients' quality of life through questionnaires|Assess the patients' overall medication preferences|Assess the patients' overall medication performance,Cephalon|Teva Pharmaceutical Industries,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,500,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C25608/3040/BP/US,2005-03-01,null,2007-05-01,2005-09-29,null,2014-05-09,"MedSearch, Calera, Alabama, United States|Clinical Research Consultants, Inc., Hoover, Alabama, United States|Arizona Research Center, Phoenix, Arizona, United States|NEA Clinic, Jonesboro, Arkansas, United States|Lynn Institute of the Rockies, Colorado Springs, Colorado, United States|Radiant Research-Daytona Beach, Daytona Beach, Florida, United States|Advent Clinical Research Centers, Inc., St. Petersburg, Florida, United States|Gold Coast Research, Weston, Florida, United States|Center for Prospective Outcome Studies, Inc., Atlanta, Georgia, United States|Advent Clinical Research Centers, Inc., Atlanta, Georgia, United States|Center for Prospective Outcome Studies, Inc., Marietta, Georgia, United States|North Fulton Regional Hospital Pain Center, Roswell, Georgia, United States|Carmen Research, Smyrna, Georgia, United States|Orthopedic Health Care, Boise, Idaho, United States|Medisphere Medical Research Center, LLC, Evansville, Indiana, United States|Tri-State Arthritis & Rheumatology Center, LLC, Evansville, Indiana, United States|Iowa Pain Management Clinic, PC, Des Moines, Iowa, United States|Mid-America Physiatrists, PA, Overland Park, Kansas, United States|Capital Clinical Research Associates, LLC, Rockville, Maryland, United States|Brigham Women's Hospital, Attn: Pain Trials Center, Boston, Massachusetts, United States|MedVadis Research, Wellesley Hills, Massachusetts, United States|Medex Healthcare Research Center, St. Louis, Missouri, United States|Radiant Research - St. Louis, St. Louis, Missouri, United States|Clinical Research Center of Nevada, Las Vegas, Nevada, United States|Northshore University Hospital, Beth Page, New York, United States|NYU Pain Management Center, New York, New York, United States|Research Across America, New York, New York, United States|The Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Southern Oregon Health & Wellness, Medford, Oregon, United States|Clinical Research Center of Reading, LLP, West Reading, Pennsylvania, United States|Healthstar Physicians, Morristown, Tennessee, United States|Biopharma Research Associates, Sugar Land, Texas, United States|Lifetree Clinical Research, Salt Lake City, Utah, United States|Radiant Research, Salt Lake City, Utah, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Pain Management Center, South Burlington, Vermont, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Rowan Research, Spokane, Washington, United States",,https://ClinicalTrials.gov/show/NCT00228605
868,NCT01418092,ALK37-007: Evaluation of Safety and Efficacy of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC),,Completed,No Results Available,OIC,Drug: ALKS 37|Drug: Placebo,Change from baseline in the weekly average of complete spontaneous bowel movements during treatment,"Alkermes, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,91,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ALK37-007,2011-09-01,2012-06-01,2012-06-01,2011-08-16,null,2012-08-07,"Alkermes Investigational Site, Anaheim, California, United States|Alkermes Investigational Site, Orange, California, United States|Alkermes Investigational Site, Daytona Beach, Florida, United States|Alkermes Investigational Site, Plantation, Florida, United States|Alkermes Investigational Site, Marietta, Georgia, United States|Alkermes Investigational Site, Indianapolis, Indiana, United States|Alkermes Investigational Site, Los Vegas, Nevada, United States|Alkermes Investigational Site, Willingboro, New Jersey, United States|Alkermes Investigational Site, Raleigh, North Carolina, United States|Alkermes Investigational Site, Philadelphia, Pennsylvania, United States|Alkermes Investigational Site, Austin, Texas, United States|Alkermes Investigational Site, Houston, Texas, United States|Alkermes Investigational Site, Bellevue, Washington, United States",,https://ClinicalTrials.gov/show/NCT01418092
869,NCT01240863,Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time,,Completed,Has Results,Chronic Pain,Drug: Hydrocodone ER|Drug: Placebo,"Change From Baseline to Week 12 in Weekly Average Pain Intensity (wAPI)|Percentage of Participants Withdrawn From the Study During the Double-Blind Treatment Period By Reason|Kaplan-Meier Estimates for Time to Discontinuation From the Study|Participants With a Weekly Average Pain Intensity (wAPI) Increase From Baseline Exceeding 33%|Participants With a Weekly Average Pain Intensity (wAPI) Increase From Baseline Exceeding 50%|Weekly Average Pain Intensity (wAPI) Scores During the Double-blind Treatment Period|Weekly Average Worst Pain Intensity (WPI) Scores During the Double-blind Treatment Period|Clinician Assessment of Patient Function (CAPF) at Week 4|Clinician Assessment of Patient Function (CAPF) at Week 8|Clinician Assessment of Patient Function (CAPF) at Week 12|Clinician Assessment of Patient Function (CAPF) at Endpoint|Patient Assessment of Function (PAF) at Week 4|Patient Assessment of Function (PAF) at Week 8|Patient Assessment of Function (PAF) at Week 12|Patient Assessment of Function (PAF) at Endpoint|Clinician Global Impression of Severity (CGI-S) of Illness Scores During the Double-blind Treatment Period|Short-Form Health Survey (SF-36) Physical and Mental Component Summary Scores at Baseline, Week 12 and Endpoint|Brief Pain Inventory - Short Form (BPI-SF) Pain Interference Mean Score During the Double-Blind Treatment Period|Participants With Adverse Events|Participants With Potentially Clinically Significant Abnormal Vital Signs Values During the Double-Blind Treatment Period|Participants With Potentially Clinically Significant Abnormal Laboratory Values During the Double-Blind Treatment Period|Subjective Opiate Withdrawal Scales (SOWS) Scores During the Double-Blind Treatment Period|Clinical Opiate Withdrawal Scales (COWS) Scores During the Double-Blind Treatment Period|Addiction Behavior Checklist (ABC) Total Scores During Both the Open-Label Titration and Double-Blind Treatment Periods|Current Opioid Misuse Measures (COMM) Total Scores During Both the Open-Label Titration and Double-Blind Treatment Periods|Change From Baseline to Endpoint in the Double-Blind Treatment Phase in Electrocardiogram (ECG) Parameters","Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,391,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",C33237/3079,2010-11-01,2011-08-01,2011-08-01,2010-11-15,2017-06-05,2017-06-05,"Horizon Research Group LLC, Mobile, Alabama, United States|Radiant Research, Inc., Chandler, Arizona, United States|Radiant Research, Inc., Scottsdale, Arizona, United States|Radiant Research Inc., Tucson, Arizona, United States|Physician Alliance Research Center, Anaheim, California, United States|Associated Pharmaceutical Research Center, Inc., Buena Park, California, United States|Providence Clinical Research, Burbank, California, United States|Synergy Clinical Research, Escondido, California, United States|Research Center of Fresno, Inc., Fresno, California, United States|Pacific Coast Pain Management Center, Laguna Hills, California, United States|South Orange County Surgical Medical Group, Laguna Hills, California, United States|Robert M. Karns, MD A Medical Corporation, Los Angeles, California, United States|Accelovance, Inc., San Diego, California, United States|Radiant Research, Inc., Santa Rosa, California, United States|Bayview Research Group, LLC, Valley Village, California, United States|Radiant Research, Inc, Denver, Colorado, United States|Clinical Research of West Florida, Inc., Clearwater, Florida, United States|Avail Clinical Research, LLC, DeLand, Florida, United States|International Research Associates, LLC, Miami, Florida, United States|Compass Research, Orlando, Florida, United States|Radiant Research, Inc., Pinellas Park, Florida, United States|Gold Coast Research LLC, Plantation, Florida, United States|Sarasota Pain Medicine Research LLC, Sarasota, Florida, United States|Clinical Research of West Florida, Inc., Tampa, Florida, United States|Drug Studies America, Marietta, Georgia, United States|Georgia Institute for Clinical Research, LLC, Marietta, Georgia, United States|Better Health Clinical Research, Inc., Newnan, Georgia, United States|Millennium Pain Center, Bloomington, Illinois, United States|Medex Healthcare Research, Inc., Chicago, Illinois, United States|Rehabilitation Associates of Indiana, Indianapolis, Indiana, United States|International Clinical Research, Inc., Leawood, Kansas, United States|Community Research, Crestview, Kentucky, United States|The Pain Treatment Center of the Bluegrass, Lexington, Kentucky, United States|Horizon Research Group, LLC, Baton Rouge, Louisiana, United States|WK River Cities Clinical Research Center, Shreveport, Louisiana, United States|MidAtlantic Pain Medicine Center, Pikesville, Maryland, United States|Beacon Clinical Research, LLC, Brockton, Massachusetts, United States|HealthCare Research, Florissant, Missouri, United States|Medex Healthcare Research Inc., Saint Louis, Missouri, United States|Sundance Clinical Research, LLC, Saint Louis, Missouri, United States|Meridian Clinical Research, Omaha, Nebraska, United States|Clinical Research Center of Nevada, Las Vegas, Nevada, United States|Advanced Pain Consultants, Voorhees, New Jersey, United States|Upstate Clinical Research Associates, Williamsville, New York, United States|Wake Research Associates, Raleigh, North Carolina, United States|Radiant Research, Inc, Akron, Ohio, United States|Sterling Research Group, Ltd., Cincinnati, Ohio, United States|Community Research, Inc, Cincinnati, Ohio, United States|Community Research, Inc, Cincinnati, Ohio, United States|Rapid Medical Research, Cleveland, Ohio, United States|Columbus Clinical Research, Columbus, Ohio, United States|SP Research, Oklahoma City, Oklahoma, United States|Pain Research of Oregon, Eugene, Oregon, United States|Summit Research Network Inc., Portland, Oregon, United States|Brandywine Clinical Research, Downingtown, Pennsylvania, United States|Tipton Medical and Diagnostic Center, Tipton, Pennsylvania, United States|AMH Feasterville Family Health Care Center, Trevose, Pennsylvania, United States|Clinical Research Center of Reading, Wyomissing, Pennsylvania, United States|Omega Medical Research, Warwick, Rhode Island, United States|Radiant Research Inc., Anderson, South Carolina, United States|Greenville Pharmaceutical Research, Greenville, South Carolina, United States|Radiant Research, Inc, Greer, South Carolina, United States|Trident Institute of Medical Research, LLC, North Charleston, South Carolina, United States|South Carolina Pharmaceutical Research, Spartanburg, South Carolina, United States|KRK Medical Research, Dallas, Texas, United States|Radiant Research Dallas, Dallas, Texas, United States|Renaissance Clinical Research & Hypertension of Texas, PLLC, Dallas, Texas, United States|Medstar Clinical Research, Houston, Texas, United States|Benchmark Research, San Angelo, Texas, United States|DCT-Sugarland, LLC, Sugar Land, Texas, United States|Hillcrest Family Health Centers, Waco, Texas, United States|Aspen Clinical Research, LLC, Orem, Utah, United States|Lifetree Clinical Research, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT01240863
870,NCT00343733,Study to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related Chronic Pain,,Completed,No Results Available,Pain,Drug: OraVescent Fentanyl,The primary objective is to evaluate the efficacy of OraVescent fentanyl treatment compared with placebo treatment following 12 weeks of treatment in alleviating breakthrough pain (BTP) in opioid-tolerant patients with noncancer-related chronic pain.,Cephalon|Teva Pharmaceutical Industries,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,120,Industry,Interventional,Allocation: Randomized|Masking: Double|Primary Purpose: Treatment,C25608/3052/BP/US,2006-08-01,null,2007-07-01,2006-06-23,null,2014-05-09,"Hot Springs Pain Clinic, Hot Springs, Arkansas, United States|Samaritan Center for Medical, Los Gatos, California, United States|Pacific Neuroscience Medical Group, Inc., Oxnard, California, United States|Centre for Rheumatology, Fort Lauderdale, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Atlas Research, Orlando, Florida, United States|Gold Coast Research, LLC, Plantation, Florida, United States|Comprehensive Pain Care, PC, Marietta, Georgia, United States|Drug Studies America, Marietta, Georgia, United States|Best Clinical Trials, Inc., New Orleans, Louisiana, United States|Best Clinical Trials, LLC, New Orleans, Louisiana, United States|Brigham Women's Hospital, Boston, Massachusetts, United States|Pain Management Associates, Independence, Missouri, United States|Montana Neuroscience Institute, Missoula, Montana, United States|Lovelace Scientific Resources, Albuquerque, New Mexico, United States|Five Towns Neuroscience Research, Lawrence, New York, United States|PharmQuest, Greensboro, North Carolina, United States|Center for Clinical Research, Winston-Salem, North Carolina, United States|Legacy Emanuel Pain Management, PC, Portland, Oregon, United States|Clinical Research Center, West Reading, Pennsylvania, United States|Advanced Pain Management, Virginia Beach, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00343733
871,NCT03182933,Liposomal Bupivacaine Versus Standard Bupivacaine in the Adductor Canal for Total Knee Arthroplasty,,Completed,No Results Available,Pain,Drug: Peripheral Nerve Blockade|Behavioral: 10 meter walk test on post-operative day 1|Other: In person and over the phone questionnaire|Device: Force transduction of quadriceps strength,10 meter walk test|Pain Scores|Opioid Consumption|Nausea|Strength,"University of Wisconsin, Madison",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,63,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",2016-0869,2017-05-30,2018-07-16,2018-07-16,2017-06-09,null,2018-08-09,"The American Center, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT03182933
872,NCT01677650,Pharmacogenomics of Methadone in Spine Fusion Surgery,,Withdrawn,No Results Available,Scoliosis|Kyphosis,Drug: Methadone,"Time until initial request for postoperative analgesic.|The determination of minimum effective analgesic concentration of methadone.|Postoperative pain at rest and with movement (numerical rating scale, NRS)|The number of occurrences of ventilatory depression during each evaluation interval|Nausea and vomiting: number of rescue antiemetic doses and episodes of emesis|Level of sedation (modified Observer's Assessment of Alertness and Sedation Scale, modified OAA/S scale)|Occurence of pruritis|Algometry to assess pain tolerance|Degree of bother associated with opioid-related adverse effects: Opioid-related Symptom Distress Scale (OR-SDS)|Quality of Recovery: Quality of Recovery-40 score|Patient analgesic satisfaction|Assessment of back condition pre and post-operatively|Effects of common opioid related metabolic pathway polymorphisms on methadone's dose response relationships for analgesia and side effects|Pupillometry for assessment of sedation",Northwestern University,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",STU00064915,2014-03-01,2015-01-01,2015-01-01,2012-09-03,null,2015-04-22,"Northwestern Memorial Hospital, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT01677650
873,NCT00398008,HIV Risk Reduction and Drug Abuse Treatment in Iran,,Withdrawn,No Results Available,Opiate Dependence|HIV Infections,Drug: Buprenorphine/Subutex|Drug: Naltrexone|Behavioral: Drug counseling,Time to resumption of heroin use|Time to relapse|Maximum consecutive weeks of opiate abstinence|Reduction of HIV risks|Addiction-related functional status|Adverse events,Yale University|National Institute on Drug Abuse (NIDA),Male,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R01DA014718-02S1,2004-10-01,2006-12-01,2008-12-01,2006-11-10,null,2013-07-26,"Yale University School of Medicine, New Haven, Connecticut, United States|Institute for Cognitive Studies, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT00398008
874,NCT01655771,TD-1211 Single-Dose Study in Elderly and Young Healthy Subjects,,Completed,No Results Available,Constipation,Drug: TD-1211 Dose 1|Drug: TD-1211 Dose 2,Cmax|AUCt|AUCinf|Number of patients with treatment-emergent adverse events|Number patients with abnormal vital sign measurements|Number of patients with abnormal clinical laboratory results|Number of patients with abnormal corrected QTc interval,"Theravance Biopharma R & D, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,47,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,83,2012-08-01,2013-02-01,2013-03-01,2012-08-02,null,2014-12-03,"ICON Development Solutions, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT01655771
875,NCT00993863,Analgesic Efficacy and Safety of ADL5859 in Subjects With Acute Dental Pain After Third Molar Extraction,,Completed,No Results Available,Acute Pain,Drug: Placebo|Drug: ADL5859 30 mg|Drug: ADL5859 100 mg|Drug: ADL5859 200 mg|Drug: ibuprofen 400 mg,Total pain relief 0-4 hours after study medication,Cubist Pharmaceuticals LLC,All,18 Years to 50 Years   (Adult),Phase 2,201,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",33CL230,2007-06-01,2007-09-01,null,2009-10-14,null,2015-07-17,"SCIREX Research Center, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT00993863
876,NCT01068847,Drug Discrimination in Methadone-Maintained Humans Study 3,OMDD3,Completed,No Results Available,Drug Dependence,Drug: 2-4 of the drugs listed below,Drug Discrimination Performance|Self-Report Ratings|Vital Signs|ECG,University of Arkansas|National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,9,Other|NIH,Interventional,"Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",R01DA010017-03|110528|R01DA010017|DPMC,2010-02-01,2012-10-01,2012-11-01,2010-02-15,null,2013-03-07,"University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States",,https://ClinicalTrials.gov/show/NCT01068847
877,NCT00593463,Drug Discrimination in Methadone-Maintained Humans Study 1,OMDD1,Completed,No Results Available,Drug Dependence,Drug: Cycloserine|Drug: Diltiazem|Drug: Gabapentin|Drug: Isradipine|Drug: Naloxone|Drug: Nifedipine|Drug: Placebo|Device: Saline|Drug: Verapamil,Drug Discrimination Measure|Self-reported effects|Vital Signs,University of Arkansas,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,40,Other,Interventional,"Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)",R01DA010017-01|57184|R01DA010017|DPMC,2006-09-01,2010-05-01,2010-05-01,2008-01-15,null,2011-03-11,"University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States",,https://ClinicalTrials.gov/show/NCT00593463
878,NCT03278496,Recovery Housing and Drug Abuse Treatment Outcome,,Completed,No Results Available,Mental and Behavioral Disorders Due to Use of Cocaine: Harmful Use|Opiate Addiction,Behavioral: Recovery Housing plus Counseling|Behavioral: Usual Care Referral|Behavioral: Recovery Housing Only,abstinence from opiates and cocaine,Johns Hopkins University,All,18 Years to 55 Years   (Adult),Not Applicable,243,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,DA13003,2001-04-01,2008-06-01,2008-12-01,2017-09-11,null,2017-09-11,"Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT03278496
879,NCT01058642,"Study to Assess the Efficacy, Safety, and Tolerability of ADL5747 in Participants With Postherpetic Neuralgia",,Terminated,Has Results,Postherpetic Neuralgia,Drug: ADL5747|Drug: Placebo|Drug: Pregabalin,Change in Weekly Average Numeric Pain Rating Scale (NPRS) Score From Baseline to End of Treatment (Week 2 of Each Treatment Period),Cubist Pharmaceuticals LLC|Pfizer,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,41,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",40CL234,2010-01-01,2010-12-01,2010-12-01,2010-01-29,2015-07-08,2015-07-30,"Laszlo J. Mate, MD, West Palm Beach, Florida, United States",,https://ClinicalTrials.gov/show/NCT01058642
880,NCT03320889,Hepatitis C Education for Pregnant Women With Opiate Dependence - Phase 2,,Recruiting,No Results Available,Hepatitis C,Other: Educational Intervention,Number of Questions Scored Correct on the Hepatitis C Knowledge Survey,TriHealth Inc.,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,130,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,17-057,2017-10-30,2019-05-01,2019-05-01,2017-10-25,null,2018-07-23,"Good Samaritan Hospital, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03320889
881,NCT03245931,Hepatitis C Education for Pregnant Women With Opiate Addiction - Phase 1,,Recruiting,No Results Available,Hepatitis C,Other: Qualitative Interview,Discovering the gaps in patients' knowledge of Hepatitis C,TriHealth Inc.,Female,"18 Years and older   (Adult, Older Adult)",,7,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,17007,2017-07-20,2019-05-01,2019-05-01,2017-08-10,null,2018-07-23,"Good Samaritan Hospital, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03245931
882,NCT01965704,Can Ondansetron Prevent Neonatal Abstinence Syndrome (NAS) in Babies Born to Narcotic-dependent Women,AIM2NAS,Recruiting,No Results Available,Narcotic Addiction|Neonatal Abstinence Syndrome,Drug: Ondansetron|Drug: Placebo,Incidence of neonatal abstinence syndrome|Severity of neonatal abstinence syndrome,"Stanford University|Santa Clara Valley Medical Center|University of California, San Francisco|University of Utah|Johns Hopkins University|University of Tennessee Health Science Center|University of Louisville|Thomas Jefferson University",All,"up to 45 Years   (Child, Adult)",Phase 2,90,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",Aim 2_RO1-HD-070795-01A1|NAS2,2013-12-01,2018-04-01,2018-06-01,2013-10-18,null,2018-01-02,"Stanford University Medical Center, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT01965704
883,NCT02176291,Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine,IRLGREY-B,Completed,Has Results,Depression|Major Depressive Disorder,Drug: Buprenorphine|Drug: Placebo,Montgomery-Asberg Depression Rating Scale (MADRS)|Brief Symptom Inventory--Anxiety Subscale (BSI),Jordan F. Karp|National Institute of Mental Health (NIMH)|University of Pittsburgh,All,"50 Years and older   (Adult, Older Adult)",Phase 4,31,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PRO13120236|R34MH101371,2014-08-01,2017-04-01,2018-02-01,2014-06-27,2018-07-02,2018-07-02,"Western Psychiatric Institute and Clinic, University of Pittsburgh, Pittsburgh, Pennsylvania, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT02176291/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT02176291/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02176291
884,NCT01407575,Buprenorphine for Treatment Resistant Depression,BUP-TRD,Completed,Has Results,"Depression|Depressive Disorder|Depressive Disorder, Major",Drug: Buprenorphine|Drug: Placebo,Montgomery Asberg Depression Rating Scale|Blood Pressure|UKU Side Effect Rating Scale|Heart Rate|Weight|Brief Symptom Inventory -- Anxiety Subscale|Positive and Negative Affect Scale,University of Pittsburgh|National Alliance for Research on Schizophrenia and Depression,All,"21 Years and older   (Adult, Older Adult)",Phase 3,13,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BUP-TRD,2011-09-01,2013-08-01,2013-08-01,2011-08-02,2016-03-17,2018-03-09,"Western Psychiatric Institute and Clinic, University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01407575
885,NCT00842036,CRAFT Behavior Therapy: Treatment Entry Component,,Completed,No Results Available,Drug Addiction|Stimulant Dependence|Opiate Dependence|Alcohol Dependence|Substance Abuse,Behavioral: Community Reinforcement and Family Training|Behavioral: Treatment Entry Training|Behavioral: 12- step Al/Nar- Anon Facilitation,Treatment entry of the drug user|Reduction in drug use|Improvements in mood and functioning,Treatment Research Institute,All,"18 Years and older   (Adult, Older Adult)",Phase 2,180,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0406|5R01DA018696,2006-01-01,2009-12-01,2009-12-01,2009-02-12,null,2010-06-25,"TRI South Street, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00842036
886,NCT00798538,Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM),BELIEVE,Completed,No Results Available,Buprenorphine|HIV|Drug Abuse|Drug Addiction|Drug Dependence|Drug Use Disorders|Drug Use Disorder|Substance Abuse|Opiate Addiction|Substance-related Disorders,"Other: Services will be provided at one site|Other: Services remain dispersed; i.e., not centralized to one-location or provider.",Substance use outcomes measured by self-report|Urine toxicology results|Retention in and adherence to HIV care|Quality of life|HIV-related health outcomes,Yale University|Waterbury Hospital|Health Resources and Services Administration (HRSA)|The New York Academy of Medicine,All,"18 Years and older   (Adult, Older Adult)",Phase 4,60,Other|U.S. Fed,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,H97HA03800-03,2005-08-01,2010-08-01,2010-08-01,2008-11-26,null,2015-07-24,"Yale AIDS Program, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00798538
887,NCT00633243,Effective Treatment of Hepatitis C in Substance Users,,Completed,Has Results,Hepatitis C|Opiate Dependence,Procedure: Modified Directly Observed Therapy (mDOT)|Procedure: Self-Administered Therapy (SAT),Number of Participants With a Sustained Virologic Response (SVR),Yale University|National Institute on Drug Abuse (NIDA),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,21,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,0702002306|NIDA 022143,2007-04-01,2011-09-01,2011-09-01,2008-03-11,2012-11-20,2013-01-03,"South Central Rehabilitation Agency, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00633243
888,NCT00439049,Substance Abuse Pre-Treatment Screening Study,,Recruiting,No Results Available,Cocaine Abuse|Cocaine Dependence|Opiate Dependence|Alcohol Dependence|Substance Abuse,Drug: modafinil|Drug: d-amphetamine|Drug: L-Dopa|Drug: Naltrexone,Urine Toxicology|Demographics,"The University of Texas Health Science Center, Houston|National Institute on Drug Abuse (NIDA)",All,18 Years to 60 Years   (Adult),,7500,Other|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,NIDA-09262-13|P50DA009262|DPMCDA,2005-10-01,2021-06-01,2021-06-01,2007-02-22,null,2017-04-05,"University of Texas Medical School- Houston, Dept. of Psychiatry Mental Sciences Institute, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00439049
889,NCT00241943,A Video-Based HCV Curriculum for Active Injection Drug Users,,Completed,No Results Available,Hepatitis C|Opiate Dependence,Procedure: Hepatitis C educational video,"HCV testing rates, intervention vs. usual care|HAV vaccination rates, intervention vs. usual care|HBV vaccination rates, intervention vs. usual care|Improvement in knowledge, intervention vs. usual care|Improvement in attitudes toward behavior change, intervention vs. usual care|Improvement in motivations toward behavior change, intervention vs. usual care",Organization to Achieve Solutions in Substance Abuse (OASIS)|Centers for Disease Control and Prevention,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,103,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),U50/CCU923257-2|U50/CCU923257,2005-11-01,2007-08-01,2007-08-01,2005-10-19,null,2008-12-09,"HEPPAC, Oakland, California, United States",,https://ClinicalTrials.gov/show/NCT00241943
890,NCT00170339,Bone Density and Serum Testosterone in Male Methadone Maintained Patients,,Completed,No Results Available,Opiate Dependence|Osteoporosis|Erectile Dysfunction|Hypogonadism,,,Minneapolis Medical Research Foundation,Male,18 Years to 50 Years   (Adult),,60,Other,Observational,Time Perspective: Prospective,HSR-04-2404|0409M63575,2005-04-01,null,2007-04-01,2005-09-15,null,2016-09-14,"Hennepin Faculty Associates/ Hennepin County Medical Center, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00170339
891,NCT02036281,A Phase 1 Study of Substance P-Saporin in Terminal Cancer Patients With Intractable Pain,,Completed,No Results Available,"Terminally Ill|Histologically-confirmed Advanced Cancer|Pain, Intractable",Drug: Substance P-Saporin,Response Evaluation Criteria|Safety Tolerability,University of Texas Southwestern Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 1,23,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STU 102013-010,2014-01-01,2016-09-28,2016-09-28,2014-01-15,null,2018-05-15,"University of California, San Diego Mores Cancer Center, La Jolla, California, United States|UT Southwestern Medical Center Simmons Comprehensive Cancer Center, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT02036281
892,NCT00378079,Methadone Maintenance for Prisoners,MMP,Completed,Has Results,Heroin Addiction,Other: Counseling Only|Drug: Counseling + Transfer|Drug: Counseling + Methadone,Treatment Retention in the Community|Heroin Use|Cocaine Use|HIV-risk Behaviors|Criminal Activity|Employment,"Friends Research Institute, Inc.|National Institute on Drug Abuse (NIDA)",Male,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,211,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1R01DA016237-03|R01DA016237,2003-09-01,2008-01-01,2008-01-01,2006-09-19,2014-04-03,2014-04-03,"Metropolitan Transition Center, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00378079
893,NCT00218530,Effectiveness of Naltrexone and Lofexidine in Treating Detoxified Heroin Addicts - 1,,Completed,No Results Available,Heroin Dependence,Drug: Lofexidine,Retention in treatment; measured throughout 8 weeks|Frequency and amount of opiate use; measured weekly|Stress levels; measured weekly|Tolerability; measured throughout 8 weeks,National Institute on Drug Abuse (NIDA),All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 1,0,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment,NIDA-18197-1|P50-18197-1|DPMC,2003-03-01,null,2004-09-01,2005-09-22,null,2017-01-12,"Substance Abuse Treatment Unit, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00218530
894,NCT03105518,Predictors of Postoperative Pain Following Oocyte Retrieval for Assisted Reproduction,,Completed,Has Results,Oocyte Retrieval|Postoperative Pain,Drug: Fentanyl|Drug: Acetaminophen|Drug: Oxycodone,Amount of Discomfort|Amount of Discomfort Following Discharge Until Embryo Transfer,Brigham and Women's Hospital,Female,18 Years to 50 Years   (Adult),Phase 4,100,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2010-P-002310/1,2011-03-01,2011-10-30,2011-10-30,2017-04-10,2017-12-05,2017-12-05,"Brigham and Women's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03105518
895,NCT02697643,A Clinical Decision Support Tool for Electronic Health Records,BHCDS,Completed,No Results Available,Substance Abuse,Behavioral: BHCDS-based recommendations|Behavioral: Non-tailored recommendations,Change in clients' past 30-day substance use and psychosocial functioning at 1 month and 3 months post-baseline as measured by ASI-MV composite scores|Number of client treatment visits|Number of services each client receives or is referred to,"Inflexxion, Inc.",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,140,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research,19015.13,2016-03-17,2018-03-31,2018-03-31,2016-03-03,null,2018-08-13,"Stephen Butler, Waltham, Massachusetts, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02697643/SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02697643
896,NCT00000302,Study Comparing Liquid and Tablet Buprenorphine Formulations - 5,,Completed,No Results Available,Heroin Dependence,Drug: Buprenorphine,Drug use|Retention|Drug craving,National Institute on Drug Abuse (NIDA),All,21 Years to 50 Years   (Adult),Phase 3,0,NIH,Interventional,Masking: Double|Primary Purpose: Treatment,NIDA-09260-5|P50-09260-5,null,null,null,1999-09-21,null,2005-11-07,"Friends Research Institute, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT00000302
897,NCT01259115,Buprenorphine Accumulation and Description of Its Metabolites During Co-Medication of Buprenorphine Transdermal System (BTDS) and Ketoconazole,,Completed,Has Results,Healthy,Drug: Buprenorphine transdermal patch|Drug: Ketoconazole tablet|Drug: Placebo to match ketoconazole tablet,AUCt of Buprenorphine With and Without Ketoconazole.|AUCinf of Buprenorphine With and Without Ketoconazole.|Cmax of Buprenorphine With and Without Ketoconazole.|AUCt of Nor-buprenorphine With and Without Ketoconazole|AUCinf of Nor-buprenorphine With and Without Ketoconazole|Cmax of Nor-buprenorphine With and Without Ketoconazole|AUCt of Nor-buprenorphine Glucuronide With and Without Ketoconazole|AUCinf of Nor-buprenorphine Glucuronide With and Without Ketoconazole|Cmax of Nor-buprenorphine Glucuronide With and Without Ketoconazole|AUCt of Buprenorphine-3-glucuronide With and Without Ketoconazole|AUCinf of Buprenorphine-3-glucuronide With and Without Ketoconazole|Cmax of Buprenorphine-3-glucuronide With and Without Ketoconazole|CYP3A4 Inhibition by Observation of Plasma Nor-buprenorphine Production Assessed by the Erythromycin Breath Test.|The Number of Participants With Adverse Events (AEs) as a Measure of Safety.,Purdue Pharma LP,All,18 Years to 54 Years   (Adult),Phase 1,20,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)",BUP1009,2002-10-01,2003-06-01,2003-06-01,2010-12-13,2011-01-26,2014-05-19,"Clinical Research Center, New Orleans, Louisiana, United States",,https://ClinicalTrials.gov/show/NCT01259115
898,NCT01259102,Examine Plasma Concentrations of Buprenorphine Following Reapplication of Buprenorphine Transdermal System (BTDS) After Variable Application Site Rest Periods,,Completed,Has Results,Healthy,Drug: Buprenorphine transdermal patch,Period 1: AUC0-3d|Period 2: AUC0-3d.|Period 1: Cmax0-3d|Period 2: Cmax0-3d|Period 1: AUC0-7d.|Period 2: AUC0-7d|Period 1: Cmax0-7|Period 2: Cmax0-7d|Period 1: Tmax0-7d.|Period 2: Tmax0-7d.,Purdue Pharma LP,All,18 Years to 45 Years   (Adult),Phase 1,70,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),BUP1002,2000-11-01,2001-03-01,2001-03-01,2010-12-13,2011-02-07,2012-09-03,"The Ohio State University Department of Pharmacology, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01259102
899,NCT01723527,Diversion to Treatment for Injection Drug Users Arrested for Possession of Heroin,,Completed,No Results Available,Cocaine-Related Disorders|HIV|Heroin Dependence,Drug: Methadone|Drug: Buprenorphine|Behavioral: Employment-based drug abstinence reinforcement,Cocaine abstinence as assessed by urinalysis|Cocaine abstinence as assessed by self-reports|Any drug use (Y/N)|Any engagement in HIV risk behavior (Y/N)|Any criminal activity (Y/N),Johns Hopkins University|National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,1,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1R34DA033510-01,2012-12-01,2014-05-01,2014-08-01,2012-11-08,null,2014-12-11,"Center for Learning and Health, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01723527
900,NCT01148537,The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy Volunteers,,Completed,Has Results,Healthy Volunteers,Drug: Buprenorphine transdermal patch|Drug: Matching placebo transdermal patch|Drug: Avelox (moxifloxacin hydrochloride) tablet,The Comparison of BTDS to Placebo Transdermal System (TDS): the Average Difference From Baseline Using QT Corrected From Within-subject Data (QTci) on Day 13|The Comparison of Moxifloxacin to Placebo Transdermal System (TDS): the Average Difference From Baseline Using QT Interval Corrected From Within-subject Data (QTci) on Day 13|The Average Differences Between BTDS vs Placebo From Baseline by Interval Corrected From Within-subject Data (QTci) on Day 6|The Average Differences Between Moxifloxacin vs Placebo From Baseline by Interval Corrected From Within-subject Data (QTci) on Day 6|The Average Differences From Baseline Between BTDS and Placebo by Bazett Corrected QT Interval (QTcB) on Day 6 and Day 13|The Average Differences From Baseline Between Moxifloxacin and Placebo of Bazett Corrected QT Interval (QTcB) on Day 6 and Day 13|The Average Differences From Baseline Between BTDS and Placebo by Fridericia's Corrected Interval (QTcF) on Day 6 and Day 13|The Average Differences From Baseline Between Moxifloxacin and Placebo by Fridericia's Corrected Interval (QTcF) on Day 6 and Day 13,Purdue Pharma LP,All,18 Years to 55 Years   (Adult),Phase 1,132,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BUP1011,2004-07-01,2004-12-01,2004-12-01,2010-06-22,2010-09-28,2012-09-03,"PPD Development, LP, Clinics, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT01148537
901,NCT01101321,To Determine the Fasting Bioequivalence of Reformulated OXY Tablets Manufactured at Two Different Facilities,,Completed,Has Results,Healthy,Drug: Reformulated OXY (Totowa) (oxycodone HCl)|Drug: Reformulated OXY (Wilson) (oxycodone HCl),Cmax - Maximum Observed Plasma Concentration|AUC0-inf - Area Under Plasma Concentration-time Curve From Time Zero to Infinity (Extrapolated)|AUC0-t - Area Under Plasma Concentration-time Curve From Time Zero to Time of Last Non-zero Plasma Concentration,Purdue Pharma LP,All,18 Years to 50 Years   (Adult),Phase 1,58,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),OTR1015,2008-06-01,2008-08-01,2008-11-01,2010-04-09,2010-05-12,2015-11-18,"Covance Clinical Research Unit Honolulu, Honolulu, Hawaii, United States",,https://ClinicalTrials.gov/show/NCT01101321
902,NCT01101308,A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets Manufactured at Two Different Facilities,,Completed,Has Results,Healthy,Drug: Reformulated OXY (Totowa) (oxycodone HCl)|Drug: Reformulated OXY (Wilson) (oxycodone HCl),Cmax - Maximum Observed Plasma Concentration|AUC0-inf - Area Under Plasma Concentration-time Curve From Time Zero to Infinity (Extrapolated)|AUC0-t - Area Under Plasma Concentration-time Curve From Time Zero to Time of Last Non-zero Plasma Concentration,Purdue Pharma LP,All,18 Years to 50 Years   (Adult),Phase 1,55,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),OTR1013,2008-07-01,2008-08-01,2009-01-01,2010-04-09,2010-05-11,2010-05-25,"Covance Clinical Research Unit Madison, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT01101308
903,NCT01101191,A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets,,Completed,Has Results,Healthy,Drug: Reformulated OXY (oxycodone HCl)|Drug: Original OxyContin® (OXY) (oxycodone HCl),Cmax - Maximum Observed Plasma Concentration|AUC0-inf - Area Under Plasma Concentration-time Curve From Time Zero to Infinity (Extrapolated)|AUC0-t - Area Under Plasma Concentration-time Curve From Time Zero to Time of Last Non-zero Plasma Concentration,Purdue Pharma LP,All,18 Years to 50 Years   (Adult),Phase 1,84,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),OTR1009,2007-08-01,2007-10-01,2008-01-01,2010-04-09,2010-05-11,2010-05-25,"Covance Clinical Research Unit Honolulu, Honolulu, Hawaii, United States",,https://ClinicalTrials.gov/show/NCT01101191
904,NCT01101178,To Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets,,Completed,Has Results,Healthy,Drug: Reformulated OXY (oxycodone HCl)|Drug: Original OxyContin® (OXY) (oxycodone HCl),Cmax - Maximum Observed Plasma Concentration|AUC0-inf - Area Under Plasma Concentration-time Curve From Time Zero to Infinity (Extrapolated)|AUC0-t - Area Under Plasma Concentration-time Curve From Time Zero to Time of Last Non-zero Plasma Concentration,Purdue Pharma LP,All,18 Years to 50 Years   (Adult),Phase 1,79,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),OTR1008,2007-08-01,2007-11-01,2007-11-01,2010-04-09,2010-05-10,2011-10-10,"Covance Clinical Research Unit Madison, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT01101178
905,NCT01101165,To Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets,,Completed,Has Results,Healthy,Drug: Reformulated OXY (oxycodone HCl)|Drug: Original OxyContin® (OXY) (oxycodone HCl),Cmax - Maximum Observed Plasma Concentration|AUC0-inf - Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (Extrapolated)|AUC0-t - Area Under Plasma Concentration-time Curve From Time Zero to Time of Last Non-zero Plasma Concentration,Purdue Pharma LP,All,18 Years to 50 Years   (Adult),Phase 1,92,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),OTR1005,2007-02-01,2007-04-01,2007-07-01,2010-04-09,2010-05-06,2010-05-11,"Covance Clinical Research Unit - Evansville, Evansville, Indiana, United States",,https://ClinicalTrials.gov/show/NCT01101165
906,NCT01395797,Pioglitazone for Heroin and for Nicotine Dependence,,Terminated,Has Results,Heroin Dependence|Nicotine Dependence,Drug: PIO|Drug: Placebo,Drug's Break Point|Measures of Subjective Drug Effects Most Commonly Indicative of Abuse Liability.,New York State Psychiatric Institute|National Institute on Drug Abuse (NIDA)|Omeros Corporation,All,21 Years to 55 Years   (Adult),Phase 1|Phase 2,82,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",6255|R01DA031022,2011-03-01,2014-04-01,2014-06-01,2011-07-18,2017-07-13,2017-07-13,"New York State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01395797
907,NCT03305666,Trial of Injected Liposomal Bupivacaine vs Bupivacaine Infusion After Surgical Stabilization of Rib Fractures,,Recruiting,No Results Available,"Drug Effect|Rib Fractures|Rib Trauma|Surgical Procedure, Unspecified|Pain; Catheter (Other)|Nerve Pain|Local Infiltration|Anesthesia, Local|Intercostal Rib|Opioid Dependence|Chest Injury Trauma|Pneumonia",Drug: Liposomal bupivacaine injection|Drug: Bupivacaine indwelling catheter,Daily Standardized Assessment of Respiratory Function (SCARF) score|Daily narcotic requirements using equi-analgesic doses,Denver Health and Hospital Authority,All,"18 Years and older   (Adult, Older Adult)",Phase 4,34,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17-0685,2017-10-05,2019-04-01,2020-10-01,2017-10-10,null,2017-10-10,"Denver Health, Denver, Colorado, United States",,https://ClinicalTrials.gov/show/NCT03305666
908,NCT00315835,Safety of the Buprenorphine Transdermal Delivery System in Subjects With Mod-to-Sev Pain Following Orthopedic Surgery.,,Completed,No Results Available,Postoperative Pain,Drug: Buprenorphine transdermal delivery system,"clinical laboratory tests|vital signs|physical examinations|electrocardiograms|elicited opioid side effects|pulmonary function tests (O2 saturation, peak flow, forced expiratory volume, forced vital capacity, respiratory rate, and respiratory depression/hypoxia)|adverse events|application site skin observations|plasma concentrations of buprenorphine at hours 0, 2, 4, 6, 12, 24, 30, 36, 48, 54, 60, 72, 78, or at early termination|pain intensity|acceptability of therapy|quality of sleep|rescue dose usage",Purdue Pharma LP,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,BP96-0104,1996-10-01,null,1997-11-01,2006-04-19,null,2006-04-19,"Park Place Therapeutic Center, Plantation, Florida, United States",,https://ClinicalTrials.gov/show/NCT00315835
909,NCT00318760,Effect of Clonidine on Responses to Imagery Scripts,,Completed,No Results Available,Cocaine Abuse|Heroin Abuse,Drug: Clonidine|Drug: Placebo,Subjective ratings of drug craving and mood|Autonomic response (galvanic skin response [GSR])|Heart rate and blood pressure|Endocrine responses (salivary cortisol and salivary alpha-amylase),National Institute on Drug Abuse (NIDA)|National Institutes of Health Clinical Center (CC),All,18 Years to 55 Years   (Adult),Phase 1,92,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment,999905403|05-DA-N403,2005-06-14,null,2013-08-07,2006-04-27,null,2018-04-05,"National Institute on Drug Abuse, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00318760
910,NCT00574067,Buprenorphine for Prisoners,,Completed,Has Results,Heroin Addiction,Drug: Buprenorphine +OTP|Drug: Buprenorphine +CHC|Drug: Counseling +OTP|Drug: Counseling +CHC,Number of Days of Heroin Use|Drug Abuse Treatment Entry and Retention in the Community|Number of Days of Cocaine Use|Criminal Activity|Employment Status|HIV Risk Behavior Needle Sharing|HIV Risk Behavior,"Friends Research Institute, Inc.|National Institute on Drug Abuse (NIDA)",All,18 Years to 60 Years   (Adult),Phase 3,213,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,1R01DA021579-01A1|R01DA021579,2008-09-01,2013-03-01,2013-11-01,2007-12-14,2016-04-11,2016-04-11,"Metropolitan Transition Center, Baltimore, Maryland, United States|Maryland Correctional Institution for Women, Jessup, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00574067
911,NCT03123861,Gabapentin for Postop Pain After SSLF,,Recruiting,No Results Available,Pelvic Organ Prolapse,Drug: Gabapentin|Drug: Placebo oral capsule,Surgical Pain Scale question 2|Gluteal pain during normal activities question|Surgical Pain Scale question 1|Surgical Pain Scale question 3|Surgical Pain Scale question 4|Gluteal pain during rest question|PROMIS questionnaires on pain interference and pain intensity|Pain medication use|Metabolizer status,"University of North Carolina, Chapel Hill",Female,"18 Years and older   (Adult, Older Adult)",Phase 4,75,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",16-3392,2017-06-01,2019-12-01,2019-12-01,2017-04-21,null,2018-06-14,"UNC Chapel Hill, Chapel Hill, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT03123861
912,NCT01583985,Strategies for Prescribing Analgesics Comparative Effectiveness Trial,SPACE,Completed,No Results Available,Back Pain|Osteoarthritis,Other: Opioid-intensive prescribing strategy|Other: Opioid-avoidant prescribing strategy,Brief Pain Inventory Interference score|Brief Pain Inventory Severity score|Roland Disability Scale|Symptom checklist|Veterans RAND 12 Item Health Survey (VR-12)|Global impression of change|Multidimensional Fatigue Inventory|Arizona Sexual Experience scale|Falls|Hospitalizations and emergency department visits|Indiana University Telephone-Based Assessment of Neuropsychological Status (IU-TBANS)|Fullerton advanced balance scale|Gait speed test|Chair stand test,VA Office of Research and Development,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,265,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,IIR 11-125,2013-06-01,2017-01-31,2017-05-31,2012-04-24,null,2017-06-08,"Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT01583985
913,NCT01096550,Intensive Outpatient Versus Outpatient Treatment With Buprenorphine Among African Americans,,Completed,Has Results,Drug Dependence,Behavioral: Outpatient|Behavioral: Intensive Outpatient,Percentage of Participants Meeting Diagnosis of Opioid Dependence on Composite International Diagnostic Interview-2 (CIDI-2),"Friends Research Institute, Inc.|National Institute on Drug Abuse (NIDA)",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 4,319,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1RC1DA028407-01,2010-03-01,2011-10-01,2011-10-01,2010-03-31,2013-10-17,2015-04-15,"Friends Research Institute, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01096550
914,NCT00800319,ALK33-001: A Study of RDC-0313 Administered to Healthy Adults,,Completed,No Results Available,Alcohol Dependence,Drug: RDC-0313|Drug: Placebo,Maximum plasma concentrations (Cmax) of RDC-0313|Clinically significant abnormal laboratory findings,"Alkermes, Inc.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,16,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ALK33-001,2008-12-01,2009-02-01,2009-06-01,2008-12-02,null,2011-08-22,"Quintiles Phase One Services, Overland Park, Kansas, United States",,https://ClinicalTrials.gov/show/NCT00800319
915,NCT01922739,"Open-Label, Extension Study to Evaluate the Safety of Hydrocodone Bitartrate Extended-Release Tablets",,Completed,Has Results,Low Back Pain,Drug: Hydrocodone ER|Drug: Placebo,"Participants With Adverse Events|Participants With Potentially Clinically Significant Abnormal Laboratory Values|Participants With Potentially Clinically Significant Abnormal Vital Signs Values|Participants With Shifts From Normal to Abnormal in Physical Examination Findings|Shifts From Baseline to Endpoint (Treatment Period) in Electrocardiogram (ECG) Findings|Participants With Clinically Significant (CS) Hearing Changes From Baseline to the Final Visit in Pure Tone Audiometry Test Results|Change From Baseline to Weeks 2, 6, 10, 14, 18, 22 and Endpoint of the Treatment Period in Daily Worst Pain Intensity (WPI) Scores During the Previous 24 Hours for Each Visit|Change From Baseline to Weeks 2, 6, 10, 14, 18, 22 and Endpoint of the Treatment Period in Daily Average Pain Intensity (API) Scores During the Previous 24 Hours for Each Visit|Percentage of Participants Withdrawn From the Study For Lack of Efficacy","Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,182,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C33237/3104,2013-07-01,2014-08-01,2014-08-01,2013-08-14,2017-06-02,2017-06-02,"Teva Investigational Site 10412, Birmingham, Alabama, United States|Teva Investigational Site 10426, Mobile, Alabama, United States|Teva Investigational Site 10436, Montgomery, Alabama, United States|Teva Investigational Site 10363, Phoenix, Arizona, United States|Teva Investigational Site 10366, Phoenix, Arizona, United States|Teva Investigational Site 10437, Tucson, Arizona, United States|Teva Investigational Site 10358, Anaheim, California, United States|Teva Investigational Site 10408, Bell Gardens, California, United States|Teva Investigational Site 10425, Carmichael, California, United States|Teva Investigational Site 10390, Cerritos, California, United States|Teva Investigational Site 10429, El Cajon, California, United States|Teva Investigational Site 10423, Escondido, California, United States|Teva Investigational Site 10391, Huntington Park, California, United States|Teva Investigational Site 10370, Los Angeles, California, United States|Teva Investigational Site 10392, Sherman Oaks, California, United States|Teva Investigational Site 10398, Thousand Oaks, California, United States|Teva Investigational Site 10428, Torrance, California, United States|Teva Investigational Site 10361, Walnut Creek, California, United States|Teva Investigational Site 10369, DeLand, Florida, United States|Teva Investigational Site 10379, Fort Lauderdale, Florida, United States|Teva Investigational Site 10365, Jacksonville, Florida, United States|Teva Investigational Site 10445, Leesburg, Florida, United States|Teva Investigational Site 10362, Orlando, Florida, United States|Teva Investigational Site 10381, Ormond Beach, Florida, United States|Teva Investigational Site 10357, Plantation, Florida, United States|Teva Investigational Site 10435, Royal Palm Beach, Florida, United States|Teva Investigational Site 10432, Columbus, Georgia, United States|Teva Investigational Site 10383, Marietta, Georgia, United States|Teva Investigational Site 10385, Marietta, Georgia, United States|Teva Investigational Site 10444, Newnan, Georgia, United States|Teva Investigational Site 10431, Meridian, Idaho, United States|Teva Investigational Site 10743, Meridian, Idaho, United States|Teva Investigational Site 10411, Chicago, Illinois, United States|Teva Investigational Site 10440, Newburgh, Indiana, United States|Teva Investigational Site 10419, New Orleans, Louisiana, United States|Teva Investigational Site 10359, Shreveport, Louisiana, United States|Teva Investigational Site 10389, Fall River, Massachusetts, United States|Teva Investigational Site 10388, Bay City, Michigan, United States|Teva Investigational Site 10397, Biloxi, Mississippi, United States|Teva Investigational Site 10406, Hazelwood, Missouri, United States|Teva Investigational Site 10401, Saint Louis, Missouri, United States|Teva Investigational Site 10376, Omaha, Nebraska, United States|Teva Investigational Site 10399, Las Vegas, Nevada, United States|Teva Investigational Site 10409, Berlin, New Jersey, United States|Teva Investigational Site 10439, Buffalo, New York, United States|Teva Investigational Site 10410, New York, New York, United States|Teva Investigational Site 10414, Winston-Salem, North Carolina, United States|Teva Investigational Site 10446, Oklahoma City, Oklahoma, United States|Teva Investigational Site 10430, Duncansville, Pennsylvania, United States|Teva Investigational Site 10386, Mechanicsburg, Pennsylvania, United States|Teva Investigational Site 10373, Tipton, Pennsylvania, United States|Teva Investigational Site 10405, Austin, Texas, United States|Teva Investigational Site 10364, Dallas, Texas, United States|Teva Investigational Site 10372, Dallas, Texas, United States|Teva Investigational Site 10371, Houston, Texas, United States|Teva Investigational Site 10377, Lake Jackson, Texas, United States|Teva Investigational Site 10374, Plano, Texas, United States|Teva Investigational Site 10378, San Antonio, Texas, United States|Teva Investigational Site 10402, Salt Lake City, Utah, United States|Teva Investigational Site 10420, Bellevue, Washington, United States|Teva Investigational Site 10433, Everett, Washington, United States",,https://ClinicalTrials.gov/show/NCT01922739
916,NCT02789410,Spinal Morphine vs. Hydromorphone for Pain Control After Cesarean Delivery,,Completed,No Results Available,"Analgesia, Obstetrical|Obstetric Surgical Procedures",Drug: Morphine|Drug: Hydromorphone,NRS score for pain (0-10) with movement 24 hours after spinal administration,Mayo Clinic,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,134,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",15-009421,2016-05-01,2017-09-01,2018-03-15,2016-06-03,null,2018-03-21,"Mayo Clinic in Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02789410
917,NCT01789970,Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Moderate to Severe Chronic Low Back Pain,,Completed,Has Results,Low Back Pain,Drug: Hydrocodone ER|Drug: Placebo,"Change From Baseline to Week 12 of the Treatment Period in Weekly Average of Daily Worst Pain Intensity (WPI)|Change From Baseline to Week 12 of the Treatment Period in Weekly Average Pain Intensity (API)|Kaplan-Meier Estimates for Time to Loss of Efficacy|Percentage of Participants With a 30% or Greater Increase in Weekly Average Pain Intensity (API) From Baseline to Week 12 Visit, and an Average API Score of 5 or Higher at Week 12|Change From Baseline to Final On-Treatment Visit in Roland Morris Disability Questionnaire (RMDQ) Score|Participants With Adverse Events During Open-Label Titration and Double-Blind Treatment Periods|Participants With Clinically Significant Hearing Changes From Baseline to Final Assessment in Pure Tone Audiometry Test Results|Subjective Opiate Withdrawal Scales (SOWS) Total Scores During the Double-Blind Treatment Period|Clinical Opiate Withdrawal Scales (COWS) Total Scores During the Double-Blind Treatment Period|Participants With Potentially Clinically Significant Abnormal Laboratory Values During the Double-Blind Treatment Period|Participants With Potentially Clinically Significant Abnormal Vital Sign Values During the Double-Blind Treatment Period|Participants With Potentially Clinically Significant Abnormal Electrocardiogram Findings During the Double-Blind Treatment Period","Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,625,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",C33237/3103,2013-03-01,2014-02-01,2014-02-01,2013-02-12,2017-04-05,2017-06-05,"Teva Investigational Site 10416, Anniston, Alabama, United States|Teva Investigational Site 10382, Birmingham, Alabama, United States|Teva Investigational Site 10403, Birmingham, Alabama, United States|Teva Investigational Site 10412, Birmingham, Alabama, United States|Teva Investigational Site 10426, Mobile, Alabama, United States|Teva Investigational Site 10436, Montgomery, Alabama, United States|Teva Investigational Site 10363, Phoenix, Arizona, United States|Teva Investigational Site 10366, Phoenix, Arizona, United States|Teva Investigational Site 10437, Tucson, Arizona, United States|Teva Investigational Site 10358, Anaheim, California, United States|Teva Investigational Site 10408, Bell Gardens, California, United States|Teva Investigational Site 10425, Carmichael, California, United States|Teva Investigational Site 10390, Cerritos, California, United States|Teva Investigational Site 10429, El Cajon, California, United States|Teva Investigational Site 10423, Escondido, California, United States|Teva Investigational Site 10740, Garden Grove, California, United States|Teva Investigational Site 10391, Huntington Park, California, United States|Teva Investigational Site 10422, La Jolla, California, United States|Teva Investigational Site 10413, Laguna Hills, California, United States|Teva Investigational Site 10442, Laguna Hills, California, United States|Teva Investigational Site 10370, Los Angeles, California, United States|Teva Investigational Site 10392, Sherman Oaks, California, United States|Teva Investigational Site 10398, Thousand Oaks, California, United States|Teva Investigational Site 10428, Torrance, California, United States|Teva Investigational Site 10361, Walnut Creek, California, United States|Teva Investigational Site 10441, Waterbury, Connecticut, United States|Teva Investigational Site 10369, DeLand, Florida, United States|Teva Investigational Site 10744, Edgewater, Florida, United States|Teva Investigational Site 10379, Fort Lauderdale, Florida, United States|Teva Investigational Site 10365, Jacksonville, Florida, United States|Teva Investigational Site 10445, Leesburg, Florida, United States|Teva Investigational Site 10362, Orlando, Florida, United States|Teva Investigational Site 10381, Ormond Beach, Florida, United States|Teva Investigational Site 12036, Pembroke Pines, Florida, United States|Teva Investigational Site 10357, Plantation, Florida, United States|Teva Investigational Site 10367, Royal Palm Beach, Florida, United States|Teva Investigational Site 10435, Royal Palm Beach, Florida, United States|Teva Investigational Site 10742, Sanford, Florida, United States|Teva Investigational Site 10432, Columbus, Georgia, United States|Teva Investigational Site 10383, Marietta, Georgia, United States|Teva Investigational Site 10385, Marietta, Georgia, United States|Teva Investigational Site 10444, Newnan, Georgia, United States|Teva Investigational Site 10431, Meridian, Idaho, United States|Teva Investigational Site 10743, Meridian, Idaho, United States|Teva Investigational Site 10411, Chicago, Illinois, United States|Teva Investigational Site 10418, Avon, Indiana, United States|Teva Investigational Site 10380, Evansville, Indiana, United States|Teva Investigational Site 10440, Newburgh, Indiana, United States|Teva Investigational Site 10375, Overland Park, Kansas, United States|Teva Investigational Site 10419, New Orleans, Louisiana, United States|Teva Investigational Site 10359, Shreveport, Louisiana, United States|Teva Investigational Site 10389, Fall River, Massachusetts, United States|Teva Investigational Site 10388, Bay City, Michigan, United States|Teva Investigational Site 10397, Biloxi, Mississippi, United States|Teva Investigational Site 10406, Hazelwood, Missouri, United States|Teva Investigational Site 10401, Saint Louis, Missouri, United States|Teva Investigational Site 10376, Omaha, Nebraska, United States|Teva Investigational Site 10396, Omaha, Nebraska, United States|Teva Investigational Site 10417, Henderson, Nevada, United States|Teva Investigational Site 10399, Las Vegas, Nevada, United States|Teva Investigational Site 10409, Berlin, New Jersey, United States|Teva Investigational Site 10439, Buffalo, New York, United States|Teva Investigational Site 10394, New York, New York, United States|Teva Investigational Site 10407, New York, New York, United States|Teva Investigational Site 10410, New York, New York, United States|Teva Investigational Site 10443, Raleigh, North Carolina, United States|Teva Investigational Site 10414, Winston-Salem, North Carolina, United States|Teva Investigational Site 10446, Oklahoma City, Oklahoma, United States|Teva Investigational Site 10415, Altoona, Pennsylvania, United States|Teva Investigational Site 10430, Duncansville, Pennsylvania, United States|Teva Investigational Site 10386, Mechanicsburg, Pennsylvania, United States|Teva Investigational Site 10373, Tipton, Pennsylvania, United States|Teva Investigational Site 10404, North Charleston, South Carolina, United States|Teva Investigational Site 10741, Spartanburg, South Carolina, United States|Teva Investigational Site 10405, Austin, Texas, United States|Teva Investigational Site 10364, Dallas, Texas, United States|Teva Investigational Site 10372, Dallas, Texas, United States|Teva Investigational Site 10395, Dallas, Texas, United States|Teva Investigational Site 10371, Houston, Texas, United States|Teva Investigational Site 12035, Houston, Texas, United States|Teva Investigational Site 10377, Lake Jackson, Texas, United States|Teva Investigational Site 10374, Plano, Texas, United States|Teva Investigational Site 10378, San Antonio, Texas, United States|Teva Investigational Site 10402, Salt Lake City, Utah, United States|Teva Investigational Site 10438, Roanoke, Virginia, United States|Teva Investigational Site 10420, Bellevue, Washington, United States|Teva Investigational Site 10433, Everett, Washington, United States",,https://ClinicalTrials.gov/show/NCT01789970
918,NCT02124980,Automated Recovery Line for Medication Assisted Treatment,,Completed,No Results Available,Drug Dependence|Substance Use Disorders,Behavioral: Recovery Line,urine screens|self reported drug use|treatment retention|coping behaviors,"Yale University|APT Foundation, Inc.|National Institute on Drug Abuse (NIDA)",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1208010744|R01DA034678,2015-11-01,2017-04-01,2017-04-01,2014-04-28,null,2017-07-02,"MRU, APT Foundation, Inc, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT02124980
919,NCT00813488,Fentanyl Buccal Tablets Versus Immediate Release Oxycodone for Breakthrough Pain in Patients With Chronic Pain,,Completed,Has Results,Chronic Pain,Drug: Fentanyl Buccal Tablet|Drug: Immediate release oxycodone,Pain Intensity Difference (PID) at 15 Minutes Post-treatment (PID15)|Pain Intensity Difference (PID) at 5 Minutes Post-treatment|Pain Intensity Difference (PID) at 10 Minutes Post-treatment|Pain Intensity Difference (PID) at 30 Minutes Post-treatment|Pain Intensity Difference (PID) at 45 Minutes Post-treatment|Pain Intensity Difference (PID) at 60 Minutes Post-treatment|Percentage Change in Pain Intensity Difference (% PID) at 5 Minutes Post-treatment|Percentage Change in Pain Intensity Difference (% PID) at 10 Minutes Post-treatment|Percentage Change in Pain Intensity Difference (% PID) at 15 Minutes Post-treatment|Percentage Change in Pain Intensity Difference (% PID) at 30 Minutes Post-treatment|Percentage Change in Pain Intensity Difference (% PID) at 45 Minutes Post-treatment|Percentage Change in Pain Intensity Difference (% PID) at 60 Minutes Post-treatment|Sum of Pain Intensity Difference at 30 Minutes Post-treatment (SPID30)|Sum of Pain Intensity Difference at 60 Minutes Post-treatment (SPID60)|Pain Relief (PR) Score at 5 Minutes Post-treatment|Pain Relief Score at 10 Minutes Post-treatment|Pain Relief Score at 15 Minutes Post-treatment|Pain Relief Score at 30 Minutes Post-treatment|Pain Relief Score at 45 Minutes Post-treatment|Pain Relief Score at 60 Minutes Post-treatment|Total Pain Relief at 60 Minutes (TOTPAR60)|Percent Total Pain Relief at 60 Minutes Posttreatment (%TOTPAR)|Time to Any Pain Relief (APR) by Treatment - <= 5 Minutes|Time to Any Pain Relief (APR) by Treatment <=10 Minutes|Time to Any Pain Relief (APR) by Treatment <=15 Minutes|Time to Any Pain Relief (APR) by Treatment <=30 Minutes|Time to Any Pain Relief (APR) by Treatment <=45 Minutes|Time to Any Pain Relief (APR) by Treatment <=60 Minutes|Time to Meaningful Pain Relief (MPR) by Treatment - <= 5 Minutes|Time to Meaningful Pain Relief (MPR) by Treatment <=10 Minutes|Time to Meaningful Pain Relief (MPR) by Treatment <=15 Minutes|Time to Meaningful Pain Relief (MPR) by Treatment <=30 Minutes|Time to Meaningful Pain Relief (MPR) by Treatment <=45 Minutes|Time to Meaningful Pain Relief (MPR) by Treatment <=60 Minutes|Use of Standard Rescue Medication|Medication Performance Assessment 30 Minutes Post-treatment|Medication Performance Assessment 60 Minutes Post-treatment|Breakthrough Pain Preference Questionnaire|Patient Global Impression of Change (PGIC) at Visit 7- 1 Month After Open Label Treatment|Patient Global Impression of Change (PGIC) at Visit 8- 2 Months After Open Label Treatment|Patient Global Impression of Change (PGIC) at Visit 9- 3 Months After Open Label Treatment|Patient Global Impression of Change (PGIC) Endpoint|Clinician Global Impression of Change at Visit 7- 1 Month After Open Label Treatment|Clinician Global Impression of Change (CGIC) at Visit 8- 2 Months After Open Label Treatment|Clinician Global Impression of Change (CGIC) at Visit 9- 3 Months After Open Label Treatment|Clinician Global Impression of Change (CGIC)Endpoint,Cephalon|Teva Pharmaceutical Industries,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,213,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",C25608/3056/BP/US,2008-12-01,2009-11-01,2010-01-01,2008-12-23,2010-12-31,2012-05-28,"Parkway Medical Center, Birmingham, Alabama, United States|Horizon Research Group, Inc, Mobile, Alabama, United States|Robert Karns, MD a Medical Corporation, Beverly Hills, California, United States|Catalina Research Institute, LLC, Chino, California, United States|Pacific Coast Pain Management, Laguna Hills, California, United States|Loma Linda University Health, Loma Linda, California, United States|VA Northern California Health, Mather, California, United States|New England Research Associates, Trumbull, Connecticut, United States|Delray Research Associates, Delray Beach, Florida, United States|Emerald Coast Research Group Inc, Marianna, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Gold Coast Research, Plantation, Florida, United States|Sarasota Pain Medicine Research, Sarasota, Florida, United States|Suncoast Neuroscience Associates, St. Petersburg, Florida, United States|Clinical Research of West Florida, Tampa, Florida, United States|Taylor Research, Marietta, Georgia, United States|Drug Studies America, Marietta, Georgia, United States|Georgia Pain Care, Newman, Georgia, United States|South Coast Medical Group, Savannah, Georgia, United States|Millennium Pain Center, Bloomington, Illinois, United States|Suburban Clinical Research, Bolingbrook, Illinois, United States|Knight Center for Integrated Health, Peoria, Illinois, United States|Indiana Medical Research, Elkhart, Indiana, United States|Rehabilitation Associates of Indiana, Indianapolis, Indiana, United States|Indiana Pain & Spine Clinic, South Bend, Indiana, United States|ICRI Inc., Overland Park, Kansas, United States|The Pain Treatment Center of the Bluegrass, Lexington, Kentucky, United States|Gulf Coast Research Associates, Inc, Baton Rouge, Louisiana, United States|Columbia Medical Practice, Columbia, Maryland, United States|MidAtlantic Pain Medicine Center, Pikesville, Maryland, United States|Michigan Neurology Associates PC, Clinton Township, Michigan, United States|CRC of Jackson, Jackson, Mississippi, United States|Healthcare Research, Florissant, Missouri, United States|Clinical Research Center of Nevada, Las Vegas, Nevada, United States|Five Towns Neuroscience Research, Cedarhurst, New York, United States|Upstate Clinical Research Associates, Williamsville, New York, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Clinical Research Source Inc, Perrysburg, Ohio, United States|Pain Research of Oregon, Eugene, Oregon, United States|Allegheny Pain Management, Altoona, Pennsylvania, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|CRI Worldwide, Philadelphia, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Clinical Research Center, West Reading, Pennsylvania, United States|Greenville Pharmaceutical Research, Greenville, South Carolina, United States|Trident Institute of Medical Research, LLC, North Charleston, South Carolina, United States|South Carolina Pharmaceutical Research, Spartanburg, South Carolina, United States|Lovelace Scientific, Austin, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|Aspen Clinical Research, Orem, Utah, United States",,https://ClinicalTrials.gov/show/NCT00813488
920,NCT02746354,Effects of a Patient Driven Assessment Process With Complex Pain Patients,PDAP,Completed,No Results Available,Chronic Pain,Other: The MySupport tool,Pain severity and functioning|Quality of sleep|Patient skill in managing health care|Health-related quality of life|Clinician empathy|Self-care practices|Health services utilization,Kaiser Permanente,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,Pro00003197,2012-10-01,2014-12-01,2015-04-01,2016-04-21,null,2016-04-21,"Kaiser Permanente Center for Health Research, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT02746354
921,NCT00463047,Efficacy and Safety of Fentanyl Buccal Tablets Compared With Oxycodone for the Management of Break Through Pain,,Completed,Has Results,Chronic Pain,Drug: Fentanyl Buccal Tablets Compared With Immediate-Release Oxycodone,"Pain Intensity Difference (PID15) At 15 Minutes|Pain Intensity Difference (PID 5) at 5 Minutes|Pain Intensity Difference (PID 10) at 10 Minutes|Pain Intensity Difference (PID 30) at 30 Minutes|Pain Intensity Difference (PID 45) at 45 Minutes|Pain Intensity Difference (PID 60) at 60 Minutes|Percentage Change in Pain Intensity Difference (% PID) at 5 Minutes Post-treatment|Percentage Change in Pain Intensity Difference (%PID) at 10 Minutes|Percentage Change in Pain Intensity Difference (%PID) at 15 Minutes|Percentage Change in Pain Intensity Difference (%PID) at 30 Minutes|Percentage Change in Pain Intensity Difference (% PID) at 45 Minutes|Percentage Change in Pain Intensity Difference (%PID) at 60 Minutes|Sum of Pain Intensity Difference at 30 Minutes Post-treatment (SPID30)|Sum of Pain Intensity Difference at 60 Minutes Post-treatment (SPID60)|Pain Relief (PR) Score at 5 Minutes|Pain Relief Score (PR) at 10 Minutes|Pain Relief Score (PR) at 15 Minutes|Pain Relief Score (PR) at 30 Minutes|Pain Relief Score (PR) at 45 Minutes|Pain Relief Score (PR) at 60 Minutes|Total Pain Relief (TOTPAR60) at 60 Minutes|Percent Total Pain Relief at 60 Minutes Posttreatment (%TOTPAR)|Time to Any Pain Relief (APR) by Treatment, <= 5 Minutes|Time to Any Pain Relief (APR) by Treatment, <=10 Minutes|Time to Any Pain Relief (APR) by Treatment, <=15 Minutes|Time to Any Pain Relief (APR) by Treatment, <=30 Minutes|Time to Any Pain Relief (APR) by Treatment, <=45 Minutes|Time to Any Pain Relief (APR) by Treatment, <=60 Minutes|Time to Meaningful Pain Relief (MPR) by Treatment, <= 5 Minutes|Time to Meaningful Pain Relief (MPR) by Treatment, <=10 Minutes|Time to Meaningful Pain Relief (MPR) by Treatment, <=15 Minutes|Time to Meaningful Pain Relief (MPR) by Treatment, <=30 Minutes|Time to Meaningful Pain Relief (MPR) by Treatment, <=45 Minutes|Time to Meaningful Pain Relief (MPR) by Treatment, <=60 Minutes|Standard Rescue Medication Usage|Medication Performance Assessment 30 Minutes After-treatment|Medication Performance Assessment 60 Minutes After-treatment|Breakthrough Pain Preference Questionnaire|Pain Flare Treatment Satisfaction (PFTS) Questionnaire - Question 21 at the End of the First Double-blind Treatment Period (Visit 5)|Pain Flare Treatment Satisfaction (PFTS) Questionnaire - Question 21 at the End of the Second Double-blind Treatment Period (Visit 6)|Pain Flare Treatment Satisfaction (PFTS) Questionnaire - Question 21 at Endpoint (End of Second Double-blind Treatment Period or Last Observation After Start of Treatment Period)",Cephalon|Teva Pharmaceutical Industries,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,323,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",C25608/3055/BP/MN,2007-07-01,2009-02-01,2009-02-01,2007-04-19,2010-12-14,2012-05-28,"Alabama Clinical Therapeutics, Birmingham, Alabama, United States|Birmingham Pain Center, Birmingham, Alabama, United States|Arizona Research Center, Phoenix, Arizona, United States|Desert Pain & Rehab Specialists/Redpoint Research, Phoenix, Arizona, United States|Hope Research Institute, Phoenix, Arizona, United States|Lovelace Scientific Resources, Inc., Beverly Hills, California, United States|City of Hope National Medical Center, Duarte, California, United States|Samaritan Center for Medical Research, Med. Group, Los Gatos, California, United States|Advanced Diagnostic Pain Treatment Center, PC, New Haven, Connecticut, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Compass Research, Orlando, Florida, United States|AvivoClin Clinical Services, Port Orange, Florida, United States|Lovelace Scientific Resources, Inc., Sarasota, Florida, United States|Clinical Research of Tampa Bay, Inc., Spring Hill, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|Center for Prospective Outcome Studies, Inc., Atlanta, Georgia, United States|North Georgia Premier Research, Dawnsonville, Georgia, United States|Taylor Research, LLC, Marietta, Georgia, United States|DrugStudies America, Marietta, Georgia, United States|Tristate Arthritis & Rheumatology Center, LLC, Evansville, Indiana, United States|Rehabilitation Associates of Indiana, Indianapolis, Indiana, United States|Integrated Clinical Trial Services, Inc., West Des Moines, Iowa, United States|International Clinical Research Institute, Inc., Overland Park, Kansas, United States|Kansas City Bone & Joint Clinic, Inc., Overland Park, Kansas, United States|Willis-Knighton Pain Management Center, Shreveport, Louisiana, United States|The Rehabilitation Team West, Baltimore, Maryland, United States|Mid Atlantic Pain Medicine Center, Pikesville, Maryland, United States|Englewood Hospital and Medical Center, Englewood, New Jersey, United States|Lovelace Scientific Resources, Inc., Albuquerque, New Mexico, United States|Metropolitan Hospital Center, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|PharmQuest, Greensboro, North Carolina, United States|Peters Medical Research, High Point, North Carolina, United States|Raleigh Neurology Associate, Raleigh, North Carolina, United States|Columbus Clinical Research, Columbus, Ohio, United States|Allegheny Pain Management, Altoona, Pennsylvania, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Greenville Pharmaceutical, Greenville, South Carolina, United States|Comprehensive Pain Specialists, PLLC, Hendersonville, Tennessee, United States|Consultants in Pain Research, San Antonio, Texas, United States|InVisions Consultants, LLC, San Antonio, Texas, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|The Center for Pain Relief, Charleston, West Virginia, United States",,https://ClinicalTrials.gov/show/NCT00463047
922,NCT01702194,TD-1211 IV/Oral Mass Balance Study,,Completed,No Results Available,OIC,Drug: TD-1211 IV [C14]|Drug: TD-1211 PO [C14],"Area under the plasma concentration versus time curve (AUC)|Peak plasma concentration (Cmax)|Time to peak plasma concentration (Tmax)|Half-life (T 1/2)|Percent total recovery of radioactivity in blood, urine, and feces|Number of participants with adverse events","Theravance Biopharma R & D, Inc.|Theravance Biopharma Antibiotics, Inc.",Male,18 Years to 50 Years   (Adult),Phase 1,10,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,87,2012-11-01,2013-02-01,2013-03-01,2012-10-05,null,2014-09-05,"Covance, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT01702194
923,NCT01361607,Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer,SPRAY III,Completed,Has Results,Pain|Advanced Cancer,Drug: Nabiximols|Drug: Placebo (GA-0034),Percent Improvement From Baseline In Mean NRS Average Pain At End Of Treatment|Change From Baseline In Mean NRS Average Pain At End Of Treatment|Change From Baseline In Mean NRS Worst Pain At End Of Treatment|Change From Baseline In Mean Sleep Disruption NRS At End Of Treatment|Subject Global Impression Of Change At Last Visit (Up To Day 36)|Physician Global Impression Of Change At Last Visit (Up To Day 36)|Patient Satisfaction Questionnaire At Last Visit (Up To Day 36)|Change From Baseline In Daily Total Opioid Use (Morphine Equivalent) At End Of Treatment|Change From Baseline In Daily Maintenance Opioid Dose (Morphine Equivalent) At End of Treatment|Change From Baseline In Daily Break-through Opioid Dose (Morphine Equivalent) At End Of Treatment|Change From Baseline In NRS Constipation At Last Visit (Up To Day 36),"GW Pharmaceuticals Ltd.|Otsuka Pharmaceutical Development & Commercialization, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,399,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",GWCA0962|2009-016065-29,2011-05-27,2014-11-24,2014-11-24,2011-05-27,2018-04-23,2018-04-23,"Glendale, California, United States|Santa Rosa, California, United States|Clearwater, Florida, United States|Holiday, Florida, United States|Miami, Florida, United States|Stuart, Florida, United States|Marietta, Georgia, United States|Newnan, Georgia, United States|Stockbridge, Georgia, United States|Gurnee, Illinois, United States|Mount Vernon, Illinois, United States|Ashland, Kentucky, United States|Bossier City, Louisiana, United States|Shreveport, Louisiana, United States|Missoula, Montana, United States|Berlin, New Jersey, United States|New York, New York, United States|New York, New York, United States|Cleveland, Ohio, United States|Lacey, Washington, United States|Vratsa, Bulgaria|Benešov, Czechia|Jablonec Nad Nisou, Czechia|Plzen, Czechia|Sokolov, Czechia|Teplice, Czechia|České Budějovice, Czechia|České Budějovice, Czechia|Berlin, Germany|Frankfurt, Germany|Fulda, Germany|Hannover, Germany|Jena, Germany|Wiesbaden, Germany|Komarom, Hungary|Nyíregyháza, Hungary|Mexico, DF, Mexico|Chihuahua, Mexico|Monterrey, Mexico|Bydgoszcz, Poland|Czestochowa, Poland|Czestochowa, Poland|Dzialdowo, Poland|Gdansk, Poland|Klodzko, Poland|Ostrowiec Swietokrzyski, Poland|Poznan, Poland|Warszawa, Poland|Ponce, Puerto Rico|Targoviste, Dambovita, Romania|Baia Mare, Romania|Braila, Romania|Brasov, Romania|Bucuresti, Romania|Cluj-Napoca, Romania|Constanta, Romania|Focșani, Romania|Iasi, Romania|Sibiu, Romania|Suceava, Romania|Cheltenham, Gloucestershire, United Kingdom|Withington, Manchester, United Kingdom|Great Yarmouth, Norfolk, United Kingdom|Coventry, United Kingdom|Glasgow, United Kingdom|Manchester, United Kingdom|Norwich, United Kingdom|Plymouth, United Kingdom",,https://ClinicalTrials.gov/show/NCT01361607
924,NCT01262651,Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer,,Completed,Has Results,Pain|Advanced Cancer,Drug: Nabiximols|Drug: Placebo (GA-0034),Percent Improvement From Baseline In Mean NRS Average Pain At End Of Treatment|Change From Baseline In Mean NRS Average Pain At End Of Treatment|Change From Baseline In Mean NRS Worst Pain At End Of Treatment|Change From Baseline In Mean Sleep Disruption NRS At End Of Treatment|Subject Global Impression Of Change At Last Visit (Up To Day 36)|Physician Global Impression Of Change At Last Visit (Up To Day 36)|Patient Satisfaction Questionnaire At Last Visit (Up To Day 36)|Change From Baseline In Daily Total Opioid Use (Morphine Equivalent) At End Of Treatment|Change From Baseline In Daily Maintenance Opioid Dose (Morphine Equivalent) At End of Treatment|Change From Baseline In Daily Break-through Opioid Dose (Morphine Equivalent) At End Of Treatment|Change From Baseline In NRS Constipation At Last Visit (Up To Day 36),"GW Pharmaceuticals Ltd.|Otsuka Pharmaceutical Development & Commercialization, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,397,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",GWCA0958|2009-016064-36,2010-11-25,2015-07-02,2015-07-02,2010-12-17,2018-04-23,2018-04-23,"Phoenix, Arizona, United States|Phoenix, Arizona, United States|El Cajon, California, United States|Gilroy, California, United States|Brandon, Florida, United States|Daytona Beach, Florida, United States|Holiday, Florida, United States|Jacksonville, Florida, United States|Lynn Haven, Florida, United States|Stuart, Florida, United States|Winter Park, Florida, United States|Newnan, Georgia, United States|Stockbridge, Georgia, United States|Shreveport, Louisiana, United States|Saint Louis Park, Minnesota, United States|Kansas City, Missouri, United States|Berlin, New Jersey, United States|Hendersonville, North Carolina, United States|Winston-Salem, North Carolina, United States|Philadelphia, Pennsylvania, United States|Houston, Texas, United States|Houston, Texas, United States|Laredo, Texas, United States|Salt Lake City, Utah, United States|Salt Lake City, Utah, United States|Bruxelles, Belgium|Gabrovo, Bulgaria|Shumen, Bulgaria|Varna, Bulgaria|Ceske Budejovice, Czechia|Ceske Budejovice, Czechia|Hradec Kralove, Czechia|Most, Czechia|Nová Ves Pod Pleší, Czechia|Ostrava-Poruba, Czechia|Plzen, Czechia|Lunen, Germany|Stadtroda, Germany|Wetzlar, Germany|Deszk, Hungary|Kecskemét, Hungary|Komarom, Hungary|Miskolc, Hungary|Nyíregyháza, Hungary|Szekszard, Hungary|Rezekne, Latvia|Riga, Latvia|Klaipeda, Lithuania|Siauliai, Lithuania|Vilnius, Lithuania|Bialystok, Poland|Bielsko-Biala, Poland|Gliwice, Poland|Poznan, Poland|Warszawa, Poland|Ponce, Puerto Rico|San Juan, Puerto Rico|Baia Mare, Romania|Braila, Romania|Bucuresti, Romania|Craiova, Romania|Oradea, Romania|Satu Mare, Romania|Suceava, Romania|Bury Saint Edmunds, United Kingdom|Bury, United Kingdom|Edinburgh, United Kingdom|Glasgow, United Kingdom|Manchester, United Kingdom|Norwich, United Kingdom|Weston Super Mare, United Kingdom|Wolverhampton, United Kingdom",,https://ClinicalTrials.gov/show/NCT01262651
925,NCT00279487,Preanalgesic Effect of Gabapentin in Total Knee Repair,,Completed,No Results Available,Pain,Drug: Gabapentin|Drug: Placebos,,Texas Health Resources,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,24,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P768,null,null,2007-08-01,2006-01-19,null,2016-10-26,"Presbyterian Hospital of Dallas, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT00279487
926,NCT02969343,Patient Safety Learning Laboratory: Making Acute Care More Patient-Centered,PSLL,Recruiting,No Results Available,Central Line-Associated Bloodstream Infection (CLABSI)|Venous Thromboembolism|Patient Fall|Catheter-Associated Infection|Severe Hypoglycemia|Opioid-Related Severe Adverse Drug Event|Hospital Acquired Pressure Ulcer|Adverse Drug Event|Severe Hospital Acquired Delerium|Rapid Response Related to Arrhythmia,Behavioral: Patient Safety health information technology,"Clinical Outcomes: Proportion of hospitalizations with any adverse event|Clinical Inertia: When Red flag, % changed to yellow or green during hospitalization|Clinical Inertia:When Red flag, % changed to green during hospitalization|Clinical Inertia: Mean time to resolution of red flags (to green or yellow), days|Clinical Inertia:Mean time to resolution of red flags (to green), days|Patient Falls/ Mobility: % patient days of patients at fall risk due to a gait disturbance on sedatives|Patient Falls/ Mobility:% pt-days of patients at fall risk due to a gait disturbance without Physical Therapy consult order|Code Status: % patient-days on study unit with unconfirmed code status|Glucose Control: % patients with diabetes or hyperglycemia with order for basal insulin|Glucose Control: % patients with diabetes or hyperglycemia with orders for basal and nutritional insulin|Nutrition: % patient-days without any diet order|Nutrition: % pt-days NPO with insulin aspart ordered at same time|Venous thromboembolism (VTE): % pt-days with appropriate prophylaxis ordered based on risk and contraindications|Venous thromboembolism (VTE):% pt-days with appropriate prophylaxis administered based on risk and contraindications|Venous thromboembolism (VTE): % ordered pharmacologic prophylaxis doses administered|Pain Control: % pt-days with MED > 100 mg|Pain Control: % patient-days with opioids ordered and no adjunctive medications ordered|Pain Control:% pt-days with opioids administered and no Richmond Agitation-Sedation Scale (RASS) score recorded|Antibiotic Management: % patient-days with patients on broad-spectrum gram-positive and broad-spectrum gram-negative antibiotics for > 72 hours|Antibiotic Management: % pt-days with pts on broad-spectrum antibiotics for > 72 hours|Delirium Management: % patient-days Confusion Assessment Method (CAM) positive|Delirium Management: % patient-days of patients at high risk for delirium on sedatives|Delirium Management: % patient-days of patients at high risk for delirium on ramelteon|Delirium Management: % patient-days of patients with hyperactive delirium on neuroleptics|Vascular Access: % patient-days with central line in place|Foley Care: % patient-days with Foley catheter in place|Foley Care: % patient-days with Foley documented but not ordered|Foley Care: % patient-days with Foley documented but Nurse Driven Protocol (NDP) not ordered|Telemetry: % patient-days of high risk patients without any telemetry|Telemetry: % patient-days of low risk patients on telemetry > 72h|Bowel Regimen: % pt-days of patients on opioids and no bowel regimen ordered|Bowel Regimen:% patient-days where on opioids, no bowel movement 2 or more days, and no bowel regimen administered|Fall / Mobility: Patient Falls based on safety reports per 1000 patient-days|Fall / Mobility: Falls with injury based on safety reports per 1000 patient-days|Glucose Control: Patient-day-weighted mean glucose|Glucose Control: Proportion of glucose readings 70-180 mg/dL, mean per patient|Glucose Control: Proportion of patient-days with hypoglycemia|Glucose Control: Proportion of patient-days with severe hypoglycemia|Venous Thromboembolism: proportion of hospitalizations with hospital-acquired VTE|Venous Thromboembolism: proportion of hospitalizations with VTE within 30 days of discharge|Pain Control: proportion of hospitalizations with opioid induced depression of consciousness or respiration|Pain Control: proportion of hospitalizations of patients on opioids who required narcan|Pain Control: proportion of hospitalizations with severe opioid-related adverse drug event|Pain Control: proportion of hospitalizations of patients on opioids with any opioid-related Adverse Drug Event|Pressure Ulcers: proportion of hospitalizations with hospital-acquired pressure ulcer|Pressure Ulcers: proportion of hospitalizations with pressure ulcer worsening in stage from admission to discharge|Delirium Management: proportion of hospitalizations requiring mechanical restraints|Delirium Management: proportion of hospitalizations requiring code gray and requiring security|Vascular Access: Central Line Associated Blood Stream Infection (CLABSI) per 1000 patient-days|Foley Care: Central Line Associate Urinary Tract Infection per 1000 patient-days|Telemetry: proportion of hospitalizations for rapid response for arrhythmia",Brigham and Women's Hospital|Northeastern University,All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,21000,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,5P30HS023535,2015-04-01,2018-04-01,2018-09-01,2016-11-21,null,2017-03-24,"Brigham and Women's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02969343
927,NCT01431586,First in Humans Study of JDTic,,Terminated,No Results Available,Cocaine Dependence,Drug: JDtic,"To evaluate the safety and tolerability of single, escalating oral doses of JDTic in healthy male subjects|Pharmacokinetics Profile|To evaluate a potential surrogate measure of JDTic PD activity",RTI International|National Institute on Drug Abuse (NIDA),Male,18 Years to 50 Years   (Adult),Phase 1,24,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",JDTic-001|U19DA021002,null,null,null,2011-09-09,null,2012-05-10,"Celerion Inc., Tempe, Arizona, United States",,https://ClinicalTrials.gov/show/NCT01431586
928,NCT00241917,A Video-Based HCV Curriculum for Drug Users,,Completed,No Results Available,Hepatitis C|Opiate Dependence,Behavioral: Hepatitis C educational video|Other: Video,"HCV testing rates, intervention vs. usual care|HAV vaccination rates, intervention vs. usual care|HBV vaccination rates, intervention vs. usual care|Improvement in knowledge, intervention vs. usual care|Improvement in attitudes toward behavior change, intervention vs. usual care|Improvement in motivation toward behavior change, intervention vs. usual care",Organization to Achieve Solutions in Substance Abuse (OASIS)|Centers for Disease Control and Prevention,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,450,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),U50/CCU923257,2005-11-01,2007-05-01,2007-05-01,2005-10-19,null,2008-12-09,"BAART/Antioch Methadone Clinic, Antioch, California, United States|BAART/Richmond Methadone Clinic, Richmond, California, United States|BAART/Market Methadone Clinic, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT00241917
929,NCT01324570,"Safety, Pharmacokinetics (PK), and Efficacy of Buprenorphine Transdermal System (BTDS) in Children",,Completed,Has Results,Pain,Drug: Buprenorphine transdermal system,"The Number of Participants With Adverse Events as a Measure of Safety|Pharmacokinetics (PK) of Buprenorphine Following Transdermal Administration: Apparent Clearance (CL/F)|Pharmacokinetics (PK) of Buprenorphine Following Transdermal Administration: Apparent Volume of Distribution (Vc/F)|Pain Right Now Assessment by Patients Aged 7 to 11 Years, Inclusive|Pain Right Now Assessment by Patients Aged 12 to 16 Years, Inclusive|Parent/Caregiver-assessed Global Impression of Change (PGIC)",Purdue Pharma LP,All,7 Years to 16 Years   (Child),Phase 3,41,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BUP3031|2010-021954-21,2011-07-01,2016-05-01,2016-05-01,2011-03-29,2017-07-06,2017-07-06,"Long Beach Memorial Medical Center, Long Beach, California, United States|Children's Hospital of Los Angeles, Los Angeles, California, United States|Children's Health Center, Los Angeles, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|Howard University Hospital, Washington, D.C., District of Columbia, United States|Jackson Memorial Hospital / University of Miami, Miami, Florida, United States|Children's Healthcare of Atlanta at Egleston, Atlanta, Georgia, United States|University of Illinois Hospital and Health Sciences System, Chicago, Illinois, United States|Kosair Charities Pediatric Clinical Research Unit - University of Louisville, Louisville, Kentucky, United States|Willis-Knighton Physician Network, Shreveport, Louisiana, United States|Saint Peter's University Hospital, New Brunswick, New Jersey, United States|WCMC, Department of Pediatrics - Hematology/Oncology, New York, New York, United States|Stony Brook University Hospital, Stony Brook, New York, United States|Children's Hospital at Montefiore, The Bronx, New York, United States|Vidant Medical Center, Greenville, North Carolina, United States|The Center for Clinical Research - Carolina Pain Institute, Winston-Salem, North Carolina, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Department of Pediatrics, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Children's Blood and Cancer Center, Austin, Texas, United States|Road Runner Research, Ltd., San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT01324570
930,NCT01151098,Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension Study,,Completed,Has Results,Chronic Nonmalignant Pain,Drug: Buprenorphine transdermal patch,Number of Participants With Adverse Events (AEs) as a Measure of Safety.,Purdue Pharma LP,All,"18 Years and older   (Adult, Older Adult)",Phase 3,189,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BUP3201S,2001-04-01,2002-02-01,2002-02-01,2010-06-25,2010-09-23,2012-09-10,"Arizona Research Center Inc., Phoenix, Arizona, United States|Clinical Research Consultants Inc, Trumbull, Connecticut, United States|Tampa Bay Medical Research Inc, Clearwater, Florida, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|University Clinical Research Deland, Deland, Florida, United States|University Clinical Research Inc,, Pembroke Pines, Florida, United States|Gold Coast Research, LLC, Plantation, Florida, United States|Gold Coast Research LLC, Tamarac, Florida, United States|Family Medicine Associates, Evansville, Indiana, United States|Pain Management & Rehabilitation, Terre Haute, Indiana, United States|Southeastern Center for Headache and Pain, Crestview Heights, Kentucky, United States|Westside Family Medical Center PC, Kalamazoo, Michigan, United States|The Arthritis Clinic, Charlotte, North Carolina, United States|Cornerstone Research Care, High Point, North Carolina, United States|ALL-TRIALS Clinical Research LLC, Winston-Salem, North Carolina, United States|Summit Research Solutions, Memphis, Tennessee, United States|Radiant Research - Austin, Austin, Texas, United States|Wasatch Clinical Research, Salt Lake City, Utah, United States|Clinical Research Management, New Berlin, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT01151098
931,NCT00490919,Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Chronic Low Back Pain,,Completed,Has Results,Low Back Pain,Drug: Buprenorphine transdermal system|Drug: Placebo,"Average Pain Over the Last 24 Hours Scores at Week 12 of the Double-blind Phase.|The Mean Daily Number of Tablets of Nonopioid Supplemental Analgesic Medications Taken During Weeks 2 Through 12 of the Double-blind Phase|The Sleep Disturbance Subscale in the Medical Outcome Study (MOS) Sleep Scale at Weeks 4, 8, and 12 of the Double-blind Phase",Purdue Pharma LP,All,"18 Years and older   (Adult, Older Adult)",Phase 3,539,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BUP3024,2007-06-01,2008-07-01,2008-10-01,2007-06-25,2010-09-09,2012-09-10,"Research Facility, Anniston, Alabama, United States|Coastal Clinical Research, Inc., Mobile, Alabama, United States|Radiant Research; Phoenix Southeast, Chandler, Arizona, United States|Arizona Research Center Inc., Phoenix, Arizona, United States|Research Facility, Phoenix, Arizona, United States|Research Facility, Phoenix, Arizona, United States|Research Facility, Anaheim, California, United States|Lovelace Scientific Resources, Inc., Beverly Hills, California, United States|Research Facility, Carmichael, California, United States|Advance Care Medical Group, City of Industry, California, United States|Research Facility, Downey, California, United States|Research Facility, Foothill Ranch, California, United States|Research Facility, Sacramento, California, United States|Research Facility, San Luis Obispo, California, United States|Research Facility, Littleton, Colorado, United States|Research Facility, Stamford, Connecticut, United States|Clinical Research of West Florida, Clearwater, Florida, United States|Research Facility, Clearwater, Florida, United States|University Clinical Research, Deland, Florida, United States|Arthritis Associates of S. FL, Delray Beach, Florida, United States|Research Facility, Ft. Myers, Florida, United States|Century Clinical Research, Inc., Holly Hill, Florida, United States|Research Facility, Jupiter, Florida, United States|Research Facility, Largo, Florida, United States|Research Facility, Merritt Island, Florida, United States|Pharmax Research Clinic, Miami, Florida, United States|Research Facility, Orlando, Florida, United States|Research Facility, Plantation, Florida, United States|Research Facility, Port Orange, Florida, United States|Clinical Research of West Flor, Tampa, Florida, United States|Research Facility, Tampa, Florida, United States|Research Facility, West Palm Beach, Florida, United States|Independent Neurodiagnostic Clinic, Atlanta, Georgia, United States|Research Facility, Dawsonville, Georgia, United States|Druid Oaks Health Center, Decatur, Georgia, United States|Research Facility, Marietta, Georgia, United States|Research Facility, Marietta, Georgia, United States|Research Facility, Honolulu, Hawaii, United States|Research Facility, Boise, Idaho, United States|Rehabilitation Association of IN, Indianapolis, Indiana, United States|Research Facility, Overland Park, Kansas, United States|CTT Consultants, Inc., Prairie Village, Kansas, United States|Dolby Research, LLC, Baton Rouge, Louisiana, United States|Research Facility, New Orleans, Louisiana, United States|Research Facility, New Orleans, Louisiana, United States|Research Facility, Shreveport, Louisiana, United States|Research Facility, Brockton, Massachusetts, United States|East Coast Clinical Research, Haverhill, Massachusetts, United States|Research Facility, Springfield, Massachusetts, United States|Research Facility, Bay City, Michigan, United States|Research Facility, Biloxi, Mississippi, United States|Research Facility, Florissant, Missouri, United States|Research Facility, St. Louis, Missouri, United States|Research Facility, St. Louis, Missouri, United States|Sports Med Consultants, PC, St. Louis, Missouri, United States|Research Facility, Henderson, Nevada, United States|Research Facility, Las Vegas, Nevada, United States|Lovelace Scientific Resources, Albuquerque, New Mexico, United States|Research Facility, New York, New York, United States|Research Facility, New York, New York, United States|Research Facility, Charlotte, North Carolina, United States|Research Facility, Greensboro, North Carolina, United States|Research Facility, Morgantown, North Carolina, United States|Community Research, Cincinatti, Ohio, United States|Research Facility, Cincinnati, Ohio, United States|Research Facility, Columbus, Ohio, United States|Research Facility, Columbus, Ohio, United States|Research Facility, Toledo, Ohio, United States|Research Facility, Oklahoma City, Oklahoma, United States|Research Facility, Eugene, Oregon, United States|Research Facility, Medford, Oregon, United States|Research Facility, Altoona, Pennsylvania, United States|Research Facility, Chicora, Pennsylvania, United States|Research Facility, Duncansville, Pennsylvania, United States|Research Facility, Mechanicsburg, Pennsylvania, United States|Research Facility, West Reading, Pennsylvania, United States|New England Center for Clinical Research, Cranston, Rhode Island, United States|Anderson Family Care, PA, Anderson, South Carolina, United States|KRK Medical Research, Dallas, Texas, United States|Research Facility, Killeen, Texas, United States|Research Facility, Plano, Texas, United States|Research Facility, San Antonio, Texas, United States|Research Facility, San Antonio, Texas, United States|Research Facility, Sugarland, Texas, United States|Research Facility, Salt Lake City, Utah, United States|Research Facility, Roanoke, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00490919
932,NCT00531427,Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee,,Completed,Has Results,Chronic Pain|Osteoarthritis of the Knee,Drug: Buprenorphine|Drug: Placebo,"""Average Pain Over the Last 24 Hours"" Score of the Study Knee at Week 12 of the Double Blind Phase.|Mean Daily Number of Tablets of Nonopioid Supplemental Analgesic Used From Week 2 to 12 of the Double-blind Phase.|Sleep Disturbance Subscale of the MOS-Sleep Scale at Weeks 4, 8, and 12 of the Double-blind Phase.",Purdue Pharma LP,All,"40 Years and older   (Adult, Older Adult)",Phase 3,567,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BUP3025,2007-09-01,2009-04-01,2009-11-01,2007-09-18,2010-09-21,2012-09-10,"Coastal Clinical Research, Inc., Mobile, Alabama, United States|Radiant Research, Phoenix Southeast, Chandler, Arizona, United States|Arizona Research Center, Inc., Phoenix, Arizona, United States|Research Facility, Phoenix, Arizona, United States|Research Facility, Phoenix, Arizona, United States|Research Facility, Anaheim, California, United States|Lovelace Scientific Resources, Inc., Beverly Hills, California, United States|Catalina Research Institute, Chino, California, United States|Research Facility, Downey, California, United States|Research Facility, Foothill Ranch, California, United States|Research Facility, Laguna Hills, California, United States|Research Facility, Sacramento, California, United States|Research Facility, Littleton, Colorado, United States|Research Facility, Stamford, Connecticut, United States|Coastal Pain Management, Bradenton, Florida, United States|Clinical Research of West Florida, Clearwater, Florida, United States|Research Facility, Clearwater, Florida, United States|Research Facility, Jupiter, Florida, United States|Research Facility, Largo, Florida, United States|Pharmax Research Clinic, Miami, Florida, United States|Research Facility, Miami, Florida, United States|Research Facility, Orlando, Florida, United States|Research Facility, Plantation, Florida, United States|Research Facility, Royal Palm, Florida, United States|Clinical Research of West Flor, Tampa, Florida, United States|Research Facility, Tampa, Florida, United States|Research Facility, Venice, Florida, United States|Research Facility, West Palm Beach, Florida, United States|Research Facility, Atlanta, Georgia, United States|Research Facility, Augusta, Georgia, United States|AMR Research Associates, Bogart, Georgia, United States|Research Facility, Dawsonville, Georgia, United States|Research Facility, Decatur, Georgia, United States|Research Facility, Marietta, Georgia, United States|Research Facility, Honolulu, Hawaii, United States|Rehabilitation Association of IN, Indianapolis, Indiana, United States|Research Facility, Overland Park, Kansas, United States|Graves-Gilbert Clinic, Bowling Green, Kentucky, United States|Stat-Lab I, Inc., Baton Rouge, Louisiana, United States|Research Facility, New Iberia, Louisiana, United States|Research Facility, New Orleans, Louisiana, United States|Research Facility, Frederick, Maryland, United States|Research Facility, Brockton, Massachusetts, United States|East Coast Clinical Research, Haverhill, Massachusetts, United States|Research Facility, Springfield, Massachusetts, United States|Research Facility, Bay City, Michigan, United States|Premier Internal Medicine, Biloxi, Mississippi, United States|Research Facility, Florissant, Missouri, United States|Research Facility, St. Louis, Missouri, United States|Sports Med Consultants PC, St. Louis, Missouri, United States|Research Facility, Henderson, Nevada, United States|Research Facility, New York, New York, United States|Research Facility, New York, New York, United States|Research Facility, Morgantown, North Carolina, United States|Research Facility, Winston-Salem, North Carolina, United States|Research Facility, Canton, Ohio, United States|Research Facility, Cincinnati, Ohio, United States|Research Facility, Columbus, Ohio, United States|Research Facility, Columbus, Ohio, United States|Digestive Endoscopy Center, Dayton, Ohio, United States|Research Facility, Dayton, Ohio, United States|Research Facility, Middleburg Heights, Ohio, United States|Research Facility, Mt. Gilead, Ohio, United States|Research Facility, Toledo, Ohio, United States|Research Facility, Oklahoma City, Oklahoma, United States|Research Facility, Eugene, Oregon, United States|Research Facility, Medford, Oregon, United States|Paramount Clinical Research, Bridgeville, Pennsylvania, United States|Research Facility, Duncansville, Pennsylvania, United States|Oyster Point Family Health Ctr, Lancaster, Pennsylvania, United States|Research Facility, Mechanicsburg, Pennsylvania, United States|Research Facility, West Reading, Pennsylvania, United States|New England Center for Clinical Research, Cranston, Rhode Island, United States|Research Facility, Cranston, Rhode Island, United States|Greenville Pharmaceutical Research, Greenville, South Carolina, United States|Arthritis Clinic, PLLC, Jackson, Tennessee, United States|Research Facility, Austin, Texas, United States|Research Facility, Colleyville, Texas, United States|Research Facility, Dallas, Texas, United States|Research Facility, Nederland, Texas, United States|Research Facility, San Antonio, Texas, United States|Research Facility, San Antonio, Texas, United States|Research Facility, Sugarland, Texas, United States|Research Facility, Salt Lake City, Utah, United States|NDC Medical Center, Norfolk, Virginia, United States|Independence Family Medicine, Virginia Beach, Virginia, United States|Pacific Northwest Primary Care, Tacoma, Washington, United States",,https://ClinicalTrials.gov/show/NCT00531427
933,NCT03235154,A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic,,Recruiting,No Results Available,"Hepatitis C, Chronic|Hepatitis C|Opiate Dependence",Drug: sofosbuvir/velpatasvir,Percentage of Sustained Virologic Response at 12 Weeks Post Treatment (SVR-12) Achieved by Participants|Health-Related Quality of Life|Adherence to Study Treatment,Community Research Initiative of New England|Gilead Sciences,All,"18 Years and older   (Adult, Older Adult)",Phase 4,20,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15-05,2017-10-11,2018-08-01,2019-01-01,2017-08-01,null,2018-01-24,"Cambridge Health Alliance Outpatient Addiction Services, Somerville, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03235154
934,NCT00831051,Comparison of the Efficacy and Safety of Q8003 Versus Its Individual Components in Bunionectomy Patients,,Completed,No Results Available,Postoperative Pain,Drug: Q8003|Drug: Morphine sulfate|Drug: Oxycodone HCl|Drug: Oxycodone HCl 4mg,Difference in pain intensity scores from baseline|Safety: adverse events,QRxPharma Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,197,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Q8003-021,2008-12-01,2009-01-01,2009-02-01,2009-01-28,null,2012-05-17,"Associated Foot and Ankle Specialists, Phoenix, Arizona, United States|Advanced Clinical Research Institute, Anaheim, California, United States|Crossroads Research, Inc., Owings Mills, Maryland, United States|Chesapeake Foot and Ankle, Pasadena, Maryland, United States|Advanced Regional Center for Ankle and Foot Care, Altoona, Pennsylvania, United States|Jean Brown Research, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT00831051
935,NCT02099591,Phase I Pharmacokinetics and Safety Study of Naloxegol in Paediatric OIC Patients,,Recruiting,No Results Available,"Constipation, Signs and Symptoms, Digestive",Drug: Naloxegol,"To characterise the pharmacokinetics of naloxegol after single oral dose and through population pharmacokinetics in paediatric patients with opioid induced constipation|To characterise the pharmacokinetics of naloxegol after multiple, once-daily, oral dosing in paediatric opioid induced constipation patients who continue participation beyond Day 1|Palatability of naloxegol liquid drug formulation|Ability of the patient to swallow the tablet|Clinical outcome measures by assessment of laxative use",Kyowa Kirin Pharmaceutical Development Ltd,All,"6 Months to 18 Years   (Child, Adult)",Phase 1,48,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D3820C00016|UTN: U1111-1154-5575|2013-003935-32,2014-11-01,2018-12-01,2018-12-01,2014-03-31,null,2017-12-18,"Research Site, Phoenix, Arizona, United States|Research Site, Los Angeles, California, United States|Abel and Buchheim PR, Inc, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Louisville, Kentucky, United States|Research Site, Royal Oak, Michigan, United States|Research Site, Stony Brook, New York, United States|Research Site, Toledo, Ohio, United States|Research Site, Hershey, Pennsylvania, United States|Research Site, Gaffney, South Carolina, United States|Research Site, Dallas, Texas, United States|Research Site, Copenhagen, Denmark|Research Site, Odense, Denmark|Research Site, Beersheva, Israel|Research Site, Haifa, Israel|Research Site, Petach Tikva, Israel|Research Site, Ramat Gan, Israel|Research Site, Amsterdam, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Bergen, Norway|Research Site, Oslo, Norway|Pediatric Oncology Unit Hospital Vall d'Hebron, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Esplugues De Llobregat, Spain|Hospital Gregorio Maranon, Madrid, Spain|Hospital Infantil Universitario Nino Jesus, Madrid, Spain|Unidad de Hematología y Oncología Pediátrica - Hospital Universitario HM Monteprincipe, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Murcia, Spain|Research Site, Sevilla, Spain|Research Site, Leeds, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, London, United Kingdom|Royal Marsden Hospital, London, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Oxford, United Kingdom|Research Site, Sheffield, United Kingdom",,https://ClinicalTrials.gov/show/NCT02099591
936,NCT00465647,An Open-label Study of Hydromorphone Oral Solution in Subjects Aged 28 Days to 16 Years for Postoperative Pain,Palladone,Completed,Has Results,Postoperative Pain,Drug: Hydromorphone,"Population Pharmacokinetic/Pharmacodynamic (PK/PD) Model for Hydromorphone: Clearance (Cl)|Mean (SE) of Faces, Legs Activity, Cry, Consolability (FLACC) Pain Scores on Hydromorphone Alone (Oral/Supplemental) Over Time [Ages >=28 Days to <5 Years]|Mean (SE) of Faces Pain Scale-Revised (FPS-R) [Ages >= 5 Years-< 12 Years] Pain Scores on Hydromorphone Alone (Oral/Supplemental)Over Time|Mean (SE) of Visual Analog Scale (VAS) [Ages 12-16] Pain Scores on Hydromorphone Alone (Oral/Supplemental) Over Time",Purdue Pharma LP,All,up to 16 Years   (Child),Phase 4,116,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HMP4009,2007-04-01,2009-05-01,2010-04-01,2007-04-25,2011-03-11,2015-11-18,"Arkansas Children's Hospital, Little Rock, Arkansas, United States|Children's Hospital of Orange County - Pediatric Subspecialty, Orange, California, United States|Stanford University Medical Center, Stanford, California, United States|The Children's Hospital, Aurora, Colorado, United States|Yale-New Haven Children's Hospital, New Haven, Connecticut, United States|Jackson Memorial Hospital, Miami, Florida, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Saint Louis University - Department of Neurology and Psychiatry, St. Louis, Missouri, United States|The University of North Carolina - CH, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Children's Hospital Medical Center of Akron, Akron, Ohio, United States|Children's Medical Center, Dallas, Texas, United States|Texas Children's Hospital / Baylor College of Medicine, Houston, Texas, United States|The University of Texas, Health Sciences Center at Houston, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00465647
937,NCT00225797,Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant Pain,,Completed,No Results Available,Chronic Pain,Drug: Oxymorphone Extended Release,Change in pain intensity from baseline (pre-randomization) to last assessment.|Time to early discontinuation due to lack of efficacy|Patient's Global Assessment of Pain Medication|Physician's Global Assessment of Pain Medication|Safety as measured by AEs,Endo Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 3,160,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,EN3202-031,2004-11-01,null,2005-07-01,2005-09-26,null,2010-02-15,"Southern Drug Research, Hueytown, Alabama, United States|Phoenix Center for Clinical Research, Phoenix, Arizona, United States|Express Care Clinical Research, Colorado Springs, Colorado, United States|New England Research, Bridgeport, Connecticut, United States|Glasgow Family Practice, Newark, Delaware, United States|Radiant Research, Daytona Beach, Florida, United States|University Clinical Research, Deland, Florida, United States|LCFP Inc, Ft. Myers, Florida, United States|Century Clinical Research, Holly Hill, Florida, United States|Ocala Rheumatology Research Center, Ocala, Florida, United States|The Arthritis Center, Palm Harbor, Florida, United States|University Clinical Research, Pembroke Pines, Florida, United States|Radiant Research, Pinellas Park, Florida, United States|Park Place Therapeutic Center, Plantation, Florida, United States|ICSL Clinical Studies, St Petersburg, Florida, United States|Comprehensive Neurology Specialists, Atlanta, Georgia, United States|Comprehensive Neuroscience, Atlanta, Georgia, United States|Pain Specialists of Greater Chicago, Burr Ridge, Illinois, United States|Mid-America Physiatrists, Overland Park, Kansas, United States|Research Medical Center, Kansas City, Missouri, United States|Radiant Research, St. Louis, Missouri, United States|Piedmont Anesthesia, Winston-Salem, North Carolina, United States|Keystone Clinical Solutions, Altoona, Pennsylvania, United States|Perkiomen Valley Family Practice, Collegeville, Pennsylvania, United States|Feasterville Family Health Center, Feasterville, Pennsylvania, United States|Fleetwood Clinical Research, Fleetwood, Pennsylvania, United States|New England Center for Clinical Research, Cranston, Rhode Island, United States|Paragon Clinical Research, Cranston, Rhode Island, United States|Radiant Research, Greer, South Carolina, United States|Waccamaw Pain Management, Murrells Inlet, South Carolina, United States|KRK Medical Research, Richardson, Texas, United States|Intermountain Clinical Research, Salt Lake City, Utah, United States|Jean Brown Research, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT00225797
938,NCT01369615,Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children Who Completed OTR3001,,Completed,Has Results,Pain,Drug: Oxycodone hydrochloride controlled-release tablets,The Number of Participants With Adverse Events as a Measure of Safety.,Purdue Pharma LP,All,6 Years to 17 Years   (Child),Phase 3,23,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OTR3002|2011-002235-26,2011-10-01,2013-12-01,2014-05-01,2011-06-09,2015-01-15,2015-09-09,"Children's Hospital of Alabama, Birmingham, Alabama, United States|Bayview Research Group, LLC, Paramount, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Jackson Memorial Hospital, Miami, Florida, United States|University of Kentucky, Lexington, Kentucky, United States|Mercy Clinic Children's Cancer and Hematology Center, St. Louis, Missouri, United States|New York University Langone Medical Center, New York, New York, United States|Stony Brook University Hospital, Stony Brook, New York, United States|Presbyterian Blume Pediatric Hematology & Oncology Clinic, Charlotte, North Carolina, United States|Akron Children's Hospital, Akron, Ohio, United States|The Children's Hospital at Oklahoma University Medical Center, Oklahoma City, Oklahoma, United States|Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, United States|Children's Medical Center of Dallas, Dallas, Texas, United States|Schneider Children Medical Center of Israel, Petach Tikva, Israel",,https://ClinicalTrials.gov/show/NCT01369615
939,NCT01626235,AMPED Outcomes Registry of Post-ED Pain Management,AMPED,Completed,No Results Available,Soft Tissue Injuries|Gouty Arthritis|Fractures|Ureteral Colic|Dysmenorrhea,,Clinical Outcomes of pain control measures|Satisfaction and Economic Outcomes,"Radnor Registry Research, Inc|Luitpold Pharmaceuticals",All,"18 Years and older   (Adult, Older Adult)",,843,Industry,Observational,Time Perspective: Prospective,RRR-LUIT-01,2012-07-01,2014-03-01,2014-03-01,2012-06-22,null,2014-03-12,"University of Alabama at Birmingham, Birmingham, Alabama, United States|LSU Medical Center, New Orleans, Louisiana, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Cleveland Clinic, Cleveland, Ohio, United States|University of Oklahoma HSC, Tulsa, Oklahoma, United States|Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Ben Taub General Hospital, Houston, Texas, United States|University of Texas HSC at Houston, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01626235
940,NCT01685684,Oxycodone DETERx™ Versus Placebo in Chronic Low Back Pain (CLBP),,Completed,Has Results,Chronic Low Back Pain,Drug: Oxycodone DETERx|Drug: Placebo,Change in Average Pain Intensity Measured by the Change in Pain Intensity-Numeric Rating Scale (PI-NRS) Scores From Randomization Baseline to Week 12 of the Double-blind Maintenance Phase|Time-to-exit From the Study for All Causes|Percent Reduction in Pain Intensity for Responders|Weekly Changes in Pain Intensity|Rescue Medication Usage by Dose|Rescue Medication Use by Dosage|Patient Global Impression of Change (PGIC)|Changes in Quality of Life|Change in Level of Physical Disability Using the Roland Morris Disability Questionnaire (RMDQ),"Collegium Pharmaceutical, Inc.",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,740,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CP-OXYDET-08,2012-08-01,2014-06-01,2014-07-01,2012-09-14,2017-02-23,2018-03-06,"Mesa, Arizona, United States|Phoenix, Arizona, United States|Tucson, Arizona, United States|Anaheim, California, United States|Anaheim, California, United States|Buena Park, California, United States|Cerritos, California, United States|Escondido, California, United States|La Mesa, California, United States|Napa, California, United States|Pasadena, California, United States|DeLand, Florida, United States|Naples, Florida, United States|Orlando, Florida, United States|Plantation, Florida, United States|West Palm Beach, Florida, United States|Columbus, Georgia, United States|Marietta, Georgia, United States|Indianapolis, Indiana, United States|Valparaiso, Indiana, United States|Overland Park, Kansas, United States|Brockton, Massachusetts, United States|Natick, Massachusetts, United States|Watertown, Massachusetts, United States|Pascagoula, Mississippi, United States|Saint Louis, Missouri, United States|Las Vegas, Nevada, United States|Berlin, New Jersey, United States|New York, New York, United States|Rochester, New York, United States|Williamsville, New York, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Oklahoma City, Oklahoma, United States|Philadelphia, Pennsylvania, United States|Charleston, South Carolina, United States|Rapid City, South Dakota, United States|New Tazewell, Tennessee, United States|Austin, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|Orem, Utah, United States|Salt Lake City, Utah, United States|Roanoke, Virginia, United States|Bellevue, Washington, United States",,https://ClinicalTrials.gov/show/NCT01685684
941,NCT01179191,Conversion to Embeda With Rescue Trial,ConvERT,Terminated,Has Results,Chronic Disease|Pain,Drug: morphine sulfate and naltrexone hydrochloride (EMBEDA),Percentage of Participants Achieving Stable Dose of EMBEDA Within 6 Weeks Titration Phase|Percentage of Participants Achieving Stable Dose of EMBEDA Within 6 Weeks Titration Phase Stratified by Prior Opioid Therapy|Duration to Titrate Participants to Stable Dose|Duration to Titrate Participants to Stable Dose Stratified by Prior Opioid Therapy|Number of Titration Steps to Achieve Stable Dose|Number of Titration Steps to Achieve Stable Dose Stratified by Prior Opioid Therapy|Percentage of Participants With Rescue Medications Usage During Titration|Change From Baseline in Brief Pain Inventory (BPI) at Visit 3 (First Visit After Successful Titration)|Investigator's Level of Satisfaction With the EMBEDA Conversion Guide,Pfizer,All,"21 Years and older   (Adult, Older Adult)",Phase 4,684,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,ALO-01-10-4003|B4541001,2010-08-01,2011-04-01,2011-04-01,2010-08-11,2012-09-05,2012-10-11,"Adamsville Family Medicine, Adamsville, Alabama, United States|Office of David McLain, Birmingham, Alabama, United States|Monte Sano Clinical Research, LLC, Huntsville, Alabama, United States|Tennessee Valley Pain Consultants Properties, LLC, Huntsville, Alabama, United States|Sunbelt Research Group, LLC, Mobile, Alabama, United States|Office of Vaughn H. Mancha, Jr., PC, Montgomery, Alabama, United States|Dedicated Clinical Research, Goodyear, Arizona, United States|Dedicated Clinical Research, Inc, Phoenix, Arizona, United States|Redpoint Research, Phoenix, Arizona, United States|Anasazi Internal Medicine, PC, Phoenix, Arizona, United States|Cochise Clinical Research, Sierra Vista, Arizona, United States|Premiere Phamaceutical Research, LLC, Tempe, Arizona, United States|Quality of Life Medical and Research Center, LLC, Tucson, Arizona, United States|Ouachita Regional Pain Management, Hot Springs, Arkansas, United States|NEA Baptist Clinic, Jonesboro, Arkansas, United States|Hollis Family Medical Clinic, PLC, Paragould, Arkansas, United States|CSI Clinical Trials, Costa Mesa, California, United States|Global Wellness Medical Corporation, Foothill Ranch, California, United States|Chrishard Medical Group, Inglewood, California, United States|Triwest Research Associates LLC, La Mesa, California, United States|Pacific Coast Pain Management Center, Laguna Hills, California, United States|Valerius Medical Group and Research Center of Greater Long Beach, Inc., Long Beach, California, United States|LA Pain & Wellness Institute, Los Angeles, California, United States|Samaritan Center for Medical Research, Los Gatos, California, United States|Newport Beach Clinical Research Associates, Inc., Newport Beach, California, United States|Bayview Research Group, LLC, Paramount, California, United States|Pasadena Rehabilitation Institute, Pasadena, California, United States|Quality Control Research, Inc., Roseville, California, United States|Northern California Research, Sacramento, California, United States|Quality Control Research, Inc., Sacramento, California, United States|Rancho Santa Fe Medical Group, Inc., San Marcos, California, United States|Probe Clinical Research Corporation, Santa Ana, California, United States|Trinity Clinical Trials, Santa Ana, California, United States|Facility Medical Center, Upland, California, United States|Bayview Research Group, LLC, Valley Village, California, United States|Rocky Mountain Internal Medicine, PC, Aurora, Colorado, United States|Clinicos, LLC, Colorado Springs, Colorado, United States|Saint Luke's Medical Clinic, LLC, Fort Collins, Colorado, United States|ProHealth Physicians PC, Manchester, Connecticut, United States|Milford Physician Services, PC, Milford, Connecticut, United States|Orthopedic Research Institute, LLC, Boynton Beach, Florida, United States|Florida Research & Testing, LLC, Clearwater, Florida, United States|Omega Research Consultants, LLC, Debary, Florida, United States|Omega Research Consultants, LLC, DeBary, Florida, United States|West Florida Medical Associate, PA, Dunnellon, Florida, United States|International Research Associates, LLC, Hialeah, Florida, United States|Palm Springs Research Institute, Inc, Hialeah, Florida, United States|FPA Clinical Research, LLC, Kissimmee, Florida, United States|Clinical Research of Central Florida, Inc., Lakeland, Florida, United States|NextPhase Clinical Trials, Inc., Miami Beach, Florida, United States|Community Research Foundation, Inc., Miami, Florida, United States|New Horizon Research Center, Inc., Miami, Florida, United States|Harmony Clinical Research, Inc., North Miami Beach, Florida, United States|Office of Laszlo J. Mate, MD, PA, North Palm Beach, Florida, United States|Office of Richard E. Promin, MD, PA, Ocala, Florida, United States|Advent Clinical Research Centers, Inc., Pinellas Park, Florida, United States|Pain Management Strategies, Inc., Pompano Beach, Florida, United States|Sarasota Pain Medicine Research, LLC, Sarasota, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|Clinical Research Center, LLC, Wellington, Florida, United States|Perimeter Institute for Clinical Research, Inc., Atlanta, Georgia, United States|Medical Research and Health Education Foundation, Inc., Columbus, Georgia, United States|Ialum Clinical Research, LLC, Decatur, Georgia, United States|Ialum Clinical Research, LLC, Stone Mountain, Georgia, United States|Herman Clinical Research, LLC, Suwanee, Georgia, United States|Centers for Pain Management, Tifton, Georgia, United States|Chicago Clinical Research Institute Inc., Chicago, Illinois, United States|Creve Coeur Family Practice, Creve Coeur, Illinois, United States|Office of Rebecca Knight, MD, Peoria, Illinois, United States|Josephson Wallack Munshower Neurology P.C., Indianapolis, Indiana, United States|Laporte County Institute for Clinical Research Inc., Michigan City, Indiana, United States|McKinley Research, LLC, Mishawaka, Indiana, United States|Accelovance, Inc., South Bend, Indiana, United States|Des Moines Orthopaedic Surgeons, PC, West Des Moines, Iowa, United States|The Pain Treatment Center of the Bluegrass, Lexington, Kentucky, United States|Healing Options, Louisville, Kentucky, United States|Four Rivers Clinical Research, Inc., Paducah, Kentucky, United States|Lakewood Family Practice, Russell Springs, Kentucky, United States|Diseasebusters, LLC, College Park, Maryland, United States|Office of Steven C. Miller, MD, Pikesville, Maryland, United States|Beacon Clinical Research, LLC, Brockton, Massachusetts, United States|Ronald J. Rapoport, MD, PC, Fall River, Massachusetts, United States|Boston Paincare Center, Inc., Waltham, Massachusetts, United States|Clarkston Medical Group, PC, Clarkston, Michigan, United States|Apex Medical Research, AMR, Inc., Flint, Michigan, United States|East Michigan Medical Associates, Flint, Michigan, United States|PCM Medical Services, PC, Lansing, Michigan, United States|Remedica LLC, Rochester, Michigan, United States|Michigan Lifestyle Change and Health Center, PC, Sterling, Michigan, United States|MAPS Applied Research Center, Inc., Edina, Minnesota, United States|MAPS Applied Research Center, Inc., Shakopee, Minnesota, United States|Anesthesia and Pain Control Services, Biloxi, Mississippi, United States|CRC of Jackson, LLC, Jackson, Mississippi, United States|Midsouth Anesthesia Consultants, PLLC, Southhaven, Mississippi, United States|Patterson Medical Clinic, Inc., Florissant, Missouri, United States|Quality Clinical Research Inc., Florissant, Missouri, United States|Primary Care Medicine, PC, Jefferson City, Missouri, United States|The Reiter Foundation, Inc., Anaconda, Montana, United States|Medical Pain Relief Clinic, Omaha, Nebraska, United States|Omaha Clinical Research, PC, Omaha, Nebraska, United States|Atco Medical Associates, PC, Atco, New Jersey, United States|Office of John V. Bernard, MD, Belvidere, New Jersey, United States|Central Jersey Medical Research Center, Inc., Elizabeth, New Jersey, United States|Center for Pain Management, Hackensack, New Jersey, United States|Advocare Heights Primary Care, Haddon Heights, New Jersey, United States|NJ Heart, LLC, Linden, New Jersey, United States|Spine and Pain Centers, PA, Shrewsbury, New Jersey, United States|Premier Research, Inc., Trenton, New Jersey, United States|Adirondack Medical Research Center, Glens Falls, New York, United States|Long Island Gastrointestinal Research Group LLP, Great Neck, New York, United States|Drug Trials America, Inc., Hartsdale, New York, United States|Office of Roger Kasendorf, DO, Long Beach, New York, United States|Family Health Medical Services PLLC, Mayville, New York, United States|New York Spine & Wellness Center, North Syracuse, New York, United States|North American Partners in Pain Management, LLP, Valley Stream, New York, United States|Carolina Clinical Research and Consulting, LLC, Asheboro, North Carolina, United States|Carolina Clinical Research and Consulting, LLC, Asheboro, North Carolina, United States|Joint and Muscle Research Institute, Inc., Charlotte, North Carolina, United States|Catawba Valley Internal Medicine, Hickory, North Carolina, United States|Profen Research Network at ECMA, Jacksonville, North Carolina, United States|The Center For Clinical Research, LLC, Winston-Salem, North Carolina, United States|Medical Frontiers, LLC, Carlisle, Ohio, United States|Valley Medical Research, Centerville, Ohio, United States|Hightop Medical Research Center, Cincinnati, Ohio, United States|Sentral Clinical Research Services, Cincinnati, Ohio, United States|Delaware Smith Clinic Research, Delaware, Ohio, United States|Medical Frontiers, LLC, Franklin, Ohio, United States|Jeffrey J. Haggenjos, DO, Inc., New Lexington, Ohio, United States|Whole Family Medical Care LLC, Perrysburg, Ohio, United States|Office of Jocelyn F. Shimek, DO, Salem, Ohio, United States|Office of James Lassiter, Tiffin, Ohio, United States|Health Research Institute, LLC, Oklahoma City, Oklahoma, United States|Office of Siavash Nael, MD, Inc., Oklahoma City, Oklahoma, United States|Associates of Medicine/John D. Williams, MD, PLLC, Stillwater, Oklahoma, United States|Portland Rheumatology Clinic, LLC, Lake Oswego, Oregon, United States|Office of Joseph E. Yankee, DO, PC, Milwaukie, Oregon, United States|Pennsylvania Pain Specialists, PC, Allentown, Pennsylvania, United States|Ware Medical Associates, PC, Aston, Pennsylvania, United States|Altoona Center for Clinical Research, PC, Duncansville, Pennsylvania, United States|Kandra, Fierer, Kuskin Associates, Ltd., Harrisburg, Pennsylvania, United States|Onuorah Umeh, M.D. P.C, Philadelphia, Pennsylvania, United States|Founders Research Corporation, Philadelphia, Pennsylvania, United States|Progressive Pain Solutions, LLC, Wind Gap, Pennsylvania, United States|Hartwell Research Group, LLC, Anderson, South Carolina, United States|Low Country Rheumatology, PA, Charleston, South Carolina, United States|Pharmacorp Clinical Trials, Inc., Charleston, South Carolina, United States|Internal Medicine of Greer Research LLC, Greer, South Carolina, United States|Clinical Research Authority, LLC, Murrells Inlet, South Carolina, United States|Trident Institute of Medical Research, LLC, North Charleston, South Carolina, United States|Low Country Pain Center, LLC, Orangeburg, South Carolina, United States|Brown Clinic, PLLP, Watertown, South Dakota, United States|Chattanooga Medical Research, LLC, Chattanooga, Tennessee, United States|Comprehensive Pain Specialists, Hendersonville, Tennessee, United States|Corsicana Medical Research, PLLC, Corsicana, Texas, United States|DCT - Genesis Neighborhood Research, LLC, Dallas, Texas, United States|Southwest Urgent Care Center, El Paso, Texas, United States|Westbury Medical Clinic, Houston, Texas, United States|Accurate Clinical Research, Inc., Houston, Texas, United States|Medstar Clinical Research, Houston, Texas, United States|Texas Medical Research Associates, LLC, San Antonio, Texas, United States|Hillcrest Family Health Center, Division of Clinical Research, Waco, Texas, United States|Hillcrest Family Health Center, Waco, Texas, United States|Progressive Clinical Research, LLC, Bountiful, Utah, United States|Sentara Medical Group, NDC Medical Center, Norfolk, Virginia, United States|Washington Center for Pain Management PLLC, Edmonds, Washington, United States|Pain Care, PLLC, Huntington, West Virginia, United States",,https://ClinicalTrials.gov/show/NCT01179191
942,NCT01057862,Investigation of Naltrexone for Pathological Gambling,,Completed,Has Results,Pathological Gambling,Drug: Naltrexone|Other: Placebo,Yale Brown Obsessive Compulsive Scale Modified for Pathological Gambling (YBOCS-PG)|Gambling Symptom Assessment Scale (G-SAS),Yale University|National Center for Responsible Gaming,All,"18 Years and older   (Adult, Older Adult)",Phase 2,9,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",0901004667|NCRG CORE R09240,2009-02-01,2016-02-01,2017-01-01,2010-01-27,2017-09-12,2017-10-13,"Connecticut DMHAS Problem Gambling Services and Bettor Choice Programs, Middletown, Connecticut, United States|Connecticut DMHAS Problem Gambling Services and Bettor Choice Programs, New Haven, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01057862
943,NCT03491657,Virtual Reality Analgesia for Pediatric Burn Survivors,,Completed,No Results Available,"Pain, Acute",Behavioral: virtual reality distraction (Yes VR)|Behavioral: music distraction (No VR),"""Worst Pain"" rating of pain intensity during Music vs. during VR|Graphic Rating Scale ""Time spent thinking about pain"" during Music vs. during VR|Graphic Ratings Scale measure of pain unpleasantness during Music vs. during VR|Graphic Rating Scale ""Fun"" during Music vs. during VR|Graphic Rating Scale Satisfaction with pain management during Music vs. during VR|Child Health Questionnaire","The University of Texas Medical Branch, Galveston|Shriners Hospitals for Children",All,6 Years to 17 Years   (Child),Not Applicable,62,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,71011-GAL,2014-03-13,2017-01-03,2017-01-03,2018-04-09,null,2018-07-11,"Shriners Hospital for Children; Shriners Burns Hospital, Galveston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03491657
944,NCT01860287,The Effects of Buprenorphine on Responses to Verbal Tasks,,Completed,No Results Available,Basic Science,Drug: Buprenorphine|Drug: Placebo,Subjective responses to stress with and without buprenorphine|Salivary cortisol changes in response to stress with and without buprenorphine,University of Chicago,All,18 Years to 40 Years   (Adult),Phase 4,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science",UCIRB-130197,2013-09-01,2017-01-01,2017-01-01,2013-05-22,null,2017-02-13,"University of Chicago, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT01860287
945,NCT02656875,A Open-label Study to Evaluate the Safety of TRV130 in Patients With Acute Pain,ATHENA-1,Completed,No Results Available,Acute Pain,Drug: TRV130,Adverse Events,Trevena Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 3,768,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CP130-3003,2015-12-01,2017-05-01,2017-08-01,2016-01-15,null,2017-12-11,"Recruiting, Mobile, Alabama, United States|Recruiting, Pasadena, California, United States|Recruiting, Miami, Florida, United States|Recruiting, Shreveport, Louisiana, United States|Recruiting, Jackson, Mississippi, United States|Staten Island, New York, United States|Recruiting, State College, Pennsylvania, United States|Houston, Texas, United States|Houston, Texas, United States|Recruiting, Murray, Utah, United States",,https://ClinicalTrials.gov/show/NCT02656875
946,NCT02243241,The Effect of Hydrocodone Bitartrate (HYD) Extended-Release Tablets on QT /QTc Intervals in Healthy Adult Subjects,,Completed,No Results Available,Healthy,Drug: HYD|Drug: Moxifloxacin|Drug: Placebo for HYD|Drug: Placebo for moxifloxacin,"The time-matched analysis on QT data (change from baseline, placebo-subtracted) corrected for heart rate (QTc), based on an individual correction (QTcI) method",Purdue Pharma LP,All,18 Years to 50 Years   (Adult),Phase 1,208,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)",HYD1009,2012-11-01,2013-05-01,2013-05-01,2014-09-17,null,2014-09-17,"PPD Phase I Clinic, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT02243241
947,NCT01999114,The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (Mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers,,Completed,No Results Available,ECG Effects,Drug: Buprenorphine transdermal patch|Drug: Naltrexone tablet|Drug: Placebos (for TDS and for naltrexone and for moxifloxacin)|Drug: Moxifloxacin tablet,"Time-matched change from baseline in QT data corrected for heart rate (QTc), placebo-corrected, based on an individual correction (QTcI) method (ΔΔQTcI)|QTcF and QTcB for historical purposes, heart rate (HR), PR interval, QRS interval, uncorrected QT interval, ECG morphology|Correlation between the QTcI change from baseline and maximum observed plasma concentrations (Cmax) of buprenorphine and norbuprenorphine",Purdue Pharma LP,All,18 Years to 55 Years   (Adult),Phase 1,328,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BUP1025,2012-03-01,2012-10-01,2012-10-01,2013-12-03,null,2013-12-03,"PPD Phase I Clinic, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT01999114
948,NCT03087708,Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer,,Recruiting,No Results Available,Stage IIIB Lung Adenocarcinoma|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Lung Adenocarcinoma|Stage IV Non-small Cell Lung Cancer,Drug: Naloxegol|Other: Placebo|Other: Laboratory Biomarker Analysis|Other: Quality-of-Life Assessment,"Observed accrual rate defined as rate of accrual remaining >= 80% of the expected|Proportion of patients alive who continue study drug and complete the health-related quality of life and other forms|Incidence of adverse events as described and graded by the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 4.0|Change in trial outcome index|Change in function subscales|Change in lung cancer subscale of the Functional Assessment of Cancer Therapy-Lung|Patient-reported outcome assessed by Patient-Reported Outcome-Common Terminology Criteria for Adverse Events|Patient-reported outcome assessed by a urinary retention Linear Analogue Self-Assessment|Opioid-induced constipation rating scale|Level of pain|Analgesic use|Unexpected clinical outcomes with chemotherapy|Progression-free survival assessed by using the standard Response Evaluation Criteria in Solid Tumors 1.1 criteria|Overall survival|Prognostic effect of MOR expression/interaction on health-related quality of life",Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 2,204,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care",A221504|NCI-2016-01503,2017-10-13,2019-04-01,2020-10-01,2017-03-22,null,2018-08-07,"Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States|Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States|Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Anchorage Oncology Centre, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, Arkansas, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|Los Angeles County-USC Medical Center, Los Angeles, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, United States|Keck Medical Center of USC Pasadena, Pasadena, California, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers-Penrose, Colorado Springs, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Mercy Medical Center, Durango, Colorado, United States|Southwest Oncology PC, Durango, Colorado, United States|Mountain Blue Cancer Care Center, Golden, Colorado, United States|Rocky Mountain Cancer Centers-Lakewood, Lakewood, Colorado, United States|Saint Anthony Hospital, Lakewood, Colorado, United States|Littleton Adventist Hospital, Littleton, Colorado, United States|Longmont United Hospital, Longmont, Colorado, United States|Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, United States|Parker Adventist Hospital, Parker, Colorado, United States|Rocky Mountain Cancer Centers-Parker, Parker, Colorado, United States|Saint Mary Corwin Medical Center, Pueblo, Colorado, United States|Rocky Mountain Cancer Centers - Pueblo, Pueblo, Colorado, United States|Rocky Mountain Cancer Centers-Thornton, Thornton, Colorado, United States|Middlesex Hospital, Middletown, Connecticut, United States|Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida, United States|Memorial Hospital West, Pembroke Pines, Florida, United States|Hawaii Oncology Inc-Pali Momi, 'Aiea, Hawaii, United States|Pali Momi Medical Center, 'Aiea, Hawaii, United States|The Cancer Center of Hawaii-Pali Momi, 'Aiea, Hawaii, United States|Hawaii Cancer Care Inc-POB II, Honolulu, Hawaii, United States|Hawaii Oncology Inc-POB I, Honolulu, Hawaii, United States|Island Urology, Honolulu, Hawaii, United States|Queen's Medical Center, Honolulu, Hawaii, United States|Straub Clinic and Hospital, Honolulu, Hawaii, United States|University of Hawaii Cancer Center, Honolulu, Hawaii, United States|Hawaii Cancer Care Inc-Liliha, Honolulu, Hawaii, United States|Hawaii Oncology Inc-Kuakini, Honolulu, Hawaii, United States|Kuakini Medical Center, Honolulu, Hawaii, United States|The Cancer Center of Hawaii-Liliha, Honolulu, Hawaii, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Wilcox Memorial Hospital and Kauai Medical Clinic, Lihue, Hawaii, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, United States|Kootenai Medical Center, Coeur d'Alene, Idaho, United States|Walter Knox Memorial Hospital, Emmett, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Fruitland, Fruitland, Idaho, United States|Idaho Urologic Institute-Meridian, Meridian, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Meridian, Meridian, Idaho, United States|Saint Alphonsus Medical Center-Nampa, Nampa, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Nampa, Nampa, Idaho, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Kootenai Cancer Clinic, Sandpoint, Idaho, United States|Saint Luke's Mountain States Tumor Institute-Twin Falls, Twin Falls, Idaho, United States|Rush - Copley Medical Center, Aurora, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Memorial Hospital of Carbondale, Carbondale, Illinois, United States|SIH Cancer Institute, Carterville, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|University of Illinois, Chicago, Illinois, United States|Carle on Vermilion, Danville, Illinois, United States|Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Carle Physician Group-Effingham, Effingham, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|Joliet Oncology-Hematology Associates Limited, Joliet, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center, Pekin, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|OSF Saint Francis Radiation Oncology at Peoria Cancer Center, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Valley Radiation Oncology, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|West Suburban Medical Center, River Forest, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Cancer Care Specialists of Illinois-Swansea, Swansea, Illinois, United States|Southwest Illinois Health Services LLP, Swansea, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|The Carle Foundation Hospital, Urbana, Illinois, United States|Rush-Copley Healthcare Center, Yorkville, Illinois, United States|Memorial Regional Cancer Center Day Road, Mishawaka, Indiana, United States|Reid Health, Richmond, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|Mary Greeley Medical Center, Ames, Iowa, United States|McFarland Clinic PC - Ames, Ames, Iowa, United States|McFarland Clinic PC-Boone, Boone, Iowa, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Alegent Health Mercy Hospital, Council Bluffs, Iowa, United States|Greater Regional Medical Center, Creston, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Broadlawns Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|Iowa Lutheran Hospital, Des Moines, Iowa, United States|McFarland Clinic PC-Trinity Cancer Center, Fort Dodge, Iowa, United States|Trinity Regional Medical Center, Fort Dodge, Iowa, United States|McFarland Clinic PC-Jefferson, Jefferson, Iowa, United States|McFarland Clinic PC-Marshalltown, Marshalltown, Iowa, United States|Methodist West Hospital, West Des Moines, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|Cancer Center of Kansas - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas - El Dorado, El Dorado, Kansas, United States|Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|Cancer Center of Kansas-Kingman, Kingman, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Cancer Center of Kansas-Liberal, Liberal, Kansas, United States|Cancer Center of Kansas-Manhattan, Manhattan, Kansas, United States|Cancer Center of Kansas - McPherson, McPherson, Kansas, United States|Cancer Center of Kansas - Newton, Newton, Kansas, United States|Cancer Center of Kansas - Parsons, Parsons, Kansas, United States|Cancer Center of Kansas - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas - Salina, Salina, Kansas, United States|Cancer Center of Kansas - Wellington, Wellington, Kansas, United States|Associates In Womens Health, Wichita, Kansas, United States|Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas - Wichita, Wichita, Kansas, United States|Via Christi Regional Medical Center, Wichita, Kansas, United States|Cancer Center of Kansas - Winfield, Winfield, Kansas, United States|Flaget Memorial Hospital, Bardstown, Kentucky, United States|Commonwealth Cancer Center-Corbin, Corbin, Kentucky, United States|Hardin Memorial Hospital, Elizabethtown, Kentucky, United States|Saint Joseph Radiation Oncology Resource Center, Lexington, Kentucky, United States|Saint Joseph Hospital East, Lexington, Kentucky, United States|Saint Joseph London, London, Kentucky, United States|Jewish Hospital, Louisville, Kentucky, United States|Saints Mary and Elizabeth Hospital, Louisville, Kentucky, United States|Jewish Hospital Medical Center Northeast, Louisville, Kentucky, United States|Jewish Hospital Medical Center South, Shepherdsville, Kentucky, United States|Beverly Hospital, Beverly, Massachusetts, United States|Alliance for Clinical Trials in Oncology, Boston, Massachusetts, United States|Addison Gilbert Hospital, Gloucester, Massachusetts, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|IHA Hematology Oncology Consultants-Brighton, Brighton, Michigan, United States|Saint Joseph Mercy Brighton, Brighton, Michigan, United States|IHA Hematology Oncology Consultants-Canton, Canton, Michigan, United States|Saint Joseph Mercy Canton, Canton, Michigan, United States|Caro Cancer Center, Caro, Michigan, United States|IHA Hematology Oncology Consultants-Chelsea, Chelsea, Michigan, United States|Saint Joseph Mercy Chelsea, Chelsea, Michigan, United States|Hematology Oncology Consultants-Clarkston, Clarkston, Michigan, United States|Newland Medical Associates-Clarkston, Clarkston, Michigan, United States|Beaumont Hospital-Dearborn, Dearborn, Michigan, United States|Saint John Hospital and Medical Center, Detroit, Michigan, United States|Great Lakes Cancer Management Specialists-Doctors Park, East China Township, Michigan, United States|Green Bay Oncology - Escanaba, Escanaba, Michigan, United States|Genesee Cancer and Blood Disease Treatment Center, Flint, Michigan, United States|Genesee Hematology Oncology PC, Flint, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center, Grosse Pointe Woods, Michigan, United States|Lymphoma Clinic of Michigan, Grosse Pointe Woods, Michigan, United States|Michigan Breast Specialists-Grosse Pointe Woods, Grosse Pointe Woods, Michigan, United States|Allegiance Health, Jackson, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Hope Cancer Clinic, Livonia, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Medical Campus, Macomb, Michigan, United States|Michigan Breast Specialists-Macomb Township, Macomb, Michigan, United States|Saint Mary's Oncology/Hematology Associates of Marlette, Marlette, Michigan, United States|Mercy Health Mercy Campus, Muskegon, Michigan, United States|Lakeland Hospital Niles, Niles, Michigan, United States|21st Century Oncology-Pontiac, Pontiac, Michigan, United States|Hope Cancer Center, Pontiac, Michigan, United States|Newland Medical Associates-Pontiac, Pontiac, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Spectrum Health Reed City Hospital, Reed City, Michigan, United States|Great Lakes Cancer Management Specialists-Rochester Hills, Rochester Hills, Michigan, United States|Saint Mary's of Michigan, Saginaw, Michigan, United States|Oncology Hematology Associates of Saginaw Valley PC, Saginaw, Michigan, United States|Lakeland Medical Center Saint Joseph, Saint Joseph, Michigan, United States|Marie Yeager Cancer Center, Saint Joseph, Michigan, United States|Bhadresh Nayak MD PC-Sterling Heights, Sterling Heights, Michigan, United States|Saint Joseph Health System-Tawas City, Tawas City, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Advanced Breast Care Center PLLC, Warren, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Professional Building, Warren, Michigan, United States|Macomb Hematology Oncology PC, Warren, Michigan, United States|Michigan Breast Specialists-Warren, Warren, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Saint Mary's Oncology/Hematology Associates of West Branch, West Branch, Michigan, United States|Metro Health Hospital, Wyoming, Michigan, United States|Huron Gastroenterology PC, Ypsilanti, Michigan, United States|IHA Hematology Oncology Consultants-Ann Arbor, Ypsilanti, Michigan, United States|Sanford Clinic North-Bemidgi, Bemidji, Minnesota, United States|Essentia Health Saint Joseph's Medical Center, Brainerd, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Essentia Health - Deer River Clinic, Deer River, Minnesota, United States|Essentia Health Saint Mary's - Detroit Lakes Clinic, Detroit Lakes, Minnesota, United States|Essentia Health Cancer Center, Duluth, Minnesota, United States|Essentia Health Saint Mary's Medical Center, Duluth, Minnesota, United States|Miller-Dwan Hospital, Duluth, Minnesota, United States|Fairview-Southdale Hospital, Edina, Minnesota, United States|Lake Region Healthcare Corporation-Cancer Care, Fergus Falls, Minnesota, United States|Essentia Health - Fosston, Fosston, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Essentia Health Hibbing Clinic, Hibbing, Minnesota, United States|Fairview Maple Grove Medical Center, Maple Grove, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Minneapolis Veterans Medical Center, Minneapolis, Minnesota, United States|Health Partners Inc, Minneapolis, Minnesota, United States|University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|New Ulm Medical Center, New Ulm, Minnesota, United States|Essentia Health - Park Rapids, Park Rapids, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Essentia Health Sandstone, Sandstone, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Sanford Thief River Falls Medical Center, Thief River Falls, Minnesota, United States|Essentia Health Virginia Clinic, Virginia, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Sanford Cancer Center Worthington, Worthington, Minnesota, United States|Fairview Lakes Medical Center, Wyoming, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Parkland Health Center-Bonne Terre, Bonne Terre, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Capital Region Southwest Campus, Jefferson City, Missouri, United States|Kansas City Veterans Affairs Medical Center, Kansas City, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States|Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri, United States|Community Hospital of Anaconda, Anaconda, Montana, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Saint Peter's Community Hospital, Helena, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|CHI Health Saint Francis, Grand Island, Nebraska, United States|Heartland Hematology and Oncology, Kearney, Nebraska, United States|CHI Health Good Samaritan, Kearney, Nebraska, United States|Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Alegent Health Immanuel Medical Center, Omaha, Nebraska, United States|Hematology and Oncology Consultants PC, Omaha, Nebraska, United States|Alegent Health Bergan Mercy Medical Center, Omaha, Nebraska, United States|Alegent Health Lakeside Hospital, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|Midlands Community Hospital, Papillion, Nebraska, United States|New Hampshire Oncology Hematology PA-Concord, Concord, New Hampshire, United States|New Hampshire Oncology Hematology PA-Hooksett, Hooksett, New Hampshire, United States|Hematology Oncology Associates of Central New York-Auburn, Auburn, New York, United States|Veterans Affairs Western New York Health Care System-Buffalo, Buffalo, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Hematology Oncology Associates of Central New York-East Syracuse, East Syracuse, New York, United States|Arnot Ogden Medical Center/Falck Cancer Center, Elmira, New York, United States|Northwell Health/Center for Advanced Medicine, Lake Success, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|Hematology Oncology Associates of Central New York-Onondaga Hill, Syracuse, New York, United States|Southeastern Medical Oncology Center-Clinton, Clinton, North Carolina, United States|Southeastern Medical Oncology Center-Goldsboro, Goldsboro, North Carolina, United States|Wayne Memorial Hospital, Goldsboro, North Carolina, United States|Margaret R Pardee Memorial Hospital, Hendersonville, North Carolina, United States|Onslow Memorial Hospital, Jacksonville, North Carolina, United States|Southeastern Medical Oncology Center-Jacksonville, Jacksonville, North Carolina, United States|Vidant Oncology-Kinston, Kinston, North Carolina, United States|Veterans Administration Medical Center, Salisbury, North Carolina, United States|Southeastern Medical Oncology Center-Wilson, Wilson, North Carolina, United States|Sanford Bismarck Medical Center, Bismarck, North Dakota, United States|Essentia Health Cancer Center-South University Clinic, Fargo, North Dakota, United States|Sanford South University Medical Center, Fargo, North Dakota, United States|Roger Maris Cancer Center, Fargo, North Dakota, United States|Sanford Broadway Medical Center, Fargo, North Dakota, United States|Essentia Health - Jamestown Clinic, Jamestown, North Dakota, United States|Indu and Raj Soin Medical Center, Beavercreek, Ohio, United States|Strecker Cancer Center-Belpre, Belpre, Ohio, United States|Dayton Physicians LLC-Miami Valley South, Centerville, Ohio, United States|Miami Valley Hospital South, Centerville, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Kenwood, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Westside, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Anderson, Cincinnati, Ohio, United States|Mount Carmel East Hospital, Columbus, Ohio, United States|Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Grant Medical Center, Columbus, Ohio, United States|The Mark H Zangmeister Center, Columbus, Ohio, United States|Mount Carmel Health Center West, Columbus, Ohio, United States|Doctors Hospital, Columbus, Ohio, United States|Good Samaritan Hospital - Dayton, Dayton, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Dayton Physicians LLC-Samaritan North, Dayton, Ohio, United States|Samaritan North Health Center, Dayton, Ohio, United States|Delaware Health Center-Grady Cancer Center, Delaware, Ohio, United States|Delaware Radiation Oncology, Delaware, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Armes Family Cancer Center, Findlay, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Orion Cancer Care, Findlay, Ohio, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, United States|Dayton Physicians LLC-Atrium, Franklin, Ohio, United States|Dayton Physicians LLC-Wayne, Greenville, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Greater Dayton Cancer Center, Kettering, Ohio, United States|First Dayton Cancer Care, Kettering, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|OhioHealth Mansfield Hospital, Mansfield, Ohio, United States|Marietta Memorial Hospital, Marietta, Ohio, United States|OhioHealth Marion General Hospital, Marion, Ohio, United States|Knox Community Hospital, Mount Vernon, Ohio, United States|Licking Memorial Hospital, Newark, Ohio, United States|Newark Radiation Oncology, Newark, Ohio, United States|Southern Ohio Medical Center, Portsmouth, Ohio, United States|Springfield Regional Cancer Center, Springfield, Ohio, United States|Springfield Regional Medical Center, Springfield, Ohio, United States|Dayton Physicians LLC-Upper Valley, Troy, Ohio, United States|Upper Valley Medical Center, Troy, Ohio, United States|Saint Ann's Hospital, Westerville, Ohio, United States|Genesis Healthcare System Cancer Care Center, Zanesville, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma, United States|Saint Alphonsus Medical Center-Baker City, Baker City, Oregon, United States|Saint Charles Health System, Bend, Oregon, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Oncology and Hematology Care Southeast, Clackamas, Oregon, United States|Bay Area Hospital, Coos Bay, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Saint Alphonsus Medical Center-Ontario, Ontario, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Saint Charles Health System-Redmond, Redmond, Oregon, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Geisinger Medical Center-Cancer Center Hazleton, Hazleton, Pennsylvania, United States|Geisinger Medical Oncology-Lewisburg, Lewisburg, Pennsylvania, United States|Lewistown Hospital, Lewistown, Pennsylvania, United States|Geisinger Cancer Services-Pottsville, Pottsville, Pennsylvania, United States|Community Medical Center, Scranton, Pennsylvania, United States|Geisinger Medical Oncology-Selinsgrove, Selinsgrove, Pennsylvania, United States|Geisinger Medical Group, State College, Pennsylvania, United States|Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre, Pennsylvania, United States|Greenville Health System Cancer Institute-Laurens, Clinton, South Carolina, United States|Greenville Health System Cancer Institute-Easley, Easley, South Carolina, United States|Greenville Health System Cancer Institute-Butternut, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Faris, Greenville, South Carolina, United States|Greenville Memorial Hospital, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Eastside, Greenville, South Carolina, United States|Self Regional Healthcare, Greenwood, South Carolina, United States|Greenville Health System Cancer Institute-Greer, Greer, South Carolina, United States|Greenville Health System Cancer Institute-Seneca, Seneca, South Carolina, United States|Greenville Health System Cancer Institute-Spartanburg, Spartanburg, South Carolina, United States|Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|Memorial Hospital, Chattanooga, Tennessee, United States|Pulmonary Medicine Center of Chattanooga-Hixson, Hixson, Tennessee, United States|Memorial GYN Plus, Ooltewah, Tennessee, United States|Saint Joseph Regional Cancer Center, Bryan, Texas, United States|Augusta Health Cancer Center, Fishersville, Virginia, United States|Providence Regional Cancer System-Aberdeen, Aberdeen, Washington, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Harrison HealthPartners Hematology and Oncology-Bremerton, Bremerton, Washington, United States|Harrison Medical Center, Bremerton, Washington, United States|Highline Medical Center-Main Campus, Burien, Washington, United States|Providence Regional Cancer System-Centralia, Centralia, Washington, United States|Swedish Medical Center-Edmonds, Edmonds, Washington, United States|Saint Elizabeth Hospital, Enumclaw, Washington, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Saint Francis Hospital, Federal Way, Washington, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Providence Regional Cancer System-Lacey, Lacey, Washington, United States|Saint Clare Hospital, Lakewood, Washington, United States|PeaceHealth Saint John Medical Center, Longview, Washington, United States|Harrison HealthPartners Hematology and Oncology-Poulsbo, Poulsbo, Washington, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Swedish Medical Center-Ballard Campus, Seattle, Washington, United States|Kaiser Permanente Washington, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|Swedish Medical Center-Cherry Hill, Seattle, Washington, United States|PeaceHealth United General Medical Center, Sedro-Woolley, Washington, United States|Providence Regional Cancer System-Shelton, Shelton, Washington, United States|Rockwood Clinic Cancer Treatment Center-Valley, Spokane Valley, Washington, United States|Rockwood Cancer Treatment Center-DHEC-Downtown, Spokane, Washington, United States|Rockwood North Cancer Treatment Center, Spokane, Washington, United States|Franciscan Research Center-Northwest Medical Plaza, Tacoma, Washington, United States|Northwest Medical Specialties PLLC, Tacoma, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|Providence Saint Mary Regional Cancer Center, Walla Walla, Washington, United States|Providence Regional Cancer System-Yelm, Yelm, Washington, United States|Ashland Memorial Medical Center, Ashland, Wisconsin, United States|Duluth Clinic Ashland, Ashland, Wisconsin, United States|Aurora Cancer Care-Southern Lakes VLCC, Burlington, Wisconsin, United States|Marshfield Clinic Cancer Center - Eau Claire, Eau Claire, Wisconsin, United States|Aurora Health Center-Fond du Lac, Fond Du Lac, Wisconsin, United States|Aurora Health Care Germantown Health Center, Germantown, Wisconsin, United States|Aurora Cancer Care-Grafton, Grafton, Wisconsin, United States|Saint Vincent Hospital Cancer Center Green Bay, Green Bay, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay, Wisconsin, United States|Aurora BayCare Medical Center, Green Bay, Wisconsin, United States|Aurora Cancer Care-Kenosha South, Kenosha, Wisconsin, United States|Holy Family Memorial Hospital, Manitowoc, Wisconsin, United States|Aurora Bay Area Medical Group-Marinette, Marinette, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Marinette, Marinette, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Aurora Cancer Care-Milwaukee, Milwaukee, Wisconsin, United States|Aurora Saint Luke's Medical Center, Milwaukee, Wisconsin, United States|Aurora Sinai Medical Center, Milwaukee, Wisconsin, United States|Marshfield Clinic-Minocqua Center, Minocqua, Wisconsin, United States|Cancer Center of Western Wisconsin, New Richmond, Wisconsin, United States|Green Bay Oncology - Oconto Falls, Oconto Falls, Wisconsin, United States|Vince Lombardi Cancer Clinic - Oshkosh, Oshkosh, Wisconsin, United States|Aurora Cancer Care-Racine, Racine, Wisconsin, United States|Marshfield Clinic-Rice Lake Center, Rice Lake, Wisconsin, United States|HSHS Saint Nicholas Hospital, Sheboygan, Wisconsin, United States|Vince Lombardi Cancer Clinic-Sheboygan, Sheboygan, Wisconsin, United States|Marshfield Clinic Stevens Point Center, Stevens Point, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|Aurora Medical Center in Summit, Summit, Wisconsin, United States|Vince Lombardi Cancer Clinic-Two Rivers, Two Rivers, Wisconsin, United States|Marshfield Clinic-Wausau Center, Wausau, Wisconsin, United States|Aurora Cancer Care-Milwaukee West, Wauwatosa, Wisconsin, United States|Aurora West Allis Medical Center, West Allis, Wisconsin, United States|Marshfield Clinic - Weston Center, Weston, Wisconsin, United States|Billings Clinic-Cody, Cody, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States",,https://ClinicalTrials.gov/show/NCT03087708
949,NCT01784991,Study of Respiratory Depression When Using a Hydromorphone Pain Protocol,,Terminated,No Results Available,Pain|Respiratory Depression,Drug: Hydromorphone|Drug: Usual care group,Respiratory Depression|Successful treatment of patient pain|Change in VAS score|Hypoxia|Hypotension|Allergic reaction to study drug|Serious Adverse Events,Albert Einstein Healthcare Network,All,"60 Years to 90 Years   (Adult, Older Adult)",Not Applicable,116,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,(H)N - 4325,2011-12-01,2014-04-01,2014-04-01,2013-02-06,null,2014-06-25,"Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01784991
950,NCT03295721,Bunionectomy Study for Postoperative Analgesia (EPOCH 1),,Completed,No Results Available,Analgesia,Drug: HTX-011|Drug: Saline Placebo|Drug: Bupivacaine HCl|Device: Luer-lock applicator|Device: Vial access device,Mean area under the curve (AUC) of the Numeric Rating Scale of pain intensity scores with activity (NRS-A) for HTX-011 compared with saline placebo.|Mean AUC of the NRS-A pain intensity scores for HTX 011 compared with bupivacaine HCl.|Mean total postoperative opioid consumption (in morphine equivalents) for HTX 011 compared with saline placebo.|Proportion of subjects who are opioid-free for HTX-011 compared with bupivacaine HCl.|Mean total postoperative opioid consumption (in morphine equivalents) for HTX 011 compared with bupivacaine HCl.,Heron Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 3,412,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",HTX-011-301,2017-10-24,2018-01-08,2018-03-13,2017-09-28,null,2018-06-12,"Springhill Medical Center, Mobile, Alabama, United States|Orthopaedic Specialists of North America, PLLC, Mesa, Arizona, United States|Arizona Research Center, Phoenix, Arizona, United States|Anaheim Clinical Trials, LLC, Anaheim, California, United States|Trovare Clinical Research, Inc., Bakersfield, California, United States|Alliance Research Centers, Laguna Hills, California, United States|Chesapeake Research Group, LLC, Pasadena, Maryland, United States|Optimal Research , LLC, Austin, Texas, United States|Hermann Drive Surgical Hospital, Houston, Texas, United States|Westside Surgical Hospital, Houston, Texas, United States|Futuro Clinical Trials, LLC, McAllen, Texas, United States|Plano Surgical Hospital, Plano, Texas, United States|Endeavor Clinical Trials, San Antonio, Texas, United States|EPIC Medical Research, LLC, Murray, Utah, United States|Jean Brown Research, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT03295721
951,NCT03237481,Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2),,Completed,No Results Available,Analgesia,Drug: HTX-011|Drug: Bupivacaine HCl|Drug: Saline placebo|Device: Luer-lock applicator|Device: Vial access device,Mean area under the curve (AUC) of the Numeric Rating Scale of pain intensity scores with activity (NRS-A) for HTX 011 compared with saline placebo.|Mean AUC of the NRS-A pain intensity scores for HTX 011 compared with bupivacaine HCl.|Mean total postoperative opioid consumption (in morphine equivalents) for HTX 011 compared with saline placebo.|Proportion of subjects who are opioid-free for HTX-011 compared with bupivacaine HCl.|Mean total postoperative opioid consumption (in morphine equivalents) for HTX 011 compared with bupivacaine HCl.,Heron Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 3,418,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",HTX-011-302,2017-07-31,2017-12-22,2018-01-16,2017-08-02,null,2018-06-12,"Eliza Coffee Memorial Hospital, Florence, Alabama, United States|Shoals Medical Trials, Inc., Sheffield, Alabama, United States|Arizona Research Center, Phoenix, Arizona, United States|Anaheim Clinical Trials, LLC, Anaheim, California, United States|Trovare Clinical Research, Inc., Bakersfield, California, United States|Alliance Research Centers, Laguna Hills, California, United States|Lotus Clinical Research, LLC, Pasadena, California, United States|HD Research Corp, Riverside, California, United States|American Institute of Research, Whittier, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Cornerstone Research Institute, LLC, Longwood, Florida, United States|Park Place Surgery Center, Maitland, Florida, United States|University of Miami, Miami, Florida, United States|St. Louis Clinical Trials, Saint Louis, Missouri, United States|eStudySite, Las Vegas, Nevada, United States|Midwest Clinical Research, Dayton, Ohio, United States|Hermann Drive Surgical Hospital, Houston, Texas, United States|Westside Surgical Hospital, Houston, Texas, United States|Plano Surgical Hospital, Plano, Texas, United States|Endeavor Clinical Trials, P.A., San Antonio, Texas, United States|EPIC Medical Research, LLC, Murray, Utah, United States|Jean Brown Research, Salt Lake City, Utah, United States|Jessa Ziekenhuis, Hasselt, Limburg, Belgium|Ziekenhuis Oost Limburg, Genk, Belgium",,https://ClinicalTrials.gov/show/NCT03237481
952,NCT01763697,Taste Acuity and Caloric Intake After Acute Morphine Administration,,Completed,No Results Available,Taste Sweet|Taste Salty|Feeding Behavior,Behavioral: taste acuity assessment|Behavioral: Recorded meal,Taste|Calories,Johns Hopkins University|National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,36,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",NA_00046407|K24DA023186-06,2013-03-01,2014-05-01,2014-05-01,2013-01-09,null,2014-05-29,"Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01763697
953,NCT02680847,Safety and Pharmacokinetic Study of ALO-02 in Children Ages 7-17 With Pain,,Terminated,No Results Available,Moderate-severe Pain,Drug: ALO-02,"Adverse Events|Apparent Oral Clearance|Css,av|Apparent volume of distribution (Vz/F)",Pfizer,All,7 Years to 17 Years   (Child),Phase 4,32,Industry,Interventional,Masking: None (Open Label)|Primary Purpose: Treatment,B4531015|ALO-02 PHASE 4 PEDIATRIC STUDY,2016-01-21,2018-01-10,2018-01-24,2016-02-12,null,2018-06-04,"Research Center For Clinical Studies-West, Inc., Lancaster, California, United States|Children's Hopsital Los Angeles, Los Angeles, California, United States|Children's Hospital Of Los Angeles - University Of Southern California School Of Medicine, Los Angeles, California, United States|Shriners Hospitals For Children Northern California, Sacramento, California, United States|UC Davis Health Attn: Peter Trovitch, PharmD, Sacramento, California, United States|University of California Davis, Sacramento, California, United States|University of Illinois at Chicago Clinical Research Center, Chicago, Illinois, United States|University of Illinois Hospital and Health Sciences Systems, Chicago, Illinois, United States|University of Illinois Hospital at the Medical Center, Chicago, Illinois, United States|East Carolina University Brody School of Medicine(ECU), Greenville, North Carolina, United States|Leo Jenkins Cancer Center Pharmacy, Greenville, North Carolina, United States|Medical University of South Carolina Children's Hospital, Charleston, South Carolina, United States|Medical University of South Carolina, Investigational Drugs Services, Charleston, South Carolina, United States|Medical University of South Carolina, Rutledge Tower, Pediatric Clinic, Charleston, South Carolina, United States|Medical University of South Carolina, SCTR Research Nexus, Charleston, South Carolina, United States|Road Runner Research, Ltd, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT02680847
954,NCT02487745,The Long-Term Treatment of Drug Addiction and Unemployment,,Recruiting,No Results Available,"Substance Abuse, Intravenous",Behavioral: Abstinence-contingent wage supplements|Behavioral: Individual Placement and Support (IPS) supported employment,The percentage of opiate- and cocaine-negative urine samples|The percentage of participants who are employed|The percentage of participants who report injecting drugs|The percentage of participants who report trading unprotected sex for drugs or money|The percentage of participants who report sharing injection equipment|The percentage of participants with household incomes below the federal poverty level|The percentage of opiate- and cocaine-negative urine samples post-intervention|The percentage of participants who are employed post-intervention|The percentage of participants who report injecting drugs post-intervention|The percentage of participants who report trading unprotected sex for drugs or money post-intervention|The percentage of participants who report sharing injection equipment post-intervention,Johns Hopkins University|National Institute on Drug Abuse (NIDA),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NIDA-37314-1|R01DA037314-01A1,2015-11-01,2018-12-01,2019-02-01,2015-07-01,null,2017-08-16,"Center for Learning and Health, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02487745
955,NCT02334059,Effect of Single Dose Ketamine and Magnesium on Postoperative Pain in Patients Undergoing Bariatric Surgery,,"Active, not recruiting",No Results Available,Obesity,Drug: Ketamine|Drug: Ketamine plus magnesium|Other: Placebo,Total Hydromorphone use|Pain Scores using Visual Analogue Scale (VAS)|Sedation scores using Ramsey Sedation Scale|Nausea Scores using Likert Scale|Intraoperative fentanyl use|Intraoperative minimum alveolar concentration (MAC) of desflurane,Milton S. Hershey Medical Center,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,108,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",STUDY00001623,2015-11-01,2019-07-01,2019-11-01,2015-01-08,null,2018-03-02,"Milton S.Hershey Medical Center, Hershey, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02334059
956,NCT01919190,EXPAREL Administered by Infiltration Into the TAP for Prolonged Postsurgical Analgesia in Lower Abdominal Surgeries,TRANSCEND,Terminated,No Results Available,Postsurgical Analgesia,Drug: EXPAREL|Drug: Placebo,Total opioid consumption from end of surgery through 4 days postsurgery|Overall benefit of analgesic score (OBAS)|Extent and degree of anesthetic blockade|Severity of postsurgical pain|Quality of recovery|Frequency of patient calls post-discharge related to pain and unscheduled hospital/surgeon visits,"Pacira Pharmaceuticals, Inc",All,"18 Years and older   (Adult, Older Adult)",Phase 4,74,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,MSE402,2013-08-01,2013-12-01,2014-02-01,2013-08-08,null,2014-02-24,"Florida Hospital, Winter Park, Florida, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|Northwestern University, Chicago, Illinois, United States|University of Louisville, Louisville, Kentucky, United States|Berkshire Medical Center, Pittsfield, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Montefiore Medical Center, Bronx, New York, United States|Duke University, Durham, North Carolina, United States|Fairview Hospital, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|UPMC St. Margaret's Hospital, Pittsburgh, Pennsylvania, United States|St. John Hospital, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01919190
957,NCT02946073,Buprenorphine (CAM2038) in Subjects With a Recent History of Moderate to Severe Chronic Low Back Pain,CAM2038,"Active, not recruiting",No Results Available,Chronic Lower Back Pain|Chronic Pain,Drug: buprenorphine|Other: Placebo,"Change from baseline in Weekly Average of (Daily) Average Pain Intensity and the primary timepoint will be Week 12 of the Double-Blind Phase based on the 11-Point numerical rating scale with 10 being the worst pain.|Change from baseline in the Weekly Average of (Daily) Worst Pain Intensity scores at Week 12 of the Double-Blind Phase based on 11-Point numerical rating scale with 10 being the worst pain.|Percentage of subjects with a 30% or greater decrease in API from baseline to Week 12 of the Double-Blind Phase.|Rescue medication usage (total dose) during the Double-Blind Phase.|Rescue medication usage (number of days used) during the Double-Blind Phase.|Change from baseline to Week 12 of the Double-Blind Phase in EuroQol Group 5-dimension 5-level self-report questionaire score.|Change from baseline to Week 12 of the Double-Blind Phase in Work Productivity and Activity Impairment score with a range of 0-1 for 4 types of scores with higher scores indicating greater impairment.|Time to loss of efficacy, defined as discontinuation of study drug for lack of efficacy.|Summary of AEs and SAEs","Braeburn Pharmaceuticals|Medpace, Inc.|Camurus AB",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,340,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HS-16-555,2016-09-01,2018-05-01,2019-01-01,2016-10-26,null,2018-07-18,"Parkway Medical Center, Birmingham, Alabama, United States|Boyett Health Services Inc, Hamilton, Alabama, United States|National Centers for Pain Management and Research, Vestavia Hills, Alabama, United States|Elite Clinical Studies, Phoenix, Arizona, United States|Phoenix Clinical, Phoenix, Arizona, United States|Noesis Pharma, Phoenix, Arizona, United States|Arizona Research Center, Phoenix, Arizona, United States|MD Studies, Inc., Fountain Valley, California, United States|Neuro-Pain Medical Center, Fresno, California, United States|Alliance Research Centers, Laguna Hills, California, United States|Clinical Trials Research, Lincoln, California, United States|Catalina Research Institute, LLC, Montclair, California, United States|Allied Clinical Research, LLC, Sacramento, California, United States|Care Practice, San Francisco, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Universal Pain Management Group, Valencia, California, United States|Tampa Pain Relief Center-Brandon, Brandon, Florida, United States|International Research Partners, Doral, Florida, United States|Dr. Vijapura and Associates, Jacksonville, Florida, United States|Florida Institute of Medical Research, Jacksonville, Florida, United States|Lake Howell Health Center, Maitland, Florida, United States|Ocean Blue Medical Research Center, Inc., Miami Springs, Florida, United States|Scientific Clinical Research, Inc., North Miami, Florida, United States|Gold Coast Research, LLC, Plantation, Florida, United States|FMPM Research, Saint Petersburg, Florida, United States|Clinical Research of West Florida-Tampa, Tampa, Florida, United States|Tampa Pain Relief Centers-Hillsborough, Tampa, Florida, United States|Palm Beach Research Center, West Palm Beach, Florida, United States|River Birch Research Alliance LLC, Blue Ridge, Georgia, United States|Columbus Regional Research Institute, Knoxville, Georgia, United States|Drug Studies America, Marietta, Georgia, United States|Non-Surgical Orthopedics, P.C., Marietta, Georgia, United States|Injury Care Research, LLC, Boise, Idaho, United States|Millennium Pain Center, Bloomington, Illinois, United States|Clinical Investigation Specialists, Inc.-Gurnee, Gurnee, Illinois, United States|Medisphere Medical Research Center, Evansville, Indiana, United States|International Clinical Research Institute Inc., Overland Park, Kansas, United States|Phoenix Medical Research, Prairie Village, Kansas, United States|Otrimed, Edgewood, Kentucky, United States|River Cities Clinical Research Center, Shreveport, Louisiana, United States|Boston Paincare, Waltham, Massachusetts, United States|MedVadis Research Corporation, Watertown, Massachusetts, United States|Amicis Trials, Festus, Missouri, United States|Hassman Research Institute, Berlin, New Jersey, United States|New York Clinical Trials, Inc, New York, New York, United States|MedEx Healthcare Research, Inc-NY, New York, New York, United States|Upstate Clinical Research Associates, Williamsville, New York, United States|Rapha Institute for Clinical Research, Fayetteville, North Carolina, United States|OnSite Clinical Solutions, LLC-Hickory, Hickory, North Carolina, United States|Center for Clinical Research, LLC-Winston-Salem, Winston-Salem, North Carolina, United States|Aventiv Research, Inc., Columbus, Ohio, United States|Dayton Outpatient Center (DOC) Clinical Research, Dayton, Ohio, United States|Providence Health Partners-Center for Clinical Research, Dayton, Ohio, United States|Medical Research Internationl, Oklahoma City, Oklahoma, United States|SP Research, PLLC, Oklahoma City, Oklahoma, United States|Frost Medical Group, LLC, Conshohocken, Pennsylvania, United States|Suburban Research Associates, Media, Pennsylvania, United States|Coastal Carolina Research Center, Charleston, South Carolina, United States|Medical Research South, LLC, Charleston, South Carolina, United States|New Phase Research & Development, Knoxville, Tennessee, United States|FutureSearch Trials of Dallas, LP, Dallas, Texas, United States|Renaissance Clinical Research and Hypertension Clinic, Dallas, Texas, United States|Research Concepts GP, LLC-Houstion, Houston, Texas, United States|Pioneer Research Solutions Inc., Houston, Texas, United States|The Pain Relief Center, Plano, Texas, United States|The SMART Clinic/Physicians Research Options LLC, Draper, Utah, United States|EPIC Medical Research, Murray, Utah, United States|Aspen Clinical Research, Orem, Utah, United States|Mid Columbia Research, Richland, Washington, United States",,https://ClinicalTrials.gov/show/NCT02946073
958,NCT03373825,Rapid Self-Testing to Prevent Fentanyl Overdose Among Young People Who Use Drugs,RAPiDS2,Completed,No Results Available,Accidental Overdose of Opiate,Behavioral: Take home rapid drug test,Willingness to use the take-home rapid drug test|Current overdose prevention behaviors|Number of take-home rapid drug tests conducted|Change in overdose prevention behaviors|Recent non-prescription fentanyl exposure|Prevalence of take home drug tests reporting the presence of fentanyl exposure,Brown University,All,18 Years to 35 Years   (Adult),Not Applicable,93,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Screening,1612001662,2017-05-15,2017-10-18,2017-12-15,2017-12-14,null,2018-01-24,"Brown University, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT03373825
959,NCT03469310,Minimizing Narcotic Analgesics After Endocrine Surgery,,Recruiting,No Results Available,Thyroid Cancer|Thyroid Nodule|Thyroid Neoplasms|Thyroid Goitre|Thyroid Diseases|Parathyroid Diseases|Parathyroid Adenoma|Parathyroid Hyperplasia,Drug: Acetaminophen 500Mg Cap|Drug: Tylenol #3 Oral Tablet|Drug: Tramadol,Staged narcotic analgesic regimen is non-inferior to narcotics in controlling pain|Is there a difference in the duration of postoperative pain requiring medication|Is there a difference in the medication requirement|Staged regimen cross over to narcotic,"Minerva Romero Arenas, MD, MPH|Doctors Hospital at Renaissance",All,"18 Years and older   (Adult, Older Adult)",Phase 4,126,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,1177315,2018-03-09,2018-09-30,2019-03-01,2018-03-19,null,2018-03-19,"GME General Surgery Clinic, Edinburg, Texas, United States",,https://ClinicalTrials.gov/show/NCT03469310
960,NCT01755546,Long-term Open-Label Safety Study to Evaluate EN3409,,Completed,No Results Available,Low Back Pain|Osteoarthritis|Neuropathic Pain,Drug: EN3409,To determine the long-term safety and tolerability of BEMA Buprenorphine (dosed every 12 hours [Q12h]) in subjects with moderate to severe chronic pain (CP) requiring continuous around-the-clock (ATC) opioid analgesia for an extended period of time,BioDelivery Sciences International,All,"18 Years and older   (Adult, Older Adult)",Phase 3,554,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EN3409-309,2012-12-01,2014-10-01,2014-11-01,2012-12-24,null,2017-01-13,"Parkway Medical Center, Birmingham, Alabama, United States|Horizon Research Group, Inc, Mobile, Alabama, United States|Arizona Research Center, Phoenix, Arizona, United States|Global Research, LLC, Anaheim, California, United States|Synergy Clinical Research Center of Escondido, Escondido, California, United States|RX Clinical Research, Inc., Garden Grove, California, United States|Long Beach Center for Clinical Research, Long Beach, California, United States|Adam D. Karns, MD, Los Angeles, California, United States|Stamford Therapeutics Consortium, Stamford, Connecticut, United States|Clinical Research of West Florida, Inc., Clearwater, Florida, United States|Century Clinical Research, Inc., Daytona Beach, Florida, United States|Avail Clinical Research, LLC, Deland, Florida, United States|Florida Health Center, Ft. Lauderdale, Florida, United States|Eastern Research, Inc., Hialeah, Florida, United States|Southeast Clinical Research, LLC, Jacksonville, Florida, United States|Health Awareness, Inc., Jupiter, Florida, United States|Research Centers of America, LLC, Oakland Park, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Ribo Research LLC DBA Peninsula Research, Ormand Beach, Florida, United States|Gold Coast Research, LLC, Plantation, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Clinical Research of West Florida, Inc., Tampa, Florida, United States|Palm Beach Research Center, West Palm Beach, Florida, United States|National Pain Research Institute, LLC, Winter Park, Florida, United States|River Birch Research Alliance, LLC, Blue Ridge, Georgia, United States|Drug Studies America, Marietta, Georgia, United States|Taylor Research, LLC, Marietta, Georgia, United States|In-Quest Medical Research, LLC, Norcross, Georgia, United States|Global Scientific Innovations, Evansville, Indiana, United States|Integrated Clinical Trials Services, Inc., West Des Moines, Iowa, United States|Willis-Knighton Physician Network, Bossier, Louisiana, United States|Clinical Trials Management, LLC, Metairie, Louisiana, United States|Best Clinical Trials, LLC, New Orleans, Louisiana, United States|River Cities Clinical Research Center, Shreveport, Louisiana, United States|New England Center for Clinical Research, Inc., Fall River, Massachusetts, United States|Great Lakes Research Group, Inc., Bay City, Michigan, United States|Cadillac Clinical Research, Cadillac, Michigan, United States|The Center for Clinical Trials, Biloxi, Mississippi, United States|Long Island Gastrointestinal Research Group, Great Neck, New York, United States|Upstate Clinical Research Associates, Williamsville, New York, United States|The Center for Clinical Research, Winston Salem, North Carolina, United States|Plains Medical Clinic, LLC, Fargo, North Dakota, United States|Clinical Inquest Center, Ltd, Beavercreek, Ohio, United States|New Horizons Clinical Research, Cincinnati, Ohio, United States|Prestige Clinical Research, Franklin, Ohio, United States|Optimed Research, Ltd., Tiffin, Ohio, United States|Brandywine Clinical Research, Downingtown, Pennsylvania, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Pain Specialists of Charleston, P.A., Charleston, South Carolina, United States|Health Concepts, Rapid City, South Dakota, United States|FutureSearch Clinical Trials, Austin, Texas, United States|KRK Medical Research, Dallas, Texas, United States|FutureSearch Trials of Dallas, LP, Dallas, Texas, United States|Advanced Clinical Research of Houston, Houston, Texas, United States|Innovative Clinical Trials, San Antonio, Texas, United States|Highland Clinical Research, Salt Lake City, Utah, United States|Clinical Investigations Specialist, Inc., Kenosha, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT01755546
961,NCT03301623,Voices in Pain Care,,Recruiting,No Results Available,Chronic Pain,Other: Clinical Decision Support|Other: Patient Education and Activation Tools,Hierarchical Linear Model (Longitudinal Analysis) - Which communication strategy used is more effective in improving pain interference with patients' daily life for patients with chronic pain?|Hierarchical Linear Model (Longitudinal Analysis)- Which communication strategy used is more effective in improving how satisfied patients feel after communicating with their physician about chronic pain treatment risks and benefits?|Hierarchical Linear Model- Which communication strategy used during the clinical encounter is more effective in improving patient's Health-Related Quality of Life?|Hierarchical Generalized Linear Model - Which communication strategy used during the clinical encounter is more effective in reducing opioid prescriptions of more than 90 Morphine Milligram Equivalents (MME)?|Hierarchical Generalized Linear Model - Which communication strategy used during the clinical encounter is more effective in reducing co-prescriptions of opioids and benzodiazepines?,Cedars-Sinai Medical Center|Patient-Centered Outcomes Research Institute|American Chronic Pain Association|Consumer Reports,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1000,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,Pro00049085,2017-11-13,2019-09-01,2020-03-13,2017-10-04,null,2017-11-29,"Cedars-Sinai Medical Center, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT03301623
962,NCT00236093,Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain,,Completed,No Results Available,Pain|Cancer|Sickle Cell Anemia|Severe Burns,Drug: ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC]),The objective of the study is to monitor the safety (adverse event data) of longer-term use of ACTIQ treatment in children with pain and BTP who are receiving ATC opioid therapy.,Cephalon|Teva Pharmaceutical Industries,All,3 Years to 15 Years   (Child),Phase 2,null,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C8278/2022/BP/US-CA,2006-10-01,2006-12-01,null,2005-10-12,null,2014-05-09,"Children's Hospital of Arkansas, Little Rock, Arkansas, United States|Childrens Hospital of Orange, Orange, California, United States|Lucille Packard Childresns Hospital, Palo Alto, California, United States|Connecticut Childrens Medical, Hartford, Connecticut, United States|Childrens National Medical Center, Washington, District of Columbia, United States|Nemours Childrens Clinc, Jacksonville, Florida, United States|St. Joseph's Childrens Hopsital, Tampa, Florida, United States|Kapi'olani Medical Center, Honolulu, Hawaii, United States|University Hospitals of Iowa, Iowa City, Iowa, United States|David Center for Childrens Pain and Palliative Care, Hackensack, New Jersey, United States|Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|University of New Mexico, Albuquerque, New Mexico, United States|Children's Hospital at Montefiore, Bronx, New York, United States|Scottish Rite Children's Medical Center, Syracuse, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Duke University Hospital, Durham, North Carolina, United States|Akron Children's Hospital, Akron, Ohio, United States|Tod Childrens Hospital, Youngstown, Ohio, United States|Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Children's Cancer and Blood Disorders Center, San Antonio, Texas, United States|Methodist Hospital, San Antonio, Texas, United States|Sacred Heart Medical Center, Spokane, Washington, United States|West Virginia Univeristy, Morgantown, West Virginia, United States|Childrens Hospital of Wisconsin, Milwaukee, Wisconsin, United States|Iwk Health Center, Halifax, Nova Scotia, Canada|San Jorge Childrens Medical, San Juan, Puerto Rico",,https://ClinicalTrials.gov/show/NCT00236093
963,NCT01619839,"A Phase 2 Study To Assess The Efficacy, Tolerability, And Safety OF NKTR-181 In Subjects With Chronic OA Knee Pain",,Completed,No Results Available,Osteoarthritis of the Knee,Drug: NKTR-181|Drug: Placebo,The mean change from Baseline Pain Score to pain score at the end of the double-blind Randomized Treatment Period.|Time to discontinuation during the double-blind Randomized Treatment Period for any reason,Nektar Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 2,213,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",12-181-04,2012-06-01,2013-08-01,2013-09-01,2012-06-14,null,2014-08-18,"Coastal Clinical Research, Inc., Mobile, Alabama, United States|Genova Clinical Research, Inc., Tucson, Arizona, United States|SC Clinical Research, Garden Grove, California, United States|San Diego, California, United States|Diablo Clinical Research, Inc., Walnut Creek, California, United States|Westlake Medical Research, Westlake Village, California, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|Clinical Physiology Associates, Fort Meyers, Florida, United States|Pines Clinical Research, Pembroke Pines, Florida, United States|Palm Beach Research, West Palm Beach, Florida, United States|Gold Coast Research, LLD, Weston, Florida, United States|Medisphere Medical Research, Evansville, Indiana, United States|Heartland Research Associates, LLC, Wichita, Kansas, United States|L-MARC Research Center, Louisville, Kentucky, United States|Beacon Clinical Research, LLC, Brockton, Massachusetts, United States|Worcester, Massachusetts, United States|The Center for Pharmaceutical Research, Kansas City, Missouri, United States|Meridian Clinical Research, Omaha, Nebraska, United States|Clinical Research Consortium, Las Vegas, Nevada, United States|Clinical Research Consortium, Las Vegas, Nevada, United States|Comprehensive Clinical Research, Berlin, New Jersey, United States|Pain Center, Englewood, New Jersey, United States|Triad Clinical Trials, LLD, Greensboro, North Carolina, United States|Sterling Research Group, Inc., Cincinnati, Ohio, United States|Oklahoma City, Oklahoma, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|CRI Lifetree - Philadephia, Philadelphia, Pennsylvania, United States|Pain Research of Charleston, Charleston, South Carolina, United States|Premier Research Group - Austin, Austin, Texas, United States|Metroplex Clinical Research Center, Dallas, Texas, United States|San Antonio, Texas, United States|Quality Research Inc., San Antonio, Texas, United States|CRI Lifetree - Salt Lake City, Salt Lake City, Utah, United States|Clinical Investigation Specialists, Kenosha, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT01619839
964,NCT00547586,Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain,,Completed,No Results Available,Constipation,Drug: N-methylnaltrexone bromide (MOA-728)|Other: placebo,The effect of the interventional treatment will be measured by bowel movements.,"Valeant Pharmaceuticals International, Inc.|Progenics Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,120,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3200A3-2201,2007-10-01,2008-02-01,2008-02-01,2007-10-22,null,2011-07-28,"Mobile, Alabama, United States|Hot Springs, Arizona, United States|Hot Springs, Arizona, United States|Litchfield Park, Arizona, United States|Tucson, Arizona, United States|Tucson, Arizona, United States|Garden Grove, California, United States|Long Beach, California, United States|Los Angelese, California, United States|Maretta, California, United States|San Diego, California, United States|Chiefland, Florida, United States|Jacksonville, Florida, United States|Jupiter, Florida, United States|Largo, Florida, United States|Naples, Florida, United States|Ocala, Florida, United States|Ormond Beach, Florida, United States|Spring Hill, Florida, United States|Chicago, Illinois, United States|Indianapolis, Indiana, United States|Sunset, Louisiana, United States|Elkridge, Maryland, United States|Brockton, Massachusetts, United States|Cadillac, Michigan, United States|Traverse City, Michigan, United States|Biloxi, Mississippi, United States|Ocean Springs, Mississippi, United States|Las Vegas, Nevada, United States|Albuquerque, New Mexico, United States|Charlotte, North Carolina, United States|Winston-Salem, North Carolina, United States|Dayton, Ohio, United States|Toledo, Ohio, United States|Meford, Oregon, United States|Chattanooga, Tennessee, United States|Beaumont, Texas, United States|Colleyville, Texas, United States|Dallas, Texas, United States|San Antonio, Texas, United States|Alexandria, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00547586
965,NCT00351819,Effects of Testosterone Replacement on Pain Sensitivity and Pain Perception,TAP,Completed,Has Results,Pain|Hypogonadism,Drug: AndroGel|Other: Placebo,Brief Pain Inventory (BPI) at Week 14|Algometer-induced Pressure Pain at Week 14|Weighted Pinprick Stimulator-induced Mechanical Pain at Week 14|Ice Water-induced Cold Pain and Its After-sensation at Week 14|Sexual Functioning as Assessed by International Index of Erectile Function (IIEF) at Week 14|Health Quality of Life (QoL) as Assessed by Short Form 36 (SF-36) at Week 14|Pain Catastrophizing Scale (PCS) at Week 14,Boston University,Male,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2,84,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",H-27995,2006-04-01,2012-11-01,2012-11-01,2006-07-13,2017-06-28,2017-06-28,"Brigham and Women's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00351819
966,NCT00345384,Dexmedetomidine for the Control of Post-Operative Pain in Thoracotomy Patients,,Completed,Has Results,Post-operative Pain|Respiratory Depression,Drug: Dexmedetomidine|Other: Placebo (Normal Saline),Measure Any Reduction in the Amount of Opioid Administered to Patients in the Dexmedetomidine Study Arm.|Measure the Amount of Respiratory Depression in Each Groups,Baylor Research Institute,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,38,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",005-201,2008-05-01,2010-01-01,2010-01-01,2006-06-28,2015-08-20,2016-02-08,"Baylor University Medical Center - Department of Anesthesiology, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT00345384
967,NCT01081912,Phase 3 Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Low Back Pain,,Completed,Has Results,Back Pain Lower Back Chronic,Drug: Placebo|Drug: Hydrocodone bitartrate,Mean Change in 24-hour Pain Intensity Ratings Scale (NRS).|Mean Change of the Clinic NRS Pain Intensity,"Zogenix, Inc.",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,510,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ZX002-0801,2010-03-01,2011-10-01,2011-10-01,2010-03-05,2014-04-21,2014-04-21,"Arizona Research Center, Phoenix, Arizona, United States|Clopton Clinic, Jonesboro, Arkansas, United States|Advanced Clinical Research Institute, Anaheim, California, United States|Neuro-Pain Medical Center, Inc., Fresno, California, United States|Pacific Coast Pain Management Center, Laguna Hills, California, United States|Clinicos, LLC, Colorado Springs, Colorado, United States|Interwest Rehabilitation, LLC, Littleton, Colorado, United States|Stamford Therapeutics Consortium, Stamford, Connecticut, United States|Clinical Research of West Florida, Inc., Clearwater, Florida, United States|Florida Institute of Medical Research, Jacksonville, Florida, United States|Peninsula Research, Inc., Ormond Beach, Florida, United States|Gold Coast Research, Plantation, Florida, United States|Clinical Research of West Florida, Inc., Tampa, Florida, United States|Perimeter Institute for Clinical Research, Inc., Atlanta, Georgia, United States|River Birch Research Alliance, LLC, Blue Ridge, Georgia, United States|Georgia Institute for Clinical Research, LLC, Marietta, Georgia, United States|Georgia Clinical Research, Snellville, Georgia, United States|Suburban Clinical Research, Chicago, Illinois, United States|Destiny Clinical Research, LLC, Evansville, Indiana, United States|Integrated Clinical Trials Services, Inc., West Des Moines, Iowa, United States|International Clinical Research Institute, Leawood, Kansas, United States|Clinical Trials Technology, Inc, Prairie Village, Kansas, United States|Cotton O'Neil Clinical Research Center, Topeka, Kansas, United States|Clinical Trials Management, Metairie, Louisiana, United States|Best Clinical Trials, LLC, New Orleans, Louisiana, United States|River Cities Clinical Research Center, Shreveport, Louisiana, United States|NECCR Internal Medicine & Cardiology Associates, LLC, Fall River, Massachusetts, United States|Center for Clinical Trials, Biloxi, Mississippi, United States|Research West, LLC, Kalispell, Montana, United States|Office of Danka Michaels, MD, Las Vegas, Nevada, United States|South Jersey Medical Associates, Blackwood, New Jersey, United States|CRI Worldwide, LLC, Willingboro, New Jersey, United States|Five Towns Neuroscience Research, Cedarhurst, New York, United States|Upstate Clinical Research Associates, Williamsville, New York, United States|Center for Clinical Research LLC, Winston Salem, North Carolina, United States|IVA Research, Cincinnati, Ohio, United States|Prestige Clinical Research, Franklin, Ohio, United States|Neuropsychiatric Research Center, Oklahoma City, Oklahoma, United States|Brandywine Clinical Research, Downingtown, Pennsylvania, United States|Feasterville Family Health Care Center, Feasterville, Pennsylvania, United States|New England Center for Clinical Research, Cranston, Rhode Island, United States|Health Concepts, Rapid City, South Dakota, United States|Integrity Clinical Research, LLC, Milan, Tennessee, United States|InSite Clinical Research, DeSoto, Texas, United States|Clinical Trial Network, Houston, Texas, United States|Innovative Clinical Trials, San Antonio, Texas, United States|Invisions Consultants, LLC, San Antonio, Texas, United States|Clinical Trial Network, Spring, Texas, United States|Advanced Research Institute, Ogden, Utah, United States|Hypothe Test, LLC, Roanoke, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States",,https://ClinicalTrials.gov/show/NCT01081912
968,NCT00387010,Open-Label Study to Evaluate the Effect of Treatment With Fentanyl Buccal Tablets on Pain Anxiety Symptoms When Used for the Management of Breakthrough Pain,,Terminated,Has Results,Pain|Chronic Pain|Breakthrough Pain,Drug: Fentanyl Buccal Tablets,Change From Baseline in the Pain Anxiety Symptoms Scale (PASS) Total Score at Approximately Week 5|Change From Baseline in the Pain Anxiety Symptoms Scale (PASS) Subscale Scores at Approximately Week 5|Change From Baseline in the Beck Depression Inventory at Approximately Week 5|Change From Baseline in the West Haven-Yale Multidimensional Pain Inventory Subscales at Approximately Week 5|Medication Preference From the Pain Flare Treatment Satisfaction Questionnaire at Approximately Week 5|Patient Assessment of Ability to Go to Work at Approximately Week 5|Patient Assessment of Ability to Perform at Work at Approximately Week 5|Patient Assessment of Ability to Walk at Approximately Week 5|Patient Assessment of Ability to Exercise at Approximately Week 5|Patient Assessment of Ability to Participate in Social Events at Approximately Week 5|Patient Assessment of Ability to Have Sex at Approximately Week 5|Patient Assessment of Ability to Enjoy Life at Approximately Week 5|Clinical Assessment of Patient Function - General Activities - at Approximately Week 5|Clinical Assessment of Patient Function - Patient's Walking Ability - at Approximately Week 5|Clinical Assessment of Patient Function - Patient's Ability to Work/Perform Activities of Daily Living - at Approximately Week 5|Clinical Assessment of Patient Function - Patient's Relationship With Others - at Approximately Week 5|Clinical Assessment of Patient Function - Patient's Enjoyment of Life - at Approximately Week 5|Summary of Participants' Successful Dosing Levels of Fentanyl Buccal Tablets to Control Episodes of Breakthrough Pain (BTP),Cephalon|Teva Pharmaceutical Industries,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,218,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C25608/3054/BP/US,2006-12-01,2007-10-01,2007-10-01,2006-10-12,2012-10-22,2012-10-22,"Birmingham Pain Center, Birmingham, Alabama, United States|Arizona Research Center, Phoenix, Arizona, United States|Orange County Clinical Trials, Anaheim, California, United States|Vertex Clinical Research, Bakersfield, California, United States|Lovelace Scientific Resources, Inc., Beverly Hills, California, United States|Synergy Clinical Research Center, National City, California, United States|Pain Institute of Santa Monica, Santa Monica, California, United States|Integrative Pain Manage Centers, Westminster, Colorado, United States|Advanced Diagnostic Pain Treatment Center, New Haven, Connecticut, United States|Alliance Medical Research Group, Clearwater, Florida, United States|Innovative Research of West Florida, Largo, Florida, United States|Lovelace Scientific Resources, Inc., Sarasota, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Dawsonville Family Medicine, Dawsonville, Georgia, United States|Millennium Pain Center, Bloomington, Illinois, United States|Pain and Rehabilitation Clinic of Chicago, Chicago, Illinois, United States|Elkhart Clinic, LLC, Elkhart, Indiana, United States|Rehabilitation Associates of Indiana, Indianapolis, Indiana, United States|Northwest Indiana Center for Clinical Research, PC, Valparaiso, Indiana, United States|ICRI, Inc., Overland Park, Kansas, United States|Willis-Knighton Pain Management Center, Shreveport, Louisiana, United States|Montana Cancer Specialists, Missoula, Montana, United States|Lovelace Scientific Resources Center, Henderson, Nevada, United States|Clinical Research Center of Nevada, Las Vegas, Nevada, United States|SUNY - Stonybrook, Stony Brook, New York, United States|Pain Consultants of Oregon, Eugene, Oregon, United States|Allegheny Pain Management, PC, Altoona, Pennsylvania, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|DeGarmo Institute of Medical Research, Greer, South Carolina, United States|Comprehensive Pain Specialists, PLLC, Hendersonville, Tennessee, United States|KRK Medical Research, Richardson, Texas, United States|BeXar Clinical Trials, LLC, Richardson, Texas, United States|Lifetree Clinical Research, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT00387010
969,NCT00530764,A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy.,SPRAY,Completed,Has Results,Palliative Care|Pain|Cancer,Drug: Sativex Low Dose|Drug: Sativex Medium Dose|Drug: Sativex High Dose,Number of Patients With at Least 30% Improvement in Numerical Rating Scale (NRS) Average Pain Score From Baseline|Change in Cumulative Average Pain Response Curves|Change in Mean Daily NRS Pain Score (Average Pain).|Change in Mean Daily NRS Pain Score (Worst Pain).|Change in Sleep Disruption NRS|Change in Brief Pain Inventory - Short Form (BPI-SF)|Change in Patient Assessment of Constipation Quality of Life (PAC-QoL)|Change in Patient Global Impression of Change - PGIC|Change in Montgomery Asberg Depression Rating Scale (MADRS),"GW Pharmaceuticals Ltd.|Quintiles, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,360,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",GWCA0701,2007-11-01,2010-01-01,2010-01-01,2007-09-17,2011-06-17,2013-06-20,"Cancer Care Center of Tuscaloosa, Tuscaloosa, Alabama, United States|Desert Oasis Cancer Center, Casa Grande, Arizona, United States|Pacific Coast Hematology/Oncology Medical Group, Inc., Fountain Valley, California, United States|Office of Dr. Ronald Yanagihara, Gilroy, California, United States|University of California San Diego, La Jolla, California, United States|Loma Linda University, Loma Linda, California, United States|Florida Institute of Medical Research, Jacksonville, Florida, United States|Clinical Pharmacology Services, Tampa, Florida, United States|Center of Hope for Cancer and Blood Disorders, Riverdale, Georgia, United States|Louisiana Research Associates, New Orleans, Louisiana, United States|The Center for Clinical Research - Washington County Hospital, Hagerstown, Maryland, United States|Capital Comprehensive Cancer Care Clinic, Jefferson City, Missouri, United States|A & A Pain Institute of St. Louis, St. Louis, Missouri, United States|Office of Donald H. Berdeaux MD, Great Falls, Montana, United States|Summit Medical Group, Berkeley Heights, New Jersey, United States|Beth Israel Medical Center, New York, New York, United States|Metropolitan Hospital Center, New York, New York, United States|Four Seasons Hospice & Pallative Care, Flat Rock, North Carolina, United States|Center for Clinical Research, Winston-Salem, North Carolina, United States|Gabrail Cancer Center, Canton, Ohio, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Lone Star Oncology, Austin, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Jules Bordet Institute, Bruxelles, Belgium|CHU Charleroi (Hôpital civil de Charleroi), Charleroi, Belgium|UZ Leuven - Algologisch Centrum Anesthesiologie, Pellenberg, Belgium|Vancouver Health Research Center, Victoria, British Columbia, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Instituto Radio-oncológico Santiago (INRAD), Santiago, Chile|Clínica Ciudad del Mar, Viña del Mar, Chile|Ambulance pro lécbu bolesti, ARO, Benešov, Czech Republic|Ambulance pro lécbu bolesti, Ceské Budejovice, Czech Republic|Nemocnice Ceské Budejovice, Ceské Budejovice, Czech Republic|FN Hradec Králové - Klinika onkologie a radioterapie, Hradec Králové, Czech Republic|Nemocnice Jihlava, Jihlava, Czech Republic|FN a LF UP Olomouc - Ambulance pro lécbu bolesti, Olomouc, Czech Republic|AR klinika FN Plzen -Ambulance pro lécbu bolesti, Plzen, Czech Republic|Fakultní nemocnice Na Bulovce, Praha 8 - Liben, Czech Republic|ARO, Krajská zdravotni, K.Z. a.s, Nemocnice, Teplice, Czech Republic|Docrates Clinic, Helsinki, Finland|Centre hospitalier Lyon Sud, Pierre-Benite, France|Praticien hospitalier, Tarbes, France|RWTH Aachen Universität, Aachen, Germany|Schmerz- und Palliativzentrum Göppingen, Göppingen, Germany|St.-Marien-Hospital Lunen, Lunen, Germany|Schmeiz - u Pallielivzendium Wiesbaden, Wiesbaden, Germany|Yashoda Hospital, Andhra Pradesh, India|Bangalore Institute of Oncology, Bangalore,, India|CBCC- Apollo Hospital, Gandhinagar, India|Apollo Hospital, Hyderabaad, India|Indo-American Cancer Institute and Research Center, Hyderabaad, India|Bhagwaan Mahaveer Cancer Hospital and Research Centre, Jaipur, India|CHL - Apollo Hospitals, Madhya Pradesh, India|Jawaharlal Nehru Cancer Hospital, Madhya Pradesh, India|Meenakshi Mission Hospital & Research Centre, Madurai, India|All India Institute of Medical Sciences, New Delhi, India|Jehangir Clinical Development Centre Pvt. Ltd., Pune, India|Deenanath Mangeshkar Hospital and Research Center, Pune, India|Seroc Cancer Center, Rajasthan, India|Regina Elana Cancer Institute, Rom, Italy|Dir. S.C.D.U. Psicologia Clinica ed Oncologica, Turin, Italy|Hospital Aranda de la Parra, Leon, Mexico|Htal Ángeles de Pedregal, Mexico DF, Mexico|Beskidzkie Centrum Onkologii im. Jana Pawla, Bielsko-Biala, Poland|Poradnia Leczenia Bolu, Edyty Jakubow, Poland|Wojewodzki Szpital Specjalistyczny im. M. Kopernika, Gdansk, Poland|NZOZ Hospicjum Milosierdzia Bozego, Gliwice, Poland|Szpital Uniwersytecki w Krakowie, Krakow, Poland|Wielkopolskie Centrum Onkologii, Poznan, Poland|Niepubliczny Zaklad Opieki Zdrowotnej, Tychy, Poland|Centrum Onkologii - Instytut im. M. Sklodowskiej - Curie, Warszawa, Poland|Spitalul Judetean de Urgenta ""Constantin Opris"", Baia Mare, Maramures, Romania|Spitalul Judetean de Urgenta Braila, Braila, Jud. Braila, Romania|Hospice ""Casa Sperantei"", Brasov, Romania|Spitalul Universitar de Urgenta Elias, Bucuresti, Romania|S.C. IanuliMed S.R.L. Oncologie Medicala, Bucuresti, Romania|Policnica Orizont-Oncologie Medicala, Craiova, Romania|District Hospital Dr. Alexandru Simionescu, Hunedoara, Romania|Centrul de Oncologie Medicala, Iasi, Romania|Spitalul Municipal Onesti, Onesti, Jud. Bacau, Romania|Spitalul Municipal Ploiesti, Ploiesti, Romania|Spitalul Clinic Judetean Sibiu Oncologie, Sibiu, Romania|Spitalul Judetean de Urgenta ""Sf. Ioan cel Nou"", Suceava, Romania|Dr. Pirjol & Szpak Inc., Amanzimtoti, South Africa|Medi Clinic, Bloemfontein, South Africa|Pain Clinic, Cape Town, South Africa|Pretoria Urology Research Unit, Hatfield, Pretoria, South Africa|Trialtech Research - Embassy Drive Medical Centre, Hatfield, Pretoria, South Africa|Oncology/Haematology Dept Research Unit, Kimberley, South Africa|Eastleigh Breast Cancer Center, Lynnwood, South Africa|Hospital Virgen del Mar, Almeria, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Clinic i Provincial, Barcelona, Spain|HU Puerta del Mar, Oncologia, Cadiz, Spain|Hospital Universitario de Bellvitge, Feixa, Llarga, sn, Spain|Hospital Univ. Virgen de las Nieves, Granada, Spain|Hospital de la Rioja, Logrono, Spain|Hospital Los Montalvos, Salamanca, Spain|Basingstoke & North Hampshire NHS Foundation Trust, Basingstoke, United Kingdom|West Suffolk Hospital, Bury St Edmunds, United Kingdom|Fairfield General Hospital, Bury, Lancashire, United Kingdom|Edinburgh Cancer Research Centre (CRUK), Edinburgh, United Kingdom|James Paget Hospital, Gorleston on Sea, Norfolk, United Kingdom|International Observatory on End of Life Care, Lancaster, United Kingdom|St Bartholomew's Hospital, London, United Kingdom|The Royal Marsden NHS Foundation Trust, London, United Kingdom|Marie Curie Hospice Holme Tower, Penarth, United Kingdom|The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom|Weston Area Health Trust, Weston super Mare, United Kingdom|New Cross Hospital, Wolverhampton, United Kingdom",,https://ClinicalTrials.gov/show/NCT00530764
970,NCT00214942,Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for Management of Breakthrough Pain,,Completed,No Results Available,Chronic Low Back Pain,Drug: ORAVESCENT Fentanyl Citrate,,Cephalon|Teva Pharmaceutical Industries,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,null,Industry,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double|Primary Purpose: Treatment,C25608/3042/BP/US,2005-09-01,2006-03-01,null,2005-09-22,null,2014-05-09,"Clopton Clinic, Jonesboro, Arkansas, United States|Vertex Clinical Research, Inc., Bakersfield, California, United States|San Diego Arthritis Medical, San Diego, California, United States|Clinical Research of W Florida, Clearwater, Florida, United States|Florida Institute of Medical R, Jacksonville, Florida, United States|Clinical Pharmacology Services, Tampa, Florida, United States|Gold Coast Research, Weston, Florida, United States|Center for Prospective Outcome, Marietta, Georgia, United States|Georgia Medical Research, Marietta, Georgia, United States|American Medical Research, Chicago, Illinois, United States|American Medical Research, Oak Brook, Illinois, United States|American Medical Research, Valparaiso, Indiana, United States|Iowa Pain Management Clinic, P, Des Moines, Iowa, United States|Mid America Physiatrists, PA, Overland Park, Kansas, United States|Best Clinical Trial, Inc., New Orleans, Louisiana, United States|PharmQuest, Greensboro, North Carolina, United States|Northwest Clinical Research, Bellevue, Washington, United States",,https://ClinicalTrials.gov/show/NCT00214942
971,NCT00214955,Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for the Management of Breakthrough Pain,,Completed,No Results Available,Chronic Neuropathic Pain,Drug: ORAVESCENT Fentanyl Citrate,,Cephalon|Teva Pharmaceutical Industries,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,120,Industry,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double|Primary Purpose: Treatment,C25608/3041/BP/US,2005-09-01,2006-05-01,null,2005-09-22,null,2014-05-09,"Clopton Clinic, Jonesboro, Arkansas, United States|Vertex Clinical Research, Inc., Bakersfield, California, United States|San Diego Arthritis Medical, San Diego, California, United States|Clinical Research of W Florida, Clearwater, Florida, United States|Florida Institute of Medical R, Jacksonville, Florida, United States|Clinical Pharmacology Services, Tampa, Florida, United States|Gold Coast Research, Weston, Florida, United States|Center for Prospective Outcome, Marietta, Georgia, United States|Georgia Medical Research, Marietta, Georgia, United States|American Medical Research, Chicago, Illinois, United States|American Medical Research, Oak Brook, Illinois, United States|American Medical Research, Valparaiso, Indiana, United States|Iowa Pain Management Clinic, P, Des Moines, Iowa, United States|Mid America Physiatrists, PA, Overland Park, Kansas, United States|Best Clinical Trial, Inc., New Orleans, Louisiana, United States|PharmQuest, Greensboro, North Carolina, United States|Northwest Clinical Research, Bellevue, Washington, United States",,https://ClinicalTrials.gov/show/NCT00214955
972,NCT00218634,Skills Based Counseling for Adherence and Depression in HIV+ Methadone Patients - 1,,Completed,Has Results,Adherence|Depression|Heroin Dependence|Methadone|Motivational Interviewing|Substance-Related Disorders,Behavioral: CBT-AD|Behavioral: ETAU,Percent Medication Adherence at 3-month Follow-up Assessment|Percent Medication Adherence at 12-month Follow-up Assessment|Clinician-assessed Depression Rating at 3 Month Follow-up Assessment|HIV Viral Load at 12-month Follow-up Assessment|CD4+ Lymphocyte Count at 12-month Follow-up Assessment.|Clinician-assessed Depression at 12-month Follow-up Assessment|HIV Viral Load at 3-month Follow-up Assessment|CD4+ Lymphocyte Count at 3-month Follow-up Assessment.,Massachusetts General Hospital|National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,89,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,NIDA-18603-1|R01DA018603,2005-02-01,2009-07-01,2009-07-01,2005-09-22,2012-07-30,2018-01-02,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00218634
973,NCT02700451,Post-op Acetaminophen vs NSAID Use on Lumbar Spinal Fusion Outcomes,,Recruiting,No Results Available,Lumbar Osteoarthritis|Spondylosis|Lumbar Disc Disease|Spinal Stenosis,Drug: Ketorolac|Drug: Acetaminophen|Drug: Placebo,Perioperative Opioid use|Opioid Use at 4-6 weeks|Opioid Use at 3 months|Opioid Use at 1 year|Opioid Use at 2 years|Numerical Pain rating scale|Blinding assessment|Pain satisfaction|Brief Pain Inventory|Opioid related side effects|Opioid related symptom distress scale|Perioperative Complications|Days to walk 50 ft with PT|Length of stay|Veterans Rand - 12|Oswestry Disability Index|Return to work,"Hospital for Special Surgery, New York",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,300,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2014-333,2016-03-01,2019-08-01,2021-08-01,2016-03-07,null,2018-04-05,"Hospital for Special Surgery, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02700451
974,NCT00101998,Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication,,Completed,No Results Available,Constipation|Bowel Dysfunction,Drug: alvimopan|Drug: placebo,"Change in weekly SCBM frequency. A SCBM is a spontaneous and complete bowel movement, which means a bowel movement that occurs with no laxative use in the prior 24 hours and leaves the subject with the feeling of complete evacuation of the rectum.|Additional measures of Bowel movement (BM) frequency and symptoms, safety profile of the treatment regimens and any changes in pain intensity or opioid use.",Cubist Pharmaceuticals LLC|GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 2,233,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",3753-009|767905/008,2003-10-01,2006-05-01,2006-05-01,2005-01-19,null,2017-08-30,"GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Hot Springs, Arkansas, United States|GSK Investigational Site, Duarte, California, United States|GSK Investigational Site, Fountain Valley, California, United States|GSK Investigational Site, Fresno, California, United States|GSK Investigational Site, La Verne, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Los Gatos, California, United States|GSK Investigational Site, Modesto, California, United States|GSK Investigational Site, Sacramento, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, Santa Monica, California, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Washington, D.C., District of Columbia, United States|GSK Investigational Site, Washington, D.C., District of Columbia, United States|GSK Investigational Site, Gainesville, Florida, United States|GSK Investigational Site, Inverness, Florida, United States|GSK Investigational Site, Lecanto, Florida, United States|GSK Investigational Site, Miami Shores, Florida, United States|GSK Investigational Site, New Port Richey, Florida, United States|GSK Investigational Site, New Port Richey, Florida, United States|GSK Investigational Site, Ocala, Florida, United States|GSK Investigational Site, Palm Harbor, Florida, United States|GSK Investigational Site, Stuart, Florida, United States|GSK Investigational Site, Tampa, Florida, United States|GSK Investigational Site, Titusville, Florida, United States|GSK Investigational Site, Decatur, Georgia, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, West Des Moines, Iowa, United States|GSK Investigational Site, Hutchinson, Kansas, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Bethesda, Maryland, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Worcester, Massachusetts, United States|GSK Investigational Site, Ann Arbor, Michigan, United States|GSK Investigational Site, Flint, Michigan, United States|GSK Investigational Site, Saint Louis Park, Minnesota, United States|GSK Investigational Site, Kansas City, Missouri, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, Reno, Nevada, United States|GSK Investigational Site, Albuquerque, New Mexico, United States|GSK Investigational Site, Bethpage, New York, United States|GSK Investigational Site, Huntington Station, New York, United States|GSK Investigational Site, Jamaica, New York, United States|GSK Investigational Site, Chapel Hill, North Carolina, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Hendersonville, North Carolina, United States|GSK Investigational Site, Raleigh, North Carolina, United States|GSK Investigational Site, Winston-Salem, North Carolina, United States|GSK Investigational Site, Bismarck, North Dakota, United States|GSK Investigational Site, Bismarck, North Dakota, United States|GSK Investigational Site, Canton, Ohio, United States|GSK Investigational Site, Middletown, Ohio, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Amarillo, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Webster, Texas, United States|GSK Investigational Site, Norfolk, Virginia, United States|GSK Investigational Site, Portsmouth, Virginia, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Tacoma, Washington, United States|GSK Investigational Site, Milwaukee, Wisconsin, United States|GSK Investigational Site, Capital Federal, Buenos Aires, Argentina|GSK Investigational Site, Rosario, Santa Fe, Argentina|GSK Investigational Site, St Leonards, New South Wales, Australia|GSK Investigational Site, Redcliffe, Queensland, Australia|GSK Investigational Site, South Brisbane, Queensland, Australia|GSK Investigational Site, Daw Park, South Australia, Australia|GSK Investigational Site, Malvern, Victoria, Australia|GSK Investigational Site, Winnipeg, Manitoba, Canada|GSK Investigational Site, Saint John's, Newfoundland and Labrador, Canada|GSK Investigational Site, Kitchener, Ontario, Canada|GSK Investigational Site, London, Ontario, Canada|GSK Investigational Site, North Bay, Ontario, Canada|GSK Investigational Site, Oshawa, Ontario, Canada|GSK Investigational Site, Sudbury, Ontario, Canada|GSK Investigational Site, Bonaventure, Quebec, Canada|GSK Investigational Site, Chandler, Quebec, Canada|GSK Investigational Site, Levis, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Sherbrooke, Quebec, Canada|GSK Investigational Site, Quebec, Canada|GSK Investigational Site, Brno, Czechia|GSK Investigational Site, Brno, Czechia|GSK Investigational Site, Plzen, Czechia|GSK Investigational Site, Praha 10, Czechia|GSK Investigational Site, Helsinki, Finland|GSK Investigational Site, Bordeaux Cedex, France|GSK Investigational Site, Vandoeuvre-Les-Nancy, France|GSK Investigational Site, Villejuif Cedex, France|GSK Investigational Site, Goettingen, Niedersachsen, Germany|GSK Investigational Site, Goslar, Niedersachsen, Germany|GSK Investigational Site, Kwun Tong, Hong Kong|GSK Investigational Site, Pokfulam, Hong Kong|GSK Investigational Site, Shatin, Hong Kong|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Miskolc, Hungary|GSK Investigational Site, Zalaegerszeg-Pozva, Hungary|GSK Investigational Site, Bangalore, India|GSK Investigational Site, Caserta, Campania, Italy|GSK Investigational Site, Napoli, Campania, Italy|GSK Investigational Site, Forlì, Emilia-Romagna, Italy|GSK Investigational Site, Rimini, Emilia-Romagna, Italy|GSK Investigational Site, Genova, Liguria, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Pavia, Lombardia, Italy|GSK Investigational Site, Busca (CN), Piemonte, Italy|GSK Investigational Site, Novara, Piemonte, Italy|GSK Investigational Site, Catania, Sicilia, Italy|GSK Investigational Site, Firenze, Toscana, Italy|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Leeuwarden, Netherlands|GSK Investigational Site, Dunedin, New Zealand|GSK Investigational Site, Hastings, New Zealand|GSK Investigational Site, Wellington, New Zealand|GSK Investigational Site, Lahore, Pakistan|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Manila, Philippines|GSK Investigational Site, Bialystok, Poland|GSK Investigational Site, Olsztyn, Poland|GSK Investigational Site, Otwock, Poland|GSK Investigational Site, Poznan, Poland|GSK Investigational Site, Lisboa, Portugal|GSK Investigational Site, Lisboa, Portugal|GSK Investigational Site, Lisboa, Portugal|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, St'Petersburg, Russian Federation|GSK Investigational Site, Durban, KwaZulu- Natal, South Africa|GSK Investigational Site, Groenkloof, Pretoria, South Africa|GSK Investigational Site, Houghton, Johannesburg, South Africa|GSK Investigational Site, Kenilworth, Cape Town, South Africa|GSK Investigational Site, Alcorcon, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Cordoba, Spain|GSK Investigational Site, Granada, Spain|GSK Investigational Site, Jaén, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Sabadell / Barcelona, Spain|GSK Investigational Site, Serra / Valencia, Spain|GSK Investigational Site, Sevilla, Spain|GSK Investigational Site, Soria, Spain|GSK Investigational Site, Valencia, Spain|GSK Investigational Site, Taipei, Taiwan|GSK Investigational Site, Chiang Mai, Thailand|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Newcastle-upon-Tyne, United Kingdom|GSK Investigational Site, Nottingham, United Kingdom|GSK Investigational Site, Sheffield, United Kingdom|GSK Investigational Site, Surrey, United Kingdom",,https://ClinicalTrials.gov/show/NCT00101998
975,NCT03234439,Digital Tools for Coping With Chronic Pain,,Recruiting,No Results Available,Chronic Pain|Depression|Anxiety|Opioid Use,Behavioral: myStrength,Change in baseline thoughts and feelings about chronic pain as measured by Pain Catastrophizing Scale at 6 months|Change in baseline PHQ9 at 6 months|Change in baseline Current Opioid Misuse Measure at 6 months|Change in baseline confidence to live with chronic pain as measured by Pain Self-Efficacy Scale at 6 months|Change in baseline and GAD7 at 6 months,"MyStrength, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care,6/13/17,2017-12-08,2019-03-31,2019-06-30,2017-07-31,null,2018-03-23,"Craigslist, Los Angeles, California, United States|Craigslist, San Francisco, California, United States|Craigslist, Denver, Colorado, United States|Craigslist, Washington, District of Columbia, United States|Craigslist, Miami, Florida, United States|Craigslist, Atlanta, Georgia, United States|Craigslist, Boston, Massachusetts, United States|Craigslist, Minneapolis, Minnesota, United States|Craigslist, New York, New York, United States|Craigslist, Philadelphia, Pennsylvania, United States|Craigslist, Houston, Texas, United States|Craigslist, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT03234439
976,NCT01447888,Perioperative Pain Management In Spine Surgery Patients: Part I,,Unknown status,No Results Available,Pain,Drug: 150% Oral Morphine Equivalent (OME)|Other: Clinical Judgment,Immediate postoperative pain control|Pain management improvement at 24 hours after the recovery period,Abbott Northwestern Hospital|Allina Hospitals and Clinics,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,3436-3,2011-09-01,2012-04-01,2012-05-01,2011-10-06,null,2011-10-27,"Abbott Northwestern Hospital, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT01447888
977,NCT01928303,Predicting Oxycodone Dose From Oral Fluid Drug Levels,AFTSLabs,Completed,No Results Available,Chronic Pain,,original dose of drug consumed (mg) as predicted by the drug concentration in the oral fluid (ng/mL),Weill Medical College of Cornell University,All,"18 Years to 72 Years   (Adult, Older Adult)",,55,Other,Observational,Observational Model: Case Control|Time Perspective: Prospective,1212013319,2013-03-01,2014-08-01,2014-08-01,2013-08-23,null,2014-09-15,"Weill Cornell Medical College Pain Medicine Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01928303
978,NCT02178189,RCT of High- vs. Standard-Calorie Formula for Methadone-Exposed Infants,,Completed,No Results Available,Neonatal Abstinence Syndrome,Other: High Calorie Infant formula|Other: Standard Calorie Infant Formula,Weight Patterns (gain and loss)|Neonatal abstinence syndrome (NAS) severity measures,University of Pittsburgh|National Institute on Drug Abuse (NIDA),All,up to 3 Days   (Child),Phase 2,85,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",PRO09120457|R21DA029257,2010-04-01,2013-04-01,2013-12-01,2014-06-30,null,2014-06-30,"Magee-Womens Hospital of UPMC, PIttsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02178189
979,NCT01337739,Use of Dexmedetomidine for Deep Sedation in Patients Undergoing Outpatient Hysteroscopic Surgery,,Terminated,Has Results,Pain,Drug: Placebo Comparator|Drug: Active Comparator,The Primary Outcome Will be the Difference in Intraoperative Opioid (Fentanyl) Administration Between Patients Receiving Dexmedetomidine and Those Receiving Propofol.|Time to Discharge,Northwestern University,Female,18 Years to 64 Years   (Adult),Not Applicable,8,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",STU00027663,2010-10-01,2012-04-01,2012-04-01,2011-04-19,2013-07-12,2013-07-12,"Northwestern Memorial Hospital, Chicago, Illinois, United States|Prentice Womens Hospital, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT01337739
980,NCT00115180,Racial and Ethnic Disparities in Acute Pain Control,,Completed,No Results Available,Fracture|Pain,Other: No intervention,Receipt of any analgesics|Receipt of opioid analgesics|Time to first treatment with analgesic|Receipt of parenteral analgesics|Initial dose of opioid analgesic mg/kg,Agency for Healthcare Research and Quality (AHRQ),All,18 Years to 55 Years   (Adult),,285,U.S. Fed,Observational,Observational Model: Cohort|Time Perspective: Prospective,R01HS013924,2003-09-01,2006-11-01,2006-11-01,2005-06-22,null,2016-01-07,"Jacobi Medical Center Emergency Department, Bronx, New York, United States|Montefiore Medical Center Emergency Department, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT00115180
981,NCT01327677,Safety Study of Analgesia After Craniotomy Surgery With End Tidal (ET) Carbon Dioxide (CO2) Monitoring,,Completed,Has Results,Pain,Drug: Fentanyl,Respiratory Depression|Hypoxia,Johns Hopkins University,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,137,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NA_00029336,2011-05-01,2014-05-01,2014-05-01,2011-04-01,2017-05-31,2017-05-31,"The Johns Hopkins Hospital, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01327677
982,NCT00521248,Buprenorphine for the Treatment of Neonatal Abstinence Syndrome,,Completed,No Results Available,Neonatal Abstinence Syndrome,Drug: buprenorphine|Drug: Oral morphine solution,Sublingual Buprenorphine safety and tolerability in the neonate|Buprenorphine Pharmacokinetics|Efficacy: Length of treatment|Efficacy: Length of hospitalization,Thomas Jefferson University|National Institute on Drug Abuse (NIDA),All,"Child, Adult, Older Adult",Phase 1,60,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R21DA018207-01|DPMC,2004-04-01,2010-01-01,2010-01-01,2007-08-27,null,2017-01-12,"Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00521248
983,NCT02069184,IV Acetaminophen for Acute Post Operative Pain in C-Section Patients,,Unknown status,No Results Available,Post-operative Pain,Drug: IV Acetaminophen|Other: Saline as placebo,"Opioid requirements in cesarean section (c-section) patient population|Visual Analog Score (VAS) pain score|Sedation level|Adverse events (nausea, vomiting, pruritus and breathing difficulties) after the surgery|Number of patient-controlled analgesia (PCA) attempts|Re-hospitalization|Pain medication usage",Montefiore Medical Center,Female,"18 Years and older   (Adult, Older Adult)",Phase 4,66,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",13-07-144,2013-11-01,2014-03-01,2014-03-01,2014-02-24,null,2014-02-24,"Montefiore Medical Center- Weiler, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT02069184
984,NCT00235729,Lofexidine for Inpatient Opiate Detox,,Completed,No Results Available,Opiate Addiction,Drug: Lofexidine|Drug: Placebo,SOWS-Gossop score on Day 3 during the treatment phase & time-to-dropout for the subjects in the two treatment groups. during the treatment phase.,US Department of Veterans Affairs|National Institute on Drug Abuse (NIDA)|US WorldMeds LLC|VA Office of Research and Development,All,"18 Years and older   (Adult, Older Adult)",Phase 3,264,U.S. Fed|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",1024|USWM-001,2006-06-01,2007-10-01,2007-10-01,2005-10-10,null,2009-03-20,"CNS, Cerritos, Cerritos, California, United States|CNS Psychiatric Institute of Washington, Washington, District of Columbia, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Alexian Center for Psychiatric Research, Hoffman Estates, Illinois, United States|University of Kentucky, Lexington, Kentucky, United States|VA Maryland Health Care System, Baltimore, Baltimore, Maryland, United States|Wayne State University School of Medicine, Detroit, Michigan, United States|Richmond Medical Center, Staten Island, New York, United States|VA Medical Center, Philadelphia, Philadelphia, Pennsylvania, United States|VA Medical Center, Providence, Providence, Rhode Island, United States|Psychiatric Hospital at Vanderbilt, Nashville, Tennessee, United States|Research Across America, Dallas, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|VA Salt Lake City Health Care System, Salt Lake City, Salt Lake City, Utah, United States|VA Puget Sound Health Care System, Seattle, Seattle, Washington, United States|Aurora Psychiatric Hospital, Wauwatosa, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00235729
985,NCT00531349,Regional Anesthesia and Endometrial Cancer Recurrence,ECA/R,Withdrawn,No Results Available,Cancer,Procedure: propofol general anesthesia|Drug: Sevoflurane,Time to metastatic spread or local cancer recurrence|Any-cause mortality,The Cleveland Clinic,Female,"18 Years to 85 Years   (Adult, Older Adult)",Phase 3,0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",07-532,2007-11-01,2007-11-01,2007-11-01,2007-09-18,null,2016-05-09,"Cleveland Clinic, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00531349
986,NCT01016808,Comparison of the Efficacy and Safety of Q8003 Versus Its Individual Components in Bunionectomy Patients,,Completed,No Results Available,Moderate to Severe Postoperative Pain,Drug: Q8003|Drug: Morphine sulfate|Drug: Oxycodone HCl,"Difference in pain intensity scores from baseline|Safety: adverse events, moderate and severe reports of opioid-related adverse events",QRxPharma Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 3,522,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Q8003-008,2009-12-01,2010-03-01,2010-03-01,2009-11-20,null,2012-05-17,"Investigator Site, Anaheim, California, United States|Investigator Site, Owings Mills, Maryland, United States|Investigator Site, Pasadena, Maryland, United States|Investigator Site, San Antonio, Texas, United States|Investigator Site, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT01016808
987,NCT02063451,Neurohormonal & Behavioral Correlates of Obesity and Weight Loss,,Enrolling by invitation,No Results Available,Obesity,Dietary Supplement: Very Low Calorie Diet (VLCD),Change in [11C]carfentanil binding in brain in response to feeding prior to weight loss|Change in [11C]carfentanil binding in brain in response to feeding post weight loss|Change in Hunger scores on a visual analog scale in response to feeding at pre weight-loss|Change in Hunger scores on a visual analog scale in response to feeding post weight-loss,University of Michigan|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|The Brain Research Foundation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,IWMCNI_01|5K01DK092322,2011-02-01,2018-08-01,2019-08-01,2014-02-14,null,2017-09-19,"University of Michigan Medical School, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT02063451
988,NCT01550341,"HIV, Buprenorphine, and the Criminal Justice System",STRIDE,Unknown status,No Results Available,Human Immunodeficiency Virus|Acquired Immunodeficiency Syndrome|Opiate Addiction|Drug Dependence,Drug: Buprenorphine/naloxone,HIV-1 RNA levels|Improved opioid treatment outcomes|Improved criminal justice outcomes,Yale University|George Mason University|Howard University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,152,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1011007631|R01DA030768,2012-04-01,2015-11-01,2017-06-01,2012-03-12,null,2016-08-11,"Howard University, Washington, District of Columbia, United States",,https://ClinicalTrials.gov/show/NCT01550341
989,NCT01457014,Sleep Disordered Breathing and Chronic Pain,,Completed,Has Results,Sleep Apnea Syndromes,Device: servo ventilation auto|Device: Continuous positive airway pressure|Device: servo ventilation manual,Number of Sleep Related Events Per Hour|Percent Oxygen Saturation|Number of Arterial Oxygen Saturation Per Hour,Philips Respironics,All,"21 Years to 70 Years   (Adult, Older Adult)",Not Applicable,88,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,SDBPM-2011-01,2011-09-01,2013-04-01,2013-09-01,2011-10-21,2016-02-19,2016-02-19,"Sleep D/O Center of Alabama, Birmingham, Alabama, United States|Arkansas Center for Sleep Medicine, Little Rock, Arkansas, United States|NeuroTrials Research Inc., Atlanta, Georgia, United States|Clayton Sleep Institute, St. Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT01457014
990,NCT02997085,Virtual Reality for Pain Management Study,,Recruiting,No Results Available,"Pain, Acute",Device: Live-Action 360° Video Virtual Reality|Device: CGI 360° Video Virtual Reality,Post-Treatment Pain Questionnaire|Follow-Up Pain Questionnaire|Presence Inventory|Absorption Survey|Transportation Survey|VR Mood Survey|Attitudes Toward the Experience Survey|Patient Satisfaction Survey|Present Mood Questionnaire,University of Texas at Austin|Seton Healthcare Family,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2016-09-0140,2017-01-01,2019-09-01,2019-10-01,2016-12-19,null,2017-10-26,"University of Texas at Austin, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT02997085
991,NCT03419858,The Role of Opioidergic Systems in Breathing Based Analgesia,,Completed,No Results Available,Pain,Behavioral: Mindfulness Meditation|Behavioral: Placebo Meditation|Behavioral: Slow-Breathing|Drug: Naloxone|Other: Saline,Change in Visual Analog Scale Pain intensity and Unpleasantness ratings as a function of each respective cognitive manipulations and activation in response to naloxone and/or saline.|Respiration Rate Measures|State Anxiety Inventory|Pain Catastrophizing Scale (PCS)|Cohen Perceived Stress Scale (CPS)|Treatment Effectiveness Scale|Attitude Toward Treatment Scale (ATTS)|Center for Epidemiological Studies Depression Scale (CES-D)|Stress-Level Visual Analogue Scale|Naloxone Symptom Assessments,Wake Forest University Health Sciences,All,18 Years to 55 Years   (Adult),Early Phase 1,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",IRB00040519,2017-03-13,2017-06-27,2017-06-27,2018-02-02,null,2018-02-12,"Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT03419858/SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03419858
992,NCT02929602,Analgesic Use and Effectiveness for Dental Procedures,,Completed,No Results Available,Pain,,Dentist questionnaire|Dentist questionnaire - anticipated pain by patients using VAS-5 pain scale|Patient questionnaire - OHIP-14 patient reported outcomes quality of life survey (questionnaire).,Pearl Network|National Institute of Dental and Craniofacial Research (NIDCR),All,"Child, Adult, Older Adult",,2773,Other|NIH,Observational,Observational Model: Case-Only|Time Perspective: Prospective,PRL0706|U01DE016755,2007-06-01,2011-11-01,2014-06-01,2016-10-11,null,2016-10-11,"PEARL Network Sites, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02929602
993,NCT01901718,"An Observational, Non-Interventional Trial to Assess Patient Satisfaction and Safety of Subsys™ Spray.",,Terminated,No Results Available,Breakthrough Pain,,Patient Global Impression of Change|Percent of Patients Satisfied with Treatment|Study Medication Ease of Use|Quality of Life|Assessment of Sleep|Medication Dosing|Weight|Blood Glucose,International Clinical Research Institute,All,"18 Years and older   (Adult, Older Adult)",,4,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,ICRI-Subsys-001,2013-04-01,2013-12-01,2014-01-01,2013-07-17,null,2014-09-04,"International Clinical Research Institute, Overland Park, Kansas, United States",,https://ClinicalTrials.gov/show/NCT01901718
994,NCT00249496,Employment-based Reinforcement to Motivate Drug Abstinence in the Treatment of Drug Addiction. - 1,,Completed,Has Results,Alcohol Use|Drug Use|Risk Behavior|Sexual Behavior,Behavioral: Contingency management|Behavioral: Employment Only,"Percentage of Monthly Urine Samples That Are Negative for Cocaine|Percentage of Monday, Wednesday and Friday Urine Samples That Are Negative for Cocaine|Percentage of 30-day Assessment Urine Samples Negative for Opiates|Percentage of Monday, Wednesday and Friday Urine Samples That Are Negative for Opiates|HIV Risk Behaviors",Johns Hopkins University|National Institute on Drug Abuse (NIDA),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,51,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,WIRB 2093|R01DA013107,2003-10-01,2007-08-01,2007-08-01,2005-11-07,2016-12-16,2017-09-18,"The Center for Learning and Health, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00249496
995,NCT03553498,IV Acetaminophen as Adjuvant Analgesic to Hydromorphone - Emergency Department Patients,,Not yet recruiting,No Results Available,Acute Pain,Drug: Acetaminophen|Drug: Placebo|Drug: IV Hydromorphone,"Change in Numerical Rating Scale of pain (NRS) baseline to 60 minutes post-baseline|Proportion of patients who choose to forego additional pain medication at 60 minutes post-baseline|Receipt of additional pain medication before 60 minutes post-baseline (""rescue"" medication)|Receipt of additional pain medication between 60 and 120 minutes post-baseline|Incidence of side effects|Incidence of adverse events","Albert Einstein College of Medicine, Inc.",All,21 Years to 64 Years   (Adult),Phase 3,162,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2018_8886,2018-07-01,2019-07-01,2019-07-01,2018-06-12,null,2018-06-12,"Montefiore Medical Center, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT03553498
996,NCT01888146,Pain Program for Active Coping & Training,PPACT-UH2,Completed,No Results Available,Chronic Non-malignant Pain,Behavioral: Interdisciplinary pain program,Brief Pain Inventory|Health care utilization and cost,Kaiser Permanente|Oregon Health and Science University|Duke University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,1UH2AT007788-01,2013-05-01,2014-06-01,2014-06-01,2013-06-27,null,2015-12-23,"Kaiser Permanente Center for Health Research, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT01888146
997,NCT00442546,Efficacy And Safety Of Pregabalin For Pain Following Total Knee Replacement,,Completed,Has Results,Osteoarthritis|Postoperative Pain,Drug: pregabalin|Drug: Placebo,"Subject Reported Worst Pain Score in Daily Diaries Using the Worst Pain Item of the Modified Brief Pain Inventory - Short Form (m-BPI-sf)|Cumulative Total Amount of Opioids Used During the Entire Hospital Stay|Opioids Used Post Discharge|Analgesics Used During the Hospital Stay (Acetylsalicylic Acid, Ketorolac, and Paracetamol)|Analgesics Used Post Discharge (Acetylsalicylic Acid [Week 2] and Paracetamol [Weeks 2, 4, and 6]|Analgesics Used Post Discharge (Ibuprofen) for the Pregabalin 150 mg and Placebo Treatment Groups|Analgesics Used Post Discharge (Ibuprofen) for the Pregabalin 300 mg Treatment Group|Analgesics Used Post Discharge (Acetylsalicylic Acid) for the Pregabalin 150 mg and Placebo Treatment Groups at Week 4|Analgesics Used Post Discharge (Acetylsalicylic Acid) for the Pregabalin 300 mg Treatment Group at Week 4|Analgesics Used Post Discharge (Acetylsalicylic Acid) for the Pregabalin 150 mg and Placebo Treatment Groups at Week 6/ET|Analgesics Used Post Discharge (Acetylsalicylic Acid) for the Pregabalin 300 mg and Placebo Treatment Groups at Week 6/ET|The Effect of Pregabalin Compared to Placebo on the Occurrence of Opioid-Related Symptoms as Assessed Using the Opioid-Related Symptom Distress Scale (OR-SDS) - Frequency Composite Score|The Effect of Pregabalin Compared to Placebo on the Occurrence of Opioid-Related Symptoms as Assessed Using the OR-SDS - Severity Composite Score|The Effect of Pregabalin Compared to Placebo on the Occurrence of Opioid-Related Symptoms as Assessed Using the OR-SDS - Degree of Bother Composite Score|The Effect of Pregabalin Compared to Placebo on the Occurrence of Opioid-Related Symptoms as Assessed Using the OR-SDS - Overall Composite Score|Total Clinically Meaningful Event (CME) Score|Pain Interference Index Score as Measured by the m-BPI-sf|Pain Interference With Relations With People as Measured by the m-BPI-sf|Pain Interference With Enjoyment of Life as Measured by the m-BPI-sf|Pain Interference With General Activity as Measured by the m-BPI-sf|Pain Interference With Mood as Measured by the m-BPI-sf|Pain Interference With Walking Ability as Measured by the m-BPI-sf|Pain Interference With Normal Work as Measured by the m-BPI-sf|Pain Interference With Sleep as Measured by the m-BPI-sf|Daily and Weekly Worst Pain During the Hospital Stay and Post Discharge Assessed by the Pain Numerical Rating Scale (NRS)|Daily and Weekly Average Pain During the Hospital Stay and Post Discharge Assessed by the Pain NRS|Current Pain During the Hospital Stay Assessed by the Pain NRS|Pain-Related Sleep Interference Post Surgery|Change From Baseline in Visual Analogue Scale for Anxiety (VAS-Anxiety) Score Prior to Surgery|Timed Up-and-Go (TUG)|Range of Motion (ROM) Assessment of the Active Flexion of the Surgical Knee|ROM Assessment of the Passive Flexion of the Surgical Knee|Time From End of Surgery to Meet Hospital Discharge Criteria|Time From End of Surgery to Actual Discharge|Satisfaction With Current Pain Medication Measured by the Pain Treatment Satisfaction Scale (PTSS)|Satisfaction With Medication Characteristics Measured by the PTSS|Satisfaction With Medication Efficacy Measured by the PTSS|Overall Satisfaction Measured by the PTSS|Overall Pain Relief Measured by the PTSS|Number of Subjects With Global Evaluation of Study Medication Scores|Number of Subjects With Persistent Pain Based on 11-Point Verbal Rating Scale (VRS)|Neuropathic Pain Symptom Inventory (NPSI)",Pfizer,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,307,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",A0081133,2007-05-01,2008-12-01,2008-12-01,2007-03-02,2010-08-18,2011-02-18,"Pfizer Investigational Site, Northport, Alabama, United States|Pfizer Investigational Site, Tuscaloosa, Alabama, United States|Pfizer Investigational Site, Tuscaloosa, Alabama, United States|Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Little Rock, Arkansas, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, Vero Beach, Florida, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, Galesburg, Illinois, United States|Pfizer Investigational Site, Lafayette, Louisiana, United States|Pfizer Investigational Site, New Iberia, Louisiana, United States|Pfizer Investigational Site, Baltimore, Maryland, United States|Pfizer Investigational Site, Egg Harbor Township, New Jersey, United States|Pfizer Investigational Site, Pomona, New Jersey, United States|Pfizer Investigational Site, Voorhees, New Jersey, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, Charlotte, North Carolina, United States|Pfizer Investigational Site, Columbus, Ohio, United States|Pfizer Investigational Site, Columbus, Ohio, United States|Pfizer Investigational Site, Upper Arlington, Ohio, United States|Pfizer Investigational Site, Allentown, Pennsylvania, United States|Pfizer Investigational Site, King of Prussia, Pennsylvania, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Pittsburgh, Pennsylvania, United States|Pfizer Investigational Site, Pittsburgh, Pennsylvania, United States|Pfizer Investigational Site, Pittsburg, Pennsylvania, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00442546
998,NCT00679458,"Randomized, Double-Blind Cross-Over Trial Of Buprenorphine and Low-Dose Naloxone Versus Buprenorphine",,Completed,No Results Available,Pain,Drug: buprenorphine and low-dose naloxone|Drug: buprenorphine alone,Pain intensity|Self-reported side effects/adverse events,"University of California, Los Angeles|Indivior Inc.",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,12,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-06-005,2008-09-01,2009-11-01,2009-11-01,2008-05-16,null,2010-01-07,"UCLA Integrated Substance Abuse Programs Outpatient Research Center, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT00679458
999,NCT03577730,Caffeine and Neurologic Recovery Following Surgery and General Anesthesia,,Recruiting,No Results Available,"Pain, Postoperative",Drug: Caffeine Citrate|Drug: Dextrose Water,"Cumulative opioid consumption: Postoperative opioid consumption, oral morphine equivalents (mg)|Acute pain (patient-reported) as assessed by Visual Analogue Scale|Acute pain (observer-reported) as assessed by Behavioral Pain Scale|Time until anesthetic emergence|Depressive symptoms as assessed by Hospitalized Anxiety and Depression Scale (HADS-D)|Anxiety symptoms as assessed by Hospitalized Anxiety and Depression Scale (HADS-A)|Cognitive Function as assessed by Trail Making Test|Positive Affect as assessed by PANAS (Positive and Negative Affect Schedule)|Negative Affect as assessed by PANAS (Positive and Negative Affect Schedule)",University of Michigan,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HUM00135919,2018-07-10,2020-06-11,2020-07-11,2018-07-04,null,2018-07-11,"Michigan Medicine, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT03577730
1000,NCT02313675,Pain Outcomes of Intra-operative IV Tylenol and/or IV Toradol for Carpal Tunnel and Distal Radius Fracture Surgeries,,Completed,Has Results,Postoperative Pain|Carpal Tunnel Release|Distal Radius Fracture,Drug: Acetaminophen|Drug: Ketorolac Tromethamine|Drug: Saline,Postoperative Pain (Pain Scores From 0-10 Scale)|Opioid Consumption (Number of Pills Taken),John Fowler|University of Pittsburgh,All,"18 Years and older   (Adult, Older Adult)",Phase 4,44,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PRO14110464,2015-05-01,2017-05-01,2017-05-01,2014-12-10,2018-05-04,2018-05-04,"Kaufmann Building, Pittsburgh, Pennsylvania, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT02313675/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT02313675/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02313675
1001,NCT03506685,Effectiveness of Dry Needling and STM on Pain Management for ACLR,,Not yet recruiting,No Results Available,Pain and Anterior Cruciate Ligament Reconstruction,Other: Dry needling and STM,Numerical pain rating scale|Lower extremity functional scale|Global rate of change|knee range of motion,Keller Army Community Hospital,All,18 Years to 40 Years   (Adult),Not Applicable,40,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,18KACH002,2018-06-01,2019-06-01,2019-12-01,2018-04-24,null,2018-04-24,"Keller Army Community Hospital, West Point, New York, United States",,https://ClinicalTrials.gov/show/NCT03506685
1002,NCT00325858,"A Study Comparing the Effectiveness and Safety of Varying Dose Strengths (100, 200, 300 and 400 mg) of Extended-release Tramadol HCl With Placebo for the Treatment of Osteoarthritis(OA) of the Knee and/or Hip",,Completed,No Results Available,Chronic Pain,Drug: Tramadol HCl ER,"The primary outcome is the change from baseline to Week 12 in the WOMAC OA Index pain and physical function subscale scores and the patient global assessment of disease activity.|The secondary outcomes include: the change from baseline in the daily arthritis pain intensity scores from patient diaries; WOMAC OA stiffness subscale score, OA pain intensity VAS for index and non-index joints, and Chronic Pain Sleep Inventory scale.","Valeant Pharmaceuticals International, Inc.",All,"18 Years to 74 Years   (Adult, Older Adult)",Phase 3,1000,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,B02.CT3.023.TRA P03,2002-01-01,null,2003-12-01,2006-05-15,null,2012-08-27,"Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00325858
1003,NCT01859715,Emergency Department (ED) Drug Interaction in Emergency Department Patients,,Completed,Has Results,Drug Interactions,Drug: Oxycodone|Drug: Hydrocodone|Drug: Ondansetron,Difference in Clinically Significant Visual Analogue Scale for Pain and Nausea Change Between CYP2D6 Users and Non-users|Adverse Drug Events,"University of Colorado, Denver",All,"18 Years to 95 Years   (Adult, Older Adult)",Not Applicable,502,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11-1692,2012-06-01,2013-01-01,2013-02-01,2013-05-22,2016-05-05,2016-05-05,"University of Colorado, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT01859715
1004,NCT00510016,Clonidine as Adjunct Therapy for the Treatment of Neonatal Abstinence Syndrome,NAS,Completed,No Results Available,Neonatal Abstinence Syndrome,Drug: Clonidine HCL,Length of treatment for neonatal abstinence syndrome,National Institute on Drug Abuse (NIDA)|Johns Hopkins University,All,up to 14 Days   (Child),Phase 2,80,NIH|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,1R21DA016288-01A1,2002-07-01,null,2005-12-01,2007-08-01,null,2017-01-11,"Johns Hopkins Medical Institutions, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00510016
1005,NCT02108509,Bone Disease in Chronic Pancreatitis: A Complex Phenomenon,,"Active, not recruiting",No Results Available,Chronic Pancreatitis|Osteopenia|Osteoporosis,,To define the prevalence of low bone density (osteopenia or osteoporosis) in patients with chronic pancreatitis|Prevalence of hypogonadism in patients with chronic pancreatitis.|Hypogonadism and/or opioid medication use are independent risk factors for low bone density in patients with chronic pancreatitis.,University of Nebraska,All,"19 Years to 75 Years   (Adult, Older Adult)",,70,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,113-14-FB,2014-05-01,2017-12-01,2018-12-01,2014-04-09,null,2018-01-31,"University of Nebraska Medical Center, Omaha, Nebraska, United States",,https://ClinicalTrials.gov/show/NCT02108509
1006,NCT01366573,GSK1521498 Alcohol Interaction Study,,Completed,No Results Available,Alcoholism,Drug: GSK1521498|Other: Placebo,"Pharmacokinetic interaction|Safety: adverse events, vital signs, ECGs, physician/nurse observations, safety lab tests, mood assessments|Neurological assessments including Purdue Pegboard test",GlaxoSmithKline|University of Cambridge,All,21 Years to 55 Years   (Adult),Phase 1,1,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",115256,2011-05-13,2011-09-16,2011-09-16,2011-06-06,null,2017-07-21,"GSK Investigational Site, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT01366573
1007,NCT00312572,Safety and Efficacy of Dose Conversion From Vicodin® to Buprenorphine Transdermal System (Butrans™) in Subjects With OA Pain,,Completed,Has Results,Osteoarthritis,Drug: Buprenorphine transdermal patch,The Percentage of Subjects Who Completed the 14-day Double-blind Phase.,Purdue Pharma LP,All,"40 Years to 85 Years   (Adult, Older Adult)",Phase 3,204,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BUP3018,2003-06-01,2004-07-01,2004-07-01,2006-04-10,2010-09-23,2012-09-03,"Southern Drug Research, Birmingham, Alabama, United States|Redpoint Research, Phoenix, Arizona, United States|Advanced Clinical Therapeutics, Tucson, Arizona, United States|Tucson Orthopedic Institute, Tucson, Arizona, United States|Hot Springs Mercy Pain Clinic, Hot Springs, Arkansas, United States|Private Practice, Pine Bluff, Arkansas, United States|Advanced Clinical Research Institute, Anaheim, California, United States|Lovelace Scientific Resources, Beverly Hills, California, United States|Southbay Pharma Research, Buena Park, California, United States|Community Medical Providers, Clovis, California, United States|Kaiser Permanente, Escondido, California, United States|Univ. of Southern California, Santa Monica, California, United States|Arthritis Center of CT, Waterbury, Connecticut, United States|Miami Beach Anesthesiology Associates, Miami Beach, Florida, United States|Lifespan Research Foundation, Inc., Miami, Florida, United States|Neuro Science and Spine Assoc., Naples, Florida, United States|West Broward Rheumatology Association, Inc., Tamarac, Florida, United States|Intermountain Orthopaedics, Boise, Idaho, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Bluegrass Orthopaedics, Lexington, Kentucky, United States|Commonwealth Biomedical Research, LLC, Madisonville, Kentucky, United States|Dolby Providers, Inc., New Orleans, Louisiana, United States|Clinical Pharmacology Study Group, Worcester, Massachusetts, United States|Westside Family Medical Center, Kalamazoo, Michigan, United States|PCM Medical Services, Lansing, Michigan, United States|HealthCare Research LLC, St. Louis, Missouri, United States|Northeast Pain Research Center, Barrington, New Hampshire, United States|The Arthritis Clinic and Carolina Bone and Joint, Charlotte, North Carolina, United States|Dayton Primary and Urgent Care, Dayton, Ohio, United States|The Medford Medical Clinic, Medford, Oregon, United States|The Arthritis and Osteoporosis Center, Orangeburg, South Carolina, United States|CEDRA Clinical Research,, Austin, Texas, United States|Renaissance Clinical Research & Hypertension Clinic, Dallas, Texas, United States|Spine Care Southwest., Houston, Texas, United States|KRK Medical Research, Richardson, Texas, United States|Monroe Medical Foundation, Monroe, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00312572
1008,NCT00312221,Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Osteoarthritis Pain,,Terminated,Has Results,Osteoarthritis,Drug: Buprenorphine|Drug: oxycodone immediate-release,"""Average Pain Over the Last 24 Hours"" Scores at Weeks 4, 8, and 12 of the Double-blind Phase.|The Mean Daily Number of Supplemental Analgesic Medication Tablets|The Physical Function Subscale of The Western Ontario and McMaster's Universities Osteoarthritis (WOMAC OA) Index at Weeks 4, 8, and 12 of the Double Blind Phase|The Sleep Disturbance Subscale in The Medical Outcomes (MOS)-Sleep Scale at Weeks 4, 8, and 12 of the Double-blind Phase",Purdue Pharma LP,All,"40 Years and older   (Adult, Older Adult)",Phase 3,418,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BUP3019,2004-04-01,2005-07-01,2005-08-01,2006-04-07,2010-09-15,2012-09-10,"Parkway Medical Center, Birmingham, Alabama, United States|International Clinical Research Network, Chula Vista, California, United States|Clinical Trials Research, Roseville, California, United States|Accelovance, San Diego, California, United States|Torrance Clinical Research, Torrance, California, United States|Southern Colorado Clinic, Pueblo, Colorado, United States|Drug Study Institute, Jupiter, Florida, United States|Innovative Research of West Florida, Inc., Largo, Florida, United States|International Medical Research, Ormond Beach, Florida, United States|Peninsula Research, Inc., Ormond Beach, Florida, United States|Palm Beach Research Center, West Palm Beach, Florida, United States|Georgia Medical Research Institute, Marietta, Georgia, United States|Non- Surgical Orthopedic & Spine Center, P.C., Marietta, Georgia, United States|The Arthritis Center, Springfield, Illinois, United States|Commonwealth Biomedical Research, LLC, Madisonville, Kentucky, United States|Miray Medical Center, Brockton, Massachusetts, United States|Professional Clinical Research Crystal Lake Health Center, Benzonia, Michigan, United States|Rheumatology PC, Kalamazoo, Michigan, United States|Pharm Quest, Greensboro, North Carolina, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Amarillo Center for Clinical Research, Amarillo, Texas, United States|Med Search Professional Group/Pharmaceutical C-Trials Inc., Hurst, Texas, United States|Texas Medical Research Associates, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00312221
1009,NCT00365898,Efficacy and Safety of Hydromorphone Hydrochloride Extended-Release Compared to Placebo in Subjects With Persistent Pain,,Terminated,No Results Available,Chronic Non-Malignant Pain,Drug: Hydromorphone Hydrochloride Extended-Release,Time to emergence of inadequate analgesia. Emergence of inadequate analgesia is defined as one or more of the following: a) the subject has a rating of poor or fair on the Patient Global Assessment of Pain Medicatio|Patient Global Assessment of Pain Medication|Pain Control Questionnaire,Purdue Pharma LP,All,"18 Years and older   (Adult, Older Adult)",Phase 3,380,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,HMP3011,2005-07-01,null,2005-07-01,2006-08-18,null,2006-08-18,"Arizona Research Center 2525 W. Greenway Rd. Suite 114, Phoenix, Arizona, United States|Clinical Research of West Florida, Inc. 2147 NE Coachman Road, Clearwater, Florida, United States|LCFP, Inc. 12631 World Plaza Lane Building 54, Ft. Myers, Florida, United States|Pharmaceutical Research Associates 1395 N. Courtenay Pkwy, Merritt Island, Florida, United States|Stedman Clinical Trials 3212 Cove Bend Drive, Tampa, Florida, United States|Palm Beach Research Center 1897 Palm Beach Lakes Blvd., West Palm Beach, Florida, United States|Gold Coast Research 2965 Surrey Lane, Weston, Florida, United States|PharmQuest 301 E Wendover Avenue Suite 411, Greensboro, North Carolina, United States|Hightop Medical Research Center 6103 Hamilton Anenue, Cincinnati, Ohio, United States|Research Institute of Greater Dayton 1010 Woodman Drive, Dayton, Ohio, United States|Pharmacotherapy Research Associates, Inc. 3620 Court Drive, Zanesville, Ohio, United States|Allegheny Pain Management-PC 1402 Ninth Ave, Altoona, Pennsylvania, United States|he Tipton Medical & Diagnostic Center #334 Route 220, Tipton, Pennsylvania, United States|Preferred Primary Care Physicians 202 Jacob Murphy Lane, Uniontown, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00365898
1010,NCT00249574,Bridging Active Heroin Users to Hepatitis C Treatment Using Buprenorphine - 1,,Completed,No Results Available,Hepatitis C|Heroin Dependence,Drug: Buprenorphine/naloxone|Drug: pegInterferon,Safety assessments|Effectiveness of medication|Compliance,National Institute on Drug Abuse (NIDA)|Organization to Achieve Solutions in Substance Abuse (OASIS),All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,10,NIH|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NIDA-15629-1|R01-15629-1,2003-06-01,2004-03-01,2006-06-01,2005-11-07,null,2017-01-16,"O.A.S.I.S., Oakland, California, United States",,https://ClinicalTrials.gov/show/NCT00249574
1011,NCT00359151,Celebrex Total Knee Arthroplasty Study,,Terminated,No Results Available,Osteoarthritis|Pain,Drug: Celecoxib|Drug: Placebo,To assess the effects of celecoxib on the cumulative amount of opioid administered to OA subjects undergoing unilateral total knee arthroplasty.|To assess the effects of celecoxib on pain and function during the peri-operative period and the post-operative rehabilitation phase.|To assess the safety and tolerability of celecoxib in this study population.,Pfizer,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,22,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",A3191225,2006-11-01,null,2007-07-01,2006-08-01,null,2008-05-30,"Pfizer Investigational Site, Aurora, Colorado, United States|Pfizer Investigational Site, Englewood, Colorado, United States|Pfizer Investigational Site, E, Colorado, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Bellaire, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00359151
1012,NCT01452529,Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back Pain,,Completed,Has Results,Chronic Low Back Pain,Drug: Hydrocodone bitartrate q24h film-coated tablets|Drug: Placebo to match hydrocodone bitartrate q24h tablets,"Mean Pain Intensity for ""Average Pain Over the Last 24 Hours"" Score|Medical Outcome Study Sleep Scale - Revised (MOS Sleep-R) - Sleep Disturbance Subscale|Patient Global Impression of Change (PGIC)|Responder Analysis for Subjects With a ≥ 30% Reduction in Pain Compared to Baseline|Responder Analysis for Subjects With a ≥ 50% Reduction in Pain Compared to Baseline",Purdue Pharma LP,All,"18 Years and older   (Adult, Older Adult)",Phase 3,905,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",HYD3002,2011-10-01,2013-09-01,2013-10-01,2011-10-17,2014-12-04,2018-06-28,"Alliance Clinical Research, Birmingham, Alabama, United States|Coastal Clinical Research, Inc., Mobile, Alabama, United States|Arizona Research Center, Phoenix, Arizona, United States|Redpoint Research, Phoenix, Arizona, United States|Genova Clinical Research, Tucson, Arizona, United States|Quality of Life Medical & Research Center, LLC, Tucson, Arizona, United States|Redpoint Research, Tucson, Arizona, United States|ACRI-Phase 1, LLC, Anaheim, California, United States|Orange County Research Institute, Anaheim, California, United States|United Clinical Research Center, Inc., Anaheim, California, United States|Research Center of Fresno, Inc., Fresno, California, United States|TriWest Research Associates, La Mesa, California, United States|Torrance Clinical Research Institute Inc., Lomita, California, United States|Skyline Research, LLC, Long Beach, California, United States|Center for Clinical Research, Inc., Richmond, California, United States|Northern California Research, Sacramento, California, United States|Encompass Clinical Research, Spring Valley, California, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|Orthopedic Research Institute, Boynton Beach, Florida, United States|Meridien Research, Bradenton, Florida, United States|Innovative Research of West Florida, Inc., Clearwater, Florida, United States|Avail Clinical Research, LLC, DeLand, Florida, United States|Florida Health Center, Fort Lauderdale, Florida, United States|Clinical Physiology Associates, Fort Myers, Florida, United States|AGA Clinical Trials, Hialeah, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Health Awareness, Inc., Jupiter, Florida, United States|Fidelity Clinical Research, Inc., Lauderhill, Florida, United States|Neuroscience Consultants LLC, Miami, Florida, United States|International Research Associates, LLC, Miami, Florida, United States|Journey Research, Inc, Oldsmar, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Peninsula Research Inc., Ormond Beach, Florida, United States|Advent Clinical Research Centers, Inc., Pinellas Park, Florida, United States|Gold Coast Research, LLC, Plantation, Florida, United States|Sarasota Research, LLC, Sarasota, Florida, United States|Clinical Research of West Florida, Inc., Tampa, Florida, United States|Southeast Regional Research Group, Columbus, Georgia, United States|Georgia Institute for Clinical Research, LLC, Marietta, Georgia, United States|Taylor Research, LLC, Marietta, Georgia, United States|Better Health Clinical Research, Inc., Newnan, Georgia, United States|Atlanta Knee and Shoulder Clinic, PC, Stockbridge, Georgia, United States|Illinois Center for Clinical Research, Chicago, Illinois, United States|Rehabilitation Associates of Indiana, Indianapolis, Indiana, United States|Northwest Indiana Center for Clinical Research, Valparaiso, Indiana, United States|Integrated Clinical Trial Services, Inc., West Des Moines, Iowa, United States|ICRI, Overland Park, Kansas, United States|Community Research, Crestview Hills, Kentucky, United States|Commonwealth Biomedical Research, LLC, Madisonville, Kentucky, United States|Louisiana Research Associates, Inc., New Orleans, Louisiana, United States|IRC Clinics, Inc., Towson, Maryland, United States|Beacon Clinical Research, LLC, Brockton, Massachusetts, United States|MedVadis Research Corporation, Watertown, Massachusetts, United States|QUEST Research Institute, Bingham Farms, Michigan, United States|Medical Research Associates, Inc., Traverse City, Michigan, United States|Healthcare Research Network, Hazelwood, Missouri, United States|Medex Healthcare Research, Inc., Saint Louis, Missouri, United States|Advance Clinical Research, Saint Louis, Missouri, United States|Mercy Health Research, Saint Louis, Missouri, United States|Sundance Clinical Research, LLC, Saint Louis, Missouri, United States|Quality Clinical Research, Omaha, Nebraska, United States|Advanced Biomedical Research of America, Las Vegas, Nevada, United States|Research Facility, Las Vegas, Nevada, United States|Comprehensive Clinical Research, Berlin, New Jersey, United States|CRI Worldwide LLC, Willingboro, New Jersey, United States|Albuquerque Clinical Trials, Inc., Albuquerque, New Mexico, United States|Lovelace Scientific Resources, Albuquerque, New Mexico, United States|Drug Trials America, Hartsdale, New York, United States|The Medical Research Network, LLC, New York, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Upstate Clinical Research Associates, Williamsville, New York, United States|PMG Research of Charlotte, LLC, Charlotte, North Carolina, United States|PMG Research of Wilmington LLC, Wilmington, North Carolina, United States|Clinical Trials of America, Inc., Winston-Salem, North Carolina, United States|The Center for Clinical Research, Winston-Salem, North Carolina, United States|Daystar Clinical Research, Inc., Akron, Ohio, United States|IVA Research, Cincinnati, Ohio, United States|Community Research, Cincinnati, Ohio, United States|Bone Joint and Spine Surgeons, Inc., Toledo, Ohio, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|Allegheny Pain Management, P.C., Altoona, Pennsylvania, United States|CRI Worldwide, LLC, Philadelphia, Pennsylvania, United States|Founders Research Corporation, Philadelphia, Pennsylvania, United States|Tipton Medical & Diagnostic Center, Tipton, Pennsylvania, United States|Hartwell Research Group, Anderson, South Carolina, United States|Radiant Research, Inc., Greer, South Carolina, United States|Health Concepts, Rapid City, South Dakota, United States|Comprehensive Pain Specialists, LLC, Hendersonville, Tennessee, United States|Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States|Heartland Medical, PC, New Tazewell, Tennessee, United States|HCCA Clinical Research Solutions, Smyrna, Tennessee, United States|FutureSearch Trials of Neurology, Austin, Texas, United States|KRK Medical Research, Dallas, Texas, United States|Heights Doctor's Clinic, Houston, Texas, United States|R/D Clinical Research, Inc., Lake Jackson, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|Aspen Clinical Research, Orem, Utah, United States|Advanced Clinical Research, West Jordan, Utah, United States|HypotheTest, LLC, Roanoke, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Washington Center for Pain Management, Edmonds, Washington, United States",,https://ClinicalTrials.gov/show/NCT01452529
1013,NCT02113592,Pain Program for Active Coping & Training,PPACT-UH3,Completed,No Results Available,Chronic Non-malignant Pain,Behavioral: Interdisciplinary pain program,Brief Pain Inventory|Health care utilization and cost,Kaiser Permanente|Oregon Health and Science University|Duke University|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS)|National Institute on Drug Abuse (NIDA)|National Center for Complementary and Integrative Health (NCCIH),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,851,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research,4UH3NS088731-02|UH2AT007788,2014-03-01,2018-02-01,2018-02-01,2014-04-14,null,2018-06-25,"Kaiser Permanente Center for Health Research, Atlanta, Georgia, United States|Kaiser Permanente Center for Health Research, Honolulu, Hawaii, United States|Kaiser Permanente Center for Health Research, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT02113592
1014,NCT02221674,Use of Tapentadol Oral Solution for Pain After Surgery in Children From Newborn to Less Than 2 Years Old,,Terminated,Has Results,Moderate to Severe Acute Postoperative Pain,Drug: Tapentadol,Pharmacokinetic Evaluation Based on Serum Concentrations of Tapentadol After a Single Dose of Tapentadol Oral Solution in Participants Aged 6 Months to Less Than 2 Years|Pharmacokinetic Evaluation Based on Serum Concentrations of Tapentadol After a Single Dose of Tapentadol Oral Solution in Participants Aged 1 Month to Less Than 6 Months|Pharmacokinetic Evaluation Based on Serum Concentrations of Tapentadol After a Single Dose of Tapentadol Oral Solution in Participants Aged From Birth to Less Than 1 Month|Pharmacokinetic Profile of Serum Concentrations of Tapentadol-O-glucuronide After a Single Dose of Tapentadol Oral Solution in Participants Aged 6 Months to Less Than 2 Years|Pharmacokinetic Profile of Serum Concentrations of Tapentadol-O-glucuronide After a Single Dose of Tapentadol Oral Solution in Participants Aged 1 Month to Less Than 6 Months|Pharmacokinetic Profile of Serum Concentrations of Tapentadol-O-glucuronide After a Single Dose of Tapentadol Oral Solution in Participants Aged From Birth to Less Than 1 Month,Grünenthal GmbH|Depomed,All,up to 23 Months   (Child),Phase 2,40,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KF5503-72|2014-000623-24|U1111-1153-1662|R331333PAI2007,2014-11-05,2016-10-14,2016-11-03,2014-08-20,2017-12-12,2018-01-29,"US001, Palo Alto, California, United States|US002, Louisville, Kentucky, United States|US006, Durham, North Carolina, United States|US004, Philadelphia, Pennsylvania, United States|PL004, Toruń, Poland|PL001, Łódź, Poland|GB001, Sheffield, United Kingdom",,https://ClinicalTrials.gov/show/NCT02221674
1015,NCT01707420,Preoperative Gabapentin for Post-tonsillectomy Pain in Children,,Completed,No Results Available,Post Operative Pain Management in Children With Tonsillectomy/Adenoidectomy,Drug: Gabapentin|Drug: liquid placebo,Total oral analgesia consumption|Self-report pain score,"University of Colorado, Denver",All,5 Years to 16 Years   (Child),Not Applicable,36,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",11-1687,2012-08-01,2015-12-01,2015-12-01,2012-10-16,null,2016-05-23,"Children's Hospital Colorado, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT01707420
1016,NCT01110759,Medical Review: Hand Surgery After Local Block Versus Non-block,,Completed,No Results Available,Carpal Tunnel Syndrome,,postoperative pain|Nausea|Vomiting,Cedars-Sinai Medical Center,All,"18 Years to 80 Years   (Adult, Older Adult)",,200,Other,Observational,Observational Model: Case Control|Time Perspective: Retrospective,Pro00019315,2009-08-01,2011-07-01,2011-07-01,2010-04-27,null,2013-11-01,"Cedars Sinai Medical Center, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT01110759
1017,NCT01074229,Transversus Abdominis Plane (TAP) Block Laparoscopic Hysterectomy,TAP HYS,Completed,Has Results,Postoperative Pain,Drug: Placebo|Drug: Drug .5% Ropivacaine|Drug: 20 cc of 0.25% ropivacaine,QoR40 on the Day After Surgery|24 Total Morphine Consumption,Northwestern University,Female,18 Years to 64 Years   (Adult),Not Applicable,75,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",STU00023440,2010-03-01,2010-10-01,2010-10-01,2010-02-24,2014-05-08,2014-05-08,"Northwestern Memorial Hospital, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT01074229
1018,NCT00684229,Regional Anesthesia in Colon Rectal Surgery,,Withdrawn,No Results Available,Colon Cancer,Procedure: Regional anesthesia and analgesia|Drug: general anesthesia followed by opioid analgesia,cancer recurrence|length of post operative hospitalization,The Cleveland Clinic,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",07-933,2007-12-01,2013-11-01,2013-11-01,2008-05-26,null,2016-09-15,"Cleveland Clinic, Cleveland, Ohio, United States|Hospital Italiano de Buenos Aires, Buenos Aires, Argentina|University of Dusseldorf, Dusseldorf, Germany",,https://ClinicalTrials.gov/show/NCT00684229
1019,NCT01267136,A Comparison of Postoperative Tramadol Versus Acetaminophen With Codeine in Children Undergoing Tonsillectomy,,Completed,Has Results,Tonsillitis|Pain,Drug: Codeine with acetaminophen|Drug: Tramadol suspension,Efficacy of Two Different Liquid Pain Medications: Tramadol vs. Codeine/Acetaminophen During the Post-tonsillectomy Recovery Period.|Number of Participants Reporting Side Effects During the Post-tonsillectomy Recovery Period.,Children's Hospitals and Clinics of Minnesota,All,4 Years to 15 Years   (Child),Phase 4,84,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1010-086,2011-01-01,2012-05-01,2012-05-01,2010-12-28,2014-04-17,2014-04-17,"Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT01267136
1020,NCT00009672,Pain Treatment for Sciatica,,Completed,No Results Available,Radiculopathy|Sciatica,Drug: Nortriptyline|Drug: Morphine,"Daily overall pain level, pain in the low back and pain in the lower extremities will be rated on a scale of 0 to 10.|End of each treatment period: Pain symptoms, Use of other meds,Use of other non-meds, questionnaires, Oswestry and Beck Depression, Disability,Patients' global satisfaction with the study medications during the period.|End of Study: Patient preference.",National Institute of Dental and Craniofacial Research (NIDCR)|National Institutes of Health Clinical Center (CC),All,"19 Years and older   (Adult, Older Adult)",Phase 2,80,NIH,Interventional,Primary Purpose: Treatment,010076|01-D-0076,2001-01-30,null,2006-12-12,2001-02-05,null,2017-07-02,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00009672
1021,NCT02915055,NSAID vs. Narcotics,,Completed,No Results Available,Multimodal Analgesia|Nonsteroidal Anti-inflammatory Drugs,Drug: Ibuprofen 600 mg|Drug: standard oxycodone/acetaminophen,Visual analogue scale (VAS) score|Pain Verbal Rating Scale,New York University School of Medicine,All,"18 Years and older   (Adult, Older Adult)",,77,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,16-01645,2016-09-01,2017-03-01,2017-03-01,2016-09-26,null,2017-05-08,"New York University School of Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02915055
1022,NCT00522626,Fetal Neurobehavior in Non-methadone Maintained Women in Substance Abuse Treatment,,Completed,Has Results,Pregnancy|Drug Abuse,Device: Maternal fetal monitoring,Fetal Heart Rate|Maternal Physiologic Parameters,Johns Hopkins University|National Institute on Drug Abuse (NIDA),Female,18 Years to 40 Years   (Adult),,19,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,1490|R01DA019934,2006-08-01,2010-02-01,2010-08-01,2007-08-30,2014-05-16,2016-03-01,"Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00522626
1023,NCT00380978,Neuraxial Versus Systemic Analgesia for Latent Phase Labor Effect on Rate of Operative Delivery,,Completed,Has Results,Labor Pain|Pregnancy,Procedure: combined spinal epidural analgesia|Procedure: late analgesia (systemic),Delivered by Cesarean Section|Instrumented Vaginal Delivery|Duration of Labor|Indication for Cesarean Delivery|Analgesia Efficacy|Nausea|Neonatal Outcome (APGAR Score < 7 at 5 Minutes)|Vomiting,Northwestern University|International Anesthesia Research Society (IARS),Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,1026,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0524-009,2001-10-01,2008-09-01,2008-09-01,2006-09-27,2011-12-08,2014-04-14,"Northwestern Memorial Hospital, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00380978
1024,NCT00200876,Effects of Anticipation of Pain Relief on Brain Mechanisms,,Completed,No Results Available,Pain,Procedure: Hypertonic saline|Procedure: Isotonic saline,Placebo-induced activation of brain opioid neurotransmission,University of Michigan|National Center for Complementary and Integrative Health (NCCIH),All,20 Years to 30 Years   (Adult),Not Applicable,60,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic",R01AT001415-01A1,2003-09-01,2008-02-01,2008-06-01,2005-09-20,null,2017-03-24,"University of Michigan Medical Center, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT00200876
1025,NCT00468845,Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo For Treatment Of Post-Surgical Pain From Hysterectomy,,Completed,Has Results,"Pain, Postoperative",Drug: pregabalin (Lyrica)|Drug: matched placebo,Worst Pain Using the Modified Brief Pain Inventory - Short Form (m-BPI-sf)|Current Pain - Pain With Movement Caused by Sitting|Current Pain - Pain With Movement Caused by Peak Expiratory (PEF) Test|Area Under the Curve (AUC) Pain - Pain With Movement Caused by Sitting|Area Under the Curve (AUC) Pain - Pain With Movement Caused by Peak Expiratory Flow (PEF) Test|Current Pain at Rest|Area Under the Curve (AUC) of Pain at Rest During the First Two Days of Hospital Stay|Total Cumulative Dose of Opioids Following Surgery|Integrated Analgesic Score|Non-opioid Rescue Medication - Paracetamol|Anxiety Before and After Surgery|Non-opioid Rescue Medication - Ibuprofen|Percent Change From Baseline in Peak Expiratory Flow|Timed Up-and-Go (TUG)|Average Daily Pain|Worst Daily Pain|Sleep Interference|Brief Pain Inventory-Short Form (m-BPI-sf): Pain Interference Index Scores|Brief Pain Inventory-Short Form (m-BPI-sf): Pain Severity Index Scores|Participant Satisfaction With Study Medication - Surgery Day|Participant Satisfaction With Study Medication - Day 1 PS|Participant Satisfaction With Study Medication - Day 2 PS|Participant Satisfaction With Study Medication - Day 3 PS|Participant Satisfaction With Study Medication - Day 4 PS|Participant Satisfaction With Study Medication - Day 5 PS|Participant Satisfaction With Study Medication - Discharge|Participant Satisfaction With Study Medication - Day 7 PS|Participant Satisfaction With Study Medication - Day 14 PS|Participant Satisfaction With Study Medication - Day 28 PS|Pain Treatment Satisfaction Scale (PTSS): Satisfaction With Current Pain Medication|Pain Treatment Satisfaction Scale (PTSS): Impact of Current Pain Medication|Quality of Life Using EuroQol (EQ-5D) Health State Profile|Time to Meet Hospital Discharge Criteria|Time to Actual Discharge|Incidence of Chronic Post-operative Pain|Total Clinically Meaningful Event (CME) Score,Pfizer,Female,"25 Years to 70 Years   (Adult, Older Adult)",Phase 3,501,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",A0081153,2007-06-01,2010-05-01,2010-10-01,2007-05-03,2011-05-26,2011-06-09,"Pfizer Investigational Site, Mobile, Alabama, United States|Pfizer Investigational Site, Glendale, Arizona, United States|Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Glendale, California, United States|Pfizer Investigational Site, Pasadena, California, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Pittsburgh, Pennsylvania, United States|Pfizer Investigational Site, Pittsburgh, Pennsylvania, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Calgary, Alberta, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Sherbrooke, Quebec, Canada|Pfizer Investigational Site, Praha 5, Czech Republic|Pfizer Investigational Site, Kowloon, Hong Kong|Pfizer Investigational Site, Shatin, Hong Kong|Pfizer Investigational Site, Johannesburg, Gauteng, South Africa|Pfizer Investigational Site, Krugersdorp, Gauteng, South Africa|Pfizer Investigational Site, Pretoria, Gauteng, South Africa|Pfizer Investigational Site, Newcastle, KwaZulu Natal, South Africa|Pfizer Investigational Site, Ladysmith, KZN, South Africa|Pfizer Investigational Site, Cape Town, Western Cape, South Africa|Pfizer Investigational Site, Parktown, South Africa|Pfizer Investigational Site, Cadiz, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Valencia, Spain|Pfizer Investigational Site, Lund, Sweden|Pfizer Investigational Site, Orebro, Sweden|Pfizer Investigational Site, Stockholm, Sweden|Pfizer Investigational Site, Bangkoknoi, Bangkok, Thailand|Pfizer Investigational Site, Muang, Chiang Mai, Thailand|Pfizer Investigational Site, Muang, Khon Kaen, Thailand|Pfizer Investigational Site, Leicester, Leicestershire, United Kingdom|Pfizer Investigational Site, Edinburgh, Scotland, United Kingdom|Pfizer Investigational Site, Birmingham, United Kingdom|Pfizer Investigational Site, Liverpool, United Kingdom|Pfizer Investigational Site, Livingstone, United Kingdom",,https://ClinicalTrials.gov/show/NCT00468845
1026,NCT01975285,Efficacy of Popliteal Nerve Blocks With and Without Dexamethasone on the Duration of Analgesia for Foot & Ankle Surgery,,Completed,Has Results,Foot and Ankle Procedures,Drug: Dexamethasone|Drug: Saline,Postoperative Pain|Opioid Consumption|Length of Analgesia|Patient Satisfaction With Regional Nerve Block|Patient Satisfaction With Pain Management,Cedars-Sinai Medical Center,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 4,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",Pro00032547,2013-08-01,2014-06-01,2014-06-01,2013-11-04,2016-05-06,2016-05-06,"Cedars Sinai Medical center, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT01975285
1027,NCT03107481,Acetaminophen IV vs Hydromorphone IV in the ED,,Completed,No Results Available,"Pain, Acute",Drug: Acetaminophen|Drug: Hydromorphone,NRS Change at 60 minutes|Forego Additional Pain Medication|Receive Rescue Medication|Experience Medication Side Effects,Montefiore Medical Center,All,21 Years to 64 Years   (Adult),Phase 4,220,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2016-7296,2017-06-04,2017-11-14,2017-11-14,2017-04-11,null,2017-11-17,"Montefiore Medical Center, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT03107481
1028,NCT00032955,Buprenorphine/Naloxone Versus Clonidine for Inpatient Opiate Detoxification - 1,,Completed,No Results Available,Heroin Dependence|Morphine Dependence|Substance Withdrawal Syndrome,Drug: Buprenorphine/naloxone,Drug use|Degree of drug craving|Adverse events|Drug craving|Decreased frequency of HIV related behavior|Adverse effect measures,"University of California, Los Angeles|National Institute on Drug Abuse (NIDA)",All,"15 Years and older   (Child, Adult, Older Adult)",Phase 3,163,Other,Interventional,Masking: None (Open Label)|Primary Purpose: Treatment,NIDA-CTN-0001-1,2001-02-01,2002-08-01,2002-08-01,2002-04-08,null,2017-01-12,"Betty Ford Center, Rancho Mirage, California, United States|The Center For Drug-Free Living, Orlando, Florida, United States|Operation PAR, Inc., Pinellas Park, Florida, United States|Self Help Addiction Rehabilitation (SHAR), Inc., Detroit, Michigan, United States|Phoenix House, New York, New York, United States|Maryhaven, Inc., Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00032955
1029,NCT01608308,Intraoperative and Post-operative Analgesic Effect of IV Acetaminophen for Sinus Surgery,IVAPAP,Completed,Has Results,Chronic Sinusitis,Drug: IV Acetaminophen|Drug: Placebo,Pain Level Assessed Using a Visual Analogue Scale (VAS) Scale|Total Doses of Postoperative Opiate (Morphine) Use|Number of Participants Who Received Intraoperative Supplemental Fentanyl|Number of Participants Who Experienced Postoperative Morbidity (Nausea)|Postoperative Vital Sign (Systolic Blood Pressure)|Postoperative Vital Sign (Diastolic Blood Pressure)|Postoperative Vital Sign (Pulse)|Postoperative Vital Sign (Temperature)|Postoperative Vital Sign (Respiratory Rate),"The University of Texas Health Science Center, Houston|Mallinckrodt",All,"18 Years to 68 Years   (Adult, Older Adult)",Not Applicable,62,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",HSC-MS-12-0111,2012-07-01,2014-09-01,2014-09-01,2012-05-31,2015-09-04,2015-10-16,"The University of Texas Health Sciences Center at Houston, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01608308
1030,NCT00403234,Safety of Buprenorphine Transdermal System (BTDS) in Subjects With Acute Postoperative Pain After Total Knee Replacement,,Terminated,Has Results,Postoperative Pain,Drug: Buprenorphine transdermal patch|Drug: Placebo BTDS,Number of Participants With Adverse Events (AEs) as a Measure of Safety,Purdue Pharma LP,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,10,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BUP2003,2006-11-01,2007-04-01,2007-08-01,2006-11-23,2010-09-21,2012-09-03,"Arizona Research Center, Phoenix, Arizona, United States|Accurate Clinical Trials, Inc, San Clemente, California, United States|Southeastern Clinical Research Consultants, Orlando, Florida, United States|Greater Chesapeake Orthopaedic Associates, Baltimore, Maryland, United States|Sewickley Valley Hospital, Sewickley, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00403234
1031,NCT01365195,Effect of Ketamine on Postoperative Clinical Outcomes,,Enrolling by invitation,No Results Available,Colorectal Surgery,Drug: Placebo|Drug: Ketamine high-dose|Drug: Ketamine low-dose,Opioid consumption obtained from the recorded data|Postoperative pain using a Verbal Rating Scale|Nausea and vomiting will be measured with follow up|Constipation (Ileus),Cedars-Sinai Medical Center,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,102,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",Pro00024533,2011-05-01,2020-03-01,2020-10-01,2011-06-03,null,2018-04-04,"Cedars Sinai Medical center, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT01365195
1032,NCT01539642,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™) for the Treatment of Post-Operative Pain in Patients After Open Abdominal Surgery",,Completed,Has Results,Post-Operative Pain,Drug: Sufentanil NanoTab PCA System/15 mcg|Drug: Placebo Sufentanil NanoTab PCA System,Time-weighted Summed Pain Intensity Difference (SPID) Over the 48-hour Study Period (SPID-48).,"AcelRx Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,172,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IAP310,2012-02-01,2013-01-01,2013-02-01,2012-02-27,2014-02-03,2015-10-20,"Surgical Associates of Mobile, Mobile, Alabama, United States|Caring Clinical Research Corporation, Laguna Hills, California, United States|The Stamford Hospital, Stamford, Connecticut, United States|G&G Research, Vero Beach, Florida, United States|Rush Pain Center, Chicago, Illinois, United States|CRC of Jackson, Jackson, Mississippi, United States|Cooper University Hospital, Camden, New Jersey, United States|Phoenix OB GYN Associates, Moorestown, New Jersey, United States|New York Methodist Hospital, Brooklyn, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Jefferson Hospital, Philadelphia, Pennsylvania, United States|Memorial Hermann -Memorial City Medical Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01539642
1033,NCT02945293,"Cognitive, Behavioral and Aging Effects of Pain Medication in Alcohol Users",CAAP,Recruiting,No Results Available,Mild to Heavy Alcohol Consumption,Other: Oxycodone,"response to a pain stimulus|medication impact , opioid adjective checklist|functional measure of balance modified berg balance test|Pupil size|verbal memory performance on list learning task",University of Washington|National Institutes of Health (NIH)|National Institute on Aging (NIA)|Seattle Institute for Biomedical and Clinical Research,All,"35 Years and older   (Adult, Older Adult)",Phase 4,160,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,STUDY00001018|5R01AG047979,2015-11-01,2019-04-01,2019-04-01,2016-10-26,null,2017-11-17,"Univ. of Washington Medical Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT02945293
1034,NCT03560076,Implementation and Evaluation of SBIRT,,"Active, not recruiting",No Results Available,Substance Use Disorders,Other: SBIRT Training and Implementation Strategies,SBIRT Process|Cost of SBIRT implementation,Indiana University,All,"18 Years and older   (Adult, Older Adult)",,2562,Other,Observational,Observational Model: Cohort|Time Perspective: Other,1801646970,2018-01-01,2019-07-31,2019-07-31,2018-06-18,null,2018-06-19,"Indiana University, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT03560076
1035,NCT02241967,Dose Dependent Effects of tDCS on Post-Operative Pain,tDCS-TKA,Recruiting,No Results Available,Total Knee Arthroplasty (Postoperative Pain)|Total Hip Arthroplasty(Postoperative Pain),Device: Transcranial Direct Current Stimulation,Post-operative opioid pain medication dose|Patient-reported pain ratings,VA Office of Research and Development,All,"19 Years to 90 Years   (Adult, Older Adult)",Phase 1,120,U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CLIN-005-13F|CX001078,2014-10-01,2018-10-01,2018-10-01,2014-09-16,null,2018-05-11,"Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT02241967
1036,NCT01839461,Pharmacogenetic Morphine Spine Study,,Enrolling by invitation,No Results Available,Pain,,Immediate postoperative pain scores in the recovery room|postoperative intravenous morphine requirement|Chronic pain pre-operatively|Chronic pain post-operatively,"Children's Hospital Medical Center, Cincinnati",All,"10 Years to 18 Years   (Child, Adult)",,300,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,2009-0973,2009-07-01,2020-12-01,2020-12-01,2013-04-24,null,2017-11-14,"Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01839461
1037,NCT01943565,Intrathecal Hydromorphone for Post-cesarean Delivery Pain - a Dose Finding Study,,Terminated,Has Results,Healthy|Pain|Pregnancy,Drug: Hydromorphone 25mcg|Drug: Hydromorphone 50mcg|Drug: Hydromorphone 100mcg|Drug: spinal anesthesia,"24hr Post-partum IV Opioid Requirement|Oxygen Saturation, Need for Supplemental Oxygen|Patients With Nausea and Vomiting Requiring Rescue Medication|Number of Patients With Hypothermia (Body Temperature < 95F/35C)|Number of Patients With Visual Disturbances|Number of Patients With Pruritus|Intraoperative Vasopressor Use: Ephedrine Equivalents|Intraoperative Vasopressor Use: Phenylephrine Equivalents",Brigham and Women's Hospital,Female,18 Years to 40 Years   (Adult),Phase 4,29,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other",2013P001850|Hydromorphone_IT,2014-12-01,2016-07-01,2016-08-01,2013-09-17,2017-06-19,2017-06-19,"Brigham and Women's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01943565
1038,NCT02625155,Standard of Care Versus Urine Testing With Selective PHarmacogenomics for Effective Drug and Dosing REgimens,SPHERE,Recruiting,No Results Available,Target Drug-related Adverse Events,"Other: Urine diagnostic testing as SOC, drug regimen changes per SOC|Other: Urine diagnostic testing with selective PGx testing, drug regimen changes based on PGx test results","The proportion of subjects who experience target drug-related adverse events (TDRAE) over the 90-day period following enrollment|All TDRAE as quantified within each of the four classes of medications|TDRAE driving a change in the subject's drug regimen (dose change, discontinuation, substation, or addition of a new drug)|Severe TDRAE, defined as a TDRAE that meets the criteria for a Serious Adverse Event|Ineffective therapeutic response, determined by the Investigator|Supra-therapeutic response, as determined by the Investigator|Frequency of subjects with changes in drug regimen|Healthcare resource utilization, as measured by the number of outpatient clinic visits, emergency room/urgent care visits, and hospitalizations; tabulated over the 90-day period following enrollment",InSource Diagnostics|Syntactx,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 4,14000,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2017-001,2015-12-01,2018-12-01,null,2015-12-09,null,2018-02-28,"Donald H. Deaton, Jr., DO, Tazewell, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT02625155
1039,NCT03104816,The Effectiveness of IV/PO Acetaminophen in the Perioperative Period in Reducing Opiate Use After Lumbar Spine Fusion,,Recruiting,No Results Available,"Fusion of Spine, Lumbar Region",Drug: Acetaminophen IV Soln 10 MG/ML|Drug: Acetaminophen|Drug: Hydromorphone,Postoperative opioid use|Postoperative numerical pain rating scale|Postoperative patient's satisfaction scale|Opioid-related side effects|PACU length of stay,University of Southern California,All,"18 Years and older   (Adult, Older Adult)",Phase 4,128,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HS-15-00615,2016-10-01,2017-10-01,2017-12-01,2017-04-07,null,2017-04-07,"Keck Hospital of USC, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT03104816
1040,NCT00457080,Application of Capnography Monitoring on the General Care Nursing Unit,ETCO2,Completed,No Results Available,Postoperative Complications,"Device: Alaris ETCO2 monitor - cont. resp. rate, & apnea events",Increase the detection of undiagnosed obstructive sleep apnea (OSA)|Increase the sensitivity for detection of respiratory depression (< 6 breaths per minute) in post operative patients on the general care nursing unit,Texas Health Resources,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,CAPNO-P806,2006-10-01,null,2007-02-01,2007-04-05,null,2008-07-09,"Presbyterian Hospital of Dallas, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT00457080
1041,NCT01474304,Intravenous Acetaminophen for Craniotomy Patients,IVAC,Recruiting,No Results Available,Craniotomy,Drug: Acetaminophen,Total narcotic dose administered over the first 12 hours of postoperative recovery.|Incidence of nausea during postoperative recovery|Incidence of vomiting during postoperative recovery|Severity of nausea during postoperative recovery|Severity of vomiting during postoperative recovery,Swedish Medical Center|Mallinckrodt,All,"18 Years and older   (Adult, Older Adult)",Phase 2,80,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,IVAC|20111619,2011-11-01,2017-06-01,null,2011-11-18,null,2016-09-29,"Swedish Medical Center Cherry Hill Campus, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01474304
1042,NCT01723137,Measuring Changes in Acute Pain in the Emergency Department Using Patient Reported Scales,,Completed,No Results Available,Acute Pain,,Change in Patient Described Stress|Change in Patient described anxiety.|Change in patient described satisfaction with ongoing treatment.|Change in patient described pain.,Minneapolis Medical Research Foundation,All,"18 Years and older   (Adult, Older Adult)",,3630,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Oct-89,2010-05-01,2013-01-01,2013-01-01,2012-11-07,null,2013-10-25,"Hennepin County Medical Center, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT01723137
1043,NCT00743730,Parent Nurse Controlled Analgesic in Pediatric Patients With Developmental Delay,PNCA,Completed,Has Results,Post Operative Pain,Other: Pain and standard side effect management for PNCA with basal method.|Other: Pain and standard side effect management with PNCA without basal|Other: Pain and standard side effect management with IV on an as needed basis method.,"Median Pain Score During Shift 1, as Measured With the Face, Legs, Activity, Cry, Consolability Scale|Side Effect Profile (Administration of Medications to Treat Side Effects)|Parent Satisfaction With the Administration Technique","Medical College of Wisconsin|Children's Hospital and Health System Foundation, Wisconsin",All,"4 Years to 18 Years   (Child, Adult)",Not Applicable,94,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"CHW 05/02, HRRC 008-05",2005-06-01,2010-02-01,2010-02-01,2008-08-29,2016-11-15,2018-07-31,"Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00743730
1044,NCT00088296,"Effects of Osteoarthritis Pain, Morphine, and Placebo on Neuroendocrine Function in Men",,Completed,No Results Available,Osteoarthritis,Procedure: Blood Draw,,National Center for Complementary and Integrative Health (NCCIH)|National Institutes of Health Clinical Center (CC),Male,"30 Years to 65 Years   (Adult, Older Adult)",Phase 2,72,NIH,Interventional,Primary Purpose: Treatment,040239|04-AT-0239,2004-07-13,null,2007-10-18,2004-07-26,null,2017-07-02,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00088296
1045,NCT01789476,A Phase 2 Study to Evaluate Analgesic Effect of IV CR845 For Pain Following Bunionectomy Surgery,,Completed,Has Results,Acute Pain,Drug: CR845|Drug: Placebo,Summed Pain Intensity Differences Over 24 Hours (SPID 0-24) Following the Initial Administration of Study Drug|Summed Pain Intensity Differences Over 36 Hours (SPID 0-36) Following the Initial Administration of Study Drug|Summed Pain Intensity Differences Over 48 Hours (SPID 0-48) Following the Initial Administration of Study Drug,"Cara Therapeutics, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,51,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CR845 CLIN2003,2013-05-01,2013-08-01,2013-08-01,2013-02-12,2015-04-30,2015-04-30,"Jean Brown Research, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT01789476
1046,NCT01141283,Safety of BTDS in Subjects With Osteoarthritic (OA) Pain of Hip or Knee: A 6-Month Open-label Extension Phase,,Completed,Has Results,Osteoarthritis,Drug: Buprenorphine transdermal patch,The Number of Participants With Adverse Events as a Measure of Safety and Tolerability,Purdue Pharma LP,All,"40 Years to 75 Years   (Adult, Older Adult)",Phase 3,290,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BUP3012S,2003-04-01,2004-07-01,2004-07-01,2010-06-10,2010-09-21,2012-09-03,"Vista Medical Research Inc., Mesa, Arizona, United States|Arthrocare, Arthritis Care and Research, Phoenix, Arizona, United States|Arizona Rheumatology Ctr and Phoenix Ctr for Clinical Research, Phoenix, Arizona, United States|Arizona Research Center, Phoenix, Arizona, United States|Research Facility, Tucson, Arizona, United States|Advanced Pain Medicine, Bakersfield, California, United States|Orange County Clinical Research, Cypress, California, United States|San Diego Arthritis & Osteoporosis Medical Clinic, San Diego, California, United States|Research Facility, San Diego, California, United States|Research Facility, San Francisco, California, United States|Research Facility, Denver, Colorado, United States|Research Facility, Westminster, Colorado, United States|Research Facility, Bridgeport, Connecticut, United States|Research Facility, Atlantis, Florida, United States|Allergy, Asthma, Arthritis & Lung, Daytona Beach, Florida, United States|University Clinical Research Deland, Deland, Florida, United States|Research Facility, Jupiter, Florida, United States|Coastal Medical Research, Orange City, Florida, United States|Research Facility, Plantation, Florida, United States|Research Facility, West Palm Beach, Florida, United States|Research Facility, Marietta, Georgia, United States|Research Facility, Columbus, Indiana, United States|Research Facility, Evansville, Indiana, United States|Primary Care Medical Center, Murray, Kentucky, United States|Great Lakes Family Care, Cadillac, Michigan, United States|Research Facility, Traverse City, Michigan, United States|Beth Israel/Dept. of Pain, New York, New York, United States|Research Facility, Winston-Salem, North Carolina, United States|Research Facility, Cresson, Pennsylvania, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|University Orthopedics & Sport Medicine Center, State College, Pennsylvania, United States|Research Facility, West Reading, Pennsylvania, United States|Low Country Rheumatology, PA, Charleston, South Carolina, United States|Central Plains Clin-Brown Site, Watertown, South Dakota, United States|Research Facility, Dallas, Texas, United States|Research Facility, Harker Heights, Texas, United States|Research Facility, San Antonio, Texas, United States|Research Facility, Seguin, Texas, United States|Granger Medical Clinic, West Valley City, Utah, United States|Hilltop Medical Center, Virginia Beach, Virginia, United States|Research Facility, Bellevue, Washington, United States|Internal Medicine Northwest, Tacoma, Washington, United States",,https://ClinicalTrials.gov/show/NCT01141283
1047,NCT01135524,Safety of Buprenorphine Transdermal Patch (BTDS) in Osteoarthritis Pain: a 52-Week Extension Phase,,Terminated,Has Results,Osteoarthritis,Drug: Buprenorphine transdermal patch,The Number of Participants With Adverse Events as a Measure of Safety and Tolerability,Purdue Pharma LP,All,"40 Years and older   (Adult, Older Adult)",Phase 3,196,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BUP3019S,2004-04-01,2005-08-01,2005-08-01,2010-06-02,2010-09-23,2012-09-10,"Alabama Neurology and Pain Medicine, Alabaster, Alabama, United States|Research Facility, Birmingham, Alabama, United States|The Birmingham Pain Center, Birmingham, Alabama, United States|University of Alabama Hospital, Birmingham, Alabama, United States|HealthSouth Metro West Hospital, Fairfield, Alabama, United States|Research Facility, Phoenix, Arizona, United States|Arizona Research Center, Phoenix, Arizona, United States|Research Facility, Phoenix, Arizona, United States|Research Facility, Tucson, Arizona, United States|Hot Springs Pain Clinic, Hot Springs, Arkansas, United States|Research Facility, Buena Park, California, United States|Research Facility, Chula Vista, California, United States|Research Facility, Fresno, California, United States|Research Facility, Los Gatos, California, United States|Research Facility, Roseville, California, United States|NTOUCH Research Corporation, San Diego, California, United States|Research Facility, San Diego, California, United States|Research Facility, Torrence, California, United States|Research Facility, Upland, California, United States|Research Facility, Pueblo, Colorado, United States|Research Facility, Bridgeport, Connecticut, United States|Research Facility, Coral Gables, Florida, United States|Research Facility, Daytona Beach, Florida, United States|Research Facility, Hialeah, Florida, United States|Research Facility, Jupiter, Florida, United States|Research Facility, Largo, Florida, United States|Research Facility, Miami, Florida, United States|Research Facility, North Miami Beach, Florida, United States|Research Facility, Ocala, Florida, United States|Research Facility, Ormond Beach, Florida, United States|Research Facility, Palm Harbor, Florida, United States|Research Facility, Pembroke Pines, Florida, United States|Radiant Research, Pinellas Park, Florida, United States|Research Facility, Plantation, Florida, United States|Research Facility, Port Orange, Florida, United States|Research Facility, Tampa, Florida, United States|Research Facility, West Palm Beach, Florida, United States|Research Facility, Marietta, Georgia, United States|Research Facility, Boise, Idaho, United States|Idaho Arthritis Osteoporosis, Meridian, Idaho, United States|Research Facility, Chicago, Illinois, United States|Research Facility, Springfield, Illinois, United States|Integrated Clinical Trials, West Des Moines, Iowa, United States|Louisville Endocrinology PSC, Louisville, Kentucky, United States|Research Facility, Madisonville, Kentucky, United States|Research Facility, New Orleans, Louisiana, United States|Research Facility, New Orleans, Louisiana, United States|Dolby Providers, New Orleans, Louisiana, United States|Research Facility, Baltimore, Maryland, United States|Patuxent Medical Group, Columbia, Maryland, United States|Research Facility, Hagerstown, Maryland, United States|Research Facility, Brockton, Massachusetts, United States|Crystal Lake Health Center, Benzonia, Michigan, United States|Rheumatology PC, Kalamazoo, Michigan, United States|Research Facility, Lansing, Michigan, United States|KC Pain Centers East, Independence, Missouri, United States|Research Facility, St. Louis, Missouri, United States|HealthCare Research LLC, St. Louis, Missouri, United States|Research Facility, Las Vegas, Nevada, United States|Research Facility, Las Vegas, Nevada, United States|Research Facility, New York, New York, United States|Research Facility, Syracuse, New York, United States|The Arthritis Clinic and Carolina Bone and Joint, Charlotte, North Carolina, United States|Triangle Orthopaedic Associates, Durham, North Carolina, United States|Research Facility, Greensboro, North Carolina, United States|Research Facility, Hickory, North Carolina, United States|Cornerstone Research Care, High Point, North Carolina, United States|Research Facility, Cincinnati, Ohio, United States|Research Facility, Columbus, Ohio, United States|Research Facility, Oklahoma City, Oklahoma, United States|Research Facility, Eugene, Oregon, United States|Research Facility, Altoona, Pennsylvania, United States|Research Facility, Duncansville, Pennsylvania, United States|The Clinical Trial Center, Jenkintown, Pennsylvania, United States|Research Facility, Mechanicsburg, Pennsylvania, United States|New England Center for Clinical Research, Cranston, Rhode Island, United States|Radiant Research, Greer, South Carolina, United States|Allergy ARTS, Amarillo, Texas, United States|Research Facility, Conroe, Texas, United States|Family Practice Associates, Corpus Christi, Texas, United States|Research Facility, Dallas, Texas, United States|Research Facility, Dallas, Texas, United States|Research Facility, Houston, Texas, United States|KRK Medical Research, Richardson, Texas, United States|Research Facility, San Antonio, Texas, United States|Research Facility, San Antonio, Texas, United States|Research Facility, Spokane, Washington, United States|Research Facility, Milwaukee, Wisconsin, United States|Research Facility, New Berlin, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT01135524
1048,NCT01125917,Safety of BTDS in Subjects With Low Back Pain: A 52-Week Extension Phase of BUP3015,,Terminated,Has Results,Back Pain Lower Back Chronic,Drug: Buprenorphine transdermal patch,Number of Participants With Adverse Events (AEs) as a Measure of Safety,Purdue Pharma LP,All,"18 Years and older   (Adult, Older Adult)",Phase 3,354,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BUP3015S,2004-06-01,2005-09-01,2008-01-01,2010-05-19,2010-09-21,2012-09-03,"Birmingham Pain Center, Birmingham, Alabama, United States|Arthritis Clinical Intervention Program, Birmingham, Alabama, United States|Winston Physician Services, Inc, Haleyville, Alabama, United States|Arizona Research Center Inc, Phoenix, Arizona, United States|Radiant Research, Phoenix, Arizona, United States|Advanced Clinical Therapeutics, Tucson, Arizona, United States|Hot Springs Pain Clinic, Hot Springs, Arkansas, United States|NuLife Clinical Research, Inc., Anaheim, California, United States|Lovelace Scientific Resources, Beverly Hills, California, United States|Northern California Research Corp, Carmichael, California, United States|International Clinical Research Network, Chula Vista, California, United States|Shreenath Clinical Service, Fountain Valley, California, United States|U of Calif at Davis, Med Ctr, Pain Management Center, Sacramento, California, United States|Accelovance, San Diego, California, United States|Southern Colorado Clinic, Pueblo, Colorado, United States|Chiefland Medical Center, Chiefland, Florida, United States|University Clinical Research Deland, Deland, Florida, United States|Drug Study Institute, Jupiter, Florida, United States|Innovative Research of West Florida, Inc., Largo, Florida, United States|Renstar Medical, Ocala, Florida, United States|Peninsula Research Inc., Ormond Beach, Florida, United States|The Arthritis Center, Palm Harbor, Florida, United States|University Clinical Research, Inc., Pembroke Pines, Florida, United States|Gold Coast Research, LLC, Plantation, Florida, United States|Palm Beach Research Center, West Palm Beach, Florida, United States|Georgia Medical Research Institute, Marietta, Georgia, United States|Atlanta Knee & Shoulder Clinic, Stockbridge, Georgia, United States|Pain Care Boise, Boise, Idaho, United States|Idaho Arthritis and Osteoporosis Center, Meridian, Idaho, United States|Pain and Rehabilitation Clinic of Chicago, Chicago, Illinois, United States|GFI Research Center, Evansville, Indiana, United States|MediSphere Medical Research Center, LLC, Evansville, Indiana, United States|Medical Associates Clinics, Dubuque, Iowa, United States|Vince and Associates Clinical Research, Overland Park, Kansas, United States|CTT, Inc., Prairie Village, Kansas, United States|Commonwealth Biomedical Research, LLC, Madisonville, Kentucky, United States|New Orleans Clinical Trial Management Inc., Metairie, Louisiana, United States|Louisiana Research Associates, Inc., New Orleans, Louisiana, United States|Best Clinical Trials, LLC, New Orleans, Louisiana, United States|Research Center of Louisiana, New Orleans, Louisiana, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Future Care Studies, Springfield, Massachusetts, United States|Rheumatology PC, Kalamazoo, Michigan, United States|Lake Michigan Clinical Research & Consulting, Inc., Saint Joseph, Michigan, United States|Medex Healthcare Research Inc, St Louis, Missouri, United States|HealthCare Research, St Louis, Missouri, United States|Meridian Clinical Research, LLC, Omaha, Nebraska, United States|Lovelace Scientific Resources, Henderson, Nevada, United States|Pivotal Research Centers, North Las Vegas, Nevada, United States|Research Across America, New York, New York, United States|Pain and Orthopedic Neurology , Charlotte Spine Center,, Charlotte, North Carolina, United States|Metrolina Medical Research, Charlotte, North Carolina, United States|Triangle Orthopaedic Associates, Durham, North Carolina, United States|Pharmquest, Greensboro, North Carolina, United States|MedArk Clinical Research, Morgantown, North Carolina, United States|Wake Research Associates, LLC, Raleigh, North Carolina, United States|Center for Clinical Research, Winston Salem, North Carolina, United States|Odyssey Research, Bismark, North Dakota, United States|COR Clinical Research, LLC, Oklahoma City, Oklahoma, United States|Associated Medical Services Inc, Oklahoma City, Oklahoma, United States|Keystone Clinical Research, Altoona, Pennsylvania, United States|Valley Pain Specialists, Bethlehem, Pennsylvania, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Central Pennsylvania Clinical Research, Mechanicsburg, Pennsylvania, United States|BioMedical Research Associates, Shippensburg, Pennsylvania, United States|University Orthopedics Center, State College, Pennsylvania, United States|New England Center Clinical Research, Cranston, Rhode Island, United States|Omega Medical Research, Warwick, Rhode Island, United States|The Arthritis and Osteoporosis Center, Orangeburg, South Carolina, United States|Brown Clinic, Watertown, South Dakota, United States|Holston Medical Group, Bristol, Tennessee, United States|Tri Cities Medical Research, Bristol, Tennessee, United States|Holston Medical Group, Kingsport, Tennessee, United States|Galenos Research, Dallas, Texas, United States|Benchmark Research, Fort Worth, Texas, United States|Team Research of Central Texas, Harker Heights, Texas, United States|KRK Medical Research, Richardson, Texas, United States|Benchmark Research, San Angelo, Texas, United States|Unlimited Research, San Antonio, Texas, United States|Texas Medical Research Associates, San Antonio, Texas, United States|Clinical Trial Network Oaks Medical Center, Spring, Texas, United States|N. Texas Neuro Research, Wichita Falls, Texas, United States|Lifetree Clinical Research, Salt Lake City, Utah, United States|Dean Medical Center, Oregon, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT01125917
1049,NCT00315887,The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Chronic Back Pain.,,Completed,No Results Available,Chronic Low Back Pain,Drug: Buprenorphine transdermal delivery system,"Patient Satisfaction With Medication for Pain and Average Pain Intensity scores on days 0, 7, 14, 21, 28, 35, 42, 49, 56 and, if applicable, at early termination.|Average Pain Intensity and Patient Satisfaction With Medication for Pain scores (Patient Global Efficacy Rating)|incidence of and time to early discontinuation due to lack of efficacy|investigator’s assessment of therapeutic response|dose level at the end of titration",Purdue Pharma LP,All,"18 Years and older   (Adult, Older Adult)",Phase 3,250,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,BP98-1201,1999-04-01,null,1999-10-01,2006-04-19,null,2006-05-03,"Rheumatology Associates of North Alabama, Huntsville, Alabama, United States|Arizona Research Center, Phoenix, Arizona, United States|Arthritis Center of Connecticut, Waterbury, Connecticut, United States|University Clinical Research, Deland, Florida, United States|Gainesville Clinical Research Center, Gainesville, Florida, United States|Miami Research Associates, Miami, Florida, United States|Sarasota Arthritis Center, Sarasota, Florida, United States|Coastal Medical Research, South Daytona Beach, Florida, United States|Palm Beach Research Center, West Palm Beach, Florida, United States|Private Practice, Weston, Florida, United States|Pain Management & Rehabilitation, Terre Haute, Indiana, United States|Mid-America Rheumatology Consultants, Overland Park, Kansas, United States|Riverhills Healthcare, Crestview Hills, Kentucky, United States|Arthritis & Osteoporosis Treatment & Research Center, Jackson, Mississippi, United States|Center for Pharmaceutical Research, Kansas City, Missouri, United States|PrecisionMed, Inc., Las Vegas, Nevada, United States|Cornerstone Research Care, High Point, North Carolina, United States|Consultants for Clinical Research, Cincinnati, Ohio, United States|Center for Clinical Research, Austin, Texas, United States|The Arthritis Clinic of Northern Virginia, Arlington, Virginia, United States|Evergreen Clinical Research, Edmonds, Washington, United States|Private Practice, Wauwatosa, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00315887
1050,NCT00315874,The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Chronic Low Back Pain.,,Completed,No Results Available,Back Pain,Drug: Buprenorphine transdermal delivery system,"Pain on average and pain right now scores at days 0, 9, 15, 30, 45, 60, or if applicable, at early termination.|Brief Pain Inventory|dropouts due to lack of efficacy|MOS health survey|VAS pain intensity|therapeutic response|patient preference|daily patient diary|and number of oxycodone/acetaminophen or placebo tablets taken",Purdue Pharma LP,All,"18 Years and older   (Adult, Older Adult)",Phase 3,225,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,BP96-0102,1997-04-01,null,1998-01-01,2006-04-19,null,2013-05-14,"Hawthorne & York, Intl, Ltd, Phoenix, Arizona, United States|Arizona Research & Education, Phoenix, Arizona, United States|Gainesville Clinical Research Center, Gainesville, Florida, United States|Park Place Therapeutic Center, Plantation, Florida, United States|Atlanta Research Center, Atlanta, Georgia, United States|Rheumatology Associates, Inc., Indianapolis, Indiana, United States|Westside Family Medical Center, Kalamazoo, Michigan, United States|The Center for Pharmaceutical Research, Kansas City, Missouri, United States|The New York Hospital Cornell Medical Center, New York, New York, United States|NC Clinical Research, Inc., Raleigh, North Carolina, United States|Pain Control Ctr Bowman Gray School of Med, Winston-Salem, North Carolina, United States|Metroplex Clinical Research Center, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT00315874
1051,NCT00315445,The Safety and Efficacy of the Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Back Pain.,BP96-0604,Completed,Has Results,Back Pain,Drug: Buprenorphine transdermal patch|Drug: Placebo oxycodone/acetaminophen tablets|Drug: OXY/APAP|Drug: Placebo transdermal patch (TDS),"Pain on the Average, Mean Change From Baseline Days 21-84 (Last Observation Carried Forward [LOCF])|Pain Right Now, Mean Change From Baseline, Days 21-84 (LOCF)|""Physical Functioning"" Scale of the Medical Outcomes Survey (MOS) 36 Item Short-Form Health Survey (SF-36): Mean Percent ± Standard Error of the Mean (SEM) at Day 84 (LOCF)|""Physical Role"" Scale (MOS SF-36): Mean Percent ± SEM at Day 84(LOCF)|""Bodily Pain"" (MOS SF-36): Mean Percent at Day 84 (LOCF)|""General Health"" (MOS SF-36): Mean Percent ± SEM at Day 84 (LOCF)|""Vitality"" (MOS SF-36): Mean Percent ± SEM at Day 84 (LOCF)|""Social Functioning"" (MOS SF-36): Mean Percent ± SEM at Day 84 (LOCF)|""Emotional Role"" (MOS SF-36): Mean Percent ± SEM at Day 84 (LOCF)|""Mental Health"" (MOS SF-36):Mean Percent ± SEM at Day 84 (LOCF)|Therapeutic Response - Investigator: Mean ± SEM (Day 84)(LOCF)|Therapeutic Response - Subject: Mean ± SEM (Day 84) (LOCF)|Subject Comparison to Prestudy Analgesic: Mean ± SEM (Day 84)(LOCF)|Subject Satisfaction: Mean ± SEM (Day 84)(LOCF)|Time to Stable Pain Management|The Time to Discontinuation Due to Lack of Efficacy",Purdue Pharma LP,All,"18 Years and older   (Adult, Older Adult)",Phase 3,134,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP96-0604,1997-12-01,1998-05-01,1998-05-01,2006-04-18,2011-08-10,2012-09-03,"Rheumatology Associates of North Alabama, Huntsville, Alabama, United States|Phoenix Center for Clinical Research, Phoenix, Arizona, United States|Phoenix Orthopedic Center, Ltd., Phoenix, Arizona, United States|Gainesville Clinical Research Center, Gainesville, Florida, United States|SeaView Research, Miami, Florida, United States|Park Place Therapeutic Center, Plantation, Florida, United States|Atlanta Research Center, Decatur, Georgia, United States|The Center for Pharmaceutical Research, P.C., Kansas City, Missouri, United States|New Jersey Research Foundation, Linwood, New Jersey, United States|North Carolina Clinical Research, Inc., Raleigh, North Carolina, United States|Research Across America, Dallas, Texas, United States|Metroplex Clinical Research Center, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT00315445
1052,NCT00836264,Pharmacogenomics Analysis of Morphine Pharmacokinetics in Pediatric Tonsillectomy and Adenoidectomy,,Suspended,No Results Available,Tonsillectomy|Adenoidectomy|Pharmacokinetics,,The primary endpoint will be to identify genetic variants that contribute to the variability of morphine analgesic response following pediatric day surgery T&A.,"Children's Hospital of Philadelphia|Children's Anesthesiology Associates, Ltd.",All,"4 Years to 18 Years   (Child, Adult)",,1650,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,08-007023,2015-12-01,2018-12-01,2019-06-01,2009-02-04,null,2017-01-20,"The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00836264
1053,NCT01179113,Esmolol Infusion During Laminectomy: Effect on Quality of Recovery,,Terminated,Has Results,Laminectomy,Drug: Esmolol|Drug: Saline,Post-operative Pain Using Verbal Rating Scale (VRS)|Opioid Consumption in PACU Obtained From the Recorded Data|Postoperative Nausea and Vomiting,Cedars-Sinai Medical Center,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,33,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)",Pro00019850,2011-06-01,2015-05-01,2015-05-01,2010-08-11,2016-08-30,2016-11-02,"Cedars Sinai Medical Center, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT01179113
1054,NCT01731873,Patient Controlled Analgesia Pharmacogenetic Study,,Enrolling by invitation,No Results Available,Pain,,Number of adverse events|Post-operative pain,"Children's Hospital Medical Center, Cincinnati",All,"up to 18 Years   (Child, Adult)",,650,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,2010-2268,2011-05-22,2021-05-21,2021-05-21,2012-11-22,null,2017-08-01,"Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01731873
1055,NCT00414453,Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis,,Terminated,Has Results,Neuropathic Pain|Chronic Pain|Multiple Sclerosis,Drug: Lidocaine patch 5%|Drug: Extended-release oxycodone|Drug: Placebo extended-release oxycodone pills|Drug: Placebo lidocaine patches,"Mean Daily Diary Pain Ratings During Final Week of Each Treatment Period|Tolerability (e.g., Number of Adverse Effects, Number of Drop-outs)|Safety (i.e., Number of Serious Adverse Events)|Brief Pain Inventory Interference Items|Daily Diary Sleep Interference Ratings|Beck Depression Inventory|Short-form Health Survey 36 (SF-36)|Short-Form McGill Pain Questionnaire|Patient Global Impression of Change Scale|Kurtzke Expanded Disability Status Scale",University of Rochester|Endo Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 4,19,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",TALENT-MS,2007-01-01,2011-08-01,2011-08-01,2006-12-21,2015-07-17,2015-07-17,"University of Rochester Medical Center, Rochester, New York, United States",,https://ClinicalTrials.gov/show/NCT00414453
1056,NCT00032968,Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1,,Completed,No Results Available,Heroin Dependence|Morphine Dependence|Substance Withdrawal Syndrome,Drug: Buprenorphine/naloxone,Drug use|Degree of drug craving|Opiate craving|Adverse events|Drug craving|Decreased frequency of HIV related behavior|Adverse effect measures,"University of California, Los Angeles|National Institute on Drug Abuse (NIDA)",All,"15 Years and older   (Child, Adult, Older Adult)",Phase 3,341,Other,Interventional,Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment,NIDA-CTN-0002-1,2001-01-01,2002-08-01,2002-08-01,2002-04-08,null,2017-01-12,"Haight-Ashbury Free Clinic, Berkeley, California, United States|Aegis Medical Systems, Inc., Oxnard, California, United States|Midtown Community Mental Health Center, Indianapolis, Indiana, United States|UMDNJ - Robert Wood Johnson Medical School, Piscataway, New Jersey, United States|Addiction Research and Treatment Corp, Brooklyn, New York, United States|Bellevue, New York, New York, United States|Kaiser Permanente Northwest, Division of Addiction, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT00032968
1057,NCT01826851,Parasternal Nerve Block in Cardiac Patients,,Completed,Has Results,"Coronary Artery Disease|Pain, Postoperative",Drug: Exparel|Drug: Placebo,Median Cumulative Morphine Equivalent|Median Pain Levels|Time to Extubation (Hours)|ICU Length of Stay (Hours)|Time to First Bowel Movement (Days)|Hospital Length of Stay (Days)|Time to Return to Work or Daily Activities,Peter A Knight|University of Rochester,All,"18 Years and older   (Adult, Older Adult)",Phase 2,79,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RSRB 00044181,2013-03-01,2017-06-01,2017-06-01,2013-04-09,2018-08-01,2018-08-01,"University of Rochester Medical Center, Rochester, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT01826851/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01826851
1058,NCT01775371,Effectiveness and Feasibility of Patient Controlled Analgesia in the ED,,Completed,No Results Available,Pain,Procedure: Patient controlled analgesia|Procedure: Usual Care,Rate of change in pain intensity|Incidence of adverse events|Patient satisfaction with pain management,"Albert Einstein College of Medicine, Inc.|Jacobi Medical Center|Montefiore Medical Center|University of Pennsylvania|National Institute of Nursing Research (NINR)",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,636,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2012-485|R01NR013980,2013-04-01,2016-02-01,2016-02-01,2013-01-25,null,2018-05-15,"Jacobi Medical Center, Bronx, New York, United States|Montefiore Medical Center - Moses Division, Bronx, New York, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01775371
1059,NCT00001008,A Study of Azidothymidine Plus Methadone in Patients With AIDS and AIDS Related Complex (ARC),,Completed,No Results Available,HIV Infections,Drug: Methadone hydrochloride|Drug: Zidovudine,,National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,18,NIH,Interventional,Intervention Model: Parallel Assignment|Primary Purpose: Treatment,ACTG 055,null,1991-03-01,null,2001-08-31,null,2011-03-14,"Montefiore Med Ctr / Bronx Municipal Hosp, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT00001008
1060,NCT00886236,Study of the Effect of the Drug Gabapentin on Postoperative Pain and Incidence of Postoperative Nausea and Vomiting,,Unknown status,No Results Available,"Obesity, Morbid|Postoperative Pain|Postoperative Nausea and Vomiting",Drug: Gabapentin|Drug: Placebo,Effect of preoperative and postoperative administration of gabapentin on postoperative opioid requirement.|Effect of preoperative and postoperative administration of gabapentin on incidence of postoperative nausea and vomiting.|Effective of preoperative and postoperative Gabapentin on the incidence of respiratory depression as evidenced by pulse oximetry data,Medical University of South Carolina,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,150,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HR # 18041 Gaba Bariatric,2008-07-01,2009-12-01,2009-12-01,2009-04-22,null,2009-04-22,"Medical University of South Carolina, Charleston, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT00886236
1061,NCT01003496,Comparing Acute and Continuous Drug Abuse Treatment: A Randomized Clinical Trial,,Unknown status,No Results Available,Drug Addiction,Behavioral: Treatment as Usual (TAU)|Behavioral: TAU + Long-Term Recovery Management,The main outcome is weeks of abstinence from the primary drug of dependence.|Secondary outcomes include drug-free days and reduction in HIV risk behaviors.,Wright State University|National Institute on Drug Abuse (NIDA)|Maryhaven|University of Arkansas,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,204,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NIDA/NIH 1RC1DA028467-01|1RC1DA028467-01,2009-11-01,2011-07-01,2011-07-01,2009-10-28,null,2010-10-07,"Maryhaven, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01003496
1062,NCT01431742,Longterm Safety Study of BEMA Buprenorphine in Subjects With Chronic Low Back Pain,,Withdrawn,No Results Available,Pain|Low Back Pain,Drug: BEMA Buprenorphine,Mean change in pain intensity,BioDelivery Sciences International,All,"18 Years and older   (Adult, Older Adult)",Phase 3,0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BUP-306,2012-07-01,2013-07-01,2013-07-01,2011-09-12,null,2012-04-17,"Marietta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT01431742
1063,NCT01660243,Efficacy and Safety of MT-9938 for Treatment of Uremic Pruritus in Subjects With End-stage Renal Disease Receiving Hemodialysis,,Terminated,No Results Available,Uremic Pruritus,Drug: Nalfurafine hydrochloride(MT-9938) 2.5μg|Drug: Nalfurafine hydrochloride(MT-9938) 5μg|Drug: Nalfurafine hydrochloride(MT-9938) 10μg|Drug: Placebo,Change from baseline in Worst-itching 11-point Numerical Rating Scale (NRS)|Change from baseline in Worst-itching Visual Analog Scale (VAS)|Change from baseline in Itch Severity Score|Change from baseline in Sleep quality assessment|Change from baseline in Excoriation|Change from baseline in QoL assessment|Change from baseline in Treatment satisfaction (Patient's Global Impression of Change )|Number of Participants with Adverse Events as a Measure of Safety and Tolerability,"Toray Industries, Inc",All,"18 Years and older   (Adult, Older Adult)",Phase 2,45,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MT-9938-A01,2012-09-01,2014-03-01,2014-03-01,2012-08-08,null,2016-03-17,"Los Angeles, California, United States|New York, New York, United States|Rosedale, New York, United States|San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT01660243
1064,NCT00841711,Transitions: Linkages From Jail To Community,,Completed,No Results Available,HIV|Substance Abuse|HIV Infections,Behavioral: Intensive Case Management,Substance use outcomes measured by self-report|Urine toxicology results,Yale University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,127,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,0711003262|H97HA08541,2008-09-01,2012-08-01,2013-08-01,2009-02-11,null,2016-08-12,"Yale Clinical Research, New Haven, Connecticut, United States|Waterbury Hosp ID Clinic, Waterbury, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00841711
1065,NCT00979953,Efficacy and Safety Study Evaluating ADL5859 and ADL5747 in Participants With Pain Due to Osteoarthritis of the Knee,,Completed,Has Results,Osteoarthritis of the Knee,Drug: ADL5859|Drug: ADL5747|Drug: Oxycodone CR|Drug: Placebo,Change From Baseline in the Average Pain Score (NPRS) for Week 2,Cubist Pharmaceuticals LLC|Pfizer,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,408,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",44CL240,2009-10-01,2010-04-01,2010-06-01,2009-09-18,2015-05-07,2015-08-14,"Covance CRU, Inc, Daytona Beach, Florida, United States|Atlanta Knee and Shoulder Clinic, PC, Stockbridge, Georgia, United States|University Rheumatoloty Center for Clinical Research, Chicago, Illinois, United States|Clinical Investigation Specialists, Inc, Gurnee, Illinois, United States|Cresent Medical Research, Salisbury, North Carolina, United States|New Hanover Medical Research, Wilmington, North Carolina, United States|Columbus Clinical Research, Columbus, Ohio, United States|PSB Research, Mt Gilead, Ohio, United States|Bone Joint & Spine Surgeons, Inc, Toledo, Ohio, United States|Radient Research, Anderson, South Carolina, United States|Quality Research, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00979953
1066,NCT00640042,"Evaluation of Risk Minimization, Assessment and Outcomes in Patients With Chronic Pain Taking Avinza",ACCESS 2008,Completed,Has Results,Pain,Drug: morphine sulfate extended release capsules,Difference From Baseline (Week 0) in the Average Pain Score at Visit 3 (Week 6)|Difference From Baseline (Week 0) in the Average Pain Score at Visit 4 (Week 10)|Difference From Baseline (Week 0) in the Average Pain Score at Visit 5 (Week 14 / End of Study)|Number of Subjects With Treatment Emergent Adverse Events|Number of Subjects at Each Level of Risk for Opioid Misuse or Abuse at Visit 3 (Week 6)|Number of Subjects at Each Level of Risk for Opioid Misuse or Abuse at Visit 4 (Week 10)|Number of Cases in Which Investigators Were Satisfied or Very Satisfied With the Utility of the Risk Minimization Program in This Study.|Number of Investigators Who Reported Continued Use of One or More Risk Minimization Tools Within 3 Months Post Study Completion.|Number of Investigators Who Reported Continued Use of One or More Risk Minimization Tools Within 3 to 6 Months Post Study Completion.,Pfizer,All,"21 Years and older   (Adult, Older Adult)",Phase 4,1570,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,K284-07-4001,2008-03-01,2008-11-01,2008-12-01,2008-03-20,2010-02-15,2012-06-11,"Adamsville, Alabama, United States|Phoenix, Arizona, United States|Scottsdale, Arizona, United States|Sun City, Arizona, United States|Sun Lakes, Arizona, United States|Tucson, Arizona, United States|Tucson, Arizona, United States|Burlingame, California, United States|Castro Valley, California, United States|Fountain Valley, California, United States|Hemet, California, United States|Lakewood, California, United States|Livermore, California, United States|Los Gatos, California, United States|Murrieta, California, United States|Murrieta, California, United States|Nevada City, California, United States|Oakland, California, United States|Rocklin, California, United States|Sacramento, California, United States|San Diego, California, United States|San Fransisco, California, United States|West Hollywood, California, United States|Whittier, California, United States|Yuba City, California, United States|Aurora, Colorado, United States|Colorado Springs, Colorado, United States|Denver, Colorado, United States|Denver, Colorado, United States|Fort Collins, Colorado, United States|Fort Collins, Colorado, United States|Northglenn, Colorado, United States|Thornton, Colorado, United States|Wheat Ridge, Colorado, United States|Wheatridge, Colorado, United States|Manchester, Connecticut, United States|Milford, Connecticut, United States|New Haven, Connecticut, United States|North Haven, Connecticut, United States|Norwich, Connecticut, United States|Georgetown, Delaware, United States|Milton, Delaware, United States|Wilmington, Delaware, United States|Wilmington, Delaware, United States|Wilmington, Delaware, United States|Apopka, Florida, United States|Bradenton, Florida, United States|Brandon, Florida, United States|Cape Coral, Florida, United States|Daytona Beach, Florida, United States|Deland, Florida, United States|Delray Beach, Florida, United States|Deltona, Florida, United States|Dunnellon, Florida, United States|Estero, Florida, United States|Eustis, Florida, United States|Loxahatchee, Florida, United States|Maitland, Florida, United States|Margate, Florida, United States|Miami, Florida, United States|Mount Dora, Florida, United States|N. Miami Beach, Florida, United States|New Smyrna Beach, Florida, United States|Oakland Park, Florida, United States|Oldsmar, Florida, United States|Orlando, Florida, United States|Ormond Beach, Florida, United States|Oviedo, Florida, United States|Pembroke Pines, Florida, United States|Port Richey, Florida, United States|Royal Palm Beach, Florida, United States|South Miami, Florida, United States|Tampa, Florida, United States|Tampa, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Augusta, Georgia, United States|Augusta, Georgia, United States|Cave Spring, Georgia, United States|Conyers, Georgia, United States|Covington, Georgia, United States|Decatur, Georgia, United States|Rome, Georgia, United States|Statesboro, Georgia, United States|Sugar Hill, Georgia, United States|Rexburg, Idaho, United States|Clinton, Illinois, United States|Crestwood, Illinois, United States|Creve Coeur, Illinois, United States|Danville, Illinois, United States|Dekalb, Illinois, United States|Elmwood Park, Illinois, United States|Flossmoor, Illinois, United States|Gurnee, Illinois, United States|Lockport, Illinois, United States|Maryville, Illinois, United States|Morton, Illinois, United States|Naperville, Illinois, United States|Oak Park, Illinois, United States|Oak Park, Illinois, United States|Pekin, Illinois, United States|Peoria, Illinois, United States|Peoria, Illinois, United States|St Charles, Illinois, United States|Washington, Illinois, United States|Washington, Illinois, United States|Zion, Illinois, United States|Anderson, Indiana, United States|Anderson, Indiana, United States|Anderson, Indiana, United States|Evansville, Indiana, United States|Franklin, Indiana, United States|Highland, Indiana, United States|Indianapolis, Indiana, United States|Laporte, Indiana, United States|Lawrenceburg, Indiana, United States|Newburgh, Indiana, United States|Rushville, Indiana, United States|Seymour, Indiana, United States|Whiteland, Indiana, United States|Des Moines, Iowa, United States|Le Claire, Iowa, United States|Newton, Iowa, United States|Kansas City, Kansas, United States|Kansas City, Kansas, United States|Kansas City, Kansas, United States|Lansing, Kansas, United States|Shawnee, Kansas, United States|Florence, Kentucky, United States|London, Kentucky, United States|Louisville, Kentucky, United States|Monticello, Kentucky, United States|Russell Springs, Kentucky, United States|Somerset, Kentucky, United States|Baltimore, Maryland, United States|Chester, Maryland, United States|Havre De Grace, Maryland, United States|Ocean City, Maryland, United States|Brockton, Massachusetts, United States|Springfield, Massachusetts, United States|Bloomfield Hills, Michigan, United States|Clarkston, Michigan, United States|Clinton, Michigan, United States|Dearborn Heights, Michigan, United States|Dearborn, Michigan, United States|Farmington Hills, Michigan, United States|Grand Rapids, Michigan, United States|Lansing, Michigan, United States|Lansing, Michigan, United States|Lansing, Michigan, United States|Lansing, Michigan, United States|Leslie, Michigan, United States|Livonia, Michigan, United States|Mason, Michigan, United States|Muskegon, Michigan, United States|Muskegon, Michigan, United States|Northville, Michigan, United States|Okemos, Michigan, United States|Okemos, Michigan, United States|Owosso, Michigan, United States|Pigeon, Michigan, United States|Rochester Hills, Michigan, United States|Southgate, Michigan, United States|Sterling Heights, Michigan, United States|Troy, Michigan, United States|Waterford, Michigan, United States|Cold Spring, Minnesota, United States|Ballwin, Missouri, United States|Cape Girardeau, Missouri, United States|Chesterfield, Missouri, United States|Clinton, Missouri, United States|Florissant, Missouri, United States|Hazelwood, Missouri, United States|Jefferson City, Missouri, United States|Kansas City, Missouri, United States|Kansas City, Missouri, United States|Kansas City, Missouri, United States|Kansas City, Missouri, United States|Mexico, Missouri, United States|Mt Vernon, Missouri, United States|Platte City, Missouri, United States|Raymore, Missouri, United States|St Joseph, Missouri, United States|St Louis, Missouri, United States|St Louis, Missouri, United States|St Louis, Missouri, United States|St. Charles, Missouri, United States|St. Louis, Missouri, United States|Warrenton, Missouri, United States|Washington, Missouri, United States|Weston, Missouri, United States|Henderson, Nevada, United States|Henderson, Nevada, United States|Las Vegas, Nevada, United States|Las Vegas, Nevada, United States|Atco, New Jersey, United States|Blackwood, New Jersey, United States|Bloomfield, New Jersey, United States|Brigantine, New Jersey, United States|East Orange, New Jersey, United States|Green Brook, New Jersey, United States|Irvington, New Jersey, United States|Irvington, New Jersey, United States|Iselin, New Jersey, United States|Jersey City, New Jersey, United States|Jersey City, New Jersey, United States|Kenilworth, New Jersey, United States|Lakewood, New Jersey, United States|Mays Landing, New Jersey, United States|Millburn, New Jersey, United States|Millburn, New Jersey, United States|Nutley, New Jersey, United States|Scotch Plains, New Jersey, United States|South Bound Brook, New Jersey, United States|Totowa, New Jersey, United States|Union, New Jersey, United States|Wenonah, New Jersey, United States|Westville, New Jersey, United States|Brooklyn, New York, United States|Glendale, New York, United States|Kenmore, New York, United States|Mayville, New York, United States|New York, New York, United States|New York, New York, United States|Orchard Park, New York, United States|Port Jefferson Station, New York, United States|Rochester, New York, United States|Staten Island, New York, United States|Staten Island, New York, United States|Suffern, New York, United States|Asheboro, North Carolina, United States|Jacksonville, North Carolina, United States|Raleigh, North Carolina, United States|Raleigh, North Carolina, United States|Akron, Ohio, United States|Akron, Ohio, United States|Ashtabula, Ohio, United States|Bowling Green, Ohio, United States|Canal Winchester, Ohio, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Cuyahoga Falls, Ohio, United States|Dayton, Ohio, United States|Defiance, Ohio, United States|Fairfield, Ohio, United States|Fremont, Ohio, United States|Gahanna, Ohio, United States|Genoa, Ohio, United States|Hamilton, Ohio, United States|Hamilton, Ohio, United States|Kent, Ohio, United States|Kingston, Ohio, United States|Lancaster, Ohio, United States|Maumee, Ohio, United States|New Lexington, Ohio, United States|Perrysburg, Ohio, United States|Pickerington, Ohio, United States|Springboro, Ohio, United States|Stow, Ohio, United States|Toledo, Ohio, United States|Toledo, Ohio, United States|Toledo, Ohio, United States|Toledo, Ohio, United States|Toledo, Ohio, United States|Warren, Ohio, United States|Youngstown, Ohio, United States|Youngstown, Ohio, United States|Stillwater, Oklahoma, United States|Estacada, Oregon, United States|Eugene, Oregon, United States|Lake Oswego, Oregon, United States|Milwaukie, Oregon, United States|Oregon City, Oregon, United States|Portland, Oregon, United States|Portland, Oregon, United States|Portland, Oregon, United States|Salem, Oregon, United States|Tualatin, Oregon, United States|Aliquippa, Pennsylvania, United States|Archbald, Pennsylvania, United States|Aston, Pennsylvania, United States|Avoca, Pennsylvania, United States|Bala Cynwyd, Pennsylvania, United States|Bensalem, Pennsylvania, United States|Carbondale, Pennsylvania, United States|Chicora, Pennsylvania, United States|Clarks Summit, Pennsylvania, United States|Collegeville, Pennsylvania, United States|Conneaut Lake, Pennsylvania, United States|Cowansville, Pennsylvania, United States|Downingtown, Pennsylvania, United States|Doylestown, Pennsylvania, United States|Drexel Hill, Pennsylvania, United States|Drums, Pennsylvania, United States|Dublin, Pennsylvania, United States|Elizabeth, Pennsylvania, United States|Elkins Park, Pennsylvania, United States|Ford City, Pennsylvania, United States|Greensburg, Pennsylvania, United States|Honesdale, Pennsylvania, United States|King Of Prussia, Pennsylvania, United States|Levittown, Pennsylvania, United States|McKeesport, Pennsylvania, United States|Montrose, Pennsylvania, United States|Moon Township, Pennsylvania, United States|Morrisville, Pennsylvania, United States|Mt. Pleasant, Pennsylvania, United States|New Castle, Pennsylvania, United States|New Wilmington, Pennsylvania, United States|Norristown, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Phoenixville, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Royersford, Pennsylvania, United States|Scranton, Pennsylvania, United States|Scranton, Pennsylvania, United States|Shippensburg, Pennsylvania, United States|Southampton, Pennsylvania, United States|Springfield, Pennsylvania, United States|Stoneboro, Pennsylvania, United States|Union City, Pennsylvania, United States|Warminster, Pennsylvania, United States|Wilkes-Barre, Pennsylvania, United States|Yardley, Pennsylvania, United States|Camden, South Carolina, United States|Charleston, South Carolina, United States|Charleston, South Carolina, United States|Columbia, South Carolina, United States|Greer, South Carolina, United States|Marion, South Carolina, United States|Marion, South Carolina, United States|West Columbia, South Carolina, United States|Ashland City, Tennessee, United States|Collierville, Tennessee, United States|Dyersburg, Tennessee, United States|Hendersonville, Tennessee, United States|Hermitage, Tennessee, United States|Lebanon, Tennessee, United States|McKenzie, Tennessee, United States|Memphis, Tennessee, United States|Nashville, Tennessee, United States|Nashville, Tennessee, United States|Newport, Tennessee, United States|Springfield, Tennessee, United States|Sweetwater, Tennessee, United States|Woodbury, Tennessee, United States|Arlington, Texas, United States|Ft Worth, Texas, United States|Irving, Texas, United States|Rusk, Texas, United States|Southlake, Texas, United States|Layton, Utah, United States|Layton, Utah, United States|South Jordan, Utah, United States|West Jordan, Utah, United States|West Valley City, Utah, United States|Annandale, Virginia, United States|Ashburn, Virginia, United States|Fairfax, Virginia, United States|Fairfax, Virginia, United States|Falls Church, Virginia, United States|Lynchburg, Virginia, United States|Reston, Virginia, United States|Edmonds, Washington, United States|Marysville, Washington, United States|Olympia, Washington, United States|Seattle, Washington, United States|Huntington, West Virginia, United States|Milwaukee, Wisconsin, United States|Milwaukee, Wisconsin, United States|Carolina, Puerto Rico|Cidra, Puerto Rico|Hato Rey, Puerto Rico|Juncos, Puerto Rico|Ponce, Puerto Rico|San Juan, Puerto Rico",,https://ClinicalTrials.gov/show/NCT00640042
1067,NCT01337089,Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain,,Completed,Has Results,Pain|Advanced Cancer,Drug: Nabiximols,Percent Of Participants With Treatment-emergent Adverse Events|Change From Baseline In Mean NRS Average Pain During The Last Period|Change From Baseline In Mean Sleep Disruption NRS During The Last Period|Patient Satisfaction Questionnaire At Last Visit (Up To Day 183)|Change From Baseline In NRS Constipation At Last Visit (Up To Day 183),"GW Pharmaceuticals Ltd.|Otsuka Pharmaceutical Development & Commercialization, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,660,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GWCA0999|2009-016529-32,2011-01-19,2016-01-27,2016-01-27,2011-04-18,2018-04-23,2018-04-23,"Phoenix, Arizona, United States|Phoenix, Arizona, United States|El Cajon, California, United States|Gilroy, California, United States|Glendale, California, United States|Santa Rosa, California, United States|Clearwater, Florida, United States|Daytona Beach, Florida, United States|Holiday, Florida, United States|Jacksonville, Florida, United States|Lynn Haven, Florida, United States|Miami, Florida, United States|Stuart, Florida, United States|Tampa, Florida, United States|Winter Park, Florida, United States|Marietta, Georgia, United States|Newnan, Georgia, United States|Stockbridge, Georgia, United States|Woodlawn, Illinois, United States|Ashland, Kentucky, United States|Bossier City, Louisiana, United States|Shreveport, Louisiana, United States|Saint Louis Park, Minnesota, United States|Kansas City, Missouri, United States|Missoula, Montana, United States|Berlin, New Jersey, United States|New York, New York, United States|New York, New York, United States|Flat Rock, North Carolina, United States|Winston-Salem, North Carolina, United States|Cleveland, Ohio, United States|Philadelphia, Pennsylvania, United States|Houston, Texas, United States|Laredo, Texas, United States|Salt Lake City, Utah, United States|Salt Lake City, Utah, United States|Lacey, Washington, United States|Parkville, Australia|Bruxelles, Belgium|Gabrovo, Bulgaria|Varna, Bulgaria|Vratsa, Bulgaria|Benešov, Czechia|Jablonec Nad Nisou, Czechia|Most, Czechia|Nová Ves Pod Pleší, Czechia|Ostrava, Czechia|Plzen, Czechia|Sokolov, Czechia|Teplice, Czechia|České Budějovice, Czechia|České Budějovice, Czechia|Berlin, Germany|Frankfurt, Germany|Jena, Germany|Lunen, Germany|Stadtroda, Germany|Wetzlar, Germany|Wiesbaden, Germany|Deszk, Hungary|Komarom, Hungary|Miskolc, Hungary|Nyíregyháza, Hungary|Szekszard, Hungary|Szikszo, Hungary|Beer Sheva, Israel|Haifa, Israel|Ramat Gan, Israel|Zerifin, Israel|Garbagnate Milanese, Italy|Piacenza, Italy|Torino, Italy|Riga, Latvia|Rēzekne, Latvia|Klaipeda, Lithuania|Siauliai, Lithuania|Vilnius, Lithuania|Chihuahua, Mexico|Distrito Federal, Mexico|Białystok, Poland|Bielsko-Biala, Poland|Bydgoszcz, Poland|Czeladz, Poland|Częstochowa, Poland|Częstochowa, Poland|Działdowo, Poland|Gdansk, Poland|Gliwice, Poland|Klodzko, Poland|Opole, Poland|Ostrowiec Swietokrzyski, Poland|Poznan, Poland|Warszawa, Poland|Warszawa, Poland|Wloclawek, Poland|Ponce, Puerto Rico|San Juan, Puerto Rico|Baia Mare, Romania|Baia Mare, Romania|Braila, Romania|Bucuresti, Romania|Bucuresti, Romania|Cluj-Napoca, Romania|Constanţa, Romania|Craiova, Romania|Focsani, Romania|Iaşi, Romania|Oradea, Romania|Satu Mare, Romania|Sibiu, Romania|Suceava, Romania|Târgovişte, Romania|Granada, Spain|Taichung, Taiwan|Tainan City, Taiwan|Bury Saint Edmunds, United Kingdom|Bury, United Kingdom|Cheltenham, United Kingdom|Crumpsall, United Kingdom|Edinburgh, United Kingdom|Edinburgh, United Kingdom|Gorleston-on-Sea, United Kingdom|Leeds, United Kingdom|Manchester, United Kingdom|Norwich, United Kingdom|Plymouth, United Kingdom|Weston-super-Mare, United Kingdom|Withington, United Kingdom",,https://ClinicalTrials.gov/show/NCT01337089
1068,NCT00295776,Lamictal in the Treatment of Post-Herpetic Neuralgia,,Terminated,No Results Available,"Neuralgia, Postherpetic",Drug: Lamictal in the treatment of Post-Herpetic Neuralgia,,George Washington University|GlaxoSmithKline,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,null,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double,Lamictal PHN,2005-02-01,2007-12-01,null,2006-02-24,null,2013-03-13,"Medical Faculty Associates, Washington DC, District of Columbia, United States",,https://ClinicalTrials.gov/show/NCT00295776
1069,NCT01221740,Pain Assessment and Quality of Life in Back Pain Patients: Role of Milnacipran,,Withdrawn,No Results Available,Back Pain,Drug: Savella,Decreased Back Pain,Brigham and Women's Hospital|Forest Laboratories,All,"18 Years and older   (Adult, Older Adult)",Phase 3,0,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2010-P-00977/1,2010-08-01,2011-08-01,2011-08-01,2010-10-15,null,2017-01-12,"Brigham and Women's Hospital Pain Trials Center, Chestnut Hill, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01221740
1070,NCT01694199,Pulsed Radiofrequency Energy to Treat Post-Bunionectomy Pain,,Terminated,Has Results,Post-operative Pain,Device: Pulsed Radiofrequency Energy (PRFE)|Device: No Pulsed Radiofrequency Energy (PRFE),"Overall Analgesic Efficacy (Via SPID 0-72 Hrs)|TOTPAR-Pain Relief Experienced by Patients T0-72 Hours|Opioid Consumption Measured in Morphine Equivalents T0-72 Hours|Number of Participants Who Assessed Pain Control at 72 Hours as Good, Very Good, or Excellent|Time to First Use of Supplemental Analgesic Medication","Regenesis Biomedical, Inc.",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,139,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",RBI.2012.003.P.2,2012-09-01,2012-11-01,2012-12-01,2012-09-27,2017-05-02,2017-05-02,"Lotus Clinical Research, Pasadena, California, United States|Chesapeake Research Group, Pasadena, Maryland, United States|Endeavor Clinical Trials, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT01694199
1071,NCT00749489,Improving Pain and Function in Hip Fracture,,Completed,No Results Available,Pain|Hip Fractures,Procedure: Femoral Nerve Block,Pain; 11-point Numeric Rating Scale|Delirium; Confusion Assessment Method (CAM).,Icahn School of Medicine at Mount Sinai|National Institute on Aging (NIA),All,"60 Years and older   (Adult, Older Adult)",Phase 3,164,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,GCO 06-0721|AG030141-01 A1,2008-11-01,2014-05-01,2014-05-01,2008-09-09,null,2014-06-25,"Beth Israel, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Maimonides Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00749489
1072,NCT00385684,Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT),LDOT,Completed,Has Results,"Alzheimer Disease|Dementia|Dementia, Vascular|Pain",Drug: hydrocodone/APAP w placebo PRN|Drug: hydrocodone/APAP|Drug: placebo with hydrocodone/APAP PRN,Pain Assessment in Advanced Dementia (PAINAD),VA Office of Research and Development,All,"55 Years and older   (Adult, Older Adult)",Phase 4,11,U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",F4483-I,2007-10-01,2011-12-01,2014-06-01,2006-10-11,2015-11-20,2015-11-20,"Tuscaloosa VA Medical Center, Tuscaloosa, Alabama, United States|Tuscaloosa Veterans Affairs Medical Center, Tuscaloosa, Alabama, United States|VA Medical Center, Tuscaloosa, Tuscaloosa, Alabama, United States",,https://ClinicalTrials.gov/show/NCT00385684
1073,NCT00142766,Sedation Management in Pediatric Patients Supported on Mechanical Ventilation,,Completed,No Results Available,Respiratory Failure,Behavioral: Nurse Implemented Goal-Directed Comfort Algorithm,Duration of Mechanical Ventilation|Time to Recovery of Lung Injury|Duration of Weaning from Mechanical Ventilation|Occurrence of Adverse Events|Total Exposure to Comfort Medications|Occurrence of Iatrogenic Abstinence Syndrome|PICU Length of Stay|Barriers to Successful Implementation of the Intervention|PICU costs,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Gustavus and Louise Pfeiffer Research Foundation,All,"up to 18 Years   (Child, Adult)",Phase 2,245,NIH|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R21HD045020,2004-02-01,2006-07-01,2007-03-01,2005-09-02,null,2015-10-07,"Children's National Medical Center, Washington, District of Columbia, United States|Children's Hospital Boston, Boston, Massachusetts, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00142766
1074,NCT00313846,Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or Knee,,Completed,Has Results,Osteoarthritis,Drug: Buprenorphine transdermal patch|Drug: Placebo,"The Time (Days) From First Administration of Double-blind Treatment to the Development of Inadequate Analgesia at the Primary Osteoarthritis Pain Site.|Daily Maximum ""Pain Right Now"" Score for the Primary Osteoarthritis (OA) Pain Site",Purdue Pharma LP,All,"40 Years to 75 Years   (Adult, Older Adult)",Phase 3,529,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BUP3012,2003-04-01,2004-06-01,2004-06-01,2006-04-12,2010-09-28,2012-09-03,"Vista Medical Research, Mesa, Arizona, United States|Arizona Research Center, Phoenix, Arizona, United States|Radiant Research, Phoenix, Arizona, United States|Arizona Research Center, Phoenix, Arizona, United States|ACRC/Arizona Clinical Research, Tucson, Arizona, United States|Advance Pain Medicine, Bakersfield, California, United States|Eastgate Medical Center, Cypress, California, United States|University Osteoporosis Ctr, Loma Linda, California, United States|San Diego Arthritis & Osteoporosis Medical Clinic, San Diego, California, United States|Scripps Clinic Rancho Bernard, San Diego, California, United States|CNS Clinical Trials, Inc, San Francisco, California, United States|Mountain View Clinical Research, Denver, Colorado, United States|Integrative Treatment Centers/Rocky Mtn Clin Res, Westminster, Colorado, United States|Rocky Mountain Center for Clinical Research, Wheat Ridge, Colorado, United States|Stamford Therapeutic Consortium, Bridgeport, Connecticut, United States|Medical Specialists of the Palm Beaches, Atlantis, Florida, United States|University Clinical Research Deland, Deland, Florida, United States|Drug Study Institute, Jupiter, Florida, United States|Coastal Medical Research, Orange City, Florida, United States|Coastal Medical Research, Port Orange, Florida, United States|Palm Beach Research Center, W. Palm Beach, Florida, United States|Gold Coast Research, Weston, Florida, United States|Non-Surgical Orthopedic & Spine Center, Marietta, Georgia, United States|Columbus Internal Medical Associates, Columbus, Indiana, United States|MediSphere Medical Research Ctr., Evansville, Indiana, United States|Primary Care Research, Murray, Kentucky, United States|Professional Clinical Research, Cadillac, Michigan, United States|Sound Medical At West Front Primary Care, Traverse City, Michigan, United States|Beth Israel Med Ctr Dept of Pain Medicine & Palliative Care, New York, New York, United States|All-Trials Clinical Research, LLC, Winston-Salem, North Carolina, United States|Keystone Clinical, Altoona, Pennsylvania, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|University Orthopedics Center, State College, Pennsylvania, United States|Clinical Research Center of Reading, LLP, West Reading, Pennsylvania, United States|Low Country Rheumatology, Charleston, South Carolina, United States|Brown Clinic, Watertown, South Dakota, United States|Private Practice, Dallas, Texas, United States|Team Research of Central Texas, Harker Heights, Texas, United States|Radiant Research San Antonio Northeast, San Antonio, Texas, United States|ACCU Clinical Research Trials, Inc, Seguin, Texas, United States|Wasatch Clinical Research, Salt Lake City, Utah, United States|Advance Pain Management & Rehab, Virgina Beach, Virginia, United States|Evergreen Clinical Research Associates, Edmonds, Washington, United States|Internal Medicine Northwest, Tacoma, Washington, United States",,https://ClinicalTrials.gov/show/NCT00313846
1075,NCT00313014,Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Low Back Pain,,Terminated,Has Results,Back Pain Lower Back Chronic,Drug: Buprenorphine|Drug: Oxycodone Immediate-Release,"Average Pain Over the Last 24 Hours Score at Weeks 4, 8, and 12.|Mean Daily Number of Supplemental Analgesic Tablets|Oswestry Disability Index (ODI) Score (V 2.0)|The Sleep Disturbance Subscale in the MOS-Sleep Scale at Weeks 4, 8, and 12.",Purdue Pharma LP,All,"18 Years and older   (Adult, Older Adult)",Phase 3,660,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BUP3015,2004-02-01,2005-09-01,2005-09-01,2006-04-11,2010-09-29,2012-09-03,"Birmingham Pain Center, Birmingham, Alabama, United States|Arthritis Clinical Intervention Program, Birmingham, Alabama, United States|Winston Physician Services, LLC, Haleyville, Alabama, United States|Arizona Research Center, Inc., Phoenix, Arizona, United States|Radiant Research, Phoenix, Arizona, United States|Advanced Clinical Therapeutics, Tuscon, Arizona, United States|Hot Springs Pain Clinic, Hot Springs, Arkansas, United States|NuLife Clinical Research, Inc., Anaheim, California, United States|Lovelace Scientific Resources, Inc., Beverly Hills, California, United States|Northern California Research Corp, Carmichael, California, United States|International Clinical Research Network, Chula Vista, California, United States|Shreenath Clinical Service, Fountain Valley, California, United States|U of Calif at Davis, Med Ctr, Pain Management Center, Sacramento, California, United States|Accelovance, San Diego, California, United States|Southern Colorado Clinic, Pueblo, Colorado, United States|Chiefland Medical Center, Chiefland, Florida, United States|University Clinical Research, Inc., Deland, Florida, United States|Drug Study Institute, Jupiter, Florida, United States|Innovative Research of West Florida, Inc., Largo, Florida, United States|Renstar Medical, Ocala, Florida, United States|Peninsula Research Inc., Ormond Beach, Florida, United States|The Arthritis Center, Palm Harbor, Florida, United States|University Clinical Research, Inc., Pembroke Pines, Florida, United States|Gold Coast Research, LLC, Plantation, Florida, United States|Coastal Medical Research, Port Orange, Florida, United States|Palm Beach Research Center, West Palm Beach, Florida, United States|Georgia Medical Research Institute, Marietta, Georgia, United States|Atlanta Knee & Shoulder Clinic, Stockbridge, Georgia, United States|Pain Care Boise, Boise, Idaho, United States|Idaho Arthritis and Osteoporosis Center, Meridian, Idaho, United States|Pain and Rehabilitation Clinic of Chicago, Chicago, Illinois, United States|GFI Research Center, Evansville, Indiana, United States|MediSphere Medical Research Center, LLC, Evansville, Indiana, United States|Medical Associates Clinics, Dubuque, Iowa, United States|Vince and Associates Clinical Research, Overland Park, Kansas, United States|CTT, Inc., Prairie Village, Kansas, United States|Commonwealth Biomedical Research, LLC, Madisonville, Kentucky, United States|New Orleans Clinical Trial Management Inc., Metairie, Louisiana, United States|Louisiana Research Associates, Inc., New Orleans, Louisiana, United States|Best Clinical Trials, LLC, New Orleans, Louisiana, United States|Research Center of Louisiana, New Orleans, Louisiana, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Future Care Studies, Springfield, Massachusetts, United States|Rheumatology PC, Kalamazoo, Michigan, United States|Lake Michigan Clinical Research & Consulting, Inc., Saint Joseph, Michigan, United States|Medex Healthcare Research, Inc., St Louis, Missouri, United States|HealthCare Research, St Louis, Missouri, United States|Meridian Clinical Research, LLC, Omaha, Nebraska, United States|Lovelace Scientific Resources, Henderson, Nevada, United States|Pivotal Research Centers, North Las Vegas, Nevada, United States|Research Across America, New York, New York, United States|Pain and Orthopedic Neurology , Charlotte Spine Center,, Charlotte, North Carolina, United States|Metrolina Medical Research, Charlotte, North Carolina, United States|Triangle Orthopaedic Associates, Durham, North Carolina, United States|Pharmquest, Greensboro, North Carolina, United States|MedArk Clinical Research, Morgantown, North Carolina, United States|Wake Research Associates, LLC, Raleigh, North Carolina, United States|Center for Clinical Research, Winston Salem, North Carolina, United States|Odyssey Research, Bismark, North Dakota, United States|COR Clinical Research, LLC, Oklahoma City, Oklahoma, United States|Associated Medical Services, Oklahoma City, Oklahoma, United States|Keystone Clinical Research, Altoona, Pennsylvania, United States|Valley Pain Specialists, Bethlehem, Pennsylvania, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Central Pennsylvania Clinical Research, Mechanicsburg, Pennsylvania, United States|BioMedical Research Associates, Shippensburg, Pennsylvania, United States|University Orthopedics Center, State College, Pennsylvania, United States|New England Center Clinical Research, Cranston, Rhode Island, United States|Omega Medical Research, Warwick, Rhode Island, United States|Arthritis & Osteoporosis Center, Orangeburg, South Carolina, United States|Brown Clinic, Watertown, South Dakota, United States|Holston Medical Group, Bristol, Tennessee, United States|Tri Cities Medical Research, Bristol, Tennessee, United States|Holston Medical Group, Kingsport, Tennessee, United States|Galenos Research, Dallas, Texas, United States|Benchmark Research, Fort Worth, Texas, United States|Team Research of Central Texas, Harker Heights, Texas, United States|KRK Medical Research, Richardson, Texas, United States|Benchmark Research, San Angelo, Texas, United States|Unlimited Research, San Antonio, Texas, United States|Texas Medical Research Associates, San Antonio, Texas, United States|Clinical Trial Network Oaks Medical Center, Spring, Texas, United States|N. Texas Neuro Research, Wichita Falls, Texas, United States|Lifetree Clinical Research, Salt Lake City, Utah, United States|Dean Medical Center, Oregon, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00313014
1076,NCT00312195,Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Nonmalignant Pain,,Completed,Has Results,Chronic Non-malignant Pain,Drug: Buprenorphine transdermal patch|Drug: Placebo to match BTDS,The Number of Subjects With Ineffective Treatment During the Double-blind Evaluation Phase.|Time (Days) From the Initial Dose of Study Drug in the Double-blind Evaluation Phase to Ineffective Treatment|The Number of Subjects Who Had Ineffective Treatment or Who Discontinued Due to Reasons Other Than Ineffective Treatment in the Double-blind Phase|The Amount of Rescue Medication Used for Pain (Average Daily Number of Acetaminophen Tablets).,Purdue Pharma LP|Napp Pharmaceuticals Limited,All,"18 Years and older   (Adult, Older Adult)",Phase 3,267,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BUP3201,2001-03-01,2001-07-01,2001-07-01,2006-04-07,2010-10-15,2012-09-10,"Hawthorne and York, Phoenix, Arizona, United States|Arizona Research Center Inc, Phoenix, Arizona, United States|Clinical Research Consultants Inc, Trumbull, Connecticut, United States|Tampa Bay Medical Research Inc, Clearwater, Florida, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|University Clinical Research Deland, Deland, Florida, United States|University Clinical Research Inc,, Pembroke Pines, Florida, United States|Gold Coast Research LLC, Plantation, Florida, United States|Gold Coast Research LLC, Tamarac, Florida, United States|Family Medicine Associates, Evansville, Indiana, United States|Pain Management and Rehabilitation, Terre Haute, Indiana, United States|Southeastern Center for Headache and Pain, Crestview Heights, Kentucky, United States|Westside Family Medical Center PC, Kalamazoo, Michigan, United States|The Arthritis Clinic, Charlotte, North Carolina, United States|Cornerstone Research Care, High Point, North Carolina, United States|ALL-TRIALS Clinical Research LLC, Winston-Salem, North Carolina, United States|Private Practice, Chardon, Ohio, United States|Summit Research Solutions, Memphis, Tennessee, United States|Radiant Research, Austin, Texas, United States|Wasatch Clinical Research, Salt Lake City, Utah, United States|Clinical Research Management, New Berlin, Wisconsin, United States|Whiteabbey Health Centre, Newtownabbey, Belfast, United Kingdom|Antrim Coast Fundholding Group, Lame, Co Antrim, United Kingdom|Portglenone Health Centre, Portglenone, CO Antrim, United Kingdom|Garden Street Surgery, Magherafelt, Co Derry, United Kingdom|Springhill Surgery, Bangor, Co Down, United Kingdom|Bennett Road Surgery, Keresley End, Coventry, United Kingdom|Little Common Surgery, Bexhill-on-Sea, E Sussex, United Kingdom|Old Town Surgery, Bexhill-on-Sea, E Sussex, United Kingdom|Roebuck House Surgery, Hastings, E Sussex, United Kingdom|Leslie Surgery, Glenrothes, Fife, United Kingdom|Valleyfield Health Centre, High Valleyfield, Fife, United Kingdom|Ashvale Health Centre, Aldershot, Hants, United Kingdom|The Academy Medical Practice, Coatbridge, Lanarkshire, United Kingdom|Sanbury Health Centre Group Practice, Sunbury-on-Thames, Middx, United Kingdom|Houston Surgery, Houston, Renfrewshire, United Kingdom|The Burns Practice, Doncaster, S Yorkshire, United Kingdom|Grosvenor Medical Centre, Tunbridge Wells, W Sussex, United Kingdom|Gables Medical Section, Coventry, Warwickshire, United Kingdom|The Ridge Medical Practice, Great Horton, Bradford, West Yorkshire, United Kingdom|Townhead Health Centre, Glasgow, United Kingdom|Castlemilk Health Centre, Glasgow, United Kingdom",,https://ClinicalTrials.gov/show/NCT00312195
1077,NCT01400139,Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period.,,Completed,Has Results,Chronic Nonmalignant and Nonneuropathic Pain,Drug: Hydrocodone bitartrate q24h film-coated tablets,"The Number of Participants With Adverse Events as a Measure of Safety|Daily ""Average Pain Over the Last 24 Hours""|""Pain Right Now"" Score|Medical Outcomes Study (MOS) Sleep Scale - Revised (MOS Sleep-R)|Brief Pain Inventory Short Form (BPI-SF) - Pain Interference|Medical Outcomes Study 36-item Short Form (SF-36)|Patient Global Impression of Change (PGIC)|Treatment Satisfaction Questionnaire (TSQ) - Part I|Treatment Satisfaction Questionnaire (TSQ) - Part II",Purdue Pharma LP,All,"18 Years and older   (Adult, Older Adult)",Phase 3,922,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HYD3003,2011-07-01,2013-08-01,2013-10-01,2011-07-22,2014-12-04,2017-10-24,"Alliance Clinical Research, Birmingham, Alabama, United States|Arizona Research Center, Phoenix, Arizona, United States|Genova Clinical Research, Tucson, Arizona, United States|Quality of Life Medical & Research Center, LLC, Tucson, Arizona, United States|ACRI -Phase1, LLC, Anaheim, California, United States|United Clinical Research Center, Inc., Anaheim, California, United States|Med Center, Carmichael, California, United States|Research Center of Fresno, Inc., Fresno, California, United States|TriWest Research Associates, La Mesa, California, United States|Torrance Clinical Research, Lomita, California, United States|Skyline Research, LLC, Long Beach, California, United States|Lotus Clinical Research, LLC, Pasadena, California, United States|Center for Clinical Research, Inc, Richmond, California, United States|Northern California Research, Sacramento, California, United States|Encompass Clinical Research, Spring Valley, California, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|Meridien Research, Bradenton, Florida, United States|Innovative Research of West Florida, Inc., Clearwater, Florida, United States|Avail Clinical Research, LLC, DeLand, Florida, United States|Clinical Physiology Associates, Fort Myers, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|AGA Clinical Trials, Hialeah, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Health Awareness, Inc., Jupiter, Florida, United States|Fidelity Clinical Research, Inc., Lauderhill, Florida, United States|Neuroscience Consultants LLC, Miami, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Peninsula Research, Inc., Ormond Beach, Florida, United States|Gold Coast Research, LLC, Plantation, Florida, United States|Clinical Research of West Florida, Inc., Tampa, Florida, United States|Southeast Regional Research Group, Columbus, Georgia, United States|Georgia Institute for Clinical Research, LLC, Marietta, Georgia, United States|Taylor Research, LLC, Marietta, Georgia, United States|Atlanta Knee and Shoulder Clinic, PC, Stockbridge, Georgia, United States|Illinois Center for Clinical Research, Chicago, Illinois, United States|Rehabilitation Associates of Indiana, Indianapolis, Indiana, United States|Northwest Indiana Center for Clinical Research, Valparaiso, Indiana, United States|Integrated Clinical Trial Services, Inc., West Des Moines, Iowa, United States|ICRI, Leawood, Kansas, United States|Community Research, Crestview Hills, Kentucky, United States|Commonwealth Biomedical Research, LLC, Madisonville, Kentucky, United States|Louisiana Research Associates, Inc., New Orleans, Louisiana, United States|Beacon Clinical Research, LLC, Brockton, Massachusetts, United States|MedVadis Research Corporation, Watertown, Massachusetts, United States|Medical Research Associates, Inc., Traverse City, Michigan, United States|Medex Healthcare Research, Inc., Saint Louis, Missouri, United States|Advance Clinical Research, Saint Louis, Missouri, United States|Mercy Health Research, Saint Louis, Missouri, United States|Sundance Clinical Research, LLC, Saint Louis, Missouri, United States|Quality Clinical Research, Omaha, Nebraska, United States|Advanced Biomedical Research of America, Las Vegas, Nevada, United States|Research Facility, Las Vegas, Nevada, United States|Comprehensive Clinical Research, Berlin, New Jersey, United States|CRI Worldwide LLC, Willingboro, New Jersey, United States|Lovelace Scientific Resources, Albuquerque, New Mexico, United States|Drug Trials America, Hartsdale, New York, United States|Research Across America, New York, New York, United States|The Medical Research Network, LLC, New York, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Upstate Clinical Research Associates, Williamsville, New York, United States|PMG Research of Charlotte, LLC, Charlotte, North Carolina, United States|PMG Research of Wilmington LLC, Wilmington, North Carolina, United States|Clinical Trials of America, Inc., Winston-Salem, North Carolina, United States|The Center for Clinical Research, Winston-Salem, North Carolina, United States|Daystar Clinical Research, Inc., Akron, Ohio, United States|IVA Research, Cincinnati, Ohio, United States|Community Research, Cincinnati, Ohio, United States|Bone Joint and Spine Surgeons, Inc., Toledo, Ohio, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|Allegheny Pain Management, P.C., Altoona, Pennsylvania, United States|Pennsylvania Research Institute, Bensalem, Pennsylvania, United States|CRI Worldwide LLC, Philadelphia, Pennsylvania, United States|Founders Research Corporation, Philadelphia, Pennsylvania, United States|Tipton Medical & Diagnostic Center, Tipton, Pennsylvania, United States|Hartwell Research Group, Anderson, South Carolina, United States|Pain Research of Charleston, Charleston, South Carolina, United States|Radiant Research, Inc., Greer, South Carolina, United States|Health Concepts, Rapid City, South Dakota, United States|Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States|Heartland Medical, PC, New Tazewell, Tennessee, United States|HCCA Clinical Research Solutions, Smyrna, Tennessee, United States|FutureSearch Trials of Neurology, Austin, Texas, United States|Lovelace Scientific Resources, Inc., Austin, Texas, United States|KRK Medical Research, Dallas, Texas, United States|Heights Doctor's Clinic, Houston, Texas, United States|JVC Family Medicine, Houston, Texas, United States|Pioneer Research Solutions, Inc., Houston, Texas, United States|TEAM Research of Central Texas, Killeen, Texas, United States|R/D Clinical Research, Inc., Lake Jackson, Texas, United States|DCOL Center for Clinical Research, Longview, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|Martin Diagnostic Clinic, Tomball, Texas, United States|Aspen Clinical Research, Orem, Utah, United States|Advanced Clinical Research, West Jordan, Utah, United States|HypotheTest, LLC, Roanoke, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Washington Center for Pain Management, Edmonds, Washington, United States",,https://ClinicalTrials.gov/show/NCT01400139
1078,NCT00314652,Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.,,Completed,No Results Available,Osteoarthritis,Drug: Buprenorphine transdermal delivery system,Percentage of patients who were treated successfully for pain management|a patient fails if he or she discontinues early due to ineffective treatment or has a Patient Satisfaction Scale score of poor or fair at the final visit|Average pain intensity and patient satisfaction scores|Incidence of early discontinuation due to lack of efficacy|Time to early discontinuation due to lack of efficacy|Dose level at end of titration|Investigator’s assessment of therapeutic response|Diary pain scores,Purdue Pharma LP,All,"18 Years and older   (Adult, Older Adult)",Phase 3,260,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,BP99-0203,1999-06-01,null,1999-10-01,2006-04-14,null,2006-05-03,"Hawthorne & York, International, Ltd., Phoenix, Arizona, United States|Arizona Research Center, LLC, Phoenix, Arizona, United States|ACRC/Arizona Clinical Research, Tucson, Arizona, United States|Advanced Clinical Therapeutics, Tucson, Arizona, United States|San Diego Arthritis and Osteoporosis Research, San Diego, California, United States|Scripps Clinic Rancho Bernardo, San Diego, California, United States|Clinical Research Consultants, Inc., Trumbull, Connecticut, United States|Tampa Bay Medical Research, Inc., Clearwater, Florida, United States|University Clinical Research, Deland, Florida, United States|Gainesville Clinical Research Center, Gainesville, Florida, United States|Physicians Research Associates Jacksonville, Jacksonville, Florida, United States|University Clinical Research, Inc., Pembroke Pines, Florida, United States|Gold Coast Research, Inc., Weston, Florida, United States|MediSphere Medical Research Center, LLC, Evansville, Indiana, United States|Westside Family Medical Center, Kalamazoo, Michigan, United States|Center for Pharmaceutical Research, Kansas City, Missouri, United States|NJP Clinical Research, Passaic, New Jersey, United States|PW Clinical Research, LLC, Winston-Salem, North Carolina, United States|New Century Research Center, Ltd., Beaverbrook, Ohio, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Mid-South Clinical Research Institute, Memphis, Tennessee, United States|Advanced Clinical Research, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT00314652
1079,NCT00315848,The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.,,Completed,No Results Available,Osteoarthritis,Drug: Buprenorphine transdermal delivery system,"Pain on average and pain right now scores at days 0, 9, 15, 30, 45, 60, or at early termination.|Brief Pain Inventory|dropouts due to lack of efficacy|MOS health survey|VAS pain intensity|therapeutic response|patient preference|daily patient diary|and number of oxycodone/acetaminophen or placebo tablets taken",Purdue Pharma LP,All,"18 Years and older   (Adult, Older Adult)",Phase 3,225,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,BP96-0101,1996-11-01,null,1999-12-01,2006-04-19,null,2006-05-03,"Rheumatology Associates of North Alabama, Huntsville, Alabama, United States|Arizona Research and Education, Phoenix, Arizona, United States|Phoenix Center for Clinical Research, Phoenix, Arizona, United States|Western Integrated Pain Treatment Centers, Westminster, Colorado, United States|Gainesville Clinical Research Center, Gainesville, Florida, United States|Park Place Therapeutic Center, Plantation, Florida, United States|MediSphere Medical Research Center, L.L.C., Evansville, Indiana, United States|Stratton VA Medical Center, Albany, New York, United States|Metroplex Clinical Research Center, Dallas, Texas, United States|Arthritis Diagnostic and Treatment Center, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00315848
1080,NCT00226395,Efficacy and Safety of Oxymorphone Immediate Release in Post-surgical Acute Pain,,Completed,No Results Available,Acute Pain,Drug: Oxymorphone immediate release,Time to discontinuation due to all causes|The following are the secondary endpoints during the initial 6 hours following the first dose of study medication:|- 6-Hour Sum of Pain Intensity Differences (SPID; VAS and categorical)|- 6-Hour Total Pain Relief Scores (TOTPAR; VAS and categorical)|- Time (in hours) to First Perceptible Pain Relief|- Time (in hours) to Meaningful Pain Relief|- Hourly Pain Relief Scores|- Hourly Pain Intensity Difference Scores|The following are the secondary endpoints during the multiple dosing phase:|- Mean average pain intensity scores collected during the dosing intervals.|- Mean current pain intensity (VAS) collected during the dosing intervals.|- Patient's global evaluation of study medication at the end of study.|- Physician's global evaluation of study medication at the end of study.,Endo Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 3,320,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,EN3203-009,2004-09-01,null,2005-08-01,2005-09-27,null,2010-02-15,"Brookwood Medical Center, Birmingham, Alabama, United States|The Medical Center, Dept. Clinical research, Birmingham, Alabama, United States|Montgomery Women's Health Associates, Montgomery, Alabama, United States|Arrowhead Community Hospital, Phoenix, Arizona, United States|John C Lincoln Hospital, Phoenix, Arizona, United States|Paradise Valley Hospital, Phoenix, Arizona, United States|Glendale Adventist Medical Center, Glendale, California, United States|Saddleback Memorial Medical Center, Laguna Hills, California, United States|Huntington Memorial Hospital, Pasadena, California, United States|Palm West Hospital, Palm Springs, Florida, United States|Sacred Heart Hospital, Pensacola, Florida, United States|Duke University Medical Center, Durham, North Carolina, United States|Forsyth Medical Center, Winston-Salem, North Carolina, United States|Medical Park Hospital, Winston-Salem, North Carolina, United States|Univ. Pittsburgh Hospital, Pittsburgh, Pennsylvania, United States|Univ. Pittsburgh Medical center, Pittsburgh, Pennsylvania, United States|Memorial Hermann Memorial City Hospital, Houston, Texas, United States|The Methodist Hospital, Houston, Texas, United States|Cottonwood Hospital, Salt Lake City, Utah, United States|LDS Hospital, Salt Lake City, Utah, United States|McKay-Dee Hospital, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT00226395
1081,NCT02858726,Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus,,Completed,No Results Available,Uremic Pruritus,Drug: CR845 0.5 mcg/kg|Drug: CR845 1 mcg/kg|Drug: CR845 1.5mcg/kg|Drug: Placebo,"Part A: An assessment of 3 dose levels of CR845 and placebo in reducing the intensity of itch in hemodialysis patients|Part B: An assessment of CR845 compared to placebo in reducing the intensity of itch in hemodialysis patients|Part A and Part B: Safety of IV CR845 will be assessed by physical examination, monitoring of adverse events, vital signs and laboratory assessments|Part A: The pharmacokinetic profile of CR845 will be determined between Week 1 and Week 8. The calculation of the accumulation ratio between the first and last doses with respect to Cmax will be reported.|Part A: The pharmacokinetic profile of CR845 will be determined between Week 1 and Week 8. The calculation of the accumulation ratio between the first and last doses with respect to AUC will be reported.","Cara Therapeutics, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,175,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CR845-CLIN2101,2016-06-01,2017-03-14,2017-03-14,2016-08-08,null,2018-07-19,"Cara Therapeutics Investigator Site, Phoenix, Arizona, United States|Cara Therapeutics Study Site, Pine Bluff, Arkansas, United States|Cara Therapeutics Investigator Site, Long Beach, California, United States|Cara Therapeutics Study Site, Northridge, California, United States|Cara Therapeutics Study Site, Whittier, California, United States|Cara Therapeutics Study Site, Denver, Colorado, United States|Cara Therapeutics Study Site, Hollywood, Florida, United States|Cara Therapeutics Study Site, Tampa, Florida, United States|Cara Therapeutics Study Site, Winter Park, Florida, United States|Cara Therapeutics Study Site, Augusta, Georgia, United States|Cara Therapeutics Study Site, Meridian, Idaho, United States|Cara Therapetics Study Site, Creve Coeur, Missouri, United States|Cara Therapeutics Study Site, Kansas City, Missouri, United States|Cara Therapeutics Study Site, Kansas City, Missouri, United States|Cara Therapeutics Study Site, Omaha, Nebraska, United States|Cara Therapetics Investigator Site, Albuquerque, New Mexico, United States|Cara Therapeutics Study Site, Gallup, New Mexico, United States|Cara Therapeutics Study Site, College Point, New York, United States|Cara Therapeutics Investigator Site, Mineola, New York, United States|Cara Therapeutics Investigator Site, Wilmington, North Carolina, United States|Cara Therapeutics Study Site, Winston-Salem, North Carolina, United States|Cara Therapeutics Study Site, Bethlehem, Pennsylvania, United States|Cara Therapeutics Investigator Site, Philadelphia, Pennsylvania, United States|Cara Therapeutics Study Site, Chattanooga, Tennessee, United States|Cara Therapetics Study Site, Knoxville, Tennessee, United States|Cara Therapeutics Study Site, San Antonio, Texas, United States|Cara Therapeutics Study Site, San Antonio, Texas, United States|Cara Therapeutics Study Site, San Antonio, Texas, United States|Cara Therapeutics Study Site, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02858726
1082,NCT02229929,"Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus",,Completed,No Results Available,Pruritus|Uremic Pruritus,Drug: Part A: Placebo|Drug: Part A: CR845 0.5 mcg/kg|Drug: Part A: CR845 1.0 mcg/kg|Drug: Part A: CR845 2.5 mcg/kg|Drug: Part B: Placebo|Drug: Part B: CR845 1.0 mcg/kg,"Part A: Determine the Pharmacokinetics of Repeated Doses of CR845 in Hemodialysis Patients (half-life, Cmax, Tmax, AUC, Vd)|Part B: Change in Worst Itching Intensity using a 100-mm Visual Analog Scale|Part B: Change in quality-of-life assessed using the Skindex-10 survey|Part B: Sleep disturbance assessed using Itch Medical Outcomes Study (MOS) survey","Cara Therapeutics, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,89,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CR845-CLIN2005,2014-07-01,2015-07-01,2015-07-01,2014-09-03,null,2016-08-10,"US Renal Care, Pine Bluff, Arkansas, United States|US Renal Care, Chula Vista, California, United States|US Renal Care, Long Beach, California, United States|Valley Renal Medical Group, Northridge, California, United States|Nephrology Specialists Medical Group, Inc, Orange, California, United States|North American Research Institute, San Dimas, California, United States|University of Florida College of Medicine Jacksonville, Jacksonville, Florida, United States|Orlando Clinical Research Center, Orlando, Florida, United States|Pines Clinical Research, Inc., Pembroke Pines, Florida, United States|Emory Dialysis Center at Northside, Atlanta, Georgia, United States|Western New England Renal & Transplant Associates, PC, Springfield, Massachusetts, United States|US Renal Care, Gallup, New Mexico, United States|Trude Weishaupt Memorial Dialysis Center, Fresh Meadows, New York, United States|Winthrop University Hospital, Mineola, New York, United States|Brookview Hills Research Associates, LLC, Winston Salem, North Carolina, United States|US Renal Care, Aiken, South Carolina, United States|Southeast Renal Research Institute, Chattanooga, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|US Renal Care, Grand Prairie, Texas, United States|US Renal Care, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT02229929
1083,NCT00279110,Directly Administered HIV Therapy in Methadone Clinics,,Completed,No Results Available,HIV Infections|Heroin Dependence,Behavioral: Directly administered antiretroviral therapy (DAART),HIV RNA < 50 c/mL|Log10 change in HIV RNA from baseline|HIV RNA < 50 c/mL 6 mos. after intervention|Log10 change in HIV RNA from baseline 6 months post intervention|Change in CD4 cell count from baseline|ART utilization|Development of antiretroviral resistance|Retention to substance abuse treatment|Urine drug screen positivity in follow-up|Electronically monitored adherence,Johns Hopkins University|National Institute on Drug Abuse (NIDA),All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,107,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R01DA018577,2006-04-01,2011-05-01,2011-05-01,2006-01-19,null,2015-04-15,"Baltimore VA Drug Dependency Program, Baltimore, Maryland, United States|Program for Alcohol and Other Drug Dependencies, Baltimore, Maryland, United States|Man Alive, Inc., Baltimore, Maryland, United States|New Hope Treatment Center, Baltimore, Maryland, United States|Day Break Methadone Clinic, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00279110
1084,NCT02524197,A Study of the Safety and Effectiveness of Orally Administered CR845 in Patients With Osteoarthritis of the Hip or Knee,,Completed,No Results Available,Osteoarthritis,Drug: CR845 0.25 mg|Drug: CR845 0.50 mg|Drug: CR845 1 mg|Drug: CR845 5 mg,"To assess the Safety and Tolerability of orally-administered CR845 in patients with osteoarthritis of the hip or the knee, in sequentially escalating doses (0.25 mg, 0.50 mg, 1 mg and 5 mg).|To characterize the pharmacokinetic (pk) profile of orally-administered CR845 with twice a day (b.i.d) dosing|To explore the effectiveness of orally administered CR845 in this patient population","Cara Therapeutics, Inc.",All,"25 Years and older   (Adult, Older Adult)",Phase 2,81,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,CR845-CLIN2001-PO,2015-08-01,2016-01-01,2016-01-01,2015-08-14,null,2017-01-31,"Heartland Clinical Research, Omaha, Nebraska, United States|Matthew Barton, MD, Las Vegas, Nevada, United States|Triad Clinical Trials, LLC, Greensboro, North Carolina, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Clinical Investgations of Texas, Plano, Texas, United States",,https://ClinicalTrials.gov/show/NCT02524197
1085,NCT02603705,Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain,,Completed,No Results Available,Moderate-to-severe Chronic Noncancer Pain,Drug: Oxycodone extended-release,"Incidence of TEAEs during the Open-label Treatment Period, including those leading to treatment withdrawal, and/or abnormal physical examination findings, vital signs measurements, ECGs, and clinical laboratory test results, related to treatment|Findings of the Brief Pain Inventory-Short Form (BPI-SF) during the Open-label Treatment Period",Egalet Ltd,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,281,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OC-EG-303,2016-03-07,2017-06-15,2017-06-15,2015-11-13,null,2018-03-05,"Site 334, Huntsville, Alabama, United States|Site 328, Tucson, Arizona, United States|Site 332, Jacksonville, Florida, United States|Site 340, Miami Gardens, Florida, United States|Site 320, Plantation, Florida, United States|Site 302, Tampa, Florida, United States|Site 315, Tampa, Florida, United States|Site 310, Winter Haven, Florida, United States|Site 316, Dawsonville, Georgia, United States|Site 311, Marietta, Georgia, United States|Site 336, Bloomington, Illinois, United States|Site 345, Blue Island, Illinois, United States|Site 304, Evansville, Indiana, United States|Site 325, Valparaiso, Indiana, United States|Site 321, Overland Park, Kansas, United States|Site 342, Wichita, Kansas, United States|Site 329, New Orleans, Louisiana, United States|Site 326, Quincy, Massachusetts, United States|Site 303, Saint Louis, Missouri, United States|Site 306, Las Vegas, Nevada, United States|Site 313, Belvidere, New Jersey, United States|Site 346, Blackwood, New Jersey, United States|Site 323, Hartsdale, New York, United States|Site 338, Mooresville, North Carolina, United States|Site 333, Cincinnati, Ohio, United States|Site 343, Cleveland, Ohio, United States|Site 308, Huber Heights, Ohio, United States|Site 347, Kettering, Ohio, United States|Site 335, Oklahoma City, Oklahoma, United States|Site 312, Eugene, Oregon, United States|Site 322, Duncansville, Pennsylvania, United States|Site 324, Wyomissing, Pennsylvania, United States|Site 344, Myrtle Beach, South Carolina, United States|Site 314, Summerville, South Carolina, United States|Site 341, New Tazewell, Tennessee, United States|Site 318, Austin, Texas, United States|Site 330, Dallas, Texas, United States|Site 309, San Antonio, Texas, United States|Site 331, West Jordan, Utah, United States",,https://ClinicalTrials.gov/show/NCT02603705
1086,NCT00801398,Open-Label Safety and Tolerability Study of Oxymorphone for Acute Postoperative Pain in Pediatric Subjects.,,Completed,No Results Available,Postoperative Pain,Drug: Oxymorphone IR,"During the Single-Dose Period, the safety of oxymorphone IR in children >12-17 years requiring an opioid to treat their acute postoperative pain of various etiologies will be assessed.",Endo Pharmaceuticals,All,12 Years to 17 Years   (Child),Phase 3,60,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EN3203-010,2008-12-01,2011-09-01,2011-11-01,2008-12-03,null,2015-06-12,"Arkansas Children's Hospital, Little Rock, Arkansas, United States|Stanford University School of Medicine, Stanford, California, United States|The Children's Hospital, Aurora, Colorado, United States|Children's Research Institute, Washington, District of Columbia, United States|St. Joseph's Children's Hospital of Tampa, Tampa, Florida, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|Hershey Medical Center, Hershey, Pennsylvania, United States|The Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Washington, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00801398
1087,NCT00313833,Safety and Effectiveness of Buprenorphine Transdermal System in Elderly Subjects With Chronic Pain: Pilot Study.,,Completed,No Results Available,Chronic Pain,Drug: Buprenorphine transdermal delivery system,"Pilot study.|The following outcome variables were assessed:|average pain intensity in the last 24 hours|acceptability of analgesic therapy|number of nighttime awakenings due to pain last night|quality of sleep|bowel status during the last 24 hours|pain management evaluation|symptom evaluation|staff evaluation of functional independence|resident-defined activity impairment scale|treatment satisfaction questionnaire|Health Assessment Questionnaire|Timed ""Up & Go"" evaluation|trail making test|digit span test|end of study global evaluation of therapeutic response|modified mini-mental state|examination and geriatric depression scale.|The following measures of health resource utilization were assessed:|use of analgesic medications (usual care plus BTDS) by product type|use of analgesic medications (usual care plus BTDS) by medication and dosage form|use of pain-related adjuvant medications by product type|number of phone calls to physicians for pain management|number of physician visits for pain management|and use of medications for the treatment of drug-related adverse events.",Purdue Pharma LP,All,"55 Years and older   (Adult, Older Adult)",Phase 3,100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,BUP3002,2000-12-01,null,2001-11-01,2006-04-12,null,2006-05-03,"Birmingham Health Center, Birmingham, Alabama, United States|Arizona Research Center, Phoenix, Arizona, United States|Advanced Clinical Research Institute, Anaheim, California, United States|Associated Physicians of Southbury, Southbury, Connecticut, United States|Life Care Home Health Services, Delray Beach, Florida, United States|Ward Parkway Health Services, Leawood, Kansas, United States|Atlantic Medical Group LLC, Baltimore, Maryland, United States|Bortz Health Care of Warren, Warren, Michigan, United States|Bio-Test Clinic, Springfield, Missouri, United States|Kings Harbor Multicare Center, Bronx, New York, United States|Glengariff Health Care Center, Glen Cove, New York, United States|Regency Manor, Columbus, Ohio, United States|Associated Medical Services Inc, Oklahoma City, Oklahoma, United States|Town Center Village, Portland, Oregon, United States|Center for Pain Management, Altoona, Pennsylvania, United States|LAS/Health and Wellness Center, Zelienople, Pennsylvania, United States|Geriatric Associates of America Inc PA, Baytown, Texas, United States|Wisconsin Veterans Home, King, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00313833
1088,NCT01539538,"A Multicenter, Randomized, Open-Label, Parallel-Group Trial to Compare the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™)to Intravenous Patient-Controlled Analgesia With Morphine for the Treatment of Acute Post-Operative Pain",,Completed,Has Results,Post-Operative Pain,Drug: Sufentanil NanoTab PCA System/15 mcg|Drug: morphine IV PCA,Patient Global Satisfaction,"AcelRx Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,357,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IAP309,2012-04-01,2012-12-01,2012-12-01,2012-02-27,2014-03-27,2015-10-01,"Eliza Coffee Memorial Hospital, Florence, Alabama, United States|Drug Research and Analysis Corp, Montgomery, Alabama, United States|Shoals Medical Trials, Inc, Sheffield, Alabama, United States|Arizona Research Center, Phoenix, Arizona, United States|Lotus Clinical Research, Pasadena, California, United States|Thorton Hospital, San Diego, California, United States|Florida Research Associates, LLC, DeLand, Florida, United States|River City Clinical Research, Jacksonville, Florida, United States|Pensacola Research Consultants, Inc, Pensacola, Florida, United States|Gulfcoast Research Institute, Sarasota, Florida, United States|Phoenix Clinical Research LLC, Tamarac, Florida, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Access Clinical Trials, Nashville, Tennessee, United States|Endeavor Clinical Trials, PA, San Antonio, Texas, United States|Jean Brown Research, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT01539538
1089,NCT02574520,Trial of Extended Release Bupivacaine for Pain Relief After Surgery,PERSIST,Completed,No Results Available,Post Operative Pain,Drug: SABER®-Bupivacaine|Drug: Bupivacaine HCl,Pain intensity using the NPRS-11 with movement|Total IV morphine-equivalent dose of rescue opioids|Composite endpoint of Silverman's Integrated Analgesic (SIA) assessment score|Proportion of patients taking no opioid rescue medication from PACU discharge|Time to first opioid rescue medication use after discharge from the PACU|Time to PACU discharge eligibility as assessed by modified Post-Anesthesia Discharge Scoring System (mPADSS),Durect,All,"18 Years and older   (Adult, Older Adult)",Phase 3,296,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",C803-028,2015-11-01,2017-06-01,2017-08-01,2015-10-14,null,2018-05-25,"Durect Study Site 04, Florence, Alabama, United States|Durect Study Site 03, Sheffield, Alabama, United States|DURECT Study Site 24, Arcadia, California, United States|Durect Study Site 15, Fontana, California, United States|Durect Study Site 02, Laguna Hills, California, United States|Durect Study Site 18, Laguna Hills, California, United States|Durect Study Site 22, Pensacola, Florida, United States|Durect Study Site 12, Indianapolis, Indiana, United States|Durect Study Site 21, Royal Oak, Michigan, United States|Durect Study Site 17, Jackson, Mississippi, United States|Durect Study Site 16, Las Vegas, Nevada, United States|Durect Study Site 20, Las Vegas, Nevada, United States|Durect Study Site 05, Stony Brook, New York, United States|Durect Study Site 13, Durham, North Carolina, United States|Durect Study Site 09, Cleveland, Ohio, United States|Durect Study Site 11, Cleveland, Ohio, United States|Durect Study Site 07, Cleveland, Ohio, United States|Durect Study Site 14, Philadelphia, Pennsylvania, United States|Durect Study Site 08, Houston, Texas, United States|DURECT Study Site 01, Houston, Texas, United States|Durect Study Site 23, Plano, Texas, United States",,https://ClinicalTrials.gov/show/NCT02574520
1090,NCT01402492,Cocaine Use Reduction With Buprenorphine,CURB,Completed,No Results Available,Cocaine Dependence,Drug: Buprenorphine + Naltrexone|Drug: Placebo + Naltrexone,"Cocaine use days as measured by self-report, corroborated by thrice-weekly urine drug screens","Walter Ling|National Institute on Drug Abuse (NIDA)|The EMMES Corporation|University of California, Los Angeles",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,302,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NIDA-CTN-0048|U10DA013045,2011-09-01,2013-01-01,2013-03-01,2011-07-26,null,2016-01-29,"UCLA Integrated Substance Abuse Programs (ISAP), Los Angeles, California, United States|Bay Area Addiction Research and Treatment (BAART), San Francisco, California, United States|Addiction Research and Treatment Services (ARTS), Denver, Colorado, United States|Howard University Hospital, Washington, District of Columbia, United States|Atlanta VA Medical Center, Atlanta, Georgia, United States|Albert Einstein College of Medicine - Division of Substance Abuse, Bronx, New York, United States|Bellevue Hospital Center, New York, New York, United States|Maryhaven, Columbus, Ohio, United States|CODA, Inc., Portland, Oregon, United States|South Texas Veterans Health Care System, San Antonio, Texas, United States|Recovery Centers of King County (RCKC), Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01402492
1091,NCT00609466,A Trial to Evaluate CG5503 Efficacy and Safety in Acute Pain After Bunionectomy,,Completed,Has Results,Bunionectomy|Pain|Postoperative Pain|Acute Pain,Drug: CG5503 IR|Drug: Morphine|Drug: Placebo,Sum of Pain Intensity Differences Relative to the Baseline Pain Intensity.|Number of Participants Using Rescue Medication|Total Pain Relief (TOTPAR)|Sum of Pain Intensity Differences Over 6 Hours (SPID6) Relative to the Baseline Pain Intensity|Sum of Pain Intensity Differences Over 12 Hours (SPID12) Relative to the Baseline Pain Intensity|Sum of Pain Intensity Differences Over 24 Hours (SPID24) Relative to the Baseline Pain Intensity|Sum of Pain Intensity Differences Over 72 Hours (SPID72) Relative to the Baseline Pain Intensity,"Grünenthal GmbH|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,291,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",574139,2007-09-01,2008-02-01,2008-02-01,2008-02-07,2009-11-25,2011-11-16,"Site 104, Pasadena, Maryland, United States|Site 101, Austin, Texas, United States|Site 102, Houston, Texas, United States|Site 105, San Antonio, Texas, United States|Site 103, San Marcos, Texas, United States|Site 106, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT00609466
1092,NCT01052012,Bupivacaine Effectiveness and Safety in SABER™ Trial,BESST,Completed,No Results Available,Postoperative Pain|Abdominal Surgery,Drug: SABER™-Bupivacaine|Drug: Bupivacaine HCl|Drug: SABER™-Placebo,Pain intensity on movement|Supplemental opioid use|Mean pain intensity on movement|Mean total morphine-equivalent dose|Proportion of patients who have evidence of a wound infection|Time-to-first use of opioid rescue medication|Incidence of opioid-related side effects|Mean pain intensity at rest during|Mean pain intensity at rest|Mean scores on the Recovery Index|Modified Post-Anesthetic Discharge Scoring System|Treatment satisfaction,"Durect|Nycomed|Hospira, now a wholly owned subsidiary of Pfizer",All,"18 Years and older   (Adult, Older Adult)",Phase 3,305,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",C803-025,2009-12-01,2011-09-01,2011-09-01,2010-01-20,null,2011-12-22,"DURECT Study Site, Birmingham, Alabama, United States|DURECT Study Site, Florence, Alabama, United States|DURECT Study Site, Mobile, Alabama, United States|DURECT Study Site, Mobile, Alabama, United States|DURECT Study Site, Montgomery, Alabama, United States|DURECT Study Site, Sheffield, Alabama, United States|DURECT Study Site, Arcadia, California, United States|DURECT Study Site, Fontana, California, United States|DURECT Study Site, Laguna Hills, California, United States|DURECT Study Site, Pasadena, California, United States|DURECT Study Site, Tampa, Florida, United States|DURECT Study Site, Powder Springs, Georgia, United States|DURECT Study Site, Indianapolis, Indiana, United States|DURECT Study Site, Boston, Massachusetts, United States|DURECT Study Site, Troy, Michigan, United States|DURECT Study Site, Duluth, Minnesota, United States|DURECT Study Site, New York, New York, United States|DURECT Study Site, Durham, North Carolina, United States|DURECT Study Site, Columbus, Ohio, United States|DURECT Study Site, Hershey, Pennsylvania, United States|DURECT Study Site, Houston, Texas, United States|DURECT Study Site, Temple, Texas, United States|DURECT Study Site, Woodville South, South Australia, Australia|DURECT Study Site, Box Hill, Victoria, Australia|DURECT Study Site, Ringwood East, Victoria, Australia|DURECT Study Site, Christchurch, New Zealand",,https://ClinicalTrials.gov/show/NCT01052012
1093,NCT02944448,A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee,,Completed,No Results Available,"Osteoarthritis, Hip|Osteoarthritis, Knee|Arthritis|Joint Diseases|Musculoskeletal Diseases|Rheumatic Diseases",Drug: CR845 tablet 1 mg|Drug: CR845 tablet 2.5 mg|Drug: CR845 tablet 5 mg|Drug: Placebo tablet,"The change from Baseline at Week 8/Day 57 with respect to the weekly mean of the daily pain intensity score at the index joint, function and stiffness as measured by the Numeric Rating Scale (NRS).|The effect of treatment on patient function, pain and stiffness between CR845 and placebo-treated patients as measured by the Western Ontario and McMaster Osteoarthritis Index (WOMAC).|The effect of treatment on the Patient Global Impression of Change (PGIC) between CR845- and placebo-treated patients.|The use of analgesic rescue medications between CR845- and placebo-treated patients as recorded in the patient's daily pain diary.|Safety and tolerability of titration-to-effect administration of oral CR845 assessed by detailed medical and surgical history, ECGs, physical examinations, monitoring of treatment emergent adverse events (TEAEs), vital signs, and laboratory evaluations.","Cara Therapeutics, Inc.",All,"25 Years and older   (Adult, Older Adult)",Phase 2,480,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CR845-CLIN2002-PO,2016-09-01,2017-05-01,2017-06-01,2016-10-25,null,2018-07-19,"Cara Therapeutics Study Site, Birmingham, Alabama, United States|Cara Therapeutics Study Site, Peoria, Arizona, United States|Cara Therapeutics Study Site, Phoenix, Arizona, United States|Cara Therapeutics Study Site, Carmichael, California, United States|Cara Therapeutics Study Site, San Diego, California, United States|Cara Therapeutics Study Site, Tustin, California, United States|Cara Therapeutics Study Site, Homestead, Florida, United States|Cara Therapeutics Study Site, Jupiter, Florida, United States|Cara Therapeutics Study Site, Lake Worth, Florida, United States|Cara Therapeutics Study Site, Miami, Florida, United States|Cara Therapeutics Study Site, Oldsmar, Florida, United States|Cara Therapeutics Study Site, Orlando, Florida, United States|Cara Therapeutics Study Site, Plantation, Florida, United States|Cara Therapeutics Study Site, South Miami, Florida, United States|Cara Therapeutics Study Site, Tampa, Florida, United States|Cara Therapeutics Study Site, Savannah, Georgia, United States|Cara Therapeutics Study Site, Hazelwood, Missouri, United States|Cara Therapeutics Study Site, Omaha, Nebraska, United States|Cara Therapeutics Study Site, Las Vegas, Nevada, United States|Cara Therapeutics Study Site, Berlin, New Jersey, United States|Cara Therapeutics Study Site, Binghamton, New York, United States|Cara Therapeutics Study Site, Rochester, New York, United States|Cara Therapeutics Study Site, Cincinnati, Ohio, United States|Cara Therapeutics Study Site, Cincinnati, Ohio, United States|Cara Therapeutics Study Site, Oklahoma City, Oklahoma, United States|Cara Therapeutics Study Site, Duncansville, Pennsylvania, United States|Cara Therapeutics Study Site, Charleston, South Carolina, United States|Cara Therapeutics Study Site, Charleston, South Carolina, United States|Cara Therapeutics Study Site, Greenville, South Carolina, United States|Cara Therapeutics Study Site, Austin, Texas, United States|Cara Therapeutics Study Site, Dallas, Texas, United States|Cara Therapeutics Study Site, Plano, Texas, United States|Cara Therapeutics Study Site, Plano, Texas, United States|Cara Therapeutics Study Site, San Antonio, Texas, United States|Cara Therapeutics Study Site, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02944448
1094,NCT00418457,Regional Anesthesia and Breast Cancer Recurrence,,"Active, not recruiting",No Results Available,Breast Neoplasms,Drug: General anesthesia and opioids|Drug: Regional analgesia and propofol,Cancer recurrence rate|post-surgical pain,The Cleveland Clinic,Female,"18 Years to 85 Years   (Adult, Older Adult)",Phase 3,1311,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,06-692,2007-01-01,2018-02-01,2019-03-01,2007-01-04,null,2018-07-17,"Cleveland Clinic Foundation, Cleveland, Ohio, United States|Medical University of Vienna, Vienna, Austria|Peking Union Medical College Hospital, Beijing, China|University of Düsseldorf, Düsseldorf, Germany|Mater Misericordiae Hospital, Dublin, Ireland|Tan Tock Seng Hospital, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT00418457
1095,NCT02336685,"Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001",,Completed,No Results Available,Osteoarthritis|Pain,Drug: Placebo|Drug: Fulranumab 1 mg|Drug: Fulranumab 3 mg|Drug: Opioid,"Change from baseline to the end of Week 16 in Western Ontario and McMaster University Arthritis Index (WOMAC) pain subscale score|Change from baseline to the end of Week 16 in Western Ontario and McMaster University Arthritis Index (WOMAC) physical function subscale score|Change from baseline to the end of Week 16 in Patient Global Assessment (PGA) score|Change from baseline to the end of Week 16 in WOMAC Stiffness subscale score|Change from baseline to the end of Week 16 in daily numerical rating scale (NRS) score|Change from baseline to the end of Week 16 in Medical Outcomes Study (MOS) Sleep subscale scores|Change from baseline to the end of Week 16 in Short-Form-36 (SF-36) subscale scores|Change from baseline to the end of Week 16 in EuroQol, 5 dimensions, 5 levels (EQ-5D-5L) scale score|Change from baseline to the end of Week 16 in the percentage of participants who are responders based on WOMAC pain and physical function subscale scores and PGA scale scores|Change from baseline to the end of Week 16 in the percentage of participants who are responders based on OMERACT-OARSI, MCII, and PASS scale scores|Change from baseline to the end of Week 16 in the percentage of participants who use rescue medication and other osteoarthritis (OA) analgesia","Janssen Research & Development, LLC",All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,79,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CR100068|42160443PAI3001|2013-001830-16,2015-07-07,2016-09-16,2016-09-16,2015-01-13,null,2017-10-02,"Birmingham, Alabama, United States|Huntsville, Alabama, United States|Cerritos, California, United States|Denver, Colorado, United States|Stamford, Connecticut, United States|Lewes, Delaware, United States|Newark, Delaware, United States|Crystal River, Florida, United States|Fort Lauderdale, Florida, United States|Hialeah, Florida, United States|Opa-locka, Florida, United States|Port Orange, Florida, United States|Marietta, Georgia, United States|Woodstock, Georgia, United States|Chicago, Illinois, United States|Rockford, Illinois, United States|Prairie Village, Kansas, United States|Lake Charles, Louisiana, United States|New Orleans, Louisiana, United States|Frederick, Maryland, United States|Worcester, Massachusetts, United States|Las Vegas, Nevada, United States|Albuquerque, New Mexico, United States|Brooklyn, New York, United States|Lake Success, New York, United States|Oklahoma City, Oklahoma, United States|Downingtown, Pennsylvania, United States|Duncansville, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Wyomissing, Pennsylvania, United States|Jackson, Tennessee, United States|Austin, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|West Jordan, Utah, United States|Richmond, Virginia, United States|Burlington, Ontario, Canada|Sarnia, Ontario, Canada|Baja, Hungary|Szeged, Hungary|Canterbury, New Zealand|Newtown, New Zealand|Takapuna, New Zealand|Tauranga, New Zealand|Bialystok, Poland|Gdansk, Poland|Myslenice, Poland|Blackpool, United Kingdom|Cannock, United Kingdom|Greater Manchester, United Kingdom|Mancheter, United Kingdom|Matrix Park Buckshow Willage, United Kingdom|Stourton, United Kingdom",,https://ClinicalTrials.gov/show/NCT02336685
1096,NCT01291901,NP2 Enkephalin For Treatment of Intractable Cancer Pain,,Completed,No Results Available,Intractable Pain|Neoplasms,Biological: NP2|Biological: Placebo,Pain Measured by the Numerical Rating Scale (NRS)|Opioid Pain Medication Usage Morphine Equivalent Units (MEU)|Quality of Life ECOG|Quality of Life SF-12|Pain SF-MPQ,"Diamyd Inc|Paragon Biomedical|invivodata, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,33,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NP2/P2/10/2,2011-01-01,2012-07-01,2013-11-01,2011-02-09,null,2014-08-08,"HOPE Research Institute, Phoenix, Arizona, United States|Arizona Clinical Research Center, Tucson, Arizona, United States|Compassionate Cancer Care Medical Group, Inc., Corona, California, United States|Cancer Care Associates, Fresno, California, United States|TriWest Research Associates, La Mesa, California, United States|White Memorial Medical Center, Los Angeles, California, United States|Hematology Oncology Associates, Oakland, California, United States|Advanced Pharma CR, Miami, Florida, United States|Better Health Clinical Research Inc, Newnan, Georgia, United States|Christie Clinic, Champaign, Illinois, United States|Global Scientific Innovations, Evansville, Indiana, United States|Montana Cancer Institute Foundation, Missoula, Montana, United States|Center for Clinical Research, Winston-Salem, North Carolina, United States|Signal Point Clinical research Center, Middletown, Ohio, United States|Pain Research of Oregon, Eugene, Oregon, United States|Hematology Oncology Associatesof Rhode Island, Cranston, Rhode Island, United States|Medical Therapy and Research, San Antonio, Texas, United States|Medical Oncology Associates, Spokane, Washington, United States",,https://ClinicalTrials.gov/show/NCT01291901
1097,NCT00487435,An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain,,Completed,Has Results,Pain|Osteoarthritis|Low Back Pain,Drug: Tapentadol (CG5503) Extended Release (ER),Number of Subjects With Treatment-emergent Adverse Events (TEAE)|Change From Baseline in Average Pain Intensity Scores at Week 52 Using the Numerical Rating Scale (NRS),"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Grünenthal GmbH",All,"18 Years and older   (Adult, Older Adult)",Phase 3,1166,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CR013567|R331333PAI3010|KF18,2007-06-01,2009-06-01,2009-06-01,2007-06-18,2010-07-23,2014-05-09,"Birmingham, Alabama, United States|Hoover, Alabama, United States|Mobile, Alabama, United States|Mesa, Arizona, United States|Phoenix, Arizona, United States|Tempe, Arizona, United States|Tucson, Arizona, United States|Jonesboro, Arkansas, United States|Little Rock, Arkansas, United States|Anaheim, California, United States|Carmichael, California, United States|Encinitas, California, United States|Fresno, California, United States|Huntington Park, California, United States|Laguna Hills, California, United States|Los Gatos, California, United States|Pico Rivera, California, United States|Pismo Beach, California, United States|Sacramento, California, United States|San Diego, California, United States|Upland, California, United States|Westlake Village, California, United States|Stamford, Connecticut, United States|Trumbull, Connecticut, United States|Chiefland, Florida, United States|Clearwater, Florida, United States|Fort Myers, Florida, United States|Hallandale Beach, Florida, United States|Hollywood, Florida, United States|Jacksonville, Florida, United States|Kissimmee, Florida, United States|Miami, Florida, United States|New Port Richey, Florida, United States|Oldsmar, Florida, United States|Pembroke Pines, Florida, United States|Plantation, Florida, United States|Port Orange, Florida, United States|Sarasota, Florida, United States|Tamarac, Florida, United States|Tampa, Florida, United States|Athens, Georgia, United States|Augusta, Georgia, United States|Decatur, Georgia, United States|Marietta, Georgia, United States|Perry, Georgia, United States|Suwanee, Georgia, United States|Woodstock, Georgia, United States|Honolulu, Hawaii, United States|Boise, Idaho, United States|Meridian, Idaho, United States|Chicago, Illinois, United States|Avon, Indiana, United States|Evansville, Indiana, United States|Indianapolis, Indiana, United States|Valparaiso, Indiana, United States|West Des Moines, Iowa, United States|Overland Park, Kansas, United States|Prairie Village, Kansas, United States|Topeka, Kansas, United States|Madisonville, Kentucky, United States|Baton Rouge, Louisiana, United States|Lake Charles, Louisiana, United States|Mandeville, Louisiana, United States|Metairie, Louisiana, United States|New Orleans, Louisiana, United States|Columbia, Maryland, United States|Owings Mills, Maryland, United States|Rockville, Maryland, United States|Boston, Massachusetts, United States|Brighton, Massachusetts, United States|Fall River, Massachusetts, United States|N Dartmouth, Massachusetts, United States|W Yarmouth, Massachusetts, United States|Wellesley Hills, Massachusetts, United States|East Lansing, Michigan, United States|Grand Blanc, Michigan, United States|Kalamazoo, Michigan, United States|Troy, Michigan, United States|Saint Louis, Missouri, United States|Omaha, Nebraska, United States|Cherry Hill, New Jersey, United States|Albuquerque, New Mexico, United States|Mamaroneck, New York, United States|New York, New York, United States|Williamsville, New York, United States|Greensboro, North Carolina, United States|Raleigh, North Carolina, United States|Winston Salem, North Carolina, United States|Cincinnati, Ohio, United States|Kettering, Ohio, United States|Toledo, Ohio, United States|Oklahoma City, Oklahoma, United States|Medford, Oregon, United States|Allentown, Pennsylvania, United States|Chester, Pennsylvania, United States|Duncansville, Pennsylvania, United States|Morrisville, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Greenville, South Carolina, United States|Prosperity, South Carolina, United States|Sioux Falls, South Dakota, United States|Clarksville, Tennessee, United States|Nashville, Tennessee, United States|Amarillo, Texas, United States|Austin, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|Hurst, Texas, United States|Lubbock, Texas, United States|Odessa, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Danville, Virginia, United States|Roanoke, Virginia, United States|Virginia Beach, Virginia, United States|Bellevue, Washington, United States|Tacoma, Washington, United States|Milwaukee, Wisconsin, United States|Adelaide, Australia|Melbourne, Australia|Newcastle, Australia|Woodville North, Australia|Chilliwack, British Columbia, Canada|Kelowna, British Columbia, Canada|Penticton, British Columbia, Canada|Vancouver, British Columbia, Canada|St. John'S, Newfoundland and Labrador, Canada|Ajax, Ontario, Canada|Brampton, Ontario, Canada|Kitchener, Ontario, Canada|London, Ontario, Canada|Markham, Ontario, Canada|Mississauga, Ontario, Canada|Ottawa, Ontario, Canada|Sarnia, Ontario, Canada|Sudbury, Ontario, Canada|Toronto, Ontario, Canada|Vancouver, Ontario, Canada|Charlottetown, Prince Edward Island, Canada|Montreal, Quebec, Canada|Pointe-Claire, Quebec, Canada|Sherbrooke, Quebec, Canada|St. Romuald, Quebec, Canada|Saskatoon, Saskatchewan, Canada|Halifax, Canada|Christchurch, New Zealand|Tauranga, New Zealand|Wellington, New Zealand",,https://ClinicalTrials.gov/show/NCT00487435
1098,NCT00420992,"A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee",,Completed,Has Results,Osteoarthritis|Chronic Pain,Drug: ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release)|Drug: Placebo,Mean Change From Randomization to 12 Weeks Following Randomization in Diary Brief Pain Inventory Score of Average Pain (Daily Scores of Average Pain Averaged Over 7 Days),Pfizer,All,"21 Years and older   (Adult, Older Adult)",Phase 3,547,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ALO-KNT-301,2006-12-01,2007-11-01,2007-11-01,2007-01-11,2009-10-30,2013-09-20,"The Birmingham Pain Center, Birmingham, Alabama, United States|Horizon Research Group, Mobile, Alabama, United States|Arizona Center for Clinical Research, Peoria, Arizona, United States|Arizona Research Center, Inc, Phoenix, Arizona, United States|Premiere Pharmaceutical Research, LLC, Tempe, Arizona, United States|Advanced Clinical Research Institute, Anaheim, California, United States|Orange County Clinical Trials, Anaheim, California, United States|STAT-CARE / Crest Clinical Trials, Anaheim, California, United States|Southbay Pharma Research, Buena Park, California, United States|Providence Clinical Res. (C-trials), Burbank, California, United States|Med Investigators Inc, Fair Oaks, California, United States|Quality of Life Medical Center, LLC, Hawaiian Gardens, California, United States|NervePro Research, Irvine, California, United States|UCSD Pain and Palliative Care, La Jolla, California, United States|USCD Pain and Palliative Care, La Jolla, California, United States|Private Practice, Pico Rivera, California, United States|Pain Institute of Santa Monica, Santa Monica, California, United States|Boling Clinical Trials, Upland, California, United States|Mountain View Clinical Research, Inc, Denver, Colorado, United States|Stamford Therapeutics Consortium, Stamford, Connecticut, United States|New England Research Associates, LLC, Trumbull, Connecticut, United States|MD Clinical, Hallandale Beach, Florida, United States|Eastern Research, Hialeah, Florida, United States|Florida Institute of Medical Research, Jacksonville, Florida, United States|Drug Study Institiute, Jupiter, Florida, United States|FPA Clinical Research, Kissimmee, Florida, United States|Innovative Research of West Florida, Largo, Florida, United States|Pharmaceutical Research Associates Inc, Merritt Island, Florida, United States|Ormond Medical Arts - Pharmaceutical Research Center, Ormond Beach, Florida, United States|University Clinical Research, Inc, Pembroke Pines, Florida, United States|Coastal Medical Research, Port Orange, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Gold Coast Research LLC, Weston, Florida, United States|River Birch Research Alliance, Blue Ridge, Georgia, United States|Best Clinical Research, Decatur, Georgia, United States|Non-Surgical Orthopaedic and Spine Center, Marietta, Georgia, United States|Drug Studies America, Marietta, Georgia, United States|Northwest Clinical Trials, Boise, Idaho, United States|Research Associates of Central Illinois, Peoria, Illinois, United States|MediSphere Medical Research Center, LLC, Evansville, Indiana, United States|Welborn Clinic, Newburgh, Indiana, United States|International Clinical Research Institute, Inc, Overland Park, Kansas, United States|Clinical Trials Management, LLC, Mandeville, Louisiana, United States|Lousiana Research Associates Inc., New Orleans, Louisiana, United States|Internal Research Center, Towson, Maryland, United States|Phase III Clinical Research, Fall River, Massachusetts, United States|Northeast Medical Research Associates, Inc, No Dartmouth, Massachusetts, United States|FutureCare Studies, Springfield, Massachusetts, United States|Synergy Medical Education Alliance, Saginaw, Michigan, United States|Medex Healthcare Research Inc, St. Louis, Missouri, United States|Lovelace Scientific, Henderson, Nevada, United States|Advanced Biomedical Research of America, Las Vegas, Nevada, United States|Partners in Primary Care, Voorhees, New Jersey, United States|Elkind Headache Center, Mount Vernon, New York, United States|The Arthritis Clinic and Carolina Bone and Joint, Charlotte, North Carolina, United States|The Center for Clinical Research, LLC, Winston-Salem, North Carolina, United States|Community Research, Cincinnati, Ohio, United States|Community Research, Cincinnati, Ohio, United States|Clinical Research Source, Inc, Toledo, Ohio, United States|COR Clinical Research, Oklahoma City, Oklahoma, United States|Health Research Institute, Oklahoma City, Oklahoma, United States|Cutting Edge Research, Oklahoma City, Oklahoma, United States|Tulsa Clinical Research, Tulsa, Oklahoma, United States|LVH Neurosciences and Pain Research, Allentown, Pennsylvania, United States|Pennsylvania Research Institute, Bensalem, Pennsylvania, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Commonwealth Primary Care / Fleetwood Clinical Research, Fleetwood, Pennsylvania, United States|Pivotal Clinical Research, LLC, Souderton, Pennsylvania, United States|Tipton Medical and Diagnostic Center, Tipton, Pennsylvania, United States|Premier Medical Group, Clarksville, Tennessee, United States|SCRI, Cordova, Tennessee, United States|Comprehensive Pain Specialists, Hendersonville, Tennessee, United States|SCRI, Memphis, Tennessee, United States|Integrity Clinical Research, LLC, Milan, Tennessee, United States|Walter F. Chase, MD, PA, Austin, Texas, United States|InSite Clinical Research, DeSoto, Texas, United States|Team Research of Central Texas, Killeen, Texas, United States|Radiant Research, San Antonio Northeast, San Antonio, Texas, United States|North San Antonio Healthcare Associates, San Antonio, Texas, United States|Progressive Clinical Research, San Antonio, Texas, United States|HypotheTest, LLC, Roanoke, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00420992
1099,NCT01926444,"A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy",,Completed,No Results Available,Pain|Cancer|Colonic Diseases,Drug: GIC-1001,"Measurements of visceral pain, using a 100-mm Visual Analog Scale (VAS)|Time to Caecum|Colonoscopy completion rate (%)|Safety",gicare Pharma Inc.|JSS Medical Research Inc.|Algorithme Pharma Inc,All,"40 Years to 70 Years   (Adult, Older Adult)",Phase 2,308,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",GIC13-01,2013-07-01,2014-03-01,2014-03-01,2013-08-21,null,2016-08-10,"Mayo Clinic, Scottsdale, Arizona, United States|Anaheim Clinical Trials, Anaheim, California, United States|Precision Research Institute, Chula Vista, California, United States|Precision Research Institute, San Diego, California, United States|Avail Clinical Research LLC, Deland, Florida, United States|The Center for GI Disorders, Hollywood, Florida, United States|Mid-Atlantic Medical Research Centers, Hollywood, Maryland, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|PharmaTrials, Hillsborough, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Gastroenterology Associates of Orangeburg, Orangeburg, South Carolina, United States|GIRI (GI Research Institute), Vancouver, British Columbia, Canada|Toronto Digestive Disease Associates, Toronto, Ontario, Canada|Clinique 1037, Montreal, Quebec, Canada|Spécialistes MD Specialists, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01926444
1100,NCT02542384,A Study Evaluating the Overall Pain Relief and Safety of Intravenous (IV) CR845 in Patients Undergoing Abdominal Surgery,,Completed,No Results Available,Post Abdominal Surgery Pain,Drug: CR845 IV 1 mcg/kg|Drug: CR845 IV 0.5 mcg/kg|Drug: Placebo IV,A comparison of the change in Pain Intensity over time using the Numeric Rating Scale|A study of the comparison of Post Surgical Nausea and Vomiting (PONV) scores|A comparison of the number of rescue medication doses administered|Patient Global Assessment of study drug,"Cara Therapeutics, Inc.",All,"21 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,451,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CR845-CLIN3001,2015-09-01,2018-04-01,2018-06-01,2015-09-07,null,2018-06-11,"Cara Therapeutics Study Site, Sheffield, Alabama, United States|Cara Therapeutics Study Site, New Haven, Connecticut, United States|Cara Therapeutics Study Site, Bradenton, Florida, United States|Cara Therapeutics Study Site, Gainesville, Florida, United States|Cara Therapeutics Study Site, Maitland, Florida, United States|Cara Therapeutics Study Site, Miami Gardens, Florida, United States|Cara Therapeutics Study Site, Pensacola, Florida, United States|Cara Therapeutics Study Site, Saint Petersburg, Florida, United States|Cara Therapeutics Study Site, Chicago, Illinois, United States|Cara Therapeutics Study Site, Boston, Massachusetts, United States|Cara Therapeutics Study Site, Camden, New Jersey, United States|Cara Therapeutics Study Site, Neptune, New Jersey, United States|Cara Therapeutics Study Site, Durham, North Carolina, United States|Cara Therapeutics Study Site, Cleveland, Ohio, United States|Cara Therapeutics Study Site, Columbus, Ohio, United States|Cara Therapeutics Study Site, Pittsburgh, Pennsylvania, United States|Cara Therapeutics Study Site, Chattanooga, Tennessee, United States|Cara Therapeutics Study Site, Bellaire, Texas, United States|Cara Therapeutics Study Site, Fort Worth, Texas, United States|Cara Therapeutics Study Site, Houston, Texas, United States|Cara Therapeutics Study Site, Plano, Texas, United States|Cara Therapeutics Study Site, San Antonio, Texas, United States|Cara Therapeutics Study Site, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT02542384
1101,NCT01361568,Study to Evaluate Analgesic Effect of IV Administration of Kappa Agonist CR845 For Hysterectomy Surgery,,Completed,Has Results,Postoperative Pain,Drug: CR845|Drug: Placebo,Total Morphine Consumption in the First 24 Hours Following Postoperative Study Drug Treatment|Summed Pain Intensity Difference From 0-24 Hours (SPID 0-24) Following Postoperative Study Drug Treatment Using Last Observation Carried Forward (LOCF)|Morphine Consumption Following Postoperative Study Drug Treatment in the 2-24 Hour Period After Recovery in the Post-Anesthesia Care Unit (Post-PACU)|Total Pain Relief Within the First 2 Hours (TOTPAR 0-2) Following Postoperative Study Drug Treatment Using LOCF|Global Evaluation Responder Analysis|Total Number of Patients Reporting At Least One Episode of Nausea|Total Number of Patients Reporting At Least One Episode of Vomiting,"Cara Therapeutics, Inc.",Female,"21 Years to 65 Years   (Adult, Older Adult)",Phase 2,203,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CR845 CLIN2002,2011-07-01,2012-04-01,2012-04-01,2011-05-27,2014-05-19,2014-05-29,"Shoals Clinical Research Associates, Florence, Alabama, United States|Horizon Research Group, Mobile, Alabama, United States|Wilmax, Mobile, Alabama, United States|Drug Research and Analysis Corp, Montgomery, Alabama, United States|Shoals Medical Trials, INC, Sheffield, Alabama, United States|Precision Clinical Trials, Phoenix, Arizona, United States|Woodland Healthcare California Clinical Research, Inc, Davis, California, United States|Olive View-UCLA Medical Center, Sylmar, California, United States|Visions Clinical Research, Boynton Beach, Florida, United States|Riverside Clinical Research, Edgewater, Florida, United States|University of Miami, Dept of, Miami, Florida, United States|Cypress Medical Research, Wichita, Kansas, United States|Cooper University Hospital, Camden, New Jersey, United States|Duke University, Durham, North Carolina, United States|Ohio State University Medical, Dept of Anesthesia, Columbus, Ohio, United States|Palmetto Clinical Research,, Greenville, South Carolina, United States|Chattanooga Medical Research, Chattanooga, Tennessee, United States|Texas Health Care, PLLC, Fort Worth, Texas, United States",,https://ClinicalTrials.gov/show/NCT01361568
1102,NCT00877799,Study to Evaluate Analgesic Effect of Intravenous Administration of Kappa Agonist CR845 After Hysterectomy Surgery,,Completed,Has Results,Acute Pain,Drug: CR845|Drug: Placebo,Responders on Pain Intensity(PI) and Pain Relief (PR) Composite Endpoint|Total PCA Morphine Consumption in the 0-16 Hour Period Following Postoperative Study Drug Treatment,"Cara Therapeutics, Inc.",Female,21 Years to 60 Years   (Adult),Phase 2,114,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CR845-CLIN2001,2009-03-01,2009-12-01,2010-01-01,2009-04-08,2015-05-12,2015-05-12,"Mobile Infirmary Medical Center, Mobile, Alabama, United States|Springhill Medical Center, Mobile, Alabama, United States|Helen Keller Hospital, Sheffield, Alabama, United States|Paradise Valley Hospital, Phoenix, Arizona, United States|Adventist Medical Center, Glendale, California, United States|Saddleback Memorial Hospital, Laguna Hills, California, United States|Huntington Memorial Hospital, Pasadena, California, United States|Palms West Hospital, Loxahatchee, Florida, United States|University of Miami/Jackson Memorial Hospital, Miami, Florida, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|Memorial Hermann - Memorial City Medical Center, Houston, Texas, United States|The Woman's Hospital of Texas, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00877799